FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Wong, K Boone, T Munoz, A AF Wong, Kelvin Boone, Timothy Munoz, Alvaro TI FUNCTIONAL-MRI DURING BLADDER CYSTOMETRY IN SPINAL CORD-INJURED AND INTACT FEMALE RATS SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion (SUFU) CY FEB 25-MAR 01, 2014 CL Miami, FL SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Wong, Kelvin; Munoz, Alvaro] Houston Methodist Res Inst, Houston, TX USA. [Boone, Timothy] Houston Methodist Hosp, MHRI, Houston, TX USA. [Boone, Timothy] VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2014 VL 33 IS 2 BP 194 EP 194 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AA3SO UT WOS:000331012800073 ER PT J AU Cao, HY Cristofaro, V Goyal, RK Sullivan, MP AF Cao, Hongying Cristofaro, Vivian Goyal, Raj K. Sullivan, Maryrose P. TI MYOSIN VA REGULATES EXCITATORY NEUROTRANSMISSION IN THE BLADDER SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion (SUFU) CY FEB 25-MAR 01, 2014 CL Miami, FL SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Cao, Hongying; Goyal, Raj K.; Sullivan, Maryrose P.] Boston VA Healthcare Syst, Boston, MA USA. [Cristofaro, Vivian] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2014 VL 33 IS 2 BP 195 EP 195 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AA3SO UT WOS:000331012800074 ER PT J AU Boone, T Munoz, A AF Boone, Timothy Munoz, Alvaro TI INHIBITION OF P2 x 7 RECEPTORS AFTER DORSAL-HORN TRANSECTION IMPROVES NEUROGENIC BLADDER DYSFUNCTION IN FEMALE RATS SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion (SUFU) CY FEB 25-MAR 01, 2014 CL Miami, FL SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Boone, Timothy] Houston Methodist Hosp, HMRI, Houston, TX USA. [Boone, Timothy] VA Med Ctr, Houston, TX USA. [Munoz, Alvaro] Houston Methodist Res Inst, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2014 VL 33 IS 2 BP 198 EP 198 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AA3SO UT WOS:000331012800081 ER PT J AU Ferguson, A Sutton, B Boone, T Ford, A Munoz, A AF Ferguson, Andrew Sutton, Broderick Boone, Timothy Ford, Anthony Munoz, Alvaro TI EFFECTS OF UROTHELIAL P2 x 3 RECEPTOR INHIBITION ON RAT BLADDER CONTRACTILITY SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion (SUFU) CY FEB 25-MAR 01, 2014 CL Miami, FL SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Ferguson, Andrew; Sutton, Broderick; Munoz, Alvaro] Houston Methodist Res Inst, Houston, TX USA. [Boone, Timothy] Houston Methodist Hosp, MHRI, Houston, TX USA. [Boone, Timothy] VA Med Ctr, Houston, TX USA. [Ford, Anthony] Afferent Pharmaceut, San Mateo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2014 VL 33 IS 2 BP 203 EP 203 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AA3SO UT WOS:000331012800093 ER PT J AU Shah, NR Chokshi, DA AF Shah, Nirav R. Chokshi, Dave A. TI Should Health Care Systems Become Insurers? SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB Incentives under the Affordable Care Act are making more health care systems assume the risk of paying for patient care, making boundaries between care delivery organizations and insurers less clear-cut. Bundled payments, value-based purchasing, and accountable care organizations transfer financial risk from payers to health care systems. The goal of health care systems that adopt risk contracts is to contain costs due to the increase in financial pressures as Medicaid expands and reimbursements for Medicare and fee-for-service care shrink. Accountable care organization contracts have shown promise in slowing the increase in medical expenditures for public and private payers. Some health care systems hold ownership in an associated health plan, with increasing numbers of systems developing new ways of engaging with health plans. Physicians and hospitals must distinguish between different types of arrangements. A full ownership partnership encompasses joint governance between the insurance plan and health care system; all participants in the plan receive care from the associated health system. In partial ownership, the health care system owns a stake in the insurer, but governance and care relationships are not totally overlapping. In a partnership, the formal relationship with the insurance plan preferentially refers patients to the health care system, and the system enters into risk contracts for the patients. Finally, in contractual arrangements, health systems enter into risk-bearing contracts with insurance plans for specific patient populations. For health systems that assume risk, the arrangement drives integration, such that most of a patient's health care needs and associated payments are addressed by a single network, allowing care to be better coordinated. Care provided outside the network is paid for by the insurer. Cost savings are generated by decreasing volume-based incentives in fee-for-service payment systems that can create overuse. Linking health care systems and payers can also overcome a lack of price transparency. One challenge is whether health care system-insurer partnerships will conflict with existing state and federal regulations designed to maintain a competitive marketplace. These include antitrust regulations, bans on the corporate practice of medicine, and prohibitions on fee-splitting. Another concern is that the health care system and insurers do not necessarily have the same goals and human resources. Merging these models will require significant investments of energy and capital that may distract from core activities. In addition, most health systems are ill-equipped to handle the complex operations of the insurance business. Systems must maintain adequate capital reserves to be a financially viable health plan. Therefore, health systems must be more judicious about assuming risk and managing population health and costs. Successful partnerships between health care systems and insurers will require certain components. (1) The integrated arrangement must rest on a foundation of high-functioning primary health care. (2) It must incorporate system-wide processes for quality improvement. (3) It must engage patients with outreach initiatives for disease self-management and preventive care. (4) Systems must be able to manage costs of care. With care delivery transformation as the ultimate goal, the leaders of health systems must nurture and build on momentum in a sustainable way. C1 [Shah, Nirav R.] New York State Dept Hlth, Albany, NY 12201 USA. US Dept Vet Affairs, Washington, DC USA. RP Shah, NR (reprint author), New York State Dept Hlth, Albany, NY 12201 USA. OI Chokshi, Dave/0000-0001-7467-4591 NR 0 TC 0 Z9 0 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD FEB PY 2014 VL 69 IS 2 BP 69 EP 70 DI 10.1097/01.ogx.0000444674.43584.fc PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AB1HK UT WOS:000331541900005 ER PT J AU Kopans, DB AF Kopans, Daniel B. TI Arguments Against Mammography Screening Continue to be Based on Faulty Science SO ONCOLOGIST LA English DT Editorial Material ID BREAST-CANCER MORTALITY; SWEDISH 2-COUNTY TRIAL; CARCINOMA IN-SITU; WOMEN 40-49 YEARS; 3 DECADES; OVERDIAGNOSIS; REDUCTION; MODEL; NORWAY; TRENDS C1 [Kopans, Daniel B.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Kopans, Daniel B.] Massachusetts Gen Hosp, Breast Imaging Div, Boston, MA 02114 USA. RP Kopans, DB (reprint author), Massachusetts Gen Hosp, Avon Comprehens Breast Ctr, Dept Radiol, Breast Imaging Div, Suite 240,15 Parkman St, Boston, MA 02114 USA. EM kopans.daniel@mgh.harvard.edu NR 53 TC 18 Z9 18 U1 0 U2 5 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD FEB PY 2014 VL 19 IS 2 BP 107 EP 112 DI 10.1634/theoncologist.2013-0184 PG 6 WC Oncology SC Oncology GA AB8YY UT WOS:000332077300002 PM 24536051 ER PT J AU Jagsi, R Spence, R Rathmell, WK Bradbury, A Peppercorn, J Grubbs, S Moy, B AF Jagsi, Reshma Spence, Rebecca Rathmell, W. Kimryn Bradbury, Angela Peppercorn, Jeffrey Grubbs, Stephen Moy, Beverly TI Ethical Considerations for the Clinical Oncologist in an Era of Oncology Drug Shortages SO ONCOLOGIST LA English DT Article DE Oncology; Drug; Shortage; Policy; Ethics; Recommendations ID FRAMEWORK; CANCER; RESOURCES; IMPACT; CARE AB Shortages of injectable drugs affect many cancer patients and providers in the U. S. today. Scholars and policymakers have recently begun to devote increased attention to these issues, but only a few tangible resources exist to guide clinical oncologists in developing strategies for dealing with drug shortages on a recurring basis. This article discusses existing information from the scholarly literature, policy analyses, and other relevant sources and seeks to provide practical ethical guidance to the broad audience of oncology professionals who are increasingly confronted with such cases in their practice. We begin by providing a brief overview of the history, causes, and regulatory context of oncology drug shortages in the U. S., followed by a discussion of ethical frameworks that have been proposed in this setting. We conclude with practical recommendations for ethical professional behavior in these increasingly common and challenging situations. C1 [Jagsi, Reshma] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. [Spence, Rebecca] Amer Soc Clin Oncol, Alexandria, VA USA. [Rathmell, W. Kimryn] Univ N Carolina, Chapel Hill, NC USA. [Bradbury, Angela] Univ Penn, Philadelphia, PA 19104 USA. [Peppercorn, Jeffrey] Duke Univ, Durham, NC USA. [Grubbs, Stephen] Med Oncol Hematol Consultants, Newark, DE USA. [Moy, Beverly] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jagsi, R (reprint author), Univ Michigan, Dept Radiat Oncol, UHB2C490, SPC 5010, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM rjagsi@med.umich.edu OI Jagsi, Reshma/0000-0001-6562-1228 FU Novartis; AVEO; AbbVie FX Jeffrey Peppercorn: GlaxoSmithKline (E [spouse]); Genentech (C/A), Novartis (RF); Ownership interest: GlaxoSmithKline (OI [spouse]); W. Kimryn Rathmell: GlaxoSmithKline, Siemens, Seattle Genetics, AVEO (RF); Reshma Jagsi: AbbVie (RF [support]); Eviti (SAB). The other authors indicated no financial relationships. NR 37 TC 3 Z9 3 U1 0 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD FEB PY 2014 VL 19 IS 2 BP 186 EP 192 DI 10.1634/theoncologist.2013-0301 PG 7 WC Oncology SC Oncology GA AB8YY UT WOS:000332077300011 PM 24449096 ER PT J AU Dizon, DS Suzin, D McIlvenna, S AF Dizon, Don S. Suzin, Daphne McIlvenna, Susanne TI Sexual Health as a Survivorship Issue for Female Cancer Survivors SO ONCOLOGIST LA English DT Article DE Breast cancer; Cancer survivor; Gynecologic cancer; Sexual health; Quality of life ID QUALITY-OF-LIFE; TRANSDERMAL TESTOSTERONE TREATMENT; RANDOMIZED-CONTROLLED-TRIAL; BREAST-CANCER; POSTMENOPAUSAL WOMEN; LONG-TERM; DESIRE DISORDER; CERVICAL-CANCER; BODY-IMAGE; RADICAL HYSTERECTOMY AB As more and more people are successfully treated for and live longer with cancer, greater attention is being directed toward the survivorship needs of this population. Women treated for cancer often experience issues related to sexual health and intimacy, which are frequently cited as areas of concern, even among long-term survivors. Unfortunately, data suggest that providers infrequently discuss these issues. We reviewed a contemporary understanding of sexual health of women and the impact of treatment on both sexual function and intimacy. We also provide a review of the diagnosis using the newest classification put forth by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, and potential treatments, including both endocrine and nonendocrine treatments that the general oncologist may be asked about when discussing sexual health with his or her patients. C1 [Dizon, Don S.; Suzin, Daphne; McIlvenna, Susanne] Massachusetts Gen Hosp, Gillette Ctr Gynecol Oncol, Boston, MA 02114 USA. [Dizon, Don S.] Massachusetts Gen Hosp, Oncol Sexual Hlth Clin, Boston, MA 02114 USA. RP Dizon, DS (reprint author), 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM ddizon@partners.org NR 79 TC 11 Z9 11 U1 2 U2 7 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD FEB PY 2014 VL 19 IS 2 BP 202 EP 210 DI 10.1634/theoncologist.2013-0302 PG 9 WC Oncology SC Oncology GA AB8YY UT WOS:000332077300013 PM 24396051 ER PT J AU Pulloor, NK Nair, S Kostic, AD Bist, P Weaver, JD Riley, AM Tyagi, R Uchil, PD York, JD Snyder, SH Garcia-Sastre, A Potter, BVL Lin, RT Shears, SB Xavier, RJ Krishnan, MN AF Pulloor, Niyas Kudukkil Nair, Sajith Kostic, Aleksandar D. Bist, Pradeep Weaver, Jeremy D. Riley, Andrew M. Tyagi, Richa Uchil, Pradeep D. York, John D. Snyder, Solomon H. Garcia-Sastre, Adolfo Potter, Barry V. L. Lin, Rongtuan Shears, Stephen B. Xavier, Ramnik J. Krishnan, Manoj N. TI Human Genome-Wide RNAi Screen Identifies an Essential Role for Inositol Pyrophosphates in Type-I Interferon Response SO PLOS PATHOGENS LA English DT Article ID DOUBLE-STRANDED-RNA; INNATE IMMUNE-RESPONSE; IRF-3 TRANSCRIPTION FACTOR; HEXAKISPHOSPHATE KINASE 1; SENSORS RIG-I; ANTIVIRAL RESPONSE; VIRUS-INFECTION; REGULATORY FACTOR-3; PP-INSP(5) KINASE; UBIQUITIN LIGASE AB The pattern recognition receptor RIG-I is critical for Type-I interferon production. However, the global regulation of RIG-I signaling is only partially understood. Using a human genome-wide RNAi-screen, we identified 226 novel regulatory proteins of RIG-I mediated interferon- production. Furthermore, the screen identified a metabolic pathway that synthesizes the inositol pyrophosphate 1-IP7 as a previously unrecognized positive regulator of interferon production. Detailed genetic and biochemical experiments demonstrated that the kinase activities of IPPK, PPIP5K1 and PPIP5K2 (which convert IP5 to1-IP7) were critical for both interferon induction, and the control of cellular infection by Sendai and influenza A viruses. Conversely, ectopically expressed inositol pyrophosphate-hydrolases DIPPs attenuated interferon transcription. Mechanistic experiments in intact cells revealed that the expression of IPPK, PPIP5K1 and PPIP5K2 was needed for the phosphorylation and activation of IRF3, a transcription factor for interferon. The addition of purified individual inositol pyrophosphates to a cell free reconstituted RIG-I signaling assay further identified 1-IP7 as an essential component required for IRF3 activation. The inositol pyrophosphate may act by -phosphoryl transfer, since its action was not recapitulated by a synthetic phosphonoacetate analogue of 1-IP7. This study thus identified several novel regulators of RIG-I, and a new role for inositol pyrophosphates in augmenting innate immune responses to viral infection that may have therapeutic applications. Author Summary The innate immune system is critical for viral infection control by host organisms. The type I interferons are a family of major antiviral cytokines produced upon the activation of innate immune pattern recognition receptors (PRRs) by viruses. The RIG-I is a major PRR that uniquely detects RNA viruses within the cytoplasm. In this study, we aimed to discover cellular genes and pathways that play regulatory roles in the transcriptional induction of type I interferon- (IFN). Using a human genome wide RNA interference (RNAi) screening, we identified 226 genes whose expression is important for proper IFN production. Through bioinformatics-based mining of the RNAi screen results, we identified that the cellular pathway synthesizing inositol pyrophosphates, a class of inositol phosphates with high-energy diphosphates, is a key positive regulator of RIG-I mediated IFN production. The kinases IPPK, PPIP5K1 and PPIP5K2, that synthesize inositol pyrophosphate 1-IP7, regulated IFN response in a catalytically dependent manner. Mechanistic studies identified that 1-IP7 synthesis pathway was needed for efficient phosphorylation of IRF3. The DIPP family of inositol pyrophosphate hydrolases negatively regulated the IFN response, upon ectopic expression. In summary, this study generated a global view of the regulation of RIG-I signaling, and identified inositol pyrophosphates as important regulators of antiviral response. C1 [Pulloor, Niyas Kudukkil; Nair, Sajith; Bist, Pradeep; Krishnan, Manoj N.] DUKE NUS Grad Med Sch, Program Emerging Infect Dis, Singapore, Singapore. [Kostic, Aleksandar D.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA. [Weaver, Jeremy D.; Shears, Stephen B.] NIH, NIEHS, DHHS, Lab Signal Transduct,Inositol Signaling Grp, Res Triangle Pk, NC USA. [Riley, Andrew M.; Potter, Barry V. L.] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England. [Tyagi, Richa; Snyder, Solomon H.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD USA. [Tyagi, Richa; Snyder, Solomon H.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. [Tyagi, Richa; Snyder, Solomon H.] Johns Hopkins Univ, Sch Med, Dept Behav Sci, Baltimore, MD USA. [Uchil, Pradeep D.] Yale Univ, Sch Med, Sect Microbial Pathogenesis, New Haven, CT USA. [York, John D.] Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN USA. [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, Dept Med, Div Infect Dis,Dept Microbiol, New York, NY USA. [Lin, Rongtuan] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada. RP Pulloor, NK (reprint author), DUKE NUS Grad Med Sch, Program Emerging Infect Dis, Singapore, Singapore. EM manoj.krishnan@duke-nus.edu.sg RI Lin, Rongtuan/A-1442-2008; tyagi, richa/A-7261-2015; OI Lin, Rongtuan/0000-0002-2238-3503; Kostic, Aleksandar/0000-0002-0837-4360; Garcia-Sastre, Adolfo/0000-0002-6551-1827; McCaffrey, Kathleen/0000-0002-6544-2649 FU ASTAR; Ministry of Education; NIH [MH-18501]; Canadian Institutes of Health Research [MOP42562]; NIAID [U19AI083025]; CRIP (Center for Research on Influenza Pathogenesis); Center of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN266200700010C]; Intramural Research Program of the NIH, National Institute of Environmental Health Sciences; Wellcome Trust [082837, 101010] FX MNK was funded by ASTAR and Ministry of Education. SHS was funded by NIH grant MH-18501. RL was funded by the Canadian Institutes of Health Research grant MOP42562. AGS was funded by NIAID grant U19AI083025 and by CRIP (Center for Research on Influenza Pathogenesis), a NIAD-funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN266200700010C). SBS was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. AMR and BVLP were funded by the Wellcome Trust (Programme Grant 082837). BVLP is a Wellcome Trust Senior Investigator (Grant 101010) NR 72 TC 25 Z9 25 U1 0 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD FEB PY 2014 VL 10 IS 2 AR e1003981 DI 10.1371/journal.ppat.1003981 PG 16 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA AB9CC UT WOS:000332085900052 PM 24586175 ER PT J AU Stanley, SA Barczak, AK Silvis, MR Luo, SS Sogi, K Vokes, M Bray, MA Carpenter, AE Moore, CB Siddiqi, N Rubin, EJ Hung, DT AF Stanley, Sarah A. Barczak, Amy K. Silvis, Melanie R. Luo, Samantha S. Sogi, Kimberly Vokes, Martha Bray, Mark-Anthony Carpenter, Anne E. Moore, Christopher B. Siddiqi, Noman Rubin, Eric J. Hung, Deborah T. TI Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth SO PLOS PATHOGENS LA English DT Article ID FACTOR RECEPTOR; HUMAN MACROPHAGES; INHIBITORS; ACTIVATION; SEROTONIN; IMMUNITY; MECHANISM; SURVIVAL; CELLS; INFECTIONS AB Mycobacterium tuberculosis remains a significant threat to global health. Macrophages are the host cell for M. tuberculosis infection, and although bacteria are able to replicate intracellularly under certain conditions, it is also clear that macrophages are capable of killing M. tuberculosis if appropriately activated. The outcome of infection is determined at least in part by the host-pathogen interaction within the macrophage; however, we lack a complete understanding of which host pathways are critical for bacterial survival and replication. To add to our understanding of the molecular processes involved in intracellular infection, we performed a chemical screen using a high-content microscopic assay to identify small molecules that restrict mycobacterial growth in macrophages by targeting host functions and pathways. The identified host-targeted inhibitors restrict bacterial growth exclusively in the context of macrophage infection and predominantly fall into five categories: G-protein coupled receptor modulators, ion channel inhibitors, membrane transport proteins, anti-inflammatories, and kinase modulators. We found that fluoxetine, a selective serotonin reuptake inhibitor, enhances secretion of pro-inflammatory cytokine TNF- and induces autophagy in infected macrophages, and gefitinib, an inhibitor of the Epidermal Growth Factor Receptor (EGFR), also activates autophagy and restricts growth. We demonstrate that during infection signaling through EGFR activates a p38 MAPK signaling pathway that prevents macrophages from effectively responding to infection. Inhibition of this pathway using gefitinib during in vivo infection reduces growth of M. tuberculosis in the lungs of infected mice. Our results support the concept that screening for inhibitors using intracellular models results in the identification of tool compounds for probing pathways during in vivo infection and may also result in the identification of new anti-tuberculosis agents that work by modulating host pathways. Given the existing experience with some of our identified compounds for other therapeutic indications, further clinically-directed study of these compounds is merited. Author Summary Infection with the bacterial pathogen Mycobacterium tuberculosis causes the disease tuberculosis (TB) that imposes significant worldwide morbidity and mortality. Approximately 2 billion people are infected with M. tuberculosis, and almost 1.5 million people die annually from TB. With increasing drug resistance and few novel drug candidates, our inability to effectively treat all infected individuals necessitates a deeper understanding of the host-pathogen interface to facilitate new approaches to treatment. In addition, the current anti-tuberculosis regimen requires months of strict compliance to clear infection; targeting host immune function could play a strategic role in reducing the duration and complexity of treatment while effectively treating drug-resistant strains. Here we use a microscopy-based screen to identify molecules that target host pathways and inhibit the growth of M. tuberculosis in macrophages. We identified several host pathways not previously implicated in tuberculosis. The identified inhibitors prevent growth either by blocking host pathways exploited by M. tuberculosis for virulence, or by activating immune responses that target intracellular bacteria. Fluoxetine, used clinically for treating depression, induces autophagy and enhances production of TNF-. Similarly, gefitinib, used clinically for treating cancer, inhibits M. tuberculosis growth in macrophages. Importantly, gefitinib treatment reduces bacterial replication in the lungs of M. tuberculosis-infected mice. C1 [Stanley, Sarah A.; Barczak, Amy K.; Silvis, Melanie R.; Vokes, Martha; Bray, Mark-Anthony; Carpenter, Anne E.; Moore, Christopher B.; Hung, Deborah T.] Broad Inst MIT & Harvard, Cambridge, MA 02141 USA. [Stanley, Sarah A.; Sogi, Kimberly] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA. [Barczak, Amy K.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Barczak, Amy K.; Luo, Samantha S.; Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Barczak, Amy K.; Luo, Samantha S.; Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Siddiqi, Noman; Rubin, Eric J.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA. RP Stanley, SA (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02141 USA. EM hung@molbio.mgh.harvard.edu RI Bray, Mark/C-5973-2008; Carpenter, Anne/C-4982-2008; OI Bray, Mark/0000-0002-9748-3592; Carpenter, Anne/0000-0003-1555-8261; Silvis, Melanie/0000-0002-0732-9744 FU Novartis; Helen Hay Whitney Foundation; NIH [K08 AI080944, R01 GM089652] FX SAS gratefully acknowledges Novartis and the Helen Hay Whitney Foundation for funding. AKB gratefully acknowledges funding through NIH K08 AI080944. AEC gratefully acknowledges funding through NIH R01 GM089652. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 63 TC 60 Z9 60 U1 2 U2 30 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD FEB PY 2014 VL 10 IS 2 AR e1003946 DI 10.1371/journal.ppat.1003946 PG 16 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA AB9CC UT WOS:000332085900047 PM 24586159 ER PT J AU Collins, AE Niles, BL Mori, DL Silberbogen, AK Seligowski, AV AF Collins, Allison E. Niles, Barbara L. Mori, DeAnna L. Silberbogen, Amy K. Seligowski, Antonia V. TI A Telephone-Based Intervention to Promote Diabetes Management in Veterans With Posttraumatic Stress Symptoms SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE diabetes; posttraumatic stress; telehealth ID RANDOMIZED-TRIAL; HEALTH BEHAVIORS; MENTAL-HEALTH; SELF-CARE; DISORDER; AFGHANISTAN; PREVALENCE; DISEASE; SCALE; POOR AB The primary objective of this pilot study was to develop and implement a telephone intervention for veterans with diabetes and posttraumatic stress symptoms (PTSS). Additional objectives were to evaluate study feasibility and to conduct exploratory analyses of the influence of the intervention on diabetic self-care, quality of life, treatment adherence, and mental health functioning. Twenty-three veterans with PTSS and diabetes enrolled in the study and received an initial assessment interview and intervention session. Twenty participants completed the study protocol in its entirety and also received 7 weekly motivational telephone calls with a clinician and a final assessment. Results revealed high levels of compliance with telephone calls. Participants reported satisfaction with and benefit from the intervention that occurred during weekly telephone calls. Participants reported a statistically significant increase in exercise behaviors and healthy eating from pre- to postintervention. Results also revealed a decrease in psychological distress. Although these data are preliminary, they speak to the feasibility and benefits of a brief telephone intervention to address self-care behaviors critical to the management of diabetes for individuals with PTSS. C1 [Collins, Allison E.; Niles, Barbara L.; Mori, DeAnna L.; Silberbogen, Amy K.; Seligowski, Antonia V.] VA Boston Healthcare Syst, Boston, MA USA. [Collins, Allison E.; Niles, Barbara L.; Mori, DeAnna L.; Silberbogen, Amy K.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Niles, Barbara L.; Seligowski, Antonia V.] Natl Ctr PTSD, Behav Sci Div, Boston, MA USA. RP Collins, AE (reprint author), John D Dingell VA Med Ctr, 4646 John R Rd 11-MH, Detroit, MI 48201 USA. EM allison.collins2@va.gov NR 37 TC 3 Z9 3 U1 1 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 EI 1939-1323 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD FEB PY 2014 VL 45 IS 1 BP 20 EP 26 DI 10.1037/a0032604 PG 7 WC Psychology, Multidisciplinary SC Psychology GA AC2MH UT WOS:000332334700004 ER PT J AU Zollfrank, A Trevino, K Cadge, W Balboni, M Gallivan, K Thiel, MM VanderWeele, T Balboni, T AF Zollfrank, Angelika Trevino, Kelly Cadge, Wendy Balboni, Michael Gallivan, Kathy Thiel, Mary Martha VanderWeele, Tyler Balboni, Tracy TI Teaching Healthcare Providers How to Provide Spiritual Care: A Pilot Study SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Zollfrank, Angelika] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Trevino, Kelly] Rowan Univ, Glassboro, NJ USA. [Cadge, Wendy] Brandeis Univ, Waltham, MA USA. [Balboni, Michael; Balboni, Tracy] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gallivan, Kathy] Brigham & Womens Hosp, Boston, MA 02115 USA. [Thiel, Mary Martha] Hebrew Senior Life, Boston, MA USA. [VanderWeele, Tyler] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 10 EP 11 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700018 ER PT J AU Ross, S Tarquini, S Frumer-Styron, N AF Ross, Sarah Tarquini, Sarah Frumer-Styron, Nancy TI Ethical Dilemmas Involved in Pediatric Bone Marrow Donor Evaluation: Demonstrating the Need for Standards of Care SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Ross, Sarah; Tarquini, Sarah] Dana Farber Canc Inst, Boston, MA 02115 USA. [Frumer-Styron, Nancy] Massachusetts Sch Profess Psychol, Newton, MA USA. [Frumer-Styron, Nancy] Childrens Room, Arlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 19 EP 19 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700033 ER PT J AU Northman, L Morris, M Ross, S Ullrich, N Manley, P AF Northman, Lisa Morris, Marybeth Ross, Sarah Ullrich, Nicole Manley, Peter TI The School Liaison Program's Effect on Parental Satisfaction and Understanding of Special Education Services SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Northman, Lisa; Morris, Marybeth; Ross, Sarah; Ullrich, Nicole; Manley, Peter] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ullrich, Nicole; Manley, Peter] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 20 EP 20 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700035 ER PT J AU Sherman-Bien, S Patenaude, AF Battles, H Elkin, D Friebert, S Kearney, J Kupst, MJ Madan-Swain, A Mullins, L Pao, M Phipps, S Zadeh, S Wiener, L AF Sherman-Bien, Sandra Patenaude, Andrea Farkas Battles, Haven Elkin, David Friebert, Sarah Kearney, Julia Kupst, Mary Jo Madan-Swain, Avi Mullins, Larry Pao, Maryland Phipps, Sean Zadeh, Sima Wiener, Lori TI Meeting the Needs of Their Children: Correlates of Distress for Lone Parents of Children With Cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Sherman-Bien, Sandra] Miller Childrens Hosp, Jonathan Jacques Childrens Canc Ctr, Long Beach, CA USA. [Patenaude, Andrea Farkas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Battles, Haven; Pao, Maryland; Zadeh, Sima; Wiener, Lori] NCI, NIH, Bethesda, MD 20892 USA. [Elkin, David] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Friebert, Sarah] Akron Childrens Hosp, Akron, OH USA. [Kearney, Julia] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Kupst, Mary Jo] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Madan-Swain, Avi] Univ Alabama Birmingham, Birmingham, AL USA. [Mullins, Larry] Oklahoma State Univ, Stillwater, OK 74078 USA. [Phipps, Sean] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 30 EP 31 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700052 ER PT J AU Wiener, L Loucas, C Pelletier, W Battles, H Vasserman-Stokes, E Zadeh, S Muriel, A AF Wiener, Lori Loucas, Caitlyn Pelletier, Wendy Battles, Haven Vasserman-Stokes, Elaina Zadeh, Sima Muriel, Anna TI Parental Dyadic Adjustment in the Face of Childhood Cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Wiener, Lori; Battles, Haven; Vasserman-Stokes, Elaina; Zadeh, Sima] NCI, NIH, Bethesda, MD 20892 USA. [Loucas, Caitlyn; Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pelletier, Wendy] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 40 EP 41 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700071 ER PT J AU Trevino, K Abbott, C Fisch, M Friedlander, R Duberstein, P Prigerson, H AF Trevino, Kelly Abbott, Caroline Fisch, Michael Friedlander, Robert Duberstein, Paul Prigerson, Holly TI Patient-Oncologist Alliance as Protection Against Suicidal Ideation in Young Adults With Advanced Cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Trevino, Kelly] Rowan Univ, Glassboro, NJ USA. [Abbott, Caroline; Prigerson, Holly] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fisch, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Friedlander, Robert] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Duberstein, Paul] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 52 EP 53 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700093 ER PT J AU Irwin, K Knight, H Pirl, W AF Irwin, Kelly Knight, Helen Pirl, William TI Providing Quality Breast Cancer Care to Individuals With Schizophrenia: Barriers and Facilitators SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Irwin, Kelly; Knight, Helen; Pirl, William] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Pirl, William] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 58 EP 59 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700103 ER PT J AU Cooley, M Nayak, M Lobach, D Abrahm, J Rabin, M Halpenny, B Pimentel, SO Finn, K Berry, D AF Cooley, Mary Nayak, Manan Lobach, David Abrahm, Janet Rabin, Michael Halpenny, Barbara Pimentel, Sindy Ortiz Finn, Kathleen Berry, Donna TI Evaluation of a Coordinated Symptom Assessment and Management Intervention System for Patients With Lung Cancer: Patient Perspectives SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Cooley, Mary; Nayak, Manan; Abrahm, Janet; Rabin, Michael; Halpenny, Barbara; Pimentel, Sindy Ortiz; Berry, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cooley, Mary; Nayak, Manan] Univ Massachusetts, Boston, MA 02125 USA. [Lobach, David] Duke Univ, Med Ctr, Durham, NC USA. [Finn, Kathleen] Boston Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 59 EP 60 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700104 ER PT J AU Tofthagen, C Loy, I Passmore, D Berrry, D AF Tofthagen, Cindy Loy, Ian Passmore, Denise Berrry, Donna TI Usability and Acceptability of a Web-Based Program for Chemotherapy-Induced Peripheral Neuropathy SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Tofthagen, Cindy; Loy, Ian; Passmore, Denise] Univ S Florida, Tampa, FL USA. [Berrry, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 60 EP 61 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700106 ER PT J AU Moore, C Muriel, A Rauch, P AF Moore, Cynthia Muriel, Anna Rauch, Paula TI An Assessment of Parenting Concerns in Adults With Cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Moore, Cynthia; Rauch, Paula] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 63 EP 63 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700111 ER PT J AU Carrion, I Nedjat-Haiem, F Estrada, LF AF Carrion, Iraida Nedjat-Haiem, Frances Estrada, Lucia Franco TI Understanding Factors That Facilitate Treatment Decisions Among Latinos With Cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Carrion, Iraida; Estrada, Lucia Franco] Univ S Florida, Tampa, FL 33620 USA. [Nedjat-Haiem, Frances] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 77 EP 77 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700136 ER PT J AU Muriel, A Whitley, K Duncan, C AF Muriel, Anna Whitley, Katherine Duncan, Christine TI Psychopharmacology in Pediatric Stem Cell Transplant: Identifying a Vulnerable Population SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Muriel, Anna; Whitley, Katherine; Duncan, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 86 EP 86 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700153 ER PT J AU Muriel, A Moore, C Park, E Rauch, P AF Muriel, Anna Moore, Cynthia Park, Elyse Rauch, Paula TI What Do Children Wish for From a Dying Parent? A Qualitative Exploration SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Moore, Cynthia; Park, Elyse; Rauch, Paula] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 107 EP 108 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700190 ER PT J AU Loucas, C Muriel, A Zadeh, S Pelletier, W Battles, H Vasserman-Stokes, E Wiener, L AF Loucas, Caitlyn Muriel, Anna Zadeh, Sima Pelletier, Wendy Battles, Haven Vasserman-Stokes, Elaina Wiener, Lori TI He Loves Me, She Loves Me Not: Self-Reports of Parental Marital Stress and Closeness During Pediatric Cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Loucas, Caitlyn; Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zadeh, Sima; Battles, Haven; Vasserman-Stokes, Elaina; Wiener, Lori] NIH, Bethesda, MD 20892 USA. [Pelletier, Wendy] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 108 EP 108 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700191 ER PT J AU Zabora, J Buzaglo, J Kennedy, V Richards, T Schapmire, T Zebrack, B Ghobrial, I AF Zabora, James Buzaglo, Joanne Kennedy, Vicki Richards, Tiffany Schapmire, Tara Zebrack, Brad Ghobrial, Irene TI Linking Psychosocial Care to the Disease Continuum in Patients With Multiple Myeloma and Their Family Caregivers SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Zabora, James] Inova Hlth Syst, Life Canc, Fairfax, VA USA. [Buzaglo, Joanne; Kennedy, Vicki] Canc Support Community, Washington, DC USA. [Richards, Tiffany] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Schapmire, Tara] Univ Louisville, Sch Med, Louisville, KY 40292 USA. [Zebrack, Brad] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA. [Ghobrial, Irene] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 110 EP 111 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700196 ER PT J AU Fujisawa, D Fujimori, M Basaki-Tange, A Umezawa, S Ueda-Nouno, J Adachi, A Hisamura, K Suzuki, Y Miyashita, M AF Fujisawa, Daisuke Fujimori, Maiko Basaki-Tange, Ado Umezawa, Shino Ueda-Nouno, Junko Adachi, Akiko Hisamura, Kazuho Suzuki, Yuriko Miyashita, Mitsunori TI Perceived Stigma and Social Discrimination Among Cancer Survivors in Japan - A Web-Based Survey SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Fujisawa, Daisuke] Massachusetts Gen Hosp, Ctr Psychiat Oncol & Behav Sci, Boston, MA 02114 USA. [Fujisawa, Daisuke; Adachi, Akiko] Keio Univ, Sch Med, Palliat Care Ctr, Tokyo, Japan. [Fujimori, Maiko; Basaki-Tange, Ado; Umezawa, Shino; Ueda-Nouno, Junko] Natl Canc Ctr East, Psychooncol Div, Kashiwa, Chiba, Japan. [Fujimori, Maiko; Suzuki, Yuriko] Natl Ctr Neurol & Psychiat, Tokyo, Japan. [Umezawa, Shino] Tokyo Med & Dent Univ, Sect Liaison Psychiat & Palliat Med, Tokyo, Japan. [Hisamura, Kazuho] Komatsu Municipal Hosp, Komatsu, Ishikawa, Japan. [Miyashita, Mitsunori] Tohoku Univ, Dept Palliat Care Nursing, Sendai, Miyagi 980, Japan. NR 0 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 126 EP 127 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700224 ER PT J AU Hyland, K Lennes, I Pirl, W Smith, K Park, E AF Hyland, Kelly Lennes, Inga Pirl, William Smith, Kelly Park, Elyse TI Cancer Survivors' Adherence to the American Cancer Society Post-treatment Health and Wellness Guidelines SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Hyland, Kelly; Lennes, Inga; Pirl, William; Park, Elyse] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smith, Kelly] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 1M9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 128 EP 129 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700227 ER PT J AU Park, E Kirchhoff, A Perez-Lougee, G Leisenring, W Weissman, J Donelan, K Mertens, A Reschovsky, J Armstrong, G Robison, L Diller, L Recklitis, C Kuhlthau, K AF Park, Elyse Kirchhoff, Anne Perez-Lougee, Giselle Leisenring, Wendy Weissman, Joel Donelan, Karen Mertens, Ann Reschovsky, Jim Armstrong, Gregory Robison, Leslie Diller, Lisa Recklitis, Christopher Kuhlthau, Karen TI Childhood Cancer Survivor Study Participants' Familiarity With the Affordable Care Act SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Park, Elyse; Perez-Lougee, Giselle; Donelan, Karen; Kuhlthau, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kirchhoff, Anne] Huntsman Canc Inst, Salt Lake City, UT USA. [Leisenring, Wendy] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Weissman, Joel] Brigham & Womens Hosp, Boston, MA 02115 USA. [Mertens, Ann] Emory Univ, Sch Med, Atlanta, GA USA. [Reschovsky, Jim] Ctr Studying Hlth Syst Change, Washington, DC USA. [Armstrong, Gregory; Robison, Leslie] St Jude Childrens Res, Memphis, TN USA. [Diller, Lisa; Recklitis, Christopher] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 133 EP 133 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700234 ER PT J AU Eusebio, J Hyland, K Lennes, I Kumar, P Temel, J Pirl, W Park, E AF Eusebio, Justin Hyland, Kelly Lennes, Inga Kumar, Pallavi Temel, Jennifer Pirl, William Park, Elyse TI Pulmonary Nodule and Lung Screening: An Opportunity for Smoking Cessation Intervention SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Eusebio, Justin; Hyland, Kelly; Lennes, Inga; Kumar, Pallavi; Temel, Jennifer; Pirl, William; Park, Elyse] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Pirl, William; Park, Elyse] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 135 EP 136 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700239 ER PT J AU Heringa, SM van den Berg, E Reijmer, YD Nijpels, G Stehouwer, CDA Schalkwijk, CG Teerlink, T Scheffer, PG van den Hurk, K Kappelle, LJ Dekker, JM Biessels, GJ AF Heringa, S. M. van den Berg, E. Reijmer, Y. D. Nijpels, G. Stehouwer, C. D. A. Schalkwijk, C. G. Teerlink, T. Scheffer, P. G. van den Hurk, K. Kappelle, L. J. Dekker, J. M. Biessels, G. J. TI Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the Hoorn Study SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Low-grade inflammation; Endothelial dysfunction; Cognitive functioning; Vascular risk factors; Cardiovascular disease ID C-REACTIVE PROTEIN; VASCULAR DEMENTIA; COGNITIVE DECLINE; GENERAL-POPULATION; ALZHEIMERS-DISEASE; METABOLIC SYNDROME; DIABETES-MELLITUS; RISK-FACTORS; ASSOCIATION; DEPRESSION AB Low-grade inflammation and endothelial dysfunction are related to cognitive decline and dementia, in a complex interplay with vascular factors and aging. We investigated, in an older population, low-grade inflammation and endothelial dysfunction in relation to detailed assessment of cognitive functioning. Furthermore, we explored this association within the context of vascular factors. 377 participants (73 +/- 6 years) of the population-based Hoorn Study were included. In plasma samples of 2000-2001 (n = 363) and/or 2005-2008 (n = 323), biomarkers were determined of low-grade inflammation (CRP, TNF-alpha, IL-6, IL-8, SAA, MPO, and sICAM-1) and endothelial dysfunction (vWF, sICAM-1, sVCAM-1, sTM, sE-selectin). In 2005-2008, all participants underwent neuropsychological examination. Composite z-scores were computed for low-grade inflammation and endothelial dysfunction at both time points, and for six domains of cognitive functioning (abstract reasoning, memory, information processing speed, attention and executive functioning, visuoconstruction, and language). The association between low-grade inflammation and endothelial dysfunction, and cognitive functioning was evaluated with linear regression analysis. In secondary analyses, we explored the relation with vascular risk factors and cardiovascular disease. Low-grade inflammation and endothelial dysfunction were associated with worse performance on information processing speed and attention and executive functioning, in prospective and cross-sectional analyses (standardized betas ranging from -0.20 to -0.10). No significant relation with other cognitive domains was observed. Adjusting for vascular factors slightly attenuated the associations. Low-grade inflammation and endothelial dysfunction accounted for only 2.6% explained variance in cognitive functioning, on top of related vascular risk factors and cardiovascular disease. Bootstrapping analyses show that low-grade inflammation and endothelial dysfunction mediate the relation between vascular risk factors and cognitive functioning. This study shows that low-grade inflammation and endothelial dysfunction contribute to reduced information processing speed and executive functioning in an older population. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Heringa, S. M.; van den Berg, E.; Kappelle, L. J.; Biessels, G. J.] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, NL-3508 GA Utrecht, Netherlands. [van den Berg, E.] Univ Utrecht, Helmholtz Inst, Dept Expt Psychol, Utrecht, Netherlands. [Reijmer, Y. D.] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA. [Nijpels, G.; Dekker, J. M.] Vrije Univ Amsterdam, Med Ctr, Inst Res Extramural Med, EMGO Inst, Amsterdam, Netherlands. [Nijpels, G.] Vrije Univ Amsterdam, Med Ctr, Dept Gen Practice, Amsterdam, Netherlands. [Stehouwer, C. D. A.; Schalkwijk, C. G.] Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands. [Stehouwer, C. D. A.; Schalkwijk, C. G.] Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands. [Teerlink, T.; Scheffer, P. G.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Amsterdam, Netherlands. [van den Hurk, K.] Sanquin Blood Supply, Dept Donor Studies, Amsterdam, Netherlands. RP Heringa, SM (reprint author), Univ Med Ctr Utrecht, Dept Neurol, G03-232,POB 85500, NL-3508 GA Utrecht, Netherlands. EM s.m.heringa@umcutrecht.nl FU Dutch Diabetes Research Foundation [2003.01.004]; Netherlands Heart Foundation [2010T073]; Internationale Stichting Alzheimer Onderzoek (ISAO) [10506] FX The research of GJB is supported by grant 2003.01.004 of the Dutch Diabetes Research Foundation and grant 2010T073 from the Netherlands Heart Foundation. SMH is supported by a Internationale Stichting Alzheimer Onderzoek (ISAO) grant 10506. The authors have no relevant conflict of interest. NR 53 TC 18 Z9 18 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD FEB PY 2014 VL 40 BP 108 EP 118 DI 10.1016/j.psyneuen.2013.11.011 PG 11 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA AB6TB UT WOS:000331921300013 PM 24485482 ER PT J AU Golier, JA Caramanica, K Makotkine, L Sher, L Yehuda, R AF Golier, Julia A. Caramanica, Kimberly Makotkine, Louri Sher, Leo Yehuda, Rachel TI Cortisol response to cosyntropin administration in military veterans with or without posttraumatic stress disorder SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Post-traumatic stress disorder (PTSD); Veterans; Cosyntropin; Cortisol; ACTH ID CORTICOTROPIN-RELEASING HORMONE; CHILDHOOD ABUSE; MAJOR DEPRESSION; GULF-WAR; PTSD; STIMULATION; SENSITIVITY; SUPPRESSION; HYDROCORTISONE; CHALLENGE AB Studies have demonstrated altered sensitivity of the hypothalamic-pituitary-adrenal (HPA) axis to its direct regulators in veterans with posttraumatic stress disorder (PTSD), but little is known about the adrenal response to hormonal stimulation in PTSD. An increased cortisol response to synthetic corticotropin-releasing factor (CRF) was recently found to be associated with war-zone deployment and not PTSD specifically. To more accurately assess whether there is altered adrenocortical responsivity to hormonal stimulation in relation to war-zone deployment or PTSD, we performed the low-dose cosyntropin stimulation test in a sample of 45 male veterans: 13 war-zone exposed veterans with chronic PTSD (PTSD+), 22 war-zone exposed veterans without chronic PTSD (PTSD-), and 10 veterans not exposed to a war-zone and without chronic PTSD (nonexposed). Plasma cortisol and ACTH were measured at baseline and at intervals over a one hour period following intravenous administration of 1 mu g of cosyntropin. A significant main effect of group (PTSD+, PTSD-, non-exposed) on the cortisol response to cosyntropin was observed. Cosyntropin-stimulated plasma cortisol levels were significantly higher in the PTSD+ and PTSD-groups compared to the non-exposed group. A significant main effect of group was also observed on peak cortisol levels. These findings suggest that war-zone exposure itself has persistent effects on adrenocortical activity. Published by Elsevier Ltd. C1 [Golier, Julia A.; Caramanica, Kimberly; Makotkine, Louri; Sher, Leo; Yehuda, Rachel] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. [Golier, Julia A.; Makotkine, Louri; Sher, Leo; Yehuda, Rachel] Mt Sinai Hosp, New York, NY USA. RP Golier, JA (reprint author), James J Peters VA Med Ctr, OOMH 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM julia.golier@va.gov FU VA MERIT award; National Institute of Health (NIH) [5 M01 RR00071] FX Funding for this study was provided by a VA MERIT award to Dr. Golier and by a grant (5 M01 RR00071) for the Mount Sinai General Clinical Research Center from the National Institute of Health (NIH). The VA and NIH had no further rote in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. NR 30 TC 2 Z9 3 U1 3 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD FEB PY 2014 VL 40 BP 151 EP 158 DI 10.1016/j.psyneuen.2013.10.020 PG 8 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA AB6TB UT WOS:000331921300018 PM 24485487 ER PT J AU Lehrner, A Bierer, LM Passarelli, V Pratchett, LC Flory, JD Bader, HN Harris, IR Bedi, A Daskalakis, NP Makotkine, I Yehuda, R AF Lehrner, Amy Bierer, Linda M. Passarelli, Vincent Pratchett, Laura C. Flory, Janine D. Bader, Heather N. Harris, Iris R. Bedi, Aarti Daskalakis, Nikolaos P. Makotkine, Iouri Yehuda, Rachel TI Maternal PTSD associates with greater glucocorticoid sensitivity in offspring of Holocaust survivors SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE PTSD; Risk factor; Glucocorticoid receptor; Cortisol; Dexamethasone suppression test; Intergenerational; Holocaust; Trauma ID POSTTRAUMATIC-STRESS-DISORDER; PERIPHERAL MONONUCLEAR LEUKOCYTES; PARENTAL PTSD; RECEPTOR RESPONSE; CHILDHOOD TRAUMA; LOW CORTISOL; DEPRESSION; DEXAMETHASONE; RISK; VULNERABILITY AB Intergenerational effects of trauma have been observed clinically in a wide range of populations, and parental PTSD has been associated with an increased risk for psychopathology in offspring. In studies of Holocaust survivor offspring, parental PTSD, and particularly maternal PTSD, has been associated with increased risk for PTSD, low basal urinary cortisol excretion and enhanced cortisol suppression in response to dexamethasone. Such findings implicate maternally derived glucocorticoid programming in the intergenerational transmission of trauma-related consequences, potentially resulting from in utero influences or early life experiences. This study investigated the relative influence of Holocaust exposure and PTSD in mothers and fathers on glucocorticoid sensitivity in offspring. Eighty Holocaust offspring and 15 offspring of non-exposed Jewish parents completed evaluations and provided blood and urine samples. Glucocorticoid sensitivity was evaluated using the lysozyme suppression test (LST), an in vitro measure of glucocorticoid receptor sensitivity in a peripheral tissue, the dexamethasone suppression test (DST), and 24-h urinary cortisol excretion. Maternal PTSD was associated with greater glucocorticoid sensitivity in offspring across all three measures of glucocorticoid function. An interaction of maternal and paternal PTSD on the DST and 24-h urinary cortisol showed an effect of decreased glucocorticoid sensitivity in offspring with paternal, but not maternal, PTSD. Although indirect, these findings are consistent with the hypothesis that epigenetic programming may be involved in the intergenerational transmission of trauma-related effects on glucocorticoid regulation. Published by Elsevier Ltd. C1 [Lehrner, Amy; Bierer, Linda M.; Passarelli, Vincent; Pratchett, Laura C.; Flory, Janine D.; Harris, Iris R.; Daskalakis, Nikolaos P.; Makotkine, Iouri; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, PTSD Program, Bronx, NY 10468 USA. [Bierer, Linda M.; Pratchett, Laura C.; Flory, Janine D.; Bader, Heather N.; Bedi, Aarti; Daskalakis, Nikolaos P.; Makotkine, Iouri; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. RP Lehrner, A (reprint author), James J Peters Vet Affairs Med Ctr, PTSD Program, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM amy.lehrner@va.gov RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 FU Identification of an Epigenetic Risk Marker for PTSD [1RC1MH088101-01]; National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1TR000067] FX This work was supported by 1RC1MH088101-01 "Identification of an Epigenetic Risk Marker for PTSD" and Grant Number #UL1TR000067 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The NIMH and NIH had no further role in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication. NR 48 TC 23 Z9 23 U1 6 U2 27 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD FEB PY 2014 VL 40 BP 213 EP 220 DI 10.1016/j.psyneuen.2013.11.019 PG 8 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA AB6TB UT WOS:000331921300024 PM 24485493 ER PT J AU Choy, E Jacobs, IA AF Choy, Edwin Jacobs, Ira Allen TI Biosimilar Safety Considerations in Clinical Practice SO SEMINARS IN ONCOLOGY LA English DT Review ID CHALLENGE; IMMUNOGENICITY; ARTHRITIS; PRODUCTS; SCIENCE AB Biologics are important treatments for a number of cancers. Patents for several biologics will expire over the next decade, removing a barrier to the development and commercialization of biosimilars. As biologics differ from small-molecule drugs due to their size and complexity, multifaceted manufacturing process, and their potential for immunogenicity, biosimilars cannot be considered "generic versions" of currently approved biologics. In highly regulated markets, biosimilars can be authorized only if they are demonstrated to be highly similar to the original drug from an analytical and clinical perspective. Any differences must be justified and shown to have no clinically meaningful effect on the safety and efficacy of the biosimilar The European Medicines Agency has approved a number of biosimilars and the recent approval of the biosimilar inffiximab monoclonal antibody is another regulatory milestone. This article will provide context regarding key safety issues addressed in biosimilar development, approval, and delivery, as well as inform oncologists on matters of safety to consider when prescribing biosimilars. Pertinent issues about safety from countries or regions where biosimilars are currently in use also will be reviewed. (C) 2014 Elsevier Inc. All rights reserved. C1 [Choy, Edwin] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Jacobs, Ira Allen] Pfizer Emerging Markets Established Prod Med Dev, New York, NY USA. RP Choy, E (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM echoy@partners.org FU Pfizer Inc. FX This supplement was funded by Pfizer Inc. NR 42 TC 7 Z9 9 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0093-7754 EI 1532-8708 J9 SEMIN ONCOL JI Semin. Oncol. PD FEB PY 2014 VL 41 IS 1 SU 1 BP S3 EP S14 DI 10.1053/j.seminoncol.2013.12.001 PG 12 WC Oncology SC Oncology GA AC2PU UT WOS:000332347200002 PM 24560025 ER PT J AU Hall, MR McGillicuddy, E Kaplan, LJ AF Hall, Michael R. McGillicuddy, Edward Kaplan, Lewis J. TI Biofilm: Basic Principles, Pathophysiology, and Implications for Clinicians SO SURGICAL INFECTIONS LA English DT Article ID PSEUDOMONAS-AERUGINOSA BIOFILMS; BACTERIAL BIOFILMS; PHYSIOLOGICAL HETEROGENEITY; HELICOBACTER-PYLORI; RANDOMIZED-TRIAL; PERSISTER CELLS; INFECTIONS; ANTIBIOTICS; SURVIVAL; COMMUNITIES AB Background: Biofilm is ubiquitous throughout nature including bacteria, fungi, protozoa-associated bacteriophages, and viruses. Whereas it is adaptive for certain organisms in a variety of environments, biofilm is important in understanding and treating clinically relevant infections, especially those involving temporarily or durably implanted devices. Methods: Review of pertinent English-language literature. Results: Important advances have been made in understanding biofilm structure and function that elucidate key events in biofilm-based infectious processes. Wounds, oral cavity, urinary tract, gastrointestinal tract, and device-associated biofilm-based infections dominate clinically relevant infections. Criteria have been articulated to detect and diagnose biofilm-associated infection but there are hurdles to overcome to treat effectively such infection. Native biofilm resistance mechanisms as well as incompletely effective human immune system responses impede successful infection resolution. Biofilm-appropriate education appears under-represented in standardized surgical education curriculum. Conclusion: Several potential methods of enabling primary prevention as well as treatment of biofilm-associated infection are on the near horizon. There is an opportunity to enhance surgical education regarding biofilm prevention, diagnosis, and therapy. C1 [Hall, Michael R.; McGillicuddy, Edward] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Kaplan, LJ (reprint author), Philadelphia VAMC, Surg Serv, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Lewis.Kaplan@va.gov NR 60 TC 24 Z9 24 U1 3 U2 22 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 EI 1557-8674 J9 SURG INFECT JI Surg. Infect. PD FEB 1 PY 2014 VL 15 IS 1 BP 1 EP 7 DI 10.1089/sur.2012.129 PG 7 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA AA9BE UT WOS:000331387900001 PM 24476019 ER PT J AU Stange, JP Sylvia, LG Magalhaes, PVD Miklowitz, DJ Otto, MW Frank, E Berk, M Hansen, NS Dougherty, DD Nierenberg, AA Deckersbach, T AF Stange, Jonathan P. Sylvia, Louisa G. da Silva Magalhaes, Pedro Vieira Miklowitz, David J. Otto, Michael W. Frank, Ellen Berk, Michael Hansen, Natasha S. Dougherty, Darin D. Nierenberg, Andrew A. Deckersbach, Thilo TI Extreme attributions predict suicidal ideation and suicide attempts in bipolar disorder: prospective data from STEP-BD SO WORLD PSYCHIATRY LA English DT Letter ID DEPRESSION; TRIAL; STYLE C1 [Stange, Jonathan P.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. [Sylvia, Louisa G.; Hansen, Natasha S.; Dougherty, Darin D.; Nierenberg, Andrew A.; Deckersbach, Thilo] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Sylvia, Louisa G.; Hansen, Natasha S.; Dougherty, Darin D.; Nierenberg, Andrew A.; Deckersbach, Thilo] Harvard Univ, Sch Med, Boston, MA USA. [da Silva Magalhaes, Pedro Vieira] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Natl Inst Translat Med, BR-90046900 Porto Alegre, RS, Brazil. [Miklowitz, David J.] UCLA Sch Med, Div Child & Adolescent Psychiat, Los Angeles, CA USA. [Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Frank, Ellen] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Berk, Michael] Deakin Univ, Sch Med, Geelong, Vic 3217, Australia. [Berk, Michael] Univ Melbourne, Orygen Youth Hlth Res Ctr, Parkville, Vic 3052, Australia. [Berk, Michael] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia. RP Stange, JP (reprint author), Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. RI Magalhaes, Pedro/A-8519-2008; OI Magalhaes, Pedro/0000-0002-5644-6357; Miklowitz, David/0000-0002-9647-6147; Berk, Michael/0000-0002-5554-6946 FU NIMH NIH HHS [R01 MH093676] NR 10 TC 6 Z9 6 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1723-8617 EI 2051-5545 J9 WORLD PSYCHIATRY JI World Psychiatry PD FEB PY 2014 VL 13 IS 1 BP 95 EP 96 DI 10.1002/wps.20093 PG 2 WC Psychiatry SC Psychiatry GA AA6YA UT WOS:000331242900026 PM 24497260 ER PT J AU Ullrich, PM Sahay, A Stetler, CB AF Ullrich, Philip M. Sahay, Anju Stetler, Cheryl B. TI Use of Implementation Theory: A Focus on PARIHS SO WORLDVIEWS ON EVIDENCE-BASED NURSING LA English DT Article DE PARIHS; implementation; theory; health services; framework; evidence; context; facilitation; translation; effectiveness ID QUALITATIVE CONTENT-ANALYSIS; CONCEPTUAL-FRAMEWORK; INTERVENTIONS; STRATEGIES; MODELS AB BackgroundLimited understanding and application of theory in implementation research contributes to variable effectiveness of implementation studies. Better understanding of direct experiences with theory could improve implementation research and the potency of interventions. AimsThis study was a conceptual exercise aimed at characterizing experiences with and applications of the Promoting Action on Research Implementation in Health Services (PARIHS) framework. MethodsThis was a structured, qualitative study involving document reviews and interviews used to answer the following overarching questions about nine implementation research centers: Why and how was PARIHS used? What strengths and weaknesses were identified for PARIHS? FindingsPARIHS was being used for varied purposes, at varied levels, in varied ways, and to a varying extent within and across centers. Lack of implementation theory use in investigators' early years was common. Variability in the nature of theory use was attributable to characteristics of the centers, individual investigators, and features of PARIHS. Strengths and weaknesses of the PARIHS framework were identified. Linking Evidence to ActionThe study provides information to researchers and theorists about the use of one well-known implementation framework. The information suggests areas for improvements in PARIHS as well as theory use in general, and should assist in the development of theory-based programs of research. C1 [Ullrich, Philip M.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury QUERI, Seattle, WA 98108 USA. [Sahay, Anju] VA Palo Alto Hlth Care Syst, Chron Heart Failure QUERI Ctr, Palo Alto, CA USA. [Stetler, Cheryl B.] Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA USA. RP Ullrich, PM (reprint author), VA Puget Sound Hlth Care Syst, Spinal Cord Injury QUERI, 1600 S Columbian Way, Seattle, WA 98108 USA. EM philip.ullrich@va.gov FU U.S. Department of Veterans Affairs, Office of Research, and Development Health Services RD Program FX This material is based upon work supported by the U.S. Department of Veterans Affairs, Office of Research, and Development Health Services R&D Program. We wish to acknowledge the important contributions of Jeffrey Smith to the paper. The views expressed in this article are the authors' and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 25 TC 5 Z9 6 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-102X EI 1741-6787 J9 WORLDV EVID-BASED NU JI Worldviews Evid.-Based Nurs. PD FEB PY 2014 VL 11 IS 1 BP 26 EP 34 DI 10.1111/wvn.12016 PG 9 WC Nursing SC Nursing GA AB3OV UT WOS:000331701000004 PM 24103045 ER PT J AU Rebets, Y Lupoli, T Qiao, Y Schirner, K Villet, R Hooper, D Kahne, D Walker, S AF Rebets, Yuriy Lupoli, Tania Qiao, Yuan Schirner, Kathrin Villet, Regis Hooper, David Kahne, Daniel Walker, Suzanne TI Moenomycin Resistance Mutations in Staphylococcus aureus Reduce Peptidoglycan Chain Length and Cause Aberrant Cell Division SO ACS CHEMICAL BIOLOGY LA English DT Article ID MONOFUNCTIONAL GLYCOSYLTRANSFERASE; KINETIC CHARACTERIZATION; TRANSGLYCOSYLATION STEP; STRUCTURAL-ANALYSIS; ESCHERICHIA-COLI; WALL SYNTHESIS; BIOSYNTHESIS; STRAINS; PBP2; ARCHITECTURE AB Staphylococcus aureus is a Gram-positive pathogen with an unusual mode of cell division in that it divides in orthogonal rather than parallel planes. Through selection using moenomycin, an antibiotic proposed to target peptidoglycan glycosyltransferases (PGTs), we have generated resistant mutants containing a single point mutation in the active site of the PGT domain of an essential peptidoglycan (PG) biosynthetic enzyme, PBP2. Using cell free polymerization assays, we show that this mutation alters PGT activity so that much shorter PG chains are made. The same mutation in another S. aureus PGT, SgtB, has a similar effect on glycan chain length. Moenomycin-resistant S. aureus strains containing mutated PGTs that make only short glycan polymers display major cell division defects, implicating PG chain length in determining bacterial cell morphology and division site placement. C1 [Rebets, Yuriy; Lupoli, Tania; Qiao, Yuan; Schirner, Kathrin; Walker, Suzanne] Harvard Univ, Sch Med, Dept Immunol & Microbiol, Boston, MA 02115 USA. [Lupoli, Tania; Qiao, Yuan; Kahne, Daniel] Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA. [Villet, Regis; Hooper, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis & Med Serv, Boston, MA 02114 USA. RP Walker, S (reprint author), Harvard Univ, Sch Med, Dept Immunol & Microbiol, Boston, MA 02115 USA. EM suzanne_walker@hms.harvard.edu FU National Institutes of Health [GM076710]; Harvard-Wide Antibiotic Resistance Program [AI083214]; NERCE [AI057159]; Agency for Science, Technology and Research (A*STAR) of Singapore; Deutsche Forschungsgemeinschaft (DFG) FX This research was supported by the National Institutes of Health (GM076710), the Harvard-Wide Antibiotic Resistance Program (AI083214), and NERCE (AI057159). Y.Q, gratefully acknowledges Agency for Science, Technology and Research (A*STAR) of Singapore for a Ph.D. scholarship. K.S. gratefully acknowledges the Deutsche Forschungsgemeinschaft (DFG) for a research fellowship. We would like to thank M. Lazarus for assistance with generating PyMOL images. NR 51 TC 9 Z9 9 U1 2 U2 20 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD FEB PY 2014 VL 9 IS 2 BP 459 EP 467 DI 10.1021/cb4006744 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AB6VG UT WOS:000331927000020 PM 24255971 ER PT J AU Merchant, FM Sayadi, O Puppala, D Moazzami, K Heller, V Armoundas, AA AF Merchant, Faisal M. Sayadi, Omid Puppala, Dheeraj Moazzami, Kasra Heller, Victoria Armoundas, Antonis A. TI A translational approach to probe the proarrhythmic potential of cardiac alternans: a reversible overture to arrhythmogenesis? SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Review DE cardiac alternans; sudden cardiac death; ventricular tachycardia; ventricular fibrillation ID T-WAVE ALTERNANS; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; POSTMYOCARDIAL INFARCTION PATIENTS; RETICULUM CA2+ RELEASE; ISOLATED RABBIT HEARTS; REPOLARIZATION ALTERNANS; SARCOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; RYANODINE RECEPTOR; INTRACELLULAR CALCIUM AB Electrocardiographic alternans, a phenomenon of beat-to-beat alternation in cardiac electrical waveforms, has been implicated in the pathogenesis of ventricular arrhythmias and sudden cardiac death (SCD). In the clinical setting, a positive microvolt T-wave alternans test has been associated with a heightened risk of arrhythmic mortality and SCD during medium- and long-term follow-up. However, rather than merely being associated with an increased risk for SCD, several lines of preclinical and clinical evidence suggest that cardiac alternans may play a causative role in generating the acute electrophysiological substrate necessary for the onset of ventricular arrhythmias. Deficiencies in Ca2+ transport processes have been implicated in the genesis of alternans at the subcellular and cellular level and are hypothesized to contribute to the conditions necessary for dispersion of refractoriness, wave break, reentry, and onset of arrhythmia. As such, detecting acute surges in alternans may provide a mechanism for predicting the impending onset of arrhythmia and opens the door to delivering upstream antiarrhythmic therapies. In this review, we discuss the preclinical and clinical evidence to support a causative association between alternans and acute arrhythmogenesis and outline the potential clinical implications of such an association. C1 [Merchant, Faisal M.] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA. [Sayadi, Omid; Puppala, Dheeraj; Moazzami, Kasra; Heller, Victoria; Armoundas, Antonis A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. RP Armoundas, AA (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA. EM aarmoundas@partners.org OI Stary, Victoria/0000-0002-3854-9934 FU National Institute of Aging [1R21-AG-035128]; American Heart Association Founders Affiliate Postdoctoral Fellowship [12POST9310001]; Center for Integration of Medicine and Innovative Technology; Deane Institute for Integrative Research in Atrial Fibrillation and Stroke; Cardiovascular Research Society FX This work was supported by National Institute of Aging Grant 1R21-AG-035128 and American Heart Association Founders Affiliate Postdoctoral Fellowship 12POST9310001. This work was also supported by a fellowship and a science award from the Center for Integration of Medicine and Innovative Technology, the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke, and the Cardiovascular Research Society. NR 91 TC 2 Z9 2 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD FEB PY 2014 VL 306 IS 4 BP H465 EP H474 DI 10.1152/ajpheart.00639.2013 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA AB6JT UT WOS:000331895000001 PM 24322612 ER PT J AU Pieretti, AC Ahmed, AM Roberts, JD Kelleher, CM AF Pieretti, Alberto C. Ahmed, Alwiya M. Roberts, Jesse D., Jr. Kelleher, Cassandra M. TI A Novel In Vitro Model to Study Alveologenesis SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE alveolarization; secondary septation; postnatal lung growth; organ culture ID SMOOTH-MUSCLE-CELLS; FETAL-RAT LUNG; BRONCHOPULMONARY DYSPLASIA; BRANCHING MORPHOGENESIS; MOUSE LUNG; GROWTH; PROLIFERATION; DISEASE; CULTURE; DIFFERENTIATION AB Many pediatric pulmonary diseases are associated with significant morbidity and mortality due to impairment of alveolar development. The lack of an appropriate in vitro model system limits the identification of therapies aimed at improving alveolarization. Herein, we characterize an ex vivo lung culture model that facilitates investigation of signaling pathways that influence alveolar septation. Postnatal Day 4 (P4) mouse pup lungs were inflated with 0.4% agarose, sliced, and cultured within a collagen matrix in medium that was optimized to support cell proliferation and promote septation. Lung slices were grown with and without 1D11, an active transforming growth factor-beta-neutralizing antibody. After 4 days, the lung sections (designated P4 + 4) and noncultured lung sections were examined using quantitative morphometry to assess alveolar septation and immunohistochemistry to evaluate cell proliferation and differentiation. We observed that the P4 + 4 lung sections exhibited ex vivo alveolarization, as evidenced by an increase in septal density, thinning of septal walls, and a decrease in mean linear intercept comparable to P8, age-matched, uncultured lungs. Moreover, immunostaining showed ongoing cell proliferation and differentiation in cultured lungs that were similar to P8 controls. Cultured lungs exposed to 1D11 had a distinct phenotype of decreased septal density when compared with untreated P4 + 4 lungs, indicating the utility of investigating signaling in these lung slices. These results indicate that this novel lung culture system is optimized to permit the investigation of pathways involved in septation, and potentially the identification of therapeutic targets that enhance alveolarization. C1 [Ahmed, Alwiya M.; Kelleher, Cassandra M.] MassGen Hosp Children, Dept Pediat Surg, Boston, MA 02114 USA. [Pieretti, Alberto C.; Kelleher, Cassandra M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Roberts, Jesse D., Jr.] Massachusetts Gen Hosp, Dept Anesthesia, Boston, MA 02114 USA. [Roberts, Jesse D., Jr.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Roberts, Jesse D., Jr.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Kelleher, CM (reprint author), MassGen Hosp Children, Dept Pediat Surg, 55 Fruit St WRN 11, Boston, MA 02114 USA. EM ckelleher3@partners.org FU American Pediatric Surgical Association Foundation Grant; Landry Award for Neonatal Research; Eleanor and Miles Shore grant; Massachusetts General Hospital Department of Surgery; National Institutes of Health [HL094608] FX This work was supported by the American Pediatric Surgical Association Foundation Grant, the Landry Award for Neonatal Research, an Eleanor and Miles Shore grant (C.M.K.), the Massachusetts General Hospital Department of Surgery, and National Institutes of Health grant HL094608 (J.D.R.). NR 38 TC 6 Z9 6 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1044-1549 EI 1535-4989 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD FEB PY 2014 VL 50 IS 2 BP 459 EP 469 DI 10.1165/rcmb.2013-0056OC PG 11 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA AB4YJ UT WOS:000331795600021 PM 24066869 ER PT J AU Miller, CL Specht, MC Skolny, MN Horick, N Jammallo, LS O'Toole, J Shenouda, MN Sadek, BT Smith, BL Taghian, AG AF Miller, Cynthia L. Specht, Michelle C. Skolny, Melissa N. Horick, Nora Jammallo, Lauren S. O'Toole, Jean Shenouda, Mina N. Sadek, Betro T. Smith, Barbara L. Taghian, Alphonse G. TI Risk of lymphedema after mastectomy: potential benefit of applying ACOSOG Z0011 protocol to mastectomy patients SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Mastectomy; Lymphedema; Quality of life; Radiation therapy; Sentinel lymph node biopsy ID CANCER-RELATED LYMPHEDEMA; BREAST-CANCER; AXILLARY DISSECTION; NODE DISSECTION; ARM LYMPHEDEMA; POSTMASTECTOMY RADIATION; IRRADIATION; BIOPSY; THERAPY; WOMEN AB Axillary lymph node dissection (ALND) and radiation therapy (RT) are commonly recommended for mastectomy patients with positive sentinel lymph node biopsy (SLNB). Effective alternatives to ALND that reduce lymphedema risk are needed. We evaluated rates of lymphedema in mastectomy patients who received SLNB with RT, compared to ALND with or without RT. 627 breast cancer patients who underwent 664 mastectomies between 2005 and 2013 were prospectively screened for lymphedema, median 22.8 months follow-up (range 3.0-86.9). Each mastectomy was categorized as SLNB-no RT, SLNB + RT, ALND-no RT, or ALND + RT. RT included chest wall +/- A nodal radiation. Perometer arm volume measurements were obtained pre- and post-operatively. Lymphedema was defined as a parts per thousand yen10 % arm volume increase. Kaplan-Meier and Cox regression analyses were performed to determine lymphedema rates and risk factors. Of 664 mastectomies, 52 % (343/664) were SLNB-no RT, 5 % (34/664) SLNB + RT, 9 % (58/664) ALND-no RT, and 34 % (229/664) ALND + RT. The 2 year cumulative lymphedema incidence was 10.0 % (95 % CI 2.6-34.4 %) for SLNB + RT compared with 19.3 % (95 % CI 10.8-33.1 %) for ALND-no RT, and 30.1 % (95 % CI 23.7-37.8 %) for ALND + RT. The lowest cumulative incidence was 2.19 % (95 % CI 0.88-5.40 %) for SLNB-no RT. By multivariate analysis, factors significantly associated with increased lymphedema risk included RT (p = 0.0017), ALND (p = 0.0001), greater number of lymph nodes removed (p = 0.0006), no reconstruction (p = 0.0418), higher BMI (p < 0.0001) and older age (p = 0.0021). In conclusion, avoiding completion ALND and instead receiving SLNB with RT may decrease lymphedema risk in patients requiring mastectomy. Future trials should investigate the safety of applying the ACOSOG Z0011 protocol to mastectomy patients. C1 [Miller, Cynthia L.; Skolny, Melissa N.; Jammallo, Lauren S.; Shenouda, Mina N.; Sadek, Betro T.; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Specht, Michelle C.; Smith, Barbara L.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. [Horick, Nora] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. [O'Toole, Jean] Massachusetts Gen Hosp, Dept Phys & Occupat Therapy, Boston, MA 02114 USA. RP Taghian, AG (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St, Boston, MA 02114 USA. EM ataghian@partners.org RI Sadek, Betro/I-7734-2013 OI Sadek, Betro/0000-0003-0119-7207 FU National Cancer Institute [R01CA139118, P50CA089393]; Adele McKinnon fund for the Lymphedema Research Program at Massachusetts General Hospital FX This project was supported by Award R01CA139118 (AGT) and Award P50CA089393 (AGT) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institutes of Health. In addition, this work was partially supported by the Adele McKinnon fund for the Lymphedema Research Program at Massachusetts General Hospital. NR 39 TC 15 Z9 16 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD FEB PY 2014 VL 144 IS 1 BP 71 EP 77 DI 10.1007/s10549-014-2856-3 PG 7 WC Oncology SC Oncology GA AB2VD UT WOS:000331649300007 PM 24500108 ER PT J AU Lee, RJ Smith, MR AF Lee, Richard J. Smith, Matthew R. TI Cabozantinib and Prostate Cancer: Inhibiting Seed and Disrupting Soil? SO CLINICAL CANCER RESEARCH LA English DT Editorial Material AB Treatment with cabozantinib, an inhibitor of MET and VEGFR2 signaling, has demonstrated clinical benefit in early trials in men with metastatic prostate cancer. Preclinical evidence suggests that cabozantinib can kill cancer cell seeds while disrupting angiogenesis and stromal cells in the metastatic soil. (C) 2013 AACR. C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Lee, Richard J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Lee, RJ (reprint author), Harvard Univ, Sch Med, 55 Fruit St,Yawkey 7E, Boston, MA 02114 USA. EM rjlee@partners.org FU NCI NIH HHS [5K24CA121990, K24 CA121990] NR 5 TC 6 Z9 6 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2014 VL 20 IS 3 BP 525 EP 527 DI 10.1158/1078-0432.CCR-13-2636 PG 3 WC Oncology SC Oncology GA AB2XR UT WOS:000331656000001 PM 24284057 ER PT J AU O'Neill, AF Dearling, JLJ Wang, YC Tupper, T Sun, YP Aster, JC Calicchio, ML Perez-Atayde, AR Packard, AB Kung, AL AF O'Neill, Allison F. Dearling, Jason L. J. Wang, Yuchuan Tupper, Tanya Sun, Yanping Aster, Jon C. Calicchio, Monica L. Perez-Atayde, Antonio R. Packard, Alan B. Kung, Andrew L. TI Targeted Imaging of Ewing Sarcoma in Preclinical Models Using a Cu-64-Labeled Anti-CD99 Antibody SO CLINICAL CANCER RESEARCH LA English DT Article ID NEUROECTODERMAL TUMOR; METASTASES; BONE; CT; INTERGROUP; PROTEINS; THERAPY; MIC2; MRI AB Purpose: Ewing sarcoma is a tumor of the bone and soft tissue characterized by diffuse cell membrane expression of CD99 (MIC2). Single-site, surgically resectable disease is associated with an excellent 5-year event-free survival; conversely, patients with distant metastases have a poor prognosis. Noninvasive imaging is the standard approach to identifying sites of metastatic disease. We sought to develop a CD99-targeted imaging agent for staging Ewing sarcoma and other CD99-expressing tumors. Experimental Design: We identified a CD99 antibody with highly specific binding in vitro and labeled this antibody with Cu-64. Mice with either subcutaneous Ewing sarcoma xenograft tumors or micrometastases were imaged with the Cu-64-labeled anti-CD99 antibody and these results were compared with conventional MRI and 2[18F] fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) imaging. Results: Cu-64-labeled anti-CD99 antibody demonstrated high avidity for the CD99-positive subcutaneous tumors, with a high tumor-to-background ratio, greater than that demonstrated with FDG-PET. Micrometastases, measuring 1 to 2 mm on MRI, were not detected with FDG-PET but were readily visualized with the Cu-64-labeled anti-CD99 antibody. Probe biodistribution studies demonstrated high specificity of the probe for CD99-positive tumors. Conclusions: Cu-64-labeled anti-CD99 antibody can detect subcutaneous Ewing sarcoma tumors and metastatic sites with high sensitivity, outperforming FDG-PET in preclinical studies. This targeted radiotracer may have important implications for the diagnosis, surveillance, and treatment of Ewing sarcoma. Similarly, it may impact the management of other CD99 positive tumors. (C) 2013 AACR. C1 [O'Neill, Allison F.] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. [O'Neill, Allison F.; Dearling, Jason L. J.; Aster, Jon C.; Calicchio, Monica L.; Perez-Atayde, Antonio R.; Packard, Alan B.] Harvard Univ, Sch Med, Boston, MA USA. [Dearling, Jason L. J.; Packard, Alan B.] Boston Childrens Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA USA. [Wang, Yuchuan; Tupper, Tanya; Sun, Yanping] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02115 USA. [Aster, Jon C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Calicchio, Monica L.; Perez-Atayde, Antonio R.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Kung, Andrew L.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA. RP Kung, AL (reprint author), Columbia Univ, Med Ctr, 3959 Broadway,CHN 10-01, New York, NY 10032 USA. EM akung@columbia.edu OI Wang, Yuchuan/0000-0001-5111-6562; Kung, Andrew/0000-0002-9091-488X FU Hyundai Hope on Wheels Foundation; National Cancer Institute [R21EB010085, R24CA86307] FX The authors thank the Hyundai Hope on Wheels Foundation and the National Cancer Institute (grant R21EB010085) for funding and support. Copper-64 was produced at Washington University School of Medicine (St. Louis, MO) under the support of the National Cancer Institute (grant R24CA86307). Murine tissue histologic and immunohistologic analyses were carried out in the Dana Farber-Harvard Cancer Center Specialized Histopathology Services Core Laboratory. NR 28 TC 5 Z9 5 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2014 VL 20 IS 3 BP 678 EP 687 DI 10.1158/1078-0432.CCR-13-1660 PG 10 WC Oncology SC Oncology GA AB2XR UT WOS:000331656000017 PM 24218512 ER PT J AU Berry, DL Cunningham, T Eisenberg, S Wickline, M Hammer, M Berg, C AF Berry, Donna L. Cunningham, Terri Eisenberg, Seth Wickline, Mihkaila Hammer, Marilyn Berg, Carolina TI Improving Patient Knowledge of Discharge Medications in an Oncology Setting SO CLINICAL JOURNAL OF ONCOLOGY NURSING LA English DT Article DE medication adherence; discharge planning; patient education ID CARE AB Discharge medications for a patient with cancer typically are numerous and complex. During the transition between inpatient stays and ambulatory follow-up visits, patients commonly misunderstand medication instructions, placing them at risk for under- or overdosing. This column discusses the results of an evidence-based practice change project at the Seattle Cancer Care Alliance to improve adult patient knowledge and use of discharge medications. Ensuring patient receipt of written discharge medication instructions, and checking in with patients after discharge may be an approach to maximize the safety of self-administered medication. C1 [Berry, Donna L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Berry, Donna L.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Cunningham, Terri; Eisenberg, Seth] Seattle Canc Care Alliance, Seattle, WA USA. [Cunningham, Terri; Wickline, Mihkaila] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Hammer, Marilyn] NYU, Coll Nursing, New York, NY USA. [Berg, Carolina] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA. RP Berry, DL (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM donna_berry@dfci.harvard.edu NR 8 TC 3 Z9 3 U1 3 U2 5 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 1092-1095 EI 1538-067X J9 CLIN J ONCOL NURS JI Clin. J. Oncol. Nurs. PD FEB PY 2014 VL 18 IS 1 BP 35 EP 37 DI 10.1188/14.CJON.35-37 PG 3 WC Oncology; Nursing SC Oncology; Nursing GA AB2AC UT WOS:000331594400008 PM 24476724 ER PT J AU Saleh, RR Bouganim, N Hilton, J Arnaout, A Clemons, M AF Saleh, R. R. Bouganim, N. Hilton, J. Arnaout, A. Clemons, M. TI Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again? SO CURRENT ONCOLOGY LA English DT Review DE Medical oncology; breast cancer; neoadjuvant therapy; endocrine therapy ID PHASE-II TRIAL; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; CLINICAL-PRACTICE; DOUBLE-BLIND; THERAPY; LETROZOLE; TAMOXIFEN; CHEMOTHERAPY; ANASTROZOLE AB In recent years, considerable attention has been paid to the role of neoadjuvant chemotherapy as a pluri-potential test bed for the treatment of breast cancer. Although traditionally reserved to render inoperable disease operable, neoadjuvant chemotherapy is increasingly being used to improve the chance for breast-conserving surgery, to gain information on pathologic response rates for a more rapid assessment of new chemotherapy-biologic regimens, and also to study in vivo tumour sensitivity or resistance to the agent being used. Similarly, use of neoadjuvant endocrine treatment was also traditionally restricted to elderly or frail patients who were felt to be unsuitable for chemotherapy. It is therefore not surprising that, given the increasing realization of the pivotal role of endocrine therapy in patient care, there is enhanced interest in neoadjuvant endocrine therapy not only as a less-toxic alternative to chemotherapy, but also to assess tumour sensitivity or resistance to endocrine agents. The availability of newer endocrine manipulations and increasing evidence that the benefits of chemotherapy are frequently marginal in many hormone-positive patients is making endocrine therapy increasingly important in the clinical setting. The hope is that, one day, instead of preoperative endocrine therapy being restricted to the infirm and the elderly, it will be used in the time between biopsy diagnosis and surgery to predict which patients will or will not benefit from chemotherapy in the adjuvant setting. C1 [Saleh, R. R.; Bouganim, N.] McGill Univ Hlth Ctr, Div Med Oncol, Montreal, PQ, Canada. [Hilton, J.] Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA. [Arnaout, A.] Ottawa Hosp Canc Ctr, Dept Surg, Ottawa, ON K1H 8L6, Canada. [Arnaout, A.] Univ Ottawa, Dept Surg, Ottawa, ON, Canada. [Clemons, M.] Ottawa Hosp Canc Ctr, Div Med Oncol, Ottawa, ON K1H 8L6, Canada. [Clemons, M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada. RP Clemons, M (reprint author), Ottawa Hosp Canc Ctr, Div Med Oncol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada. EM mclemons@toh.on.ca NR 42 TC 5 Z9 5 U1 0 U2 3 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1198-0052 J9 CURR ONCOL JI Curr. Oncol. PD FEB PY 2014 VL 21 IS 1 BP E122 EP E128 DI 10.3747/co.21.1627 PG 7 WC Oncology SC Oncology GA AB2KH UT WOS:000331621100014 PM 24523609 ER PT J AU Schreiner, CE Polley, DB AF Schreiner, Christoph E. Polley, Daniel B. TI Auditory map plasticity: diversity in causes and consequences SO CURRENT OPINION IN NEUROBIOLOGY LA English DT Article ID RECEPTIVE-FIELD PLASTICITY; EXPERIENCE-DEPENDENT PLASTICITY; INFERIOR COLLICULUS NEURONS; CRITICAL PERIOD PLASTICITY; HEARING-LOSS; CAT PRIMARY; ACOUSTIC ENVIRONMENT; CORTICAL-NEURONS; NUCLEUS BASALIS; FREQUENCY REPRESENTATION AB Auditory cortical maps have been a long-standing focus of studies that assess the expression, mechanisms, and consequences of sensory plasticity. Here we discuss recent progress in understanding how auditory experience transforms spatially organized sound representations at higher levels of the central auditory pathways. New insights into the mechanisms underlying map changes have been achieved and more refined interpretations of various map plasticity effects and their consequences in terms of behavioral corollaries and learning as well as other cognitive aspects have been offered. The systematic organizational principles of cortical sound processing remain a key aspect in studying and interpreting the role of plasticity in hearing. C1 [Schreiner, Christoph E.] Univ Calif San Francisco, Coleman Mem Lab, UCSF Ctr Integrat Neurosci, San Francisco, CA 94143 USA. [Polley, Daniel B.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Eaton Peabody Lab,Dept Otol & Laryngol, Boston, MA 02114 USA. RP Schreiner, CE (reprint author), Univ Calif San Francisco, Coleman Mem Lab, UCSF Ctr Integrat Neurosci, San Francisco, CA 94143 USA. EM chris@phy.ucsf.edu OI Schreiner, Christoph/0000-0002-4571-4328; Polley, Daniel/0000-0002-5120-2409 FU National Institute of Health [DC02260, MH077970, DC00983, DC012894] FX The work of the authors has been supported by the National Institute of Health (CES: DC02260 and MH077970; DBP: DC00983 and DC012894). NR 148 TC 31 Z9 31 U1 2 U2 25 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0959-4388 EI 1873-6882 J9 CURR OPIN NEUROBIOL JI Curr. Opin. Neurobiol. PD FEB PY 2014 VL 24 BP 143 EP 156 DI 10.1016/j.conb.2013.11.009 PG 14 WC Neurosciences SC Neurosciences & Neurology GA AB0VF UT WOS:000331509500021 PM 24492090 ER PT J AU Tanaka, N Peters, JM Prohl, AK Takaya, S Madsen, JR Bourgeois, BF Dworetzky, BA Hamalainen, MS Stufflebeam, SM AF Tanaka, Naoaki Peters, Jurriaan M. Prohl, Anna K. Takaya, Shigetoshi Madsen, Joseph R. Bourgeois, Blaise F. Dworetzky, Barbara A. Haemaelaeinen, Matti S. Stufflebeam, Steven M. TI Clinical value of magnetoencephalographic spike propagation represented by spatiotemporal source analysis: Correlation with surgical outcome SO EPILEPSY RESEARCH LA English DT Article DE Magnetoencephalography (MEG); Temporal lobe epilepsy; Epilepsy surgery; Spike propagation; Minimum norm estimate (MNE) ID TEMPORAL-LOBE EPILEPSY; SPACE SEPARATION METHOD; SURFACE-BASED ANALYSIS; INTERICTAL DISCHARGES; EPILEPTIFORM ACTIVITY; INTRACTABLE EPILEPSY; SOURCE LOCALIZATION; NORMAL MRI; SURGERY; EEG AB Objective: To investigate the correlation between spike propagation represented by spatiotemporal source analysis of magnetoencephalographic (MEG) spikes and surgical outcome in patients with temporal lobe epilepsy. Methods: Thirty-seven patients were divided into mesial (n=27) and non-mesial (n=10) groups based on the presurgical evaluation. In each patient, ten ipsilateral spikes were averaged, and spatiotemporal source maps of the averaged spike were obtained by using minimum norm estimate. Regions of interest (ROIs) were created including temporoparietal, inferior frontal, mesial temporal, anterior and posterior part of the lateral temporal cortex. We extracted activation values from the source maps and the threshold was set at half of the maximum activation at the peak latency. The leading and propagated areas of the spike were defined as those ROIs with activation reaching the threshold at the earliest and at the peak latencies, respectively. Surgical outcome was assessed based on Engel's classification. Binary variables were created from leading areas (restricted to the anterior and mesial temporal ROIs or not) and from propagation areas (involving the temporoparietal ROI or not), and for surgical outcome (Class I or not). Fisher's exact test was used for significance testing. Results: In total and mesial group, restricted anterior/mesial temporal leading areas were correlated with Class I (p < 0.05). Temporoparietal propagation was correlated with Class II-IV (p < 0.05). For the non-mesial group, no significant relation was found. Conclusions: Spike propagation patterns represented by spatiotemporal source analysis of MEG spikes may provide useful information for prognostic implication in presurgical evaluation of epilepsy. (C) 2013 Elsevier B.V. All rights reserved. C1 [Tanaka, Naoaki; Takaya, Shigetoshi; Haemaelaeinen, Matti S.; Stufflebeam, Steven M.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA. [Peters, Jurriaan M.; Prohl, Anna K.; Bourgeois, Blaise F.] Boston Childrens Hosp, Div Epilepsy & Clin Neurophysiol, Boston, MA 02115 USA. [Madsen, Joseph R.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Dworetzky, Barbara A.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. RP Tanaka, N (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 Thirteenth St,Suite 2301, Boston, MA 02129 USA. EM naoro@nmr.mgh.harvard.edu RI Hamalainen, Matti/C-8507-2013; OI Dworetzky, Barbara/0000-0002-3364-2347; Peters, Jurriaan/0000-0002-6725-2814 FU National Institutes of Health [S10RR014978, 1R01NS069696-01A1]; NIBIB [P41EB015896] FX This work was supported by National Institutes of Health (S10RR014978, 1R01NS069696-01A1) and NIBIB (P41EB015896). NR 36 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 EI 1872-6844 J9 EPILEPSY RES JI Epilepsy Res. PD FEB PY 2014 VL 108 IS 2 BP 280 EP 288 DI 10.1016/j.eplepsyres.2013.11.006 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA AB3GF UT WOS:000331678600014 PM 24315019 ER PT J AU van der Laan, AM ter Horst, EN Delewi, R Begieneman, MPV Krijnen, PA Hirsch, A Lavaei, M Nahrendorf, M Horrevoets, AJ Niessen, HW Piek, JJ AF van der Laan, Anja M. ter Horst, Ellis N. Delewi, Ronak Begieneman, Mark P. V. Krijnen, Paul A. J. Hirsch, Alexander Lavaei, Mehrdad Nahrendorf, Matthias Horrevoets, Anton J. Niessen, Hans W. M. Piek, Jan J. TI Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir SO EUROPEAN HEART JOURNAL LA English DT Article DE Acute myocardial infarction; Inflammation; Monocytes; Spleen; Bone marrow ID C-REACTIVE PROTEIN; DENDRITIC CELLS; BLOOD; ATHEROSCLEROSIS; INFLAMMATION; MACROPHAGES; COMPLEMENT; REPAIR AB Monocytes are critical mediators of healing following acute myocardial infarction (AMI), making them an interesting target to improve myocardial repair. The purpose of this study was a gain of insight into the source and recruitment of monocytes following AMI in humans. Post-mortem tissue specimens of myocardium, spleen and bone marrow were collected from 28 patients who died at different time points after AMI. Twelve patients who died from other causes served as controls. The presence and localization of monocytes (CD14 cells), and their CD14CD16 and CD14CD16 subsets, were evaluated by immunohistochemical and immunofluorescence analyses. CD14 cells localized at distinct regions of the infarcted myocardium in different phases of healing following AMI. In the inflammatory phase after AMI, CD14 cells were predominantly located in the infarct border zone, adjacent to cardiomyocytes, and consisted for 85 (7892) of CD14CD16 cells. In contrast, in the subsequent post-AMI proliferative phase, massive accumulation of CD14 cells was observed in the infarct core, containing comparable proportions of both the CD14CD16 [60 (3167)] and CD14CD16 subsets [40 (3369)]. Importantly, in AMI patients, of the number of CD14 cells was decreased by 39 in the bone marrow and by 58 in the spleen, in comparison with control patients (P 0.02 and 0.001, respectively). Overall, this study showed a unique spatiotemporal pattern of monocyte accumulation in the human myocardium following AMI that coincides with a marked depletion of monocytes from the spleen, suggesting that the human spleen contains an important reservoir function for monocytes. C1 [van der Laan, Anja M.; ter Horst, Ellis N.; Delewi, Ronak; Hirsch, Alexander; Piek, Jan J.] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands. [ter Horst, Ellis N.; Begieneman, Mark P. V.; Krijnen, Paul A. J.; Lavaei, Mehrdad; Niessen, Hans W. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands. [ter Horst, Ellis N.; Begieneman, Mark P. V.; Krijnen, Paul A. J.; Horrevoets, Anton J.; Niessen, Hans W. M.] Vrije Univ Amsterdam Med Ctr, ICaR VU, Amsterdam, Netherlands. [ter Horst, Ellis N.] Interuniv Cardiol, Inst Netherlands, Utrecht, Netherlands. [Nahrendorf, Matthias] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Horrevoets, Anton J.] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands. [Niessen, Hans W. M.] Vrije Univ Amsterdam Med Ctr, Dept Cardiac Surg, Amsterdam, Netherlands. [Nahrendorf, Matthias] Harvard Univ, Sch Med, Boston, MA USA. RP Piek, JJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands. EM j.j.piek@amc.uva.nl FU Interuniversity Cardiology Institute of the Netherlands (ICIN), Utrecht, the Netherlands; Netherlands Heart Foundation [2005T101]; Graduate School for Medical Sciences of the Academic Medical Centre, Amsterdam, the Netherlands; ICIN; Dutch Forensic Institute, the Hague, the Netherlands [34]; National Institutes of Health [R01HL096576] FX This study is financially supported by funds provided by the Interuniversity Cardiology Institute of the Netherlands (ICIN), Utrecht, the Netherlands, and the Netherlands Heart Foundation (grant 2005T101). A.M.L. was supported by the Graduate School for Medical Sciences of the Academic Medical Centre, Amsterdam, the Netherlands, E.N.H by the ICIN, M.P.V.B by the Dutch Forensic Institute, the Hague, the Netherlands (34), and M.N. by the National Institutes of Health (grant R01HL096576). NR 29 TC 54 Z9 55 U1 4 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD FEB PY 2014 VL 35 IS 6 BP 376 EP 385 DI 10.1093/eurheartj/eht331 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AB5FO UT WOS:000331814500012 PM 23966310 ER PT J AU Bhattacharya, A Hamilton, R Jernigan, A Zhang, YQ Sabia, M Rahnian, MM Li, Y Wei, R Chaudhuri, A Van Remmen, H AF Bhattacharya, Arunabh Hamilton, Ryan Jernigan, Amanda Zhang, Yiqiang Sabia, Marian Rahnian, Md. M. Li, Yan Wei, Rochelle Chaudhuri, Asish Van Remmen, Holly TI Genetic ablation of 12/15-lipoxygenase but not 5-lipoxygenase protects against denervation-induced muscle atrophy SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE 12/15-Lipoxygenase; 5-Lipoxygenase; NADPH oxidase; Denervation; Muscle atrophy; Free radicals ID AMYOTROPHIC-LATERAL-SCLEROSIS; UBIQUITIN-PROTEASOME PATHWAY; FATTY LIVER-DISEASE; SKELETAL-MUSCLE; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; MOUSE MODEL; TRANSCRIPTION FACTOR; NITROSATIVE STRESS AB Skeletal muscle atrophy is a debilitating outcome of a number of chronic diseases and conditions associated with loss of muscle innervation by motor neurons, such as aging and neurodegenerative diseases. We previously reported that denervation-induced loss of muscle mass is associated with activation of cytosolic phospholipase A(2) (cPLA(2)), the rate-limiting step for the release of arachidonic acid from membrane phospholipids, which then acts as a substrate for metabolic pathways that generate bioactive lipid mediators. In this study, we asked whether 5- and 12/15-lipoxygenase (LO) lipid metabolic pathways downstream of cPLA2 mediate denervation-induced muscle atrophy in mice. Both 5- and 12/15-LO were activated in response to surgical denervation; however, 12/15-LO activity was increased similar to 2.5-fold versus an similar to 1.5-fold increase in activity of 5-LO. Genetic and pharmacological inhibition of 12/15-LO (but not 5-LO) significantly protected against denervation-induced muscle atrophy, suggesting a selective role for the 12/15-LO pathway in neurogenic muscle atrophy. The activation of the 12/15-LO pathway (but not 5-LO) during muscle atrophy increased NADPH oxidase activity, protein ubiquitination, and ubiquitin-proteasome-mediated proteolytic degradation. In conclusion, this study reveals a novel pathway for neurogenic muscle atrophy and suggests that 12/15-LO may be a potential therapeutic target in diseases associated with loss of innervation and muscle atrophy. (C) 2013 Published by Elsevier Inc. C1 [Bhattacharya, Arunabh; Hamilton, Ryan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Bhattacharya, Arunabh; Hamilton, Ryan; Jernigan, Amanda; Zhang, Yiqiang; Sabia, Marian; Rahnian, Md. M.; Li, Yan; Wei, Rochelle; Chaudhuri, Asish; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Zhang, Yiqiang; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Rahnian, Md. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Chaudhuri, Asish; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Bhattacharya, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Cellular & Struct Biol, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM bhattacharya@uthscsa.edu FU National Institutes of Health [K01AG038555]; American Federation for Aging Research; Muscular Dystrophy Association FX This work was supported by grants to A.B. from the National Institutes of Health (K01AG038555) and the American Federation for Aging Research and by a Muscular Dystrophy Association grant to H.V.R. NR 57 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD FEB PY 2014 VL 67 BP 30 EP 40 DI 10.1016/j.freeradbiomed.2013.10.002 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA AB5UM UT WOS:000331854200004 PM 24121057 ER PT J AU Chaiswing, L Zhong, WX Oberley, TD AF Chaiswing, Luksana Zhong, Weixiong Oberley, Terry D. TI Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE ECSOD; MnSOD; Prx; Trx1; Prostate cancer; Posttranslational modifications; Redox balance; Free radicals ID MANGANESE SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; CYSTEINE OXIDATION; BREAST-CANCER; CELL INVASION; THIOREDOXIN; DAMAGE; GROWTH; TISSUE; PEROXIREDOXINS AB A metabolomics study demonstrated a decrease in glutathione and an increase in cysteine (Cys) levels in human prostate cancer (PCa) tissues as Gleason scores increased, indicating redox imbalance with PCa progression. These results were extended in the present study by analyzing the redox state of the protein thioredoxin 1 (Trx1) and sulfinylation (SO3) of peroxiredoxins (Prxs) (PrxSO(3)) in PCa tissues and cell lines. Lysates of paired human PCa tissues with varying degrees of aggressiveness and adjacent benign (BN) tissues were used for analysis. Redox Western blot analysis of Trx1 demonstrated low levels of reduced and high levels of oxidized Trx1 (functional and nonfunctional, respectively) in high-grade PCa (Gleason scores 4+4 to 4+5) in comparison to intermediate-grade PCa (Gleason scores 3+3 to 3+4) or BN tissues. PrxSO(3) were increased in high-grade PCa. Oxidized Trx1 and PrxSO(3) are indicators of oxidative stress. To study whether redox imbalance may potentially affect enzyme activities of antioxidant proteins (APs), we determined the levels of selected APs in PCa tissues by Western blot analysis and found that mitochondrial manganese superoxide dismutase (MnSOD), Prx3, and Trx1 were increased in high-grade PCa tissues compared with BN tissues. Enzyme activities of MnSOD in high-grade PCa tissues were significantly increased but at a lower magnitude compared with the levels of MnSOD protein (0.5-fold vs 2-fold increase). Trx1 activity was not changed in high-grade PCa tissues despite a large. increase in Trx1 protein expression. Further studies demonstrated a significant increase in posttranslational modifications of tyrosine and lysine residues in MnSOD protein and oxidation of Cys at the active site (Cys32 and Cys35) and the regulatory site (Cys62 and Cys69) of Trx1 in high-grade PCa compared to BN tissues. These discordant changes between protein levels and enzyme activities are consistent with protein inactivation by redox imbalance and/or posttranslational modifications. In contrast, the protein level and activity of extracellular superoxide dismutase were significantly decreased in high-grade PCa compared with adjacent BN tissues. Results from cell lines mirror those from PCa tissues. Knowledge of redox-state profiles in specific cancers may help to predict the behavior and response of each cancer to chemotherapeutic drugs and radiation. (C) 2013 Elsevier Inc. All rights reserved. C1 [Chaiswing, Luksana; Zhong, Weixiong; Oberley, Terry D.] Dept Pathol & Lab Med, Madison, WI 53705 USA. [Zhong, Weixiong; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Chaiswing, L (reprint author), 1111 Highland Ave WIMR Bldg Rm 7168a, Madison, WI 53705 USA. EM lchaiswing@wisc.edu; toberley@wisc.edu FU University of Wisconsin; Department of Pathology Research and Development Committee, University of Wisconsin at Madison Graduate School; UW Carbone Cancer Center (NIH) [P30 CA014520]; NIH [RO1 CA07359902, RO1 CA09485301]; Society for Free Radical Biology Medicine FX The contents do not represent the views of the U.S. Department of Veterans Affairs. This work was supported in part by funds from the University of Wisconsin, Department of Pathology Research and Development Committee, University of Wisconsin at Madison Graduate School, UW Carbone Cancer Center (NIH Grant P30 CA014520), NIH Grants RO1 CA07359902 and RO1 CA09485301 to Daret St. Clair (T.D.O.; Co-I), and a 2010 mini-fellowship award from the Society for Free Radical Biology & Medicine. We acknowledge Weihua Shan for her technical assistance in redox Western experiments and the use of resources and facilities at the William S. Middleton Memorial Veterans Hospital (Madison, WI, USA). We would like to dedicate this article to the memory of Dr. Terry D. Oberley. His dedication to the field of free radical biology and medicine was an inspiration to all of us. NR 46 TC 13 Z9 13 U1 0 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD FEB PY 2014 VL 67 BP 342 EP 352 DI 10.1016/j.freeradbiomed.2013.11.006 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA AB5UM UT WOS:000331854200032 PM 24269899 ER PT J AU Hunger, T Schnell-Inderst, P Hintringer, K Schwarzer, R Seifert-Klauss, V Gothe, H Wasem, J Siebert, U AF Hunger, Theresa Schnell-Inderst, Petra Hintringer, Katharina Schwarzer, Ruth Seifert-Klauss, Vanadin Gothe, Holger Wasem, Jurgen Siebert, Uwe TI Health technology assessment of utilization, practice and ethical issues of self-pay services in the German ambulatory health care setting SO INTERNATIONAL JOURNAL OF PUBLIC HEALTH LA English DT Article DE IGeL; Individual health services; Self-pay services; German Statutory Health Insurance; Health care quality, access, and evaluation; Cost sharing ID PROSTATE; TRIAL; LUNG AB The provision of self-pay medical services is common across health care systems, but understudied. According to the German Medical Association, such services should be medically necessary, recommended or at least justifiable, and requested by the patient. We investigated the empirical evidence regarding frequency and practice of self-pay services as well as related ethical, social, and legal issues (ELSI). A systematic literature search in electronic databases and a structured internet search on stakeholder websites with qualitative and quantitative information synthesis. Of 1,345 references, we included 64 articles. Between 19 and 53 % of insured persons received self-pay service offers from their physician; 16-19 % actively requested such services. Intraocular pressure measurement was the most common service, followed by ultrasound investigations. There is a major discussion about ELSI in the context of individual health services. Self-pay services are common medical procedures in Germany. However, the empirical evidence is limited in quality and extent, even for the most frequently provided services. Transparency of their provision should be increased and independent evidence-based patient information should be supplied. C1 [Hunger, Theresa; Schnell-Inderst, Petra; Hintringer, Katharina; Schwarzer, Ruth; Gothe, Holger; Siebert, Uwe] UMIT Univ, Dept Publ Hlth & Hlth Technol Assessment, Inst Publ Hlth, Hall In Tirol, Austria. [Hunger, Theresa; Schnell-Inderst, Petra; Schwarzer, Ruth; Gothe, Holger; Siebert, Uwe] Ctr Personalized Canc Med, Innsbruck, Austria. [Hintringer, Katharina] Ludwig Boltzmann Inst Hlth Technol Assessment, Vienna, Austria. [Seifert-Klauss, Vanadin] Tech Univ Munich, Dept Obstet & Gynecol, Munich, Germany. [Wasem, Jurgen] Univ Duisburg Essen, Inst Hlth Care Management & Res, Essen, Germany. [Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Siebert, Uwe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA USA. [Siebert, Uwe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. RP Hunger, T (reprint author), UMIT Univ, Dept Publ Hlth & Hlth Technol Assessment, Inst Publ Hlth, Eduard Wallnoefer Ctr 1,6060 Hall iT, Hall In Tirol, Austria. EM t.hunger@umit.at OI Hunger, Theresa/0000-0003-2771-5092; Wasem, Juergen/0000-0001-9653-168X NR 56 TC 1 Z9 1 U1 3 U2 8 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1661-8556 EI 1661-8564 J9 INT J PUBLIC HEALTH JI Int. J. Public Health PD FEB PY 2014 VL 59 IS 1 BP 175 EP 187 DI 10.1007/s00038-013-0494-x PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AB7IL UT WOS:000331962900018 PM 23903284 ER PT J AU Wiggs, JL Pawlyk, B Connolly, E Adamian, M Miller, JW Pasquale, LR Haddadin, RI Grosskreutz, CL Rhee, DJ Li, T AF Wiggs, Janey L. Pawlyk, Basil Connolly, Edward Adamian, Michael Miller, Joan W. Pasquale, Louis R. Haddadin, Ramez I. Grosskreutz, Cynthia L. Rhee, Douglas J. Li, Tiansen TI Disruption of the Blood-Aqueous Barrier and Lens Abnormalities in Mice Lacking Lysyl Oxidase-Like 1 (LOXL1) SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE exfoliation syndrome; LOXL1; glaucoma ID PSEUDOEXFOLIATION SYNDROME; EXFOLIATION GLAUCOMA; LAMINA-CRIBROSA; ELASTOSIS; PROTEIN; PHACOEMULSIFICATION; SYNDROME/GLAUCOMA; FIBRILLOPATHY; POPULATION; MICROSCOPY AB PURPOSE. Exfoliation syndrome (ES) is commonly associated with glaucoma, premature cataracts, and other ocular and systemic pathologies. LOXL1 gene variants are significantly associated with ES; however, the role of the protein in ES development remains unclear. The purpose of this study was to characterize the ocular phenotype in Loxl1(-/-) (null) mice. METHODS. Loxl1 null mice and strain-matched controls (C57BL) were evaluated by clinical and histologic analyses. RESULTS. Anterior segment histology showed a pronounced vesiculation of the anterior lens in the null mice. The lesions were subcapsular and in direct apposition with the posterior iris surface. Fluorescein angiography showed increased diffusion of fluorescein into the anterior chamber of the null mice compared with age-matched controls (P = 0.003, two-tailed, unequal variance t-test), suggesting compromise of the blood-aqueous barrier. Intraocular pressure measurements were within the normal range (16.5 +/- 2.0 mm Hg) in null mice up to 1 year of age. Immunohistochemistry showed decreased elastin in the iris and ciliary body in the null mouse compared with controls. CONCLUSIONS. Elimination of LOXL1 in mice impairs the blood-aqueous humor barrier in the ocular anterior segment and causes lens abnormalities consistent with cataract formation, but does not result in deposition of macromolecular material or glaucoma. These results show that mice lacking LOXL1 have some ES features but that complete disease manifestation requires other factors that could be genetic and/or environmental. C1 [Wiggs, Janey L.; Pawlyk, Basil; Connolly, Edward; Adamian, Michael; Miller, Joan W.; Pasquale, Louis R.; Haddadin, Ramez I.; Grosskreutz, Cynthia L.; Rhee, Douglas J.; Li, Tiansen] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Berman Gund & Angiogenesis Labs, Boston, MA USA. [Li, Tiansen] NEI, Bethesda, MD 20892 USA. RP Wiggs, JL (reprint author), 243 Charles St, Boston, MA 02114 USA. EM janey_wiggs@meei.harvard.edu; tiansen.li@nih.gov FU National Institutes of Health [R21EY019161, R01EY020928, P30EY014104]; Research to Prevent Blindness; Massachusetts Lions Eye Research Fund; Harvard Glaucoma Center of Excellence; Distinguished Ophthalmology Scholar award FX Supported by National Institutes of Health Grants R21EY019161 (TL), R01EY020928 (JLW), and P30EY014104; Research to Prevent Blindness; the Massachusetts Lions Eye Research Fund; the Harvard Glaucoma Center of Excellence; and a Distinguished Ophthalmology Scholar award (LRP). The authors alone are responsible for the content and writing of the paper. NR 46 TC 8 Z9 8 U1 0 U2 4 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD FEB PY 2014 VL 55 IS 2 BP 856 EP 864 DI 10.1167/iovs.13-13033 PG 9 WC Ophthalmology SC Ophthalmology GA AB6IU UT WOS:000331891700029 PM 24425853 ER PT J AU Bharti, K Rao, M Hull, SC Stroncek, D Brooks, BP Feigal, E van Meurs, JC Huang, CA Miller, SS AF Bharti, Kapil Rao, Mahendra Hull, Sara Chandros Stroncek, David Brooks, Brian P. Feigal, Ellen van Meurs, Jan C. Huang, Christene A. Miller, Sheldon S. TI Developing Cellular Therapies for Retinal Degenerative Diseases SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE cell-based therapy; stem cells; age-related macular degeneration; retinitis pigmentosa ID PLURIPOTENT STEM-CELLS; INDUCED IMMUNE DEVIATION; PIGMENT EPITHELIUM; MACULAR DEGENERATION; SUBMACULAR SURGERY; INFORMED-CONSENT; ANTERIOR-CHAMBER; HUMANIZED MICE; SOMATIC-CELLS; CHOROID GRAFT AB Biomedical advances in vision research have been greatly facilitated by the clinical accessibility of the visual system, its ease of experimental manipulation, and its ability to be functionally monitored in real time with noninvasive imaging techniques at the level of single cells and with quantitative end-point measures. A recent example is the development of stem cell-based therapies for degenerative eye diseases including AMD. Two phase I clinical trials using embryonic stem cell-derived RPE are already underway and several others using both pluripotent and multipotent adult stem cells are in earlier stages of development. These clinical trials will use a variety of cell types, including embryonic or induced pluripotent stem cell-derived RPE, bone marrow- or umbilical cord-derived mesenchymal stem cells, fetal neural or retinal progenitor cells, and adult RPE stem cells-derived RPE. Although quite distinct, these approaches, share common principles, concerns and issues across the clinical development pipeline. These considerations were a central part of the discussions at a recent National Eye Institute meeting on the development of cellular therapies for retinal degenerative disease. At this meeting, emphasis was placed on the general value of identifying and sharing information in the so-called "precompetitive space.'' The utility of this behavior was described in terms of how it could allow us to remove road blocks in the clinical development pipeline, and more efficiently and economically move stem cell-based therapies for retinal degenerative diseases toward the clinic. Many of the ocular stem cell approaches we discuss are also being used more broadly, for nonocular conditions and therefore the model we develop here, using the precompetitive space, should benefit the entire scientific community. C1 [Bharti, Kapil] NEI, Unit Ocular & Stem Cell Translat Res, NIH, Bethesda, MD 20892 USA. [Rao, Mahendra] NIH, Ctr Regenerat Med, Bethesda, MD 20892 USA. [Hull, Sara Chandros] NHGRI, Bioeth Core, Off Clin Director, NIH, Bethesda, MD 20892 USA. [Hull, Sara Chandros] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA. [Stroncek, David] NIH, Cell Proc Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA. [Brooks, Brian P.] NEI, Unit Pediat Dev & Genet Ophthalmol, NIH, Bethesda, MD 20892 USA. [Feigal, Ellen] Calif Inst Regenerat Med, San Francisco, CA USA. [van Meurs, Jan C.] Rotterdam Univ Eye Hosp, Rotterdam, Netherlands. [Huang, Christene A.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Miller, Sheldon S.] NEI, Sect Epithelial & Retinal Physiol & Dis, NIH, Bethesda, MD 20892 USA. RP Bharti, K (reprint author), NEI, Unit Ocular & Stem Cell Translat Res, NIH, Bldg 10,Room 10B10,10 Ctr Dr, Bethesda, MD 20892 USA. EM kapilbharti@nei.nih.gov; millers@nei.nih.gov FU Division of Intramural Research, National Eye Institute, National Institutes of Health; NIH Center for Regenerative Medicine FX Supported by the Division of Intramural Research, National Eye Institute, National Institutes of Health, and the NIH Center for Regenerative Medicine. NR 56 TC 25 Z9 28 U1 1 U2 21 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD FEB PY 2014 VL 55 IS 2 BP 1191 EP 1201 DI 10.1167/iovs.13-13481 PG 11 WC Ophthalmology SC Ophthalmology GA AB6IU UT WOS:000331891700068 PM 24573369 ER PT J AU Jeffries, AM Killian, NJ Pezaris, JS AF Jeffries, Ailsa M. Killian, Nathaniel J. Pezaris, John S. TI Mapping the primate lateral geniculate nucleus: A review of experiments, and methods SO JOURNAL OF PHYSIOLOGY-PARIS LA English DT Review DE LGN; Thalamus; Reverse correlation; Early visual system; Extra-classical receptive field ID RECEPTIVE-FIELD PROPERTIES; PRIMARY VISUAL-CORTEX; RETINAL GANGLION-CELLS; CAT STRIATE CORTEX; MACAQUE MONKEYS; THALAMIC MICROSTIMULATION; KONIOCELLULAR CELLS; SPATIAL SUMMATION; NATURAL STIMULI; COLOR-VISION AB Mapping neuronal responses in the lateral geniculate nucleus (LGN) is key to understanding how visual information is processed in the brain. This paper focuses on our current knowledge of the dynamics the receptive field (RF) as broken down into the classical receptive field (CRF) and the extra-classical receptive field (ECRF) in primate LGN. CRFs in the LGN are known to be similar to those in the retinal ganglion cell layer in terms of both spatial and temporal characteristics, leading to the standard interpretation of the LGN as a relay center from retina to primary visual cortex. ECRFs have generally been found to be large and inhibitory, with some differences in magnitude between the magno-, parvo-, and koniocellular pathways. The specific contributions of the retina, thalamus, and visual cortex to LGN ECRF properties are presently unknown. Some reports suggest a retinal origin for extra-classical suppression based on latency arguments and other reports have suggested a thalamic origin for extra-classical suppression. This issue is complicated by the use of anesthetized animals, where cortical activity is likely to be altered. Thus further study of LGN ECRFs is warranted to reconcile these discrepancies. Producing descriptions of RF properties of LGN neurons could be enhanced by employing preferred naturalistic stimuli. Although there has been significant work in cats with natural scene stimuli and noise that statistically imitates natural scenes, we highlight a need for similar data from primates. Obtaining these data may be aided by recent advancements in experimental and analytical techniques that permit the efficient study of nonlinear RF characteristics in addition to traditional linear factors. In light of the reviewed topics, we conclude by suggesting experiments to more clearly elucidate the spatial and temporal structure of ECRFs of primate LGN neurons. (C) 2013 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved. C1 [Jeffries, Ailsa M.; Killian, Nathaniel J.; Pezaris, John S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Pezaris, JS (reprint author), Massachusetts Gen Hosp, 55 Fruit St,THR-425, Boston, MA 02114 USA. EM pezaris.john@mgh.harvard.edu OI Killian, Nathaniel/0000-0002-4546-0516 FU National Eye Institute of the National Institutes of Health [R01EY019679]; NIMA Foundation; Rappaport Foundation FX Research reported in this publication was supported by the National Eye Institute of the National Institutes of Health under Award Number R01EY019679, The NIMA Foundation, and The Rappaport Foundation. The content is solely the responsibility of the authors and does not necessarily represent official views of the sponsors. NR 88 TC 4 Z9 4 U1 1 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0928-4257 EI 1769-7115 J9 J PHYSIOL-PARIS JI J. Physiol.-Paris PD FEB PY 2014 VL 108 IS 1 SI SI BP 3 EP 10 DI 10.1016/j.jphysparis.2013.10.001 PG 8 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA AB3GZ UT WOS:000331680600002 PM 24270042 ER PT J AU Sylvia, LG Bernstein, EE Hubbard, JL Keating, L Anderson, EJ AF Sylvia, Louisa G. Bernstein, Emily E. Hubbard, Jane L. Keating, Leigh Anderson, Ellen J. TI Practical Guide to Measuring Physical Activity SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Editorial Material DE Physical activity; Assessment; Research; Methodology; Exercise ID DOUBLY LABELED WATER; ASSESS ENERGY-EXPENDITURE; SEVERE MENTAL-ILLNESS; SELF-REPORT MEASURES; SEDENTARY BEHAVIOR; ACTIVITY QUESTIONNAIRE; ACTIVITY-MONITOR; HEART-RATE; CONVERGENT VALIDITY; ACTIVITY RECALL C1 [Sylvia, Louisa G.; Bernstein, Emily E.] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA. [Hubbard, Jane L.; Anderson, Ellen J.] Massachusetts Gen Hosp, Clin Res Ctr, Boston, MA 02114 USA. [Keating, Leigh] Brigham & Womens Hosp, Clin Ctr Invest, Boston, MA 02115 USA. RP Sylvia, LG (reprint author), Massachusetts Gen Hosp, Bipolar Clin & Res Program, 50 Staniford St,Suite 580, Boston, MA 02114 USA. EM lsylvia2@partners.org OI Bernstein, Emily/0000-0001-8609-3153 FU NCATS NIH HHS [8 UL1TR000170-05, UL1 TR000170]; NCRR NIH HHS [1 UL1 RR025758-04, UL1 RR025758]; NIMH NIH HHS [5K23MH091182-02, K23 MH091182] NR 123 TC 5 Z9 5 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD FEB PY 2014 VL 114 IS 2 BP 199 EP 208 DI 10.1016/j.jand.2013.09.018 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AB5UB UT WOS:000331853100005 PM 24290836 ER PT J AU Anderson, EJ Sylvia, LG Lynch, M Sonnenberg, L Lee, H Nathan, DM AF Anderson, Ellen J. Sylvia, Louisa G. Lynch, Martha Sonnenberg, Lillian Lee, Hang Nathan, David M. TI Comparison of Energy Assessment Methods in Overweight Individuals SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Indirect calorimetry; MedGem; Overweight; Resting energy expenditure ID HELD INDIRECT CALORIMETER; RESTING METABOLIC-RATE; EXPENDITURE; EQUATION; ADULTS; REQUIREMENTS; OBESITY; RATES AB Practical methods of assessing resting energy expenditure (REE) could be useful in large populations of overweight and obese individuals during phases of weight loss and weight-loss maintenance to address weight regain. We compared predicted and measured REE using the MedGem handheld device and a traditional, indirect calorimeter in middle-aged men and women who were overweight and obese (body mass index >= 25.0 and <40.0). Each subject (n=88) completed traditional, indirect calorimetry and handheld calorimetry in random order. A subset of participants (n=10) completed each of these assessments at three different time points to examine their test-retest reliability. We found that MedGem estimates of REE were significantly greater than estimates with the traditional, indirect calorimeter and the predicted REE using the Harris-Benedict equation (P<0.01). Intra-class correlations were .70 (P=0.15) for repeated recordings with the MedGem and .84 (P=0.65) for traditional indirect calorimetry. The MedGem can overestimate REE in middle-aged overweight/obese individuals and has moderate test-retest reliability. Indirect calorimetry is the preferred measurement of REE in this population. C1 [Anderson, Ellen J.; Nathan, David M.] Massachusetts Gen Hosp, Clin Res Ctr, Boston, MA 02114 USA. [Anderson, Ellen J.; Nathan, David M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Anderson, Ellen J.; Nathan, David M.] Massachusetts Gen Hosp, Diabet Res Ctr, Boston, MA 02114 USA. [Sylvia, Louisa G.] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA. [Sylvia, Louisa G.] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. [Sylvia, Louisa G.; Sonnenberg, Lillian; Nathan, David M.] Harvard Univ, Sch Med, Boston, MA USA. [Lynch, Martha; Sonnenberg, Lillian] Massachusetts Gen Hosp, Dept Nutr & Food Serv, Boston, MA 02114 USA. [Lee, Hang] Mallinckrodt Gen Clin Res Ctr, Boston, MA USA. RP Anderson, EJ (reprint author), Diabet Res Ctr, 50 Staniford St,Suite 340, Boston, MA 02114 USA. EM eanderson1@partners.org FU Earle Charlton Fund for Innovative Diabetes Research (Diabetes Research Center); Massachusetts General Hospital Clinical Research Center from the National Center for Research Resources [1 UL1 RR025758-01] FX The project described was supported by the Earle Charlton Fund for Innovative Diabetes Research (Diabetes Research Center) and Grant Number 1 UL1 RR025758-01 (Massachusetts General Hospital Clinical Research Center) from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. NR 28 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD FEB PY 2014 VL 114 IS 2 BP 273 EP 278 DI 10.1016/j.jand.2013.07.008 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AB5UB UT WOS:000331853100014 PM 24051107 ER PT J AU Doyle, LA Jo, VY Hornick, JL Raut, CP Sholl, LM Lindeman, NI Fletcher, CDM Wagner, AJ AF Doyle, L. A. Jo, V. Y. Hornick, J. L. Raut, C. P. Sholl, L. M. Lindeman, N. I. Fletcher, C. D. M. Wagner, A. J. TI Genomic Analysis of 423 Sarcomas: A Single Institution Experience SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 51 BP 16A EP 16A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800052 ER PT J AU Price, RL Kurt, H Harkins, L Chiocca, AE Zhang, PZ Iwenofu, OH AF Price, R. L. Kurt, H. Harkins, L. Chiocca, A. E. Zhang, P. Z. Iwenofu, O. H. TI Human Cytomegalovirus Is Present in Alveolar Soft Part Sarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Ohio State Univ, Columbus, OH 43210 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Hosp Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 90 BP 26A EP 26A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800091 ER PT J AU Wojcik, JB Chebib, IA Rosenberg, AE Nielsen, GP Desphande, V AF Wojcik, J. B. Chebib, I. A. Rosenberg, A. E. Nielsen, G. P. Desphande, V. TI Denosumab-Treated Giant Cell Tumor of Bone May Mimic Primary Benign and Malignant Tumors of Bone SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Miami, Miller Sch Med, Jackson Mem Hosp, Miami, FL 33136 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 118 BP 32A EP 32A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800119 ER PT J AU Wojcik, JB Hornick, JL Bellizzi, AM Dal Cin, P Fletcher, CDM Nielsen, GP AF Wojcik, J. B. Hornick, J. L. Bellizzi, A. M. Dal Cin, P. Fletcher, C. D. M. Nielsen, G. P. TI Primary Sclerosing Epithelioid Fibrosarcoma of Bone: Analysis of a Series SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Iowa, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 117 BP 32A EP 32A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800118 ER PT J AU Zhang, Y Bauer, TW Wojcik, JB Nielsen, GP Rosenberg, AE AF Zhang, Y. Bauer, T. W. Wojcik, J. B. Nielsen, G. P. Rosenberg, A. E. TI Giant Cell Tumor of Bone in Children and Adolescent -A Series of 43 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Cleveland Clin, Cleveland, OH 44106 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Miami, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 124 BP 33A EP 33A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800125 ER PT J AU Beca, F Martins, D Schmitt, F AF Beca, F. Martins, D. Schmitt, F. TI PPP2R2A Expression Identifies a Subgroup of Luminal Breast Cancer with Increased Risk of Relapse and Death SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal. Univ Toronto, Fac Med, Toronto, ON, Canada. Univ Hlth Network, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 142 BP 38A EP 38A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800143 ER PT J AU Chiang, S Cole, KS Baker, G Singh, K Batten, JM Iafrate, AJ Schnitt, SJ AF Chiang, S. Cole, K. S. Baker, G. Singh, K. Batten, J. M. Iafrate, A. J. Schnitt, S. J. TI Solid Papillary Neoplasms with Reverse Polarization (SPNRPs): Histologic, Immunophenotypic and Genotypic Characterization of a Distinctive Breast Tumor SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Montefiore Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 155 BP 41A EP 41A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800156 ER PT J AU Collins, LC Wagle, N Gelber, S Larsen, B Ruddy, K White, S Brachtel, E Schapira, L Come, SE Borges, V Warner, E Winer, E Partridge, A AF Collins, L. C. Wagle, N. Gelber, S. Larsen, B. Ruddy, K. White, S. Brachtel, E. Schapira, L. Come, S. E. Borges, V. Warner, E. Winer, E. Partridge, A. TI Whole Exome Sequencing (WES): A Pilot Study in Young Women with Breast Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Dana Farber Canc Ctr, Boston, MA USA. Broad Inst Harvard & MIT, Cambridge, MA USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 159 BP 42A EP 42A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800160 ER PT J AU DeNicola, M Phan, RT Nham, P Moatamed, NA AF DeNicola, M. Phan, R. T. Nham, P. Moatamed, N. A. TI Deletion of EGFR Exon 19 in Invasive Lobular Breast Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 168 BP 44A EP 44A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800169 ER PT J AU Dong, F Lerwill, MF Brachtel, EF Knoblauch, NW Montaser-Kouhsari, L Jones, NC Wilbur, DC Beck, AH AF Dong, F. Lerwill, M. F. Brachtel, E. F. Knoblauch, N. W. Montaser-Kouhsari, L. Jones, N. C. Wilbur, D. C. Beck, A. H. TI Computational Image Analysis of Nuclear Morphology Distinguishes Ductal Carcinoma In Situ from Usual Ductal Hyperplasia of the Breast SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 175 BP 45A EP 46A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800176 ER PT J AU Stone, JR Semigran, MJ Parks, KA AF Stone, J. R. Semigran, M. J. Parks, K. A. TI Elevated Myocardial Expression of Heterogeneous Nuclear Ribonucleoprotein C Predicts Recovery in Patients with Acute Systolic Heart Failure SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Stone, J. R.; Semigran, M. J.; Parks, K. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 373 BP 94A EP 94A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800374 ER PT J AU Chebib, I Nielsen, GP Deshpande, V AF Chebib, I. Nielsen, G. P. Deshpande, V. TI Cytomorphologic Features That Distinguish Schwannoma from Other Low-Grade Spindle Cell Lesions SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 391 BP 98A EP 98A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800392 ER PT J AU Nishino, M Hoang, M Boussahmain, C Della Pelle, P Morales-Oyarvide, V Mark, EJ Mino-Kenudson, M AF Nishino, M. Hoang, M. Boussahmain, C. Della Pelle, P. Morales-Oyarvide, V. Mark, E. J. Mino-Kenudson, M. TI NapsinA/p40 Antibody Cocktail to Distinguish Adenocarcinoma from Squamous Cell Carcinoma of the Lung on Cytology and Small Biopsy Specimens SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 460 BP 115A EP 115A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800461 ER PT J AU Pusztaszeri, M Sadow, PM Ushiku, A Mckee, TA Faquin, WC AF Pusztaszeri, M. Sadow, P. M. Ushiku, A. McKee, T. A. Faquin, W. C. TI MYB Immunostaining Is a Useful Ancillary Test for Distinguishing Adenoid Cystic Carcinoma from Pleomorphic Adenoma in FNAB Specimens SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Hosp Geneva, Geneva, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 469 BP 117A EP 117A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800470 ER PT J AU Pusztaszeri, M Sadow, PM Faquin, WC AF Pusztaszeri, M. Sadow, P. M. Faquin, W. C. TI CD117 May Be Useful as an Ancillary Marker for Papillary Thyroid Carcinoma in FNAB Specimens SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Hosp Geneva, Geneva, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 470 BP 117A EP 117A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800471 ER PT J AU Tabatabai, ZL Laucirica, R Barkan, GA Kurtycz, DFI Souers, R Tambouret, RH AF Tabatabai, Z. L. Laucirica, R. Barkan, G. A. Kurtycz, D. F. I. Souers, R. Tambouret, R. H. TI Pitfalls in the Diagnosis of Benign Renal Fine Needle Aspiration (FNA) Cytology Cases: Analysis of 2080 Responses from the College of American Pathologists (CAP) Nongynecologic Cytopathology Education (NGC) Program SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Baylor Coll Med, Houston, TX 77030 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. Coll Amer Pathologists, Northfield, IL USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 497 BP 124A EP 124A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800498 ER PT J AU Vaickus, LJ Tambouret, R AF Vaickus, L. J. Tambouret, R. TI A Detailed Method for Cytology Workflow Tracking SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Vaickus, L. J.; Tambouret, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 502 BP 125A EP 125A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800503 ER PT J AU Zhao, C Moriarty, AT Tambouret, RH Ghofrani, M Husain, M Laucirica, R Laser, A Fischer, A Ocal, IT Souers, RJ Russell, DK Crothers, BA AF Zhao, C. Moriarty, A. T. Tambouret, R. H. Ghofrani, M. Husain, M. Laucirica, R. Laser, A. Fischer, A. Ocal, I. T. Souers, R. J. Russell, D. K. Crothers, B. A. TI HPV Testing and Reporting Rates in 2012 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. AmeriPath, Indianapolis, IN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. PeaceHlth Lab, Vancouver, WA USA. Univ Cent Florida, Orlando, FL 32816 USA. Baylor Coll Med, Houston, TX 77030 USA. North Shore LIJ Hlth Syst, New Hyde Pk, NY USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Mayo, Scottsdale, AZ USA. CAP, Chicago, IL USA. Rochester Med Ctr, Rochester, NY USA. Col Mil US WRNMMC, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 512 BP 128A EP 128A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800513 ER PT J AU Primiani, A Muralil, M Kroshinsky, D Duncan, LM Nazarian, RM AF Primiani, A. Muralil, M. Kroshinsky, D. Duncan, L. M. Nazarian, R. M. TI Immunologic Overlap of Th17 and Th22 Cells in Acute Psoriasis and Acute Atopic Dermatitis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Primiani, A.; Muralil, M.; Kroshinsky, D.; Duncan, L. M.; Nazarian, R. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 565 BP 141A EP 141A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800566 ER PT J AU Garcia, CM Guo, Z Hardin, H Buehler, D Nose, V Asioli, S Righi, A Maletta, F Sapino, A Chen, H Lloyd, RV AF Garcia, C. Montemayor Guo, Z. Hardin, H. Buehler, D. Nose, V. Asioli, S. Righi, A. Maletta, F. Sapino, A. Chen, H. Lloyd, R. V. TI Paired Related Homeobox 1 (PRRX1) Is Associated with Epithelial-Mesenchymal Transition (EMT) in Thyroid Tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Wisconsin, Sch Medicne & Publ Hlth, Madison, WI USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Turin, Turin, Italy. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 632 BP 156A EP 156A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800633 ER PT J AU Mete, O Nose, V Asa, SL AF Mete, O. Nose, V. Asa, S. L. TI CD5 in Squamoid Morulae of Cribriform-Morular Variant Papillary Thyroid Carcinoma: A Possible Link to Divergent Thymic Differentiation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Hlth Network, Toronto, ON, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 630 BP 156A EP 156A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800631 ER PT J AU Mordes, DA Lynch, K Campbell, S Dias-Santagata, D Nose, V Louis, DN Hoang, MP AF Mordes, D. A. Lynch, K. Campbell, S. Dias-Santagata, D. Nose, V. Louis, D. N. Hoang, M. P. TI VE1 Antibody Expression in Normal Anterior Pituitary and Adrenal Cortex without Detectable BRAF V600E Mutations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Mordes, D. A.; Lynch, K.; Campbell, S.; Dias-Santagata, D.; Nose, V.; Louis, D. N.; Hoang, M. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 633 BP 156A EP 156A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800634 ER PT J AU Rinehart, EM Capelletti, M Haddad, RI Janne, PA Chau, NG Barletta, JA AF Rinehart, E. M. Capelletti, M. Haddad, R. I. Janne, P. A. Chau, N. G. Barletta, J. A. TI RAS Mutations in Medullary Thyroid Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 642 BP 158A EP 158A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800643 ER PT J AU Arnason, T Kamionek, M Yang, X Yantiss, RK Misdraji, J AF Arnason, T. Kamionek, M. Yang, X. Yantiss, R. K. Misdraji, J. TI Significance of Proximal Margin Involvement in Low Grade Appendiceal Mucinous Neoplasm SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 662 BP 163A EP 163A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800663 ER PT J AU Bledsoe, JR Shahid, M Ting, DT Rivera, MN Yilmaz, OH Deshpande, V AF Bledsoe, J. R. Shahid, M. Ting, D. T. Rivera, M. N. Yilmaz, O. H. Deshpande, V. TI Lgr5 Is Widely Expressed in the Human Gut and Overexpression Is a Biomarker of Colonic and Barrett's Esophagus-Related Dysplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Bledsoe, J. R.; Shahid, M.; Ting, D. T.; Rivera, M. N.; Yilmaz, O. H.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 672 BP 165A EP 166A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800673 ER PT J AU Bledsoe, JR Kamionek, M Mino-Kenudson, M AF Bledsoe, J. R. Kamionek, M. Mino-Kenudson, M. TI BRAF V600E Immunohistochemistry Is Sensitive and Specific for Mutation Status in Colorectal Adenocarcinoma and Is Valid before and after (Neo)Adjuvant Therapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Bledsoe, J. R.; Kamionek, M.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 673 BP 166A EP 166A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800674 ER PT J AU Hagen, C Forcione, D Puricelli, W Hui, C Nishioka, N Lauwers, GY AF Hagen, C. Forcione, D. Puricelli, W. Hui, C. Nishioka, N. Lauwers, G. Y. TI Evaluation of Basal Crypt Dysplasia in Neoplastic BE: A Single Center Study of EMR Specimens SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Hagen, C.; Forcione, D.; Puricelli, W.; Hui, C.; Nishioka, N.; Lauwers, G. Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 724 BP 178A EP 178A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800725 ER PT J AU Kamionek, M Arnason, T Lauwers, GY AF Kamionek, M. Arnason, T. Lauwers, G. Y. TI Deeply Eosinophilic Variant of CDH1 Deficient Hereditary Diffuse Gastric Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. Dalhousie Univ, Halifax, NS, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 744 BP 183A EP 183A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800745 ER PT J AU Liu, TC vanDussen, K Gao, F Li, D Towfic, F Modiano, N Winter, R Dhall, D Targan, S Xavier, R McGovern, D Stappenbeck, T AF Liu, T-C vanDussen, K. Gao, F. Li, D. Towfic, F. Modiano, N. Winter, R. Dhall, D. Targan, S. Xavier, R. McGovern, D. Stappenbeck, T. TI Paneth Cell Phenotype Correlates with Genetics, Transcriptome Profile, Pathologic Hallmark and Predicts Clinical Outcome in Crohn Disease Patients SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Washington Univ, St Louis, MO USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 779 BP 192A EP 192A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800780 ER PT J AU Primiani, A Mohamoud, F Borger, DR Deshpande, V AF Primiani, A. Mohamoud, F. Borger, D. R. Deshpande, V. TI Albumin: A Useful Marker of Bile Duct Adenoma in Its Distinction from Metastatic Pancreatic Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Primiani, A.; Mohamoud, F.; Borger, D. R.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 806 BP 198A EP 198A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801024 ER PT J AU Rice-Stitt, TL Mubeen, A Shahid, M Rivera, M Ting, D Deshpande, V AF Rice-Stitt, T. L. Mubeen, A. Shahid, M. Rivera, M. Ting, D. Deshpande, V. TI Chromogenic In Situ Hybridization for Albumin Distinguishes Intrahepatic Cholangiocarcinoma from Non-Hepatic Neoplasms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Rice-Stitt, T. L.; Mubeen, A.; Shahid, M.; Rivera, M.; Ting, D.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 812 BP 199A EP 199A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801030 ER PT J AU Sajed, D Bledsoe, J Arora, K Mino-Kenudson, M Ting, D Deshpande, V AF Sajed, D. Bledsoe, J. Arora, K. Mino-Kenudson, M. Ting, D. Deshpande, V. TI RNA In Situ Hybridization as a Surrogate Marker of LINE-1 Methylation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Sajed, D.; Bledsoe, J.; Arora, K.; Mino-Kenudson, M.; Ting, D.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 819 BP 201A EP 201A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801037 ER PT J AU Cornejo, KM Young, RH AF Cornejo, K. M. Young, R. H. TI Adult Granulosa Cell Tumors of the Testis: A Case Series of 31 Patients SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Cornejo, K. M.; Young, R. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 912 BP 222A EP 222A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801130 ER PT J AU Cornejo, KM Dong, F Wu, CL Young, RH Braaten, K Sadow, PM Nielsen, GP Oliva, E AF Cornejo, K. M. Dong, F. Wu, C-L Young, R. H. Braaten, K. Sadow, P. M. Nielsen, G. P. Oliva, E. TI Papillary Renal Cell Carcinoma: Correlation of Tumor Grade and Histologic Characteristics with Clinical Outcome SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Cornejo, K. M.; Dong, F.; Wu, C-L; Young, R. H.; Braaten, K.; Sadow, P. M.; Nielsen, G. P.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 911 BP 222A EP 222A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801129 ER PT J AU Cortazar, JM Howitt, BE O'Donnell, E Sweeney, C Ulbright, T Hirsch, MS AF Cortazar, J. M. Howitt, B. E. O'Donnell, E. Sweeney, C. Ulbright, T. Hirsch, M. S. TI Hilar Soft Tissue Involvement by Testicular Germ Cell Tumors Is Associated with Advanced Stage Indicators SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Brookline, MA USA. Indiana Univ, Bloomington, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 913 BP 223A EP 223A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801131 ER PT J AU Lis, RT Ye, H True, LD Loda, M Peng, W Kheoh, T Tran, N Molina, A Kantoff, PW Taplin, ME Troncoso, P AF Lis, R. T. Ye, H. True, L. D. Loda, M. Peng, W. Kheoh, T. Tran, N. Molina, A. Kantoff, P. W. Taplin, M-E Troncoso, P. TI A Novel Metric to Assess Tumor Load (TL) in the Neoadjuvant Setting: Data from a Randomized, Phase 2 Trial in Patients (pts) with Localized, High-Risk Prostate Cancer (LHRPC) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Washington, Seattle, WA 98195 USA. Janssen Res & Dev, Los Angeles, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1009 BP 245A EP 245A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801227 ER PT J AU Yang, P Sadow, P Cheng, L Wang, M Xiao, Y Jiang, Z Oliva, E Feldman, AS Paul, E Thiele, EA Henske, EP Kwiatkowski, DJ Young, RH Wu, CL AF Yang, P. Sadow, P. Cheng, L. Wang, M. Xiao, Y. Jiang, Z. Oliva, E. Feldman, A. S. Paul, E. Thiele, E. A. Henske, E. P. Kwiatkowski, D. J. Young, R. H. Wu, C-L TI SDH-Deficient Renal Cell Carcinoma in Tuberous Sclerosis Complex SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1118 BP 271A EP 271A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801336 ER PT J AU Bennett, JA Dong, F Young, RH Oliva, E AF Bennett, J. A. Dong, F. Young, R. H. Oliva, E. TI A Morphologic Analysis of 95 Ovarian Clear Cell Carcinomas: Evaluating Features of Possible Prognostic Significance SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Bennett, J. A.; Dong, F.; Young, R. H.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1138 BP 276A EP 276A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801356 ER PT J AU Croce, S Young, RH Oliva, E AF Croce, S. Young, R. H. Oliva, E. TI Uterine Leiomyomas with Bizarre Nuclei. A Clinico-Pathological Study of 68 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Inst Bergonie, Bordeaux, France. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1156 BP 280A EP 280A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801374 ER PT J AU Howitt, BE Jimenez, C Barletta, JA Oliva, E Nucci, MR Hirsch, MS AF Howitt, B. E. Jimenez, C. Barletta, J. A. Oliva, E. Nucci, M. R. Hirsch, M. S. TI GATA3 Is a Sensitive and Specific Marker of Mesonephric Differentiation and Neoplasia in the Lower Mullerian Tract SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1182 BP 286A EP 286A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801400 ER PT J AU Irving, JA Lee, CH Yip, S Oliva, E McCluggage, WG Young, RH AF Irving, J. A. Lee, C-H Yip, S. Oliva, E. McCluggage, W. G. Young, R. H. TI Microcystic Stromal Tumor of the Ovary: A Distinct Ovarian Stromal Neoplasm Characterized by FOXL2, SF-1, WT-1, Cyclin D1, and beta-Catenin Nuclear Expression and CTNNB1 Mutations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Royal Jubilee Hosp, Victoria, BC, Canada. Royal Alexandra Hosp, Edmonton, AB, Canada. Univ Alberta, Edmonton, AB, Canada. Vancouver Gen Hosp, Vancouver, BC, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1187 BP 287A EP 287A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801405 ER PT J AU Lim, D Ip, P Cheung, A Kiyokawa, T Oliva, E AF Lim, D. Ip, P. Cheung, A. Kiyokawa, T. Oliva, E. TI An Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma with Clear Cell Change and Clear Cell Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Natl Univ Hlth Syst, Singapore, Singapore. Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China. Chiba Univ, Sch Med, Chiba 280, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1211 BP 293A EP 293A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801429 ER PT J AU Meserve, EE Howitt, BE Conner, JR Schulte, S Garber, J Crum, CP AF Meserve, E. E. Howitt, B. E. Conner, J. R. Schulte, S. Garber, J. Crum, C. P. TI Does BRCA plus Pelvic Serous Cancer Have a Dual Pathogenesis? The Paradox of Tubal Intraepithelial Carcinoma (TIC), Early and Advanced Disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1225 BP 296A EP 296A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801443 ER PT J AU Nucci, MR Schoolmeester, JK Sukov, W Oliva, E AF Nucci, M. R. Schoolmeester, J. K. Sukov, W. Oliva, E. TI Uterine Tumors Resembling Ovarian Sex Cord Tumor (UTROSCT) Lack Rearrangement of PHF1 by FISH SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1234 BP 298A EP 298A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801452 ER PT J AU Ojesina, AI Lichtenstein, L Murray, B Pedamallu, C Cherniack, AD Vintermyr, OK Bertelsen, B Crum, CP Salvesen, HB Meyerson, M AF Ojesina, A. I. Lichtenstein, L. Murray, B. Pedamallu, C. Cherniack, A. D. Vintermyr, O. K. Bertelsen, B. Crum, C. P. Salvesen, H. B. Meyerson, M. TI Exome Sequencing Identifies Recurrent Somatic Mutations in USP15, DSN1, PIK3CA and Chromosome 19q Gain in Cervical Adenosquamous Carcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst, Cambridge, MA USA. Univ Bergen, Bergen, Norway. Brigham & Womens Hosp, Boston, MA 02115 USA. RI salvesen, Helga/C-1187-2017 OI salvesen, Helga/0000-0002-4438-8831 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1235 BP 298A EP 299A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801453 ER PT J AU Pandya, D Shroyer, K Mallory, K Esther, O Robert, YH James, D Tornos, C AF Pandya, D. Shroyer, K. Mallory, K. Esther, O. Robert, Y. H. James, D. Tornos, C. TI Monoclonal Antibody for PAX-8 in Mesothelial Lesions of the Peritoneum: A Study of 39 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Stony Brook Univ Hosp, Stony Brook, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1237 BP 299A EP 299A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801455 ER PT J AU Reyes, C Bennett, J Rouzbahman, M Melnyk, N Huntsman, DG Nucci, MR Oliva, E Soslow, RA Lee, CH AF Reyes, C. Bennett, J. Rouzbahman, M. Melnyk, N. Huntsman, D. G. Nucci, M. R. Oliva, E. Soslow, R. A. Lee, C-H TI Fibroblastic Variant of Endometrial Stromal Sarcoma - Genetic Reclassification SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Hosp Univ Penn, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Toronto, Torontro, ON, Canada. BC Canc Agcy, Vancouver, BC, Canada. Brigham & Womens Hosp, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Alberta, Edmonton, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1252 BP 303A EP 303A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801470 ER PT J AU Shain, AF Wilbur, DC Stoler, MH Quade, BJ Kong, CS AF Shain, A. F. Wilbur, D. C. Stoler, M. H. Quade, B. J. Kong, C. S. TI Test Characteristics of Specific p16 Clones in the Detection of High-Grade Squamous Intraepithelial Lesions (HSIL) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Stanford Univ, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Virginia, Charlottesville, VA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1268 BP 307A EP 307A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801486 ER PT J AU Mochel, MC Adriano, P Lyn, DM Stefan, K AF Mochel, M. C. Adriano, P. Lyn, D. M. Stefan, K. TI Primary Mucosal Melanoma of the Aerodigestive Tract, a Clinicopathologic and Immunohistochemical Study of 35 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Mochel, M. C.; Adriano, P.; Lyn, D. M.; Stefan, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1341 BP 325A EP 325A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801559 ER PT J AU Aster, JC DeAngelo, DJ Pan, L Kluk, M Kuo, F AF Aster, J. C. DeAngelo, D. J. Pan, L. Kluk, M. Kuo, F. TI Origin of Notch-"Addicted" ETP-LL from Underlying Clonal Hematopoiesis Associated with an Acquired DNMT3a Mutation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1377 BP 334A EP 334A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801595 ER PT J AU Bledsoe, JR Hasserjian, RP Soumerai, JD Boyer, DF Nishino, HT Ferry, JA Harris, NL Abramson, JS Sohani, AR AF Bledsoe, J. R. Hasserjian, R. P. Soumerai, J. D. Boyer, D. F. Nishino, H. T. Ferry, J. A. Harris, N. L. Abramson, J. S. Sohani, A. R. TI Immunohistochemical Prognostic Markers in Primary Mediastinal Large B-Cell Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Michigan, Ann Arbor, MI 48109 USA. North Shore Med Ctr, Salem, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1385 BP 336A EP 336A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801603 ER PT J AU Boyer, DF Wang, SA Hasserjian, RP AF Boyer, D. F. Wang, S. A. Hasserjian, R. P. TI Increased FLI1 Expression in Pure Erythroid Leukemia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Michigan, Ann Arbor, MI 48109 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1393 BP 338A EP 338A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801611 ER PT J AU Chou, DB Chi, A Siddiquee, Z Kovach, AE Hasserjian, RP Sohani, AR Ryan, RJH AF Chou, D. B. Chi, A. Siddiquee, Z. Kovach, A. E. Hasserjian, R. P. Sohani, A. R. Ryan, R. J. H. TI Mef2b Expression Correlates with Bcl6 and Myc in Diffuse Large B Cell Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Chou, D. B.; Chi, A.; Siddiquee, Z.; Kovach, A. E.; Hasserjian, R. P.; Sohani, A. R.; Ryan, R. J. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1412 BP 343A EP 343A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801630 ER PT J AU Cleven, AHG Nardi, V Hamid, MAA Hasserjian, RP AF Cleven, A. H. G. Nardi, V. Hamid, M. A. Abdul Hasserjian, R. P. TI High p53 Expression Is Correlated with Complex Karyotype and Poorer Survival in Therapy-Related Myeloid Neoplasms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Leiden Univ, Med Ctr, Leiden, Netherlands. Massachusetts Gen Hosp, Boston, MA 02114 USA. Maastricht Univ, Med Ctr, Maastricht, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1414 BP 343A EP 343A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801632 ER PT J AU Czader, M Chin, A Perkins, SL Hussong, JW Dhiran, KP Felgar, RE Monaco, S Hudnall, SD Swerdlow, SH Kinney, MC Hasserjian, RP AF Czader, M. Chin, A. Perkins, S. L. Hussong, J. W. Dhiran, K. P. Felgar, R. E. Monaco, S. Hudnall, S. D. Swerdlow, S. H. Kinney, M. C. Hasserjian, R. P. TI Core Needle Biopsy in Lymphoma Diagnosis:A Multi-Institutional Study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Indiana Univ, Indianapolis, IN 46204 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Utah, Salt Lake City, UT USA. Univ Pittsburgh, Pittsburgh, PA USA. Yale Univ, Sch Med, New Haven, CT USA. Univ Texas HSC, San Antonio, TX USA. Massachussetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1417 BP 344A EP 344A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801635 ER PT J AU Hamadeh, F MacNamara, S Bacon, CM Sohani, AR Swerdlow, SH Cook, JR AF Hamadeh, F. MacNamara, S. Bacon, C. M. Sohani, A. R. Swerdlow, S. H. Cook, J. R. TI Gamma Heavy Chain Disease Lacks the MYD88 L265P Mutation Associated with Lymphoplasmacytic Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Cleveland Clin, Cleveland, OH 44106 USA. Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1441 BP 350A EP 350A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155801659 ER PT J AU Ho, YH Xu, L Treon, SP Rodig, SJ Harris, NL Sohani, AR AF Ho, Y. H. Xu, L. Treon, S. P. Rodig, S. J. Harris, N. L. Sohani, A. R. TI MYD88 L265P Mutation Analysis Aids in Classifying Nodal Small B-Cell Lymphomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Tan Tock Seng Hosp, Singapore, Singapore. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1448 BP 351A EP 351A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802004 ER PT J AU Ho, YH Xu, L Severson, EA Pinkus, GS Lindeman, NI Rodig, SJ Treon, SP Harris, NL Sohani, AR AF Ho, Y. H. Xu, L. Severson, E. A. Pinkus, G. S. Lindeman, N. I. Rodig, S. J. Treon, S. P. Harris, N. L. Sohani, A. R. TI New Immunophenotypic and Genetic Markers in the Classification of Splenic Small B-Cell Lymphomas with Prominent Red Pulp Involvement SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Tan Tock Seng Hosp, Singapore, Singapore. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1449 BP 352A EP 352A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802005 ER PT J AU Kerr, D Huck, A Tse, J Rivera, M Ting, D Ferry, J Deshpande, V AF Kerr, D. Huck, A. Tse, J. Rivera, M. Ting, D. Ferry, J. Deshpande, V. TI Chromogenic In Situ Hybridization Is Diagnostically Useful in Determining B Cell Clonality SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Kerr, D.; Huck, A.; Tse, J.; Rivera, M.; Ting, D.; Ferry, J.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1461 BP 354A EP 355A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802017 ER PT J AU Kovach, AE Fathi, AT Chen, YB Hasserjian, RP AF Kovach, A. E. Fathi, A. T. Chen, Y-B Hasserjian, R. P. TI Prognostic Significance of Residual Disease in Bone Marrow Specimens from Acute Myeloid Leukemia (AML) Patients Prior to Allogeneic Stem Cell Transplantation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Kovach, A. E.; Fathi, A. T.; Chen, Y-B; Hasserjian, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1466 BP 356A EP 356A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802022 ER PT J AU Kvasnicka, HM Thiele, J Bueso-Ramos, CE Hasserjian, RP Gianelli, U Van der Walt, J Molina, TJ Orazi, A AF Kvasnicka, H. M. Thiele, J. Bueso-Ramos, C. E. Hasserjian, R. P. Gianelli, U. Van der Walt, J. Molina, T. J. Orazi, A. TI Criteria for Therapy Response and Progression in Patients with Myelofibrosis Based on Bone Marrow Features. The International European LeukemiaNet Consensus Project SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Goethe Univ Frankfurt, D-60054 Frankfurt, Germany. Univ Cologne, D-50931 Cologne, Germany. Weill Cornell Med Coll, New York, NY USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Milan, Sch Med, Milan, Italy. St Thomas Hosp, London, England. Hop Univ Paris Ctr, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1469 BP 357A EP 357A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802025 ER PT J AU Nardi, V Pulluqi, O Abramson, J Dal Cin, P Hasserjian, RP AF Nardi, V. Pulluqi, O. Abramson, J. Dal Cin, P. Hasserjian, R. P. TI Conventional Karyotyping of Lymphoma Staging Bone Marrow Samples Does Not Contribute Clinically Relevant Information SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1495 BP 363A EP 363A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802051 ER PT J AU Pozdnyakova, O Wu, K Patki, A Rodig, SJ Thiele, J Hasserjian, R AF Pozdnyakova, O. Wu, K. Patki, A. Rodig, S. J. Thiele, J. Hasserjian, R. TI High Concordance in Grading Reticulin Fibrosis and Hematopoietic Cellularity in Patients with Myeloproliferative Neoplasms Enrolled on Fedratinib (A JAK2 Inhibitor) Trials SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Sanofi Oncol, Cambridge, MA USA. Univ Cologne, D-50931 Cologne, Germany. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1528 BP 371A EP 372A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802084 ER PT J AU Rosado, FGN Oliveira, JL Sohani, AR Schroyens, W Sykes, DB Kenderian, SJ Lacy, MQ Hoyer, JD AF Rosado, F. G. N. Oliveira, J. L. Sohani, A. R. Schroyens, W. Sykes, D. B. Kenderian, S. J. Lacy, M. Q. Hoyer, J. D. TI Bone Marrow Findings of the Newly Described TEMPI Syndrome: When Erythrocytosis and Plasma Cell Neoplasms Coincide SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Antwerp Hosp, Antwerp, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1538 BP 374A EP 375A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802094 ER PT J AU Samols, MA Kim, YH Kim, J Cappel, MA Louissaint, A Knudson, RA Ketterling, RP Harris, NL Feldman, AL Gratzinger, D AF Samols, M. A. Kim, Y. H. Kim, J. Cappel, M. A. Louissaint, A., Jr. Knudson, R. A. Ketterling, R. P. Harris, N. L. Feldman, A. L. Gratzinger, D. TI Intralymphatic Localization of Anaplastic Large Cell Lymphoma in Skin Biopsies May Represent Part of the Spectrum of Cutaneous Anaplastic Large Cell Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Stanford Univ, Sch Med, Stanford, CA 94305 USA. Mayo Clin, Jacksonville, FL 32224 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1542 BP 376A EP 376A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802098 ER PT J AU Shi, M Sun, HH Liao, X Shipp, MA Freeman, GJ Rodig, SJ AF Shi, M. Sun, H. H. Liao, X. Shipp, M. A. Freeman, G. J. Rodig, S. J. TI Expression of PD-L2, a Potent Inhibitor of Anti-Tumor Immunity, Is Characteristic of Primary Mediastinal (Thymic) Large B-Cell Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1556 BP 379A EP 379A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802112 ER PT J AU Wilbur, DC Brachtel, E Gilbertson, JR Vallone, J Krishnamurthy, S AF Wilbur, D. C. Brachtel, E. Gilbertson, J. R. Vallone, J. Krishnamurthy, S. TI Accuracy, Precision, and Reproducibility Studies of the Philips Herceptest (TM) Using Manual Glass Slide and Whole Slide Image Review SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ So Calif, Los Angeles, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1651 BP 404A EP 404A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802207 ER PT J AU Balbas, MD Burgess, MR Murali, R Wongvipat, J Skaggs, BJ Mundel, P Sawyers, CL AF Balbas, M. D. Burgess, M. R. Murali, R. Wongvipat, J. Skaggs, B. J. Mundel, P. Sawyers, C. L. TI Expression of the Multi-PDZ Domain Scaffold Protein MAGI-2 Is Necessary for Maintenance of Glomerular Slit Diaphragm Integrity SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Sawyers, Charles/G-5327-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1661 BP 406A EP 406A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802217 ER PT J AU Weins, A Mundel, P AF Weins, A. Mundel, P. TI Hic-5 and Glomerular Senescence in Chronic Proteinuric Glomerulopathies SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1704 BP 416A EP 416A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802260 ER PT J AU Arnason, T Borger, D Corless, C Hagen, C Iafrate, J Sapp, H Tsui, WM Wanless, IR Toro, TZ Lauwers, GY AF Arnason, T. Borger, D. Corless, C. Hagen, C. Iafrate, J. Sapp, H. Tsui, W. M. Wanless, I. R. Toro, T. Zuluaga Lauwers, G. Y. TI Morphology, Tumor Genetics, and Outcomes in Five Cases of Biliary Adenofibroma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Queen Elizabeth II HSC, Halifax, NS, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Caritas Med Ctr, Kowloon, Hong Kong, Peoples R China. Univ Florida, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1708 BP 417A EP 417A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802264 ER PT J AU Johncilla, M Misdraji, J Srivastava, A Pratt, DS Doyle, LA AF Johncilla, M. Misdraji, J. Srivastava, A. Pratt, D. S. Doyle, L. A. TI Ipilimumab Induced Hepatitis: Clinicopathologic Characterization in a Series of Seven Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1727 BP 421A EP 422A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802283 ER PT J AU Tse, JY Mubeen, A Shahid, M Kakar, S Bateman, A Rivera, M Ting, D Deshpande, V AF Tse, J. Y. Mubeen, A. Shahid, M. Kakar, S. Bateman, A. Rivera, M. Ting, D. Deshpande, V. TI Chromogenic In Situ Hybridization for Albumin with Branch Chain Technology Is a Robust Marker of Hepatocellular Differentiation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1764 BP 430A EP 431A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802320 ER PT J AU Fazlollahi, L Dias-Santagata, D Solus, J Bernardo, LA Marchegiani, G Fernandez-del Castillo, C Pitman, MB Mino-Kenudson, M AF Fazlollahi, L. Dias-Santagata, D. Solus, J. Bernardo, L. A. Marchegiani, G. Fernandez-del Castillo, C. Pitman, M. B. Mino-Kenudson, M. TI GNAS Mutations Are Associated with an Intestinal Lineage IPMN SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Fazlollahi, L.; Dias-Santagata, D.; Solus, J.; Bernardo, L. A.; Marchegiani, G.; Fernandez-del Castillo, C.; Pitman, M. B.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1844 BP 449A EP 449A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802400 ER PT J AU Gupta, RK Deshpande, V AF Gupta, R. K. Deshpande, V. TI The Pathology of Type 2 Autoimmune Pancreatitis: A Retrospective Analysis of Cases Resected over Last 2 Decades SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Tennessee HSC, Coll Med, Memphis, TN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1846 BP 449A EP 449A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802402 ER PT J AU Gupta, RK Santos, DD Ferrone, C Deshpande, V AF Gupta, R. K. Santos, D. D. Ferrone, C. Deshpande, V. TI Prognostic Role of Neuroendocrine Differentiation in Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Tennessee, HSC Coll Med, Memphis, TN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1847 BP 450A EP 450A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802403 ER PT J AU Sahora, K Fernandez-del Castillo, C Dong, F Marchegiani, G Mino-Kenudson, M AF Sahora, K. Fernandez-del Castillo, C. Dong, F. Marchegiani, G. Mino-Kenudson, M. TI Not All Combined Intraductal Papillary Mucinous Neoplasms Behave like Main-Duct Lesions: Implications of Minimal Involvement of the Main Pancreatic Duct SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Sahora, K.; Fernandez-del Castillo, C.; Dong, F.; Marchegiani, G.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1862 BP 453A EP 453A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802418 ER PT J AU Solus, JF Fazlollahi, L Fernandez-del Castillo, C Marchegiani, G Pitman, MB Mino-Kenudson, M AF Solus, J. F. Fazlollahi, L. Fernandez-del Castillo, C. Marchegiani, G. Pitman, M. B. Mino-Kenudson, M. TI Invasive IPMN:Two Distinct Patterns of Microscopic Invasion with Different Biology SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Solus, J. F.; Fazlollahi, L.; Fernandez-del Castillo, C.; Marchegiani, G.; Pitman, M. B.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1870 BP 455A EP 455A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802426 ER PT J AU Wu, RI Sluss, PM Mino-Kenudson, M Brugge, WR Pitman, MB AF Wu, R. I. Sluss, P. M. Mino-Kenudson, M. Brugge, W. R. Pitman, M. B. TI Analysis of VEGF/PIGF Heterodimer Level in Pancreatic Cyst Fluid as a Biomarker for Serous Cystadenoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Wu, R. I.; Sluss, P. M.; Mino-Kenudson, M.; Brugge, W. R.; Pitman, M. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1878 BP 457A EP 457A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802434 ER PT J AU Chi, A Johnstone, S Nishino, M Mark, E Mino-Kenudson, M AF Chi, A. Johnstone, S. Nishino, M. Mark, E. Mino-Kenudson, M. TI The Prevalence and Implication of Adenocarcinoma Component in Lung Cancer with Morphological Diagnosis of Squamous Cell Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1952 BP 475A EP 475A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802508 ER PT J AU Chi, AW Johnstone, SE Heist, R Mark, E Mino-Kenudson, M AF Chi, A. W. Johnstone, S. E. Heist, R. Mark, E. Mino-Kenudson, M. TI Evaluation of BCL2 and BIM Expression and KRAS Mutations in Lung Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Chi, A. W.; Johnstone, S. E.; Heist, R.; Mark, E.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1951 BP 475A EP 475A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802507 ER PT J AU Chi, AWS Johnstone, SE Wang, CI Mark, E Mino-Kenudson, M AF Chi, A. W. S. Johnstone, S. E. Wang, C. I. Mark, E. Mino-Kenudson, M. TI PIK3CA/AKT Pathway Alterations in Squamous Cell Carcinoma of the Lung SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Chi, A. W. S.; Johnstone, S. E.; Wang, C. I.; Mark, E.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1950 BP 475A EP 475A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802506 ER PT J AU Johnstone, SE Chi, A Mark, E Mino-Kenudson, M AF Johnstone, S. E. Chi, A. Mark, E. Mino-Kenudson, M. TI The Frequency of Chromatin Regulator Disruption in Squamous Cell Carcinoma of the Lung and Role for a Distinct Molecular Pathway in Tumorigenesis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Johnstone, S. E.; Chi, A.; Mark, E.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 1978 BP 481A EP 481A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802534 ER PT J AU Suzuki, M Ota, S Inayama, Y Yokoi, T Kawachi, K Wakasa, K Iijima, T Mori, D Tsukamoto, Y Yokoyama, S Takemura, T Honda, Y Haba, R Matsubara, O Mark, EJ Nakatani, Y AF Suzuki, M. Ota, S. Inayama, Y. Yokoi, T. Kawachi, K. Wakasa, K. Iijima, T. Mori, D. Tsukamoto, Y. Yokoyama, S. Takemura, T. Honda, Y. Haba, R. Matsubara, O. Mark, E. J. Nakatani, Y. TI Blastomatoid Carcinosarcoma of the Lung Is a Biphasic Tumor of High-Grade Malignancy That Needs to Be Distinguished from Pulmonary Blastoma: A Clinicopathological and Immunohistochemical Analysis of 13 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Chiba Univ, Grad Sch Med, Chiba, Japan. Chiba Univ Hosp, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 2035 BP 496A EP 496A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155802591 ER PT J AU Brown, JR AF Brown, Jennifer R. TI Ibrutinib in chronic lymphocytic leukemia and B cell malignancies SO LEUKEMIA & LYMPHOMA LA English DT Review DE Ibrutinib; BTK; CLL; NHL ID BRUTON TYROSINE KINASE; PHASE-II; IN-VIVO; PCI-32765; LYMPHOMA; MUTATIONS; RITUXIMAB; RESPONSES; TRIAL AB Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This review evaluates the data from ongoing clinical and correlative studies of ibrutinib in B cell malignancies with a particular focus on CLL, and considers these data in the context of other B cell receptor pathway inhibitors. C1 [Brown, Jennifer R.] Dana Farber Canc Inst, CLL Ctr, Dept Med Oncol, Boston, MA 02215 USA. [Brown, Jennifer R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Brown, JR (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM jbrown2@partners.org FU Leukemia and Lymphoma Society; American Cancer Society FX J.R.B. is a Scholar in Clinical Research of the Leukemia and Lymphoma Society and is supported by grants from the Leukemia and Lymphoma Society and the American Cancer Society. NR 43 TC 11 Z9 11 U1 0 U2 17 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 EI 1029-2403 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD FEB PY 2014 VL 55 IS 2 BP 263 EP 269 DI 10.3109/10428194.2013.803226 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 304FS UT WOS:000330733100008 PM 23656200 ER PT J AU Doyle, LA Jo, VY Hornick, JL Raut, CP Sholl, LM Lindeman, NI Fletcher, CDM Wagner, AJ AF Doyle, L. A. Jo, V. Y. Hornick, J. L. Raut, C. P. Sholl, L. M. Lindeman, N. I. Fletcher, C. D. M. Wagner, A. J. TI Genomic Analysis of 423 Sarcomas: A Single Institution Experience SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 51 BP 16A EP 16A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200052 ER PT J AU Price, RL Kurt, H Harkins, L Chiocca, AE Zhang, PZ Iwenofu, OH AF Price, R. L. Kurt, H. Harkins, L. Chiocca, A. E. Zhang, P. Z. Iwenofu, O. H. TI Human Cytomegalovirus Is Present in Alveolar Soft Part Sarcoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Ohio State Univ, Columbus, OH 43210 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Hosp Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 90 BP 26A EP 26A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200091 ER PT J AU Wojcik, JB Chebib, IA Rosenberg, AE Nielsen, GP Desphande, V AF Wojcik, J. B. Chebib, I. A. Rosenberg, A. E. Nielsen, G. P. Desphande, V. TI Denosumab-Treated Giant Cell Tumor of Bone May Mimic Primary Benign and Malignant Tumors of Bone SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Miami, Miller Sch Med, Jackson Mem Hosp, Miami, FL 33136 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 118 BP 32A EP 32A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200119 ER PT J AU Wojcik, JB Hornick, JL Bellizzi, AM Dal Cin, P Fletcher, CDM Nielsen, GP AF Wojcik, J. B. Hornick, J. L. Bellizzi, A. M. Dal Cin, P. Fletcher, C. D. M. Nielsen, G. P. TI Primary Sclerosing Epithelioid Fibrosarcoma of Bone: Analysis of a Series SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Iowa, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 117 BP 32A EP 32A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200118 ER PT J AU Zhang, Y Bauer, TW Wojcik, JB Nielsen, GP Rosenberg, AE AF Zhang, Y. Bauer, T. W. Wojcik, J. B. Nielsen, G. P. Rosenberg, A. E. TI Giant Cell Tumor of Bone in Children and Adolescent -A Series of 43 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Cleveland Clin, Cleveland, OH 44106 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Miami, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 124 BP 33A EP 33A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200125 ER PT J AU Beca, F Martins, D Schmitt, F AF Beca, F. Martins, D. Schmitt, F. TI PPP2R2A Expression Identifies a Subgroup of Luminal Breast Cancer with Increased Risk of Relapse and Death SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal. Univ Toronto, Fac Med, Toronto, ON, Canada. Univ Hlth Network, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 142 BP 38A EP 38A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200143 ER PT J AU Chiang, S Cole, KS Baker, G Singh, K Batten, JM Iafrate, AJ Schnitt, SJ AF Chiang, S. Cole, K. S. Baker, G. Singh, K. Batten, J. M. Iafrate, A. J. Schnitt, S. J. TI Solid Papillary Neoplasms with Reverse Polarization (SPNRPs): Histologic, Immunophenotypic and Genotypic Characterization of a Distinctive Breast Tumor SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Montefiore Med Ctr, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 155 BP 41A EP 41A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200156 ER PT J AU Collins, LC Wagle, N Gelber, S Larsen, B Ruddy, K White, S Brachtel, E Schapira, L Come, SE Borges, V Warner, E Winer, E Partridge, A AF Collins, L. C. Wagle, N. Gelber, S. Larsen, B. Ruddy, K. White, S. Brachtel, E. Schapira, L. Come, S. E. Borges, V. Warner, E. Winer, E. Partridge, A. TI Whole Exome Sequencing (WES): A Pilot Study in Young Women with Breast Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Dana Farber Canc Ctr, Boston, MA USA. Broad Inst Harvard & MIT, Cambridge, MA USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 159 BP 42A EP 42A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200160 ER PT J AU DeNicola, M Phan, RT Nham, P Moatamed, NA AF DeNicola, M. Phan, R. T. Nham, P. Moatamed, N. A. TI Deletion of EGFR Exon 19 in Invasive Lobular Breast Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 168 BP 44A EP 44A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200169 ER PT J AU Dong, F Lerwill, MF Brachtel, EF Knoblauch, NW Montaser-Kouhsari, L Jones, NC Wilbur, DC Beck, AH AF Dong, F. Lerwill, M. F. Brachtel, E. F. Knoblauch, N. W. Montaser-Kouhsari, L. Jones, N. C. Wilbur, D. C. Beck, A. H. TI Computational Image Analysis of Nuclear Morphology Distinguishes Ductal Carcinoma In Situ from Usual Ductal Hyperplasia of the Breast SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 175 BP 45A EP 46A PG 2 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200176 ER PT J AU Stone, JR Semigran, MJ Parks, KA AF Stone, J. R. Semigran, M. J. Parks, K. A. TI Elevated Myocardial Expression of Heterogeneous Nuclear Ribonucleoprotein C Predicts Recovery in Patients with Acute Systolic Heart Failure SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Stone, J. R.; Semigran, M. J.; Parks, K. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 373 BP 94A EP 94A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200373 ER PT J AU Chebib, I Nielsen, GP Deshpande, V AF Chebib, I. Nielsen, G. P. Deshpande, V. TI Cytomorphologic Features That Distinguish Schwannoma from Other Low-Grade Spindle Cell Lesions SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 391 BP 98A EP 98A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200390 ER PT J AU Nishino, M Hoang, M Boussahmain, C Della Pelle, P Morales-Oyarvide, V Mark, EJ Mino-Kenudson, M AF Nishino, M. Hoang, M. Boussahmain, C. Della Pelle, P. Morales-Oyarvide, V. Mark, E. J. Mino-Kenudson, M. TI NapsinA/p40 Antibody Cocktail to Distinguish Adenocarcinoma from Squamous Cell Carcinoma of the Lung on Cytology and Small Biopsy Specimens SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 460 BP 115A EP 115A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200459 ER PT J AU Pusztaszeri, M Sadow, PM Faquin, WC AF Pusztaszeri, M. Sadow, P. M. Faquin, W. C. TI CD117 May Be Useful as an Ancillary Marker for Papillary Thyroid Carcinoma in FNAB Specimens SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Hosp Geneva, Geneva, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 470 BP 117A EP 117A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200469 ER PT J AU Pusztaszeri, M Sadow, PM Ushiku, A McKee, TA Faquin, WC AF Pusztaszeri, M. Sadow, P. M. Ushiku, A. McKee, T. A. Faquin, W. C. TI MYB Immunostaining Is a Useful Ancillary Test for Distinguishing Adenoid Cystic Carcinoma from Pleomorphic Adenoma in FNAB Specimens SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Hosp Geneva, Geneva, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 469 BP 117A EP 117A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200468 ER PT J AU Tabatabai, ZL Laucirica, R Barkan, GA Kurtycz, DFI Souers, R Tambouret, RH AF Tabatabai, Z. L. Laucirica, R. Barkan, G. A. Kurtycz, D. F. I. Souers, R. Tambouret, R. H. TI Pitfalls in the Diagnosis of Benign Renal Fine Needle Aspiration (FNA) Cytology Cases: Analysis of 2080 Responses from the College of American Pathologists (CAP) Nongynecologic Cytopathology Education (NGC) Program SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Baylor Coll Med, Houston, TX 77030 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. Coll Amer Pathologists, Northfield, IL USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 497 BP 124A EP 124A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200496 ER PT J AU Vaickus, LJ Tambouret, R AF Vaickus, L. J. Tambouret, R. TI A Detailed Method for Cytology Workflow Tracking SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Vaickus, L. J.; Tambouret, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 502 BP 125A EP 125A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200501 ER PT J AU Zhao, C Moriarty, AT Tambouret, RH Ghofrani, M Husain, M Laucirica, R Laser, A Fischer, A Ocal, IT Souers, RJ Russell, DK Crothers, BA AF Zhao, C. Moriarty, A. T. Tambouret, R. H. Ghofrani, M. Husain, M. Laucirica, R. Laser, A. Fischer, A. Ocal, I. T. Souers, R. J. Russell, D. K. Crothers, B. A. TI HPV Testing and Reporting Rates in 2012 SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. AmeriPath, Indianapolis, IN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. PeaceHlth Lab, Vancouver, WA USA. Univ Cent Florida, Orlando, FL 32816 USA. Baylor Coll Med, Houston, TX 77030 USA. North Shore LIJ Hlth Syst, New Hyde Pk, NY USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Mayo, Scottsdale, AZ USA. CAP, Chicago, IL USA. Rochester Med Ctr, Rochester, NY USA. Col Mil US WRNMMC, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 512 BP 128A EP 128A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200511 ER PT J AU Primtani, A Muralil, M Kroshinsky, D Duncan, LM Nazarian, RM AF Primtani, A. Muralil, M. Kroshinsky, D. Duncan, L. M. Nazarian, R. M. TI Immunologic Overlap of Th17 and Th22 Cells in Acute Psoriasis and Acute Atopic Dermatitis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Primtani, A.; Muralil, M.; Kroshinsky, D.; Duncan, L. M.; Nazarian, R. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 565 BP 141A EP 141A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200564 ER PT J AU Garcia, CM Guo, Z Hardin, H Buehler, D Nose, V Asioli, S Righi, A Maletta, F Sapino, A Chen, H Lloyd, RV AF Garcia, C. Montemayor Guo, Z. Hardin, H. Buehler, D. Nose, V. Asioli, S. Righi, A. Maletta, F. Sapino, A. Chen, H. Lloyd, R. V. TI Paired Related Homeobox 1 (PRRX1) Is Associated with Epithelial-Mesenchymal Transition (EMT) in Thyroid Tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. Massachussetts Gen Hosp, Boston, MA USA. Univ Turin, Turin, Italy. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 632 BP 156A EP 156A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200631 ER PT J AU Mete, O Nose, V Asa, SL AF Mete, O. Nose, V. Asa, S. L. TI CD5 in Squamoid Morulae of Cribriform-Morular Variant Papillary Thyroid Carcinoma: A Possible Link to Divergent Thymic Differentiation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Hlth Network, Toronto, ON, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 630 BP 156A EP 156A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200629 ER PT J AU Mordes, DA Lynch, K Campbell, S Dias-Santagata, D Nose, V Louis, DN Hoang, MP AF Mordes, D. A. Lynch, K. Campbell, S. Dias-Santagata, D. Nose, V. Louis, D. N. Hoang, M. P. TI VE1 Antibody Expression in Normal Anterior Pituitary and Adrenal Cortex without Detectable BRAF V600E Mutations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Mordes, D. A.; Lynch, K.; Campbell, S.; Dias-Santagata, D.; Nose, V.; Louis, D. N.; Hoang, M. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 633 BP 156A EP 156A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200632 ER PT J AU Rinehart, EM Capelletti, M Haddad, RI Janne, PA Chau, NG Barletta, JA AF Rinehart, E. M. Capelletti, M. Haddad, R. I. Janne, P. A. Chau, N. G. Barletta, J. A. TI RAS Mutations in Medullary Thyroid Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 642 BP 158A EP 158A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200641 ER PT J AU Arnason, T Kamionek, M Yang, X Yantiss, RK Misdraji, J AF Arnason, T. Kamionek, M. Yang, X. Yantiss, R. K. Misdraji, J. TI Significance of Proximal Margin Involvement in Low Grade Appendiceal Mucinous Neoplasm SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 662 BP 163A EP 163A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200661 ER PT J AU Bledsoe, JR Shahid, M Ting, DT Rivera, MN Yilmaz, OH Deshpande, V AF Bledsoe, J. R. Shahid, M. Ting, D. T. Rivera, M. N. Yilmaz, O. H. Deshpande, V. TI Lgr5 Is Widely Expressed in the Human Gut and Overexpression Is a Biomarker of Colonic and Barrett's Esophagus-Related Dysplasia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Bledsoe, J. R.; Shahid, M.; Ting, D. T.; Rivera, M. N.; Yilmaz, O. H.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 672 BP 165A EP 166A PG 2 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200671 ER PT J AU Bledsoe, JR Kamionek, M Mino-Kenudson, M AF Bledsoe, J. R. Kamionek, M. Mino-Kenudson, M. TI BRAF V600E Immunohistochemistry Is Sensitive and Specific for Mutation Status in Colorectal Adenocarcinoma and Is Valid before and after (Neo)Adjuvant Therapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Bledsoe, J. R.; Kamionek, M.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 673 BP 166A EP 166A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200672 ER PT J AU Hagen, C Forcione, D Puricelli, W Hur, C Nishioka, N Lauwers, GY AF Hagen, C. Forcione, D. Puricelli, W. Hur, C. Nishioka, N. Lauwers, G. Y. TI Evaluation of Basal Crypt Dysplasia in Neoplastic BE: A Single Center Study of EMR Specimens SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Hagen, C.; Forcione, D.; Puricelli, W.; Hur, C.; Nishioka, N.; Lauwers, G. Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 724 BP 178A EP 178A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201039 ER PT J AU Kamionek, M Arnason, T Lanwers, GY AF Kamionek, M. Arnason, T. Lanwers, G. Y. TI Deeply Eosinophilic Variant of CDH1 Deficient Hereditary Diffuse Gastric Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. Dalhousie Univ, Halifax, NS, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 744 BP 183A EP 183A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201059 ER PT J AU Liu, TC vanDussen, K Gao, F Li, D Towfic, F Modiano, N Winter, R Dhall, D Targan, S Xavier, R McGovern, D AF Liu, T-C vanDussen, K. Gao, F. Li, D. Towfic, F. Modiano, N. Winter, R. Dhall, D. Targan, S. Xavier, R. McGovern, D. TI Paneth Cell Phenotype Correlates with Genetics, Transcriptome Profile, Pathologic Hallmark and Predicts Clinical Outcome in Crohn Disease Patients SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Washington Univ, St Louis, MO USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 779 BP 192A EP 192A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201094 ER PT J AU Primiani, A Mohamoud, F Borger, DR Deshpande, V AF Primiani, A. Mohamoud, F. Borger, D. R. Deshpande, V. TI Albumin: A Useful Marker of Bile Duct Adenoma in Its Distinction from Metastatic Pancreatic Adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Primiani, A.; Mohamoud, F.; Borger, D. R.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 806 BP 198A EP 198A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201121 ER PT J AU Rice-Stitt, TL Mubeen, A Shahid, M Rivera, M Ting, D Deshpande, V AF Rice-Stitt, T. L. Mubeen, A. Shahid, M. Rivera, M. Ting, D. Deshpande, V. TI Chromogenic In Situ Hybridization for Albumin Distinguishes Intrahepatic Cholangiocarcinoma from Non-Hepatic Neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Rice-Stitt, T. L.; Mubeen, A.; Shahid, M.; Rivera, M.; Ting, D.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 812 BP 199A EP 199A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201127 ER PT J AU Sajed, D Bledsoe, J Arora, K Mino-Kenudson, M Ting, D Deshpande, V AF Sajed, D. Bledsoe, J. Arora, K. Mino-Kenudson, M. Ting, D. Deshpande, V. TI RNA In Situ Hybridization as a Surrogate Marker of LINE-1 Methylation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Sajed, D.; Bledsoe, J.; Arora, K.; Mino-Kenudson, M.; Ting, D.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 819 BP 201A EP 201A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201134 ER PT J AU Cornejo, KM Young, RH AF Cornejo, K. M. Young, R. H. TI Adult Granulosa Cell Tumors of the Testis: A Case Series of 31 Patients SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Cornejo, K. M.; Young, R. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 912 BP 222A EP 222A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201227 ER PT J AU Cornejo, KM Dong, F Wu, CL Young, RH Braaten, K Sadow, PM Nielsen, GP Oliva, E AF Cornejo, K. M. Dong, F. Wu, C-L Young, R. H. Braaten, K. Sadow, P. M. Nielsen, G. P. Oliva, E. TI Papillary Renal Cell Carcinoma: Correlation of Tumor Grade and Histologic Characteristics with Clinical Outcome SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Cornejo, K. M.; Dong, F.; Wu, C-L; Young, R. H.; Braaten, K.; Sadow, P. M.; Nielsen, G. P.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 911 BP 222A EP 222A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201226 ER PT J AU Cortazar, JM Howitt, BE O'Donnell, E Sweeney, C Ulbright, T Hirsch, MS AF Cortazar, J. M. Howitt, B. E. O'Donnell, E. Sweeney, C. Ulbright, T. Hirsch, M. S. TI Hilar Soft Tissue Involvement by Testicular Germ Cell Tumors Is Associated with Advanced Stage Indicators SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Brookline, MA USA. Indiana Univ, Bloomington, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 913 BP 223A EP 223A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201228 ER PT J AU Lis, RT Ye, H True, LD Loda, M Peng, W Kheoh, T Tran, N Molina, A Kantoff, PW Taplin, ME Troncoso, P AF Lis, R. T. Ye, H. True, L. D. Loda, M. Peng, W. Kheoh, T. Tran, N. Molina, A. Kantoff, P. W. Taplin, M-E Troncoso, P. TI A Novel Metric to Assess Tumor Load (TL) in the Neoadjuvant Setting: Data from a Randomized, Phase 2 Trial in Patients (pts) with Localized, High-Risk Prostate Cancer (LHRPC) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Washington, Seattle, WA 98195 USA. Janssen Res & Dev, Los Angeles, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1009 BP 245A EP 245A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201324 ER PT J AU Yang, P Sadow, P Cheng, L Wang, M Xiao, Y Jiang, Z Oliva, E Feldman, AS Paul, E Thiele, EA Henske, EP Kwiatkowski, DJ Young, RH Wu, CL AF Yang, P. Sadow, P. Cheng, L. Wang, M. Xiao, Y. Jiang, Z. Oliva, E. Feldman, A. S. Paul, E. Thiele, E. A. Henske, E. P. Kwiatkowski, D. J. Young, R. H. Wu, C-L TI SDH-Deficient Renal Cell Carcinoma in Tuberous Sclerosis Complex SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1118 BP 271A EP 271A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201433 ER PT J AU Bennett, JA Dong, F Young, RH Oliva, E AF Bennett, J. A. Dong, F. Young, R. H. Oliva, E. TI A Morphologic Analysis of 95 Ovarian Clear Cell Carcinomas: Evaluating Features of Possible Prognostic Significance SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Bennett, J. A.; Dong, F.; Young, R. H.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1138 BP 276A EP 276A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201453 ER PT J AU Croce, S Young, RH Oliva, E AF Croce, S. Young, R. H. Oliva, E. TI Uterine Leiomyomas with Bizarre Nuclei. A Clinico-Pathological Study of 68 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Inst Bergonie, Bordeaux, France. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1156 BP 280A EP 280A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201471 ER PT J AU Howitt, BE Jimenez, C Barletta, JA Oliva, E Nucci, MR Hirsch, MS AF Howitt, B. E. Jimenez, C. Barletta, J. A. Oliva, E. Nucci, M. R. Hirsch, M. S. TI GATA3 Is a Sensitive and Specific Marker of Mesonephric Differentiation and Neoplasia in the Lower Mullerian Tract SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1182 BP 286A EP 286A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201497 ER PT J AU Lim, D Ip, P Cheung, A Kiyokawa, T Oliva, E AF Lim, D. Ip, P. Cheung, A. Kiyokawa, T. Oliva, E. TI An Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma with Clear Cell Change and Clear Cell Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Natl Univ Hlth Syst, Singapore, Singapore. Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China. Chiba Univ, Sch Med, Chiba 280, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1211 BP 293A EP 293A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201526 ER PT J AU Meserve, EE Howitt, BE Conner, JR Schulte, S Garber, J Crum, CP AF Meserve, E. E. Howitt, B. E. Conner, J. R. Schulte, S. Garber, J. Crum, C. P. TI Does BRCA plus Pelvic Serous Cancer Have a Dual Pathogenesis? The Paradox of Tubal Intraepithelial Carcinoma (TIC), Early and Advanced Disease SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1225 BP 296A EP 296A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201540 ER PT J AU Nucci, MR Schoolmeester, JK Sukov, W Oliva, E AF Nucci, M. R. Schoolmeester, J. K. Sukov, W. Oliva, E. TI Uterine Tumors Resembling Ovarian Sex Cord Tumor (UTROSCT) Lack Rearrangement of PHF1 by FISH SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1234 BP 298A EP 298A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201549 ER PT J AU Ojesina, AI Lichtenstein, L Murray, B Pedamallu, C Cherniack, AD Vintermyr, OK Bertelsen, B Crum, CP Salvesen, HB Meyerson, M AF Ojesina, A. I. Lichtenstein, L. Murray, B. Pedamallu, C. Cherniack, A. D. Vintermyr, O. K. Bertelsen, B. Crum, C. P. Salvesen, H. B. Meyerson, M. TI Exome Sequencing Identifies Recurrent Somatic Mutations in USP15, DSN1, PIK3CA and Chromosome 19q Gain in Cervical Adenosquamous Carcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst, Cambridge, MA USA. Univ Bergen, Bergen, Norway. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1235 BP 298A EP 299A PG 2 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201550 ER PT J AU Pandya, D Shroyer, K Mallory, K Esther, O Robert, YH James, D Tornos, C AF Pandya, D. Shroyer, K. Mallory, K. Esther, O. Robert, Y. H. James, D. Tornos, C. TI Monoclonal Antibody for PAX-8 in Mesothelial Lesions of the Peritoneum: A Study of 39 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Stony Brook Univ Hosp, Stony Brook, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1237 BP 299A EP 299A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201552 ER PT J AU Reyes, C Bennett, J Rouzbahman, M Melnyk, N Huntsman, DG Nucci, MR Oliva, E Soslow, RA Lee, CH AF Reyes, C. Bennett, J. Rouzbahman, M. Melnyk, N. Huntsman, D. G. Nucci, M. R. Oliva, E. Soslow, R. A. Lee, C-H TI Fibroblastic Variant of Endometrial Stromal Sarcoma - Genetic Reclassification SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Hosp Univ Penn, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Toronto, Torontro, ON, Canada. BC Canc Agcy, Vancouver, BC, Canada. Brigham & Womens Hosp, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Alberta, Edmonton, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1252 BP 303A EP 303A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201567 ER PT J AU Shain, AF Wilbur, DC Stoler, MH Quade, BJ Kong, CS AF Shain, A. F. Wilbur, D. C. Stoler, M. H. Quade, B. J. Kong, C. S. TI Test Characteristics of Specific p16 Clones in the Detection of High-Grade Squamous Intraepithelial Lesions (HSIL) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Stanford Univ, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Virginia, Charlottesville, VA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1268 BP 307A EP 307A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201583 ER PT J AU Mochel, MC Adriano, P Lyn, DM Stefan, K AF Mochel, M. C. Adriano, P. Lyn, D. M. Stefan, K. TI Primary Mucosal Melanoma of the Aerodigestive Tract, a Clinicopathologic and Immunohistochemical Study of 35 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Mochel, M. C.; Adriano, P.; Lyn, D. M.; Stefan, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1341 BP 325A EP 325A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201656 ER PT J AU Aster, JC DeAngelo, DJ Pan, L Kluk, M Kuo, F AF Aster, J. C. DeAngelo, D. J. Pan, L. Kluk, M. Kuo, F. TI Origin of Notch-"Addicted" ETP-LL from Underlying Clonal Hematopoiesis Associated with an Acquired DNMT3a Mutation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1377 BP 334A EP 334A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201692 ER PT J AU Bledsoe, JR Hasserjian, RP Soumerai, JD Boyer, DF Nishino, HT Ferry, JA Harris, NL Abramson, JS Sohani, AR AF Bledsoe, J. R. Hasserjian, R. P. Soumerai, J. D. Boyer, D. F. Nishino, H. T. Ferry, J. A. Harris, N. L. Abramson, J. S. Sohani, A. R. TI Immunohistochemical Prognostic Markers in Primary Mediastinal Large B-Cell Lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Michigan, Ann Arbor, MI 48109 USA. North Shore Med Ctr, Salem, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1385 BP 336A EP 336A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201700 ER PT J AU Boyer, DF Wang, SA Hasserjian, RP AF Boyer, D. F. Wang, S. A. Hasserjian, R. P. TI Increased FLI1 Expression in Pure Erythroid Leukemia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Michigan, Ann Arbor, MI 48109 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1393 BP 338A EP 338A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201708 ER PT J AU Chou, DB Chi, A Siddiquee, Z Kovach, AE Hasserjian, RP Sohani, AR Ryan, RJH AF Chou, D. B. Chi, A. Siddiquee, Z. Kovach, A. E. Hasserjian, R. P. Sohani, A. R. Ryan, R. J. H. TI Mef2b Expression Correlates with Bcl6 and Myc in Diffuse Large B Cell Lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Chou, D. B.; Chi, A.; Siddiquee, Z.; Kovach, A. E.; Hasserjian, R. P.; Sohani, A. R.; Ryan, R. J. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1412 BP 343A EP 343A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201727 ER PT J AU Cleven, AHG Nardi, V Hamid, MAA Hasserjian, RP AF Cleven, A. H. G. Nardi, V. Hamid, M. A. Abdul Hasserjian, R. P. TI High p53 Expression Is Correlated with Complex Karyotype and Poorer Survival in Therapy-Related Myeloid Neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Leiden Univ, Med Ctr, Leiden, Netherlands. Massachusetts Gen Hosp, Boston, MA 02114 USA. Maastricht Univ, Med Ctr, Maastricht, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1414 BP 343A EP 343A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201729 ER PT J AU Czader, M Chiu, A Perkins, SL Hussong, JW Dhiran, KP Felgar, RE Monaco, S Hudnall, SD Swerdlow, SH Kinney, MC Hasserjian, RP AF Czader, M. Chiu, A. Perkins, S. L. Hussong, J. W. Dhiran, K. P. Felgar, R. E. Monaco, S. Hudnall, S. D. Swerdlow, S. H. Kinney, M. C. Hasserjian, R. P. TI Core Needle Biopsy in Lymphoma Diagnosis:A Multi-Institutional Study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Indiana Univ, Indianapolis, IN 46204 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Utah, Salt Lake City, UT USA. Univ Pittsburgh, Pittsburgh, PA USA. Yale Univ, Sch Med, New Haven, CT USA. Univ Texas HSC, San Antonio, TX USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1417 BP 344A EP 344A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201732 ER PT J AU Hamadeh, F MacNamara, S Bacon, CM Sohani, AR Swerdlow, SH Cook, JR AF Hamadeh, F. MacNamara, S. Bacon, C. M. Sohani, A. R. Swerdlow, S. H. Cook, J. R. TI Gamma Heavy Chain Disease Lacks the MYD88 L265P Mutation Associated with Lymphoplasmacytic Lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Cleveland Clin, Cleveland, OH 44106 USA. Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1441 BP 350A EP 350A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502201756 ER PT J AU Ho, YH Xu, L Treon, SP Rodig, SJ Harris, NL Sohani, AR AF Ho, Y. H. Xu, L. Treon, S. P. Rodig, S. J. Harris, N. L. Sohani, A. R. TI MYD88 L265P Mutation Analysis Aids in Classifying Nodal Small B-Cell Lymphomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Tan Tock Seng Hosp, Singapore, Singapore. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1448 BP 351A EP 351A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202004 ER PT J AU Ho, YH Xu, L Severson, EA Pinkus, GS Lindeman, NI Rodig, SJ Treon, SP Harris, NL Sohani, AR AF Ho, Y. H. Xu, L. Severson, E. A. Pinkus, G. S. Lindeman, N. I. Rodig, S. J. Treon, S. P. Harris, N. L. Sohani, A. R. TI New Immunophenotypic and Genetic Markers in the Classification of Splenic Small B-Cell Lymphomas with Prominent Red Pulp Involvement SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Tan Tock Seng Hosp, Singapore, Singapore. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1449 BP 352A EP 352A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202005 ER PT J AU Kerr, D Huck, A Tse, J Rivera, M Ting, D Ferry, J Deshpande, V AF Kerr, D. Huck, A. Tse, J. Rivera, M. Ting, D. Ferry, J. Deshpande, V. TI Chromogenic In Situ Hybridization Is Diagnostically Useful in Determining B Cell Clonality SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Kerr, D.; Huck, A.; Tse, J.; Rivera, M.; Ting, D.; Ferry, J.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1461 BP 354A EP 355A PG 2 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202017 ER PT J AU Kovach, AE Fathi, AT Chen, YB Hasserjian, RP AF Kovach, A. E. Fathi, A. T. Chen, Y-B Hasserjian, R. P. TI Prognostic Significance of Residual Disease in Bone Marrow Specimens from Acute Myeloid Leukemia (AML) Patients Prior to Allogeneic Stem Cell Transplantation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Kovach, A. E.; Fathi, A. T.; Chen, Y-B; Hasserjian, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1466 BP 356A EP 356A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202022 ER PT J AU Kvasnicka, HM Thiele, J Bueso-Ramos, CE Hasserjian, RP Gianelli, U Van der Walt, J Molina, TJ Orazi, A AF Kvasnicka, H. M. Thiele, J. Bueso-Ramos, C. E. Hasserjian, R. P. Gianelli, U. Van der Walt, J. Molina, T. J. Orazi, A. TI Criteria for Therapy Response and Progression in Patients with Myelofibrosis Based on Bone Marrow Features. The International European LeukemiaNet Consensus Project SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Goethe Univ Frankfurt, D-60054 Frankfurt, Germany. Univ Cologne, D-50931 Cologne, Germany. Weill Cornell Med Coll, New York, NY USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Milan, Sch Med, Milan, Italy. St Thomas Hosp, London, England. Hop Univ Paris Ctr, Paris, France. RI Kvasnicka, Hans Michael/E-7993-2011 OI Kvasnicka, Hans Michael/0000-0002-3081-1395 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1469 BP 357A EP 357A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202025 ER PT J AU Nardi, V Pulluqi, O Abramson, J Dal Cin, P Hasserjian, RP AF Nardi, V. Pulluqi, O. Abramson, J. Dal Cin, P. Hasserjian, R. P. TI Conventional Karyotyping of Lymphoma Staging Bone Marrow Samples Does Not Contribute Clinically Relevant Information SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1495 BP 363A EP 363A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202051 ER PT J AU Pozdnyakova, O Wu, K Patki, A Rodig, SJ Thiele, J Hasserjian, R AF Pozdnyakova, O. Wu, K. Patki, A. Rodig, S. J. Thiele, J. Hasserjian, R. TI High Concordance in Grading Reticulin Fibrosis and Hematopoietic Cellularity in Patients with Myeloproliferative Neoplasms Enrolled on Fedratinib (A JAK2 Inhibitor) Trials SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Sanofi Oncol, Cambridge, MA USA. Univ Cologne, D-50931 Cologne, Germany. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1528 BP 371A EP 372A PG 2 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202084 ER PT J AU Rosado, FGN Oliveira, JL Sohani, AR Schroyens, W Sykes, DB Kenderian, SJ Lacy, MQ Hoyer, JD AF Rosado, F. G. N. Oliveira, J. L. Sohani, A. R. Schroyens, W. Sykes, D. B. Kenderian, S. J. Lacy, M. Q. Hoyer, J. D. TI Bone Marrow Findings of the Newly Described TEMPI Syndrome: When Erythrocytosis and Plasma Cell Neoplasms Coincide SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Antwerp Hosp, Antwerp, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1538 BP 374A EP 375A PG 2 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202094 ER PT J AU Samols, MA Kim, YH Kim, J Cappel, MA Louissaint, A Knudson, RA Ketterling, RP Harris, NL Feldman, AL Gratzinger, D AF Samols, M. A. Kim, Y. H. Kim, J. Cappel, M. A. Louissaint, A., Jr. Knudson, R. A. Ketterling, R. P. Harris, N. L. Feldman, A. L. Gratzinger, D. TI Intralymphatic Localization of Anaplastic Large Cell Lymphoma in Skin Biopsies May Represent Part of the Spectrum of Cutaneous Anaplastic Large Cell Lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Stanford Univ, Sch Med, Stanford, CA 94305 USA. Mayo Clin, Jacksonville, FL 32224 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1542 BP 376A EP 376A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202098 ER PT J AU Shi, M Sun, HH Liao, X Shipp, MA Freeman, GJ Rodig, SJ AF Shi, M. Sun, H. H. Liao, X. Shipp, M. A. Freeman, G. J. Rodig, S. J. TI Expression of PD-L2, a Potent Inhibitor of Anti-Tumor Immunity, Is Characteristic of Primary Mediastinal (Thymic) Large B-Cell Lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1556 BP 379A EP 379A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202112 ER PT J AU Wilbur, DC Brachtel, E Gilbertson, JR Vallone, J Krishnamurthy, S AF Wilbur, D. C. Brachtel, E. Gilbertson, J. R. Vallone, J. Krishnamurthy, S. TI Accuracy, Precision, and Reproducibility Studies of the Philips Herceptest (TM) Using Manual Glass Slide and Whole Slide Image Review SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ So Calif, Los Angeles, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1651 BP 404A EP 404A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202207 ER PT J AU Balbas, MD Burgess, MR Murali, R Wongvipat, J Skaggs, BJ Mundel, P Sawyers, CL AF Balbas, M. D. Burgess, M. R. Murali, R. Wongvipat, J. Skaggs, B. J. Mundel, P. Sawyers, C. L. TI Expression of the Multi-PDZ Domain Scaffold Protein MAGI-2 Is Necessary for Maintenance of Glomerular Slit Diaphragm Integrity SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1661 BP 406A EP 406A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202217 ER PT J AU Weins, A Mundel, P AF Weins, A. Mundel, P. TI Hic-5 and Glomerular Senescence in Chronic Proteinuric Glomerulopathies SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1704 BP 416A EP 416A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202260 ER PT J AU Arnason, T Borger, D Corless, C Hagen, C Iafrate, J Sapp, H Tsui, WM Wanless, IR Toro, TZ Lauwers, GY AF Arnason, T. Borger, D. Corless, C. Hagen, C. Iafrate, J. Sapp, H. Tsui, W. M. Wanless, I. R. Toro, T. Zuluaga Lauwers, G. Y. TI Morphology, Tumor Genetics, and Outcomes in Five Cases of Biliary Adenofibroma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Queen Elizabeth II HSC, Halifax, NS, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Caritas Med Ctr, Kowloon, Hong Kong, Peoples R China. Univ Florida, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1708 BP 417A EP 417A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202264 ER PT J AU Johncilla, M Misdraji, J Srivastava, A Pratt, DS Doyle, LA AF Johncilla, M. Misdraji, J. Srivastava, A. Pratt, D. S. Doyle, L. A. TI Ipilimumab Induced Hepatitis: Clinicopathologic Characterization in a Series of Seven Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1727 BP 421A EP 422A PG 2 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202283 ER PT J AU Tse, JY Mubeen, A Shahid, M Kakar, S Bateman, A Rivera, M Ting, D Deshpande, V AF Tse, J. Y. Mubeen, A. Shahid, M. Kakar, S. Bateman, A. Rivera, M. Ting, D. Deshpande, V. TI Chromogenic In Situ Hybridization for Albumin with Branch Chain Technology Is a Robust Marker of Hepatocellular Differentiation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1764 BP 430A EP 431A PG 2 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202320 ER PT J AU Fazlollahi, L Dias-Santagata, D Solus, J Bernardo, LA Marchegiani, G Fernandez-del Castillo, C Pitman, MB Mino-Kenudson, M AF Fazlollahi, L. Dias-Santagata, D. Solus, J. Bernardo, L. A. Marchegiani, G. Fernandez-del Castillo, C. Pitman, M. B. Mino-Kenudson, M. TI GNAS Mutations Are Associated with an Intestinal Lineage IPMN SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Fazlollahi, L.; Dias-Santagata, D.; Solus, J.; Bernardo, L. A.; Marchegiani, G.; Fernandez-del Castillo, C.; Pitman, M. B.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1844 BP 449A EP 449A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202400 ER PT J AU Gupta, RK Santos, DD Ferrone, C Deshpande, V AF Gupta, R. K. Santos, D. D. Ferrone, C. Deshpande, V. TI Prognostic Role of Neuroendocrine Differentiation in Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Tennessee HSC, Coll Med, Memphis, TN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1847 BP 450A EP 450A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202403 ER PT J AU Sahora, K Fernandez-del Castillo, C Dong, F Marchegiani, G Mino-Kenudson, M AF Sahora, K. Fernandez-del Castillo, C. Dong, F. Marchegiani, G. Mino-Kenudson, M. TI Not All Combined Intraductal Papillary Mucinous Neoplasms Behave like Main-Duct Lesions: Implications of Minimal Involvement of the Main Pancreatic Duct SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Sahora, K.; Fernandez-del Castillo, C.; Dong, F.; Marchegiani, G.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1862 BP 453A EP 453A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202418 ER PT J AU Solus, JF Fazlollahi, L Fernandez-del Castillo, C Marchegiani, G Pitman, MB Mino-Kenudson, M AF Solus, J. F. Fazlollahi, L. Fernandez-del Castillo, C. Marchegiani, G. Pitman, M. B. Mino-Kenudson, M. TI Invasive IPMN: Two Distinct Patterns of Microscopic Invasion with Different Biology SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Solus, J. F.; Fazlollahi, L.; Fernandez-del Castillo, C.; Marchegiani, G.; Pitman, M. B.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1870 BP 455A EP 455A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202426 ER PT J AU Wu, RI Sluss, PM Mino-Kenudson, M Brugge, WR Pitman, MB AF Wu, R. I. Sluss, P. M. Mino-Kenudson, M. Brugge, W. R. Pitman, M. B. TI Analysis of VEGF/PIGF Heterodimer Level in Pancreatic Cyst Fluid as a Biomarker for Serous Cystadenoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Wu, R. I.; Sluss, P. M.; Mino-Kenudson, M.; Brugge, W. R.; Pitman, M. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1878 BP 457A EP 457A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202434 ER PT J AU Chi, A Johnstone, S Nishino, M Mark, E Mino-Kenudson, M AF Chi, A. Johnstone, S. Nishino, M. Mark, E. Mino-Kenudson, M. TI The Prevalence and Implication of Adenocarcinoma Component in Lung Cancer with Morphological Diagnosis of Squamous Cell Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1952 BP 475A EP 475A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202508 ER PT J AU Chi, AW Johnstone, SE Heist, R Mark, E Mino-Kenudson, M AF Chi, A. W. Johnstone, S. E. Heist, R. Mark, E. Mino-Kenudson, M. TI Evaluation of BCL2 and BIM Expression and KRAS Mutations in Lung Adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Chi, A. W.; Johnstone, S. E.; Heist, R.; Mark, E.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1951 BP 475A EP 475A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202507 ER PT J AU Chi, AWS Johnstone, SE Wang, CI Mark, E Mino-Kenudson, M AF Chi, A. W. S. Johnstone, S. E. Wang, C. I. Mark, E. Mino-Kenudson, M. TI PIK3CA/AKT Pathway Alterations in Squamous Cell Carcinoma of the Lung SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Chi, A. W. S.; Johnstone, S. E.; Wang, C. I.; Mark, E.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1950 BP 475A EP 475A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202506 ER PT J AU Johnstone, SE Chi, A Mark, E Mino-Kenudson, M AF Johnstone, S. E. Chi, A. Mark, E. Mino-Kenudson, M. TI The Frequency of Chromatin Regulator Disruption in Squamous Cell Carcinoma of the Lung and Role for a Distinct Molecular Pathway in Tumorigenesis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 [Johnstone, S. E.; Chi, A.; Mark, E.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 1978 BP 481A EP 481A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202534 ER PT J AU Suzuki, M Ota, S Inayama, Y Yokoi, T Kawachi, K Wakasa, K Iijima, T Mori, D Tsukamoto, Y Yokoyama, S Takemura, T Honda, Y Haba, R Matsubara, O Mark, EJ Nakatani, Y AF Suzuki, M. Ota, S. Inayama, Y. Yokoi, T. Kawachi, K. Wakasa, K. Iijima, T. Mori, D. Tsukamoto, Y. Yokoyama, S. Takemura, T. Honda, Y. Haba, R. Matsubara, O. Mark, E. J. Nakatani, Y. TI Blastomatoid Carcinosarcoma of the Lung Is a Biphasic Tumor of High-Grade Malignancy That Needs to Be Distinguished from Pulmonary Blastoma: A Clinicopathological and Immunohistochemical Analysis of 13 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Chiba Univ, Grad Sch Med, Chiba, Japan. Chiba Univ Hosp, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 2035 BP 496A EP 496A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502202591 ER PT J AU Williamson, CA Wahlster, S Shafi, MM Westover, MB AF Williamson, Craig A. Wahlster, Sarah Shafi, Mouhsin M. Westover, M. Brandon TI Sensitivity of Compressed Spectral Arrays for Detecting Seizures in Acutely Ill Adults SO NEUROCRITICAL CARE LA English DT Article DE Continuous EEG monitoring; Quantitative EEG; Compressed spectral array; Seizures ID INTENSIVE-CARE-UNIT; AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAPHY; NONCONVULSIVE STATUS EPILEPTICUS; CEREBRAL FUNCTION MONITOR; CRITICALLY-ILL; CONTINUOUS EEG; QUANTITATIVE EEG; COMATOSE PATIENTS; BRAIN-INJURY; PATTERNS AB Continuous EEG recordings (cEEGs) are increasingly used in evaluation of acutely ill adults. Pre-screening using compressed data formats, such as compressed spectral array (CSA), may accelerate EEG review. We tested whether screening with CSA can enable detection of seizures and other relevant patterns. Two individuals reviewed the CSA displays of 113 cEEGs. While blinded to the raw EEG data, they marked each visually homogeneous CSA segment. An independent experienced electroencephalographer reviewed the raw EEG within 60 s on either side of each mark and recorded any seizures (and isolated epileptiform discharges, periodic epileptiform discharges (PEDs), rhythmic delta activity (RDA), and focal or generalized slowing). Seizures were considered to have been detected if the CSA mark was within 60 s of the seizure. The electroencephalographer then determined the total number of seizures (and other critical findings) for each record by exhaustive, page-by-page review of the entire raw EEG. Within each of the 39 cEEG recordings containing seizures, one CSA reviewer identified at least one seizure, while the second CSA reviewer identified 38/39 patients with seizures. The overall detection rate was 89.0 % of 1,190 total seizures. When present, an average of 87.9 % of seizures were detected per individual patient. Detection rates for other critical findings were as follows: epileptiform discharges, 94.0 %; PEDs, 100 %; RDA, 97.9 %; focal slowing, 100 %; and generalized slowing, 100 %. CSA-guided review can support sensitive screening of critical pathological information in cEEG recordings. However, some patients with seizures may not be identified. C1 [Williamson, Craig A.] Univ Michigan Hosp, Dept Neurosurg, Ann Arbor, MI 48109 USA. [Wahlster, Sarah; Shafi, Mouhsin M.; Westover, M. Brandon] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Shafi, Mouhsin M.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. RP Shafi, MM (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurol, 330 Brookline Ave,West Baker 5, Boston, MA 02215 USA. EM craigaw@med.umich.edu; swahlster@partners.org; mouhsin.shafi@gmail.com; mwestover@partners.org FU American Brain Foundation; NIH/NINDS [NS062092]; NIH/NCATS [8KL2TR000168-05] FX This study was supported in part by the following grants: American Brain Foundation (MBW), NIH/NINDS NS062092 (MBW); NIH/NCATS 8KL2TR000168-05 (MS). NR 29 TC 10 Z9 10 U1 2 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 EI 1556-0961 J9 NEUROCRIT CARE JI Neurocrit. Care PD FEB PY 2014 VL 20 IS 1 BP 32 EP 39 DI 10.1007/s12028-013-9912-4 PG 8 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA AB2RI UT WOS:000331639400005 PM 24052456 ER PT J AU Petersen, NH Ortega-Gutierrez, S Reccius, A Masurkar, A Huang, A Marshall, RS AF Petersen, Nils H. Ortega-Gutierrez, Santiago Reccius, Andres Masurkar, Arjun Huang, Amy Marshall, Randolph S. TI Comparison of Non-invasive and Invasive Arterial Blood Pressure Measurement for Assessment of Dynamic Cerebral Autoregulation SO NEUROCRITICAL CARE LA English DT Article DE Dynamic cerebral autoregulation; Cerebral blood flow; Transcranial Doppler ultrasound; Arterial blood pressure; Finapres; Transfer function analysis ID ACUTE ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; TRANSCRANIAL DOPPLER; AUTO-REGULATION; FLOW VELOCITY; FLUCTUATIONS; AGREEMENT; INJURY AB There is a growing interest in measuring cerebral autoregulation in patients with acute brain injury. Non-invasive finger photo-plethysmography (Finapres) is the method of choice to relate arterial blood pressure to changes in cerebral blood flow. Among acutely ill patients, however, peripheral vasoconstriction often limits the use of Finapres requiring direct intravascular blood pressure measurement. We evaluated how these two different forms of blood pressure monitoring affect the parameters of dynamic cerebral autoregulation (DCA). We performed 37 simultaneous recordings of BP and cerebral blood flow velocity in 15 patients with acute brain injury. DCA was estimated in the frequency domain using transfer function analysis to calculate phase shift, gain, and coherence. In addition the mean velocity index (Mx) was calculated for assessment of DCA in the time domain. The mean patient age was 58.1 +/- A 15.9 years, 80 % (n = 12) were women. We found good inter-method agreement between Finapres and direct intravascular measurement using Bland-Altman and correlation analyses. Finapres gives higher values for the efficiency of dynamic CA compared with values derived from radial artery catheter, as indicated by biases in the phase (26.3 +/- A 11.6A degrees vs. 21.7 +/- A 10.5A degrees, p = 0.001) and Mx (0.571 +/- A 0.137 vs. 0.649 +/- A 0.128, p < 0.001). Gain in the low frequency range did not significantly differ between the two arterial blood pressure methods. The average coherence between CBFV and ABP was higher when BP was measured with arterial catheter for frequencies above 0.05 Hz (0.8 vs. 0.73, p < 0.001). Overall, both methods yield similar results and can be used for the assessment of DCA. However, there was a small but significant difference for both mean Mx and phase shift, which would need to be adjusted for during monitoring of patients when using both methods. When available, invasive arterial blood pressure monitoring may improve accuracy and thus should be the preferred method for DCA assessment in the ICU. C1 [Petersen, Nils H.; Ortega-Gutierrez, Santiago; Masurkar, Arjun; Huang, Amy; Marshall, Randolph S.] Columbia Univ, Dept Neurol, Stroke Div, New York, NY USA. [Petersen, Nils H.] Massachusetts Gen Hosp, Neurosci Intens Care Unit, Boston, MA 02114 USA. [Reccius, Andres] Univ Desarrollocat, Clin Alemana, Dept Crit Care, Santiago, Chile. RP Petersen, NH (reprint author), Massachusetts Gen Hosp, Neurosci Intens Care Unit, 55 Fruit St,Lunder 650, Boston, MA 02114 USA. EM npetersen1@partners.org NR 29 TC 3 Z9 3 U1 1 U2 12 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 EI 1556-0961 J9 NEUROCRIT CARE JI Neurocrit. Care PD FEB PY 2014 VL 20 IS 1 BP 60 EP 68 DI 10.1007/s12028-013-9898-y PG 9 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA AB2RI UT WOS:000331639400009 PM 24452959 ER PT J AU Kumar, MA Boland, TA Baiou, M Moussouttas, M Herman, JH Bell, RD Rosenwasser, RH Kasner, SE Dechant, VE AF Kumar, Monisha A. Boland, Torrey A. Baiou, Mohamed Moussouttas, Michael Herman, Jay H. Bell, Rodney D. Rosenwasser, Robert H. Kasner, Scott E. Dechant, Valerie E. TI Red Blood Cell Transfusion Increases the Risk of Thrombotic Events in Patients with Subarachnoid Hemorrhage SO NEUROCRITICAL CARE LA English DT Article DE Subarachnoid hemorrhage; Hypercoagulable; Vasospasm; Delayed cerebral ischemia; Transfusion; Red blood cell; Venous thromboembolism ID OXYGEN DELIVERY; STORED-BLOOD; NITRIC-OXIDE; STORAGE; COMPLICATIONS; THROMBOEMBOLISM; FIBRINOLYSIS; COAGULATION; ACTIVATION; MANAGEMENT AB Red blood cell transfusion (RBCT) may increase the risk of thrombotic events (TE) in patients with subarachnoid hemorrhage (SAH) through changes induced by storage coupled with SAH-related hypercoagulability. We sought to investigate the association between RBCT and the risk of TE in patients with SAH. 205 consecutive patients with acute, aneurysmal SAH admitted to the neurovascular intensive care unit of a tertiary care, academic medical center between 3/2008 and 7/2009 were enrolled in a retrospective, observational cohort study. TE were defined as the composite of venous thromboembolism (VTE), myocardial infarction (MI), and cerebral infarction noted on brain CT scan. Secondary endpoints included the risk of VTE, poor outcome (modified Rankin score 3-6 at discharge), and in-hospital mortality. 86/205 (42 %) received RBCT. Eighty-eight (43 %) had a thrombotic complication. Forty (34 %) of 119 non-transfused and 48/86 (56 %) transfused patients had a TE (p = 0.002). In multivariate analysis, RBCT was associated with more TE by [OR 2.4; 95 % CI (1.2, 4.6); p = 0.01], VTE [OR 2.3; 95 % CI (1.0, 5.2); p = 0.04], and poor outcome [OR 5.0; 95 % CI (1.9, 12.8); p < 0.01]. The risk of TE increased by 55 % per unit transfused when controlling for univariate variables. Neither mean nor maximum age of blood was significantly associated with thrombotic risk. RBCT is associated with an increased risk of TE and VTE in SAH patients. A dose-dependent relationship exists between number of units transfused and thrombosis. Age of blood does not appear to play a role. C1 [Kumar, Monisha A.; Kasner, Scott E.] Univ Penn, Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Kumar, Monisha A.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA. [Kumar, Monisha A.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Boland, Torrey A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Baiou, Mohamed; Moussouttas, Michael; Bell, Rodney D.] Thomas Jefferson Univ Hosp, Dept Neurol, Philadelphia, PA 19107 USA. [Herman, Jay H.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Transfus Med Serv, Philadelphia, PA 19107 USA. [Rosenwasser, Robert H.] Thomas Jefferson Univ Hosp, Dept Neurosurg, Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA. [Dechant, Valerie E.] Christiana Care Hlth Syst, Dept Neurol, Ctr Heart & Vasc Hlth, Newark, DE 19718 USA. RP Kumar, MA (reprint author), Univ Penn, Hosp Univ Penn, Dept Neurol, 3 West Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM Monisha.Kumar@uphs.upenn.edu NR 34 TC 12 Z9 12 U1 1 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 EI 1556-0961 J9 NEUROCRIT CARE JI Neurocrit. Care PD FEB PY 2014 VL 20 IS 1 BP 84 EP 90 DI 10.1007/s12028-013-9819-0 PG 7 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA AB2RI UT WOS:000331639400012 PM 23423719 ER PT J AU Clark, DG Wadley, VG Kapur, P DeRamus, TP Singletary, B Nicholas, AP Blanton, PD Lokken, K Deshpande, H Marson, D Deutsch, G AF Clark, D. G. Wadley, V. G. Kapur, P. DeRamus, T. P. Singletary, B. Nicholas, A. P. Blanton, P. D. Lokken, K. Deshpande, H. Marson, D. Deutsch, G. TI Lexical factors and cerebral regions influencing verbal fluency performance in MCI SO NEUROPSYCHOLOGIA LA English DT Article DE Alzheimer's disease; Mild cognitive impairment; Verbal fluency; Semantic memory; Natural language processing ID MILD COGNITIVE IMPAIRMENT; SURFACE-BASED ANALYSIS; TEMPORAL-LOBE LESIONS; ALZHEIMERS-DISEASE; SEMANTIC DEMENTIA; CORTICAL SURFACE; HUNTINGTONS-DISEASE; COORDINATE SYSTEM; NORMATIVE DATA; NEURAL BASIS AB Objective: To evaluate assumptions regarding semantic (noun), verb, and letter fluency in mild cognitive impairment (MCI) and Alzheimer disease (AD) using novel techniques for measuring word similarity in fluency lists and a region of interest (ROI) analysis of gray matter correlates. Method: Fifty-eight individuals with normal cognition (NC, n=25), MCI (n=23), or AD (n=10) underwent neuropsychological tests, including 10 verbal fluency tasks (three letter tasks [F, A, S], six noun categories [animals, water creatures, fruits and vegetables, tools, vehicles, boats], and verbs). All pairs of words generated by each participant on each task were compared in terms of semantic (meaning), orthographic (spelling), and phonemic (pronunciation) similarity. We used mixed-effects logistic regression to determine which lexical factors were predictive of word adjacency within the lists. Associations between each fluency raw score and gray matter volumes in sixteen ROIs were identified by means of multiple linear regression. We evaluated causal models for both types of analyses to specify the contributions of diagnosis and various mediator variables to the outcomes of word adjacency and fluency raw score. Results: Semantic similarity between words emerged as the strongest predictor of word adjacency for all fluency tasks, including the letter fluency tasks. Seman.tic similarity mediated the effect of cognitive impairment on word adjacency only for three fluency tasks employing a biological cue. Orthographic similarity was predictive of word adjacency for the A and S tasks, while phonemic similarity was predictive only for the S task and one semantic task (vehicles). The ROI analysis revealed different patterns of correlations among the various fluency tasks, with the most common associations in the right lower temporal and bilateral dorsal frontal regions. Following correction with gray matter volumes from the opposite hemisphere, significant associations persisted for animals, vehicles, and a composite nouns score in the left inferior frontal gyrus, but for letter A, letter S, and a composite FAS score in the right inferior frontal gyrus. These regressions also revealed a lateralized association of the left subcortical nuclei with all letter fluency scores and fruits and vegetables fluency, and an association of the right lower temporal ROI with letter A, FAS, and verb fluency. Gray matter volume in several bihemispheric ROIs (left dorsal frontal, right lower temporal, right occipital, and bilateral mesial temporal) mediated the relationship between cognitive impairment and fluency for fruits and vegetables. Gray matter volume in the right lower temporal ROI mediated the relationship between cognitive impairment and five fluency raw scores (animals, fruits and vegetables, tools, verbs, and the composite nouns score). Conclusion: Semantic memory exerts the strongest influence on word adjacency in letter fluency as well as semantic verbal fluency tasks. Orthography is a stronger influence than pronunciation. All types of fluency task raw scores (letter, noun, and verb) correlate with cerebral regions known to support verbal or nonverbal semantic memory. The findings emphasize the contribution of right hemisphere regions to fluency task performance, particularly for verb and letter fluency. The relationship between diagnosis and semantic fluency performance is mediated by semantic similarity of words and by gray matter volume in the right lower temporal region. Published by Elsevier Ltd. C1 [Clark, D. G.; Nicholas, A. P.; Blanton, P. D.; Lokken, K.] Birmingham VA Med Ctr, Birmingham, AL USA. [Clark, D. G.; Nicholas, A. P.; Marson, D.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA. [Wadley, V. G.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Kapur, P.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [DeRamus, T. P.] Univ Alabama Birmingham, Dept Psychol & Behav Neurosci, Birmingham, AL USA. [Singletary, B.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL USA. [Deshpande, H.; Deutsch, G.] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA. RP Clark, DG (reprint author), 1720,7th Ave South,SC 620C, Birmingham, AL 35294 USA. EM dgclark@uab.edu FU VA [E6553W] FX VA (E6553W). NR 78 TC 5 Z9 7 U1 4 U2 23 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 EI 1873-3514 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD FEB PY 2014 VL 54 BP 98 EP 111 DI 10.1016/j.neuropsychologia.2013.12.010 PG 14 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA AB3IT UT WOS:000331685200011 PM 24384308 ER PT J AU Lazzari, AA Dussault, P Davis, S AF Lazzari, A. A. Dussault, P. Davis, S. TI LATERAL VERTEBRAL ASSESSMENT (LVA) AND DETECTION OF COMPRESSION DEFORMITIES IN MALE PATIENTS RECEIVING ANTIEPILEPTIC DRUGS SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT International-Osteoporosis-Foundation (IOF) - International-Society-for-Clinical-Densitometry (ISCD) Skeletal Health Meeting CY FEB 20-22, 2014 CL Orlando, FL SP Int Osteoporosis Fdn, Int Soc Clin Densitometry ID FRACTURES; EPILEPSY C1 [Lazzari, A. A.; Dussault, P.] Boston Univ, Boston, MA 02215 USA. [Davis, S.] Boston Univ, Osteoporosis Clin, VA Boston HCS, Boston, MA 02215 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2014 VL 25 SU 1 BP S44 EP S45 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AB3ML UT WOS:000331694800067 ER PT J AU Zamarioli, A Maranho, DAC Battaglino, RA Morse, LR Volpon, JB Shimano, AC AF Zamarioli, A. Maranho, D. A. C. Battaglino, R. A. Morse, L. R. Volpon, J. B. Shimano, A. C. TI MECHANICAL-LOADING THROUGH PASSIVE WEIGH-BEARING AND ARTIFICIAL ELECTRICAL STIMULATION PREVENT AND EVEN REVERT SCI-INDUCED BONE LOSS QUALITY SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT International-Osteoporosis-Foundation (IOF) - International-Society-for-Clinical-Densitometry (ISCD) Skeletal Health Meeting CY FEB 20-22, 2014 CL Orlando, FL SP Int Osteoporosis Fdn, Int Soc Clin Densitometry C1 [Zamarioli, A.; Battaglino, R. A.; Morse, L. R.] Forsyth Inst, Dept Cytokine Biol, Cambridge, MA USA. [Zamarioli, A.; Maranho, D. A. C.; Volpon, J. B.; Shimano, A. C.] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil. [Battaglino, R. A.] Harvard Univ, Sch Med, Dept Oral Med Infect & Immun, Boston, MA USA. [Morse, L. R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Morse, L. R.] Spaulding Rehabil Hosp, Boston, MA USA. RI Volpon, Jose /D-3041-2012; Maranho, Daniel Augusto/C-1337-2013; Zamarioli, Ariane/K-7001-2012; Shimano, Antonio/E-1455-2014 OI Volpon, Jose /0000-0002-2120-0138; Maranho, Daniel Augusto/0000-0002-3893-0292; Zamarioli, Ariane/0000-0002-7939-0528; NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2014 VL 25 SU 1 BP S19 EP S20 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AB3ML UT WOS:000331694800018 ER PT J AU Lerner, B Roberts, JS Shwartz, M Roter, DL Green, RC Clark, JA AF Lerner, Barbara Roberts, J. Scott Shwartz, Michael Roter, Debra L. Green, Robert C. Clark, Jack A. TI Distinct communication patterns during genetic counseling for late-onset Alzheimer's risk assessment SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Alzheimer's disease; Genetic testing; Genetic counseling; Patient-provider communication; Patient-centeredness ID APOE GENOTYPE; PRIMARY-CARE; PATIENT COMMUNICATION; DISEASE; OUTCOMES; CONSULTATIONS; DISCLOSURE; PHYSICIANS; RELATIVES; DEMENTIA AB Objective: To identify and characterize patient-provider communication patterns during disclosure of Alzheimer's disease genetic susceptibility test results and to assess whether these patterns reflect differing models of genetic counseling. Methods: 262 genetic counseling session audio-recordings were coded using the Rater Interactional Analysis System. Cluster analysis was used to distinguish communication patterns. Bivariate analyses were used to identify characteristics associated with the patterns. Results: Three patterns were identified: Biomedical-Provider-Teaching (40%), Biomedical-PatientDriven (34.4%), and Psychosocial-Patient-Centered (26%). Psychosocial-Patient-Centered and Biomedical-Provider-Teaching sessions included more female participants while the Biomedical-Patient-Driven sessions included more male participants (p = 0.04). Conclusion: Communication patterns observed reflected the teaching model primarily, with genetic counseling models less frequently used. The emphasis on biomedical communication may potentially be at the expense of more patient-centered approaches. Practice implications: To deliver more patient-centered care, providers may need to better balance the ratio of verbal exchange with their patients, as well as their educational and psychosocial discussions. The delineation of these patterns provides insights into the genetic counseling process that can be used to improve the delivery of genetic counseling care. These results can also be used in future research designed to study the association between patient-centered genetic counseling communication and improved patient outcomes. Published by Elsevier Ireland Ltd. C1 [Lerner, Barbara] VA Boston Healthcare Syst, Boston, MA USA. [Roberts, J. Scott] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Shwartz, Michael] Boston Univ, Sch Management, Boston, MA 02215 USA. [Roter, Debra L.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Green, Robert C.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Green, Robert C.] Harvard Univ, Sch Med, Boston, MA USA. [Clark, Jack A.] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. RP Lerner, B (reprint author), Ctr Healthcare Org & Implementat Res, Vet Adm 152M, 150 South Huntington Ave, Boston, MA 02130 USA. EM barbara.lemer@va.gov RI Roter, Debra/N-8830-2014 FU AHRQ HHS [R36HS017988, R36 HS017988]; NHGRI NIH HHS [5 R01 HG02213-06, R01 HG002213]; NIA NIH HHS [K24 AG027841, R03 AG025914, R03 AG025914-01A1] NR 45 TC 0 Z9 0 U1 3 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD FEB PY 2014 VL 94 IS 2 BP 170 EP 179 DI 10.1016/j.pec.2013.10.019 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA AB6TZ UT WOS:000331923700005 PM 24316056 ER PT J AU Park, LG Howie-Esquivel, J Chung, ML Dracup, K AF Park, Linda G. Howie-Esquivel, Jill Chung, Misook L. Dracup, Kathleen TI A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Text messaging; Mobile phone; Medication adherence; Antiplatelets; Statins; Coronary heart disease ID IMPROVE ADHERENCE; STENT THROMBOSIS; OUTCOMES; PREDICTORS; CONTINUATION; METAANALYSIS; PREVENTION; PROGRAM; SCALE; RATES AB Objective: Pharmacologic treatment for secondary prevention of coronary heart disease (CHD) is critical to prevent adverse clinical outcomes. In a randomized controlled trial, we compared antiplatelet and statin adherence among patients with CHD who received: (1) text messages (TM) for medication reminders and education, (2) educational TM only, or (3) No TM. Methods: A mobile health intervention delivered customized TM for 30 days. We assessed and analyzed medication adherence with electronic monitoring devices [Medication Event Monitoring System (MEMS)] by one-way ANOVA and Welch tests, two-way TM response rates by t-tests, and self-reported adherence (Morisky Medication Adherence Scale) by Repeated Measures ANOVA. Results: Among 90 patients (76% male, mean age 59.2 years), MEMS revealed patients who received TM for antiplatelets had a higher percentage of correct doses taken (p = 0.02), percentage number of doses taken (p = 0.01), and percentage of prescribed doses taken on schedule (p = 0.01). TM response rates were higher for antiplatelets than statins (p = 0.005). Self-reported adherence revealed no significant differences among groups. Conclusion: TM increased adherence to antiplatelet therapy demonstrated by MEMS and TM responses. Practice implications: Feasibility and high satisfaction were established. Mobile health interventions show promise in promoting medication adherence. Published by Elsevier Ireland Ltd. C1 [Park, Linda G.] San Francisco VA Med Ctr, Div Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA. [Howie-Esquivel, Jill; Dracup, Kathleen] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA. [Chung, Misook L.] Univ Kentucky, Coll Nursing, Lexington, KY 40506 USA. RP Park, LG (reprint author), San Francisco VA Med Ctr, Div Geriatr Palliat & Extended Care, 4150 Clement St,Bldg 1 207 181G, San Francisco, CA 94121 USA. EM linda.park@ucsf.edu RI Emchi, Karma/Q-1952-2016 FU Graduate Division of University of California, San Francisco; UCSF/Hartford Center of Geriatric Nursing Excellence FX Funding for research materials was provided by a grant from the Graduate Division of University of California, San Francisco and a scholarship from the UCSF/Hartford Center of Geriatric Nursing Excellence. CareSpeak Communications provided the use of the mobile Health manager platform, which is designed to improve medical therapy adherence using two-way text messaging. NR 43 TC 35 Z9 37 U1 2 U2 26 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD FEB PY 2014 VL 94 IS 2 BP 261 EP 268 DI 10.1016/j.pec.2013.10.027 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA AB6TZ UT WOS:000331923700018 PM 24321403 ER PT J AU Garcia, HA McGeary, CA McGeary, DD Finley, EP Peterson, AL AF Garcia, Hector A. McGeary, Cindy A. McGeary, Donald D. Finley, Erin P. Peterson, Alan L. TI Burnout in Veterans Health Administration Mental Health Providers in Posttraumatic Stress Clinics SO PSYCHOLOGICAL SERVICES LA English DT Article DE burnout; Veterans Health Administration; posttraumatic stress disorder; workplace stressors; absenteeism ID JOB BURNOUT; SATISFACTION; TURNOVER; PSYCHOLOGISTS; STAFF; WORK; CARE; DISSEMINATION; PREDICTORS; CONSTRUCT AB The purpose of this study was to conduct the first assessment of burnout among Veterans Health Administration (VHA) mental health clinicians providing evidence-based posttraumatic stress disorder (PTSD) care. This study consisted of 138 participants and the sample was mostly female (67%), Caucasian (non-Hispanic; 81%), and married (70%) with a mean age of 44.3 years (SD = 11.2). Recruitment was directed through VHA PTSD Clinical Teams (PCT) throughout the United States based on a nationwide mailing list of PCT Clinic Directors. Participants completed an electronic survey that assessed demographics, organizational work factors, absenteeism, and burnout (assessed through the Maslach Burnout Inventory-General Survey, MBI-GS). Twelve percent of the sample reported low Professional Efficacy, 50% reported high levels of Exhaustion, and 47% reported high levels of Cynicism as determined by the MBI-GS cut-off scores. Only workplace characteristics were significantly associated with provider scores on all 3 scales. Exhaustion and Cynicism were most impacted by perceptions of organizational politics/bureaucracy, increased clinical workload, and control over how work is done. Organizational factors were also significantly associated with provider absenteeism and intent to leave his or her job. Findings suggest that providers in VHA specialty PTSD-care settings may benefit from programs or supports aimed at preventing and/or ameliorating burnout. C1 [Garcia, Hector A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Garcia, Hector A.; McGeary, Donald D.; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [McGeary, Cindy A.] Univ Texas Arlington, Dept Psychol, Arlington, TX USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Garcia, HA (reprint author), Frank Tejeda Outpatient Clin, 5788 Eckhert Rd, San Antonio, TX 78240 USA. EM Hector.Garcia2@va.gov OI Finley, Erin/0000-0003-4497-7721 FU NIMH NIH HHS [R25 MH080916, R25 MH080916-01A2] NR 50 TC 5 Z9 5 U1 5 U2 12 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2014 VL 11 IS 1 BP 50 EP 59 DI 10.1037/a0035643 PG 10 WC Psychology, Clinical SC Psychology GA AB6AL UT WOS:000331869700006 PM 24564443 ER PT J AU Vogt, D Di Leone, BAL Wang, JM Sayer, NA Pineles, SL Litz, BT AF Vogt, Dawne Di Leone, Brooke A. L. Wang, Joyce M. Sayer, Nina A. Pineles, Suzanne L. Litz, Brett T. TI Endorsed and Anticipated Stigma Inventory (EASI): A Tool for Assessing Beliefs About Mental Illness and Mental Health Treatment Among Military Personnel and Veterans SO PSYCHOLOGICAL SERVICES LA English DT Article DE stigma; barriers to care; VA health care use; veterans; military ID BECK DEPRESSION INVENTORY; PERCEIVED STIGMA; HELP-SEEKING; PRIMARY-CARE; FIT INDEXES; BARRIERS; QUESTIONNAIRE; DISORDERS; ATTITUDES; MODEL AB Many military personnel and veterans who would benefit from mental health treatment do not seek care, underscoring the need to identify factors that influence initiation and retention in mental health care. Both endorsed and anticipated mental health stigma may serve as principal barriers to treatment seeking. To date, most research on mental health stigma in military and veteran populations has relied on nonvalidated measures with limited content coverage and confounding in the assessment of different domains of mental health stigma. This article describes the development and psychometric evaluation of the Endorsed and Anticipated Stigma Inventory (EASI), which was designed to assess different dimensions of stigma-related beliefs about mental health among military and veteran populations. Findings based on a national sample of U.S. veterans deployed in support of Operation Enduring Freedom (OEF) in Afghanistan or Operation Iraqi Freedom (OIF) in Iraq suggest that the EASI is a psychometrically sound instrument. Specifically, results revealed evidence for the internal consistency reliability, content validity, convergent and discriminant validity, and discriminative validity of EASI scales. In addition, confirmatory factor analysis results supported the proposed factor structure for this inventory of scales. C1 [Vogt, Dawne; Di Leone, Brooke A. L.; Wang, Joyce M.; Pineles, Suzanne L.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA 02130 USA. [Vogt, Dawne; Pineles, Suzanne L.; Litz, Brett T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Sayer, Nina A.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Sayer, Nina A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. RP Vogt, D (reprint author), VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, 116B-3,150 South Huntington Ave, Boston, MA 02130 USA. EM dawne.vogt@va.gov RI Sayer, Nina/E-3249-2016 NR 62 TC 11 Z9 11 U1 17 U2 29 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2014 VL 11 IS 1 BP 105 EP 113 DI 10.1037/a0032780 PG 9 WC Psychology, Clinical SC Psychology GA AB6AL UT WOS:000331869700012 PM 24274110 ER PT J AU Whealin, JM Stotzer, RL Pietrzak, RH Vogt, D Shore, J Morland, L Southwick, SM AF Whealin, Julia M. Stotzer, Rebecca L. Pietrzak, Robert H. Vogt, Dawne Shore, Jay Morland, Leslie Southwick, Steven M. TI Deployment-Related Sequelae and Treatment Utilization in Rural and Urban War Veterans in Hawaii SO PSYCHOLOGICAL SERVICES LA English DT Article DE military; Pacific Islands; mental health services; mental health access; mental health utilization ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-CARE; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; AFGHANISTAN VETERANS; MILITARY PERSONNEL; SERVICE USE; CAGE QUESTIONNAIRE; NATIONAL SAMPLE; SOCIAL SUPPORT AB This study compared common deployment-related health issues and correlates of mental health service utilization among rural and urban veterans of Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND) living in Hawaii. Frequency of utilization of a broad range of mental health resources, including clergy/spiritual leaders, videoconference/online programs, and traditional/alternative healers, was also characterized. A random sample of 116 rural and 117 urban ethnoracially diverse veterans completed a mail survey. Rural veterans were more likely than urban veterans to meet screening criteria for posttraumatic stress disorder (PTSD), deployment-related concussion with persistent postconcussive symptoms, and alcohol use problems. Over one third of veterans who desired help for a mental health problem reported no current use of any services. Rural veterans were more likely than urban veterans to have accessed Veteran Readjustment Centers, but they did not differ with respect to utilization of other services. Correlates of mental health service utilization included higher education, PTSD, and lower mental-health-related quality of life. Results of this study underscore the need for dissemination efforts to enable OEF/OIF/OND veterans to access mental health resources. C1 [Whealin, Julia M.] VA Pacific Isl HealthCare Syst, Natl Ctr PTSD, Pacific Isl Div, Honolulu, HI 96819 USA. [Whealin, Julia M.] Univ Hawaii, John A Burns Sch Med, Dept Psychiat, Honolulu, HI 96822 USA. [Stotzer, Rebecca L.] Univ Hawaii, Myron B Thompson Sch Social Work, Honolulu, HI 96822 USA. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Vogt, Dawne] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA. [Vogt, Dawne] Boston Univ, Dept Psychiat, Boston, MA 02215 USA. [Shore, Jay] US Dept Vet Affairs Off Rural Vet, Rural Hlth Resource Ctr Western Reg, Salt Lake City, UT USA. [Shore, Jay] Ctr Amer Indian & Alaska Native Hlth, Dept Psychiat, Denver, CO USA. [Morland, Leslie] VA Pacific Isl HealthCare Syst, Natl Ctr Posttraumat Stress Disorder, Pacific Isl Div, Honolulu, HI 96819 USA. [Morland, Leslie] Univ Hawaii, Sch Med, Dept Psychiat, Honolulu, HI 96822 USA. [Southwick, Steven M.] VA Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. [Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. RP Whealin, JM (reprint author), VA Pacific Isl HealthCare Syst, Natl Ctr PTSD, 3375 Koapaka St,Suite I-150, Honolulu, HI 96819 USA. EM julia.whealin@va.gov NR 69 TC 6 Z9 6 U1 4 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2014 VL 11 IS 1 BP 114 EP 123 DI 10.1037/a0032782 PG 10 WC Psychology, Clinical SC Psychology GA AB6AL UT WOS:000331869700013 PM 24099457 ER PT J AU Solomon, DH Kremer, JM Fisher, M Curtis, JR Furer, V Harrold, LR Hochberg, MC Reed, G Tsao, P Greenberg, JD AF Solomon, Daniel H. Kremer, Joel M. Fisher, Mark Curtis, Jeffrey R. Furer, Victoria Harrold, Leslie R. Hochberg, Marc C. Reed, George Tsao, Peter Greenberg, Jeffrey D. TI Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE Rheumatoid arthritis; Cancer; DMARDs; Epidemiology; Methotrexate ID NECROSIS-FACTOR THERAPY; RANDOMIZED CONTROLLED-TRIALS; RHEUMATOID-ARTHRITIS PATIENTS; PROPENSITY SCORE; SKIN-CANCER; LYMPHOMA; MALIGNANCIES; METAANALYSIS; EXPOSURE; NEOPLASMS AB Objective: There is little information comparing the potential risk of cancer across conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). Methotrexate has not been the focus of most contemporary pharmacoepidemiologic studies of cancer. Methods: We conducted a comparative effectiveness study with cancer as the outcome. A large observational cohort of RA was followed up from 2001 to 2010. Reports of any cancer prompted a confirmation process that included adjudication of the primary cancer records. We used a propensity score (PS) with relevant covariates and cohort trimming to improve the balance between DMARD cohorts. Cox proportional hazard regression models were constructed to estimate the risk of cancer with various DMARDs, all compared with methotrexate. Results: We identified 6806 DMARD courses for analysis (1566 methotrexate; 904 nbDMARDs; 3761 TNF antagonists; 408 abatacept; and 167 rituximab). Non-biologic DMARDs (HR 0.17, 95% CI 0.05-0.65) and TNF antagonists (HR 0.29, 95% CI 0.05-0.65) were associated with a reduced adjusted risk of cancer compared with methotrexate. Abatacept (HR 1.55, 95% CI 0.40-5.97) and rituximab (HR 0.42, 95% CI 0.07-2.60) were similar in risk of cancer with methotrexate. These results were robust to sensitivity analyses. After controlling for DMARD exposures, risk factors for cancer included male gender, age, and alcohol consumption. Conclusions: Cancer risk was elevated for methotrexate users compared with nbDMARDs and TNF antagonists. (C) 2014 Elsevier Inc. All rights reserved. C1 [Solomon, Daniel H.; Tsao, Peter] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA. [Solomon, Daniel H.] Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA. [Kremer, Joel M.] Albany Med Coll, Div Rheumatol, Albany, NY 12208 USA. [Fisher, Mark] Massachusetts Gen Hosp, Div Rheumatol, Boston, MA 02114 USA. [Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Harrold, Leslie R.] Univ Massachusetts, Sch Med, Div Rheumatol, Worcester, MA USA. [Hochberg, Marc C.] Univ Maryland, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA. [Hochberg, Marc C.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Div Gerontol, Baltimore, MD 21201 USA. [Reed, George] Univ Massachusetts, Med Ctr, Dept Biostat, Worcester, MA USA. [Furer, Victoria; Greenberg, Jeffrey D.] NYU, Sch Med, Div Rheumatol, Clin Trials Unit, New York, NY USA. RP Solomon, DH (reprint author), Brigham & Womens Hosp, Div Rheumatol, Div Pharmacoepidemiol, 75 Francis St, Boston, MA 02115 USA. EM dsolomon@partners.org FU NIH [AR AR055989, AR 047782, AR053351, K23AR054412]; AHRQ Amgen; Lilly; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23AR053856]; AHRQ [R01HS018517] FX There was no specific support for these analyses. CORRONA has received general support in the last 2 years from Abbott, Amgen, Astra Zeneca, Genentech, Janssen (Centocor), Lilly, and Pfizer. Dr. Solomon receives salary support from research grants from the NIH (AR AR055989 and AR 047782), AHRQ Amgen, and Lilly. Jeffrey Curtis receives salary support from NIH (AR053351). Dr. Harrold was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and holds a research grant from CORRONA. Dr. Greenberg receives salary support from the NIH (K23AR054412) and AHRQ (R01HS018517). NR 41 TC 25 Z9 25 U1 2 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0049-0172 EI 1532-866X J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD FEB PY 2014 VL 43 IS 4 BP 489 EP 497 DI 10.1016/j.semarthrit.2013.08.003 PG 9 WC Rheumatology SC Rheumatology GA AB2BQ UT WOS:000331598400008 PM 24012043 ER PT J AU Hamel, LP Sheen, J Seguin, A AF Hamel, Louis-Philippe Sheen, Jen Seguin, Armand TI Ancient signals: comparative genomics of green plant CDPKs SO TRENDS IN PLANT SCIENCE LA English DT Review DE calcium signaling; CDPKs; green plant lineages; evolution ID DEPENDENT PROTEIN-KINASE; CALMODULIN-LIKE DOMAIN; LAND PLANTS; ABSCISIC-ACID; GENE FAMILY; WIDE IDENTIFICATION; ANION CHANNEL; CA2+-REGULATORY REGION; SUBSTRATE RECOGNITION; CHLOROPLAST GENOME AB Calcium-dependent protein kinases (CDPKs) are multifunctional proteins that combine calcium-binding and signaling capabilities within a single gene product. This unique-versatility enables multiple plant biological processes to be controlled, including developmental programs and stress responses. The genome of flowering plants typically encodes around 30 CDPK homologs that cluster in four conserved clades. In this review, we take advantage of the recent availability of genome sequences from green algae and early land plants to examine how well the previously described CDPK family from angiosperms compares to the broader evolutionary states associated with early diverging green plant lineages. Our analysis suggests that the current architecture of the CDPK family was shaped during the colonization of the land by plants, whereas CDPKs from ancestor green algae have continued to evolve independently. C1 [Hamel, Louis-Philippe] Univ Sherbrooke, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada. [Sheen, Jen] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Mol Biol,Dept Genet, Boston, MA 02114 USA. [Sheen, Jen] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Computat & Integrat Biol,Dept Genet, Boston, MA 02114 USA. [Seguin, Armand] Nat Resources Canada, Laurentian Forestry Ctr, Canadian Forest Serv, Stn St Foy, PQ G1V 4C7, Canada. RP Hamel, LP (reprint author), Univ Sherbrooke, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada. EM Louis-Philippe.Hamel@USherbrooke.ca; Armand.Seguin@RNCan-NRCan.gc.ca FU Fonds Quebecois de la Recherche sur la Nature et les Technologies (FQRNT); Natural Sciences and Engineering Research Council (NSERC) of Canada; US National Institutes of Health [R01 GM70567] FX L.-P.H. was the recipient of a postdoctoral fellowship from the Fonds Quebecois de la Recherche sur la Nature et les Technologies (FQRNT). This work was also supported by a grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada to A.S., and a US National Institutes of Health grant (R01 GM70567) to J.S. We apologize to our colleagues whose work could not be cited here owing to space limitations. NR 84 TC 32 Z9 32 U1 4 U2 46 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1360-1385 J9 TRENDS PLANT SCI JI Trends Plant Sci. PD FEB PY 2014 VL 19 IS 2 BP 79 EP 89 DI 10.1016/j.tplants.2013.10.009 PG 11 WC Plant Sciences SC Plant Sciences GA AB3HE UT WOS:000331681100003 PM 24342084 ER PT J AU Mariappan, MM DeSilva, K Sorice, GP Muscogiuri, G Jimenez, F Ahuja, S Barnes, JL Choudhury, GG Musi, N DeFronzo, R Kasinath, BS AF Mariappan, Meenalakshmi M. DeSilva, Kristin Sorice, Gian Pio Muscogiuri, Giovanna Jimenez, Fabio Ahuja, Seema Barnes, Jefferey L. Choudhury, Goutam Ghosh Musi, Nicolas DeFronzo, Ralph Kasinath, Balakuntalam S. TI Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE hyperglycemia; hyperinsulinemia; renal fibrosis; TGF-beta; mTOR; laminin ID MESSENGER-RNA TRANSLATION; RENAL EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; DIABETIC-NEPHROPATHY; HIGH GLUCOSE; TGF-BETA; POSTPRANDIAL HYPERGLYCEMIA; CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS AB Increase in matrix protein content in the kidney is a cardinal feature of diabetic kidney disease. While renal matrix protein content is increased by chronic hyperglycemia, whether it is regulated by acute elevation of glucose and insulin has not been addressed. In this study, we aimed to evaluate whether short duration of combined hyperglycemia and hyperinsulinemia, mimicking the metabolic environment of prediabetes and early type 2 diabetes, induces kidney injury. Normal rats were subjected to either saline infusion (control, n = 4) or 7 h of combined hyperglycemic-hyperinsulinemic clamp (HG + HI clamp; n = 6). During the clamp, plasma glucose and plasma insulin were maintained at about 350 mg/dl and 16 ng/ml, respectively. HG + HI clamp increased the expression of renal cortical transforming growth factor-beta (TGF-alpha) and renal matrix proteins, laminin and fibronectin. This was associated with the activation of SMAD3, Akt, mammalian target of rapamycin (mTOR) complexes, and ERK signaling pathways and their downstream target events in the initiation and elongation phases of mRNA translation, an important step in protein synthesis. Additionally, HG + HI clamp provoked renal inflammation as shown by the activation of Toll-like receptor 4 (TLR4) and infiltration of CD68-positive monocytes. Urinary F2t isoprostane excretion, an index of renal oxidant stress, was increased in the HG + HI clamp rats. We conclude that even a short duration of hyperglycemia and hyperinsulinemia contributes to activation of pathways that regulate matrix protein synthesis, inflammation, and oxidative stress in the kidney. This finding could have implications for the control of short-term rises in blood glucose in diabetic individuals at risk of developing kidney disease. C1 [Mariappan, Meenalakshmi M.; DeSilva, Kristin; Jimenez, Fabio; Ahuja, Seema; Barnes, Jefferey L.; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Sorice, Gian Pio; Muscogiuri, Giovanna; Musi, Nicolas; DeFronzo, Ralph] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabetes, San Antonio, TX 78229 USA. [Mariappan, Meenalakshmi M.; Jimenez, Fabio; Ahuja, Seema; Barnes, Jefferey L.; Choudhury, Goutam Ghosh; Musi, Nicolas; DeFronzo, Ralph; Kasinath, Balakuntalam S.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Mariappan, MM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM malini@uthscsa.edu FU National Institutes of Health (NIH) [DK-077295, RC2 AG-036613]; VA Merit Review Program and American Diabetes Association; Juvenile Diabetes Research Foundation and the National Kidney Foundation of South and Central Texas; VA Senior Research Career Scientist Award [NIH-R01 (DK-050190)] FX This work was supported by National Institutes of Health (NIH) Grants DK-077295 and RC2 AG-036613 (B. S. Kasinath), VA Merit Review Program and American Diabetes Association (B. S. Kasinath), and Juvenile Diabetes Research Foundation and the National Kidney Foundation of South and Central Texas (M. M. Mariappan). G. G. Choudhury is supported by NIH-R01 (DK-050190) and VA Merit Review Grants and is a recipient of the VA Senior Research Career Scientist Award. NR 52 TC 6 Z9 6 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD FEB PY 2014 VL 306 IS 3 BP C202 EP C211 DI 10.1152/ajpcell.00144.2013 PG 10 WC Cell Biology; Physiology SC Cell Biology; Physiology GA AA9YU UT WOS:000331449800004 PM 24108867 ER PT J AU Ananthanarayanan, V Pan, Y Tretiakova, M Amin, MB Cheng, L Epstein, JI Grignon, DJ Hansel, DE Jimenez, RE McKenney, JK Montironi, R Oliva, E Osunkoya, AO Rao, P Reuter, VE Ro, JY Shen, SS Srigley, JR Tsuzuki, T Yao, JL Antic, T Haber, M Taxy, JB Paner, GP AF Ananthanarayanan, Vijayalakshmi Pan, Yi Tretiakova, Maria Amin, Mahul B. Cheng, Liang Epstein, Jonathan I. Grignon, David J. Hansel, Donna E. Jimenez, Rafael E. McKenney, Jesse K. Montironi, Rodolfo Oliva, Esther Osunkoya, Adeboye O. Rao, Priya Reuter, Victor E. Ro, Jae Y. Shen, Steven S. Srigley, John R. Tsuzuki, Toyonori Yao, Jorge L. Antic, Tatjana Haber, Michael Taxy, Jerome B. Paner, Gladell P. TI Influence of Histologic Criteria and Confounding Factors in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (pT3a) An Interobserver Study Among Genitourinary Pathologists SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE bladder; cancer; pT3a; staging; interobserver; reproducibility ID TRANSITIONAL-CELL CARCINOMA; EAU INTERNATIONAL CONSULTATION; AMERICAN JOINT COMMITTEE; ADVANCED BLADDER-CANCER; PHASE-III TRIAL; UROTHELIAL CARCINOMA; ADJUVANT CHEMOTHERAPY; RADICAL CYSTECTOMY; URINARY-BLADDER; LAMINA PROPRIA AB Current oncology guidelines and clinical trials consider giving adjuvant chemotherapy to bladder cancer patients with at least microscopic perivesical tissue invasion (MPVTI) (pT3a) on cystectomy. The boundary of muscularis propria (MP) and perivesical tissue is commonly ill defined, and hence, when the tumor involves the interface, interpretation of MPVTI is likely to be subjective. In this study, 20 sets of static images that included 1 nontumoral bladder wall for defining MP-perivesical tissue boundary and 19 bladder cancer cases equivocal for MPVTI with confounding factors were sent to 17 expert genitourinary pathologists for review. The confounding factors were histoanatomic, as defined by the irregular MP-perivesical tissue boundary, and tumor related, such as fibrosis, dense inflammation, tumor cells at the edge of the outermost MP muscle bundle, and lymphovascular invasion. These equivocal cases were divided into 3 categories according to the following factors: (1) histoanatomic only (7/19), (2) histoanatomic+tumor related (7/19), and (3) tumor related only (5/19). Participating genitourinary pathologists used different criteria to assess MPVTI: (A) drawing a straight horizontal line using the outermost MP muscle bundle edge as the MP-perivesical tissue boundary reference (3/17); (B) drawing multiple straight lines interconnecting the outermost MP muscle bundle edges (9/17); (C) following the curves of every outermost MP muscle bundle edge (4/17). In category 1 cases, most pathologists who used the A criterion called for absence (6/7), whereas those who used the C criterion called for presence (5/7) of MPVTI, which resulted in disparity in 4/7 cases. There was no circumstance in which criteria A and C agreed on the presence or absence of MPVTI but was opposed by the B criterion in category 1 cases. Median pairwise agreement among all pathologists (regardless of criteria) for all cases (regardless of category) was only fair (=0.281). However, when only the B criterion was assessed for category 1 cases, median agreement was substantial (=0.696), and pairwise rater comparisons included 6/36 (17%) near perfect, 13/36 (36%) substantial, and 11/36 (31%) moderate agreements. When all cases with histoanatomic factors (categories 1 and 2) were combined, median pairwise agreements were: (A) =0.588, (B) =0.423, and (C) =0.512, and the B criterion rater comparisons included 0/36 (0%) near perfect, 6/36 (17%) substantial, and 16/36 (44%) moderate agreements, which showed the confounding effect of tumor-related factors. For category 3 cases, median pairwise agreement for all pathologists was fair (=0.286), with consensus agreement in only 2/5 of these equivocal cases. Lymphovascular invasion only at the MP-perivesical tissue boundary was not staged as MPVTI by 87.5% of pathologists. In conclusion, this study showed that interpretation of equivocal cases for MPVTI can be made difficult by factors intrinsic to bladder histoanatomy, defined by an irregular MP-perivesical tissue boundary, and factors related to tumor spread. There are at least 3 different approaches to demarcating an irregular outer MP boundary, and agreement is improved on equivocal cases when a common histoanatomic criterion is used. However, inconsistent agreement of anatomic criteria may cause systematic discrepancy in assessing MPVTI. Tumor-related factors such as dense fibrosis or desmoplasia, obscuring inflammation, tumor cells at the edge of the outermost MP muscle bundle, and admixed lymphovascular invasion can also negatively influence the agreement on interpretation of MPVTI. This study highlights the need to adopt common criteria in defining the outer MP boundary. Future studies may identify the most clinically relevant histoanatomic criteria for MPVTI. C1 [Ananthanarayanan, Vijayalakshmi; Tretiakova, Maria; Antic, Tatjana; Taxy, Jerome B.; Paner, Gladell P.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. [Pan, Yi; Haber, Michael] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA. [Osunkoya, Adeboye O.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Amin, Mahul B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Cheng, Liang; Grignon, David J.] Indiana Univ, Dept Pathol & Lab Med, Indianapolis, IN 46204 USA. [Epstein, Jonathan I.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA. [Hansel, Donna E.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA. [Jimenez, Rafael E.] Mayo Clin, Div Anat Pathol, Rochester, MN USA. [McKenney, Jesse K.] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA. [Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Rao, Priya] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Ro, Jae Y.; Shen, Steven S.] Methodist Hosp, Dept Pathol, Houston, TX 77030 USA. [Reuter, Victor E.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Yao, Jorge L.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA. [Montironi, Rodolfo] Polytech Univ Marche Reg, Sect Pathol Anat, Ancona, Italy. [Srigley, John R.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada. [Tsuzuki, Toyonori] Nagoya Daini Red Cross Hosp, Dept Pathol, Nagoya, Aichi, Japan. RP Paner, GP (reprint author), Univ Chicago, Dept Pathol, 5841S Maryland Ave,Room AMB S626 MC 6101, Chicago, IL 60637 USA. EM gladell.paner@uchospitals.edu NR 28 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD FEB PY 2014 VL 38 IS 2 BP 167 EP 175 DI 10.1097/PAS.0000000000000096 PG 9 WC Pathology; Surgery SC Pathology; Surgery GA AA6NN UT WOS:000331215100003 PM 24145655 ER PT J AU Burandt, E Young, RH AF Burandt, Eike Young, Robert H. TI Pregnancy Luteoma A Study of 20 Cases on the Occasion of the 50th Anniversary of its Description by Dr William H. Sternberg, With an Emphasis on the Common Presence of Follicle-like Spaces and Their Diagnostic Implications SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE pregnancy luteoma; follicle-like spaces; ovary ID OVARIAN-TUMORS AB Twenty cases of the distinctive tumor-like lesion of the ovary, pregnancy luteoma, are described, with emphasis on pathologic features. The masses occurred in patients from 15 to 44 years of age and were typically incidental findings at or near term. Four patients experienced androgenic manifestations. The luteoma was documented to be bilateral in only 4 cases, but the opposite ovary was usually not evaluated pathologically. They ranged up to 15 cm. Sectioning typically showed multiple nodules or a single discrete mass with a multinodular sectioned surface and a soft bulging appearance. Most lesions were brown, but a few were black or yellow at least focally. Foci of hemorrhage were common. The most common microscopic appearance was a diffuse growth, but it was punctuated in about three quarters of the cases by follicle-like spaces often containing colloid-like secretion. These spaces are much more characteristic of the pregnancy luteoma than of the lesion most often in the differential diagnosis, a steroid cell tumor, and accordingly may be of diagnostic aid. However, they may cause confusion, as follicle-like spaces are a nonspecific feature of a number of neoplasms involving the ovary and potentially in the differential diagnosis. Awareness of the clinical background and frequency of finding follicle-like spaces in pregnancy luteoma are important diagnostically, and standard immunohistochemical stains will aid should they be warranted. C1 [Burandt, Eike; Young, Robert H.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA. [Burandt, Eike; Young, Robert H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Burandt, E (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 2,55 Fruit St, Boston, MA 02114 USA. EM eburandt@partners.org NR 15 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD FEB PY 2014 VL 38 IS 2 BP 239 EP 244 DI 10.1097/PAS.0000000000000100 PG 6 WC Pathology; Surgery SC Pathology; Surgery GA AA6NN UT WOS:000331215100012 PM 24335664 ER PT J AU Boyer, DF Lindeman, NI Harris, NL Ferry, JA AF Boyer, Daniel F. Lindeman, Neal I. Harris, Nancy Lee Ferry, Judith Ann TI Peripheral T-cell Lymphomas With Cytotoxic Phenotype in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE composite lymphoma; chronic lymphocytic leukemia; anaplastic large cell lymphoma; peripheral T-cell lymphoma; cytotoxic T cells ID NON-HODGKINS-LYMPHOMA; B-CELL; RICHTERS TRANSFORMATION; CLL PATIENTS; ASSOCIATION; FLUDARABINE; POPULATION; EXPRESSION; RISK AB Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is relatively common, and patients occasionally develop other neoplasms; however, patients who develop other types of lymphomas are rare. We encountered 3 patients with CLL/SLL (one 59-y-old man and 2 women aged 56 and 66 y) who developed T-cell lymphomas. Both women developed ALK(+) anaplastic large cell lymphomas (ALCLs), whereas the man developed CD8(+) peripheral T-cell lymphoma, not otherwise specified. All 3 T-cell lymphomas expressed granzyme B and perforin, indicating a cytotoxic immunophenotype. In 1 case, the first presentation was a lymph nodal composite lymphoma. In the other 2 cases, the T-cell lymphomas arose <1 year after the diagnosis of CLL/SLL and were identified in a lymph node in one case and in the spleen in the other. The patient with a composite lymphoma (SLL/ALK(+) ALCL) was treated and was free of disease at last follow-up, whereas the other 2 patients succumbed to their disease, 1 month and 7 months after the diagnosis of T-cell lymphoma. Peripheral T-cell lymphomas rarely occur in CLL/SLL patients. On the basis of our small series, those with a cytotoxic phenotype appear to be more common in this setting. The occurrence of ALK(+) ALCL in 2 older patients was especially surprising and suggested that CLL/SLL may have played a role in the development of ALCL. C1 [Boyer, Daniel F.; Harris, Nancy Lee; Ferry, Judith Ann] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lindeman, Neal I.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Ferry, JA (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. EM jferry@partners.org NR 34 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD FEB PY 2014 VL 38 IS 2 BP 279 EP 288 DI 10.1097/PAS.0000000000000140 PG 10 WC Pathology; Surgery SC Pathology; Surgery GA AA6NN UT WOS:000331215100017 PM 24418862 ER PT J AU Leung, DT Das, SK Malek, MA Qadri, F Faruque, ASG Ryan, ET AF Leung, Daniel T. Das, Sumon K. Malek, M. A. Qadri, Firdausi Faruque, A. S. G. Ryan, Edward T. TI Impact of Ramadan on Clinical and Microbiologic Parameters of Patients Seen at a Diarrheal Hospital in Urban Dhaka, Bangladesh, 1996-2012 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID DISEASE AB Ramadan is a month in the Islamic calendar when Muslims fast during daylight hours. We used data from the surveillance system of the International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka Hospital in Dhaka. Bangladesh, a predominantly Muslim country, to compare the etiology and clinical presentation of patients who presented with diarrhea during Ramadan to that of control periods, defined as the 30 days immediately before Ramadan. The proportion of infecting pathogens was largely the same, although Shigella spp. were less likely to be identified during Ramadan. Clinical presentations during Ramadan among adult Muslim diarrheal patients were also comparable to those admitted during control periods. A subgroup of cholera patients who presented after sunset during Ramadan had a shorter duration of diarrhea and higher prevalence of severe thirst, drowsiness, and severe dehydration. Our findings suggest that Ramadan has few effects on the profile of enteric pathogens and clinical features of adults seeking medical care for diarrhea. C1 [Leung, Daniel T.] Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, Dhaka 1000, Bangladesh. Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. Ctr Nutr & Food Secur, Dhaka, Bangladesh. Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. RP Leung, DT (reprint author), Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, GPO Box 128, Dhaka 1000, Bangladesh. EM dleung@icddrb.org OI leung, daniel/0000-0001-8401-0801 FU International Centre for Diarrhocal Disease Research; Australian Agency for International Development; Government of the People's Republic of Bangladesh; Canadian International Development Agency; Swedish International Development Cooperation Agency; Department for International Development, United Kingdom; National Institutes of Health, National Institute of Allergy and Infectious Diseases [A1100023, A1106878, AI077883, A1058935, A1100923]; Thrasher Research Fund Early Career Award; American Society of Tropical Medicine and Hygiene/Burroughs Wellcome Fund FX This study was supported by the International Centre for Diarrhocal Disease Research and its donors, which provide unrestricted support for its operations and research. Current donors providing unrestricted support include the Australian Agency for International Development, the Government of the People's Republic of Bangladesh, the Canadian International Development Agency, the Swedish International Development Cooperation Agency, and the Department for International Development, United Kingdom. This study was also supported by grants from the National Institutes of Health, including National Institute of Allergy and Infectious Diseases grants A1100023, A1106878, AI077883, A1058935 (Edward T. Ryan), A1100923 (Daniel T. Leung), a Thrasher Research Fund Early Career Award (Daniel T. Leung), and a Postdoctoral Fellowship in Tropical Infectious Diseases from the American Society of Tropical Medicine and Hygiene/Burroughs Wellcome Fund (to Daniel T. Leung). NR 12 TC 1 Z9 1 U1 1 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2014 VL 90 IS 2 BP 294 EP 298 DI 10.4269/ajtmh.13-0513 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AA3RC UT WOS:000331009000021 PM 24394479 ER PT J AU Ponzoni, M Issa, S Batchelor, TT Rubenstein, JL AF Ponzoni, M. Issa, S. Batchelor, T. T. Rubenstein, J. L. TI Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma SO ANNALS OF ONCOLOGY LA English DT Review DE B-cell receptor; novel agents; primary CNS lymphoma; protein kinases; tumor microenvironment ID CENTRAL-NERVOUS-SYSTEM; B-CELL LYMPHOMA; COMPARATIVE GENOMIC HYBRIDIZATION; SMALL-MOLECULE INHIBITOR; LONG-TERM SURVIVAL; DEFERRED RADIOTHERAPY; INTRAOCULAR LYMPHOMA; COMBINATION CHEMOTHERAPY; CEREBROSPINAL-FLUID; 1ST-LINE TREATMENT AB While there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease. We reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been identified and confirmed by more than one investigator or methodology. While PCNSL tumors usually express a BCL6+, MUM1+ 'activated, germinal center' immunophenotype, they exhibit multiple shared genetic properties with ABC-type diffuse large B-cell lymphomas. Candidate targets and pathways include NFkB, the B-cell receptor, the JAK/STAT pathway, IRF4, BCL-6 as well as PIM kinases. Elements of the tumor microenvironment that may be exploited therapeutically include chemokine pathways, as well as macrophage and T-cell responses. There is a significant need for developing novel therapies in PCNSL, given that an increasing proportion of patients are not eligible for high-dose chemotherapy and brain radiation is associated with detrimental cognitive side-effects. We provide an overview of potential drug targets and novel agents that may be integrated with existing strategies in order to make further progress in this disease. C1 [Ponzoni, M.] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy. [Ponzoni, M.] Ist Sci San Raffaele, Unit Lymphoid Malignancies, I-20132 Milan, Italy. [Issa, S.] Middlemore Hosp, Dept Haematol, Auckland 6, New Zealand. [Batchelor, T. T.] Massachusetts Gen Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02114 USA. [Batchelor, T. T.] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Neurooncol, Boston, MA 02114 USA. [Rubenstein, J. L.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, Div Hematol Oncol, San Francisco, CA 94143 USA. RP Rubenstein, JL (reprint author), Univ Calif San Francisco, Div Hematol Oncol, M1282 Box 1270, San Francisco, CA 94143 USA. EM jamesr@medicine.ucsf.edu FU National Institutes of Health; University of California San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30 AI027763]; NIH [R01CA139-83-01A1]; UCSF Brain Tumor SPORE; Leukemia & Lymphoma Society; [R13 CA124293-06A1] FX The work was supported by the National Institutes of Health, University of California San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (P30 AI027763), NIH R01CA139-83-01A1, UCSF Brain Tumor SPORE, the Leukemia & Lymphoma Society (JLR) and R13 CA124293-06A1 (TTB). NR 99 TC 18 Z9 19 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2014 VL 25 IS 2 BP 316 EP 322 DI 10.1093/annonc/mdt385 PG 7 WC Oncology SC Oncology GA AA7HZ UT WOS:000331269600004 PM 24265352 ER PT J AU Ravi, P Gray, KP O'Donnell, EK Sweeney, CJ AF Ravi, P. Gray, K. P. O'Donnell, E. K. Sweeney, C. J. TI A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor SO ANNALS OF ONCOLOGY LA English DT Review DE complete remission; retroperitoneal lymph node dissection; testicular cancer ID LYMPH-NODE DISSECTION; POSTCHEMOTHERAPY RETROPERITONEAL SURGERY; TESTICULAR CANCER; COMPLETE REMISSION; MASSES; PREDICTION; MANAGEMENT; RISKS; NSGCT; BIAS AB Approximately a quarter of men with metastatic non-seminomatous germ cell tumor (NSGCT) have a residual mass, typically in the retroperitoneum, after chemotherapy. The management of small residual masses (< 1 cm) is controversial, with good outcomes seen with either post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) or surveillance. We sought to review our experience of surveillance and synthesize the cumulative findings with the current literature in the form of a meta-analysis. We searched PubMed, EMBASE and abstracts from ASCO and AUA to identify relevant, English-language studies for the meta-analysis. The DFCI (Dana Farber Cancer Institute) database was constructed from a database of men undergoing cisplatin-based chemotherapy for metastatic NSGCT. The outcomes of interest were the proportion with necrosis, teratoma or active cancer on histology at PC-RPLND (literature) and the total number of relapses, RP-only relapses and overall survival in men undergoing surveillance (literature and DFCI cohort). Three of 47 men undergoing post-chemotherapy surveillance at our institution relapsed over a median follow-up of 5.4 years. All three were alive at a median of 4.2 years after relapse. On meta-analysis, the pooled estimates of necrosis, teratoma and active cancer in the 588 men who underwent PC-RPLND were 71, 24 and 4%, respectively. Of the combined 455 men who underwent surveillance, the pooled estimate of the relapse rate was 5%, with an RP-only relapse rate of 3%. Of the 15 men who suffered an RP-only relapse on surveillance, two died of disease. Surveillance is a reasonable strategy for men with minimal residual RP disease after chemotherapy and avoids an RPLND in similar to 97% of men who are cured with chemotherapy alone. C1 [Ravi, P.] Univ Cambridge, Christs Coll, Cambridge, England. [Gray, K. P.] Dana Farber Canc Inst, Dept Biostat & Computat Biol Boston, Boston, MA 02215 USA. [O'Donnell, E. K.; Sweeney, C. J.] Dana Farber Canc Inst, Dept Med, Boston, MA 02215 USA. [Gray, K. P.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Sweeney, C. J.] Harvard Univ, Sch Med, Boston, MA USA. RP Sweeney, CJ (reprint author), Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Dept Med, 450 Brookline Ave,Suite D1230, Boston, MA 02215 USA. EM christopher_sweeney@dfci.harvard.edu FU NCI NIH HHS [T32 CA009172] NR 38 TC 3 Z9 3 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2014 VL 25 IS 2 BP 331 EP 338 DI 10.1093/annonc/mdt425 PG 8 WC Oncology SC Oncology GA AA7HZ UT WOS:000331269600006 PM 24276027 ER PT J AU Besse, B Leighl, N Bennouna, J Papadimitrakopoulou, VA Blais, N Traynor, AM Soria, JC Gogov, S Miller, N Jehl, V Johnson, BE AF Besse, B. Leighl, N. Bennouna, J. Papadimitrakopoulou, V. A. Blais, N. Traynor, A. M. Soria, J. -C. Gogov, S. Miller, N. Jehl, V. Johnson, B. E. TI Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer SO ANNALS OF ONCOLOGY LA English DT Article DE disease control rate; erlotinib; everolimus; non-small-cell lung cancer; progression-free survival; stomatitis ID TRIAL; CHEMOTHERAPY; THERAPY; PATHWAY; RAD001; INHIBITORS; GEFITINIB; RADIATION; TOXICITY; SURVIVAL AB Based on the results of a multicenter, open-label, phase II study conducted among patients with previously treated, advanced NSCLC, the combination of everolimus 5 mg/day plus erlotinib 150 mg/day does not warrant further investigation in light of increased toxicity and lack of substantial improvement in disease stabilization compared with erlotinib monotherapy.Preclinical data suggest combining a mammalian target of rapamycin inhibitor with erlotinib could provide synergistic antitumor effects in advanced non-small-cell lung cancer (NSCLC). In this multicenter, open-label, phase II study, patients with advanced NSCLC that progressed after one to two previous chemotherapy regimens were randomized 1:1 to erlotinib 150 mg/day +/- everolimus 5 mg/day. Primary end point was the disease control rate (DCR) at 3 months; secondary end points included progression-free survival (PFS) and safety. One hundred thirty-three patients received everolimus-erlotinib (n = 66) or erlotinib alone (n = 67). The DCR at 3 months was 39.4% and 28.4%, respectively. The probability for the difference in disease control at 3 months to be >= 15% was estimated to be 29.8%, which was below the prespecified probability threshold of >= 40%. Median PFS was 2.9 and 2.0 months, respectively. Grade 3/4 adverse events occurred in 72.7% and 32.3% of patients, respectively. Grade 3/4 stomatitis was observed in 31.8% of combination therapy recipients. Everolimus 5 mg/day plus erlotinib 150 mg/day was not considered sufficiently efficacious per the predefined study criteria. The combination does not warrant further investigation based on increased toxicity and the lack of substantial improvement in disease stabilization. C1 [Besse, B.; Soria, J. -C.] Inst Gustave Roussy, Dept Canc Med, Thorac Unit, F-94805 Villejuif, France. [Besse, B.; Soria, J. -C.] South Paris Univ, Dept Oncol Med, Paris, France. [Leighl, N.] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada. [Bennouna, J.] Inst Cancerol Ouest, Dept Med Oncol, Nantes, France. [Papadimitrakopoulou, V. A.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA. [Blais, N.] CHUM, Ctr Integre Cancerol, Montreal, PQ, Canada. [Traynor, A. M.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA. [Gogov, S.; Miller, N.; Jehl, V.] Novartis Pharma AG, Basel, Switzerland. [Johnson, B. E.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. RP Besse, B (reprint author), Inst Gustave Roussy, Dept Canc Med, Thorac Unit, 114 Rue Edouard Vaillant, F-94805 Villejuif, France. EM benjamin.besse@gustaveroussy.fr RI bennouna, jaafar/K-9350-2015 FU Novartis Pharmaceuticals Corporation FX This study was supported by Novartis Pharmaceuticals Corporation. NR 22 TC 14 Z9 14 U1 1 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2014 VL 25 IS 2 BP 409 EP 415 DI 10.1093/annonc/mdt536 PG 7 WC Oncology SC Oncology GA AA7HZ UT WOS:000331269600018 PM 24368400 ER PT J AU Ou, SHI Janne, PA Bartlett, CH Tang, Y Kim, DW Otterson, GA Crino, L Selaru, P Cohen, DP Clark, JW Riely, GJ AF Ou, S. -H. I. Jaenne, P. A. Bartlett, C. H. Tang, Y. Kim, D. -W. Otterson, G. A. Crino, L. Selaru, P. Cohen, D. P. Clark, J. W. Riely, G. J. TI Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC SO ANNALS OF ONCOLOGY LA English DT Article DE treatment beyond disease progression; crizotinib; TKI; RECIST; oncogene addiction; ALK-positive NSCLC ID CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; BREAST-CANCER; DISCONTINUATION; CHEMOTHERAPY; TRASTUZUMAB; MUTATIONS; GEFITINIB; ERLOTINIB AB We compared the clinicopathologic characteristics and survival outcomes of 194 ALK+ NSCLC patients who had progressed on crizotinib according to whether they continued crizotinib beyond disease progression or not. Overall survival also favored significantly patients who were able to continue crizotinib beyond disease progression. Multivariate analysis revealed ability to continue crizotinib beyond disease progression is an independent favorable prognostic factor for improved survival outcome.Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We investigated whether continuing ALK inhibition with crizotinib beyond PD (CBPD) is clinically beneficial and attempted to identify clinicopathologic characteristics associated with patients who experience clinical benefit. Patients with advanced ALK-positive NSCLC enrolled in two ongoing multicenter, single-arm trials who developed RECIST-defined PD were allowed to continue crizotinib if they were deriving ongoing clinical benefit. In the present retrospective analysis, continuation of CBPD was defined as > 3 weeks of crizotinib treatment after PD documentation. Patients who had PD as best response to initial crizotinib treatment were excluded. Baseline and post-progression characteristics, sites of PD, and overall survival (OS) were compared in patients who continued CBPD versus those who did not. The impact of continuing CBPD on OS after adjusting for potential confounding factors was assessed. Among 194 crizotinib-treated patients with RECIST-defined PD, 120 (62%) continued CBPD. A significantly higher proportion of patients who continued CBPD than patients who did not had an ECOG performance status (PS) of 0/1 at PD (96% versus 82%; P = 0.02). CBPD patients had significantly longer OS from the time of PD [median 16.4 versus 3.9 months; hazards ratio (HR) 0.27, 95% confidence interval (CI): 0.17-0.42; P < 0.0001] and from the time of initial crizotinib treatment (median 29.6 versus 10.8 months; HR 0.30, 95% CI: 0.19-0.46; P < 0.0001). The multiple-covariate Cox regression analysis revealed that CBPD remained significantly associated with improved OS after adjusting for relevant factors. Patients who continued CBPD were more likely to have good ECOG PS (0/1) at the time of PD. Continuing ALK inhibition with crizotinib after PD may provide survival benefit to patients with advanced ALK-positive NSCLC. C1 [Ou, S. -H. I.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA. [Jaenne, P. A.] Harvard Univ, Sch Med, Lowe Ctr Thorac Oncol, Boston, MA USA. [Jaenne, P. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. [Bartlett, C. H.] Pfizer Oncol, New York, NY USA. [Tang, Y.; Selaru, P.; Cohen, D. P.] Pfizer Oncol, La Jolla, CA USA. [Kim, D. -W.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea. [Otterson, G. A.] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Columbus, OH 43210 USA. [Crino, L.] Univ Hosp Perugia, Dept Oncol, Perugia, Italy. [Clark, J. W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. [Riely, G. J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. RP Ou, SHI (reprint author), Univ Calif Irvine, Sch Med, Chao Family Comprehens Canc Ctr, 101 City Dr,Bldg 56,RT81, Orange, CA 92868 USA. EM ignatius.ou@uci.edu FU Pfizer Inc. FX This work was sponsored by Pfizer Inc. Editorial support was provided by Wendy Sacks at ACUMED (R) (New York, NY, USA) and was funded by Pfizer Inc [no grant numbers]. NR 25 TC 78 Z9 83 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2014 VL 25 IS 2 BP 415 EP 422 DI 10.1093/annonc/mdt572 PG 8 WC Oncology SC Oncology GA AA7HZ UT WOS:000331269600019 PM 24478318 ER PT J AU Besse, B Heist, RS Papadmitrakopoulou, VA Camidge, DR Beck, JT Schmid, P Mulatero, C Miller, N Dimitrijevic, S Urva, S Pylvaenaeinen, I Petrovic, K Johnson, BE AF Besse, B. Heist, R. S. Papadmitrakopoulou, V. A. Camidge, D. R. Beck, J. T. Schmid, P. Mulatero, C. Miller, N. Dimitrijevic, S. Urva, S. Pylvaenaeinen, I. Petrovic, K. Johnson, B. E. TI A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer SO ANNALS OF ONCOLOGY LA English DT Article DE cisplatin; etoposide; everolimus; phase I; small-cell lung cancer ID ADVANCED SOLID TUMORS; RAPAMYCIN PATHWAY; MAMMALIAN TARGET; III-TRIAL; INHIBITION; CHEMOTHERAPY; PROLIFERATION; SENSITIVITY; COMBINATION; DISEASE AB Background: This phase Ib study aimed to establish the feasible everolimus dose given with standard-dose etoposide plus cisplatin (EP) for extensive-stage small-cell lung cancer (SCLC). An adaptive Bayesian dose-escalation model and investigator opinion were used to identify feasible daily or weekly everolimus doses given with EP in adults with treatment-naive extensive-stage SCLC. A protocol amendment mandated prophylactic granulocyte colony-stimulating factor (G-CSF). Primary end point was cycle 1 dose-limiting toxicity (DLT) rate. Secondary end points included safety, relative EP dose intensity, pharmacokinetics, and tumor response. Patients received everolimus 2.5 or 5 mg/day without G-CSF (n = 10; cohort A), 20 or 30 mg/week without G-CSF (n = 18; cohort B), or 2.5 or 5 mg/day with G-CSF (n = 12; cohort C); all received EP. Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively. Cycle 1 DLTs were neutropenia (cohorts A and B), febrile neutropenia (all cohorts), and thrombocytopenia (cohorts A and C). The most common grade 3/4 adverse events were hematologic. Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively). Everolimus 2.5 mg/day plus G-CSF was the only feasible dose given with standard-dose EP in untreated extensive-stage SCLC. C1 [Besse, B.] Inst Gustave Roussy, Dept Canc Med, Thorac Unit, F-94805 Villejuif, France. [Heist, R. S.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. [Papadmitrakopoulou, V. A.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA. [Camidge, D. R.] Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Aurora, CO USA. [Beck, J. T.] Highlands Oncol Grp, Fayetteville, AR USA. [Schmid, P.] Univ Sussex, Barts Brighton Expt Canc Med Ctr, Brighton & Sussex Med Sch, Dept Canc Med, Brighton, E Sussex, England. [Mulatero, C.] St James Univ Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England. [Miller, N.; Dimitrijevic, S.; Pylvaenaeinen, I.; Petrovic, K.] Novartis Pharma AG, Basel, Switzerland. [Urva, S.] Novartis Pharmaceut, Florham Pk, NJ USA. [Johnson, B. E.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. RP Besse, B (reprint author), Inst Gustave Roussy, Dept Canc Med, Thorac Unit, 114 Rue Edouard Vaillant, F-94805 Villejuif, France. EM benjamin.besse@gustaveroussy.fr FU Novartis Pharmaceuticals FX This study was supported by Novartis Pharmaceuticals. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. NR 21 TC 7 Z9 7 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2014 VL 25 IS 2 BP 505 EP 511 DI 10.1093/annonc/mdt535 PG 7 WC Oncology SC Oncology GA AA7HZ UT WOS:000331269600034 PM 24368401 ER PT J AU Park, H Schoenfeld, J Mucci, L AF Park, H. Schoenfeld, J. Mucci, L. TI Reply to 'Meta-analysis procedure for the effect of statin on the recurrence of prostate cancer' by T. Kawada SO ANNALS OF ONCOLOGY LA English DT Letter ID RADICAL PROSTATECTOMY; RADIATION-THERAPY; EXPERIENCE AB Our meta-analysis is the first to examine the differential effect of statins on prostate cancer biochemical recurrence by primary cancer treatment modality. Extracting information to determine pooled estimates of the outcome variable can be challenging, but we have taken several measures to ensure that our choice of selection criteria does not significantly bias of our findings. C1 [Park, H.] Yale Univ, Sch Med, Dept Therapeut Radiol, Smilow Canc Hosp, New Haven, CT 06510 USA. [Schoenfeld, J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Mucci, L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Park, H (reprint author), Yale Univ, Sch Med, Dept Therapeut Radiol, Smilow Canc Hosp, New Haven, CT 06510 USA. EM henry.park@yale.edu OI Park, Henry/0000-0002-9366-8514 NR 7 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2014 VL 25 IS 2 BP 543 EP 544 DI 10.1093/annonc/mdt565 PG 2 WC Oncology SC Oncology GA AA7HZ UT WOS:000331269600043 PM 24419238 ER PT J AU Jeong, W Kim, SB Sohn, BH Park, YY Park, BS Kim, SC Kim, SS Johnson, RL Birrer, M Bowtell, DSL Mills, GB Sood, A Lee, JS AF Jeong, Woojin Kim, Sang-Bae Sohn, Bo Hwa Park, Yun-Yong Park, Bun Sung Kim, Sang Cheol Kim, Sung Soo Johnson, Randy L. Birrer, Michael Bowtell, David S. L. Mills, Gordon B. Sood, Anil Lee, Ju-Seog TI Activation of YAP1 Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer SO ANTICANCER RESEARCH LA English DT Article DE DNA microarrays; ovarian cancer; prognosis; taxane; YAP1 ID ORGAN SIZE CONTROL; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; HIPPO PATHWAY; CELLS; PREDICTION; MIGRATION; ONCOGENE; PROTEIN; GROWTH AB Aim: We aimed to investigate the clinical significance of the activation of Yes-Associated Protein 1 (YAP1), a key downstream effector of Hippo tumor-suppressor pathway, in ovarian cancer. Materials and Methods: A gene expression signature reflecting activation of YAP1 was developed from gene expression data of 267 samples from patients with ovarian cancer. A refined ovarian cancer YAP1 signature was validated in an independent ovarian cancer cohort (n=185). Associations between the YAP1 signature and prognosis were assessed using Kaplan-Meier plots, the log-rank test, and a Cox proportional hazards model. Results: We identified a 612-gene expression signature reflecting YAP1 activation in ovarian cancer. In multivariate analysis, the signature was an independent predictor of overall survival (hazard ratio=1.66; 95% confidence interval=1.1 to 2.53; p=0.01). In subset analysis, the signature identified patients likely to benefit from taxane-based adjuvant chemotherapy. Conclusion: Activation of YAP1 is significantly associated with prognosis and the YAP1 signature can predict response to taxane-based adjuvant chemotherapy in patients with ovarian cancer. C1 [Jeong, Woojin] Ewha Womans Univ, Dept Life Sci, Div Life & Pharmaceut Sci, Seoul, South Korea. [Jeong, Woojin] Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Seoul, South Korea. [Kim, Sang-Bae; Sohn, Bo Hwa; Park, Yun-Yong; Mills, Gordon B.; Lee, Ju-Seog] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77054 USA. [Johnson, Randy L.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77054 USA. [Sood, Anil] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77054 USA. [Sood, Anil] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77054 USA. [Kim, Sang-Bae; Sohn, Bo Hwa; Park, Yun-Yong; Mills, Gordon B.; Lee, Ju-Seog] Univ Texas MD Anderson Canc Ctr, Kleberg Ctr Mol Markers, Houston, TX 77054 USA. [Sood, Anil] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77054 USA. [Park, Bun Sung] Yonsei Univ, Coll Med, Inst Med Convergence, Seoul, South Korea. [Kim, Sang Cheol] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Samsung Genome Inst, Seoul, South Korea. [Kim, Sung Soo; Lee, Ju-Seog] Kyung Hee Univ, Dept Biochem & Mol Biol, Med Res Ctr, Seoul, South Korea. [Kim, Sung Soo; Lee, Ju-Seog] Kyung Hee Univ, Inst Biomed Sci, Sch Med, Seoul, South Korea. [Birrer, Michael] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA. [Bowtell, David S. L.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. RP Lee, JS (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St,Room 2SCR3-2018, Houston, TX 77054 USA. EM jlee@mdanderson.org RI Bowtell, David/H-1007-2016 OI Bowtell, David/0000-0001-9089-7525 FU University of Texas MD Anderson Cancer Center; Sheikh Khalifa Bin Zayed Institute for Personalized Cancer Therapy; Ovarian SPORE [NCIP50CA083639]; Bio & Medical Technology Development Program Grant, Korea [M10642040002-07N4204-00210]; Scientific Research Center Program Grant, Korea [2012R1A5A1048236] FX The study was funded by a grant from The University of Texas MD Anderson Cancer Center, Sheikh Khalifa Bin Zayed Institute for Personalized Cancer Therapy, Ovarian SPORE (NCIP50CA083639), Bio & Medical Technology Development Program Grant, Korea (M10642040002-07N4204-00210), and Scientific Research Center Program Grant, Korea (2012R1A5A1048236). NR 28 TC 13 Z9 13 U1 1 U2 2 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 EI 1791-7530 J9 ANTICANCER RES JI Anticancer Res. PD FEB PY 2014 VL 34 IS 2 BP 811 EP 817 PG 7 WC Oncology SC Oncology GA AB0QM UT WOS:000331497200035 PM 24511017 ER PT J AU Romanatto, T Fiamoncini, J Wang, B Curi, R Kang, JX AF Romanatto, Talita Fiamoncini, Jarlei Wang, Bin Curi, Rui Kang, Jing X. TI Elevated tissue omega-3 fatty acid status prevents age-related glucose intolerance in fat-1 transgenic mice SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE LA English DT Article DE Glucose homeostasis; Aging; Omega-3 fatty acid; Lipogenesis; Gluconeogenesis; Inflammation ID INDUCED INSULIN-RESISTANCE; POLYUNSATURATED FATTY-ACIDS; SUCROSE-RICH DIET; FISH-OIL; DOCOSAHEXAENOIC ACID; NUCLEAR RECEPTORS; GENE-EXPRESSION; PLASMA-GLUCOSE; PPAR-GAMMA; OBESITY AB The objective of this study was to investigate the impact of elevated tissue omega-3 (n-3) polyunsaturated fatty acids (PUFA) status on age-related glucose intolerance utilizing the fat-1 transgenic mouse model, which can endogenously synthesize n-3 PUFA from omega-6 (n-6) PUFA. Fat-1 and wild-type mice, maintained on the same dietary regime of a 10% corn oil diet were tested at two different ages (2 months old and 8 months old) for various glucose homeostasis parameters and related gene expression. The older wild-type mice exhibited significantly increased levels of blood insulin, fasting blood glucose, liver triglycerides, and glucose intolerance, compared to the younger mice, indicating an age-related impairment of glucose homeostasis. In contrast, these age-related changes in glucose metabolism were largely prevented in the older fat-1 mice. Compared to the older wild-type mice, the older fat-1 mice also displayed a lower capacity for gluconeogenesis, as measured by pyruvate tolerance testing (PTT) and hepatic gene expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6 phosphatase (G6Pase). Furthermore, the older fat-1 mice showed a significant decrease in body weight, epididymal fat mass, inflammatory activity (NF kappa-B and p-I kappa B expression), and hepatic lipogenesis (acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) expression), as well as increased peroxisomal activity (70-kDa peroxisomal membrane protein (PMP70) and acyl-CoA oxidase1 (ACOX1) expression). Altogether, the older fat-1 mice exhibit improved glucose homeostasis in comparison to the older wild-type mice. These findings support the beneficial effects of elevated tissue n-3 fatty acid status in the prevention and treatment of age-related chronic metabolic diseases. (C) 2013 Elsevier B.V. All rights reserved. C1 [Romanatto, Talita; Wang, Bin; Kang, Jing X.] Massachusetts Gen Hosp, Lab Lipid Med & Technol, Boston, MA 02114 USA. [Romanatto, Talita; Wang, Bin; Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA USA. [Romanatto, Talita; Fiamoncini, Jarlei; Curi, Rui] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo, Brazil. RP Kang, JX (reprint author), Massachusetts Gen Hosp, Lab Lipid Med & Technol, Dept Med, 149-13th St, Charlestown, MA 02129 USA. EM kang.jing@mgh.harvard.edu RI Curi , Rui/C-9351-2012 FU Sansun Life Sciences; Fortune Education Foundation; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) FX This study was supported by the generous funding from Sansun Life Sciences, the Fortune Education Foundation, and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP). The authors are also grateful to Marina Kang for her editorial assistance. NR 51 TC 13 Z9 14 U1 0 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4439 EI 0006-3002 J9 BBA-MOL BASIS DIS JI Biochim. Biophys. Acta-Mol. Basis Dis. PD FEB PY 2014 VL 1842 IS 2 BP 186 EP 191 DI 10.1016/j.bbadis.2013.10.017 PG 6 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA AA9LL UT WOS:000331414900007 PM 24211484 ER PT J AU Suzuki, M Bartlett, JD AF Suzuki, Maiko Bartlett, John D. TI Sirtuin1 and autophagy protect cells from fluoride-induced cell stress SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE LA English DT Article DE Sirt1; Autophagy; Fluoride; Enamel; Ameloblast; Dental fluorosis ID ENDOPLASMIC-RETICULUM STRESS; EPITHELIAL LUNG-CELLS; OXIDATIVE STRESS; DENTAL FLUOROSIS; SIRT1 ACTIVATION; ENAMEL FORMATION; SODIUM-FLUORIDE; AMPK ACTIVATION; RAT INCISOR; IN-VITRO AB Sirtuin1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD(+))-dependent deacetylase functioning in the regulation of metabolism, cell survival and organismal lifespan. Active SIRT1 regulates autophagy during cell stress, including calorie restriction, endoplasmic reticulum (ER) stress and oxidative stress. Previously, we reported that fluoride induces ER-stress in ameloblasts responsible for enamel formation, suggesting that ER-stress plays a role in dental fluorosis. However, the molecular mechanism of how cells respond to fluoride-induced cell stress is unclear. Here, we demonstrate that fluoride activates SIRT1 and initiates autophagy to protect cells from fluoride exposure. Fluoride treatment of ameloblast-derived cells (LS8) significantly increased Sirt1 expression and induced SIRT1 phosphorylation resulting in the augmentation of SIRT1 deacetylase activity. To demonstrate that fluoride exposure initiates autophagy, we characterized the expression of autophagy related genes (Atg); Atg5, Atg7 and Atg8/LC3 and showed that both their transcript and protein levels were significantly increased following fluoride treatment. To confirm that SIRT1 plays a protective role in fluoride toxicity, we used resveratrol (RES) to augment SIRT1 activity in fluoride treated LS8 cells. RES increased autophagy, inhibited apoptosis, and decreased fluoride cytotoxicity. Rats treated with fluoride (0, 50, 100 and 125 ppm) in drinking water for 6 weeks had significantly elevated expression levels of Sirt1, Atg5, Atg7 and Atg8/LC3 in their maturation stage enamel organs. increased protein levels of p-SIRT1, ATG5 and ATG8/LC3 were present in fluoride-treated rat maturation stage ameloblasts. Therefore, the SIRT1/autophagy pathway may play a critical role as a protective response to help prevent dental fluorosis. (C) 2013 Elsevier B.V. All rights reserved. C1 [Bartlett, John D.] Forsyth Inst, Dept Mineralized Tissue Biol, Cambridge, MA 02142 USA. Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. RP Bartlett, JD (reprint author), Forsyth Inst, Dept Mineralized Tissue Biol, 245 First St, Cambridge, MA 02142 USA. EM jbartlett@forsyth.org FU National Institute of Dental and Craniofacial Research of the National Institutes of Health [R01DE08106] FX We thank Justine Dobeck for histology expertise and Malcolm Snead for generously providing us with LS8 cells. Research reported in this publication was supported by the National Institute of Dental and Craniofacial Research of the National Institutes of Health under award number R01DE08106 (to J.D.B.). NR 93 TC 20 Z9 21 U1 1 U2 21 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4439 EI 0006-3002 J9 BBA-MOL BASIS DIS JI Biochim. Biophys. Acta-Mol. Basis Dis. PD FEB PY 2014 VL 1842 IS 2 BP 245 EP 255 DI 10.1016/j.bbadis.2013.11.023 PG 11 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA AA9LL UT WOS:000331414900013 PM 24296261 ER PT J AU Antin, JH AF Antin, Joseph H. TI Steroid-Refractory Acute Graft-versus-Host Disease: Is There an Effective Therapy? SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Editorial Material ID MESENCHYMAL STROMAL CELLS; STEM-CELLS; TRIAL; PHOTOPHERESIS; MULTICENTER; TRANSPLANT; RESISTANT C1 Dana Farber Canc Inst, Boston, MA 02215 USA. RP Antin, JH (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM jantin@partners.org NR 12 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 BP 146 EP 148 DI 10.1016/j.bbmt.2013.11.012 PG 3 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QS UT WOS:000331155300002 PM 24269707 ER PT J AU Warlick, ED Paulson, K Brazauskas, R Zhong, X Miller, AM Camitta, BM George, B Savani, BN Ustun, C Marks, DI Waller, EK Baron, F Freytes, CO Socie, G Akpek, G Schouten, HC Lazarus, HM Horwitz, EM Koreth, J Cahn, JY Bornhauser, M Seftel, M Cairo, MS Laughlin, MJ Sabloff, M Ringden, O Gale, RP Kamble, RT Vij, R Gergis, U Mathews, V Saber, W Chen, YB Liesveld, JL Cutler, CS Ghobadi, A Uy, GL Eapen, M Weisdorf, DJ Litzow, MR AF Warlick, Erica D. Paulson, Kristjan Brazauskas, Ruta Zhong, Xiaobo Miller, Alan M. Camitta, Bruce M. George, Biju Savani, Bipin N. Ustun, Celalettin Marks, David I. Waller, Edmund K. Baron, Frederic Freytes, Cesar O. Socie, Gerard Akpek, Gorgun Schouten, Harry C. Lazarus, Hillard M. Horwitz, Edwin M. Koreth, John Cahn, Jean-Yves Bornhauser, Martin Seftel, Matthew Cairo, Mitchell S. Laughlin, Mary. J. Sabloff, Mitchell Ringden, Olle Gale, Robert Peter Kamble, Rammurti T. Vij, Ravi Gergis, Usama Mathews, Vikram Saber, Wael Chen, Yi-Bin Liesveld, Jane L. Cutler, Corey S. Ghobadi, Armin Uy, Geoffrey L. Eapen, Mary Weisdorf, Daniel J. Litzow, Mark R. TI Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE AML; RIC; Cytarabine consolidation ID STEM-CELL TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; HIGH-DOSE CYTARABINE; PREPARATIVE REGIMENS; CHEMOTHERAPY; SURVIVAL; IMPACT; ADULTS; BLOOD AB The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremission consolidation. Three-year survival rates were 36% (95% confidence interval [CI], 29% to 43%) in the no consolidation arm and 42% (95% CI, 37% to 47%) in the cytarabine consolidation arm (P = .16). Disease-free survival was 34% (95% Cl, 27% to 41%) and 41% (95% CI, 35% to 46%; P = .15), respectively. Three-year cumulative incidences of relapse were 37% (95% CI, 30% to 44%) and 38% (95% Cl, 33% to 43%), respectively (P = .80). Multivariate regression confirmed no effect of consolidation on relapse, disease-free survival, and survival. Before reduced-intensity or nonmyeloablative conditioning Ha, these data suggest pre-HCT consolidation cytarabine does not significantly alter outcomes and support prompt transition to transplant as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required. (C) 2014 American Society for Blood and Marrow Transplantation. C1 [Warlick, Erica D.; Ustun, Celalettin] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA. [Paulson, Kristjan; Seftel, Matthew] Univ Manitoba, Dept Hematol, Winnipeg, MB, Canada. [Brazauskas, Ruta; Zhong, Xiaobo; Saber, Wael; Eapen, Mary] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA. [Miller, Alan M.] Baylor Univ, Med Ctr, Dept Oncol, Dallas, TX USA. [Camitta, Bruce M.] Med Coll Wisconsin, Midwest Ctr Canc & Blood Disorders, Dept Pediat, Milwaukee, WI 53226 USA. [Camitta, Bruce M.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [George, Biju] Christian Med Coll & Hosp, Dept Hematol, Vellore, Tamil Nadu, India. [Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Marks, David I.] Bristol Childrens Hosp, Bristol Adult BMT Unit, Bristol, Avon, England. [Waller, Edmund K.] Emory Univ Hosp, Bone Marrow & Stem Cell Transplant Ctr, Atlanta, GA 30322 USA. [Baron, Frederic] Univ Liege, Ctr Hosp Univ Sart Tilman, Liege, Belgium. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, Stem Cell Transplant Program, Dept Hematopoiet, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Socie, Gerard] Hop St Louis, Serv Hematol, Paris, France. [Akpek, Gorgun] Banner MD Anderson Canc Ctr, SCTCT Program, Gilbert, AZ USA. [Schouten, Harry C.] Acad Ziekenhuis Maastricht, Div Hematol, Maastricht, Netherlands. [Lazarus, Hillard M.] Univ Hosp, Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Horwitz, Edwin M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Koreth, John] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Cahn, Jean-Yves] Univ Hosp, Dept Hematol, Grenoble, France. [Bornhauser, Martin] Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany. [Cairo, Mitchell S.] New York Med Coll, Maria Fareri Childrens Hosp, Dept Pediat Hematol Oncol & Stem Cell Transplanta, New York, NY USA. [Laughlin, Mary. J.] Univ Virginia, Hematopoiet Cell Transplantat Program, Charlottesville, VA USA. [Cairo, Mitchell S.] Univ Ottawa, Dept Med, Div Hematol, Ottawa, ON, Canada. [Ringden, Olle] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden. [Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Sect Hematol, London, England. [Kamble, Rammurti T.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA. [Gergis, Usama] Weill Cornell Med Coll, New York, NY USA. [Chen, Yi-Bin] Massachusetts Gen Hosp, Dept BMT, Boston, MA 02114 USA. [Liesveld, Jane L.] Univ Rochester, Med Ctr, Strong Mem Hosp, Dept Hematol Oncol, Rochester, NY 14642 USA. [Ghobadi, Armin] MD Anderson Canc Res Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA. [Litzow, Mark R.] Mayo Clin Rochester, Dept Hematol & Internal Med, Rochester, MN USA. RP Warlick, ED (reprint author), Univ Minnesota, Div Hematol Oncol & Transplantat, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA. EM ewarlick@umn.edu RI Cahn, Jean-Yves/M-6493-2014; OI Uy, Geoffrey/0000-0002-7809-0996 FU Public Health Service from the National Cancer Institute (NCI) [U24 CA076518]; National Heart, Lung and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases; NHLBI [U10 HL069294]; NCI; Health Resources and Services Administration/US Department of Health and Human Services [HHSH250201200016C]; Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039]; Allos Therapeutics, Inc.; Amgen, Inc. FX Financial disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24 CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement U10 HL069294 from the NHLBI and NCI; contract HHSH250201200016C from Health Resources and Services Administration/US Department of Health and Human Services; 2 grants (N00014-12-1-0142 and N00014-13-1-0039) from the Office of Naval Research; and grants from Allos Therapeutics, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Celgene Corporation; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Histogenetics, Inc.; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Remedy Informatics; Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; TerumoBCT; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government. NR 25 TC 9 Z9 9 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 BP 202 EP 208 DI 10.1016/j.bbmt.2013.10.023 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QS UT WOS:000331155300010 PM 24184335 ER PT J AU Issa, NC Marty, FM Leblebjian, H Galar, A Shea, MM Antin, JH Soiffer, RJ Baden, LR AF Issa, Nicolas C. Marty, Francisco M. Leblebjian, Houry Galar, Alicia Shea, Margaret M. Antin, Joseph H. Soiffer, Robert J. Baden, Lindsey R. TI Live Attenuated Varicella-Zoster Vaccine in Hematopoietic Stem Cell Transplantation Recipients SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Varicella-zoster vaccine; HSCT ID LOW-DOSE ACYCLOVIR; BONE-MARROW-TRANSPLANTATION; LONG-TERM ACYCLOVIR; HEALTHY-CHILDREN; HERPES-ZOSTER; VIRUS DISEASE; RISK-FACTORS; INFECTION; PREVENTION; ADULTS AB Hematopoietic stem cell transplantation (HSCT) recipients are at risk for varicella-zoster virus (VZV) reactivation. Vaccination may help restore VZV immunity; however, the available live attenuated VZV vaccine (Zostavax) is contraindicated in immunocompromised hosts. We report our experience with using a single dose of VZV vaccine in 110 adult autologous and allogeneic HSCT recipients who were about 2 years after transplantation, free of graft-versus-host disease, and not receiving immunosuppression. One hundred eight vaccine recipients (98.2%) had no clinically apparent adverse events with a median follow-up period of 9.5 months (interquartile range, 6 to 16; range, 2 to 28). Two vaccine recipients (1.8%) developed a skin rash (one zoster-like rash with associated pain, one varicella-like) within 42 days post-vaccination that resolved with antiviral therapy. We could not confirm if these rashes were due to vaccine (Oka) or wild-type VZV. No other possible cases of VZV reactivation have occurred with about 1178 months of follow-up. Live attenuated zoster vaccine appears generally safe in this population when vaccinated as noted; the overall vaccination risk needs to be weighed against the risk of wild-type VZV disease in this high-risk population. (C) 2014 American Society for Blood and Marrow Transplantation. C1 [Issa, Nicolas C.; Marty, Francisco M.; Galar, Alicia; Shea, Margaret M.; Baden, Lindsey R.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Issa, Nicolas C.; Marty, Francisco M.; Antin, Joseph H.; Soiffer, Robert J.; Baden, Lindsey R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Issa, Nicolas C.; Marty, Francisco M.; Galar, Alicia; Antin, Joseph H.; Soiffer, Robert J.; Baden, Lindsey R.] Harvard Univ, Sch Med, Boston, MA USA. [Leblebjian, Houry] Dana Farber Canc Inst, Dept Pharm, Boston, MA 02115 USA. RP Issa, NC (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St,PBB A4, Boston, MA 02115 USA. EM nissa@partners.org OI Galar, Alicia/0000-0002-9310-8752 FU R J Corman research fund FX Financial disclosure: Supported in part by the R J Corman research fund. NR 23 TC 17 Z9 18 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 BP 285 EP 287 DI 10.1016/j.bbmt.2013.11.013 PG 3 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QS UT WOS:000331155300023 PM 24269706 ER PT J AU Antin, JH Deeg, HJ Korman, S Bonfim, C Nakamura, R Horowitz, MM Weisdorf, D Eapen, M Pulsipher, MA AF Antin, Joseph H. Deeg, H. Joachim Korman, Sandra Bonfim, Carmem Nakamura, Ryotaro Horowitz, Mary M. Weisdorf, Daniel Eapen, Mary Pulsipher, Michael A. TI Effect of Antithymocyte Globulin Source on Outcomes of Bone Marrow Transplantation for Severe Aplastic Anemia SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Deeg, H. Joachim] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Program, Seattle, WA 98104 USA. [Korman, Sandra] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Bonfim, Carmem] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil. [Nakamura, Ryotaro] City Hope Natl Med Ctr, Hematol Hematopoiet Cell Transplantat, Duarte, CA USA. [Horowitz, Mary M.; Eapen, Mary] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Weisdorf, Daniel] Univ Minnesota, Minneapolis, MN USA. [Pulsipher, Michael A.] Univ Utah, Sch Med, Primary Childrens Med Ctr, Salt Lake City, UT USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 7 BP S27 EP S27 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400012 ER PT J AU Armand, P Kim, HT Virtanen, J Itala-Remes, M Majhail, NS Burns, LJ Defor, T Trottier, B Platzbecker, U Antin, JH Wermke, M AF Armand, Philippe Kim, Haesook T. Virtanen, Johanna Itala-Remes, Maija Majhail, Navneet S. Burns, Linda J. Defor, Todd Trottier, Bryan Platzbecker, Uwe Antin, Joseph H. Wermke, Martin TI Iron Overload in Allogeneic Stem Cell Transplantation Outcome: A Meta-Analysis SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Armand, Philippe; Kim, Haesook T.; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Virtanen, Johanna; Itala-Remes, Maija] Turku Univ Hosp, FIN-20520 Turku, Finland. [Majhail, Navneet S.] Cleveland Clin Fdn, Blood & Marrow Transplant Program, Cleveland, OH 44195 USA. [Burns, Linda J.; Trottier, Bryan] Univ Minnesota, Minneapolis, MN USA. [Defor, Todd] Univ Minnesota, BMT Res Program, Minneapolis, MN USA. [Platzbecker, Uwe] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, D-01062 Dresden, Germany. [Wermke, Martin] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin 1, D-01062 Dresden, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 8 BP S27 EP S28 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400013 ER PT J AU Ballen, KK Majhail, NS Brazauskas, R Wang, ZW Aljurf, MD Dandoy, C Frangoul, HA Freytes, CO Lazarus, HM LeMaistre, CF Parsons, SK Smith, FO Steinberg, A Szwajcer, D Ustun, C Wood, WA Joffe, S AF Ballen, Karen K. Majhail, Navneet S. Brazauskas, Ruta Wang, Zhiwei Aljurf, Mahmoud D. Dandoy, Christopher Frangoul, Haydar A. Freytes, Cesar O. Lazarus, Hillard M. LeMaistre, Charles F. Parsons, Susan K. Smith, Franklin O. Steinberg, Amir Szwajcer, David Ustun, Celalettin Wood, William A. Joffe, Steven TI Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison Among Alternative Graft Sources SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Majhail, Navneet S.] Cleveland Clin Fdn, Blood & Marrow Transplant Program, Cleveland, OH 44195 USA. [Brazauskas, Ruta] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Wang, Zhiwei] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Aljurf, Mahmoud D.] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia. [Dandoy, Christopher] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Frangoul, Haydar A.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [LeMaistre, Charles F.] Sarah Cannon BMT Program, Nashville, TN USA. [Parsons, Susan K.] Tufts Med Ctr, Boston, MA USA. [Smith, Franklin O.] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA. [Steinberg, Amir] Mt Sinai Med Ctr, Los Angeles, CA USA. [Szwajcer, David] Univ Manitoba, CancerCare Manitoba, Winnipeg, MB, Canada. [Ustun, Celalettin] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Wood, William A.] Univ North Carolina Hosp, Chapel Hill, NC USA. [Joffe, Steven] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 104 BP S92 EP S92 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400109 ER PT J AU Ballen, KK Chen, M Ahn, KW Boeckh, MJ Auletta, JJ Szabolcs, P Tomblyn, MR AF Ballen, Karen K. Chen, Min Ahn, Kwang Woo Boeckh, Michael J. Auletta, Jeffery J. Szabolcs, Paul Tomblyn, Marcie R. TI Comparison of Infection Rates Among Acute Leukemia Patients in Remission Receiving Alternative Donor Hematopoietic Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chen, Min] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Ahn, Kwang Woo] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Boeckh, Michael J.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA. [Auletta, Jeffery J.] Nationwide Childrens Hosp, Pediat Bone Marrow Transplant, Columbus, OH USA. [Szabolcs, Paul] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Tomblyn, Marcie R.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 103 BP S91 EP S92 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400108 ER PT J AU Bona, K Lehmann, LE London, WB Wolfe, J AF Bona, Kira Lehmann, Leslie E. London, Wendy B. Wolfe, Joanne TI Prevalence and Impact of Poverty in Pediatric Allogeneic Hematopoetic Stem Cell Transplant SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Bona, Kira; Lehmann, Leslie E.; Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bona, Kira; London, Wendy B.; Wolfe, Joanne] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 240 BP S166 EP S167 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400245 ER PT J AU Chen, N Radhakrishnan, K Krajewski, J Ricci, A Geyer, M Harrison, L Ozkaynak, MF Cheerva, A Talano, JA Moore, TB Gillio, AP Walters, M Baxter-Lowe, LA Cairo, MS AF Chen, Nan Radhakrishnan, Kavita Krajewski, Jennifer Ricci, Angela Geyer, Mark Harrison, Lauren Ozkaynak, M. Fevzi Cheerva, Alexandra Talano, Julie-An Moore, Theodore B. Gillio, Alfred P. Walters, Mark Baxter-Lowe, Lee Ann Cairo, Mitchell S. TI Low Day 100 Transplant-Related Mortality and Relapse Rate Following Clofarabine in Combination with Cytarabine, Total Body Irradiation and Allogenic Stem Cell Transplantaiton in Children, Adolescents and Young Adults with Poor-Risk Acute Leukemia SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Chen, Nan; Harrison, Lauren; Ozkaynak, M. Fevzi; Cairo, Mitchell S.] New York Med Coll, Valhalla, NY 10595 USA. [Radhakrishnan, Kavita] Univ San Francisco, San Francisco, NY USA. [Krajewski, Jennifer] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Ricci, Angela] Boston Childrens Hosp, Boston, MA USA. [Geyer, Mark] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Cheerva, Alexandra] Univ Louisville, Louisville, KY 40292 USA. [Talano, Julie-An] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Talano, Julie-An] Childrens Hosp Wisconsin, BMT, Milwaukee, WI 53201 USA. [Moore, Theodore B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gillio, Alfred P.] HUMC, Hackensack, NJ USA. [Walters, Mark] Childrens Hosp & Res Ctr, Oakland, CA USA. [Baxter-Lowe, Lee Ann] UCSF, Immunogent & Transplantat Lab, San Francsico, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 84 BP S79 EP S80 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400089 ER PT J AU Chen, YB Li, SL Del Rio, C Coughlin, E Ballen, KK Cutler, CS Dey, BR Ho, VT McAfee, SL Spitzer, TR Alyea, EP AF Chen, Yi-Bin Li, Shuli Del Rio, Candice Coughlin, Erin Ballen, Karen K. Cutler, Corey S. Dey, Bimalangshu R. Ho, Vincent T. McAfee, Steven L. Spitzer, Thomas R. Alyea, Edwin P., III TI Phase II Trial of Reduced Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Chen, Yi-Bin; Coughlin, Erin; Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Li, Shuli; Cutler, Corey S.; Ho, Vincent T.; Alyea, Edwin P., III] Dana Farber Canc Inst, Boston, MA 02115 USA. [Del Rio, Candice; Dey, Bimalangshu R.; Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 334 BP S217 EP S218 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400339 ER PT J AU Chen, YB Li, SL Lane, AA Del Rio, C Connolly, C Ballen, KK Cutler, CS Dey, BR Fathi, AT Ho, VT Joyce, A McAfee, SL Spitzer, TR Levis, M Soiffer, RJ AF Chen, Yi-Bin Li, Shuli Lane, Andrew A. Del Rio, Candice Connolly, Christine Ballen, Karen K. Cutler, Corey S. Dey, Bimalangshu R. Fathi, Amir T. Ho, Vincent T. Joyce, Amy McAfee, Steven L. Spitzer, Thomas R. Levis, Mark Soiffer, Robert J. TI Phase I Trial of Maintenance Sorafenib after Allogeneic HSCT for Patients with FLT3-ITD AML SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Chen, Yi-Bin; Connolly, Christine; Ballen, Karen K.; Fathi, Amir T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Li, Shuli; Lane, Andrew A.; Cutler, Corey S.; Ho, Vincent T.; Joyce, Amy; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Del Rio, Candice; Dey, Bimalangshu R.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA. [Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplantat Unit, Boston, MA 02114 USA. [Levis, Mark] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 213 BP S152 EP S152 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400218 ER PT J AU Chen, YB Lane, AA Logan, BR Maziarz, RT Zhu, XC Akpek, G Lazarus, HM Bredeson, CN Olsson, R Saber, W Hale, GA Smith, FO Aljurf, MD Artz, AS Ho, VT McCarthy, PL Pasquini, MC Cooke, KR AF Chen, Yi-Bin Lane, Andrew A. Logan, Brent R. Maziarz, Richard T. Zhu, Xiaochun Akpek, Goergun Lazarus, Hillard M. Bredeson, Christopher N. Olsson, Richard Saber, Wael Hale, Gregory A. Smith, Franklin O. Aljurf, Mahmoud D. Artz, Andrew S. Ho, Vincent T. McCarthy, Philip L. Pasquini, Marcelo C. Cooke, Kenneth R. TI Incidence and Risk Factors for the Development of Idiopathic Pneumonitis Syndrome (IPS) after Autologous Hematopoietic Cell Transplantation (AutoHCT) for Patients with Lymphoma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lane, Andrew A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Logan, Brent R.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Zhu, Xiaochun; Saber, Wael] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Akpek, Goergun] Banner MD Anderson Canc Ctr, Gilbert, AZ USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Bredeson, Christopher N.] Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada. [Olsson, Richard] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden. [Hale, Gregory A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA. [Smith, Franklin O.] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA. [Aljurf, Mahmoud D.] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia. [Artz, Andrew S.] Univ Chicago Hosp, Chicago, IL 60637 USA. [Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [McCarthy, Philip L.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Pasquini, Marcelo C.] CIBMTR Med Coll Wisconsin, CIBMTR, Milwaukee, WI USA. [Cooke, Kenneth R.] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 128 BP S106 EP S106 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400133 ER PT J AU Chen, YB Li, SL Del Rio, C Driscoll, J Sadrzadeh, H Abramson, JS Armand, P Barnes, J Cutler, CS Fisher, DC Ho, VT Hochberg, E McAfee, SL Takvorian, R Antin, JH Soiffer, RJ Jacobsen, E AF Chen, Yi-Bin Li, Shuli Del Rio, Candice Driscoll, Jessica Sadrzadeh, Hossein Abramson, Jeremy S. Armand, Philippe Barnes, Jeffrey Cutler, Corey S. Fisher, David C. Ho, Vincent T. Hochberg, Ephraim McAfee, Steven L. Takvorian, Ronald Antin, Joseph H. Soiffer, Robert J. Jacobsen, Eric TI Phase II Trial of Busulfan-Based Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed By Reduced Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Chen, Yi-Bin; Abramson, Jeremy S.; Barnes, Jeffrey; Hochberg, Ephraim; Takvorian, Ronald] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Li, Shuli; Armand, Philippe; Cutler, Corey S.; Fisher, David C.; Ho, Vincent T.; Antin, Joseph H.; Soiffer, Robert J.; Jacobsen, Eric] Dana Farber Canc Inst, Boston, MA 02115 USA. [Del Rio, Candice; Driscoll, Jessica; Sadrzadeh, Hossein] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 76 BP S73 EP S73 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400081 ER PT J AU Driscoll, J Geary, K AF Driscoll, Jessica Geary, Kristin TI The Lived Experience of an Autologous Hematopoietic Stem Cell Transplantation: a Qualitative Study SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Driscoll, Jessica] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Geary, Kristin] Simmons Coll, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 474 BP S300 EP S300 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400478 ER PT J AU Duncan, C Majhail, NS Brazauskas, R Wang, ZW Cahn, JY Kamble, RT Frangoul, HA Hayashi, RJ Hsu, JW Jacobsohn, DA Kasow, KA Khera, N Lazarus, HM Loren, AW Maziarz, RT Mehta, P Myers, KC Pidala, J Porter, DL Reddy, V Saber, W Schouten, HC Steinberg, A Yu, LC Wall, DA Warwick, AB Wood, WA Savani, BN Sorror, ML AF Duncan, Christine Majhail, Navneet S. Brazauskas, Ruta Wang, Zhiwei Cahn, Jean-Yves Kamble, Rammurti T. Frangoul, Haydar A. Hayashi, Robert J. Hsu, Jack W. Jacobsohn, David A. Kasow, Kimberly A. Khera, Nandita Lazarus, Hillard M. Loren, Allison W. Maziarz, Richard T. Mehta, Paulette Myers, Kasiani C. Pidala, Joseph Porter, David L. Reddy, Vijay Saber, Wael Schouten, Harry C. Steinberg, Amir Yu, Lolie C. Wall, Donna A. Warwick, Anne B. Wood, William A. Savani, Bipin N. Sorror, Mohamed L. TI Long-Term Survival and Late Effects Among 1-year Survivors of Second Allogeneic Hematopoietic Cell Transplantation (2nd Allo HCT) for Relapsed Acute Leukemia and Myelodysplastic Syndrome: A Report from the Cibmtr SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Duncan, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA. [Majhail, Navneet S.] Cleveland Clin Fdn, Blood & Marrow Transplant Program, Cleveland, OH 44195 USA. [Brazauskas, Ruta] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Wang, Zhiwei; Saber, Wael] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Cahn, Jean-Yves] Univ Hosp, Grenoble, France. [Kamble, Rammurti T.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Frangoul, Haydar A.; Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Hayashi, Robert J.] Washington Univ, St Louis Childrens Hosp, St Louis, MO USA. [Hsu, Jack W.; Reddy, Vijay] Univ Florida, Gainesville, FL USA. [Jacobsohn, David A.] Childrens Natl Med Ctr, Div Blood & Marrow Transplantat, Washington, DC 20010 USA. [Kasow, Kimberly A.] Univ N Carolina, Chapel Hill, NC USA. [Khera, Nandita] Mayo Clin Arizona, Phoenix, AZ USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Loren, Allison W.] Univ Penn, Med Ctr, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Mehta, Paulette] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Myers, Kasiani C.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Porter, David L.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Blood & Marrow Transplantat Program, Philadelphia, PA 19104 USA. [Schouten, Harry C.] Acad Ziekenhuis, Maastricht, Netherlands. [Steinberg, Amir] Mt Sinai Med Ctr, Los Angeles, CA USA. [Yu, Lolie C.] Childrens Hosp, New Orleans, LA USA. [Wall, Donna A.] Univ Manitoba, CancerCare Manitoba, Winnipeg, MB, Canada. [Warwick, Anne B.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Wood, William A.] Univ North Carolina Hosp, Chapel Hill, NC USA. [Sorror, Mohamed L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RI Cahn, Jean-Yves/M-6493-2014 NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 63 BP S64 EP S64 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400068 ER PT J AU El-Jawahri, A Li, SL Coughlin, E Ho, VT Alyea, EP Armand, P Ballen, KK Dey, BR Glotzbecker, B Koreth, J McAfee, SL Spitzer, TR Soiffer, RJ Antin, JH Cutler, CS Chen, YB AF El-Jawahri, Areej Li, Shuli Coughlin, Erin Ho, Vincent T. Alyea, Edwin P., III Armand, Philippe Ballen, Karen K. Dey, Bimalangshu R. Glotzbecker, Brett Koreth, John McAfee, Steven L. Spitzer, Thomas R. Soiffer, Robert J. Antin, Joseph H. Cutler, Corey S. Chen, Yi-Bin TI Improved Overall Survival in Patients with Grade III and IV Acute Graft-Versus-Host Disease SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [El-Jawahri, Areej; Li, Shuli; Ho, Vincent T.; Alyea, Edwin P., III; Armand, Philippe; Glotzbecker, Brett; Koreth, John; Soiffer, Robert J.; Antin, Joseph H.; Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [El-Jawahri, Areej; Coughlin, Erin; Ballen, Karen K.; Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dey, Bimalangshu R.; Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 412 BP S265 EP S265 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400417 ER PT J AU El-Jawahri, A Traegers, L Kuzmuk, K Eusebio, J Gallagher, E VanDusen, H Greer, J Pirl, W Ballen, KK Spitzer, TR McAfee, SL Deys, BR Jackson, V Chen, YB Temel, J AF El-Jawahri, Areej Traegers, Lara Kuzmuk, Kailyn Eusebio, Justin Gallagher, Emily VanDusen, Harry Greer, Joseph Pirl, William Ballen, Karen K. Spitzer, Thomas R. McAfee, Steven L. Deys, Bimalangshu R. Jackson, Vicki Chen, Yi-Bin Temel, Jennifer TI Physical and Psychological Symptom Burden and Prognostic Understanding during Hospitalization for Hematopoietic Stem Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [El-Jawahri, Areej; Traegers, Lara; Kuzmuk, Kailyn; Eusebio, Justin; Gallagher, Emily; VanDusen, Harry; Greer, Joseph; Pirl, William; Ballen, Karen K.; Jackson, Vicki; Chen, Yi-Bin; Temel, Jennifer] Massachusetts Gen Hosp, Boston, MA 02114 USA. [El-Jawahri, Areej] Dana Farber Canc Inst, Boston, MA 02115 USA. [Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplantat Unit, Boston, MA 02114 USA. [McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA. [Deys, Bimalangshu R.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 288 BP S193 EP S193 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400293 ER PT J AU El-Jawahri, A Pidala, J Chai, XY Wood, WA Khera, N Arora, M Jaglowski, S Lee, SJ Chen, YB AF El-Jawahri, Areej Pidala, Joseph Chai, Xiaoyu Wood, William A. Khera, Nandita Arora, Mukta Jaglowski, Samantha Lee, Stephanie J. Chen, Yi-Bin TI The Impact of Age on Quality of Life, Functional Status, and Overall Survival in Patients with Moderate-Severe Chronic Graft-Versus-Host Disease SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [El-Jawahri, Areej] Dana Farber Canc Inst, Boston, MA 02115 USA. [El-Jawahri, Areej; Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Chai, Xiaoyu] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Wood, William A.] Univ North Carolina Hosp, Chapel Hill, NC USA. [Khera, Nandita] Mayo Clin Arizona, Phoenix, AZ USA. [Arora, Mukta] Univ Minnesota, Minneapolis, MN USA. [Jaglowski, Samantha] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA. [Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RI Jaglowski, Samantha/E-3304-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 64 BP S65 EP S65 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400069 ER PT J AU Glotzbecker, B Kim, HT Cutler, CS Koreth, J Armand, P Nikiforow, S Antin, JH Soiffer, RJ Alyea, EP Ho, VT AF Glotzbecker, Brett Kim, Haesook T. Cutler, Corey S. Koreth, John Armand, Philippe Nikiforow, Sarah Antin, Joseph H. Soiffer, Robert J. Alyea, Edwin P., III Ho, Vincent T. TI Risk Factors for Graft Failure and Survival after Reduced Intensity (RIC) Conditioning Allogeneic Hematopoietic Cell Transplantation (HUT) for Myelofibrosis SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Glotzbecker, Brett; Kim, Haesook T.; Cutler, Corey S.; Koreth, John; Armand, Philippe; Nikiforow, Sarah; Antin, Joseph H.; Soiffer, Robert J.; Alyea, Edwin P., III; Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 17 BP S34 EP S34 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400022 ER PT J AU Hanley, PJ Nikiforow, S Melenhorst, J Scheinberg, P Savoldo, B Dotti, G Rooney, CM Heslop, HE Shpall, EJ Barrett, AJ Bollard, CM AF Hanley, Patrick J. Nikiforow, Sarah Melenhorst, Jan Scheinberg, Phillip Savoldo, Barbara Dotti, Gianpietro Rooney, Cliona M. Heslop, Helen E. Shpall, Elizabeth J. Barrett, A. John Bollard, Catherine M. TI Extending the Option of CMV-Specific T Cells from the CMV-Seronegative Donor SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Hanley, Patrick J.; Bollard, Catherine M.] Childrens Natl Med Ctr, Ctr Canc & Immunol Res, Washington, DC 20010 USA. [Nikiforow, Sarah] Dana Farber Canc Inst, Boston, MA 02115 USA. [Melenhorst, Jan] NHLBI, NIH, Bethesda, MD 20892 USA. [Scheinberg, Phillip] Hosp Beneficencia Portuguesa Sao Paulo, Antonio Ermirio de Moraes Oncol Ctr, Sao Paulo, Brazil. [Savoldo, Barbara; Rooney, Cliona M.] Texas Childrens Hosp, Houston, TX 77030 USA. [Dotti, Gianpietro; Bollard, Catherine M.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Rooney, Cliona M.] Houston Methodist Hosp, Baylor Coll Med, Dept Mol Virol & Microbiol, Ctr Cell & Gene Therapy,Dept Pediat, Houston, TX USA. [Heslop, Helen E.] Methodist Hosp, Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Shpall, Elizabeth J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Barrett, A. John] NHLBI, Hematol Branch, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 178 BP S131 EP S131 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400183 ER PT J AU Huang, JT Lehmann, L Duncan, C Saavedra, A AF Huang, Jennifer T. Lehmann, Leslie Duncan, Christine Saavedra, Arturo TI Eosinophilia, Edema, and Nail Dystrophy: Harbingers of Severe Chronic Graft Versus Host Disease of the Skin in Children SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Huang, Jennifer T.] Boston Childrens Hosp, Dermatol Program, Boston, MA USA. [Lehmann, Leslie; Duncan, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA. [Saavedra, Arturo] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 250 BP S171 EP S172 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400255 ER PT J AU Jagasia, MH Chai, XY Pidala, J Inamoto, Y Arora, M Cutler, CS Flowers, MED Johnston, L Pavletic, SZ Lee, SJ AF Jagasia, Madan H. Chai, Xiaoyu Pidala, Joseph Inamoto, Yoshihiro Arora, Mukta Cutler, Corey S. Flowers, Mary E. D. Johnston, Laura Pavletic, Steven Z. Lee, Stephanie J. TI Ocular Gvhd: Epidemiology, Risk Factors and Impact on Quality of Life-a Chronic Gvhd Consortium Study SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Chai, Xiaoyu] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Inamoto, Yoshihiro; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Arora, Mukta] Univ Minnesota, Minneapolis, MN USA. [Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Johnston, Laura] Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 418 BP S269 EP S269 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400423 ER PT J AU King, B Albert, C Caloggero, S Powers, P Coles, P Jacobsen, E AF King, Bethany Albert, Cindy Caloggero, Susan Powers, Peggy Coles, Peg Jacobsen, Eric TI Experiences with Design and Implementation of a Match Related Donor Satisfaction Survey SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [King, Bethany; Jacobsen, Eric] Dana Farber Canc Inst, Boston, MA 02115 USA. [Albert, Cindy; Caloggero, Susan; Powers, Peggy; Coles, Peg] Dana Farber Canc Inst, SCT Donor Serv, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 161 BP S122 EP S122 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400166 ER PT J AU LaCasce, A Sawas, A Bociek, RG Ansell, S Vose, J O'Meara, M Advani, R AF LaCasce, Ann Sawas, Ahmed Bociek, R. Gregory Ansell, Stephen Vose, Julie O'Meara, Megan Advani, Ranjana TI A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma in the First Salvage Setting: Interim Results SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sawas, Ahmed] Columbia Univ, Med Ctr, New York, NY USA. [Bociek, R. Gregory; Vose, Julie] Univ Nebraska Med Ctr, Omaha, NE USA. [Ansell, Stephen] Mayo Clin, Rochester, MN USA. [O'Meara, Megan] Seattle Genet Inc, Bothell, WA USA. [Advani, Ranjana] Stanford Canc Ctr, Stanford, CA USA. NR 0 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 230 BP S161 EP S161 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400235 ER PT J AU Lane, AA Chen, YB Logan, BR Akpek, G Zhu, XC Lazarus, HM Bredeson, CN Olsson, R Saber, W Aljurf, MD Artz, AS McCarthy, PL Cooke, KR Ho, VT Pasquini, MC AF Lane, Andrew A. Chen, Yi-Bin Logan, Brent R. Akpek, Goergun Zhu, Xiaochun Lazarus, Hillard M. Bredeson, Christopher N. Olsson, Richard Saber, Wael Aljurf, Mahmoud D. Artz, Andrew S. McCarthy, Philip L. Cooke, Kenneth R. Ho, Vincent T. Pasquini, Marcelo C. TI Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation (AutoHCT) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Lane, Andrew A.; Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Logan, Brent R.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Akpek, Goergun] Banner MD Anderson Canc Ctr, Gilbert, AZ USA. [Zhu, Xiaochun; Saber, Wael; Pasquini, Marcelo C.] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Bredeson, Christopher N.] Ottawa Hosp Blood & Marrow Transplant Program, Ottawa, ON, Canada. [Olsson, Richard] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden. [Aljurf, Mahmoud D.] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia. [Artz, Andrew S.] Univ Chicago Hosp, Chicago, IL 60637 USA. [McCarthy, Philip L.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Cooke, Kenneth R.] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 36 BP S45 EP S46 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400041 ER PT J AU Lehmann, LE Nagy, A AF Lehmann, Leslie E. Nagy, Ahmed TI The Contribution of Cardiac Hypertrophy on Transplant Outcome in Patients with HLH Undergoing BMT SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Lehmann, Leslie E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nagy, Ahmed] Ain Shams Med Sch, Cairo, Egypt. [Nagy, Ahmed] McGill Univ, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 261 BP S177 EP S178 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400266 ER PT J AU Lehmann, LE Williams, DA London, WB Agarwal, S AF Lehmann, Leslie E. Williams, David A. London, Wendy B. Agarwal, Suneet TI A Prospective Trial of Minimal Intensity Conditioning with Fludarabine and Anti-CD52 Antibody Alone in Dyskeratosis Congenita SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Lehmann, Leslie E.; Williams, David A.; London, Wendy B.; Agarwal, Suneet] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lehmann, Leslie E.; Williams, David A.; London, Wendy B.; Agarwal, Suneet] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 238 BP S166 EP S166 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400243 ER PT J AU Liney, D Arsenault, T Alyea, EP AF Liney, Deborah Arsenault, Theona Alyea, Edwin P., III TI Standardizing the Consent Form: A Quality Improvement SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Liney, Deborah; Arsenault, Theona; Alyea, Edwin P., III] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 162 BP S122 EP S123 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400167 ER PT J AU McDonnell, AM Glotzbecker, B Soiffer, RJ Antin, JH Alyea, EP Bartel, S Connelly, K Li, SL AF McDonnell, Anne M. Glotzbecker, Brett Soiffer, Robert J. Antin, Joseph H. Alyea, Edwin P., III Bartel, Sylvia Connelly, Kelly Li, Shuli TI Risk Factors for Falls with Injury for Patients Admitted for Hematopoietic Stem Cell Transplant SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [McDonnell, Anne M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Glotzbecker, Brett; Soiffer, Robert J.; Antin, Joseph H.; Alyea, Edwin P., III; Bartel, Sylvia; Li, Shuli] Dana Farber Canc Inst, Boston, MA 02115 USA. [Connelly, Kelly] Smilow Canc Hosp Yale New Haven, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 295 BP S197 EP S197 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400300 ER PT J AU Mosadegh, S O'Connor, M AF Mosadegh, Sara O'Connor, Melissa TI Red Bag Review: A Medication Reconciliation Initiative SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Mosadegh, Sara; O'Connor, Melissa] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 487 BP S305 EP S305 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400491 ER PT J AU Nikiforow, S Korman, S Eapen, M Antin, JH AF Nikiforow, Sarah Korman, Sandra Eapen, Mary Antin, Joseph H. TI Outcomes after Allogeneic Stem Cell Transplantation in Adults for Histiocytic Disorders Including Hemophagocytic Lymphohistiocytosis SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Nikiforow, Sarah; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Korman, Sandra; Eapen, Mary] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 375 BP S243 EP S243 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400380 ER PT J AU Nikiforow, S Kim, HT McDonough, SM Emerson, R Hamm, D Ballen, KK Boussiotis, VA Soiffer, RJ Antin, JH Ritz, J Cutler, CS AF Nikiforow, Sarah Kim, Haesook T. McDonough, Sean M. Emerson, Ryan Hamm, David Ballen, Karen K. Boussiotis, Vassiliki A. Soiffer, Robert J. Antin, Joseph H. Ritz, Jerome Cutler, Corey S. TI Recipient T-Cell Repertoire Diversity after Double Umbilical Cord Transplantation Correlates with Non-Relapse Mortality and Survival SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Nikiforow, Sarah; Kim, Haesook T.; McDonough, Sean M.; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome; Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Emerson, Ryan; Hamm, David] Adapt Biotechnol, Seattle, WA USA. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Boussiotis, Vassiliki A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 376 BP S243 EP S244 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400381 ER PT J AU Pasquini, MC Le Rademacher, J Flowers, C Lill, M Costa, LJ Shore, TB Vaughan, W Craig, M Freytes, CO Shea, TC Horwitz, ME Fay, JW Mineishi, S Rondelli, D Mason, J Reddy, V Braunschweig, I Ai, WY Armstrong, E Smith, A Zhao, C Elekes, A Carreras, J Kato, K Waller, EK AF Pasquini, Marcelo C. Le Rademacher, Jennifer Flowers, Christopher Lill, Michael Costa, Luciano J. Shore, Tsiporah B. Vaughan, William Craig, Michael Freytes, Cesar O. Shea, Thomas C. Horwitz, Mitchell E. Fay, Joseph W. Mineishi, Shin Rondelli, Damiano Mason, James Reddy, Vijay Braunschweig, Ira Ai, Weiyun Armstrong, Elizabeth Smith, Angela Zhao, Cathy Elekes, Agnes Carreras, Jeanette Kato, Kazunobu Waller, Edmund K. TI Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Pasquini, Marcelo C.; Carreras, Jeanette] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Le Rademacher, Jennifer] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Flowers, Christopher; Waller, Edmund K.] Emory Univ, Div BMT, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. [Lill, Michael] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Costa, Luciano J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Shore, Tsiporah B.] New York Hosp, Cornell Med Ctr Hematol Oncol, New York, NY 10021 USA. [Vaughan, William] Univ Alabama Birmingham, Bone Marrow Transplantat & Cell Therapy Program, Birmingham, AL USA. [Craig, Michael] W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shea, Thomas C.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA. [Horwitz, Mitchell E.] Duke Univ, Med Ctr, Dept Med, Adult Stem Cell Transplant Program,Div Cellular T, Durham, NC 27710 USA. [Fay, Joseph W.] Baylor Univ, Med Ctr, Dallas, TX USA. [Mineishi, Shin] Univ Alabama Birmingham, Bone Marrow Transplantat Program, Birmingham, AL USA. [Rondelli, Damiano] Univ Illinois Hosp & Hlth Sci Syst, Dept Med, Sect Hematol Oncol, Chicago, IL USA. [Mason, James] Scripps Clin, La Jolla, CA 92037 USA. [Reddy, Vijay] Univ Florida, Gainesville, FL USA. [Braunschweig, Ira] Montefiore Med Ctr, Bronx, NY 10467 USA. [Ai, Weiyun] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Armstrong, Elizabeth; Smith, Angela; Zhao, Cathy; Elekes, Agnes; Kato, Kazunobu] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. RI Flowers, Christopher/F-1953-2010 OI Flowers, Christopher/0000-0002-9524-3990 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 232 BP S162 EP S162 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400237 ER PT J AU Politikos, I Kim, HT Nikiforow, S Nellore, A Li, LQ McDonough, SM Soiffer, RJ Antin, JH Ballen, KK Cutler, CS Ritz, J Boussiotis, VA AF Politikos, Ioannis Kim, Haesook T. Nikiforow, Sarah Nellore, Anoma Li, Lequn McDonough, Sean M. Soiffer, Robert J. Antin, Joseph H. Ballen, Karen K. Cutler, Corey S. Ritz, Jerome Boussiotis, Vassiliki A. TI Maintenance of Naive T Cells and a Diverse TCR Repertoire Are Critical for Reconstitution of EBV-Specific Immunity after Double Cord Blood Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Politikos, Ioannis; Nellore, Anoma; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA. [Kim, Haesook T.; Nikiforow, Sarah; McDonough, Sean M.; Soiffer, Robert J.; Antin, Joseph H.; Cutler, Corey S.; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. OI Politikos, Ioannis/0000-0002-8925-2399 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 201 BP S145 EP S146 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400206 ER PT J AU Rosati, C Haughton, C AF Rosati, Christine Haughton, Christina TI Bridging the Gaps: Reducing Communication Barriers in the Pediatric Hematopietic Stem Cell Transplant Program SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Rosati, Christine] Dana Farber Boston Childrens Hosp, Pediat Stem Cell Transplant Program, Canc & Blood Disorders Ctr, Boston, MA USA. [Haughton, Christina] Boston Childrens Hosp, Dana Farber Canc Inst, Pediat Stem Cell Transplant Program, Canc & Blood Disorders Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 166 BP S124 EP S125 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400171 ER PT J AU Rosenblatt, J Stone, RM Uhl, L Neuberg, D Vasir, B Somaiya, P Joyce, R Levine, JD Boussiotis, VA Zwicker, J Arnason, JE Luptakova, K Steensma, DP DeAngelo, DJ Galinsky, I Delaney, C Mills, H Breault, E Stroopinsky, D Kufe, D Avigan, D AF Rosenblatt, Jacalyn Stone, Richard M. Uhl, Lynne Neuberg, Donna Vasir, Baldev Somaiya, Poorvi Joyce, Robin Levine, James D. Boussiotis, Vassiliki A. Zwicker, Jeffrey Arnason, Jon E. Luptakova, Katarina Steensma, David P. DeAngelo, Daniel J. Galinsky, Ilene Delaney, Carol Mills, Heidi Breault, Emma Stroopinsky, Dina Kufe, Donald Avigan, David TI Clinical Trial Evaluating DC/AML Fusion Cell Vaccination in AML Patients Who Achieve a Chemotherapy-Induced Remission SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Rosenblatt, Jacalyn; Uhl, Lynne; Somaiya, Poorvi; Joyce, Robin; Levine, James D.; Boussiotis, Vassiliki A.; Zwicker, Jeffrey; Arnason, Jon E.; Luptakova, Katarina; Delaney, Carol; Mills, Heidi; Breault, Emma; Stroopinsky, Dina; Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Stone, Richard M.; Neuberg, Donna; Vasir, Baldev; Steensma, David P.; DeAngelo, Daniel J.; Galinsky, Ilene; Kufe, Donald] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 44 BP S50 EP S50 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400049 ER PT J AU Shulman, DS Lehmann, LE Margossian, S AF Shulman, David Stephen Lehmann, Leslie E. Margossian, Steven TI Bone Marrow Transplant for Children with CML Presenting in Blast Crisis in the Era of TKIs SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Shulman, David Stephen] Boston Childrens Hosp, Boston, MA USA. [Lehmann, Leslie E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Margossian, Steven] Childrens Hosp Boston, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 267 BP S180 EP S181 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400272 ER PT J AU Suprunova, J Yoon, C Tilearcio, MC AF Suprunova, Julia Yoon, Clara Tilearcio, Marion C. TI An Online Secure Shared Drive Proves Crucial to Data Management SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Suprunova, Julia; Yoon, Clara; Tilearcio, Marion C.] Birgham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 318 BP S210 EP S210 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400323 ER PT J AU Toro, JJ Schneider, D Alonzo, R Hasan, A Lee, S Gushiken, F Haile, DJ Freytes, CO AF Toro, Juan J. Schneider, Deanna Alonzo, Rosalinda Hasan, Abida Lee, Shuko Gushiken, Francisco Haile, David J. Freytes, Cesar O. TI A Prospective, Randomized Clinical Trial of Cryotherapy Vs. Supersaturated Calcium Phosphate Rinses Vs. Saline Rinses for the Prevention of Oral Mucositis in Patients with Multiple Myeloma (MM) Receiving High-Dose Melphalan (HDM) and Autotransplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Toro, Juan J.; Schneider, Deanna; Alonzo, Rosalinda; Hasan, Abida; Lee, Shuko; Gushiken, Francisco; Haile, David J.; Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 309 BP S204 EP S205 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400314 ER PT J AU Yoon, C Tilearcio, MC Supruriova, J AF Yoon, Clara Tilearcio, Marion C. Supruriova, Julia TI Critical Audit Field Quality Initiative SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Yoon, Clara; Tilearcio, Marion C.; Supruriova, Julia] Birgham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 319 BP S210 EP S210 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400324 ER PT J AU Fisher, MB Henning, EA Soegaard, NB Dodge, GR Steinberg, DR Mauck, RL AF Fisher, Matthew B. Henning, Elizabeth A. Soeegaard, Nicole B. Dodge, George R. Steinberg, David R. Mauck, Robert L. TI Maximizing cartilage formation and integration via a trajectory-based tissue engineering approach SO BIOMATERIALS LA English DT Article DE Tissue engineering; Hyaluronic acid; Hydrogels; Cartilage; Integration; Maturation ID AUTOLOGOUS CHONDROCYTE IMPLANTATION; MESENCHYMAL STEM-CELLS; CHONDROGENIC DIFFERENTIATION; EXTRACELLULAR-MATRIX; AGAROSE CULTURE; GOAT MODEL; FOLLOW-UP; REPAIR; KNEE; TRANSPLANTATION AB Given the limitations of current surgical approaches to treat articular cartilage injuries, tissue engineering (TE) approaches have been aggressively pursued. Despite reproduction of key mechanical attributes of native tissue, the ability of TE cartilage constructs to integrate with native tissue must also be optimized for clinical success. In this paper, we propose a "trajectory-based" tissue engineering (TB-TE) approach, based on the hypothesis that time-dependent increases in construct maturation in-vitro prior to implantation (i.e. positive rates) may provide a reliable predictor of in-vivo success. As an example TE system, we utilized hyaluronic acid hydrogels laden with mesenchymal stem cells. We first modeled the maturation of these constructs in-vitro to capture time-dependent changes. We then performed a sensitivity analysis of the model to optimize the timing and amount of data collection. Finally, we showed that integration to cartilage in-vitro is not correlated to the maturation state of TE constructs, but rather their maturation rate, providing a proof-of-concept for the use of TB-TE to enhance treatment outcomes following cartilage injury. This new approach challenges the traditional TE paradigm of matching only native state parameters of maturity and emphasizes the importance of also establishing an in-vitro trajectory in constructs in order to improve the chance of in-vivo success. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Fisher, Matthew B.; Henning, Elizabeth A.; Soeegaard, Nicole B.; Dodge, George R.; Steinberg, David R.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Henning, Elizabeth A.; Dodge, George R.; Steinberg, David R.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01 EB008722, F32 AR062971]; Department of Veterans Affairs [101 RX000700] FX This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (R01 EB008722 and F32 AR062971) and the Department of Veterans Affairs (101 RX000700). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. The authors would like to thank Dr. Jason Burdick for providing the hyaluronic acid. NR 46 TC 13 Z9 13 U1 0 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 EI 1878-5905 J9 BIOMATERIALS JI Biomaterials PD FEB PY 2014 VL 35 IS 7 BP 2140 EP 2148 DI 10.1016/j.biomaterials.2013.11.031 PG 9 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA AB0SL UT WOS:000331502300007 PM 24314553 ER PT J AU Stygelbout, V Leroy, K Pouillon, V Ando, K D'Amico, E Jia, YH Luo, HR Duyckaerts, C Erneux, C Schurmans, S Brion, JP AF Stygelbout, Virginie Leroy, Karelle Pouillon, Valerie Ando, Kunie D'Amico, Eva Jia, Yonghui Luo, H. Robert Duyckaerts, Charles Erneux, Christophe Schurmans, Stephane Brion, Jean-Pierre TI Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology SO BRAIN LA English DT Article DE Alzheimer pathology; inositol phosphates; ITPKB; inositol (1,3,4,5) tetrakisphosphate ID ACTIVATED PROTEIN-KINASE; GENOME-WIDE ASSOCIATION; TAU-PROTEIN; 1,4,5-TRISPHOSPHATE 3-KINASE; IDENTIFIES VARIANTS; TRANSGENIC MICE; CELL-DEATH; DISEASE; EXPRESSION; PHOSPHORYLATION AB ITPKB phosphorylates inositol 1,4,5-trisphosphate into inositol 1,3,4,5-tetrakisphosphate and controls signal transduction in various hematopoietic cells. Surprisingly, it has been reported that the ITPKB messenger RNA level is significantly increased in the cerebral cortex of patients with Alzheimer's disease, compared with control subjects. As extracellular signal-regulated kinases 1/2 activation is increased in the Alzheimer brain and as ITPKB is a regulator of extracellular signal-regulated kinases 1/2 activation in some hematopoietic cells, we tested whether this increased activation in Alzheimer's disease might be related to an increased activity of ITPKB. We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased beta-secretase 1 activity leading to overproduction of amyloid-beta peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-beta peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and beta-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-beta(40) peptide production and tau hyperphosphorylation. No impact on pathology was observed in the 5X familial Alzheimer's disease mouse model when a catalytically inactive ITPKB protein was overexpressed. Together, our results point to the ITPKB/inositol 1,3,4,5-tetrakisphosphate/extracellular signal-regulated kinases 1/2 signalling pathway as an important regulator of neuronal cell apoptosis, APP processing and tau phosphorylation in Alzheimer's disease, and suggest that ITPKB could represent a new target for reducing pathology in human patients with Alzheimer's disease with ITPKB expression. C1 [Stygelbout, Virginie; Pouillon, Valerie; D'Amico, Eva; Erneux, Christophe; Schurmans, Stephane] Univ Libre Brussels, Inst Rech Interdisciplinaires Biol Humaine & Mol, B-6041 Gosselies, Belgium. [Stygelbout, Virginie; Pouillon, Valerie; D'Amico, Eva; Schurmans, Stephane] Univ Libre Brussels, Inst Biol & Med Mol, B-6041 Gosselies, Belgium. [Stygelbout, Virginie; Leroy, Karelle; Brion, Jean-Pierre] Univ Libre Brussels, Lab Histol Neuroanat & Neuropathol, B-1070 Brussels, Belgium. [Ando, Kunie; Duyckaerts, Charles] Hop La Pitie Salpetriere, AP HP, Lab Neuropathol Escourolle, F-75013 Paris, France. [Ando, Kunie; Duyckaerts, Charles] Hop La Pitie Salpetriere, AP HP, Ctr Rech ICM, F-75013 Paris, France. [Jia, Yonghui; Luo, H. Robert] Harvard Univ, Sch Med, Dept Pathol, Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA. [Jia, Yonghui; Luo, H. Robert] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Schurmans, Stephane] Univ Liege, GIGA Res Ctr, Lab Genet Fonct, B-4000 Liege, Belgium. [Schurmans, Stephane] Univ Liege, Dept Sci Fonct, Sect Biochim Metab, B-4000 Liege, Belgium. [Schurmans, Stephane] Univ Liege, Welbio, B-4000 Liege, Belgium. RP Schurmans, S (reprint author), Univ Liege, GIGA Res Ctr, Lab Genet Fonct, Bldg 34,Rue Hop 1, B-4000 Liege, Belgium. EM sschurmans@ulg.ac.be OI Leroy, Karelle/0000-0002-8661-5262 FU Fonds de la Recherche Scientifique-FNRS (FRS-FNRS); Fonds pour la Formation a la Recherche dans l'Industrie et l'Agriculture (FRIA); Fonds de la Recherche Scientifique Medicale (FRSM); Action de Recherche Concertee de la Communaute francaise de Belgique (ARC); Universite Libre de Bruxelles (ULB); Interuniversity Attraction Poles program of the Belgian Federal Science Policy Office (BELSPO) (IAP); Diane program (Walloon region) FX This work was supported by the Fonds de la Recherche Scientifique-FNRS (FRS-FNRS to V.P. and S.S.), the Fonds pour la Formation a la Recherche dans l'Industrie et l'Agriculture (FRIA, to V.S.), the Fonds de la Recherche Scientifique Medicale (FRSM, to S.S., C.E. and J.P.B.), Action de Recherche Concertee de la Communaute francaise de Belgique (ARC; to S.S.), The Universite Libre de Bruxelles (ULB, to V. S.), the Interuniversity Attraction Poles program of the Belgian Federal Science Policy Office (BELSPO) (IAP, to J.P.B), and the Diane program (Walloon region, to J.P.B). Some of the human brain tissue samples were provided by the GIE NeuroCEB Brain Bank (France Alzheimer, France Parkinson, ARSEP, CSC). NR 46 TC 7 Z9 10 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD FEB PY 2014 VL 137 BP 537 EP 552 DI 10.1093/brain/awt344 PN 2 PG 16 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA7QB UT WOS:000331290900020 PM 24401760 ER PT J AU Chandler, PD Scott, JB Drake, BF Ng, K Manson, JE Rifai, N Chan, AT Bennett, GG Hollis, BW Giovannucci, EL Emmons, KM Fuchs, CS AF Chandler, Paulette D. Scott, Jamil B. Drake, Bettina F. Ng, Kimmie Manson, Joann E. Rifai, Nader Chan, Andrew T. Bennett, Gary G. Hollis, Bruce W. Giovannucci, Edward L. Emmons, Karen M. Fuchs, Charles S. TI Impact of Vitamin D Supplementation on Inflammatory Markers in African Americans: Results of a Four-Arm, Randomized, Placebo-Controlled Trial SO CANCER PREVENTION RESEARCH LA English DT Article ID C-REACTIVE PROTEIN; NECROSIS-FACTOR-ALPHA; CARDIOVASCULAR-DISEASE; 25-HYDROXYVITAMIN D; DIABETES-MELLITUS; COLORECTAL-CANCER; PREVENTION; BIOMARKERS; OBESITY; HEALTH AB African Americans have a disproportionate burden of inflammation-associated chronic diseases such as cancer and lower circulating levels of 25-hydroxyvitamin D [25(OH)D]. The effect of vitamin D-3 (cholecalciferol) supplementation on inflammatory markers is uncertain. We conducted a randomized, double-blind, placebo-controlled trial of supplemental oral vitamin D(placebo, 1,000, 2,000, or 4,000 IU/day of vitamin D-3 orally for 3 months) in 328 African Americans (median age, 51 years) of public housing communities in Boston, MA, who were enrolled over three consecutive winter periods (2007-2010). Change from 0 to 3 months of plasma levels of 25(OH) D, high-sensitivity C-reactive protein (CRP), interleukin (IL)-6, IL-10, and soluble TNF-alpha receptor type 2 (sTNF-R2) in 292 (89%) participants were measured. Overall, no statistically significant changes in CRP, IL-6, IL-10, and sTNF-R2 were observed after the vitamin D supplementation period. Baseline CRP was significantly inversely associated with the baseline 25(OH) D level (P < 0.001) in unadjusted and adjusted models. An interaction between baseline 25(OH) D and vitamin D supplementation was observed for outcome change in log CRP (month 3-month 0; P for interaction = 0.04). Within an unselected population of African Americans, short-term exposure to vitamin D supplementation produced no change in circulating inflammatory markers. This study confirms the strong independent association of CRP with 25(OH)D status even after adjusting for body mass index. Future studies of longer supplemental vitamin D-3 duration are necessary to examine the complex influence of vitamin D-3 on CRP and other chronic inflammatory cytokines for possible reduction of cancer health disparities in African Americans. (C)2013 AACR. C1 [Chandler, Paulette D.; Manson, Joann E.] Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02215 USA. [Giovannucci, Edward L.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02215 USA. [Ng, Kimmie; Fuchs, Charles S.] Harvard Univ, Sch Publ Hlth, Dept Med Oncol, Boston, MA 02115 USA. [Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Rifai, Nader] Harvard Univ, Sch Publ Hlth, Boston Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Chan, Andrew T.] Harvard Univ, Sch Publ Hlth, Dept Gastroenterol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Chandler, Paulette D.; Ng, Kimmie; Manson, Joann E.; Chan, Andrew T.; Giovannucci, Edward L.; Emmons, Karen M.; Fuchs, Charles S.] Harvard Univ, Sch Med, Boston, MA USA. [Scott, Jamil B.] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA. [Drake, Bettina F.] Washington Univ, Sch Med, Dept Surg, Div Publ Hlth Sci, St Louis, MO 63110 USA. [Bennett, Gary G.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA. [Hollis, Bruce W.] Med Univ S Carolina, Div Pediat, Charleston, SC 29425 USA. RP Chandler, PD (reprint author), Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave,3rd Floor, Boston, MA 02215 USA. EM pchandler@partners.org OI Drake, Bettina/0000-0001-9340-5848 FU National Cancer Institute [P50CA127003, K07CA148894, K22CA126992, 5K05CA124415, U01CA138962]; Department of Defense Prostate Cancer Research Program [PC081669]; American Society of Clinical Oncology Career Development Award; Pharmavite LLC FX This study was funded by the National Cancer Institute [P50CA127003; K07CA148894 (K. Ng); K22CA126992; 5K05CA124415 (K.M. Emmons); U01CA138962 (P.D. Chandler)], the Department of Defense Prostate Cancer Research Program (PC081669; to B.F. Drake), the American Society of Clinical Oncology Career Development Award (K. Ng), and Pharmavite LLC. NR 36 TC 26 Z9 26 U1 0 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD FEB PY 2014 VL 7 IS 2 BP 218 EP 225 DI 10.1158/1940-6207.CAPR-13-0338-T PG 8 WC Oncology SC Oncology GA AA5FW UT WOS:000331122500006 PM 24327720 ER PT J AU Bronisz, A Wang, Y Nowicki, MO Peruzzi, P Ansari, KI Ogawa, D Balaj, L De Rienzo, G Mineo, M Nakano, I Ostrowski, MC Hochberg, F Weissleder, R Lawler, SE Chiocca, EA Godlewski, J AF Bronisz, Agnieszka Wang, Yan Nowicki, Michal O. Peruzzi, Pierpaolo Ansari, Khairul I. Ogawa, Daisuke Balaj, Leonora De Rienzo, Gianluca Mineo, Marco Nakano, Ichiro Ostrowski, Michael C. Hochberg, Fred Weissleder, Ralph Lawler, Sean E. Chiocca, E. Antonio Godlewski, Jakub TI Extracellular Vesicles Modulate the Glioblastoma Microenvironment via a Tumor Suppression Signaling Network Directed by miR-1 SO CANCER RESEARCH LA English DT Article ID STEM-CELL; SELF-RENEWAL; GLIOMA-CELLS; CANCER; EXOSOMES; GROWTH; IDENTIFICATION; MICRORNAS; GENE; PROLIFERATION AB Extracellular vesicles have emerged as important mediators of intercellular communication in cancer, including by conveying tumor-promoting microRNAs between cells, but their regulation is poorly understood. In this study, we report the findings of a comparative microRNA profiling and functional analysis in human glioblastoma that identifies miR-1 as an orchestrator of extracellular vesicle function and glioblastoma growth and invasion. Ectopic expression of miR-1 in glioblastoma cells blocked in vivo growth, neovascularization, and invasiveness. These effects were associated with a role for miR-1 in intercellular communication in the microenvironment mediated by extracellular vesicles released by cancer stem-like glioblastoma cells. An extracellular vesicle-dependent phenotype defined by glioblastoma invasion, neurosphere growth, and endothelial tube formation was mitigated by loading miR-1 into glioblastoma-derived extracellular vesicles. Protein cargo in extracellular vesicles was characterized to learn how miR-1 directed extracellular vesicle function. The mRNA encoding Annexin A2 (ANXA2), one of the most abundant proteins in glioblastoma-derived extracellular vesicles, was found to be a direct target of miR-1 control. In addition, extracellular vesicle-derived miR-1 along with other ANXA2 extracellular vesicle networking partners targeted multiple pro-oncogenic signals in cells within the glioblastoma microenvironment. Together, our results showed how extracellular vesicle signaling promotes the malignant character of glioblastoma and how ectopic expression of miR-1 can mitigate this character, with possible implications for how to develop a unique miRNA-based therapy for glioblastoma management. (C) 2013 AACR. C1 [Bronisz, Agnieszka; Nowicki, Michal O.; Ansari, Khairul I.; Ogawa, Daisuke; De Rienzo, Gianluca; Mineo, Marco; Lawler, Sean E.; Chiocca, E. Antonio; Godlewski, Jakub] Harvard Univ, Sch Med, Brigham & Womens Hosp, Harvey Cushing Neurooncol Labs,Dept Neurosurg, Boston, MA 02115 USA. [Balaj, Leonora; Hochberg, Fred; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA. [Wang, Yan; Nowicki, Michal O.; Peruzzi, Pierpaolo; Ogawa, Daisuke; Nakano, Ichiro; Lawler, Sean E.; Chiocca, E. Antonio; Godlewski, Jakub] Ohio State Univ, Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA. [Bronisz, Agnieszka; Ostrowski, Michael C.] Ohio State Univ, Med Ctr, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA. RP Godlewski, J (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, 4 Blackfan Circle, Boston, MA 02115 USA. EM EAChiocca@partners.org; jgodlewski@partners.org RI Ostrowski, Michael/H-3108-2011 OI Ostrowski, Michael/0000-0003-2948-6297 FU NCI P01 [108778]; institutional sundry fund FX This work was supported by NCI P01 (# 108778; E.A. Chiocca, F. Hochberg, R. Weissleder) and an institutional sundry fund (E.A. Chiocca). NR 49 TC 46 Z9 48 U1 2 U2 19 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2014 VL 74 IS 3 BP 738 EP 750 DI 10.1158/0008-5472.CAN-13-2650 PG 13 WC Oncology SC Oncology GA AA4NX UT WOS:000331073900012 PM 24310399 ER PT J AU Chin, YR Yoshida, T Marusyk, A Beck, AH Polyak, K Toker, A AF Chin, Y. Rebecca Yoshida, Taku Marusyk, Andriy Beck, Andrew H. Polyak, Kornelia Toker, Alex TI Targeting Akt3 Signaling in Triple-Negative Breast Cancer SO CANCER RESEARCH LA English DT Article ID PROTEIN-KINASE; MOLECULAR SUBTYPES; PROSTATE-CANCER; CELL-MIGRATION; UP-REGULATION; INVASION; TUMORS; PATHWAY; OVEREXPRESSION; TRANSCRIPTION AB Triple-negative breast cancer (TNBC) is currently the only major breast tumor subtype without effective targeted therapy and, as a consequence, in general has a poor outcome. To identify new therapeutic targets in TNBC, we performed a short hairpin RNA (shRNA) screen for protein kinases commonly amplified and overexpressed in breast cancer. Using this approach, we identified AKT3 as a gene preferentially required for the growth of TNBCs. Downregulation of Akt3 significantly inhibits the growth of TNBC lines in three-dimensional (3D) spheroid cultures and in mouse xenograft models, whereas loss of Akt1 or Akt2 have more modest effects. Akt3 silencing markedly upregulates the p27 cell-cycle inhibitor and this is critical for the ability of Akt3 to inhibit spheroid growth. In contrast with Akt1, Akt3 silencing results in only a minor enhancement of migration and does not promote invasion. Depletion of Akt3 in TNBC sensitizes cells to the pan-Akt inhibitor GSK690693. These results imply that Akt3 has a specific function in TNBCs; thus, its therapeutic targeting may provide a new treatment option for this tumor subtype. (C) 2013 AACR. C1 [Chin, Y. Rebecca; Beck, Andrew H.; Toker, Alex] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Yoshida, Taku; Marusyk, Andriy; Polyak, Kornelia] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. [Yoshida, Taku; Marusyk, Andriy; Polyak, Kornelia] Brigham & Womens Hosp, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Polyak, Kornelia] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. RP Toker, A (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,EC CLS 633A, Boston, MA 02215 USA. EM kornelia_polyak@dfci.harvard.edu; atoker@bidmc.harvard.edu OI CHIN, Yuet Ming Rebecca/0000-0001-8976-3466 FU NIH [K99CA157945, CA092644, T32 CA081156-09]; Susan G. Komen Foundation; ImClone/Eli Lilly; Klarman Family Foundation FX This study was supported in part by grants from the NIH (K99CA157945 to Y.R. Chin; CA092644 and T32 CA081156-09 to A. Toker), the Susan G. Komen Foundation (K. Polyak), from a sponsored research grant from ImClone/Eli Lilly (A. Toker and Y.R. Chin), and from an award from the Klarman Family Foundation (A.H. Beck). NR 40 TC 30 Z9 32 U1 4 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2014 VL 74 IS 3 BP 964 EP 973 DI 10.1158/0008-5472.CAN-13-2175 PG 10 WC Oncology SC Oncology GA AA4NX UT WOS:000331073900032 PM 24335962 ER PT J AU Gkotzamanidou, M Papadimitriou, CA AF Gkotzamanidou, Maria Papadimitriou, Christos A. TI Peripheral T-cell lymphoma: The role of hematopoietic stem cell transplantation SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY LA English DT Review DE Peripheral T-cell lymphoma; PTCL; Autologous stem cell transplantation; ASCT; High-dose chemotherapy; Transplantation ID HIGH-DOSE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; DETUDE-DES-LYMPHOMES; INTERNATIONAL PROGNOSTIC INDEX; FRONT-LINE AUTOTRANSPLANTATION; BONE-MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; LONG-TERM REMISSIONS; PHASE-II; EUROPEAN GROUP AB Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas (NHLs). Whereas the incidence of the disease appears to increase during last decades and the prognosis remains dramatically poor, so far no standard treatment has been established. High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) has been proven effective in relapsed PTCL, while retrospective studies have shown a survival benefit as first-line treatment in some subsets of PTCL patients. However, given disease rarity, there is a paucity of randomized trials in both upfront and relapse setting. Here, we critically evaluated eligible prospective and retrospective studies that address the role of ASCT in treatment of PTCL, with respect to quality of design and performance. Additionally, the role of allogeneic transplantation has been reviewed. The comparison of ASCT with novel agents that emerge or the combination of both, are to be ascertained via prospective randomized trials in this field. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Gkotzamanidou, Maria] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Papadimitriou, Christos A.] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, GR-10679 Athens, Greece. RP Gkotzamanidou, M (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, M551, Boston, MA 02115 USA. EM maria_gkotzamanidou@dfci.harvard.edu NR 85 TC 7 Z9 8 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1040-8428 EI 1879-0461 J9 CRIT REV ONCOL HEMAT JI Crit. Rev. Oncol./Hematol. PD FEB PY 2014 VL 89 IS 2 BP 248 EP 261 DI 10.1016/j.critrevonc.2013.08.016 PG 14 WC Oncology; Hematology SC Oncology; Hematology GA AB0MW UT WOS:000331487600006 PM 24075060 ER PT J AU Shore, S Borgerding, JA Gylys-Colwell, I McDermott, K Ho, PM Tillquist, MN Lowy, E McGuire, DK Stolker, JM Arnold, SV Kosiborod, M Maddox, TM AF Shore, Supriya Borgerding, Joleen A. Gylys-Colwell, Ina McDermott, Kelly Ho, P. Michael Tillquist, Maggie N. Lowy, Elliott McGuire, Darren K. Stolker, Joshua M. Arnold, Suzanne V. Kosiborod, Mikhail Maddox, Thomas M. TI Association Between Hyperglycemia at Admission During Hospitalization for Acute Myocardial Infarction and Subsequent Diabetes: Insights From the Veterans Administration Cardiac Care Follow-up Clinical Study SO DIABETES CARE LA English DT Article ID ACUTE CORONARY SYNDROME; BLOOD-GLUCOSE CONTROL; TIMI RISK SCORE; STRESS HYPERGLYCEMIA; NONDIABETIC PATIENTS; THROMBOLYTIC ERA; MELLITUS; PREVALENCE; OUTCOMES; AFFAIRS AB OBJECTIVEAmong patients with acute myocardial infarction (AMI) without known diabetes, hyperglycemia at admission is common and associated with worse outcomes. It may represent developing diabetes, but this association is unclear. Therefore, we examined the association between hyperglycemia (140 mg/dL) at admission and evidence of diabetes among patients with AMI without known diabetes within 6 months of their hospitalization.RESEARCH DESIGN AND METHODSWe studied a national cohort of consecutive patients with AMI without known diabetes presenting at 127 Veterans Affairs hospitals between October 2005 and March 2011. Evidence of diabetes either at discharge or in the following 6 months was ascertained using diagnostic codes, medication prescriptions, and/or elevated hemoglobin A(1c). Association between hyperglycemia at admission and evidence of diabetes was evaluated using regression modeling.RESULTSAmong 10,499 patients with AMI without known diabetes, 98% were men and 1,761 (16.8%) had hyperglycemia at admission. Within 6 months following their index hospitalization, 208 patients (11.8%) with hyperglycemia at admission had evidence of diabetes compared with 443 patients (5.1%) without hyperglycemia at admission (P < 0.001). After multivariable adjustment, hyperglycemia at admission was significantly associated with subsequent diabetes odds ratio 2.56 (95% CI 2.15-3.06). Among those with new evidence of diabetes, 41% patients (267 of 651) had a hemoglobin A(1c) 6.5% without accompanying diagnostic codes or medication prescriptions, suggesting they had unrecognized diabetes.CONCLUSIONSHyperglycemia at admission occurred in one of six patients with AMI without known diabetes and was significantly associated with new evidence of diabetes in the 6 months following hospitalization. In addition, two of five patients with evidence of diabetes were potentially unrecognized. Accordingly, diabetes-screening programs for hyperglycemic patients with AMI may be an important component of optimal care. C1 [Shore, Supriya] Univ Colorado, Sch Publ Hlth, Denver, CO 80202 USA. [Borgerding, Joleen A.; Gylys-Colwell, Ina; Lowy, Elliott] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Northwest Ctr Excellence, Seattle, WA USA. [McDermott, Kelly] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. [Ho, P. Michael; Maddox, Thomas M.] VA Eastern Colorado Hlth Care Syst, Cardiol Sect, Denver, CO USA. [Ho, P. Michael; Tillquist, Maggie N.; Maddox, Thomas M.] Univ Colorado, Sch Med, Dept Med, Div Cardiol, Denver, CO USA. [McGuire, Darren K.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Stolker, Joshua M.] St Louis Univ, Dept Med, Div Cardiol, St Louis, MO 63103 USA. [Arnold, Suzanne V.; Kosiborod, Mikhail] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA. RP Maddox, TM (reprint author), St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA. EM thomas.maddox@va.gov FU VA Health Services Research and Development Career Development Award FX T.M.M. is supported by a VA Health Services Research and Development Career Development Award. NR 32 TC 10 Z9 10 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2014 VL 37 IS 2 BP 409 EP 418 DI 10.2337/dc13-1125 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA4NM UT WOS:000331072800028 PM 24089537 ER PT J AU Hruby, A Meigs, JB O'Donnell, CJ Jacques, PF McKeown, NM AF Hruby, Adela Meigs, James B. O'Donnell, Christopher J. Jacques, Paul F. McKeown, Nicola M. TI Higher Magnesium Intake Reduces Risk of Impaired Glucose and Insulin Metabolism and Progression From Prediabetes to Diabetes in Middle-Aged Americans SO DIABETES CARE LA English DT Article ID FOOD FREQUENCY QUESTIONNAIRE; BETA-CELL FUNCTION; DOUBLE-BLIND; CARDIOVASCULAR-DISEASE; NONDIABETIC SUBJECTS; PROSPECTIVE COHORT; DIETARY MAGNESIUM; RANDOMIZED-TRIAL; RESISTANCE; SENSITIVITY AB OBJECTIVETo assess 7-year associations between magnesium intake and incident prediabetes and/or insulin resistance (IR), and progression from these states to type 2 diabetes.RESEARCH DESIGN AND METHODSIn 2,582 community-dwelling participants 26-81 years old at baseline, magnesium intake and risk of incident metabolic impairment, defined as impaired fasting glucose (FG) (5.6 to <7.0 mmol/L), impaired glucose tolerance (2-h postload glucose 7.8 to <11.1 mmol/L), IR, or hyperinsulinemia (90th percentile of homeostasis model assessment of IR or fasting insulin, respectively), was estimated among those with normal baseline status, and risk of incident diabetes was estimated among those with baseline metabolic impairment. In participants without incident diabetes, we examined magnesium intake in relation to 7-year changes in fasting and postload glucose and insulin, IR, and insulin sensitivity.RESULTSAfter adjusting for age, sex, and energy intake, compared with those with the lowest magnesium intake, those with the highest intake had 37% lower risk of incident metabolic impairment (P trend = 0.02), and in those with baseline metabolic impairment, higher intake was associated with 32% lower risk of incident diabetes (P trend = 0.05). In the combined population, the risk in those with the highest intake was 53% (P trend = 0.0004) of those with the lowest intake. Adjusting for risk factors and dietary fiber attenuated associations in the baseline normal population but did not substantially affect associations in the metabolically impaired. Higher magnesium intake tended to associate with lower follow-up FG and IR, but not fasting insulin, postload values, or insulin sensitivity.CONCLUSIONSMagnesium intake may be particularly beneficial in offsetting risk of developing diabetes among those at high risk. Magnesium's long-term associations with non-steady-state (dynamic) measures deserve further research. C1 [Hruby, Adela; Jacques, Paul F.; McKeown, Nicola M.] Tufts Univ, Jean Mayer US Dept Agr, Nutr Epidemiol Program, Human Nutr Res Ctr Aging, Boston, MA 02111 USA. [Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA. [Meigs, James B.; O'Donnell, Christopher J.] Harvard Univ, Sch Med, Boston, MA USA. [O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Framingham, MA USA. [O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA. [O'Donnell, Christopher J.] MGH, Dept Med, Div Cardiovasc, Boston, MA USA. RP McKeown, NM (reprint author), Tufts Univ, Jean Mayer US Dept Agr, Nutr Epidemiol Program, Human Nutr Res Ctr Aging, Boston, MA 02111 USA. EM nicola.mckeown@tufts.edu FU National Heart, Lung, and Blood Institute's FHS [N01-HC-25195]; U.S. Department of Agriculture [58-1950-0-014]; [K24-DK-080140] FX At the time of writing, A.H. was an American Heart Association Predoctoral Fellow. This work was also supported by the National Heart, Lung, and Blood Institute's FHS (Contract N01-HC-25195) and the U.S. Department of Agriculture (Agreement 58-1950-0-014). J.B.M. is supported by K24-DK-080140. NR 41 TC 19 Z9 19 U1 1 U2 11 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2014 VL 37 IS 2 BP 419 EP 427 DI 10.2337/dc13-1397 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA4NM UT WOS:000331072800029 PM 24089547 ER PT J AU Hulten, E Bittencourt, MS O'Leary, D Shah, R Ghoshhajra, B Christman, MP Montana, P Steigner, M Truong, QA Nasir, K Rybicki, F Hainer, J Brady, TJ Di Carli, MF Hoffmann, U Abbara, S Blankstein, R AF Hulten, Edward Bittencourt, Marcio Sommer O'Leary, Daniel Shah, Ravi Ghoshhajra, Brian Christman, Mitalee P. Montana, Philip Steigner, Michael Truong, Quynh A. Nasir, Khurram Rybicki, Frank Hainer, Jon Brady, Thomas J. Di Carli, Marcelo F. Hoffmann, Udo Abbara, Suhny Blankstein, Ron TI Cardiometabolic Risk Is Associated With Atherosclerotic Burden and Prognosis: Results From the Partners Coronary Computed Tomography Angiography Registry SO DIABETES CARE LA English DT Article ID INTERNATIONAL MULTICENTER REGISTRY; AMERICAN-DIABETES-ASSOCIATION; BODY-MASS INDEX; ALL-CAUSE MORTALITY; ARTERY-DISEASE; METABOLIC SYNDROME; CLINICAL-OUTCOMES; CT ANGIOGRAPHY; CARDIOVASCULAR-DISEASE; WAIST CIRCUMFERENCE AB OBJECTIVEOur purpose was to evaluate coronary artery disease (CAD) prevalence and prognosis according to cardiometabolic (CM) risk.RESEARCH DESIGN AND METHODSRegistry of all patients without prior CAD referred for coronary computed tomography angiography (CCTA). Patients were stratified by groups of increasing CM risk factors (hypertension, low HDL, hypertriglyceridemia, obesity, and dysglycemia) as follows: patients without type 2 diabetes mellitus (T2DM) with fewer than three or with three or more CM risk factors, patients with T2DM not requiring insulin, or those with T2DM requiring insulin. Patients were followed for a primary end point of major adverse cardiovascular events (MACE) composed of unstable angina, late coronary revascularization, myocardial infarction (MI), and cardiovascular mortality.RESULTSAmong 1,118 patients (mean age 57 13 years) followed for a mean 3.1 years, there were 21 (1.9%) cardiovascular deaths and 13 (1.2%) MIs. There was a stepwise increase in the prevalence of obstructive CAD with increasing CM risk, from 15% in those without diabetes and fewer than three CM risk factors to as high as 46% in patients with T2DM requiring insulin (P < 0.001). Insulin exposure was associated with the highest adjusted hazard of MACE (hazard ratio 3.29 [95% CI 1.28-8.45], P = 0.01), whereas both T2DM without insulin (1.35, P = 0.3) and three or more CM risk factors without T2DM (1.48, P = 0.3) were associated with a similar rate of MACE.CONCLUSIONSPatients without diabetes who have multiple metabolic risk factors have a similar prognosis and burden of CAD as those with T2DM not requiring insulin. Among patients with diabetes, the need for insulin therapy is associated with greater burden of CAD as well as worse prognosis. C1 [Hulten, Edward; Bittencourt, Marcio Sommer; O'Leary, Daniel; Shah, Ravi; Christman, Mitalee P.; Montana, Philip; Steigner, Michael; Rybicki, Frank; Hainer, Jon; Di Carli, Marcelo F.; Hoffmann, Udo; Abbara, Suhny; Blankstein, Ron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Noninvas Cardiovasc Imaging Program, Boston, MA 02115 USA. [Hulten, Edward; Bittencourt, Marcio Sommer; O'Leary, Daniel; Shah, Ravi; Christman, Mitalee P.; Montana, Philip; Steigner, Michael; Rybicki, Frank; Hainer, Jon; Di Carli, Marcelo F.; Hoffmann, Udo; Abbara, Suhny; Blankstein, Ron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Ghoshhajra, Brian; Brady, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Cardiac MR PET CT Program, Dept Radiol,Div Cardiac Imaging,Sch Med, Boston, MA 02115 USA. [Truong, Quynh A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. [Nasir, Khurram] Baptist Hlth South Florida, Ctr Prevent & Wellness Res, Miami, FL USA. [Bittencourt, Marcio Sommer] Univ Sao Paulo, Heart Inst InCor, Sao Paulo, Brazil. RP Hulten, E (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Noninvas Cardiovasc Imaging Program, Boston, MA 02115 USA. EM ehulten@partners.org RI Bittencourt, Marcio/C-1444-2011 OI Bittencourt, Marcio/0000-0002-3711-1754 FU Siemens Medical Systems; Toshiba Medical Systems FX U. H. reports research support from Siemens Medical Systems. F. R. reports research support from Toshiba Medical Systems. No other potential conflicts of interest relevant to this article were reported. NR 55 TC 6 Z9 6 U1 1 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2014 VL 37 IS 2 BP 555 EP 564 DI 10.2337/dc13-1431 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA4NM UT WOS:000331072800047 PM 24130364 ER PT J AU Buschur, E Sarma, AV Pietropaolo, M Dunn, RL Braffett, BH Cleary, PA Cowie, C Larkin, ME Wessells, H Nathan, DM Kim, C AF Buschur, Elizabeth Sarma, Aruna V. Pietropaolo, Massimo Dunn, Rodney L. Braffett, Barbara H. Cleary, Patricia A. Cowie, Catherine Larkin, Mary E. Wessells, Hunter Nathan, David M. Kim, Catherine CA DCCT EDIC Res Grp TI Self-Reported Autoimmune Disease by Sex in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study SO DIABETES CARE LA English DT Letter C1 [Buschur, Elizabeth; Pietropaolo, Massimo] Univ Michigan, Dept Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA. [Sarma, Aruna V.; Dunn, Rodney L.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. [Braffett, Barbara H.; Cleary, Patricia A.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Cowie, Catherine] NIDDK, Bethesda, MD 20892 USA. [Larkin, Mary E.; Nathan, David M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Diabet, Boston, MA USA. [Wessells, Hunter] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Kim, Catherine] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Kim, Catherine] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA. RP Kim, C (reprint author), Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. EM cathkim@umich.edu FU NIDDK NIH HHS [U01-DK-094157, K23 DK071552, P30 DK017047, P30 DK020572, R01 DK083297, R01 DK083927, U01 DK094157, U01 DK094176, U01-DK-094176] NR 4 TC 3 Z9 3 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2014 VL 37 IS 2 BP E28 EP E29 DI 10.2337/dc13-1890 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA4NM UT WOS:000331072800004 PM 24459159 ER PT J AU Kinikoglu, B Kong, YW Liao, EC AF Kinikoglu, Beste Kong, Yawei Liao, Eric C. TI Characterization of cultured multipotent zebrafish neural crest cells SO EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article DE Neural crest cells; in vitro culture; retinoic acid; zebrafish; multipotency ID EMBRYONIC STEM-CELLS; SMOOTH-MUSCLE-CELLS; RETINOIC ACID; IN-VITRO; GENE-EXPRESSION; TRANSCRIPTION FACTOR; DIFFERENTIATION; MOUSE; PROTEINS; MODEL AB The neural crest is a unique cell population associated with vertebrate evolution. Neural crest cells (NCCs) are characterized by their multipotent and migratory potentials. While zebrafish is a powerful genetic model organism, the isolation and culture of zebrafish NCCs would provide a useful adjunct to fully interrogate the genetic networks that regulate NCC development. Here we report for the first time the isolation, in vitro culture, and characterization of NCCs from zebrafish embryos. NCCs were isolated from transgenic sox10:egfp embryos using fluorescence activated cell sorting and cultured in complex culture medium without feeder layers. NCC multilineage differentiation was determined by immunocytochemistry and real-time qPCR, cell migration was assessed by wound healing assay, and the proliferation index was calculated by immunostaining against the mitosis marker phospho-histone H3. Cultured NCCs expressed major neural crest lineage markers such as sox10, sox9a, hnk1, p75, dlx2a, and pax3, and the pluripotency markers c-myc and klf4. We showed that the cultured NCCs can be differentiated into multiple neural crest lineages, contributing to neurons, glial cells, smooth muscle cells, melanocytes, and chondrocytes. We applied the NCC in vitro model to study the effect of retinoic acid on NCC development. We showed that retinoic acid had a profound effect on NCC morphology and differentiation, significantly inhibited proliferation and enhanced cell migration. The availability of high numbers of NCCs and reproducible functional assays offers new opportunities for mechanistic studies of neural crest development, in genetic and chemical biology applications. C1 [Kinikoglu, Beste; Kong, Yawei; Liao, Eric C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA 02114 USA. [Kinikoglu, Beste; Kong, Yawei; Liao, Eric C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA 02114 USA. [Liao, Eric C.] Harvard Stem Cell Inst, Boston, MA 02114 USA. RP Liao, EC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA 02114 USA. EM cliao@partners.org FU Harvard Stem Cell Institute Seed Grant; Shriners Hospital for Children; March of Dimes Basil O'Connor Fellowship FX The authors would like to thank Christie Ciarlo, Charles Kaufman, and Leonard Zon for valuable discussions and the Center for Regenerative Medicine FACS Facility for excellent technical assistance. This work was supported by the Harvard Stem Cell Institute Seed Grant, Shriners Hospital for Children, and the March of Dimes Basil O'Connor Fellowship to ECL. NR 54 TC 7 Z9 7 U1 2 U2 12 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1535-3702 EI 1535-3699 J9 EXP BIOL MED JI Exp. Biol. Med. PD FEB PY 2014 VL 239 IS 2 BP 159 EP 168 DI 10.1177/1535370213513997 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AB1ML UT WOS:000331556100004 PM 24326414 ER PT J AU Schwamm, LH AF Schwamm, Lee H. TI Telehealth: Seven Strategies To Successfully Implement Disruptive Technology And Transform Health Care SO HEALTH AFFAIRS LA English DT Article ID STRUCTURED TELEPHONE SUPPORT; CHRONIC HEART-FAILURE; TELEMEDICINE; MANAGEMENT; METAANALYSIS; PROGRAMS; TRIAL; ONSET AB "Telehealth" refers to the use of electronic services to support a broad range of remote services, such as patient care, education, and monitoring. Telehealth must be integrated into traditional ambulatory and hospital-based practices if it is to achieve its full potential, including addressing the six domains of care quality defined by the Institute of Medicine: safe, effective, patient-centered, timely, efficient, and equitable. Telehealth is a disruptive technology that appears to threaten traditional health care delivery but has the potential to reform and transform the industry by reducing costs and increasing quality and patient satisfaction. This article outlines seven strategies critical to successful telehealth implementation: understanding patients' and providers' expectations, untethering telehealth from traditional revenue expectations, deconstructing the traditional health care encounter, being open to discovery, being mindful of the importance of space, redesigning care to improve value in health care, and being bold and visionary. C1 [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Schwamm, Lee H.] Partners TeleStroke Network, Boston, MA 02114 USA. RP Schwamm, LH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM lschwamm@partners.org OI Schwamm, Lee/0000-0003-0592-9145 FU Stroke and Traumatic Brain Injury Telehealth Services [HHSH250200927063P] FX Lee Schwamm's work was supported in part by the Stroke and Traumatic Brain Injury Telehealth Services (Grant No. HHSH250200927063P). The author gratefully acknowledges the contributions of two Massachusetts General Hospital colleagues: Sarah Sossong, for her work defining the hospital's administrative approach to implementation, and Elizabeth Mort, for mentoring the author in the field of quality improvement and measurement. NR 34 TC 13 Z9 13 U1 10 U2 29 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2014 VL 33 IS 2 BP 200 EP 206 DI 10.1377/hlthaff.2013.1021 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AA9IU UT WOS:000331407800004 PM 24493761 ER PT J AU Graetz, I Reed, M Shortell, SM Rundall, TG Bellows, J Hsu, J AF Graetz, Ilana Reed, Mary Shortell, Stephen M. Rundall, Thomas G. Bellows, Jim Hsu, John TI The Association between EHRs and Care Coordination Varies by Team Cohesion SO HEALTH SERVICES RESEARCH LA English DT Article ID ELECTRONIC HEALTH RECORDS; INFORMATION-TECHNOLOGY; AMBULATORY-CARE; QUALITY; PERFORMANCE; MEDICARE; OUTCOMES; IMPACT C1 [Graetz, Ilana] Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Graetz, Ilana] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Shortell, Stephen M.; Rundall, Thomas G.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Bellows, Jim] Kaiser Permanente, Care Management Inst, Oakland, CA USA. [Hsu, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Hlth Care Policy, Boston, MA USA. RP Reed, M (reprint author), Kaiser Permanente, Div Res, 2000 Broadway,3rd Floor, Oakland, CA 94612 USA. EM mary.e.reed@kp.org RI Graetz, Ilana/N-1189-2016 OI Graetz, Ilana/0000-0003-3664-5815 FU Agency for Healthcare Research and Quality [1R36HS021082-01, R01DK085070]; National Institute of Diabetes and Digestive and Kidney Diseases [R01HS015280] FX This research was supported by grants from the Agency for Healthcare Research and Quality (1R36HS021082-01 and R01DK085070) and the National Institute of Diabetes and Digestive and Kidney Diseases (R01HS015280). The content, findings, and conclusions of this article are the sole responsibility of the authors; the sponsors were not involved in any way in the determination of the content of this article. The authors have no conflict of interest. NR 30 TC 7 Z9 7 U1 3 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2014 VL 49 IS 1 BP 438 EP 452 PN 2 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AA3MA UT WOS:000330995400009 PM 24359592 ER PT J AU Karras, E Stephens, B Kemp, JE Bossarte, RM AF Karras, Elizabeth Stephens, Brady Kemp, Janet E. Bossarte, Robert M. TI Using media to promote suicide prevention hotlines to Veteran households SO INJURY PREVENTION LA English DT Article ID CAMPAIGNS; HEALTH; ATTITUDES; BEHAVIOR; STIGMA AB This article presents preliminary evidence that media campaigns are valuable in promoting suicide prevention hotlines to Veteran households by reporting data from 2526 telephone surveys. Findings from this study underscore the need for further investigation of the use of media campaigns to support suicide prevention initiatives aimed at Veteran populations. C1 [Karras, Elizabeth; Stephens, Brady; Bossarte, Robert M.] VISN 2 Ctr Excellence Suicide Prevent, Dept Vet Affairs, Canandaigua, NY 14424 USA. [Kemp, Janet E.] US Dept Vet Affairs, Natl Mental Hlth Program, Washington, DE USA. [Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP Karras, E (reprint author), VISN 2 Ctr Excellence Suicide Prevent, Dept Vet Affairs, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM Elizabeth.karras@va.gov FU VISN 2 Center of Excellence for Suicide Prevention at the Canandaigua VA Medical Center FX This material is the result of work supported with resources and the use of facilities at the VISN 2 Center of Excellence for Suicide Prevention at the Canandaigua VA Medical Center. We thank all of the Center of Excellence survey Center staff who participated in the data collection process. NR 19 TC 1 Z9 1 U1 4 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD FEB PY 2014 VL 20 IS 1 DI 10.1136/injuryprev-2012-040742 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA6EG UT WOS:000331191000016 ER PT J AU Rubenstein, L Khodyakov, D Hempel, S Danz, M Salem-Schatz, S Foy, R O'Neill, S Dalal, S Shekelle, P AF Rubenstein, Lisa Khodyakov, Dmitry Hempel, Susanne Danz, Margie Salem-Schatz, Susanne Foy, Robbie O'Neill, Sean Dalal, Siddhartha Shekelle, Paul TI How can we recognize continuous quality improvement? SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE continuous quality improvement; quality improvement; consultants; health care organization ID HEALTH-CARE; INTERVENTION PUBLICATIONS; CONSENSUS; DEPRESSION; COMPETENCE; STRATEGIES; GUIDELINES AB Continuous quality improvement (CQI) methods are foundational approaches to improving healthcare delivery. Publications using the term CQI, however, are methodologically heterogeneous, and labels other than CQI are used to signify relevant approaches. Standards for identifying the use of CQI based on its key methodological features could enable more effective learning across quality improvement (QI) efforts. The objective was to identify essential methodological features for recognizing CQI. Previous work with a 12-member international expert panel identified reliably abstracted CQI methodological features. We tested which features met rigorous a priori standards as essential features of CQI using a three-phase online modified-Delphi process. Primarily United States and Canada. 119 QI experts randomly assigned into four on-line panels. Participants rated CQI features and discussed their answers using online, anonymous and asynchronous discussion boards. We analyzed ratings quantitatively and discussion threads qualitatively. Panel consensus on definitional CQI features. Seventy-nine (66) panelists completed the process. Thirty-three completers self-identified as QI researchers, 18 as QI practitioners and 28 as both equally. The features systematic data guided activities, designing with local conditions in mind and iterative development and testing met a priori standards as essential CQI features. Qualitative analyses showed cross-cutting themes focused on differences between QI and CQI. We found consensus among a broad group of CQI researchers and practitioners on three features as essential for identifying QI work more specifically as CQI. All three features are needed as a minimum standard for recognizing CQI methods. C1 [Rubenstein, Lisa; Khodyakov, Dmitry; Hempel, Susanne; Danz, Margie; O'Neill, Sean; Dalal, Siddhartha; Shekelle, Paul] RAND Corp, Santa Monica, CA 90401 USA. [Rubenstein, Lisa; Danz, Margie] Vet Affairs Greater Los Angeles Sepulveda, North Hills, CA 91343 USA. [Rubenstein, Lisa] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Rubenstein, Lisa] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Salem-Schatz, Susanne] HealthCare Qual Initiat, Newton, MA 02459 USA. [Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9JT, W Yorkshire, England. [O'Neill, Sean] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Hempel, S (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90401 USA. EM susanne_hempel@rand.org OI O'Neill, Sean/0000-0001-7759-8942 FU Robert Wood Johnson Foundation [65113, 67890]; RAND Corporation; VA Health Services Research and Development Center for Implementation Practice and Research Support; Department of Veterans Affairs FX This work was supported by the Robert Wood Johnson Foundation (Grant ID 65113: Advancing the science of continuous quality improvement: a framework for identifying, classifying and evaluating continuous quality improvement studies and Grant ID 67890: Providing a framework for the identification, classification and evaluation of quality improvement initiatives) and the RAND Corporation, with additional funding provided by the VA Health Services Research and Development Center for Implementation Practice and Research Support. Funding to pay the Open Access publication charges for this article was provided by the Department of Veterans Affairs. NR 33 TC 12 Z9 12 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 EI 1464-3677 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD FEB PY 2014 VL 26 IS 1 BP 6 EP 15 DI 10.1093/intqhc/mzt085 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AA7SF UT WOS:000331296500002 PM 24311732 ER PT J AU Wang, H Troy, LM Rogers, GT Fox, CS McKeown, NM Meigs, JB Jacques, PF AF Wang, H. Troy, L. M. Rogers, G. T. Fox, C. S. McKeown, N. M. Meigs, J. B. Jacques, P. F. TI Longitudinal association between dairy consumption and changes of body weight and waist circumference: the Framingham Heart Study SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE dairy; weight; waist circumference; longitudinal; milk; yogurt ID FOOD FREQUENCY QUESTIONNAIRE; INSULIN-RESISTANCE; CARDIOVASCULAR RISK; METABOLIC SYNDROME; PROSPECTIVE COHORT; CLINICAL-TRIALS; OBESITY; ADULTS; DIET; MANAGEMENT AB BACKGROUND: Dairy foods are nutrient dense and may be protective against long-term weight gain. OBJECTIVE: We aimed to examine the longitudinal association between dairy consumption and annualized changes in weight and waist circumference (WC) in adults. METHODS: Members of the Framingham Heart Study Offspring Cohort who participated in the fifth through eighth study examinations (1991-2008) were included in these analyses (3440 participants with 11 683 observations). At each exam, dietary intake was assessed by a validated food frequency questionnaire, and weight and WC were assessed following standardized procedures. Repeated measures models were used for the longitudinal analyses of annualized weight and waist circumference changes, adjusting for time-varying or invariant covariates. RESULTS: On average, participants gained weight and WC during follow-up. Dairy intake increased across exams. After adjusting for demographic and lifestyle factors (including diet quality), participants who consumed >= 3 servings per day of total dairy had 0.10 kg (+/- 0.04) smaller annualized increment of weight (P-trend = 0.04) than those consuming <1 serving per day. Higher total dairy intake was also marginally associated with less WC gain (P-trend = 0.05). Similarly, participants who consumed >= 3 servings per week of yogurt had a 0.10 kg (+/- 0.04) and 0.13 cm (+/- 0.05) smaller annualized increment of weight (P-trend = 0.03) and WC (P-trend = 0.008) than those consuming <1 serving per week, respectively. Skim/ low-fat milk, cheese, total high-fat or total low-fat dairy intake were not associated with long-term change in weight or WC. CONCLUSION: Further longitudinal and interventional studies are warranted to confirm the beneficial role of increasing total dairy and yogurt intake, as part of a healthy and calorie-balanced dietary pattern, in the long-term prevention of gain in weight and WC. C1 [Wang, H.; Troy, L. M.; Rogers, G. T.; McKeown, N. M.; Jacques, P. F.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr Epidemiol Program, Boston, MA 02111 USA. [Troy, L. M.] Univ Massachusetts, Dept Nutr, Chenoweth Lab, Amherst, MA 01003 USA. [Troy, L. M.; McKeown, N. M.; Jacques, P. F.] Tufts Univ, Gerald J & Dorothy R Friedman Sch Nutr Sci & Poli, Boston, MA 02111 USA. [Fox, C. S.] Framingham Heart Dis Epidemiol Study, Natl Heart Lung & Blood Inst, Framingham, MA USA. [Meigs, J. B.] Massachusetts Gen Hosp, Dept Med, Gen Internal Med Unit, Boston, MA 02114 USA. RP Jacques, PF (reprint author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA. EM Paul.jacques@tufts.edu FU National Heart, Lung and Blood Institute of the National Institute of Health [NO1-HC-25195]; US Department of Agriculture [58-1950-7-707]; Dannon Company, Inc.; General Mills Bell Institute of Health and Nutrition FX We thank Kara A Livingston, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, for the help with data set management. This work was supported by the National Heart, Lung and Blood Institute of the National Institute of Health (contract number: NO1-HC-25195), US Department of Agriculture Agreement 58-1950-7-707 and research grants from The Dannon Company, Inc., and General Mills Bell Institute of Health and Nutrition. NR 53 TC 36 Z9 37 U1 4 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD FEB PY 2014 VL 38 IS 2 BP 299 EP 305 DI 10.1038/ijo.2013.78 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA AA9HL UT WOS:000331404300020 PM 23736371 ER PT J AU Menda, SA Driver, TH Neiman, AE Naseri, A Stewart, JM AF Menda, Shivali A. Driver, Todd H. Neiman, Alexandra E. Naseri, Ayman Stewart, Jay M. TI Return to the Operating Room After Resident-Performed Cataract Surgery SO JAMA OPHTHALMOLOGY LA English DT Letter ID QUALITY INDICATOR C1 [Menda, Shivali A.; Driver, Todd H.; Neiman, Alexandra E.; Naseri, Ayman; Stewart, Jay M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Neiman, Alexandra E.; Stewart, Jay M.] San Francisco Gen Hosp, Dept Ophthalmol, San Francisco, CA 94110 USA. [Naseri, Ayman] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA USA. RP Stewart, JM (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,K301, San Francisco, CA 94143 USA. EM stewartj@vision.ucsf.edu NR 6 TC 5 Z9 5 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD FEB PY 2014 VL 132 IS 2 BP 223 EP 224 DI 10.1001/jamaophthalmol.2013.5675 PG 2 WC Ophthalmology SC Ophthalmology GA AA8TJ UT WOS:000331367600015 PM 24288082 ER PT J AU Frazier, AL Camargo, CA Malspeis, S Willett, WC Young, MC AF Frazier, A. Lindsay Camargo, Carlos A., Jr. Malspeis, Susan Willett, Walter C. Young, Michael C. TI Prospective Study of Peripregnancy Consumption of Peanuts or Tree Nuts by Mothers and the Risk of Peanut or Tree Nut Allergy in Their Offspring SO JAMA PEDIATRICS LA English DT Article ID MATERNAL TRANSMISSION; GOVERNMENT ADVICE; CHILDHOOD ASTHMA; ATOPIC DISEASES; LATE PREGNANCY; FOLLOW-UP; SENSITIZATION; AVOIDANCE; CHILDREN; EXPOSURE AB IMPORTANCE The etiology of the increasing childhood prevalence of peanut or tree nut (P/TN) allergy is unknown. OBJECTIVE To examine the association between peripregnancy consumption of P/TN by mothers and the risk of P/TN allergy in their offspring. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study. The 10 907 participants in the Growing Up Today Study 2, born between January 1, 1990, and December 31, 1994, are the offspring of women who previously reported their diet during, or shortly before or after, their pregnancy with this child as part of the ongoing Nurses' Health Study II. In 2006, the offspring reported physician-diagnosed food allergy. Mothers were asked to confirm the diagnosis and to provide available medical records and allergy test results. Two board-certified pediatricians, including a board-certified allergist/immunologist, independently reviewed each potential case and assigned a confirmation code (eg, likely food allergy) to each case. Unadjusted and multivariable logistic regression analyses were used to evaluate associations between peripregnancy consumption of P/TN by mothers and incident P/TN allergy in their offspring. EXPOSURE Peripregnancy consumption of P/TN. MAIN OUTCOMES AND MEASURES Physician-diagnosed P/TN allergy in offspring. RESULTS Among 8205 children, we identified 308 cases of food allergy (any food), including 140 cases of P/TN allergy. The incidence of P/TN allergy in the offspring was significantly lower among children of the 8059 nonallergic mothers who consumed more P/TN in their peripregnancy diet (>= 5 times vs <1 time per month: odds ratio = 0.31; 95% CI, 0.13-0.75; P-trend = .004). By contrast, a nonsignificant positive association was observed between maternal peripregnancy P/TN consumption and risk of P/TN allergy in the offspring of 146 P/TN-allergic mothers (P-trend = .12). The interaction between maternal peripregnancy P/TN consumption and maternal P/TN allergy status was statistically significant (P-interaction = .004). CONCLUSIONS AND RELEVANCE Among mothers without P/TN allergy, higher peripregnancy consumption of P/TN was associated with lower risk of P/TN allergy in their offspring. Our study supports the hypothesis that early allergen exposure increases tolerance and lowers risk of childhood food allergy. C1 [Frazier, A. Lindsay] Dana Farber Childrens Canc Ctr, Dept Pediat Oncol, Boston, MA USA. [Frazier, A. Lindsay; Camargo, Carlos A., Jr.; Malspeis, Susan] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Frazier, A. Lindsay; Camargo, Carlos A., Jr.; Malspeis, Susan] Harvard Univ, Sch Med, Boston, MA USA. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Camargo, Carlos A., Jr.; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Willett, Walter C.] Boston Childrens Hosp, Div Gastroenterol & Nutr, Boston, MA USA. [Young, Michael C.] Boston Childrens Hosp, Dept Med, Boston, MA USA. RP Young, MC (reprint author), Boston Childrens Hosp, Dept Med, Div Immunol, Fegan 6,300 Longwood Ave, Boston, MA 02115 USA. EM michael.young@childrens.harvard.edu FU Food Allergy Research and Education, New York, New York FX This work was supported by Food Allergy Research and Education, New York, New York. NR 39 TC 17 Z9 17 U1 9 U2 32 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD FEB PY 2014 VL 168 IS 2 BP 156 EP 162 DI 10.1001/jamapediatrics.2013.4139 PG 7 WC Pediatrics SC Pediatrics GA AA8TD UT WOS:000331366900013 PM 24366539 ER PT J AU Baker, JT Holmes, AJ Masters, GA Yeo, BTT Krienen, F Buckner, RL Ongur, D AF Baker, Justin T. Holmes, Avram J. Masters, Grace A. Yeo, B. T. Thomas Krienen, Fenna Buckner, Randy L. Oenguer, Dost TI Disruption of Cortical Association Networks in Schizophrenia and Psychotic Bipolar Disorder SO JAMA PSYCHIATRY LA English DT Article ID INTRINSIC FUNCTIONAL CONNECTIVITY; DORSOLATERAL PREFRONTAL CORTEX; CONTEXT-PROCESSING DEFICITS; WORKING-MEMORY; AUDITORY HALLUCINATIONS; 1ST-DEGREE RELATIVES; DEFAULT NETWORK; BRAIN NETWORKS; HEAD MOTION; DYSFUNCTION AB IMPORTANCE Psychotic disorders (including schizophrenia, schizoaffective disorder, and psychotic bipolar disorder) are devastating illnesses characterized by breakdown in the integration of information processing. Recent advances in neuroimaging allow for the estimation of brain networks on the basis of intrinsic functional connectivity, but the specific network abnormalities in psychotic disorders are poorly understood. OBJECTIVE To compare intrinsic functional connectivity across the cerebral cortex in patients with schizophrenia spectrum disorders or psychotic bipolar disorder and healthy controls. DESIGN, SETTING, AND PARTICIPANTS We studied 100 patients from an academic psychiatric hospital (28 patients with schizophrenia, 32 patients with schizoaffective disorder, and 40 patients with bipolar disorder with psychosis) and 100 healthy controls matched for age, sex, race, handedness, and scan quality from December 2009 to October 2011. MAIN OUTCOMES AND MEASURES Functional connectivity profiles across 122 regions that covered the entire cerebral cortex. RESULTS Relative to the healthy controls, individuals with a psychotic illness had disruption across several brain networks, with preferential reductions in functional connectivity within the frontoparietal control network (P < .05, corrected for family-wise error rate). This functionally defined network includes portions of the dorsolateral prefrontal cortex, posteromedial prefrontal cortex, lateral parietal cortex, and posterior temporal cortex. This effect was seen across diagnoses and persisted after matching patients and controls on the basis of scan quality. CONCLUSIONS AND RELEVANCE Our study results support the view that cortical information processing is disrupted in psychosis and provides new evidence that disruptions within the frontoparietal control network may be a shared feature across both schizophrenia and affective psychosis. C1 [Baker, Justin T.; Masters, Grace A.; Oenguer, Dost] McLean Hosp, Psychot Disorders Div, Belmont, MA 02478 USA. [Baker, Justin T.; Holmes, Avram J.; Buckner, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Baker, Justin T.; Holmes, Avram J.; Buckner, Randy L.; Oenguer, Dost] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Holmes, Avram J.; Yeo, B. T. Thomas; Buckner, Randy L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Yeo, B. T. Thomas] Duke NUS Grad Med Sch, Ctr Cognit Neurosci, Singapore, Singapore. [Krienen, Fenna; Buckner, Randy L.] Harvard Univ, Dept Psychol, Ctr Brain Sci, Cambridge, MA 02138 USA. RP Baker, JT (reprint author), McLean Hosp, Psychot Disorders Div, 115 Mill St, Belmont, MA 02478 USA. EM jtbaker@partners.org OI Masters, Grace/0000-0001-6064-3786; Yeo, B.T. Thomas/0000-0002-0119-3276 FU National Institute of Mental Health [1K23MH079982-01A1, 5R01MH094594, K01MH099232]; Harvard/MIT; Taplin Family Foundation; Dupont-Warren Fellowship; APA-Pfizer; Maria Lorenz Pope Fellowship FX This study was funded by grants 1K23MH079982-01A1, 5R01MH094594 from the National Institute of Mental Health (Dr Ongur), the Clinical Investigator Training Fellowship from Harvard/MIT (Dr Ongur), and the Taplin Family Foundation. Dr Baker is supported by a Dupont-Warren Fellowship (HMS), the APA-Pfizer MD/PhD Fellowship, and the Maria Lorenz Pope Fellowship. Dr Holmes is supported by K01MH099232 from the National Institute of Mental Health. NR 46 TC 63 Z9 64 U1 2 U2 20 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD FEB PY 2014 VL 71 IS 2 BP 109 EP 118 DI 10.1001/jamapsychiatry.2013.3469 PG 10 WC Psychiatry SC Psychiatry GA AA8UN UT WOS:000331370600002 PM 24306091 ER PT J AU Steenkamp, MM Litz, BT AF Steenkamp, Maria M. Litz, Brett T. TI Prolonged Exposure Therapy in Veterans Affairs: The Full Picture SO JAMA PSYCHIATRY LA English DT Letter ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHOTHERAPY C1 [Steenkamp, Maria M.; Litz, Brett T.] VA Boston Healthcare Syst, Jamaica Plain, MA USA. RP Steenkamp, MM (reprint author), Boston VA Med Ctr, 150 S Huntington Ave,13B-73, Jamaica Plain, MA 02130 USA. EM maria.steenkamp2@va.gov NR 3 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD FEB PY 2014 VL 71 IS 2 BP 211 EP 211 PG 1 WC Psychiatry SC Psychiatry GA AA8UN UT WOS:000331370600021 PM 24500633 ER PT J AU Lin, CA Takemoto, S Kandemir, U Kuo, AC AF Lin, Carol A. Takemoto, Steven Kandemir, Utku Kuo, Alfred C. TI Mid-Term Outcomes in HIV-Positive Patients After Primary Total Hip or Knee Arthroplasty SO JOURNAL OF ARTHROPLASTY LA English DT Article DE HIV/AIDS; THA; TKA; HAART ID HUMAN-IMMUNODEFICIENCY-VIRUS; TOTAL JOINT ARTHROPLASTY; HEMOPHILIC ARTHROPATHY; ANTIRETROVIRAL THERAPY; INFECTED HEMOPHILIACS; SOCIOECONOMIC-STATUS; NATURAL-HISTORY; REPLACEMENT; COUNTS; COMORBIDITIES AB We hypothesized that infection rates following total joint arthroplasty (TJA) in those with the human immunodeficiency virus (HIV) without hemophilia or drug use would be similar to rates in HIV-negative patients. Records at an urban HIV referral hospital were searched for patients who underwent primary total hip and knee arthroplasty from 2003 to 2010. The primary outcome was revision for infection. 372 HIV-negative and 22 HIV-positive TJA patients met inclusion criteria. The HIV-positive group had more deep infections than the HIV-negative group (9.1% v 2.2%, P = 0.102). There were no infections in those with AIDS-defining CD4 counts. Those with HIV may have a higher risk of developing a deep infection. A low CD4 count is not an absolute contraindication to TJA in HIV positive patients. Published by Elsevier Inc. C1 [Lin, Carol A.] Hennepin Cty Med Ctr, Dept Orthopaed Surg, Minneapolis, MN 55415 USA. [Takemoto, Steven; Kuo, Alfred C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kandemir, Utku; Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. [Kandemir, Utku] San Francisco Gen Hosp, Dept Orthopaed Surg, San Francisco, CA 94110 USA. RP Kuo, AC (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 500 Parnassus Ave,MUW 320, San Francisco, CA 94143 USA. FU Orthopaedic Research and Education Foundation; Clinical and Translational Science Institute at the University of California, San Francisco FX This project was supported by a Resident Research Grant from the Orthopaedic Research and Education Foundation and the Clinical and Translational Science Institute at the University of California, San Francisco. These organizations played no role in the study other than in providing funding. NR 45 TC 14 Z9 14 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD FEB PY 2014 VL 29 IS 2 BP 277 EP 282 DI 10.1016/j.arth.2013.06.015 PG 6 WC Orthopedics SC Orthopedics GA AA8KY UT WOS:000331345600006 PM 23867663 ER PT J AU Emanuelli, B Vienberg, SG Smyth, G Cheng, C Stanford, KI Arumugam, M Michael, MD Adams, AC Kharitonenkov, A Kahn, CR AF Emanuelli, Brice Vienberg, Sara G. Smyth, Graham Cheng, Christine Stanford, Kristin I. Arumugam, Manimozhiyan Michael, Mervyn D. Adams, Andrew C. Kharitonenkov, Alexei Kahn, C. Ronald TI Interplay between FGF21 and insulin action in the liver regulates metabolism SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID GROWTH-FACTOR 21; BROWN ADIPOSE-TISSUE; ELEMENT-BINDING PROTEIN-1C; STEAROYL-COA DESATURASE-1; PPAR-ALPHA; BETA-KLOTHO; HEPATIC FGF21; RESISTANCE; OBESITY; ACTIVATION AB The hormone FGF21 regulates carbohydrate and lipid homeostasis as well as body weight, and increasing FGF21 improves metabolic abnormalities associated with obesity and diabetes. FGF21 is thought to act on its target tissues, including liver and adipose tissue, to improve insulin sensitivity and reduce adiposity. Here, we used mice with selective hepatic inactivation of the IR (LIRKO) to determine whether insulin sensitization in liver mediates FGF21 metabolic actions. Remarkably, hyperglycemia was completely normalized following FGF21 treatment in LIRKO mice, even though FGF21 did not reduce gluconeogenesis in these animals. Improvements in blood sugar were due in part to increased glucose uptake in brown fat, browning of white fat, and overall increased energy expenditure. These effects were preserved even after removal of the main interscapular brown fat pad. In contrast to its retained effects on reducing glucose levels, the effects of FGF21 on reducing circulating cholesterol and hepatic triglycerides and regulating the expression of key genes involved in cholesterol and lipid metabolism in liver were disrupted in LIRKO mice. Thus, FGF21 corrects hyperglycemia in diabetic mice independently of insulin action in the liver by increasing energy metabolism via activation of brown fat and browning of white fat, but intact liver insulin action is required for FGF21 to control hepatic lipid metabolism. C1 [Emanuelli, Brice; Vienberg, Sara G.; Smyth, Graham; Stanford, Kristin I.; Kahn, C. Ronald] Joslin Diabet Ctr, Boston, MA 02215 USA. [Cheng, Christine; Michael, Mervyn D.; Adams, Andrew C.; Kharitonenkov, Alexei] Lilly Diabet Res, Indianapolis, IN USA. [Arumugam, Manimozhiyan] Univ Copenhagen, Ctr Basic Metab Res, Novo Nordisk Fdn, Copenhagen, Denmark. [Arumugam, Manimozhiyan] BGI Shenzhen, Shenzhen, Peoples R China. RP Kahn, CR (reprint author), Joslin Diabet Ctr, Sect Integrat Physiol & Metab, 1 Joslin Pl, Boston, MA 02215 USA. EM c.ronald.kahn@joslin.harvard.edu RI Arumugam, Manimozhiyan/E-1211-2011; Emanuelli, Brice/M-2097-2016; OI Arumugam, Manimozhiyan/0000-0002-0886-9101; Emanuelli, Brice/0000-0001-5795-5666 FU NIH [R01-DK-033201, R01-DK031036]; Eli Lilly and Company FX This work was supported by NIH grants R01-DK-033201 and R01-DK031036 and by a grant from Eli Lilly and Company. NR 52 TC 72 Z9 74 U1 4 U2 29 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD FEB PY 2014 VL 124 IS 2 BP 515 EP 527 DI 10.1172/JCI67353 PG 13 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AA9KV UT WOS:000331413300014 PM 24401271 ER PT J AU Gutierrez, A Pan, L Groen, RWJ Baleydier, F Kentsis, A Marineau, J Grebliunaite, R Kozakewich, E Reed, C Pflumio, F Poglio, S Uzan, B Clemons, P VerPlank, L An, F Burbank, J Norton, S Tolliday, N Steen, H Weng, AP Yuan, HP Bradner, JE Mitsiades, C Look, AT Aster, JC AF Gutierrez, Alejandro Pan, Li Groen, Richard W. J. Baleydier, Frederic Kentsis, Alex Marineau, Jason Grebliunaite, Ruta Kozakewich, Elena Reed, Casie Pflumio, Francoise Poglio, Sandrine Uzan, Benjamin Clemons, Paul VerPlank, Lynn An, Frank Burbank, Jason Norton, Stephanie Tolliday, Nicola Steen, Hanno Weng, Andrew P. Yuan, Huipin Bradner, James E. Mitsiades, Constantine Look, A. Thomas Aster, Jon C. TI Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID CHRONIC LYMPHOCYTIC-LEUKEMIA; REGULATES C-MYC; TRANSGENIC ZEBRAFISH; PRECLINICAL ACTIVITY; LYMPHOID-CELLS; IN-VITRO; NOTCH1; PROTEIN; CANCER; MUTATIONS AB T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer that is frequently associated with activating mutations in NOTCH1 and dysregulation of MYC. Here, we performed 2 complementary screens to identify FDA-approved drugs and drug-like small molecules with activity against T-ALL. We developed a zebrafish system to screen small molecules for toxic activity toward MYC-overexpressing thymocytes and used a human T-ALL cell line to screen for small molecules that synergize with Notch inhibitors. We identified the antipsychotic drug perphenazine in both screens due to its ability to induce apoptosis in fish, mouse, and human T-ALL cells. Using ligand-affinity chromatography coupled with mass spectrometry, we identified protein phosphatase 2A (PP2A) as a perphenazine target. T-ALL cell lines treated with perphenazine exhibited rapid dephosphorylation of multiple PP2A substrates and subsequent apoptosis. Moreover, shRNA knockdown of specific PP2A subunits attenuated perphenazine activity, indicating that PP2A mediates the drug's antileukemic activity. Finally, human T-ALLs treated with perphenazine exhibited suppressed cell growth and dephosphorylation of PP2A targets in vitro and in vivo. Our findings provide a mechanistic explanation for the recurring identification of phenothiazines as a class of drugs with anticancer effects. Furthermore, these data suggest that pharmacologic PP2A activation in T-ALL and other cancers driven by hyperphosphorylated PP2A substrates has therapeutic potential. C1 [Gutierrez, Alejandro; Kentsis, Alex; Grebliunaite, Ruta; Kozakewich, Elena; Reed, Casie; Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Gutierrez, Alejandro; Pan, Li; Groen, Richard W. J.; Baleydier, Frederic; Kentsis, Alex; Marineau, Jason; Grebliunaite, Ruta; Kozakewich, Elena; Reed, Casie; Steen, Hanno; Bradner, James E.; Mitsiades, Constantine; Look, A. Thomas; Aster, Jon C.] Harvard Univ, Sch Med, Boston, MA USA. [Gutierrez, Alejandro; Kentsis, Alex; Look, A. Thomas] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Pan, Li; Baleydier, Frederic; Aster, Jon C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Groen, Richard W. J.; Marineau, Jason; Bradner, James E.; Mitsiades, Constantine] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Groen, Richard W. J.] Univ Med Ctr Utrecht, Dept Cell Biol, Utrecht, Netherlands. [Baleydier, Frederic] Hosp Civils Lyon, Dept Pediat Hematol, Lyon, France. [Pflumio, Francoise; Poglio, Sandrine; Uzan, Benjamin] INSERM, Commissariat Energie Atom & Energies Alternat, Lab Rech Cellules Souches Hematopoiet & Leucem, Inst Radiobiol Cellulaire & Mol,Direct Sci Vivant, Fontenay Aux Roses, France. [Pflumio, Francoise; Poglio, Sandrine; Uzan, Benjamin] Univ Paris 11, Fontenay Aux Roses, France. [Pflumio, Francoise; Poglio, Sandrine; Uzan, Benjamin] Univ Paris Diderot, Paris, France. [Clemons, Paul; VerPlank, Lynn; An, Frank; Burbank, Jason; Norton, Stephanie; Tolliday, Nicola] Broad Inst, Cambridge, MA USA. [Steen, Hanno] Boston Childrens Hosp, Prote Ctr, Boston, MA USA. [Steen, Hanno] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Weng, Andrew P.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Yuan, Huipin] Xpand Biotechnol BV, Bilthoven, Netherlands. RP Look, AT (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St,Mayer 630, Boston, MA 02115 USA. EM thomas_look@dfci.harvard.edu; jaster@rics.bwh.harvard.edu RI Weng, Andrew/I-5015-2014; Pflumio, Francoise/E-2074-2017; OI Kentsis, Alex/0000-0002-8063-9191; Gutierrez, Alejandro/0000-0002-0249-9007; Groen, Richard/0000-0002-5010-4604 FU NIH [1K08CA133103, 5P01CA109901]; Leukemia and Lymphoma Society; William Lawrence Blanche Hughes Foundation; Bear Necessities Pediatric Cancer Foundation; Ligue Nationale contre le Cancer; Association Laurette Fugain; Institut National du Cancer (INCA); Universites Paris Diderot and Paris Sud; INSERM; CEA and Canceropole Ile de France (StemPole); European Union [302428]; NCI Initiative for Chemical Genetics [N01-CO-12400] FX PP2A A alpha shRNA was a gift from W.C. Hahn. We wish to thank P. Ballerini, J. Landman-Parker, T. Leblanc, and A. Baruchel from Hopital Trousseau and Hopital R Debre for help in collection of patient samples and S. Blacklow for advice on technical and conceptual aspects of these studies. This work was supported by NIH grants 1K08CA133103 (to A. Gutierrez) and 5P01CA109901 (to A.T. Look); a Specialized Center of Research grant from the Leukemia and Lymphoma Society (to J.C. Aster and J.E. Bradner); grants from the William Lawrence Blanche Hughes Foundation (to A. Gutierrez, J.C. Aster, A.T. Look, and J.E. Bradner); a grant from the Bear Necessities Pediatric Cancer Foundation (to A. Gutierrez); and grants from Ligue Nationale contre le Cancer, Association Laurette Fugain, Institut National du Cancer (INCA), Universites Paris Diderot and Paris Sud, INSERM, CEA and Canceropole Ile de France (StemPole) (to F. Pflumio, S. Poglio, and B. Uzan). R. Groen has received funding from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013/ under REA grant agreement no. 302428. A. Gutierrez is a research fellow of the Gabrielle's Angel Foundation for Cancer Research and is a previous scholar of the American Society of Hematology Harold Amos Medical Faculty Development Program. The T-ALL cell line screen was funded in part with federal funds from the NCI Initiative for Chemical Genetics under contract no. N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. NR 73 TC 40 Z9 41 U1 2 U2 15 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD FEB PY 2014 VL 124 IS 2 BP 644 EP 655 DI 10.1172/JCI65093 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AA9KV UT WOS:000331413300024 PM 24401270 ER PT J AU Santagata, S Thakkar, A Ergonul, A Wang, B Woo, T Hu, R Harrell, JC McNamara, G Schwede, M Culhane, AC Kindelberger, D Rodig, S Richardson, A Schnitt, SJ Tamimi, RM Ince, TA AF Santagata, Sandro Thakkar, Ankita Ergonul, Ayse Wang, Bin Woo, Terri Hu, Rong Harrell, J. Chuck McNamara, George Schwede, Matthew Culhane, Aedin C. Kindelberger, David Rodig, Scott Richardson, Andrea Schnitt, Stuart J. Tamimi, Rulla M. Ince, Tan A. TI Taxonomy of breast cancer based on normal cell phenotype predicts outcome SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID GENE-EXPRESSION-DATA; ESTROGEN-RECEPTOR; ANDROGEN RECEPTOR; CLASSIFICATION; SUBTYPES; CARCINOMA; PROGNOSIS; TRANSCRIPTOME; PROGENITORS; SUBCLASSES AB Accurate classification is essential for understanding the pathophysiology of a disease and can inform therapeutic choices. For hematopoietic malignancies, a classification scheme based on the phenotypic similarity between tumor cells and normal cells has been successfully used to define tumor subtypes; however, use of normal cell types as a reference by which to classify solid tumors has not been widely emulated, in part due to more limited understanding of epithelial cell differentiation compared with hematopoiesis. To provide abetter definition of the subtypes of epithelial cells comprising the breast epithelium, we performed a systematic analysis of a large set of breast epithelial markers in more than 15,000 normal breast cells, which identified 11 differentiation states for normal luminal cells. We then applied information from this analysis to classify human breast tumors based on normal cell types into 4 major subtypes, HR0-HR3, which were differentiated by vitamin D, androgen, and estrogen hormone receptor (HR) expression. Examination of 3,157 human breast tumors revealed that these HR subtypes were distinct from the current classification scheme, which is based on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Patient outcomes were best when tumors expressed all 3 hormone receptors (subtype HR3) and worst when they expressed none of the receptors (subtype HR0). Together, these data provide an ontological classification scheme associated with patient survival differences and provides actionable insights for treating breast tumors. C1 [Santagata, Sandro; Woo, Terri; Kindelberger, David; Rodig, Scott; Richardson, Andrea] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Santagata, Sandro; Woo, Terri; Hu, Rong; Kindelberger, David; Rodig, Scott; Richardson, Andrea; Schnitt, Stuart J.; Tamimi, Rulla M.] Harvard Univ, Sch Med, Boston, MA USA. [Thakkar, Ankita; Ergonul, Ayse; Wang, Bin; McNamara, George; Ince, Tan A.] Univ Miami, Dept Pathol, Interdisciplinary Stem Cell Inst, Braman Family Breast Canc Inst, Miami, FL 33136 USA. [Thakkar, Ankita; Ergonul, Ayse; Wang, Bin; McNamara, George; Ince, Tan A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA. [Hu, Rong; Tamimi, Rulla M.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Hu, Rong; Tamimi, Rulla M.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Harrell, J. Chuck] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Schwede, Matthew; Culhane, Aedin C.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Schnitt, Stuart J.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. RP Ince, TA (reprint author), Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Braman Family Breast Canc Inst,Dept Pathol,BRB, Room 907, Miami, FL 33136 USA. EM TInce@med.miami.edu FU Breast Cancer Research Foundation; NCI [R01-CA146445-01]; NIH Roadmap Epigenomics Project; Department of Defense CDMRP BCRP [W8 1XWH-08-1-0282, BC-07456]; DHHS; GlaxoSmithKline [WE234, EPI40307]; NIH [K08NS064168]; V Foundation for Cancer Research; DFCI Women's Cancers Program; Claudia Adams Barr Program in Innovative Basic Cancer Research FX The authors acknowledge funding support from Breast Cancer Research Foundation and Play for P.I.N.K. (to T.A. Ince), Kristin Jordahl and friends (to T.A. Ince); NCI grant R01-CA146445-01, NIH Roadmap Epigenomics Project (to T.A. Ince); Department of Defense CDMRP BCRP grant W8 1XWH-08-1-0282,BC-07456 (to T.A. Ince); DHHS and GlaxoSmithKline grants WE234 and EPI40307 (to R.M. Tamimi); NIH grant K08NS064168 (to S. Santagata); V Foundation for Cancer Research (to S. Santagata); DFCI Women's Cancers Program (to A.C. Culhane and M. Schwede); and Claudia Adams Barr Program in Innovative Basic Cancer Research (to A.C. Culhane). We thank Q. Li, S. Dinn, A. Santamaria-Pang, and F. Ginty (GE Global Research Center) as well as T.D. Tlsty, J.S. Brugge, J.M. Slingerland, R.D. Cardiff, C. Gomez, M.D. Pegram, S.A. Borowsky, M. Nadji, and M. Jorda for helpful suggestions. NR 56 TC 64 Z9 64 U1 1 U2 6 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD FEB PY 2014 VL 124 IS 2 BP 859 EP 870 DI 10.1172/JCI70941 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AA9KV UT WOS:000331413300042 PM 24463450 ER PT J AU Hicks, CW Hodin, RA Savitt, L Bordeianou, L AF Hicks, Caitlin W. Hodin, Richard A. Savitt, Lieba Bordeianou, Liliana TI Does Intramesorectal Proctectomy with Rectal Eversion Affect Postoperative Complications Compared to Standard Total Mesorectal Excision in Patients with Ulcerative Colitis? SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE Ulcerative colitis; Intramesorectal proctectomy; Total mesorectal excision; Complications ID POUCH-ANAL ANASTOMOSIS; RESTORATIVE PROCTOCOLECTOMY; ANTERIOR RESECTION; SEPTIC COMPLICATIONS; SURGICAL-TREATMENT; TRANSITION ZONE; RISK-FACTORS; CANCER; INFLIXIMAB; METAANALYSIS AB Proctectomy for ulcerative colitis (UC) can be performed via intramesorectal proctectomy with concomitant rectal eversion (IMP/RE) or total mesorectal excision (TME). No data exists comparing the outcomes of the two techniques. All UC patients undergoing J-pouch surgery at a single institution over 10.5 years were included. Postoperative complications with IMP/RE vs. TME were analyzed using univariable and multivariable statistics. One hundred nineteen of 201 (59 %) patients underwent IMP/RE. Demographic and disease characteristics were similar between groups. On univariable analysis, IMP/RE had fewer total perioperative complications than TME (p = 0.02), but no differences in postoperative length of stay or readmissions. Multivariable regression accounting for patient age, comorbidities, disease severity, preoperative medications, operative technique, and follow-up time (mean 5.5 +/- 0.2 years) suggested that both anastomotic leak rate (OR 0.32; p = 0.04) and overall postoperative complications (2.10 +/- 0.17 vs. 2.60 +/- 0.20; p = 0.05) were lower in the IMP/RE group. IMP/RE may be associated with fewer overall postoperative complications compared to TME. However, further studies on functional and long-term outcomes are needed. C1 [Hicks, Caitlin W.; Hodin, Richard A.; Savitt, Lieba; Bordeianou, Liliana] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Hicks, Caitlin W.] Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA. RP Bordeianou, L (reprint author), Massachusetts Gen Hosp, Dept Surg, 15 Parkman St,ACC 460, Boston, MA 02114 USA. EM lbordeianou@partners.org NR 28 TC 4 Z9 4 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X EI 1873-4626 J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD FEB PY 2014 VL 18 IS 2 BP 385 EP 390 DI 10.1007/s11605-013-2359-2 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA AA8XU UT WOS:000331379100043 PM 24146339 ER PT J AU Gilstrap, LG Niehaus, E Malhotra, R Ton, VK Watts, J Seldin, DC Madsen, JC Semigran, MJ AF Gilstrap, Lauren Gray Niehaus, Emily Malhotra, Rajeev Ton, Van-Khue Watts, James Seldin, David C. Madsen, Joren C. Semigran, Marc J. TI Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article DE light-chain cardiac amyloidosis; survival; orthotopic heart transplantation; body mass index; autologous stem cell transplant ID STEM-CELL TRANSPLANTATION; AL AMYLOIDOSIS; CARDIAC AMYLOIDOSIS; DISEASE; BORTEZOMIB; MELPHALAN; DEXAMETHASONE; COMBINATION; EXPERIENCE; FAILURE AB BACKGROUND: Orthotopic heart transplant (OHT), followed by myeloablative chemotherapy and autologous stem cell transplant (ASCT), has been successful in the treatment of amyloid light-chain (AL) cardiac amyloidosis. The purpose of this study was to identify predictors of survival to OHT in patients with end-stage heart failure due to AL amyloidosis and compare post-OHT survival of cardiac amyloid patients with survival of other cardiomyopathy patients undergoing OHT. METHODS: From January 2000 to June 2011, 31 patients with end-stage heart failure secondary to AL amyloidosis were listed for OHT at Massachusetts General Hospital. Univariate and multivariate regression analyses identified predictors of survival to OHT. Kaplan-Meier analysis compared survival between the Massachusetts General Hospital amyloidosis patients and non-amyloid cardiomyopathy patients from the Scientific Registry of Transplant Recipients (SRTR). RESULTS: Low body mass index was the only predictor of survival to OHT in patients with end-stage heart failure caused by cardiac amyloidosis. Survival of cardiac amyloid patients who died before receiving a donor heart was only 63 45 days after listing. Patients who survived to OHT received a donor organ at 53 48 days after listing. Survival of AL amyloidosis patients on the waiting list was less than patients on the waiting list for all other non-amyloid diagnoses. The Jong-term survival of amyloid patients who underwent OHT was no different than the survival of non-amyloid, restrictive (p = 0.34), non-amyloid dilated (p = 0.34), or all non-amyloid cardiomyopathy patients (p = 0.22) in the SRTR database. CONCLUSIONS: Amyloid patients who survive to OHT, followed by ASCT, have a survival rate similar to other cardiomyopathy patients undergoing OHT; however, 35% of the patients died awaiting OHT. The only predictor of survival to OHT in AL amyloidosis patients was a low body mass index, which correlated with a shorter time on the waiting list. To optimize the survival of these patients, access to donor organs must be improved. (C) 2014 International Society for Heart and Lung Transplantation. All rights reserved. C1 [Gilstrap, Lauren Gray; Niehaus, Emily; Malhotra, Rajeev; Semigran, Marc J.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA. [Ton, Van-Khue] Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21205 USA. [Watts, James] Brooke Army Med Ctr, Dept Med, Serv Cardiol, Ft Sam Houston, TX 78234 USA. [Seldin, David C.] Boston Univ, Med Ctr, Dept Med, Sect Hematol & Oncol,Ainyloidosis Ctr, Boston, MA USA. [Madsen, Joren C.] Massachusetts Gen Hosp, Div Cardiac Surg, Dept Surg, Boston, MA 02114 USA. RP Semigran, MJ (reprint author), Massachusetts Gen Hosp, Div Cardiol, Dept Med, Bigelow 800,55 Fruit St, Boston, MA 02114 USA. EM msemigran@partners.org OI Watts, James/0000-0003-1118-838X; Malhotra, Rajeev/0000-0003-0120-4630 FU American Heart Association [11FTF7290032] FX The authors acknowledge the efforts of Megan Borase, BA. R.M. received an American Heart Association Fellow to Faculty Award (#11FTF7290032). NR 33 TC 7 Z9 7 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 EI 1557-3117 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD FEB PY 2014 VL 33 IS 2 BP 149 EP 156 DI 10.1016/j.healun.2013.09.004 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA AA5SD UT WOS:000331159000007 ER PT J AU Hunt, D AF Hunt, Dan TI Returning Hospitalists to Their Formative Training Environment for CME: The UCSF Hospitalist Mini-College SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID CONTINUING MEDICAL-EDUCATION; HEALTH; CARE C1 [Hunt, Dan] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Hunt, Dan] Massachusetts Gen Hosp, Hosp Med Unit, Dept Med, Boston, MA 02114 USA. RP Hunt, D (reprint author), Massachusetts Gen Hosp, Inpatient Clinician Educ Serv, Dept Med, 50 Staniford St,Suite 503B, Boston, MA 02114 USA. EM dphunt@partners.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD FEB PY 2014 VL 9 IS 2 BP 135 EP 135 DI 10.1002/jhm.2140 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AA7EW UT WOS:000331261100012 PM 24382786 ER PT J AU Brown, SD Donelan, K Martins, Y Sayeed, SA Mitchell, C Buchmiller, TL Burmeister, K Ecker, JL AF Brown, Stephen D. Donelan, Karen Martins, Yolanda Sayeed, Sadath A. Mitchell, Christine Buchmiller, Terry L. Burmeister, Kelly Ecker, Jeffrey L. TI Does professional orientation predict ethical sensitivities? Attitudes of paediatric and obstetric specialists toward fetuses, pregnant women and pregnancy termination SO JOURNAL OF MEDICAL ETHICS LA English DT Article DE Demographic Surveys; Attitudes; Obstetrics and Gynaecology; Paediatrics; Embryos and Fetuses; Moral and Religious Aspects ID FETAL CARE; ABORTION PROVISION; GYNECOLOGISTS; RELIGION; DISABILITIES; WILLINGNESS; ABNORMALITY; CONSCIENCE; MANAGEMENT; MEDICINE AB Background To determine (1) whether fetal care paediatric (FCP) and maternal-fetal medicine (MFM) specialists harbour differing attitudes about pregnancy termination for congenital fetal conditions, their perceived responsibilities to pregnant women and fetuses, and the fetus as a patient and (2) whether self-perceived primary responsibilities to fetuses and women and views about the fetus as a patient are associated with attitudes about clinical care. Methods Mail survey of 434 MFM and FCP specialists (response rates 60.9% and 54.2%, respectively). Results MFMs were more likely than FCPs to disagree with these statements (all p values<0.005): (1) the presence of a fetal abnormality is not an appropriate reason for a couple to consider pregnancy termination' (MFM:FCP78.4% vs 63.5%); (2) the effects that a child born with disabilities might have on marital and family relationships is not an appropriate reason for a couple to consider pregnancy termination' (MFM:FCP80.5% vs 70.2%); and (3) the cost of healthcare for the future child is not an appropriate reason for a couple to consider pregnancy termination' (MFM:FCP73.5% vs 55.9%). 65% MFMs versus 47% FCPs disagreed that their professional responsibility is to focus primarily on fetal well-being (p<0.01). Specialists did not differ regarding the fetus as a separate patient. Responses about self-perceived responsibility to focus on fetal well-being were associated with clinical practice attitudes. Conclusions Independent of demographic and sociopolitical characteristics, FCPs and MFMs possess divergent ethical sensitivities regarding pregnancy termination, pregnant women and fetuses, which may influence clinical care. C1 [Brown, Stephen D.] Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA. [Brown, Stephen D.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Donelan, Karen] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Martins, Yolanda; Burmeister, Kelly] Boston Childrens Hosp, Clin Res Ctr, Boston, MA 02115 USA. [Sayeed, Sadath A.] Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA. [Sayeed, Sadath A.; Mitchell, Christine] Harvard Univ, Sch Med, Div Med Eth, Boston, MA 02115 USA. [Mitchell, Christine] Boston Childrens Hosp, Off Eth, Boston, MA 02115 USA. [Buchmiller, Terry L.] Boston Childrens Hosp, Adv Fetal Care Ctr, Dept Surg, Boston, MA 02115 USA. [Ecker, Jeffrey L.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Maternal Fetal Med Div, Boston, MA 02114 USA. RP Brown, SD (reprint author), Boston Childrens Hosp, Dept Radiol, 300 Longwood Ave, Boston, MA 02115 USA. EM stephen.brown@childrens.harvard.edu OI Martins, Yolanda/0000-0002-3983-3531 FU Greenwall Foundation; Kornfeld Program in Bioethics and Patient Care; Harvard University Milton Fund; American Roentgen Ray Society Leonard Berlin Scholarship in Medical Professionalism; Faculty Development Award, Office of Faculty Development, Boston Children's Hospital FX (1) Greenwall Foundation; (2) Kornfeld Program in Bioethics and Patient Care; (3) Harvard University Milton Fund; (4) American Roentgen Ray Society Leonard Berlin Scholarship in Medical Professionalism; (5) Faculty Development Award, Office of Faculty Development, Boston Children's Hospital. NR 31 TC 4 Z9 4 U1 4 U2 10 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-6800 EI 1473-4257 J9 J MED ETHICS JI J. Med. Ethics PD FEB PY 2014 VL 40 IS 2 BP 117 EP 122 DI 10.1136/medethics-2012-101126 PG 6 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA AA5ZA UT WOS:000331177200014 PM 23572566 ER PT J AU Hickox, AE Liberman, MC AF Hickox, Ann E. Liberman, M. Charles TI Is noise-induced cochlear neuropathy key to the generation of hyperacusis or tinnitus? SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE acoustic startle response; prepulse inhibition; auditory brainstem response; noise-induced hearing loss; acoustic trauma ID INDUCED HEARING-LOSS; ACOUSTIC STARTLE REFLEX; AUDITORY-NERVE FIBERS; SPONTANEOUS NEURAL ACTIVITY; INTENSE SOUND EXPOSURE; PREPULSE INHIBITION; STEREOCILIA DAMAGE; INFERIOR COLLICULUS; BEHAVIORAL EVIDENCE; DETECTION DEFICITS AB Perceptual abnormalities such as hyperacusis and tinnitus often occur after acoustic overexposure. Although such exposure can also result in permanent threshold elevation, some individuals with noise-induced hyperacusis or tinnitus show clinically normal thresholds. Recent work in animals has shown that a "neuropathic" noise exposure can cause immediate, permanent degeneration of the cochlear nerve despite complete threshold recovery and lack of hair cell damage (Kujawa SG, Liberman MC. J Neurosci 29: 14077-14085, 2009; Lin HW, Furman AC, Kujawa SG, Liberman MC. J Assoc Res Otolaryngol 12: 605-616, 2011). Here we ask whether this noise-induced primary neuronal degeneration results in abnormal auditory behavior, based on the acoustic startle response (ASR) and prepulse inhibition (PPI) of startle. Responses were measured in mice exposed either to a "neuropathic" noise or to a lower-intensity, "nonneuropathic" noise and in unexposed control mice. Mice with cochlear neuropathy displayed hyperresponsivity to sound, evidenced by enhanced ASR and PPI, while exposed mice without neuronal loss showed control-like responses. Gap PPI tests, often used to assess tinnitus, revealed limited gap detection deficits in mice with cochlear neuropathy only for certain gap-startle latencies, inconsistent with the presence of tinnitus " filling in the gap." Despite significantly reduced wave 1 of the auditory brainstem response, representing cochlear nerve activity, later peaks were unchanged or enhanced, suggesting compensatory neural hyperactivity in the auditory brainstem. Considering the rapid postexposure onset of both cochlear neuropathy and exaggerated startle-based behavior, the results suggest a role for cochlear primary neuronal degeneration, per se, in the central neural excitability that could underlie the generation of hyperacusis. C1 [Hickox, Ann E.; Liberman, M. Charles] MIT, Harvard Mit Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA 02139 USA. [Hickox, Ann E.; Liberman, M. Charles] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Liberman, M. Charles] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Hickox, AE (reprint author), Purdue Univ, Dept Speech Language & Hearing Sci, W Lafayette, IN 47907 USA. EM aehickox@alum.mit.edu OI Hickox, Ann E./0000-0003-1033-9887 FU National Institute on Deafness and Other Communication Disorders [T32 DC-00038, R01 DC-00188, P30 DC-05029]; Amelia Peabody Charitable Fund FX This work was supported by National Institute on Deafness and Other Communication Disorders Grants T32 DC-00038 (A. E. Hickox), R01 DC-00188 (M. C. Liberman), and P30 DC-05029 (M. C. Liberman) and the Amelia Peabody Charitable Fund (A. E. Hickox). NR 72 TC 65 Z9 65 U1 8 U2 40 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD FEB PY 2014 VL 111 IS 3 BP 552 EP 564 DI 10.1152/jn.00184.2013 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA AA6NR UT WOS:000331215500010 PM 24198321 ER PT J AU Bernacki, R Bharija, A Gupta, M Muyot, AJ Ross, J Shah, R Talebreza, S Tatum, P Widera, E AF Bernacki, Rachelle Bharija, Ankur Gupta, Mona Muyot, Aurelio J. Ross, Jeanette Shah, Ruchir Talebreza, Shaida Tatum, Paul Widera, Eric TI Care of Older Adults with Multimorbidity: Geriatric Training for Hospice and Palliative Medicine Providers SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bharija, Ankur] Boston Univ, Sch Med, Boston, MA 02118 USA. [Gupta, Mona] Cleveland Clin, Cleveland, OH 44106 USA. [Muyot, Aurelio J.] Infin Hosp Care, Las Vegas, NV USA. [Ross, Jeanette] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shah, Ruchir] Richmond VA Med Ctr, Richmond, VA USA. [Talebreza, Shaida] Univ Utah, Sch Med, Salt Lake City, UT USA. [Tatum, Paul] Univ Missouri, Columbia, MO USA. [Widera, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 378 EP 378 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000032 ER PT J AU Abrahm, J Rosenblatt, L Vincent, A Cassell, E AF Abrahm, Janet Rosenblatt, Laurie Vincent, Adrianne Cassell, Eric TI Pain, Suffering, and Healing SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Abrahm, Janet] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abrahm, Janet] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rosenblatt, Laurie] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Vincent, Adrianne] Harvard Univ, Sch Divin, Cambridge, MA 02138 USA. [Cassell, Eric] Cornell Univ, Weill Med Coll, Delaware, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 384 EP 385 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000043 ER PT J AU Jackson, V Chittenden, E Jacobsen, J Mehta, D AF Jackson, Vicki Chittenden, Eva Jacobsen, Juliet Mehta, Darshan TI Building a Sustainable Practice-Resiliency Training for You and Your Team SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Jackson, Vicki; Chittenden, Eva; Jacobsen, Juliet; Mehta, Darshan] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 384 EP 384 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000042 ER PT J AU Ullrich, C Chen, K Wolfe, J Dussel, V Orellana, L Geyer, R Kang, T Feudtner, C AF Ullrich, Christina Chen, Kun Wolfe, Joanne Dussel, Veronica Orellana, Liliana Geyer, Russ Kang, Tammy Feudtner, Chris TI Self-Reported Fatigue in Children with Advanced Cancer: Results of the PediQUEST Study SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ullrich, Christina; Chen, Kun; Wolfe, Joanne; Dussel, Veronica] Dana Farber Canc Inst, Boston, MA 02115 USA. [Orellana, Liliana] Univ Buenos Aires, Inst Calculus, Sch Sci, Buenos Aires, DF, Argentina. [Geyer, Russ] Seattle Childrens Hosp, Seattle, WA USA. [Kang, Tammy; Feudtner, Chris] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RI Orellana, Liliana/I-5249-2013; Orellana, Liliana/S-3302-2016 OI Orellana, Liliana/0000-0003-3736-4337; Orellana, Liliana/0000-0003-3736-4337 NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 391 EP 391 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000054 ER PT J AU Moghanaki, D Cheuk, A Fosmire, H Dawson, G Anscher, M Lutz, S AF Moghanaki, Drew Cheuk, Alice Fosmire, Helen Dawson, George Anscher, Mitchell Lutz, Stephen TI Availability of Single Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Life Care Within the Veterans Healthcare Administration SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Moghanaki, Drew] Virginia Commonwealth Univ, Richmond, VA USA. [Cheuk, Alice] James J Peters VA Med Ctr, Bronx, NY USA. [Fosmire, Helen] Roudebush VA Hosp, Zionsville, IN USA. [Dawson, George] VA Med Ctr, Bronx, NY USA. [Anscher, Mitchell] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. [Lutz, Stephen] Blanchard Valley Hlth Syst, Findlay, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 393 EP 394 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000057 ER PT J AU Goulding, J Jahner, J Wright, A AF Goulding, Jonna Jahner, Jan Wright, Alexi TI How We Grieve: Practitioners Encountering Personal Loss SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Goulding, Jonna] Gifford Med Ctr, Randolph, VT USA. [Jahner, Jan] Christus St Vincent Hosp, Santa Fe, NM USA. [Wright, Alexi] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 395 EP 396 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000060 ER PT J AU Gross, D Ramchandran, K Schaefer, K Buss, M AF Gross, Dawn Ramchandran, Kavitha Schaefer, Kristen Buss, Mary TI Getting Back to the Basics: Primary Palliative Care for Nonhospiceand Palliative Medicine Subspecialists SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Gross, Dawn] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ramchandran, Kavitha] Stanford Univ, Stanford, CA 94305 USA. [Schaefer, Kristen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Buss, Mary] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 398 EP 399 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000065 ER PT J AU Healy, J Lee, SK Ross, J Sanchez-Reilly, S Chappell, P Villarreal, D AF Healy, Jennifer Lee, Shuko Ross, Jeanette Sanchez-Reilly, Sandra Chappell, Phylliss Villarreal, Deborah TI The Double Parallel Curriculum in Palliative Care(DP-PC): Using a Double Parallel Education Strategy with Multimedia to Enhance Learners Knowledge and Skills in End of Life Palliative Care (EOL-PC) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Healy, Jennifer; Ross, Jeanette; Sanchez-Reilly, Sandra; Chappell, Phylliss; Villarreal, Deborah] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ross, Jeanette; Sanchez-Reilly, Sandra] South Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 403 EP 403 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000071 ER PT J AU Lustbader, D Block, S Stuart, B Deremo, D AF Lustbader, Dana Block, Susan Stuart, Brad Deremo, Dottie TI Innovative Health System Models Of High Value Palliative Care Delivery SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Lustbader, Dana] North Shore LIJ Hlth Syst, Manhasset, NY USA. [Block, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Block, Susan] Brigham & Womens Hosp, Boston, MA 02115 USA. [Stuart, Brad] Sutter VNA & Hosp, Emeryville, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 404 EP 405 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000073 ER PT J AU Rotella, J Smith, TJ Widera, E AF Rotella, Joseph Smith, Thomas J. Widera, Eric TI Leading the Way to Wiser Choices: Communicating with Your Team, Institution, and Community About AAHPM's List of "Five Things Physicians and Patients Should Question in HPM" SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Rotella, Joseph] Hosparus, Louisville, KY USA. [Rotella, Joseph] Univ Louisville, Louisville, KY 40292 USA. [Smith, Thomas J.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Smith, Thomas J.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Widera, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Widera, Eric] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 408 EP 409 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000080 ER PT J AU Lakin, J Sullivan, E Isaacs, E Harris, H Sudore, R AF Lakin, Joshua Sullivan, Erin Isaacs, Eric Harris, Heather Sudore, Rebecca TI I Can't Find It or Use It: Exploring Emergency Department Physicians' Experiences with Advance Care Planning Documentation in the Electronic Medical Record SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Lakin, Joshua] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sullivan, Erin; Isaacs, Eric; Harris, Heather; Sudore, Rebecca] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sudore, Rebecca] VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 409 EP 409 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000081 ER PT J AU Sanderson, A Wolfe, J AF Sanderson, Amy Wolfe, Joanne TI Advance Care Discussions: Clinician Preparedness and Practices SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Sanderson, Amy; Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 409 EP 410 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000082 ER PT J AU Ahluwalia, S Ettner, S Pantoja, P Lorenz, K Tisnado, D Walling, A AF Ahluwalia, Sangeeta Ettner, Susan Pantoja, Philip Lorenz, Karl Tisnado, Diana Walling, Anne TI Early Care Planning Discussions Are Associated with Less Hospital Care at the End of Life in Veterans with Advanced Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ahluwalia, Sangeeta; Tisnado, Diana; Walling, Anne] Univ Calif Los Angeles, Los Angeles, CA USA. [Ettner, Susan] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Pantoja, Philip] Dept Vet Affairs, North Hills, CA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 410 EP 411 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000083 ER PT J AU Singer, A Lynn, J Teno, J Lunney, J Meeker, D Lorenz, K AF Singer, Adam Lynn, Joanne Teno, Joan Lunney, June Meeker, Daniella Lorenz, Karl TI Going Less Gently into That Good Night? Symptom Trends in the Last Year of Life, 1998-2010 SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Singer, Adam; Meeker, Daniella] RAND Corp, Santa Monica, CA USA. [Lynn, Joanne] Altarum Inst, Chevy Chase, MD USA. [Teno, Joan] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA. [Lunney, June] Hosp & Palliat Nurses Assoc, Kennett Sq, PA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 411 EP 412 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000084 ER PT J AU Jones, J Worley, M Bianco, A Mendlik, M Yeh, I AF Jones, Joshua Worley, Michael Bianco, Anthony Mendlik, Matt Yeh, Irene TI "Answering with the Eyes": Challenges in Communication About the End of Life in Patients with Locked-In Syndrome SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Jones, Joshua] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Worley, Michael; Bianco, Anthony] Brigham & Womens Hosp, Boston, MA 02115 USA. [Mendlik, Matt; Yeh, Irene] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 416 EP 416 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000092 ER PT J AU Schaefer, K Desai, A AF Schaefer, Kristen Desai, Akshay TI Part of the Solution-Outpatient Palliative Care for Patients with Decompensated Heart Failure SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Schaefer, Kristen] Dana Farber Canc Ctr, Boston, MA 02115 USA. [Desai, Akshay] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 416 EP 417 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000093 ER PT J AU Ahluwalia, S Prendergast, T Lorenz, K Schreibeis-Baum, H AF Ahluwalia, Sangeeta Prendergast, Thomas Lorenz, Karl Schreibeis-Baum, Hannah TI Nursing Roles, Experiences and Perspectives on Family Meetings: "We're the Most Consistent Person with Our Patients" SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ahluwalia, Sangeeta] Univ Calif Los Angeles, Los Angeles, CA USA. [Prendergast, Thomas] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Schreibeis-Baum, Hannah] Vet Adm, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 420 EP 421 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000099 ER PT J AU Bernacki, R Block, S AF Bernacki, Rachelle Block, Susan TI The Serious Illness Communication Checklist SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [Block, Susan] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 420 EP 420 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000098 ER PT J AU Cooper, Z Aslakson, R Fahy, B Rickerson, E Dunn, G AF Cooper, Zara Aslakson, Rebecca Fahy, Bridget Rickerson, Elizabeth Dunn, Geoffrey TI Challenges and Opportunities: Improving the Perioperative Experience for Patients Receiving Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Cooper, Zara] Brigham & Womens Hosp, Boston, MA 02115 USA. [Aslakson, Rebecca] Johns Hopkins Sch Med, Baltimore, MD USA. [Fahy, Bridget] Univ New Mexico, Albuquerque, NM 87131 USA. [Rickerson, Elizabeth] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dunn, Geoffrey] Hamot Med Ctr, Erie, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 424 EP 424 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000104 ER PT J AU Cooke, K Franklin, J Painter, J Weinstein, S Rodgers, J AF Cooke, Kelly Franklin, John Painter, John Weinstein, Sharon Rodgers, James TI Effects of Combat and Military Training on End of Life Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Cooke, Kelly] ProHlth Care, Waukesha, WI USA. [Franklin, John; Painter, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Weinstein, Sharon] Univ Utah, Salt Lake City, UT USA. [Rodgers, James] Vet Affairs Healthcare, Temple, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 431 EP 431 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000114 ER PT J AU Binney, Z Garrido, M Quest, T AF Binney, Zachary Garrido, Melissa Quest, Tammie TI Impact of Inpatient Palliative Care Consultation on 30-day Hospital Readmissions and Near Misses SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Binney, Zachary; Quest, Tammie] Emory Univ, Atlanta, GA 30322 USA. [Garrido, Melissa] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 438 EP 439 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000126 ER PT J AU Schaefer, K AF Schaefer, Kristen TI Discussing Prognosis and Recommending Hospice: A Resident Observed Structured Clinical Examination (OSCE) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Schaefer, Kristen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schaefer, Kristen] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 441 EP 442 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000131 ER PT J AU Garcia, J Davila, NF Cruz-Oliver, D Parikh, M Sanchez-Reilly, S Ortiz, JR AF Garcia, Jessica Davila, Natalia Fernandez Cruz-Oliver, Dulce Parikh, Manas Sanchez-Reilly, Sandra Ortiz, Jesus Roberto TI Caregivers Like Me: Cuidadores Como Yo SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Davila, Natalia Fernandez] Univ Puerto Rico, Jayuya, PR USA. [Cruz-Oliver, Dulce] St Louis Univ, Sch Med, St Louis, MO USA. [Parikh, Manas] St Louis Univ, St Louis, MO 63103 USA. [Sanchez-Reilly, Sandra; Ortiz, Jesus Roberto] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ortiz, Jesus Roberto] VA Hosp Audie Murphie, Brownsville, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 450 EP 451 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000144 ER PT J AU Rosenberg, A Wolfe, J Syrjala, K Yi-Frazier, J Curtis, JR Baker, S AF Rosenberg, Abby Wolfe, Joanne Syrjala, Karen Yi-Frazier, Joyce Curtis, J. Randall Baker, Scott TI The Impact of Personal Resilience Resources on Psychosocial Outcomes in Parents of Children with Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Rosenberg, Abby] Seattle Childrens Hosp, Seattle, WA USA. [Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. [Syrjala, Karen; Baker, Scott] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Yi-Frazier, Joyce; Curtis, J. Randall] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 1 Z9 1 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 451 EP 452 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000146 ER PT J AU Schreibeis-Baum, H Lynn, J Xenakis, L Lorenz, K Brown, G AF Schreibeis-Baum, Hannah Lynn, Joanne Xenakis, Lea Lorenz, Karl Brown, Gina TI Systematic Review of Recent Federal and State Policy in Palliative and End-of-Life Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Schreibeis-Baum, Hannah] Vet Adm, Santa Monica, CA USA. [Lynn, Joanne] Altarum Inst, Chevy Chase, MD USA. [Xenakis, Lea] Samueli Inst, New York, NY USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Brown, Gina] VA Greater Los Angeles Hlth Care Syst, Claremont, CA USA. OI Schreibeis-Baum, Hannah/0000-0001-7798-9804 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 453 EP 454 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000149 ER PT J AU Shaw, T Ajayi, T Barrett, T Lotstein, D AF Shaw, Tressia Ajayi, Toluwalase Barrett, Todd Lotstein, Debra TI Teaming Up for Transition-Palliative Care for Adults with Childhood Conditions SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Shaw, Tressia] Phoenix Childrens Hosp, Phoenix, AZ USA. [Ajayi, Toluwalase] Scripps Hlth San Diego, Inst Palliat Med, San Diego, CA USA. [Barrett, Todd] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lotstein, Debra] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 455 EP 455 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000151 ER PT J AU Chappell, P Lee, S Ross, J Healy, J Sanchez-Reilly, S AF Chappell, Phylliss Lee, Shuko Ross, Jeanette Healy, Jennifer Sanchez-Reilly, Sandra TI Communicating with Dying Patients and Their Families: Multimedia Training in End-of-Life Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Chappell, Phylliss; Ross, Jeanette; Healy, Jennifer; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko; Ross, Jeanette; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 460 EP 461 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000160 ER PT J AU Ananth, P Melvin, P Wolfe, J Berry, JG AF Ananth, Prasanna Melvin, Patrice Wolfe, Joanne Berry, Jay G. TI Trends in Hospital Utilization Among Children Receiving Inpatient Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ananth, Prasanna; Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. [Melvin, Patrice; Berry, Jay G.] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 467 EP 467 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000168 ER PT J AU Kvale, E Lisovicz, N Rocque, G Mona, F Taylor, R Martin, M AF Kvale, Elizabeth Lisovicz, Nedra Rocque, Gabrielle Mona, Fouad Taylor, Richard Martin, Michelle TI Extending Palliative Care Principles to Impact Public Health: Evaluation of a Training Program for Community Health Advisors (Lay Navigators) in Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Kvale, Elizabeth; Lisovicz, Nedra; Rocque, Gabrielle; Mona, Fouad; Taylor, Richard; Martin, Michelle] Univ Alabama Birmingham, Birmingham, AL USA. [Kvale, Elizabeth] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 489 EP 489 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000202 ER PT J AU Lendon, J Meeker, D Lorenz, K Lynne, J AF Lendon, Jessica Meeker, Daniella Lorenz, Karl Lynne, Joanne TI Trends in Caregiving Near End of Life, 2000-2008 SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Lendon, Jessica; Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Meeker, Daniella] RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 490 EP 491 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000205 ER PT J AU Meeker, D Lynn, J Leaf, D Lorenz, K AF Meeker, Daniella Lynn, Joanne Leaf, Duncan Lorenz, Karl TI Disability, Recovery, and Expenditures Among the Frail Elderly in the United States: Characteristics of an Objectively Defined Population SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Meeker, Daniella] RAND Corp, Santa Monica, CA USA. [Lynn, Joanne] Altarum Inst, Chevy Chase, MD USA. [Leaf, Duncan] Univ So Calif, Los Angeles, CA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 492 EP 493 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000208 ER PT J AU Mirmiran, A Lee, S Healy, J Sanchez-Reilly, S Mishaw, S Aziz, W AF Mirmiran, Ahmadreza Lee, Shuko Healy, Jennifer Sanchez-Reilly, Sandra Mishaw, Stephanie Aziz, Wesam TI Tertiary Hospital Cost Analysis for Palliative Care Consultation Service (T-HOPE) Study SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Lee, Shuko; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Healy, Jennifer; Sanchez-Reilly, Sandra; Aziz, Wesam] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Mishaw, Stephanie] Univ Texas Hlth Sci Ctr San Antonio, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 493 EP 494 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000209 ER PT J AU Nelson, K Mahant, S Sander, B Muir, J AF Nelson, Katherine Mahant, Sanjay Sander, Beate Muir, Jennifer TI The Role of Anti-Reflux Surgery in Tube-Feeding for Children with Severe Neurologic Impairment: A Cost-Effectiveness Analysis SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Nelson, Katherine] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mahant, Sanjay] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Sander, Beate] Publ Hlth Ontario, Toronto, ON, Canada. [Muir, Jennifer] Univ Toronto, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 494 EP 494 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000210 ER PT J AU O'Riordan, D Lindenauer, P Ferrell, B Pantilat, S Burke, R Lorenz, K AF O'Riordan, David Lindenauer, Peter Ferrell, Betty Pantilat, Steven Burke, Rebecca Lorenz, Karl TI Palliative Care Quality Network: Identifying Core Data to Drive Quality Improvement SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [O'Riordan, David] Div Hosp Med, San Francisco, CA USA. [Lindenauer, Peter] Baystate Med Ctr, Springfield, MA USA. [Ferrell, Betty] City Hope Natl Med Ctr, Duarte, CA USA. [Pantilat, Steven] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA. [Burke, Rebecca] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 496 EP 497 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000214 ER PT J AU Schreibeis-Baum, H Cary, M Casarett, D Streim, J Lorenz, K AF Schreibeis-Baum, Hannah Cary, Mark Casarett, David Streim, Joel Lorenz, Karl TI Identifying Preferences for Palliative Home Care Services Among Veterans with HF and COPD and Their Caregivers: An Adaptive Conjoint Analysis SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Schreibeis-Baum, Hannah] Vet Adm, Santa Monica, CA USA. [Cary, Mark] Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA. [Casarett, David; Streim, Joel] Univ Penn, Philadelphia, PA 19104 USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. OI Schreibeis-Baum, Hannah/0000-0001-7798-9804 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 502 EP 503 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000223 ER PT J AU Smith, G Schaefer, K AF Smith, Grant Schaefer, Kristen TI Missed Opportunities in Training Third Year Medical Students to Care for Seriously Ill Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Schaefer, Kristen] Dana Farber Canc Inst, Brookline, MA USA. [Schaefer, Kristen] Harvard Univ, Sch Med, Brookline, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 503 EP 503 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000224 ER PT J AU Wachterman, M Keating, N Lorenz, K Simon, S Lipsitz, S AF Wachterman, Melissa Keating, Nancy Lorenz, Karl Simon, Steven Lipsitz, Stuart TI Patterns of Hospice Care Among Military Veterans and Non-Veterans SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Keating, Nancy] Harvard Univ, Sch Med, Boston, MA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Simon, Steven] VA Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 506 EP 507 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000230 ER PT J AU Wiesenthal, A Ross, J Cai, K Sanchez-Reilly, S Lin, L AF Wiesenthal, Alison Ross, Jeanette Cai, Kerrington, Jr. Sanchez-Reilly, Sandra Lin, Lin TI When Cancer Blogging Helps with Healing More than One SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ross, Jeanette; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ross, Jeanette; Sanchez-Reilly, Sandra; Lin, Lin] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Cai, Kerrington, Jr.] VA Hosp, High Sch, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 511 EP 512 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000237 ER PT J AU Bekelman, DB Hooker, S Nowels, CT Main, DS Meek, P McBryde, C Hattler, B Lorenz, KA Heidenreich, PA AF Bekelman, David B. Hooker, Stephanie Nowels, Carolyn T. Main, Deborah S. Meek, Paula McBryde, Connor Hattler, Brack Lorenz, Karl A. Heidenreich, Paul A. TI Feasibility and Acceptability of a Collaborative Care Intervention To Improve Symptoms and Quality of Life in Chronic Heart Failure: Mixed Methods Pilot Trial SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PALLIATIVE CARE; DISEASE MANAGEMENT; ASSESSMENT SYSTEM; CHRONIC ILLNESS; DEPRESSION; OUTCOMES; POPULATION; IMPAIRMENT; THERAPY AB Background: People with chronic heart failure (HF) suffer from numerous symptoms that worsen quality of life. The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention was designed to improve symptoms and quality of life by integrating palliative and psychosocial care into chronic care. Objective: Our aim was to determine the feasibility and acceptability of CASA and identify necessary improvements. Methods: We conducted a prospective mixed-methods pilot trial. The CASA intervention included (1) nurse phone visits involving structured symptom assessments and guidelines to alleviate breathlessness, fatigue, pain, or depression; (2) structured phone counseling targeting adjustment to illness and depression if present; and (3) weekly team meetings with a palliative care specialist, cardiologist, and primary care physician focused on medical recommendations to primary care providers (PCPs, physician or nurse practioners) to improve symptoms. Study subjects were outpatients with chronic HF from a Veteran's Affairs hospital (n=15) and a university hospital (n=2). Measurements included feasibility (cohort retention rate, medical recommendation implementation rate, missing data, quality of care) and acceptability (an end-of-study semi-structured participant interview). Results: Participants were male with a median age of 63 years. One withdrew early and there were <5% missing data. Overall, 85% of 87 collaborative care team medical recommendations were implemented. All participants who screened positive for depression were either treated for depression or thought to not have a depressive disorder. In the qualitative interviews, patients reported a positive experience and provided several constructive critiques. Conclusions: The CASA intervention was feasible based on participant enrollment, cohort retention, implementation of medical recommendations, minimal missing data, and acceptability. Several intervention changes were made based on participant feedback. C1 [Bekelman, David B.; McBryde, Connor; Hattler, Brack] Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Denver, CO USA. [Bekelman, David B.; Nowels, Carolyn T.; McBryde, Connor; Hattler, Brack] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Meek, Paula] Univ Colorado, Sch Med, Coll Nursing, Aurora, CO USA. [Hooker, Stephanie] Univ Colorado, Dept Psychol, Denver, CO 80202 USA. [Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80202 USA. [Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Heidenreich, Paul A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Bekelman, DB (reprint author), VA Eastern Colorado Hlth Care Syst, 1055 Clermont Ave Res 151, Denver, CO 80220 USA. EM david.bekelman@va.gov OI Heidenreich, Paul/0000-0001-7730-8490; Hooker, Stephanie/0000-0003-4222-7046 FU Department of Veterans Affairs [RRP 11-239, CDA 08-022] FX No competing financial interests exist. This study was funded by the Department of Veterans Affairs, RRP 11-239. Dr. Bekelman is also funded by the Department of Veterans Affairs, CDA 08-022. NR 38 TC 9 Z9 9 U1 4 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB 1 PY 2014 VL 17 IS 2 BP 145 EP 151 DI 10.1089/jpm.2013.0143 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AA6TG UT WOS:000331230400008 PM 24329424 ER PT J AU Bays, AM Engelberg, RA Back, AL Ford, DW Downey, L Shannon, SE Doorenbos, AZ Edlund, B Christianson, P Arnold, RW O'Connor, K Kross, EK Reinke, LF Feemster, LC Fryer-Edwards, K Alexander, SC Tulsky, JA Curtis, JR AF Bays, Alison M. Engelberg, Ruth A. Back, Anthony L. Ford, Dee W. Downey, Lois Shannon, Sarah E. Doorenbos, Ardith Z. Edlund, Barbara Christianson, Phyllis Arnold, Richard W. O'Connor, Kim Kross, Erin K. Reinke, Lynn F. Feemster, Laura Cecere Fryer-Edwards, Kelly Alexander, Stewart C. Tulsky, James A. Curtis, J. Randall TI Interprofessional Communication Skills Training for Serious Illness: Evaluation of a Small-Group, Simulated Patient Intervention SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; BREAKING BAD-NEWS; EARLY PALLIATIVE CARE; CELL LUNG-CANCER; STANDARDIZED PATIENTS; MEDICAL-STUDENTS; RANDOMIZED-TRIAL; ROLE-PLAY; END; EDUCATION AB Background: Communication with patients and families is an essential component of high-quality care in serious illness. Small-group skills training can result in new communication behaviors, but past studies have used facilitators with extensive experience, raising concerns this is not scalable. Objective: The objective was to investigate the effect of an experiential communication skills building workshop (Codetalk), led by newly trained facilitators, on internal medicine trainees' and nurse practitioner students' ability to communicate bad news and express empathy. Design: Trainees participated in Codetalk; skill improvement was evaluated through pre- and post- standardized patient (SP) encounters. Setting and subjects: The subjects were internal medicine residents and nurse practitioner students at two universities. Intervention and measurements: The study was carried out in anywhere from five to eight half-day sessions over a month. The first and last sessions included audiotaped trainee SP encounters coded for effective communication behaviors. The primary outcome was change in communication scores from pre-intervention to post-intervention. We also measured trainee characteristics to identify predictors of performance and change in performance over time. Results: We enrolled 145 trainees who completed pre- and post-intervention SP interviewswith participation rates of 52% for physicians and 14% for nurse practitioners. Trainees' scores improved in 8 of 11 coded behaviors (p<0.05). The only significant predictors of performance were having participated in the intervention (p<0.001) and study site (p<0.003). The only predictor of improvement in performance over time was participating in the intervention (p<0.001). Conclusions: A communication skills intervention using newly trained facilitators was associated with improvement in trainees' skills in giving bad news and expressing empathy. Improvement in communication skills did not vary by trainee characteristics. C1 [Bays, Alison M.; Arnold, Richard W.; O'Connor, Kim] Univ Washington, Sch Nursing, Dept Med, Seattle, WA 98104 USA. [Engelberg, Ruth A.; Downey, Lois; Kross, Erin K.; Feemster, Laura Cecere; Curtis, J. Randall] Univ Washington, Sch Nursing, Dept Med, Div Pulm & Crit Care, Seattle, WA 98104 USA. [Shannon, Sarah E.; Doorenbos, Ardith Z.; Christianson, Phyllis; Reinke, Lynn F.; Curtis, J. Randall] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98104 USA. [Fryer-Edwards, Kelly; Curtis, J. Randall] Univ Washington, Sch Med, Dept Bioeth & Humanities, Seattle, WA 98104 USA. [Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Div Med Oncol,Dept Med, Seattle, WA 98104 USA. [Ford, Dee W.] Med Univ S Carolina, Dept Med, Div Pulm & Crit Care, Charleston, SC 29425 USA. [Edlund, Barbara] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Reinke, Lynn F.; Feemster, Laura Cecere] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Alexander, Stewart C.; Tulsky, James A.] Duke Univ, Dept Med, Durham, NC USA. [Alexander, Stewart C.; Tulsky, James A.] Duke Univ, Duke Palliat Care, Durham, NC USA. RP Curtis, JR (reprint author), Univ Washington, Div Pulm & Crit Care Med, 325 Ninth Ave, Seattle, WA 98104 USA. EM jrc@uw.edu FU NHLBI NIH HHS [K23 HL098745, K23 HL111116] NR 35 TC 24 Z9 24 U1 3 U2 25 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB 1 PY 2014 VL 17 IS 2 BP 159 EP 166 DI 10.1089/jpm.2013.0318 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AA6TG UT WOS:000331230400010 PM 24180700 ER PT J AU Marcum, ZA Driessen, J Thorpe, CT Gellad, WF Donohue, JM AF Marcum, Zachary A. Driessen, Julia Thorpe, Carolyn T. Gellad, Walid F. Donohue, Julie M. TI Effect of Multiple Pharmacy Use on Medication Adherence and Drug-Drug Interactions in Older Adults with Medicare Part D SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pharmacy; medication adherence; drug interactions; Medicare ID PROPENSITY SCORE; ELDERLY-PATIENTS; DOSE-RESPONSE; PRESCRIPTION; MANAGEMENT; COMPLEXITY; THERAPY; ACCESS AB ObjectivesTo assess the association between multiple pharmacy use and medication adherence and potential drug-drug interactions (DDIs) in older adults. DesignCross-sectional propensity score-weighted analysis. Setting2009 claims data. ParticipantsA nationally representative sample of 926,956 Medicare Part D beneficiaries aged 65 and older continuously enrolled in fee-for-service Medicare and Part D that year who filled one or more prescriptions at a community retail or mail order pharmacy. MeasurementsMultiple pharmacy use was defined as concurrent (overlapping time periods) or sequential use (non-overlapping time periods) of 2 pharmacies in the year. Medication adherence was calculated using a proportion of days covered of 0.80 or greater for eight therapeutic categories (beta-blockers, renin angiotensin system antagonists, calcium channel blockers, statins, sulfonylureas, biguanides (metformin), thiazolidinediones, and dipeptidyl peptidase-IV inhibitors). Potential DDIs arising from use of certain drugs across a broad set of classes were defined as the concurrent filling of two interacting drugs. ResultsOverall, 38.1% of the sample used multiple pharmacies. Those using multiple pharmacies (concurrently or sequentially) consistently had higher adjusted odds of nonadherence (ranging from 1.10 to 1.31, P<.001) across all chronic medication classes assessed after controlling for sociodemographic, health status, and access to care factors than single pharmacy users. The adjusted predicted probability of exposure to a DDI was also slightly higher for those using multiple pharmacies concurrently (3.6%) than for single pharmacy users (3.2%, adjusted odds ratio (AOR)=1.11, 95% confidence interval (CI)=1.08-1.15) but lower in individuals using multiple pharmacies sequentially (2.8%, AOR=0.85, 95% CI=0.81-0.91). ConclusionsFilling prescriptions at multiple pharmacies was associated with lower medication adherence across multiple chronic medications and a small but statistically significant greater likelihood of DDIs in concurrent pharmacy users. C1 [Marcum, Zachary A.] Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Driessen, Julia; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Thorpe, Carolyn T.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Gen Internal Med, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA. RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med, Div Geriatr Med, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM zam12@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU National Institute on Aging [P30AG024827, K07AG033174, R01AG027017]; Agency for Healthcare Research and Quality [R01HS018721]; Veterans Affairs Health Services Research and Development Service Career Development Award [CDA 09-207] FX This research was funded by National Institute on Aging Grants P30AG024827, K07AG033174, and R01AG027017 and Agency for Healthcare Research and Quality Grant R01HS018721. Dr. Gellad was supported by Veterans Affairs Health Services Research and Development Service Career Development Award CDA 09-207. NR 29 TC 6 Z9 6 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 244 EP 252 DI 10.1111/jgs.12645 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100005 PM 24521363 ER PT J AU Pugh, JA Wang, CP Espinoza, SE Noel, PH Bollinger, M Amuan, M Finley, E Pugh, MJ AF Pugh, Jacqueline A. Wang, Chen-Pin Espinoza, Sara E. Noel, Polly H. Bollinger, Mary Amuan, Megan Finley, Erin Pugh, Mary Jo TI Influence of Frailty-Related Diagnoses, High-Risk Prescribing in Elderly Adults, and Primary Care Use on Readmissions in Fewer than 30 Days for Veterans Aged 65 and Older SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE early readmissions; high-risk prescribing in the elderly; frailty; primary care ID WOMENS-HEALTH; INAPPROPRIATE MEDICATIONS; HOSPITAL READMISSIONS; 30-DAY READMISSION; QUALITY; OUTCOMES; AFFAIRS; IMPACT; PREDICTION; EXPERIENCE AB ObjectivesTo determine the effect of two variables not previously studied in the readmissions literature (frailty-related diagnoses and high-risk medications in the elderly (HRME)) and one understudied variable (volume of primary care visits in the prior year). DesignRetrospective cohort study using data from a study designed to examine outcomes associated with inappropriate prescribing in elderly adults. SettingAll Veterans Affairs (VA) facilities with acute inpatient beds in fiscal year 2006 (FY06). ParticipantsAll veterans aged 65 and older by October 1, 2005, who received VA care at least once per year between October 1, 2004, and September 30, 2006, and were hospitalized at least once during FY06 on a medical or surgical unit. MeasurementsA generalized linear interactive risk prediction model included demographic and clinical characteristics (mental health and chronic medical conditions, frailty-related diagnoses, number of medications) in FY05; incident HRME in FY06 before index hospitalization or readmission; chronic HRME in FY05; and FY05 emergency department (ED), hospital, geriatric, palliative, or primary care use. Facility-level variables were complexity, rural versus urban, and FY06 admission rate. ResultsThe mean adjusted readmission rate was 18.3%. The new frailty-related diagnoses variable is a risk factor for readmission in addition to Charlson comorbidity score. Incident HRME use was associated with lower rates of readmission, as were higher numbers of primary care visits in the prior year. ConclusionFrailty-related diagnoses may help to target individuals at higher risk of readmission to receive more-intensive care transition services. HRME use does not help in this targeting. A higher number of face-to-face primary care visits in the prior year, unlike ED and hospital use, correlates with fewer readmissions and may be another avenue for targeting prevention strategies. C1 [Pugh, Jacqueline A.; Wang, Chen-Pin; Noel, Polly H.; Bollinger, Mary; Finley, Erin; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Pugh, Jacqueline A.; Espinoza, Sara E.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, San Antonio, TX 78229 USA. [Wang, Chen-Pin; Bollinger, Mary; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Espinoza, Sara E.; Noel, Polly H.; Finley, Erin] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Amuan, Megan] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. RP Pugh, JA (reprint author), STVHCS, VERDICT 11C-6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM pugh@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Pugh, Mary Jo/0000-0003-4196-7763; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR-06-062]; Veterans Evidence-based Research, Dissemination, and Implementation Center, Audie L. Murphy VA Hospital, San Antonio, Texas; Edith Nourse Rogers Memorial VA Medical Center; Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts FX This study was funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR-06-062; Mary Jo V. Pugh, PhD). Dr. Pugh is a Research Health Scientist at the Veterans Evidence-based Research, Dissemination, and Implementation Center, San Antonio, TX. We acknowledge the support of the Veterans Evidence-based Research, Dissemination, and Implementation Center, Audie L. Murphy VA Hospital, San Antonio, Texas, and the Edith Nourse Rogers Memorial VA Medical Center, the Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts. NR 52 TC 6 Z9 6 U1 5 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 291 EP 298 DI 10.1111/jgs.12656 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100011 PM 24521365 ER PT J AU Segelman, M Szydlowski, J Kinosian, B McNabney, M Raziano, DB Eng, C van Reenen, C Greener, HT AF Segelman, Micah Szydlowski, Jill Kinosian, Bruce McNabney, Matthew Raziano, Donna B. Eng, Catherine van Reenen, Christine Greener, Helena Temkin TI Hospitalizations in the Program of All-Inclusive Care for the Elderly SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE potentially avoidable hospitalizations; dual eligible beneficiaries; home- and community-based services; long-term services and supports; PACE ID LONG-TERM-CARE; MEDICARE; PACE; MODEL AB ObjectivesTo measure the rates of hospitalization, readmission, and potentially avoidable hospitalization (PAH) in the Program of All-Inclusive Care for the Elderly (PACE). DesignRetrospective study. SettingPACE. ParticipantsPACE enrollees. MeasurementsHospitalization and PAH rates were measured per 1,000 person-years. Readmission was defined as any return to the hospital within 30days of prior hospital discharge. PAHs were defined as hospitalizations for conditions that previously established criteria have identified as possibly preventable or manageable without hospitalization. ResultsRate of hospitalization was 539/1,000, vs 962/1,000 for dually eligible aged or disabled waiver (ADW) enrollees. Thirty-day readmission was 19.3%, compared with 22.9% for the national population of dually eligible older enrollees. PAH rate was 100/1,000, compared with 250/1,000 for dually eligible ADW enrollees. Considerable variation was observed between sites. ConclusionPACE enrollees experienced lower rates of hospitalization, readmission, and PAH than similar populations. Variations in hospitalization rates between PACE sites suggest opportunities for quality improvement. C1 [Segelman, Micah; Szydlowski, Jill; Greener, Helena Temkin] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY USA. [Kinosian, Bruce] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Kinosian, Bruce] Univ Penn, Sch Med, Div Geriatr, Philadelphia, PA 19104 USA. [Kinosian, Bruce] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [McNabney, Matthew] Johns Hopkins Univ, Sch Med, Hopkins ElderPlus, Baltimore, MD USA. [Raziano, Donna B.] Catholic Hlth East Trinity Inc, Mercy Hlth Syst, Mercy LIFE, Mercy Home & Community Based Serv, Philadelphia, PA USA. [Eng, Catherine] Lok Senior Hlth Serv, San Francisco, CA USA. [Eng, Catherine] Univ Calif San Francisco, Sch Med, Dept Med, Div Geriatr, San Francisco, CA USA. [van Reenen, Christine] Natl PACE Assoc, Alexandria, VA USA. RP Segelman, M (reprint author), Dept Publ Hlth Sci, 265 Crittenden Blvd,CU 420644, Rochester, NY 14642 USA. EM micah_segelman@urmc.rochester.edu FU National PACE Association FX Support provided by the National PACE Association. NR 23 TC 5 Z9 5 U1 5 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 320 EP 324 DI 10.1111/jgs.12637 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100015 PM 24417503 ER PT J AU Maust, DT Oslin, DW Marcus, SC AF Maust, Donovan T. Oslin, David W. Marcus, Steven C. TI Effect of Age on the Profile of Psychotropic Users: Results from the 2010 National Ambulatory Medical Care Survey SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pharmacoepidemiology; psychotropic prescribing; National Ambulatory Medical Care Survey ID OLDER-ADULTS; MENTAL-ILLNESS; NURSING-HOMES; UNITED-STATES; HEALTH-CARE; TRENDS; RISK; ANTIPSYCHOTICS; ANTIDEPRESSANTS; POLYPHARMACY AB ObjectivesTo describe the effect of age on psychotropic coprescribing, psychiatric diagnoses, and other clinical characteristics. DesignAnalysis of the National Ambulatory Medical Care Survey. SettingA national sample of outpatient visits to physicians (N=2,406) in office-based practice in 2010. ParticipantsAdults prescribed psychotropic medication (N=31,229). MeasurementsOffice visits at which antidepressant, anxiolytic, sedative, hypnotic, antipsychotic, or mood stabilizer medications were prescribed were grouped according to participant age (21-64, 65) and then compared within each medication class on visit characteristics. and then compared according to variables including provider type, sex, and race; presence of diagnosed mental illness; prescription of other psychotropic agents; total number of chronic conditions; time spent with physician; and total number of medications. ResultsIn 2010, there were 90.3million antidepressant office visits; 77.7million anxiolytic/sedative/hypnotic visits; 15.5million antipsychotic visits; and 9.5million mood stabilizer visits. Nonpsychiatrists prescribed the majority of psychotropic medications for every class and age group; 17.3% of older adult antipsychotic visits and 44.9% of younger adult antipsychotic visits were to a psychiatrist (chi-square=19.58, P=.001). Older adults in every medication class were less likely to have a diagnosed mental disorder. ConclusionOlder adults prescribed psychotropic medication were less likely to have a diagnosed mental disorder than their younger counterparts. Efforts to promote quality prescribing should seek to minimize nonspecific use of psychotropic medication. C1 [Maust, Donovan T.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Maust, Donovan T.] Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Oslin, David W.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Oslin, David W.] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Networks Mental Illness Res E, Philadelphia, PA USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Maust, DT (reprint author), Univ Michigan, Dept Psychiat, NCRC 016-217W,2800 Plymouth Rd, Ann Arbor, MI 48109 USA. EM maustd@umich.edu NR 30 TC 9 Z9 9 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 358 EP 364 DI 10.1111/jgs.12640 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100022 PM 24417590 ER PT J AU Kumar, A Gumaste, P Lam, C Dostal, P Stoopler, ET Schwab, EP AF Kumar, Avishek Gumaste, Purva Lam, Carly Dostal, Patrick Stoopler, Eric T. Schwab, Edna P. TI AN UNUSUAL INGESTION IN AN OLDER PERSON: DENTURES SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Kumar, Avishek; Gumaste, Purva; Lam, Carly; Dostal, Patrick] Univ Penn, Div Geriatr Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kumar, Avishek; Gumaste, Purva; Lam, Carly; Dostal, Patrick; Stoopler, Eric T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Stoopler, Eric T.] Univ Penn, Sch Dent Med, Dept Oral Med, Philadelphia, PA 19104 USA. [Schwab, Edna P.] Univ Penn, Div Geriatr, Perelman Sch Med, Dept Clin Med, Philadelphia, PA 19104 USA. RP Kumar, A (reprint author), Univ Penn, Div Geriatr Med, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 399 EP 400 DI 10.1111/jgs.12642 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100037 PM 24521379 ER PT J AU Kertesz, SG McNeil, W Cash, JJ Desmond, R McGwin, G Kelly, J Baggett, TP AF Kertesz, Stefan G. McNeil, Whitney Cash, Julie J. Desmond, Renee McGwin, Gerald, Jr. Kelly, Jason Baggett, Travis P. TI Unmet Need for Medical Care and Safety Net Accessibility among Birmingham's Homeless SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Homeless persons; Safety net; Primary care; Survey research ID NEW-YORK-CITY; HEALTH-CARE; SPECIALTY CARE; ACCESS; ADULTS; INSURANCE; MORTALITY; SERVICES; OUTREACH; QUESTION AB Although homeless individuals often experience health problems requiring care, there are limitations to available research concerning the scale of their needs and the accessibility of safety net agencies to meet them. Traditional access-to-care surveys calculate unmet need among all persons queried (rather than persons needing care), making it difficult to calculate what percentage of persons requiring care actually obtain it. Additionally, no research has compared the relative accessibility of safety net programs to homeless persons in need. This cross-sectional, community-based survey assessed the prevalence of unmet need for several specific types of health care and compared the accessibility of agencies in Birmingham, AL. Substantial proportions of respondents reported unmet needs for general medical care (46 %), specialty care (51 %), mental health care (51 %), dental care (62 %), medications (57 %), and care of a child (23 %). The most commonly mentioned sites where care was sought included a federally funded Health Care for the Homeless (HCH) program (59 %), a religious free clinic (31 %), and a public hospital emergency department (51 %). The HCH program was most commonly cited as the location where care, once sought, could not be obtained (15 %), followed by the county hospital primary care clinics (13 %). In this survey, unmet need was common for all types of care queried, including primary care. Key components of the safety net, including a federally funded homeless health care program, had suboptimum accessibility. C1 [Kertesz, Stefan G.] Birmingham VA Med Ctr, Ctr Surg Med & Acute Care Res, Birmingham, AL USA. [Kertesz, Stefan G.; McNeil, Whitney; Desmond, Renee] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA. [Cash, Julie J.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL USA. [Kelly, Jason] Self Reg Hlth Care Family Med Residency Program, Greenwood, SC USA. [Baggett, Travis P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA. RP Kertesz, SG (reprint author), Univ Alabama Birmingham, Sch Med, 1530 3rd Ave South MT608, Birmingham, AL 35294 USA. EM skertesz@uabmc.edu OI Kertesz, Stefan/0000-0001-6101-8421 NR 40 TC 9 Z9 9 U1 1 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 EI 1468-2869 J9 J URBAN HEALTH JI J. Urban Health PD FEB PY 2014 VL 91 IS 1 BP 33 EP 45 DI 10.1007/s11524-013-9801-3 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AA4RB UT WOS:000331082500003 PM 23620012 ER PT J AU Katon, J Cypel, Y Raza, M Zephyrin, L Reiber, G Yano, EM Barth, S Schneiderman, A AF Katon, Jodie Cypel, Yasmin Raza, Mubashra Zephyrin, Laurie Reiber, Gayle Yano, Elizabeth M. Barth, Shannon Schneiderman, Aaron TI Self-Reported Infertility Among Male and Female Veterans Serving During Operation Enduring Freedom/Operation Iraqi Freedom SO JOURNAL OF WOMENS HEALTH LA English DT Article ID GULF-WAR VETERANS; AFFAIRS HEALTH-CARE; UNITED-STATES; REPRODUCTIVE HEALTH; COHORT; WOMEN; PREVALENCE; FERTILITY; PREGNANCY; PERSPECTIVE AB Background: Infertility is associated with psychosocial distress and is a growing public health concern. Our objective was to report the prevalence of lifetime history of infertility among men and women Veterans. Methods: We used data from the U.S. Department of Veterans Affairs National Health Study for a New Generation of U.S. Veterans, a nationally representative survey of Veterans serving during Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). The primary dependent variables were self-reported lifetime history of infertility among Veterans and their partners, defined as trying unsuccessfully to become pregnant for at least 12 months, and seeking medical help for infertility. Multiple logistic regression was used to determine whether gender was associated with lifetime history of infertility or seeking medical help for infertility, after adjusting for sociodemographic and military characteristics. All analyses were weighted to account for the complex survey design and nonresponse. Results: Among the 20,370 Veterans (16,056 men; 4,314 women) in our final analytic sample, the prevalence of lifetime history of infertility was 15.8% for women and 13.8% for men. After adjusting for age, ever married, education, race/ethnicity, component, branch of service, and deployment to OEF/OIF, compared with men, women Veterans had similar odds of lifetime history of infertility (odds ratio [OR] 1.07; 95% confidence interval [CI] 0.94, 1.20), but increased odds of seeking medical help for infertility (OR 1.35; 95% CI 1.06, 1.72). Conclusions: Women Veterans are more likely than their male counterparts to seek care for infertility, and given their increasing numbers, the demand for infertility evaluation and care within Veteran's Affairs may increase. C1 [Katon, Jodie; Zephyrin, Laurie] Dept Vet Affairs VA Cent Off, Off Womens Hlth Serv, Washington, DC USA. [Katon, Jodie; Reiber, Gayle] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Katon, Jodie; Reiber, Gayle] Univ Washington Sch Publ Hlth, Dept Hlth Serv, Seattle, WA USA. [Reiber, Gayle] Univ Washington Sch Publ Hlth, Dept Epidemiol, Seattle, WA USA. [Cypel, Yasmin; Raza, Mubashra; Barth, Shannon; Schneiderman, Aaron] VA Off Publ Hlth, Post Deployment Hlth Strateg Healthcare Grp, Washington, DC USA. [Zephyrin, Laurie] New York Harbor VA Healthcare Syst, New York, NY USA. [Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Study Healthcare Innovat Implementat & Policy, Hlth Serv Res & Dev Ctr, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Katon, J (reprint author), VA Med Ctr, Dept Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM jkaton@u.washington.edu FU Department of Veterans Affairs, Office of Public Health; Office of Academic Affiliations' Associated Health Post-doctoral Fellowship [TTP 61-026, RCS-98-353, RCS-05-195]; VA HSR&D Senior Research Career Scientist awards FX This study was funded by the Department of Veterans Affairs, Office of Public Health. Dr. Katon was supported by an Office of Academic Affiliations' Associated Health Post-doctoral Fellowship (No. TTP 61-026). Drs. Reiber (No. RCS-98-353) and Yano (No. RCS-05-195) are supported by VA HSR&D Senior Research Career Scientist awards. The views expressed within are solely those of the authors, and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 41 TC 3 Z9 3 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD FEB 1 PY 2014 VL 23 IS 2 BP 175 EP 183 DI 10.1089/jwh.2013.4468 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AA7HC UT WOS:000331267300011 PM 24261648 ER PT J AU Randolph, GW Kamani, D AF Randolph, Gregory W. Kamani, Dipti TI Intraoperative neural monitoring in thyroid cancer surgery SO LANGENBECKS ARCHIVES OF SURGERY LA English DT Review DE Recurrent laryngeal nerve; Electrophysiologic intraoperative neural monitoring; Continuous monitoring; Vocal cord paralysis; Voice; Thyroid surgery; Recurrent laryngeal nerve injury ID RECURRENT LARYNGEAL NERVE; PARATHYROID SURGERY; ENDOCRINE SURGEONS; ANCHOR ELECTRODE; IDENTIFICATION; COMPLICATIONS; ASSOCIATION; GUIDELINES; PARALYSIS; BRANCH AB Intraoperative neural monitoring (IONM) has increasingly garnered the attention of the surgeons performing thyroid and parathyroid surgery around the world. Current studies suggest a majority of general and head and neck surgeons utilize neural monitoring in their thyroid surgical case load in both the US and Germany. We aim to present an up-to-date review of the application of IONM specifically focusing on its utility in thyroid cancer surgery. Neural monitoring is discussed particularly as it relates to neural prognosis, the issues of staged thyroid surgery for thyroid cancer, and new horizons in the monitoring of the superior laryngeal nerve (SLN) and prevention of neural injury through continuous vagal neural monitoring. IONM, as it relates to thyroid surgery, has obtained a widespread acceptance as an adjunct to the gold standard of visual nerve identification. The value of IONM in prognosticating neural function and in intraoperative decision making regarding proceeding to bilateral surgery is also well-known. Initial data on recent extensions of IONM in the form of SLN monitoring and continuous vagal nerve monitoring are promising. Continuous vagal nerve monitoring expands the utility of IONM by providing real-time electrophysiological information, allowing surgeons to take a corrective action in impending neural injury. C1 [Randolph, Gregory W.; Kamani, Dipti] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol,Div Thyroid & Parathyroid Surg, Boston, MA 02114 USA. [Randolph, Gregory W.] Harvard Univ, Sch Med, Div Surg Oncol, Massachusetts Gen Hosp,Endocrine Surg Serv, Boston, MA 02114 USA. RP Randolph, GW (reprint author), Harvard Univ, Sch Med, Div Surg Oncol, Massachusetts Gen Hosp,Endocrine Surg Serv, Boston, MA 02114 USA. EM gregory_randolph@meei.harvard.edu; dipti_kamani@meei.harvard.edu NR 38 TC 11 Z9 11 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1435-2443 EI 1435-2451 J9 LANGENBECK ARCH SURG JI Langenbecks Arch. Surg. PD FEB PY 2014 VL 399 IS 2 BP 199 EP 207 DI 10.1007/s00423-013-1141-y PG 9 WC Surgery SC Surgery GA AA3ND UT WOS:000330998400006 PM 24281845 ER PT J AU Avram, MM AF Avram, Mathew M. TI Introduction to Clinical Section SO LASERS IN SURGERY AND MEDICINE LA English DT Editorial Material C1 Massachusetts Gen Hosp, MGH Dermatol Laser & Cosmet Ctr, Boston, MA 02114 USA. RP Avram, MM (reprint author), Massachusetts Gen Hosp, MGH Dermatol Laser & Cosmet Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2014 VL 46 IS 2 BP 73 EP 74 DI 10.1002/lsm.22237 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA AA9HF UT WOS:000331403700001 PM 24535758 ER PT J AU Garibyan, L Sipprell, WH Jalian, HR Sakamoto, FH Avram, M Anderson, RR AF Garibyan, Lilit Sipprell, William H., III Jalian, H. Ray Sakamoto, Fernanda H. Avram, Mathew Anderson, R. Rox TI Three-Dimensional Volumetric Quantification of Fat Loss Following Cryolipolysis SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE fat removal; noninvasive; volume of fat; imaging; cold induced fat loss ID NONINVASIVE CRYOLIPOLYSIS; PANNICULITIS; REDUCTION; EFFICACY; REMOVAL AB Background and ObjectivesCryolipolysis is a noninvasive and well-tolerated treatment for reduction of localized subcutaneous fat. Although several studies demonstrate the safety and efficacy of this procedure, volumetric fat reduction from this treatment has not been quantified. This prospective study investigated the change in volume of fat after cryolipolysis treatment using three-dimensional (3D) photography. Materials and MethodsA prospective study of subjects treated with cryolipolysis on the flank (love handle) was performed at Massachusetts General Hospital. Volume measurements were performed with a Canfield Scientific Vectra three-dimensional camera and software to evaluate the amount of post procedure volume change. Clinical outcomes were assessed with caliper measurements, subject surveys, and blinded physician assessment of photographs. ResultsEleven subjects were enrolled in this study. Each subject underwent a single cycle of cryolipolysis to one flank. The untreated flank served as an internal control. The follow-up time after treatment was 2 months. The mean amount of calculated absolute fat volume loss using 3D photography from baseline to 2 months follow-up visit was 56.225.6 from the treatment site and 16.6 +/- 17.6cc from the control (P<0.0001). A mean absolute difference of 39.6cc between the treated and untreated sides was calculated at 2 months post-treatment. Comparison of caliper measurements from baseline to 2 months post-treatment demonstrated significant reduction of the treated flank from 45.6 +/- 5.8mm at baseline to 38.6 +/- 4.6mm at 2 months post-treatment (P<0.001). The untreated flank did not show significant reduction with caliper measurements demonstrating 45.3 +/- 5.0mm at baseline and 44.6 +/- 5.1mm at 2 months post-treatment (P=0.360). No unexpected side effects or adverse events were reported. Post-treatment satisfaction surveys demonstrated 82% of subjects were satisfied with the results. ConclusionsCryolipolysis is a safe, well-tolerated, and effective noninvasive fat removal methodology that on average leads to 39.6cc of fat loss of the treated flank at 2 months after a single treatment cycle. Lasers Surg. Med. 46:75-80, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Garibyan, Lilit; Sipprell, William H., III; Sakamoto, Fernanda H.; Avram, Mathew; Anderson, R. Rox] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Garibyan, Lilit; Sipprell, William H., III; Sakamoto, Fernanda H.; Avram, Mathew; Anderson, R. Rox] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Jalian, H. Ray] Univ Calif Los Angeles, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA. RP Garibyan, L (reprint author), Wellman Ctr Photomed, 40 Blossom St Thier 204, Boston, MA 02114 USA. EM lgaribyan@partners.org FU Department discretionary funds; Zeltiq Aesthetics, Inc. FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and have disclosed the following: This is a PI initiated study sponsored by Department discretionary funds. Dr. Anderson and Dr. Avram serve on the Medical Advisory Board for Zeltiq Aesthetics, Inc. Dr. Anderson's employer, Massachusetts General Hospital, receives royalties for licensing intellectual property to Zeltiq Aesthetics, Inc. Dr. Anderson and Dr. Jalian serve as investigators for an unrelated clinical trial sponsored by Zeltiq Aesthetics, Inc. NR 14 TC 22 Z9 22 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2014 VL 46 IS 2 BP 75 EP 80 DI 10.1002/lsm.22207 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA AA9HF UT WOS:000331403700002 PM 24535759 ER PT J AU Ortiz, AE Avram, MM Wanner, MA AF Ortiz, Arisa E. Avram, Mathew M. Wanner, Molly A. TI A Review of Lasers and Light for the Treatment of Onychomycosis SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE fungal infection; fungus; nails; podiatry; toenails ID TRICHOPHYTON-RUBRUM; PHOTODYNAMIC THERAPY; TOENAIL ONYCHOMYCOSIS; IN-VITRO; SELECTIVE PHOTOTHERMOLYSIS; HYPERTHERMIA; DERMATOPHYTES; DIAGNOSIS; EXPOSURE; EFFICACY AB Background and ObjectiveOnychomycosis is a common fungal infection that affects many individuals. Systemic therapies are effective, but are limited by their side effects and potential for hepatotoxicity. Topical therapies have less serious side effects, yet provide only limited efficacy due to their inability to penetrate the nail plate. These limitations have led to the investigation of laser and light-based modalities as alternative treatment options for onychomycosis. This article will provide an overview and critical assessment of the field of laser and other energy-based treatments for onychomycosis. Study Design/Materials and MethodsA literature search was conducted on laser and light-based treatments for onychomycosis. ResultsEarly data are promising, however, many of these studies are small or poorly designed. ConclusionFurther evaluation and larger studies are needed to determine the optimal light source, pulse duration, and treatment schedule for long-term success. Lasers Surg. Med. 46:117-124, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Ortiz, Arisa E.; Avram, Mathew M.; Wanner, Molly A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dermatol Cosmet & Laser Ctr, Boston, MA 02114 USA. [Ortiz, Arisa E.; Avram, Mathew M.; Wanner, Molly A.] Wellman Ctr Photomed, Boston, MA 02114 USA. [Ortiz, Arisa E.] Univ Calif San Diego, San Diego, CA 92122 USA. RP Ortiz, AE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dermatol Cosmet & Laser Ctr, 50 Staniford St,St 250, Boston, MA 02114 USA. EM arisaortiz@gmail.com NR 53 TC 12 Z9 13 U1 2 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2014 VL 46 IS 2 BP 117 EP 124 DI 10.1002/lsm.22211 PG 8 WC Dermatology; Surgery SC Dermatology; Surgery GA AA9HF UT WOS:000331403700008 PM 24375507 ER PT J AU Jalian, HR AF Jalian, H. Ray TI Introduction to Basic Science Section SO LASERS IN SURGERY AND MEDICINE LA English DT Editorial Material C1 [Jalian, H. Ray] Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA 90024 USA. [Jalian, H. Ray] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Jalian, HR (reprint author), Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2014 VL 46 IS 2 BP 125 EP 126 DI 10.1002/lsm.22239 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA AA9HF UT WOS:000331403700009 PM 24535761 ER PT J AU Avci, P Gupta, GK Clark, J Wikonkal, N Hamblin, MR AF Avci, Pinar Gupta, Gaurav K. Clark, Jason Wikonkal, Norbert Hamblin, Michael R. TI Low-Level Laser (Light) Therapy (LLLT) for Treatment of Hair Loss SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE alopecia; androgenetic alopecia; hair loss; LLLT; low level laser (light) ID CHEMOTHERAPY-INDUCED ALOPECIA; ANDROGENETIC ALOPECIA; NITRIC-OXIDE; DOUBLE-BLIND; INFRARED RADIATION; MULTICENTER TRIAL; ORAL MUCOSITIS; CLINICAL-TRIAL; PART I; GROWTH AB ObjectiveAlopecia is a common disorder affecting more than half of the population worldwide. Androgenetic alopecia, the most common type, affects 50% of males over the age of 40 and 75% of females over 65. Only two drugs have been approved so far (minoxidil and finasteride) and hair transplant is the other treatment alternative. This review surveys the evidence for low-level laser therapy (LLLT) applied to the scalp as a treatment for hair loss and discusses possible mechanisms of actions. Methods and MaterialsSearches of PubMed and Google Scholar were carried out using keywords alopecia, hair loss, LLLT, photobiomodulation. ResultsStudies have shown that LLLT stimulated hair growth in mice subjected to chemotherapy-induced alopecia and also in alopecia areata. Controlled clinical trials demonstrated that LLLT stimulated hair growth in both men and women. Among various mechanisms, the main mechanism is hypothesized to be stimulation of epidermal stem cells in the hair follicle bulge and shifting the follicles into anagen phase. ConclusionLLLT for hair growth in both men and women appears to be both safe and effective. The optimum wavelength, coherence and dosimetric parameters remain to be determined. Lasers Surg. Med. 46:144-151, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Avci, Pinar; Gupta, Gaurav K.; Clark, Jason; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Avci, Pinar; Gupta, Gaurav K.; Clark, Jason; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Avci, Pinar; Wikonkal, Norbert] Semmelweis Univ, Sch Med, Dept Dermatol Venereol & Dermatooncol, H-1085 Budapest, Hungary. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Ctr Photomed, BAR 414 Wellman,40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu OI Hamblin, Michael/0000-0001-6431-4605 FU US NIH [R01AI050875] FX Research in the Hamblin Laboratory is supported by US NIH Grant R01AI050875. NR 62 TC 25 Z9 26 U1 3 U2 25 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2014 VL 46 IS 2 BP 144 EP 151 DI 10.1002/lsm.22170 PG 8 WC Dermatology; Surgery SC Dermatology; Surgery GA AA9HF UT WOS:000331403700013 PM 23970445 ER PT J AU Lonial, S Anderson, KC AF Lonial, S. Anderson, K. C. TI Association of response endpoints with survival outcomes in multiple myeloma SO LEUKEMIA LA English DT Review DE myeloma; depth of response; durability of response; survival; minimal residual disease; multidrug treatment ID STEM-CELL TRANSPLANTATION; LENALIDOMIDE PLUS DEXAMETHASONE; PEGYLATED LIPOSOMAL DOXORUBICIN; LOW-DOSE DEXAMETHASONE; BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE; RANDOMIZED CONTROLLED-TRIAL; MINIMAL RESIDUAL DISEASE; SINGLE-AGENT CARFILZOMIB; EXTENDED FOLLOW-UP; LONG-TERM SURVIVAL AB Since the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, more patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer. These improvements have afforded more robust analyses of the relationship between response and survival. Generally, these studies have demonstrated that improvements in the quality of response across all stages of treatment are associated with better disease control and longer survival. Thus, achievement of maximal response should be strongly considered, particularly in the frontline setting, but must also be balanced with tolerability, quality of life and patient preferences. In select patients, achievement of a lesser response may be adequate to prolong survival, and attempts to treat these patients to a deeper response may place them at unnecessary risk without significant benefit. Maintenance therapy has been shown to improve the quality of response and disease control and, in some studies, survival. Studies support maintenance therapy for high-risk patients as a standard of care, and there are emerging data supporting maintenance therapy in standard-risk patients to improve progression-free and possibly overall survival. Multidrug regimens combining a proteasome inhibitor and an IMiD have shown exceptional response outcomes with acceptable increases in toxicity in both the frontline and salvage settings, and are becoming a standard treatment approach. Moving forward, the use of immunophenotypic and molecular response criteria will be essential in better understanding the impact of highly active and continuous treatment regimens across myeloma patient populations. Future translational studies will help to develop antimyeloma agents to their fullest potential. The introduction of novel targeted therapies, including the IMiD pomalidomide and the proteasome inhibitors carfilzomib and ixazomib (MLN9708), will provide greater options to individualize treatment and help patients achieve a clinically meaningful response. C1 [Lonial, S.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA. [Anderson, K. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. RP Lonial, S (reprint author), Emory Univ, 1365 Clifton Rd,Bldg C,Room 4004, Atlanta, GA 30322 USA. EM sloni01@emory.edu FU 'Ray C. Osborne Fund' at Emory University School of Medicine FX Dr Lonial's position is funded, in part, by the 'Ray C. Osborne Fund' at Emory University School of Medicine. We thank Michael Raffin (Fishawack Communications) for medical writing and editorial assistance, which was supported by Onyx Pharmaceuticals, Inc. NR 116 TC 32 Z9 35 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD FEB PY 2014 VL 28 IS 2 BP 258 EP 268 DI 10.1038/leu.2013.220 PG 11 WC Oncology; Hematology SC Oncology; Hematology GA AA6QV UT WOS:000331223900004 PM 23868105 ER PT J AU Chng, WJ Dispenzieri, A Chim, CS Fonseca, R Goldschmidt, H Lentzsch, S Munshi, N Palumbo, A Miguel, JS Sonneveld, P Cavo, M Usmani, S Durie, BGM Avet-Loiseau, H AF Chng, W. J. Dispenzieri, A. Chim, C-S Fonseca, R. Goldschmidt, H. Lentzsch, S. Munshi, N. Palumbo, A. Miguel, J. S. Sonneveld, P. Cavo, M. Usmani, S. Durie, B. G. M. Avet-Loiseau, H. CA Int Myeloma Working Grp TI IMWG consensus on risk stratification in multiple myeloma SO LEUKEMIA LA English DT Review DE prognosis; treatment; biomakers ID STEM-CELL TRANSPLANTATION; INDEPENDENT PROGNOSTIC-FACTOR; IN-SITU HYBRIDIZATION; INTERNATIONAL STAGING SYSTEM; COMPLETE RESPONSE; MOLECULAR CLASSIFICATION; INTERGROUPE FRANCOPHONE; TANDEM TRANSPLANTATION; EXPRESSION SIGNATURE; PLUS DEXAMETHASONE AB Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies. C1 [Chng, W. J.] Natl Univ Hlth Syst, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore 119228, Singapore. [Chng, W. J.] Canc Sci Inst Singapore, Singapore, Singapore. [Chng, W. J.] Natl Univ Singapore, Yoo Loo Lin Sch Med, Dept Med, Singapore 117548, Singapore. [Dispenzieri, A.] Mayo Clin, Div Hematol, Rochester, MN USA. [Chim, C-S] Queen Mary Hosp, Div Hematol & Med Oncol, Hong Kong, Hong Kong, Peoples R China. [Fonseca, R.] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA. [Goldschmidt, H.] Heidelberg Univ, Heidelberg, Germany. [Lentzsch, S.] Columbia Univ, Dept Med Hematol Oncol, New York, NY 10027 USA. [Munshi, N.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Palumbo, A.] Univ Turin, Div Hematol, Myeloma Unit, Turin, Italy. [Miguel, J. S.] Hosp Univ Salamanca, CIC, IBMCC USAL CSIC, Serv Hematol, Salamanca, Spain. [Sonneveld, P.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands. [Cavo, M.] Univ Bologna, Sch Med, Inst Hematol & Med Oncol Seragnoli, Bologna, Italy. [Usmani, S.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA. [Durie, B. G. M.] Samuel Oschin Comprehens Canc, Cedars Sinai Outpatient Canc Ctr, Int Myeloma Fdn, Southwest Oncol Grp, Los Angeles, CA USA. [Avet-Loiseau, H.] Univ Hosp, Unite Genom Myelome, Toulouse, France. RP Chng, WJ (reprint author), Natl Univ Hlth Syst, Natl Univ Canc Inst, Dept Haematol Oncol, NUHS Tower Block,Level 7,1E Lower Kent Ridge Rd, Singapore 119228, Singapore. EM mdccwj@nus.edu.sg RI FACON, THIERRY/M-9736-2014; Merlini, Giampaolo/A-3817-2008; Kristinsson, Sigurdur /M-2910-2015; Garcia-Sanz, Ramon/B-7986-2017; OI FACON, THIERRY/0000-0001-7705-8460; Merlini, Giampaolo/0000-0001-7680-3254; Kristinsson, Sigurdur /0000-0002-4964-7476; Garcia-Sanz, Ramon/0000-0003-4120-2787; SAN MIGUEL, JESUS/0000-0002-9183-4857; Fonseca, Rafael/0000-0002-5938-3769; CAVO, MICHELE/0000-0003-4514-3227; nahi, hareth/0000-0003-4711-5094; Dispenzieri, Angela/0000-0001-8780-9512 NR 67 TC 101 Z9 114 U1 4 U2 30 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD FEB PY 2014 VL 28 IS 2 BP 269 EP 277 DI 10.1038/leu.2013.247 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA AA6QV UT WOS:000331223900005 PM 23974982 ER PT J AU Hideshima, T Mazitschek, R Santo, L Mimura, N Gorgun, G Richardson, PG Raje, N Anderson, KC AF Hideshima, T. Mazitschek, R. Santo, L. Mimura, N. Gorgun, G. Richardson, P. G. Raje, N. Anderson, K. C. TI Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors SO LEUKEMIA LA English DT Letter ID BORTEZOMIB; COMBINATION; CARFILZOMIB; LBH589 C1 [Hideshima, T.; Mimura, N.; Gorgun, G.; Richardson, P. G.; Anderson, K. C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Mazitschek, R.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Santo, L.; Raje, N.] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA. RP Hideshima, T (reprint author), Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. EM kenneth_anderson@dfci.harvard.edu FU NCI NIH HHS [R01 CA050947, P50 CA086355, R01 CA178264, P01 CA78378, R01 CA50947, P01 CA155258, P50 CA100707, P01 CA078378] NR 15 TC 8 Z9 8 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD FEB PY 2014 VL 28 IS 2 BP 457 EP 460 DI 10.1038/leu.2013.301 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA AA6QV UT WOS:000331223900038 PM 24150220 ER PT J AU Nativ, NI Chen, AI Yarmush, G Henry, SD Lefkowitch, JH Klein, KM Maguire, TJ Schloss, R Guarrera, JV Berthiaume, F Yarmush, ML AF Nativ, Nir I. Chen, Alvin I. Yarmush, Gabriel Henry, Scot D. Lefkowitch, Jay H. Klein, Kenneth M. Maguire, Timothy J. Schloss, Rene Guarrera, James V. Berthiaume, Francois Yarmush, Martin L. TI Automated Image Analysis Method for Detecting and Quantifying Macrovesicular Steatosis in Hematoxylin and Eosin-Stained Histology Images of Human Livers SO LIVER TRANSPLANTATION LA English DT Article ID CHRONIC HEPATITIS-C; ACTIVE CONTOUR; DONOR LIVERS; TRANSPLANTATION; INJURY; PATHOLOGIST; VALIDATION; PERFUSION; MARKERS AB Large-droplet macrovesicular steatosis (ld-MaS) in more than 30% of liver graft hepatocytes is a major risk factor for liver transplantation. An accurate assessment of the ld-MaS percentage is crucial for determining liver graft transplantability, which is currently based on pathologists' evaluations of hematoxylin and eosin (H&E)-stained liver histology specimens, with the predominant criteria being the relative size of the lipid droplets (LDs) and their propensity to displace a hepatocyte's nucleus to the cell periphery. Automated image analysis systems aimed at objectively and reproducibly quantifying ld-MaS do not accurately differentiate large LDs from small-droplet macrovesicular steatosis and do not take into account LD-mediated nuclear displacement; this leads to a poor correlation with pathologists' assessments. Here we present an improved image analysis method that incorporates nuclear displacement as a key image feature for segmenting and classifying ld-MaS from H&E-stained liver histology slides. 52,000 LDs in 54 digital images from 9 patients were analyzed, and the performance of the proposed method was compared against the performance of current image analysis methods and the ld-MaS percentage evaluations of 2 trained pathologists from different centers. We show that combining nuclear displacement and LD size information significantly improves the separation between large and small macrovesicular LDs (specificity=93.7%, sensitivity=99.3%) and the correlation with pathologists' ld-MaS percentage assessments (linear regression coefficient of determination=0.97). This performance vastly exceeds that of other automated image analyzers, which typically underestimate or overestimate pathologists' ld-MaS scores. This work demonstrates the potential of automated ld-MaS analysis in monitoring the steatotic state of livers. The image analysis principles demonstrated here may help to standardize ld-MaS scores among centers and ultimately help in the process of determining liver graft transplantability. Liver Transpl 20:228-236, 2014. (c) 2013 AASLD. C1 [Nativ, Nir I.; Chen, Alvin I.; Yarmush, Gabriel; Maguire, Timothy J.; Schloss, Rene; Berthiaume, Francois; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA. [Henry, Scot D.; Guarrera, James V.] Columbia Univ, Med Ctr, Dept Surg, Ctr Liver Dis & Transplantat, New York, NY USA. [Lefkowitch, Jay H.] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA. [Klein, Kenneth M.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA. [Yarmush, Martin L.] Massachusetts Gen Hosp, Ctr Engn Med, Surg Serv, Boston, MA 02114 USA. RP Yarmush, ML (reprint author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA. EM yarmush@rci.rutgers.edu FU National Institutes of Health [R01DK059766] FX This work was partially supported by the National Institutes of Health (grant R01DK059766). Nir I. Nativ, Alvin I. Chen, and Gabriel Yarmush were supported by a National Institutes of Health-funded biotechnology training fellowship. NR 27 TC 2 Z9 2 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD FEB PY 2014 VL 20 IS 2 BP 228 EP 236 DI 10.1002/lt.23782 PG 9 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA AA6FP UT WOS:000331194500013 PM 24339411 ER PT J AU Gazula, A Baldini, EH Chen, A Kozono, D AF Gazula, Abhilash Baldini, Elizabeth H. Chen, Aileen Kozono, David TI Comparison of Once and Twice Daily Radiotherapy for Limited Stage Small-Cell Lung Cancer SO LUNG LA English DT Article DE Small cell lung carcinoma (SCLC); Lung neoplasms; Humans; Radiotherapy; Dose fractionation; Outcome assessment ID THORACIC RADIOTHERAPY; ONCOLOGY-GROUP; METAANALYSIS; RADIATION; CHEMOTHERAPY; CONCURRENT; CARCINOMA; CRITERIA; THERAPY AB This study was designed to review outcomes of once- (QD) versus twice-daily (BID) radiotherapy (RT) for limited stage small-cell lung cancer (L-SCLC) treated at Dana-Farber Cancer Institute/Brigham and Women's Hospital. We reviewed records for all patients with L-SCLC treated with radical chemoradiotherapy at our institution between January 2005 and December 2010. Differences in patient, tumor, and treatment characteristics were assessed by Student's t test and Fisher exact test. Outcomes were compared using Kaplan-Meier estimates and Cox proportional hazards regression. Twenty patients received QD RT to a median dose of 61.2 Gy, and 26 patients received BID RT to a dose of 45 Gy. Median follow-up was 2.8 years. Overall survival (OS) was similar in both groups. 5-year locoregional control (LC) for all patients was 67 %: 80 % for the QD group and 57 % for the BID group (log-rank, P = 0.16). Grade 2 or higher dermatitis and pneumonitis were significantly higher in the QD group (15 vs. 0 %, P = 0.0014 and 13 vs. 4 %, P = 0.048, respectively), whereas Grade 2 or higher esophagitis trended higher in the BID group (44 vs. 24 %, P = 0.076). Although there were no differences in OS with QD versus BID RT, there was a trend toward increased LC in the QD group. Dermatitis and pneumonitis were more common for QD RT, and esophagitis was somewhat more common for BID RT. Possible differences in toxicities depending on RT regimen may be worth further investigation, until results from CALGB 30610 become available. C1 [Gazula, Abhilash; Baldini, Elizabeth H.; Chen, Aileen; Kozono, David] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA. RP Kozono, D (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM agazula@umich.edu; ebaldini@lroc.harvard.edu; achen@lroc.harvard.edu; dkozono@lroc.harvard.edu OI Chen, Aileen/0000-0002-5385-3360 FU Department of Radiation Oncology at the Dana-Farber Cancer Institute/Brigham and Women's Hospital FX This work was supported by internal funds of the Department of Radiation Oncology at the Dana-Farber Cancer Institute/Brigham and Women's Hospital. NR 14 TC 7 Z9 10 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0341-2040 EI 1432-1750 J9 LUNG JI Lung PD FEB PY 2014 VL 192 IS 1 BP 151 EP 158 DI 10.1007/s00408-013-9518-9 PG 8 WC Respiratory System SC Respiratory System GA AA2XR UT WOS:000330958000035 PM 24162870 ER PT J AU Wong, ES Hebert, PL Hernandez, SE Batten, A Lo, S Lemon, JM Fihn, SD Liu, CF AF Wong, Edwin S. Hebert, Paul L. Hernandez, Susan E. Batten, Adam Lo, Sophie Lemon, Jaclyn M. Fihn, Stephan D. Liu, Chuan-Fen TI Association Between Local Area Unemployment Rates and Use of Veterans Affairs Outpatient Health Services SO MEDICAL CARE LA English DT Article DE outpatient utilization; unemployment rate; enabling resources; Department of Veterans Affairs ID CARE; MEDICARE; RECESSIONS; ACCESS AB Background:Prior research indicates that federal spending on Medicare, Medicaid, and other government health programs accelerated during the Great Recession.Objectives:To examine whether local unemployment was associated with utilization of Veterans Affairs Health Care System (VA) primary care, specialty care, and mental health services during 2004-2012.Research Design:We analyzed utilization of VA health services at the clinic level using fixed-effects negative binomial models. We stratified analyses by veterans' copayment status (exempt and nonexempt) and age (under 65 and 65+) to account for differences in VA utilization because of Medicare eligibility.Subjects:A total of 11,041,855 veterans assigned to 892 clinics identified in the VA Primary Care Management Module, representing nearly all veterans receiving primary care from VA, were included.Measures:Clinic-level utilization was calculated quarterly as the total number of visits for patients assigned to a clinic. Local area unemployment rates were defined as quarterly unemployment rates within VA geographical planning sectors.Results:Higher local unemployment was associated with greater use of VA care in all categories among veterans exempt from copayments. The association between local unemployment and utilization differed by age group among veterans subject to copayments. Higher local unemployment was associated with lower use of primary and specialty care among Medicare-eligible veterans aged 65+, but greater use of primary care among veterans under age 65.Conclusions:Our findings highlight the importance of the state of the economy in interpreting and forecasting demand for government health programs including VA, particularly during periods focused on deficit reduction. C1 [Wong, Edwin S.; Hebert, Paul L.; Batten, Adam; Lemon, Jaclyn M.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA. [Wong, Edwin S.; Hebert, Paul L.; Hernandez, Susan E.; Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Lo, Sophie; Fihn, Stephan D.] Vet Hlth Adm, Off Analyt & Business Intelligence, Seattle, WA USA. RP Wong, ES (reprint author), VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eswong@uw.edu FU Veterans Health Administration Patient Centered Medical Home Demonstration Laboratory Coordination Center [XVA-61-041]; VA HSR&D Career Development Award [CDA 13-024] FX Supported by the Veterans Health Administration Patient Centered Medical Home Demonstration Laboratory Coordination Center (XVA-61-041). E. S. W. supported by a VA HSR&D Career Development Award (CDA 13-024). NR 39 TC 4 Z9 4 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2014 VL 52 IS 2 BP 137 EP 143 DI 10.1097/MLR.0000000000000079 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AA4SS UT WOS:000331087100009 PM 24374409 ER PT J AU Pugh, MJV Finley, EP Copeland, LA Wang, CP Noel, PH Amuan, ME Parsons, HM Wells, M Elizondo, B Pugh, JA AF Pugh, Mary Jo V. Finley, Erin P. Copeland, Laurel A. Wang, Chen-Pin Noel, Polly H. Amuan, Megan E. Parsons, Helen M. Wells, Margaret Elizondo, Barbara Pugh, Jacqueline A. TI Complex Comorbidity Clusters in OEF/OIF Veterans The Polytrauma Clinical Triad and Beyond SO MEDICAL CARE LA English DT Article DE Afghan Campaign 2001 (Operation Enduring Freedom); comorbidity; Iraq War 2003 (Operation Iraqi Freedom); veterans ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH DISORDERS; OPERATION-IRAQI-FREEDOM; ENDURING FREEDOM; US VETERANS; WAR; AFGHANISTAN; PAIN; CARE AB Background:A growing body of research on US Veterans from Afghanistan and Iraq [Operations Enduring and Iraqi Freedom, and Operation New Dawn (OEF/OIF)] has described the polytrauma clinical triad (PCT): traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and pain. Extant research has not explored comorbidity clusters in this population more broadly, particularly co-occurring chronic diseases.Objectives:The aim of the study was to identify comorbidity clusters among diagnoses of deployment-specific (TBI, PTSD, pain) and chronic (eg, hypertension, diabetes) conditions, and to examine the association of these clusters with health care utilization and adverse outcomes.Research Design:This was a retrospective cohort study.Subjects:The cohort comprised OEF/OIF Veterans who received care in the Veterans Health Administration in fiscal years (FY) 2008-2010.Measures:We identified comorbidity using validated ICD-9-CM code-based algorithms and FY08-09 data, followed by which we applied latent class analysis to identify the most statistically distinct and clinically meaningful patterns of comorbidity. We examined the association of these clusters with process measures/outcomes using logistic regression to correlate medication use, acute health care utilization, and adverse outcomes in FY10.Results:In this cohort (N=191,797), we found 6 comorbidity clusters. Cluster 1: PCT+Chronic Disease (5%); Cluster 2: PCT (9%); Cluster 3: Mental Health+Substance Abuse (24%); Cluster 4: Sleep, Amputation, Chronic Disease (4%); Cluster 5: Pain, Moderate PTSD (6%); and Cluster 6: Relatively Healthy (53%). Subsequent health care utilization patterns and adverse events were consistent with disease patterns.Conclusions:These comorbidity clusters extend beyond the PCT and may be used as a foundation to examine coordination/quality of care and outcomes for OEF/OIF Veterans with different patterns of comorbidity. C1 [Pugh, Mary Jo V.; Finley, Erin P.; Wang, Chen-Pin; Noel, Polly H.; Wells, Margaret; Elizondo, Barbara; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.; Wang, Chen-Pin; Parsons, Helen M.; Wells, Margaret; Elizondo, Barbara] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.; Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Bryan, TX USA. [Finley, Erin P.; Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA. [Copeland, Laurel A.] Scott & White Healthcare Syst, Temple, TX USA. [Amuan, Megan E.] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA. RP Pugh, MJV (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Maryjo.pughm@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237] FX Funded by the Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). NR 34 TC 16 Z9 16 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2014 VL 52 IS 2 BP 172 EP 181 DI 10.1097/MLR.0000000000000059 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AA4SS UT WOS:000331087100014 PM 24374417 ER PT J AU Andreyev, A Sitek, A Celler, A AF Andreyev, Andriy Sitek, Arkadiusz Celler, Anna TI EM reconstruction of dual isotope PET using staggered injections and prompt gamma positron emitters SO MEDICAL PHYSICS LA English DT Article DE positron emission tomography; dual isotope imaging; positron gamma emitter; image reconstruction; maximum likelihood expectation maximization ID EMISSION-TOMOGRAPHY; TRACER; FEASIBILITY; SEPARATION; F-18-FDG; HYPOXIA; CANCER AB Purpose: The aim of dual isotope positron emission tomography (DIPET) is to create two separate images of two coinjected PET radiotracers. DIPET shortens the duration of the study, reduces patient discomfort, and produces perfectly coregistered images compared to the case when two radiotracers would be imaged independently (sequential PET studies). Reconstruction of data from such simultaneous acquisition of two PET radiotracers is difficult because positron decay of any isotope creates only 511 keV photons; therefore, the isotopes cannot be differentiated based on the detected energy. Methods: Recently, the authors have proposed a DIPET technique that uses a combination of radio-tracer A which is a pure positron emitter (such as F-18 or C-11) and radiotracer B in which positron decay is accompanied by the emission of a high-energy (HE) prompt gamma (such as K-38 or Cu-60). Events that are detected as triple coincidences of HE gammas with the corresponding two 511 keV photons allow the authors to identify the lines-of-response (LORs) of isotope B. These LORs are used to separate the two intertwined distributions, using a dedicated image reconstruction algorithm. In this work the authors propose a new version of the DIPET EM-based reconstruction algorithm that allows the authors to include an additional, independent estimate of radiotracer A distribution which may be obtained if radioisotopes are administered using a staggered injections method. In this work the method is tested on simple simulations of static PET acquisitions. Results: The authors' experiments performed using Monte-Carlo simulations with static acquisitions demonstrate that the combined method provides better results (crosstalk errors decrease by up to 50%) than the positron-gamma DIPET method or staggered injections alone. Conclusions: The authors demonstrate that the authors' new EM algorithm which combines information from triple coincidences with prompt gammas and staggered injections improves the accuracy of DIPET reconstructions for static acquisitions so they reach almost the benchmark level calculated for perfectly separated tracers. (C) 2014 American Association of Physicists in Medicine. C1 [Andreyev, Andriy] Philips Healthcare, Highland Hts, OH 44143 USA. [Sitek, Arkadiusz] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Sitek, Arkadiusz] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Celler, Anna] Univ British Columbia, Dept Radiol, Vancouver, BC V5Z 1M9, Canada. RP Andreyev, A (reprint author), Philips Healthcare, Highland Hts, OH 44143 USA. EM andriy.andreyev_1@philips.com OI Sitek, Arkadiusz/0000-0002-0677-4002 FU National Institutes of Health (NIH) [R21HL106474, R21EB016315] FX This work was supported in parts by the National Institutes of Health (NIH) R21HL106474 and R21EB016315. NR 23 TC 0 Z9 0 U1 0 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2014 VL 41 IS 2 AR 022501 DI 10.1118/1.4861714 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AA6MV UT WOS:000331213300057 PM 24506645 ER PT J AU Craft, D Papp, D Unkelbach, J AF Craft, David Papp, David Unkelbach, Jan TI Plan averaging for multicriteria navigation of sliding window IMRT and VMAT SO MEDICAL PHYSICS LA English DT Article DE VMAT; sliding window; IMRT; dynamic; dMLC; Pareto ID MODULATED ARC THERAPY; OPTIMIZATION; QUALITY AB Purpose: To describe a method for combining sliding window plans [intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT)] for use in treatment plan averaging, which is needed for Pareto surface navigation based multicriteria treatment planning. Methods: The authors show that by taking an appropriately defined average of leaf trajectories of sliding window plans, the authors obtain a sliding window plan whose fluence map is the exact average of the fluence maps corresponding to the initial plans. In the case of static-beam IMRT, this also implies that the dose distribution of the averaged plan is the exact dosimetric average of the initial plans. In VMAT delivery, the dose distribution of the averaged plan is a close approximation of the dosimetric average of the initial plans. Results: The authors demonstrate the method on three Pareto optimal VMAT plans created for a demanding paraspinal case, where the tumor surrounds the spinal cord. The results show that the leaf averaged plans yield dose distributions that approximate the dosimetric averages of the precomputed Pareto optimal plans well. Conclusions: The proposed method enables the navigation of deliverable Pareto optimal plans directly, i.e., interactive multicriteria exploration of deliverable sliding window IMRT and VMAT plans, eliminating the need for a sequencing step after navigation and hence the dose degradation that is caused by such a sequencing step. (C) 2014 American Association of Physicists in Medicine. C1 [Craft, David] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Craft, D (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM dcraft@partners.org NR 16 TC 4 Z9 4 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2014 VL 41 IS 2 AR 021709 DI 10.1118/1.4859295 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AA6MV UT WOS:000331213300012 PM 24506600 ER PT J AU Daartz, J Maughan, RL Orton, CG AF Daartz, Juliane Maughan, Richard L. Orton, Colin G. TI The disadvantages of a multileaf collimator for proton radiotherapy outweigh its advantages SO MEDICAL PHYSICS LA English DT Editorial Material ID TUNGSTEN ALLOY MLC; MED. PHYS. 38(11); LATERAL PENUMBRA; THERAPY; SYSTEM; BEAM C1 [Daartz, Juliane] Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. [Maughan, Richard L.] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA. RP Daartz, J (reprint author), Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. EM jdaartz@partners.org; maughan@uphs.upenn.edu NR 10 TC 0 Z9 0 U1 0 U2 4 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2014 VL 41 IS 2 AR 020601 DI 10.1118/1.4824437 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AA6MV UT WOS:000331213300001 PM 24506589 ER PT J AU Jensen, C Urribarri, J Cail, D Rottmann, J Mishra, P Lingos, T Niedermayr, T Berbeco, R AF Jensen, Christopher Urribarri, Jaime Cail, Daniel Rottmann, Joerg Mishra, Pankaj Lingos, Tatiana Niedermayr, Thomas Berbeco, Ross TI Cine EPID evaluation of two non-commercial techniques for DIBH SO MEDICAL PHYSICS LA English DT Article DE DIBH; EPID; in-treatment imaging ID INSPIRATION BREATH-HOLD; CANCER PATIENTS; RADIATION-THERAPY; RADIOTHERAPY; SURVIVORS; GUIDANCE; TRIALS; HEART; RISK; LUNG AB Purpose: To evaluate the efficacy of two noncommercial techniques for deep inspiration breathhold (DIBH) treatment of left-sided breast cancer (LSBC) using cine electronic portal imaging device (EPID) images. Methods: 23 875 EPID images of 65 patients treated for LSBC at two different cancer treatment centers were retrieved. At the Milford Regional Cancer Center, DIBH stability was maintained by visual alignment of inroom lasers and patient skin tattoos (TAT). At the South Shore Hospital, a distance-measuring laser device (RTSSD) was implemented. For both centers, cine EPID images were acquired at least once per week during beam-on. Chest wall position relative to image boundary was measured and tracked over the course of treatment for every patient and treatment fraction for which data were acquired. Results: Median intrabeam chest motion was 0.31 mm for the TAT method and 0.37 mm for the RTSSD method. The maximum excursions exceeded our treatment protocol threshold of 3 mm in 0.3% of cases (TAT) and 1.2% of cases (RTSSD). The authors did not observe a clinically significant difference between the two datasets. Conclusions: Both noncommercial techniques for monitoring the DIBH location provided DIBH stability within the predetermined treatment protocol parameters (<3 mm). The intreatment imaging offered by the EPID operating in cine mode facilitates retrospective analysis and validation of both techniques. (C) 2014 American Association of Physicists in Medicine. C1 [Jensen, Christopher; Urribarri, Jaime; Cail, Daniel; Rottmann, Joerg; Mishra, Pankaj; Lingos, Tatiana; Niedermayr, Thomas; Berbeco, Ross] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Berbeco, R (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. EM rberbeco@lroc.harvard.edu NR 16 TC 4 Z9 4 U1 0 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2014 VL 41 IS 2 AR 021730 DI 10.1118/1.4862835 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AA6MV UT WOS:000331213300033 PM 24506621 ER PT J AU Tsiamas, P Mishra, P Cifter, F Berbeco, RI Marcus, K Sajo, E Zygmanski, P AF Tsiamas, P. Mishra, P. Cifter, F. Berbeco, R. I. Marcus, K. Sajo, E. Zygmanski, P. TI Low-Z linac targets for low-MV gold nanoparticle radiation therapy SO MEDICAL PHYSICS LA English DT Article DE dose enhancement; gold nanoparticle; Monte Carlo; flattening-filter-free; low-Z target ID MEGAVOLTAGE PHOTON BEAMS; DOSE ENHANCEMENT; MONTE-CARLO; BREMSSTRAHLUNG TARGETS; ACCELERATOR TARGETS; CARBON TARGET; CONTRAST; ENERGY; GENERATION; DEPENDENCE AB Purpose: To investigate the potential of low-Z/low-MV (low-Z) linac targets for gold nanoparticle radiotherapy (GNPT) and to determine the microscopic dose enhancement ratio (DER) due to GNP for the alternative beamlines. In addition, to evaluate the degradation of dose enhancement arising from the increased attenuation of x rays and larger skin dose in water for the low-MV beams compared to the standard linac. Methods: Monte Carlo simulations were used to compute dose and DER for various flattening-filterfree beams (2.5, 4, 6.5 MV). Target materials were beryllium, diamond, and tungsten-copper high-Z target. Target thicknesses were selected based on 20%, 60%, 70%, and 80% of the continuous slowing down approximation electron ranges for a given target material and energy. Evaluation of the microscopic DER was carried out for 100 nm GNP including the degradation factors due to beam attenuation. Results: The greatest increase in DER compared to the standard 6.5 MV linac was for a 2.5 MV Be-target (factor of similar to 2). Skin dose ranged from similar to 10% (Be, 6.5 MV-80%) to similar to 85% (Be, 2.5 MV20%) depending on the target case. Attenuation of 2.5 MV beams at 22 cm was higher by similar to 75% compared with the standard beam. Taking into account the attenuation at 22 cm depth, the effective dose enhancement was up to similar to 60% above the DER of the high-Z target. For these cases the effective DER ranged between similar to 1.6 and 6 compared with the standard linac. Conclusions: Low-Z (2.5 MV) GNPT is possible even after accounting for greater beam attenuation for deep-seated tumors (22 cm) and the increased skin dose. Further, it can lead to significant sparing of normal tissue while simultaneously escalating the dose in the tumor cells. (C) 2014 American Association of Physicists in Medicine. C1 [Tsiamas, P.; Mishra, P.; Berbeco, R. I.; Marcus, K.; Zygmanski, P.] Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA. [Tsiamas, P.; Mishra, P.; Berbeco, R. I.; Marcus, K.; Zygmanski, P.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Cifter, F.; Sajo, E.] Univ Massachusetts Lowell, Dept Phys & Appl Phys, Med Phys Program, Lowell, MA 01854 USA. RP Zygmanski, P (reprint author), Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA. EM Erno_Sajo@uml.edu; pzygmanski@lroc.harvard.edu NR 24 TC 4 Z9 4 U1 1 U2 9 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2014 VL 41 IS 2 AR 021701 DI 10.1118/1.4859335 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AA6MV UT WOS:000331213300004 PM 24506592 ER PT J AU Brusic, V Gottardo, R Kleinstein, SH Davis, MM AF Brusic, Vladimir Gottardo, Raphael Kleinstein, Steven H. Davis, Mark M. CA HIPC Steering Comm TI Computational resources for high-dimensional immune analysis from the Human Immunology Project Consortium SO NATURE BIOTECHNOLOGY LA English DT Letter ID FLOW-CYTOMETRY DATA; MINIMUM INFORMATION C1 [Brusic, Vladimir] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Gottardo, Raphael] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA. [Kleinstein, Steven H.] Yale Univ, Interdept Program Computat Biol & Bioinformat, New Haven, CT USA. [Kleinstein, Steven H.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. [Davis, Mark M.] Stanford Univ, Howard Hughes Med Inst, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA. [Davis, Mark M.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA. RP Brusic, V (reprint author), Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. EM vladimir_brusic@dfci.harvard.edu; rgottard@fhcrc.organd FU Howard Hughes Medical Institute; NIAID NIH HHS [U01 AI089859] NR 19 TC 20 Z9 20 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 EI 1546-1696 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD FEB PY 2014 VL 32 IS 2 BP 146 EP 148 DI 10.1038/nbt.2777 PG 3 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA AA4NY UT WOS:000331074000019 PM 24441472 ER PT J AU Brastianos, PK Taylor-Weiner, A Manley, PE Jones, RT Dias-Santagata, D Thorner, AR Lawrence, MS Rodriguez, FJ Bernardo, LA Schubert, L Sunkavalli, A Shillingford, N Calicchio, ML Lidov, HGW Taha, H Martinez-Lage, M Santi, M Storm, PB Lee, JYK Palmer, JN Adappa, ND Scott, RM Dunn, IF Laws, ER Stewart, C Ligon, KL Hoang, MP Van Hummelen, P Hahn, WC Louis, DN Resnick, AC Kieran, MW Getz, G Santagata, S AF Brastianos, Priscilla K. Taylor-Weiner, Amaro Manley, Peter E. Jones, Robert T. Dias-Santagata, Dora Thorner, Aaron R. Lawrence, Michael S. Rodriguez, Fausto J. Bernardo, Lindsay A. Schubert, Laura Sunkavalli, Ashwini Shillingford, Nick Calicchio, Monica L. Lidov, Hart G. W. Taha, Hala Martinez-Lage, Maria Santi, Mariarita Storm, Phillip B. Lee, John Y. K. Palmer, James N. Adappa, Nithin D. Scott, R. Michael Dunn, Ian F. Laws, Edward R., Jr. Stewart, Chip Ligon, Keith L. Hoang, Mai P. Van Hummelen, Paul Hahn, William C. Louis, David N. Resnick, Adam C. Kieran, Mark W. Getz, Gad Santagata, Sandro TI Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas SO NATURE GENETICS LA English DT Article ID HUMAN CANCER; ADAMANTINOMATOUS CRANIOPHARYNGIOMAS; METASTATIC MELANOMA; V600E MUTATION; GENE-MUTATIONS; BETA-CATENIN; VEMURAFENIB; TUMORS; RESISTANCE; INHIBITORS AB Craniopharyngiomas are epithelial tumors that typically arise in the suprasellar region of the brain(1). Patients experience substantial clinical sequelae from both extension of the tumors and therapeutic interventions that damage the optic chiasm, the pituitary stalk and the hypothalamic area(2-4). Using whole-exome sequencing, we identified mutations in CTNNB1 (beta-catenin) in nearly all adamantinomatous craniopharyngiomas examined (11/12, 92%) and recurrent mutations in BRAF (resulting in p. Val600Glu) in all papillary craniopharyngiomas (3/3, 100%). Targeted genotyping revealed BRAF p. Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors). The CTNNB1 and BRAF mutations were clonal in each tumor subtype, and we detected no other recurrent mutations or genomic aberrations in either subtype. Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms. C1 [Brastianos, Priscilla K.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Brastianos, Priscilla K.] Massachusetts Gen Hosp, Div Neurooncol, Boston, MA 02114 USA. [Brastianos, Priscilla K.; Dias-Santagata, Dora; Lidov, Hart G. W.; Scott, R. Michael; Dunn, Ian F.; Laws, Edward R., Jr.; Ligon, Keith L.; Hoang, Mai P.; Hahn, William C.; Louis, David N.; Kieran, Mark W.; Getz, Gad; Santagata, Sandro] Harvard Univ, Sch Med, Boston, MA USA. [Brastianos, Priscilla K.; Jones, Robert T.; Thorner, Aaron R.; Ligon, Keith L.; Van Hummelen, Paul] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Brastianos, Priscilla K.; Taylor-Weiner, Amaro; Lawrence, Michael S.; Stewart, Chip; Hahn, William C.; Getz, Gad] Broad Inst MIT & Harvard, Boston, MA USA. [Manley, Peter E.; Kieran, Mark W.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Jones, Robert T.; Thorner, Aaron R.; Schubert, Laura; Sunkavalli, Ashwini; Van Hummelen, Paul; Hahn, William C.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Dias-Santagata, Dora; Bernardo, Lindsay A.; Hoang, Mai P.; Louis, David N.; Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Rodriguez, Fausto J.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA. [Shillingford, Nick; Calicchio, Monica L.; Lidov, Hart G. W.; Ligon, Keith L.; Santagata, Sandro] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Lidov, Hart G. W.; Ligon, Keith L.; Santagata, Sandro] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Taha, Hala] Childrens Canc Hosp Egypt, Cairo, Egypt. [Martinez-Lage, Maria] Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Santi, Mariarita] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA. [Storm, Phillip B.; Lee, John Y. K.; Palmer, James N.; Resnick, Adam C.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA. [Storm, Phillip B.; Resnick, Adam C.] Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA. [Palmer, James N.; Adappa, Nithin D.] Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Scott, R. Michael] Boston Childrens Hosp, Dept Neurosurg, Boston, MA USA. [Dunn, Ian F.; Laws, Edward R., Jr.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Kieran, Mark W.] Boston Childrens Hosp, Dept Pediat, Boston, MA USA. [Santagata, Sandro] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. RP Brastianos, PK (reprint author), Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. EM pbrast@broadinstitute.org; gadgetz@broadinstitute.org; ssantagata@partners.org OI Martinez-Lage, Maria/0000-0002-5859-7562; Brastianos, Priscilla/0000-0003-4470-8425; Kieran, Mark/0000-0003-2184-7692 FU Brain Science Foundation [K12 CA090354-11, K08 NS064168]; Terri Brodeur Breast Cancer Foundation; Conquer Cancer Foundation; American Brain Tumor Association FX We thank M. Ducar for his assistance with genomic analyses; S. Chauvin for project management; L. Brown and H. Malkin for assisting with sample collection; T. Woo, B. Rich, R. Machaidze and D. Feldman for technical assistance; N. Stransky for the design of Figure 2a; and H. Taylor-Weiner and C. H. Brastianos for critical review of the manuscript. This work was supported by the Jared Branfman Sunflowers for Life Fund for Pediatric Brain and Spinal Cancer Research, the Pediatric Low-Grade Astrocytoma (PLGA) Program (S. S., W. C. H. and Charles D. Stiles), Pedals for Pediatrics and the Clark Family (P. E. M. and M. W. K.), the Stahl Family Charitable Foundation (P. E. M.), the Stop & Shop Pediatric Brain Tumor Program (P. E. M. and M. W. K.), the Pediatric Brain Tumor Clinical and Research Fund (P. E. M. and M. W. K.), the Children's Brain Tumor Foundation and the V Foundation (S. S.). S. S. is supported by grant K08 NS064168, and P. K. B. is supported by grant K12 CA090354-11, the Brain Science Foundation, Susan G. Komen for the Cure, the Terri Brodeur Breast Cancer Foundation, the Conquer Cancer Foundation and the American Brain Tumor Association. NR 50 TC 66 Z9 70 U1 3 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD FEB PY 2014 VL 46 IS 2 BP 161 EP U100 DI 10.1038/ng.2868 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA AA6KX UT WOS:000331208300012 PM 24413733 ER PT J AU Liu, DJJ Peloso, GM Zhan, XW Holmen, OL Zawistowski, M Feng, S Nikpay, M Auer, PL Goel, A Zhang, H Peters, U Farrall, M Orho-Melander, M Kooperberg, C McPherson, R Watkins, H Willer, CJ Hveem, K Melander, O Kathiresan, S Abecasis, GR AF Liu, Dajiang J. Peloso, Gina M. Zhan, Xiaowei Holmen, Oddgeir L. Zawistowski, Matthew Feng, Shuang Nikpay, Majid Auer, Paul L. Goel, Anuj Zhang, He Peters, Ulrike Farrall, Martin Orho-Melander, Marju Kooperberg, Charles McPherson, Ruth Watkins, Hugh Willer, Cristen J. Hveem, Kristian Melander, Olle Kathiresan, Sekar Abecasis, Goncalo R. TI Meta-analysis of gene- level tests for rare variant association SO NATURE GENETICS LA English DT Article ID COMPLEX TRAITS; POLYMORPHISMS; STATISTICS; SEQUENCE; DEEP; STRATEGIES; DISCOVERY; FRAMEWORK; DISEASE; MODEL AB The majority of reported complex disease associations for common genetic variants have been identified through metaanalysis, a powerful approach that enables the use of large sample sizes while protecting against common artifacts due to population structure and repeated small-sample analyses sharing individuallevel data. As the focus of genetic association studies shifts to rare variants, genes and other functional units are becoming the focus of analysis. Here we propose and evaluate new approaches for performing meta-analysis of rare variant association tests, including burden tests, weighted burden tests, variable-threshold tests and tests that allow variants with opposite effects to be grouped together. We show that our approach retains useful features from single-variant meta-analysis approaches and demonstrate its use in a study of blood lipid levels in similar to 18,500 individuals genotyped with exome arrays. C1 [Liu, Dajiang J.; Zhan, Xiaowei; Zawistowski, Matthew; Feng, Shuang; Abecasis, Goncalo R.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA. [Peloso, Gina M.; Kathiresan, Sekar] Broad Inst Harvard & MIT, Cambridge, MA USA. [Peloso, Gina M.; Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Peloso, Gina M.; Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Holmen, Oddgeir L.; Hveem, Kristian] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, HUNT Res Ctr, Levanger, Norway. [Holmen, Oddgeir L.] Univ Trondheim Hosp, St Olav Hosp, Trondheim, Norway. [Nikpay, Majid; McPherson, Ruth] Univ Ottawa, Inst Heart, Ottawa, ON, Canada. [Auer, Paul L.; Peters, Ulrike; Kooperberg, Charles] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Auer, Paul L.] Univ Wisconsin, Sch Publ Hlth, Milwaukee, WI 53201 USA. [Goel, Anuj; Farrall, Martin; Watkins, Hugh] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Goel, Anuj; Farrall, Martin; Orho-Melander, Marju; Watkins, Hugh; Melander, Olle] Univ Oxford, Dept Cardiovasc Med, Oxford, England. [Zhang, He; Willer, Cristen J.] Univ Michigan, Sch Med, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA. [Zhang, He; Willer, Cristen J.] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA. [Peters, Ulrike] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Orho-Melander, Marju; Melander, Olle] Lund Univ, Dept Clin Sci, Malmo, Sweden. [Kooperberg, Charles] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Hveem, Kristian] Nord Trondelag Hlth Trust, Levanger Hosp, Dept Med, Levanger, Norway. [Kathiresan, Sekar] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Liu, DJJ (reprint author), Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA. EM dajiang@umich.edu; goncalo@umich.edu OI Watkins, Hugh/0000-0002-5287-9016 FU National Human Genome Research Institute [R01HG007022]; National Eye Institute [R01EY022005]; National Heart, Lung, and Blood Institute [R01HL117626, T32HL007208]; Massachusetts General Hospital (MGH); Howard Goodman Fellowship from MGH, the Donovan Family Foundation [R01HL107816]; National Heart, Lung, and Blood Institute, US National Institutes of Health, US Department of Health and Human Services [N01WH22110, N01WH24152, N01WH32100-2, N01WH32105-6, N01WH32108-9, N01WH32111-13, N01WH32115, N01WH32118-32119, N01WH32122, N01WH42107-26, N01WH42129-32, N01WH44221]; Canadian Institutes of Health Research (CIHR) [MOP-82810, MOP-77682, MOP-2380941]; Canada Foundation for Innovation [11966]; Swedish Research Council; Swedish Heart and Lung Foundation; Phlsson Foundation; Novo Nordic Foundation and European Research Council [StG-282255] FX The authors would like to thank M. Boehnke, X. Wen and S. Zoellner for helpful discussions. This work was supported by research grants R01HG007022 from the National Human Genome Research Institute, R01EY022005 from the National Eye Institute and R01HL117626 from the National Heart, Lung, and Blood Institute. G. M. P. was supported by award T32HL007208 from the National Heart, Lung, and Blood Institute. S. K. is supported by a Research Scholar award from Massachusetts General Hospital (MGH), the Howard Goodman Fellowship from MGH, the Donovan Family Foundation and grant R01HL107816 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the US National Institutes of Health. The WHI program is funded by the National Heart, Lung, and Blood Institute, US National Institutes of Health, US Department of Health and Human Services through contracts N01WH22110, N01WH24152, N01WH32100-2, N01WH32105-6, N01WH32108-9, N01WH32111-13, N01WH32115, N01WH32118-32119, N01WH32122, N01WH42107-26, N01WH42129-32 and N01WH44221. This manuscript was prepared in collaboration with investigators from the WHI and has been approved by the WHI. WHI investigators are listed at https://cleo. whi. org/ researchers/SitePages/WHI% 20Investigators. aspx. The full list of PROCARDIS acknowledgments is available at http://www. procardis. org/. The Ottawa Heart Genomics Study was supported by Canadian Institutes of Health Research (CIHR) grants MOP-82810, MOP-77682 and MOP-2380941 and Canada Foundation for Innovation (CFI) grant 11966. The studies for the Malm Diet and Cancer cohort were supported by grants from the Swedish Research Council, the Swedish Heart and Lung Foundation, the Phlsson Foundation, the Novo Nordic Foundation and European Research Council starting grant StG-282255. NR 39 TC 64 Z9 65 U1 1 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD FEB PY 2014 VL 46 IS 2 BP 200 EP + DI 10.1038/ng.2852 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA AA6KX UT WOS:000331208300019 PM 24336170 ER PT J AU Zumbrennen-Bullough, K Babitt, JL AF Zumbrennen-Bullough, Kimberly Babitt, Jodie L. TI The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Review DE anemia; chronic kidney disease; hepcidin; iron; review ID TRANSFERRIN RECEPTOR 2; HEREDITARY HEMOCHROMATOSIS PROTEIN; RETICULOCYTE HEMOGLOBIN CONTENT; REGULATES HEPCIDIN EXPRESSION; CHRONIC-RENAL-FAILURE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; ANTIMICROBIAL PEPTIDE HEPCIDIN; ANEMIC HEMODIALYSIS-PATIENTS; INFLAMMATION-INDUCED ANEMIA; DIFFERENTIATION FACTOR 15 AB Iron is essential for most living organisms but iron excess can be toxic. Cellular and systemic iron balance is therefore tightly controlled. Iron homeostasis is dysregulated in chronic kidney disease (CKD) and contributes to the anemia that is prevalent in this patient population. Iron supplementation is one cornerstone of anemia management in CKD patients, but has not been rigorously studied in large prospective randomized controlled trials. This review highlights important advances from genetic studies and animal models that have provided key insights into the molecular mechanisms governing iron homeostasis and its disturbance in CKD, and summarizes how these findings may yield advances in the care of this patient population. C1 [Zumbrennen-Bullough, Kimberly; Babitt, Jodie L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Syst Biol, Program Anemia Signaling Res,Div Nephrol,Program, Boston, MA 02115 USA. RP Babitt, JL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Syst Biol, Program Anemia Signaling Res,Div Nephrol,Program, Boston, MA 02115 USA. EM babitt.jodie@mgh.harvard.edu FU NIH [RO1-DK087727]; Massachusetts General Hospital FX J.L.B. was supported in part by NIH grant RO1-DK087727 and a Howard Goodman Fellowship Award from the Massachusetts General Hospital. NR 164 TC 8 Z9 8 U1 1 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD FEB PY 2014 VL 29 IS 2 BP 263 EP 273 DI 10.1093/ndt/gft443 PG 11 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA AA9HJ UT WOS:000331404100009 PM 24235084 ER PT J AU McMahon, GM O'Seaghdha, CM Hwang, SJ Meigs, JB Fox, CS AF McMahon, Gearoid M. O'Seaghdha, Conall M. Hwang, Shih-Jen Meigs, James B. Fox, Caroline S. TI The association of a single-nucleotide polymorphism in CUBN and the risk of albuminuria and cardiovascular disease SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE epidemiology ID RENAL PROXIMAL TUBULE; DIABETIC-NEPHROPATHY; UNMODIFIED ALBUMIN; CUBILIN; KIDNEY; PROTEINURIA; HEART; MICROALBUMINURIA; CELLS; EXCRETION AB Background. Albuminuria is an important risk factor for cardiovascular disease (CVD). We have previously identified a missense single-nucleotide polymorphism (rs1801239) in the CUBN gene that is associated with albuminuria. Whether albuminuria is associated with CVD in the presence of the CUBN mutation is unknown. Methods. We analyzed participants from the Framingham Heart Study (n = 6399, mean age 47 years, 53.4% women) who underwent genotyping of rs1801239. Cox proportional hazards models were used to test the association between microalbuminuria [UACR >= 17 mg/g (men) and >= 25 mg/g (women)] and incident CVD stratified by the presence or absence of the CUBN risk allele. We tested whether the association between microalbuminuria and CVD was altered by the presence of the risk allele with interaction testing. Results. Overall, 21.1% of participants carried the risk allele. As expected, carriers of the risk (C) allele had a higher prevalence of microalbuminuria (10.7 versus 8.9%, P = 0.04). During a mean follow-up of 10.4 years, 5.6% (n = 346) of participants experienced a CVD event. Microalbuminuria was associated with an increased risk of CVD [hazards ratio (HR) 1.46, 95% confidence interval (CI) 1.14-1.88]. When stratified by risk allele carrier status, the HR for CVD was 1.95 (95% CI 1.15-3.29) among those with compared to 1.33 (95% CI 1.00-1.76) among those without the risk allele. There was no interaction between microalbuminuria and rs1801239 on CVD (P-interaction = 0.49). Conclusions. MA is associated with CVD irrespective of the presence of the CUBN risk allele. These results challenge the concept that albuminuria in the setting of this mutation is benign. C1 [McMahon, Gearoid M.; O'Seaghdha, Conall M.; Hwang, Shih-Jen; Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA. [McMahon, Gearoid M.; O'Seaghdha, Conall M.; Hwang, Shih-Jen; Fox, Caroline S.] NHLBI, Ctr Populat Studies, Framingham, MA USA. [McMahon, Gearoid M.; Fox, Caroline S.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [McMahon, Gearoid M.; Meigs, James B.; Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA. [O'Seaghdha, Conall M.] Beaumont Hosp, Div Nephrol & Transplantat, Dublin 9, Ireland. [Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA. RP Fox, CS (reprint author), NHLBI, Framingham Heart Study, Framingham, MA 01702 USA. EM foxca@nhlbi.nih.gov OI McMahon, Gearoid/0000-0002-7723-2198 FU [N01-HC-25195]; [K24 DK080140] FX The Framingham Heart Study of the National Heart, Lung and Blood Institute is supported by contract N01-HC-25195. J.B.M. is supported by K24 DK080140. NR 38 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD FEB PY 2014 VL 29 IS 2 BP 342 EP 347 DI 10.1093/ndt/gft386 PG 6 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA AA9HJ UT WOS:000331404100017 PM 24052458 ER PT J AU O'Connell, BP Schlosser, RJ Wentzel, JL Nagel, W Mulligan, JK AF O'Connell, Brendan P. Schlosser, Rodney J. Wentzel, Jennifer L. Nagel, Whitney Mulligan, Jennifer K. TI Systemic Monocyte-Derived Dendritic Cells and Associated Th2 Skewing in Chronic Rhinosinusitis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE chronic rhinosinusitis; nasal polyposis; dendritic cells; t-helper cells; Th2 inflammation ID ALLERGIC FUNGAL RHINOSINUSITIS; AIRWAY EPITHELIAL-CELLS; DUST MITE ALLERGEN; NASAL POLYPS; CHEMOKINE RECEPTORS; CHRONIC SINUSITIS; PERIPHERAL-BLOOD; CUTTING EDGE; IMMUNITY; EXPRESSION AB Introduction Monocyte-derived dendritic cells (moDCs) are antigen-presenting cells capable of directing immune responses toward T-helper 1 (Th1) or T-helper 2 (Th2) phenotypes. The systemic profile of moDCs and their association with Th1/Th2 skewing in chronic rhinosinusitis (CRS) is unclear. The purpose of this study is to characterize circulating moDCs in controls, CRS without nasal polyps (CRSsNP), and CRS with nasal polyps (CRSwNP) and correlate moDCs with Th1/Th2 skewing, mucosal inflammation on computed tomography (CT), and quality of life (QoL). Study Design Cross-sectional study. Setting Tertiary care hospital. Subjects Blood was drawn from control (n = 12), CRSsNP (n = 18), and CRSwNP (n = 15) patients during endoscopic sinus surgery. Methods Peripheral blood moDCs were analyzed with flow cytometry for expression of HLA-DR, CD209, and CD14. Th1 and Th2 cells were identified by CXCR3 and CCR8 expression, respectively. Lund-Mackay CT scores were assigned by blinded graders. Sino-Nasal Outcome Test 22 (SNOT-22) surveys were completed by patients before surgery. Results CRSsNP and CRSwNP displayed elevations in systemic moDCs compared with controls. In CRSwNP, systemic Th2 skewing was observed and circulating CD4+ Th2 cells correlated with percent moDCs. MoDCs strongly correlated with higher Lund-Mackay CT scores in CRSsNP but not in CRSwNP. No relationship between moDCs and SNOT-22 scores was observed for either subset of CRS. Conclusion These data support that CRSwNP and CRSsNP display alterations in systemic immune profiles. CRSwNP is characterized by significant elevations in circulating moDCs, which is associated with systemic Th2-biased inflammation. Circulating moDCs are associated with mucosal inflammation on CT imaging in CRSsNP. No association between moDCs and QoL is evident in either CRS subset. C1 [O'Connell, Brendan P.; Schlosser, Rodney J.; Wentzel, Jennifer L.; Nagel, Whitney; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Mulligan, JK (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu FU American Academy of Otolaryngology-Head and Neck Surgery Resident Research Award, CORE grant [277809]; Flight Attendant Medical Research Institute [092401, 113039]; Clinical Sciences Research and Development Program of the Department of Veterans Affairs [1 I01 CX000377] FX American Academy of Otolaryngology-Head and Neck Surgery Resident Research Award, CORE grant (277809 [B.P.O.]), Flight Attendant Medical Research Institute (092401 [J.K.M.] and 113039 [R.J.S.]), and Merit-review award from Clinical Sciences Research and Development Program of the Department of Veterans Affairs (1 I01 CX000377). NR 44 TC 5 Z9 5 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2014 VL 150 IS 2 BP 312 EP 320 DI 10.1177/0194599813516277 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AA6PH UT WOS:000331219800024 PM 24367054 ER PT J AU Leitzen, KP Brietzke, SE Lindsay, RW AF Leitzen, Keith P. Brietzke, Scott E. Lindsay, Robin W. TI Correlation between Nasal Anatomy and Objective Obstructive Sleep Apnea Severity SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE nasal anatomy; obstructive sleep apnea; nasal obstruction; snoring; NOSE; SOS; OSA ID VALIDATION; RESISTANCE; SURGERY; SCALE AB Objectives: To determine if a correlation exists between nasal anatomical obstruction and obstructive sleep apnea severity as measured by overnight polysomnogram (PSG). Study Design Cross-sectional study. Setting Tertiary medical center. Subjects and Methods Subjects were recruited immediately prior to an overnight, in-lab PSG. All subjects who agreed to participate underwent a standardized nasal examination performed by the senior author and then completed the Nasal Obstruction Symptom Evaluation (NOSE) questionnaire, the Snore Outcomes Survey (SOS), and the Epworth Sleepiness Scale (ESS) prior to their sleep study. In addition, tonsil size, Mallampati score, Friedman tongue position, neck circumference, uvula length, and occlusion were assessed and documented. Nasal anatomy assessments were then compared with PSG, NOSE, SOS, and ESS results. Bonferroni correction was used to account for multiple comparisons. Results One hundred subjects were included in the study. Fifty-nine subjects (59%) were found to have obstructive sleep apnea syndrome (OSAS) (mean apnea-hypopnea index, 13.1; range, 0-64). Severity of OSAS was associated with age (Spearman's = 0.386, P = .0001). No single nasal anatomy measurement or combined nasal anatomy index was found to correlate with objective sleep-disordered breathing severity measured by PSG. The sample size should have provided 90% power to detect a significant correlation if one existed. After accounting for multiple comparisons, turbinate hypertrophy was found to correlate with the NOSE score (0.3577, P = .0305 corrected), and external and internal nasal valve collapse correlated with each other (0.4986, P < .0001 corrected). Conclusions Objectively assessed abnormal nasal anatomy was not found to be significantly correlated with PSG-measured OSAS severity. Specific objective measurements of obstructive nasal anatomy were correlated to subjective measures of nasal obstruction. C1 [Leitzen, Keith P.; Brietzke, Scott E.] Walter Reed Natl Mil Med Ctr, Dept Otolaryngol Head & Neck Surg, Bethesda, MD USA. [Lindsay, Robin W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Lindsay, Robin W.] Harvard Univ, Sch Med, Boston, MA USA. RP Lindsay, RW (reprint author), Massachusetts Eye & Ear Infirm, Div Facial Plast & Reconstruct Surg, 243 Charles St, Boston, MA 02114 USA. EM robin_lindsay@meei.harvard.edu NR 24 TC 6 Z9 6 U1 1 U2 18 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2014 VL 150 IS 2 BP 325 EP 331 DI 10.1177/0194599813515838 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AA6PH UT WOS:000331219800026 PM 24334963 ER PT J AU Oto, J Chenelle, CT Marchese, AD Kacmarek, RM AF Oto, Jun Chenelle, Christopher T. Marchese, Andrew D. Kacmarek, Robert M. TI A Comparison of Leak Compensation During Pediatric Noninvasive Ventilation: A Lung Model Study SO RESPIRATORY CARE LA English DT Article DE leak compensation; pediatric noninvasive ventilation; acute care ventilator ID ACUTE RESPIRATORY-FAILURE; MECHANICAL VENTILATION; PRESSURE SUPPORT; ICU VENTILATORS; CHILDREN; ASYNCHRONY; PERFORMANCE; TRIGGER; BENCH AB BACKGROUND: Ventilators used for noninvasive ventilation (NIV) must be able to synchronize in the presence of system leaks. We compared the ability of 7 ICU ventilators and 3 dedicated NIV ventilators to compensate for leaks during pediatric NW. METHODS: Using a lung simulator, we compared the Magnet Servo-i, Drager V500, Drager Carina, Covidien PB840, Respironics V60, Respironics Vision, GE Healthcare/Engstrom Carestation, Care Fusion Avea, Hamilton C3, and Hamilton G5 during increasing (n = 6) and decreasing leaks (n = 6). With a lung simulator we tested 4 leak levels (baseline [BL] 2-3 L/min, L1 5-6 L/min, L2 9-10 L/min, and L3 19-20 L/min); 3 patient weights (10, 20, and 30 kg); and 3 lung mechanics scenarios (normal, obstructive, and restrictive). The ventilator settings were NIV mode, pressure support of 10 cm H2O, and PEEP of 5 cm H2O. The synchronization rate (synchronized cycles/total simulated respirations) was recorded for each ventilator and each leak scenario. Synchronization was defined as triggering without auto-triggering, miss-triggering, delayed cycling, or premature cycling. RESULTS: The mean synchronization rate across all ventilators was 68 +/- 27% (range 23-96%) and marked differences existed between the ventilators (P < .001). Significant differences in synchronization rate were observed between the 10-kg model (mean 57 +/- 30%, range 17-93%), the 20-kg model (69 +/- 30%, 25-98%), and the 30-kg models (77 +/- 22%, 28-97%) (P < .001). The synchronization rate for the obstructive model (60 +/- 30%, 9-94%) was significantly different from the normal model (71 +/- 29%, 18-98%) and the restrictive model (72 +/- 28%, 23-98%) (P < .001). The PB840 and the C3 had synchronization rates over 90% overall across all body weights, all lung mechanic profiles, and all leak levels. CONCLUSIONS: Leak compensation in NIV for pediatric use can partially compensate for leaks, but varies widely among ventilators, patient weights, and lung mechanics. C1 [Oto, Jun; Chenelle, Christopher T.; Marchese, Andrew D.; Kacmarek, Robert M.] Massachusetts Gen Hosp, Resp Care Serv, Boston, MA 02114 USA. RP Kacmarek, RM (reprint author), Massachusetts Gen Hosp, Resp Care Serv, 55 Fruit St, Boston, MA 02114 USA. EM rkacmarek@partners.org OI Chenelle, Christopher/0000-0002-1499-9973 FU Covidien FX This study was partly supported by Covidien. Dr Kacmarek has disclosed relationships with Maquet and Covidien. The other authors have disclosed no conflicts of interest. NR 25 TC 6 Z9 6 U1 0 U2 2 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD FEB PY 2014 VL 59 IS 2 BP 241 EP 251 DI 10.4187/respcare.02616 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AA9QK UT WOS:000331427800012 PM 23821761 ER PT J AU Pompili, M Innamorati, M Di Vittorio, C Sher, L Girardi, P Amore, M AF Pompili, Maurizio Innamorati, Marco Di Vittorio, Cristina Sher, Leo Girardi, Paolo Amore, Mario TI Sociodemographic and Clinical Differences Between Suicide Ideators and Attempters: A Study of Mood Disordered Patients 50 Years and Older SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID LATE-ONSET DEPRESSION; TOWER-OF-BABEL; BIPOLAR-DISORDER; GENERAL-POPULATION; MAJOR DEPRESSION; LIFE EVENTS; PSYCHOMETRIC PROPERTIES; GERIATRIC DEPRESSION; REVISED NOMENCLATURE; LITHIUM TREATMENT AB Our study sought to characterize mood disordered suicide ideators and attempters 50years and older admitted to a psychiatric ward either for a recent suicide attempt or for ongoing suicidal ideation. We enrolled 50 patients with suicide ideation consecutively admitted to an inpatient department and 50 patients admitted for a suicide attempt made in the last 48hours. Suicide attempters more frequently had low social support and an age of onset of mood disorder of 46years and older, and less frequently had a history of suicidal behaviors in the family members and pharmacological treatment, despite the fact that the groups did not differ with regard to antidepressants prescribed. The groups were not distinguishable based on several variables assumed to be risk factors for suicide behavior, such as proximal life events and stressors or alcohol use disorders. In both samples, comorbidity with organic diseases, the presence of stressful life events in the past 12months, and a diagnosis of major depression were frequently reported. In conclusion, the presence of low social support and the absence of a pharmacotherapy may increase suicidal behaviors in patients at risk. C1 [Pompili, Maurizio; Girardi, Paolo] Univ Roma La Sapienza, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, I-00185 Rome, Italy. [Innamorati, Marco; Di Vittorio, Cristina] Univ Parma, Dept Neurosci, Div Psychiat, I-43100 Parma, Italy. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Amore, Mario] Univ Genoa, Sect Psychiat, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy. RP Pompili, M (reprint author), St Andrea Hosp, Dept Psychiat, 1035,Via Grottarossa,1035, Rome, Italy. EM maurizio.pompili@uniroma1.it OI Innamorati, Marco/0000-0003-1389-2290; Pompili, Maurizio/0000-0003-1886-4977 NR 75 TC 6 Z9 6 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD FEB PY 2014 VL 44 IS 1 BP 34 EP 45 DI 10.1111/sltb.12051 PG 12 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA AA7CQ UT WOS:000331255100004 PM 23937195 ER PT J AU Slater, LH Clatworthy, AE Hung, DT AF Slater, Louise H. Clatworthy, Anne E. Hung, Deborah T. TI Bacterial toxins and small molecules elucidate endosomal trafficking SO TRENDS IN MICROBIOLOGY LA English DT Editorial Material ID ANTHRAX TOXIN; DELIVERY; RECEPTOR; INHIBITOR; PATHWAY; CELLS AB Bacterial toxins and small molecules are useful tools for studying eukaryotic cell biology. In a recent issue of PNAS, Gillespie and colleagues describe a novel small molecule inhibitor of bacterial toxins and virus trafficking through the endocytic pathway, 4-bromobenzaldehyde N-(2,6-dimethylphenyl)semicarbazone (EGA), that prevents transport from early to late endosomes. C1 [Slater, Louise H.] MedImmune, Cambridge, England. [Clatworthy, Anne E.; Hung, Deborah T.] Broad Inst Harvard & MIT, Program Infect Dis, Cambridge, MA 02141 USA. [Clatworthy, Anne E.; Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Clatworthy, Anne E.; Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA. RP Hung, DT (reprint author), Broad Inst Harvard & MIT, Program Infect Dis, Cambridge, MA 02141 USA. EM dhung@broadinstitute.org NR 10 TC 0 Z9 0 U1 1 U2 15 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0966-842X EI 1878-4380 J9 TRENDS MICROBIOL JI Trends Microbiol. PD FEB PY 2014 VL 22 IS 2 BP 53 EP 55 DI 10.1016/j.tim.2013.12.002 PG 3 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA AB0VT UT WOS:000331510900001 PM 24370463 ER PT J AU Lackner, JM Gudleski, GD Thakur, ER Stewart, TJ Iacobucci, GJ Spiegel, BMR AF Lackner, Jeffrey M. Gudleski, Gregory D. Thakur, Elyse R. Stewart, Travis J. Iacobucci, Gary J. Spiegel, Brennan M. R. CA IBS Outcome Study Research Grp TI The Impact of Physical Complaints, Social Environment, and Psychological Functioning on IBS Patients' Health Perceptions: Looking Beyond GI Symptom Severity SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; REPORTED OUTCOME MEASURES; SELF-RATED HEALTH; QUALITY-OF-LIFE; GASTROINTESTINAL SYMPTOMS; CLINICAL-TRIALS; UNITED-STATES; DISEASE; ILLNESS; ASSESSMENTS AB OBJECTIVES: In the absence of a reliable biomarker, clinical decisions for a functional gastrointestinal (GI) disorder like irritable bowel syndrome (IBS) depend on asking patients to appraise and communicate their health status. Self-ratings of health (SRH) have proven a powerful and consistent predictor of health outcomes, but little is known about how they relate to those relevant to IBS (e. g., quality of life (QOL), IBS symptom severity). This study examined what psychosocial factors, if any, predict SRH among a cohort of more severe IBS patients. METHODS: Subjects included 234 Rome III-positive IBS patients (mean age = 41 years, female = 78%) without comorbid organic GI disease. Subjects were administered a test battery that included the IBS Symptom Severity Scale, Screening for Somatoform Symptoms, IBS Medical Comorbidity Inventory, SF-12 Vitality Scale, Perceived Stress Scale, Beck Depression Inventory, Trait Anxiety Inventory, and Negative Interactions Scale. RESULTS: Partial correlations identified somatization, depression, fatigue, stress, anxiety, and medical comorbidities as variables with the strongest correlations with SRH (r values = 0.36-0.41, P values < 0.05). IBS symptom severity was weakly associated with SRH (r = 0.18, P < 0.05). The final regression model explained 41.3% of the variance in SRH scores (F = 8.49, P < 0.001) with significant predictors including fatigue, medical comorbidities, somatization, and negative social interactions. CONCLUSIONS: SRH are associated with psychological (anxiety, stress, depression), social (negative interactions), and extraintestinal somatic factors (fatigue, somatization, medical comorbidities). The severity of IBS symptoms appears to have a relatively modest role in how IBS patients describe their health in general. C1 [Lackner, Jeffrey M.; Gudleski, Gregory D.; Stewart, Travis J.; Iacobucci, Gary J.] SUNY Buffalo, Sch Med, Dept Med, Behav Med Clin, Buffalo, NY 14215 USA. [Thakur, Elyse R.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Lackner, JM (reprint author), SUNY Buffalo, Sch Med, ECMC, Behav Med Clin,Dept Med, 462 Grider St, Buffalo, NY 14215 USA. EM lackner@buffalo.edu FU NIH [DK77738] FX This study was funded by NIH grant DK77738. NR 61 TC 18 Z9 19 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2014 VL 109 IS 2 BP 224 EP 233 DI 10.1038/ajg.2013.410 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AA4IF UT WOS:000331058600011 PM 24419481 ER PT J AU Khanna, P Agarwal, N Khanna, D Hays, RD Chang, L Bolus, R Melmed, G Whitman, CB Kaplan, RM Ogawa, R Snyder, B Spiegel, BMR AF Khanna, Puja Agarwal, Nikhil Khanna, Dinesh Hays, Ron D. Chang, Lin Bolus, Roger Melmed, Gil Whitman, Cynthia B. Kaplan, Robert M. Ogawa, Rikke Snyder, Bradley Spiegel, Brennan M. R. TI Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID QUALITY-OF-LIFE; GASTROESOPHAGEAL-REFLUX DISEASE; IRRITABLE-BOWEL-SYNDROME; TREATMENT SATISFACTION QUESTIONNAIRE; GASTROINTESTINAL-TRACT INSTRUMENT; RANDOMIZED CONTROLLED-TRIAL; SYMPTOM-RATING-SCALE; LAPAROSCOPIC NISSEN FUNDOPLICATION; FECAL INCONTINENCE QUESTIONNAIRE; VISCERAL SENSITIVITY INDEX AB OBJECTIVES: Because gastrointestinal (GI) illnesses can cause physical, emotional, and social distress, patient-reported outcomes (PROs) are used to guide clinical decision making, conduct research, and seek drug approval. It is important to develop a mechanism for identifying, categorizing, and evaluating the over 100 GI PROs that exist. Here we describe a new, National Institutes of Health (NIH)-supported, online PRO clearinghouse-the GI-PRO database. METHODS: Using a protocol developed by the NIH Patient-Reported Outcome Measurement Information System (PROMIS (R)), we performed a systematic review to identify English-language GI PROs. We abstracted PRO items and developed an online searchable item database. We categorized symptoms into content "bins" to evaluate a framework for GI symptom reporting. Finally, we assigned a score for the methodological quality of each PRO represented in the published literature (0-20 range; higher indicates better). RESULTS: We reviewed 15,697 titles (kappa > 0.6 for title and abstract selection), from which we identified 126 PROs. Review of the PROs revealed eight GI symptom "bins" : (i) abdominal pain, (ii) bloat/gas, (iii) diarrhea, (iv) constipation, (v) bowel incontinence/soilage, (vi) heartburn/reflux, (vii) swallowing, and (viii) nausea/vomiting. In addition to these symptoms, the PROs covered four psychosocial domains: (i) behaviors, (ii) cognitions, (iii) emotions, and (iv) psychosocial impact. The quality scores were generally low (mean 8.88 +/- 4.19; 0 (min)-20 (max)). In addition, 51% did not include patient input in developing the PRO, and 41% provided no information on score interpretation. CONCLUSIONS: GI PROs cover a wide range of biopsychosocial symptoms. Although plentiful, GI PROs are limited by low methodological quality. Our online PRO library (www.researchcore.org/gipro/) can help in selecting PROs for clinical and research purposes. C1 [Khanna, Puja; Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Agarwal, Nikhil; Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA 90073 USA. [Agarwal, Nikhil; Melmed, Gil] Cedars Sinai Med Ctr, Dept Gastroenterol, Los Angeles, CA 90048 USA. [Hays, Ron D.; Kaplan, Robert M.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Hays, Ron D.; Kaplan, Robert M.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Chang, Lin; Bolus, Roger; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Bolus, Roger; Whitman, Cynthia B.; Snyder, Bradley; Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Ogawa, Rikke] Univ Calif Los Angeles, Biomed Lib Hlth Sci, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU National Institutes of Health through the NIH Roadmap for Medical Research [AR052177]; ACR Research and Education Foundation; NIAMS [K24AR063120-02]; NIH/NIA [P30-AG028748, P30-AG021684]; NCMHD [2P20MD000182]; Ironwood; Movetis; Shire Pharmaceuticals; Prometheus; Rose Pharma; Takeda; NIH/NIAMS [U01 AR057936A] FX NIH/NIAMS U01 AR057936A, the National Institutes of Health through the NIH Roadmap for Medical Research Grant (AR052177). Puja Khanna was supported by ACR Research and Education Foundation Career Development Bridge Funding Award 2011-12. Dinesh Khanna was also supported by NIAMS K24AR063120-02. Ron Hays was supported by NIH/NIA grants P30-AG028748 and P30-AG021684, and NCMHD grant 2P20MD000182. Brennan Spiegel has received grant support from Ironwood, Movetis, and Shire Pharmaceuticals. Lin Chang has received grant support from Prometheus, Rose Pharma, and Takeda. NR 169 TC 4 Z9 4 U1 4 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2014 VL 109 IS 2 BP 234 EP 248 DI 10.1038/ajg.2013.401 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AA4IF UT WOS:000331058600012 PM 24343547 ER PT J AU Ramanathan, S Johnson, S Burns, SP Kralovic, SM Goldstein, B Smith, B Gerding, DN Evans, CT AF Ramanathan, Swetha Johnson, Stuart Burns, Stephen P. Kralovic, Stephen M. Goldstein, Barry Smith, Bridget Gerding, Dale N. Evans, Charlesnika T. TI Recurrence of Clostridium difficile infection among veterans with spinal cord injury and disorder SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE C difficile infection; First recurrence; Veterans Affairs; Concomitant antibiotics; Length of stay ID PROTON PUMP INHIBITORS; 1ST RECURRENCE; RISK-FACTOR; DIARRHEA; EPIDEMIOLOGY; FIDAXOMICIN; VANCOMYCIN; DISEASE; MANAGEMENT; OUTCOMES AB Background: Recurrent Clostridiumdifficile (CDI) infection is a growing concern; however, there are little data on impact of recurrent CDI on those with spinal cord injury and disorder (SCI/D). Therefore, the objective of this study was to identify risk factors associated with recurrence of CDI among Veterans with SCI/D. Methods: This was a retrospective cohort study with data from outpatient, inpatient, and extended care settings at 83 Department of Veterans Affairs facilities from 2002 to 2009. Results: Of 1,464 cases of CDI analyzed, 315 cases (21.5%) had a first recurrence of CDI. Multivariable regression demonstrated that risk factors significantly associated with increased recurrence were concomitant fluoroquinolone use (odds ratio [OR], 1.39; 95% confidence interval [CI]: 1.08-1.80), whereas concomitant tetracycline use (OR, 0.35; 95% CI: 0.14-0.90), and cerebrovascular accident (OR, 0.46; 95% CI: 0.25-0.85) were associated with decreased recurrence. A subanalysis in those with health care facility-onset CDI showed that increased length of stay postinitial CDI was a significant risk factor for recurrence as was concomitant use of fluoroquinolones and that tetracycline remained protective for recurrence. Conclusion: Concomitant fluoroquinolone use was a risk factor for the recurrence of CDI. In contrast, tetracyclines and cerebrovascular accident were protective. Length of stay greater than 90 days from the initial CDI episode was also a risk factor for recurrence among those with health care facility-onset CDI. Future studies should focus on effective strategies to prevent these risk factors among the SCI/D population. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Ramanathan, Swetha; Smith, Bridget; Evans, Charlesnika T.] Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare & Spinal Cor, Dept Vet Affairs, Hines, IL 60141 USA. [Ramanathan, Swetha] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Johnson, Stuart; Gerding, Dale N.] Vet Affairs Edward Hines Jr Hosp, Dept Vet Affairs, Res Serv, Hines, IL 60141 USA. [Johnson, Stuart; Smith, Bridget; Gerding, Dale N.] Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA. [Burns, Stephen P.; Goldstein, Barry] SCI QUERI, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Burns, Stephen P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Kralovic, Stephen M.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Kralovic, Stephen M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Evans, Charlesnika T.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Evans, Charlesnika T.] Northwestern Univ, Ctr Healthcare Studies, Chicago, IL 60611 USA. RP Ramanathan, S (reprint author), Vet Affairs Edward Hines Jr Hosp, 5th & Roosevelt Rd 151H,Room C306,POB 5000, Hines, IL 60141 USA. EM Swetha.Ramanathan@va.gov FU VA Health Services Research and Development Service [IIR-10-148] FX Supported by VA Health Services Research and Development Service (IIR-10-148). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 39 TC 5 Z9 5 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2014 VL 42 IS 2 BP 168 EP 173 DI 10.1016/j.ajic.2013.08.009 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AA2VO UT WOS:000330952500018 PM 24485372 ER PT J AU Branch-Elliman, W Robillard, E McCarthy, G Gupta, K AF Branch-Elliman, Westyn Robillard, Ernie McCarthy, Gary, Jr. Gupta, Kalpana TI Direct feedback with the ATP luminometer as a process improvement tool for terminal cleaning of patient rooms SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Quality improvement; Environmental hygiene; Infection prevention ID ENVIRONMENTAL SERVICE WORKERS; KNOWLEDGE; SURFACES; MARKER AB We assessed the adenosine triphosphate luminometer as a tool for point- of- cleaning education. Following a terminal cleaning, infection preventionists met with cleaning staff and used the luminometer to evaluate multiple surfaces; 820 surfaces in 210 rooms were sampled. The mean proportion of clean surfaces improved significantly over the study period, P = .012. These findings suggest that direct measurement and education at the point of cleaning with an objective tool is useful for improving terminal cleaning. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Branch-Elliman, Westyn; Robillard, Ernie; Gupta, Kalpana] VA Boston HCS, Dept Med, Boston, MA 02132 USA. [Branch-Elliman, Westyn] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [McCarthy, Gary, Jr.] VA Boston HCS, Dept Environm Management Serv, Boston, MA 02132 USA. [Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Gupta, K (reprint author), VA Boston HCS, 1400 VFW Pkwy,111 MED, Boston, MA 02132 USA. EM kalpana.gupta@va.gov OI Branch-Elliman, Westyn/0000-0002-9658-5124 NR 10 TC 9 Z9 9 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2014 VL 42 IS 2 BP 195 EP 197 DI 10.1016/j.ajic.2013.08.012 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AA2VO UT WOS:000330952500025 PM 24485376 ER PT J AU Marete, I Tenge, C Pasha, O Goudar, S Chomba, E Patel, A Althabe, F Garces, A McClure, EM Saleem, S Esamai, F Kodkany, BS Belizan, JM Derman, RJ Hibberd, PL Krebs, N Buekens, P Goldenberg, RL Carlo, WA Wallace, D Moore, J Koso-Thomas, M Wright, LL Liechty, EA AF Marete, Irene Tenge, Constance Pasha, Omrana Goudar, Shivaprasad Chomba, Elwyn Patel, Archana Althabe, Fernando Garces, Ana McClure, Elizabeth M. Saleem, Sarah Esamai, Fabian Kodkany, Bhala S. Belizan, Jose M. Derman, Richard J. Hibberd, Patricia L. Krebs, Nancy Buekens, Pierre Goldenberg, Robert L. Carlo, Waldemar A. Wallace, Dennis Moore, Janet Koso-Thomas, Marion Wright, Linda L. Liechty, Edward A. TI Perinatal Outcomes of Multiple-Gestation Pregnancies in Kenya, Zambia, Pakistan, India, Guatemala, and Argentina: A Global Network Study SO AMERICAN JOURNAL OF PERINATOLOGY LA English DT Article DE multiples gestation; twins; developing countries; stillbirth; perinatal mortality rate ID UNITED-STATES; DELIVERY; TRENDS; BIRTH; CARE AB AimTo determine the rates of multiple gestation, stillbirth, and perinatal and neonatal mortality and to determine health care system characteristics related to perinatal mortality of these pregnancies in low- and middle-income countries. MethodsPregnant women residing within defined geographic boundaries located in six countries were enrolled and followed to 42 days postpartum. ResultsMultiple gestations were 0.9% of births. Multiple gestations were more likely to deliver in a health care facility compared with singletons (70 and 66%, respectively, p<0.001), to be attended by skilled health personnel (71 and 67%, p<0.001), and to be delivered by cesarean (18 versus 9%, p<0.001). Multiple-gestation fetuses had a relative risk (RR) for stillbirth of 2.65 (95% confidence interval [CI] 2.06, 3.41) and for perinatal mortality rate (PMR) a RR of 3.98 (95% CI 3.40, 4.65) relative to singletons (both p<0.0001). Neither delivery in a health facility nor the cesarean delivery rate was associated with decreased PMR. Among multiple-gestation deliveries, physician-attended delivery relative to delivery by other health providers was associated with a decreased risk of perinatal mortality. ConclusionsMultiple gestations contribute disproportionately to PMR in low-resource countries. Neither delivery in a health facility nor the cesarean delivery rate is associated with improved PMR. C1 [Marete, Irene; Tenge, Constance; Esamai, Fabian] Moi Univ, Sch Med, Dept Child Hlth & Paediat, Eldoret, Kenya. [Pasha, Omrana; Saleem, Sarah] Aga Khan Univ, Dept Community Hlth Serv, Karachi, Pakistan. [Goudar, Shivaprasad; Kodkany, Bhala S.] KLE Univ, Jawaharlal Nehru Med Coll, Belgaum, Karnataka, India. [Chomba, Elwyn] Univ Teaching Hosp, Lusaka, Zambia. [Patel, Archana] Lata Med Res Fdn, Nagpur, Maharashtra, India. [Althabe, Fernando; Belizan, Jose M.] Inst Clin Effectiveness, Buenos Aires, DF, Argentina. [Garces, Ana] Francisco Marroquin Univ, Multidisciplinary Hlth Inst, Guatemala City, Guatemala. [McClure, Elizabeth M.; Wallace, Dennis; Moore, Janet] Res Triangle Inst Int, Durham, NC USA. [Liechty, Edward A.] Indiana Univ, Dept Pediat, Riley Hosp, Indianapolis, IN 46202 USA. [Derman, Richard J.] Christiana Care Hlth Syst, Wilmington, DE USA. [Hibberd, Patricia L.] Massachusetts Gen Hosp, Divs Global Hlth, Boston, MA 02114 USA. [Krebs, Nancy] Univ Colorado, Dept Pediat, Denver, CO 80202 USA. [Buekens, Pierre] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Goldenberg, Robert L.] Columbia Univ, New York, NY USA. [Carlo, Waldemar A.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA. [Koso-Thomas, Marion; Wright, Linda L.] NICHHD, Bethesda, MD 20892 USA. RP Liechty, EA (reprint author), Indiana Univ, Dept Pediat, Riley Hosp R208, 699 Riley Hosp Dr, Indianapolis, IN 46202 USA. EM eliecht@iupui.edu OI GOUDAR, SHIVAPRASAD/0000-0002-8680-7053; Belizan, Jose/0000-0002-8412-3010 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health within the U.S. Department of Health and Human Services [U01 HD040477, U01 HD043464, U01 HD040657, U01 HD042372, U01 HD040607, U01 HD058322, U01 HD058326, U01 HD040636] FX Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health within the U.S. Department of Health and Human Services by grants U01 HD040477, U01 HD043464, U01 HD040657, U01 HD042372, U01 HD040607, U01 HD058322, U01 HD058326, and U01 HD040636. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 20 TC 6 Z9 6 U1 0 U2 3 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0735-1631 EI 1098-8785 J9 AM J PERINAT JI Am. J. Perinatol. PD FEB PY 2014 VL 31 IS 2 BP 125 EP 131 DI 10.1055/s-0033-1338173 PG 7 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA AA6FW UT WOS:000331195200006 PM 23512321 ER PT J AU Witsch, TJ Turowski, P Sakkas, E Niess, G Becker, S Herold, S Mayer, K Vadasz, I Roberts, JD Seeger, W Morty, RE AF Witsch, Thilo J. Turowski, Pawel Sakkas, Elpidoforos Niess, Gero Becker, Simone Herold, Susanne Mayer, Konstantin Vadasz, Istvn Roberts, Jesse D., Jr. Seeger, Werner Morty, Rory E. TI Deregulation of the lysyl hydroxylase matrix cross-linking system in experimental and clinical bronchopulmonary dysplasia SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE lung development; extracellular matrix; bronchopulmonary dysplasia; lysyl hydroxylase ID CHRONIC LUNG-DISEASE; BRONCHOALVEOLAR LAVAGE FLUID; SYNDROME TYPE VI; MECHANICAL VENTILATION; PRETERM LAMBS; TRANSFORMING GROWTH-FACTOR-BETA-1; LYSYL-HYDROXYLASE-3 LH3; NEONATAL MICE; INJURY; HYPEROXIA AB Bronchopulmonary dysplasia (BPD) is a common and serious complication of premature birth, characterized by a pronounced arrest of alveolar development. The underlying pathophysiological mechanisms are poorly understood although perturbations to the maturation and remodeling of the extracellular matrix (ECM) are emerging as candidate disease pathomechanisms. In this study, the expression and regulation of three members of the lysyl hydroxylase family of ECM remodeling enzymes (Plod1, Plod2, and Plod3) in clinical BPD, as well as in an experimental animal model of BPD, were addressed. All three enzymes were localized to the septal walls in developing mouse lungs, with Plod1 also expressed in the vessel walls of the developing lung and Plod3 expressed uniquely at the base of developing septa. The expression of plod1, plod2, and plod3 was upregulated in the lungs of mouse pups exposed to 85% O-2, an experimental animal model of BPD. Transforming growth factor (TGF)-beta increased plod2 mRNA levels and activated the plod2 promoter in vitro in lung epithelial cells and in lung fibroblasts. Using in vivo neutralization of TGF-beta signaling in the experimental animal model of BPD, TGF-beta was identified as the regulator of aberrant plod2 expression. PLOD2 mRNA expression was also elevated in human neonates who died with BPD or at risk for BPD, compared with neonates matched for gestational age at birth or chronological age at death. These data point to potential roles for lysyl hydroxylases in normal lung development, as well as in perturbed late lung development associated with BPD. C1 [Witsch, Thilo J.; Turowski, Pawel; Sakkas, Elpidoforos; Niess, Gero; Becker, Simone; Herold, Susanne; Mayer, Konstantin; Vadasz, Istvn; Seeger, Werner; Morty, Rory E.] Univ Giessen & Marburg Lung Ctr, Dept Internal Med Pulmonol, Giessen, Germany. [Sakkas, Elpidoforos; Niess, Gero; Becker, Simone; Seeger, Werner; Morty, Rory E.] Max Planck Inst Heart & Lung Res, Dept Lung Dev & Remodelling, D-61231 Bad Nauheim, Germany. [Roberts, Jesse D., Jr.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA. RP Morty, RE (reprint author), Max Planck Inst Heart & Lung Res, Dept Lung Dev & Remodelling, Parkstr 1, D-61231 Bad Nauheim, Germany. EM rory.morty@mpi-bn.mpg.de FU German Research Foundation [Mo 1789/1]; Excellence Cluster 147 "Cardio-Pulmonary System"; Federal Ministry of Higher Education, Research and the Arts of the State of Hessen LOEWE Program; German Center for Lung Research (Deutche Lungenforschungszentrum; all German authors); U. S. National Heart, Lung, and Blood Institute Grant [HL-094608] FX This study was supported by the German Research Foundation through Grant Mo 1789/1 (to R. Morty) and Excellence Cluster 147 "Cardio-Pulmonary System" (to S. Herold, K. Mayer, I. Vadasz, W. Seeger, and R. Morty) as well as the Federal Ministry of Higher Education, Research and the Arts of the State of Hessen LOEWE Program (to S. Herold, K. Mayer, I. Vadasz, W. Seeger, and R. Morty), the German Center for Lung Research (Deutche Lungenforschungszentrum; all German authors), and U. S. National Heart, Lung, and Blood Institute Grant HL-094608 (to J. Roberts). NR 48 TC 18 Z9 19 U1 0 U2 10 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD FEB PY 2014 VL 306 IS 3 BP L246 EP L259 DI 10.1152/ajplung.00109.2013 PG 14 WC Physiology; Respiratory System SC Physiology; Respiratory System GA AA4ME UT WOS:000331068900004 PM 24285264 ER PT J AU Goebel-Stengel, M Stengel, A Wang, LX Tache, Y AF Goebel-Stengel, Miriam Stengel, Andreas Wang, Lixin Tache, Yvette TI Orexigenic response to tail pinch: role of brain NPY1 and corticotropin releasing factor receptors SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE body weight; corticotropin releasing factor; fecal pellet output; food intake; Fos; ghrelin; neuropeptide Y; stress-induced eating; somatostatin receptor 2 antagonist; tail pinch ID STRESS-RELATED ALTERATIONS; FOOD-INTAKE; NEUROPEPTIDE-Y; BODY-WEIGHT; PARAVENTRICULAR NUCLEUS; NIGROSTRIATAL DOPAMINE; ENDOGENOUS OPIATES; INDUCED INHIBITION; ABDOMINAL-SURGERY; CENTRAL INJECTION AB Tail pinch stimulates food intake in rats. We investigated brain mechanisms of this response and the influence of repeated exposure. Sprague-Dawley rats received acute (5 min) or repeated (5 min/ day for 14 days) tail pinch using a padded clip. Acute tail pinch increased 5-min food intake compared with control (0.92 +/- 0.2 vs. 0.03 +/- 0.01 g, P < 0.01). This response was inhibited by 76% by intracerebroventricular injection of BIBP-3226, a neuropeptide Y-1 (NPY1) receptor antagonist, increased by 48% by astressin-B, a corticotropin-releasing factor (CRF) receptor antagonist, and not modified by S-406-028, a somatostatin subtype 2 antagonist. After the 5-min tail pinch without food, blood glucose rose by 21% (P < 0.01) while changes in plasma acyl ghrelin (+41%) and adrenocorticotropic hormone (+7%) were not significant. Two tail pinches (45 min apart) activate pontine and hindbrain catecholaminergic and hypothalamic paraventricular CRF neurons. After 14 days of repeated tail pinch, the 5-min orexigenic response was not significantly different from days 2 to 11 but reduced by 50% thereafter (P < 0.001). Simultaneously, the 5-min fecal pellet output increased during the last 5 days compared with the first 5 days (+8%, P < 05). At day 14, the body weight gain was reduced by 22%, with a 99% inhibition of fat gain and a 25% reduction in lean mass (P < 0.05). The orexigenic response to acute 5-min tail pinch is likely to involve the activation of brain NPY1 signaling, whereas that of CRF tends to dampen the acute response and may contribute to increased defecation and decreased body weight gain induced by repeated tail pinch. C1 [Goebel-Stengel, Miriam; Stengel, Andreas; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, CURE Digest Dis Res Ctr,Digest Dis Div, Los Angeles, CA 90024 USA. [Goebel-Stengel, Miriam; Stengel, Andreas; Wang, Lixin; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goebel-Stengel, Miriam] Martin Luther Krankenhaus Berlin, Dept Internal Med, Berlin, Germany. [Goebel-Stengel, Miriam] Martin Luther Krankenhaus Berlin, Inst Neurogastroenterol, Berlin, Germany. [Stengel, Andreas] Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, Berlin, Germany. [Stengel, Andreas] Charite, D-13353 Berlin, Germany. RP Tache, Y (reprint author), VA GLA Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Rm 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU National Institutes of Health (NIH) [R01 DK-33061, DK-41301]; Veterans Affairs Merit Award [F219-R]; Research Career Scientist Award FX This study was supported by National Institutes of Health (NIH) Grant R01 DK-33061, NIH Center Grant DK-41301 (Animal Core), and Veterans Affairs Merit Award Project F219-R, and Research Career Scientist Award. NR 72 TC 8 Z9 8 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD FEB PY 2014 VL 306 IS 3 BP R164 EP R174 DI 10.1152/ajpregu.00335.2013 PG 11 WC Physiology SC Physiology GA AA4NO UT WOS:000331073000002 PM 24338440 ER PT J AU Loebel, A Cucchiaro, J Silva, R Kroger, H Hsu, J Sarma, K Sachs, G AF Loebel, Antony Cucchiaro, Josephine Silva, Robert Kroger, Hans Hsu, Jay Sarma, Kaushik Sachs, Gary TI Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MAJOR DEPRESSION; RATING-SCALE; DSM-IV; DISORDER; EFFICACY; METAANALYSIS; PREVALENCE; SUICIDE; ZIPRASIDONE AB Objective: The authors evaluated the efficacy and safety of lurasidone in the treatment of patients with major depressive episodes associated with bipolar I disorder. Method: Patients were randomly assigned to receive double-blind treatment with lurasidone (20-60 mg/day [N=166] or 80-120 mg/day [N=169]) or placebo (N=170) for 6 weeks. Primary and key secondary endpoints were change from baseline to week 6 on the Montgomery-Asberg Depression Rating Scale (MADRS) and depression severity score on the Clinical Global Impressions scale for use in bipolar illness (CGI-BP), respectively. Results: Lurasidone treatment significantly reduced mean MADRS total scores at week 6 for both the 20-60 mg/day group (-15.4; effect size=0.51) and the 80-120 mg/day group (-15.4; effect size=0.51) compared with placebo (-10.7). Similarly, lurasidone treatment resulted in significantly greater endpoint reduction in CGI-BP depression severity scores for both the 20-60 mg/day group (-1.8; effect size=0.61) and the 80-120 mg/day group (-1.7; effect size=0.50) compared with placebo (-1.1). Both lurasidone groups also experienced significant improvements compared with placebo in anxiety symptoms and in patient-reported measures of quality of life and functional. impairment. Discontinuation rates due to adverse events were similar in the 20-60 mg/day (6.6%), 80-120 mg/day (5.9%), and placebo (6.5%) groups. The most frequent adverse events associated with lurasidone were nausea, headache, akathisia, and somnolence. Minimal changes in weight, lipids, and measures of glycemic control were observed with lurasidone. Conclusion: Monotherapy with lurasidone in the dosage range of 20-120 mg/day significantly reduced depressive symptoms in patients with bipolar I depression. Lurasidone was well tolerated, with few changes in weight or metabolic parameters. C1 [Loebel, Antony] Sunov Pharmaceut Inc, Ft Lee, NJ 07024 USA. Sunov Pharmaceut Inc, Marlborough, MA USA. Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA. Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. RP Loebel, A (reprint author), Sunov Pharmaceut Inc, Ft Lee, NJ 07024 USA. EM Antony.Loebel@sunovion.com FU Collaborative Care Initiative; Sunovion Pharmaceuticals, Inc. FX Dr. Sachs has been a consultant for Sunovion, Otsuka, Johnson & Johnson, and Grunenthal, has stock/other financial relationship with Collaborative Care Initiative, and is an employee of Bracket. Drs. Loebel, Cucchiaro, Silva, Kroger, Hsu, and Sarma are full-time employees of Sunovion Pharmaceuticals, Inc.; This study was sponsored by Sunovion Pharmaceuticals, Inc. NR 39 TC 81 Z9 83 U1 1 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2014 VL 171 IS 2 BP 160 EP 168 DI 10.1176/appi.ajp.2013.13070984 PG 9 WC Psychiatry SC Psychiatry GA 302JP UT WOS:000330601100009 PM 24170180 ER PT J AU Deckersbach, T Peters, AT Sylvia, L Urdahl, A Magalhaes, PVS Otto, MW Frank, E Miklowitz, DJ Berk, M Kinrys, G Nierenberg, A AF Deckersbach, Thilo Peters, Amy T. Sylvia, Louisa Urdahl, Anna Magalhaes, Pedro V. S. Otto, Michael W. Frank, Ellen Miklowitz, David J. Berk, Michael Kinrys, Gustavo Nierenberg, Andrew TI Do Comorbid Anxiety Disorders Moderate the Effects of Psychotherapy for Bipolar Disorder? Results From STEP-BD SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID TREATMENT ENHANCEMENT PROGRAM; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; OBSESSIVE-COMPULSIVE DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; SOCIAL RHYTHM THERAPY; I DISORDER; PSYCHOSOCIAL INTERVENTIONS; RANDOMIZED-TRIAL; PANIC DISORDER; DSM-IV AB Objective: At least 50% of individuals with bipolar disorder have a lifetime anxiety disorder. Individuals with both bipolar disorder and a co-occurring anxiety disorder experience longer illness duration, greater illness severity, and poorer treatment response. The study explored whether comorbid lifetime anxiety in bipolar patients moderates psychotherapy treatment outcome. Method: In the Systematic Treatment Enhancement Program randomized controlled trial of psychotherapy for bipolar depression, participants received up to 30 sessions of intensive psychotherapy (family-focused therapy, interpersonal and social rhythm therapy, or cognitive-behavioral therapy) or collaborative care, a three-session comparison treatment, plus pharmacotherapy. Using the number needed to treat, we computed effect sizes to analyze the relationship between lifetime anxiety disorders and rates of recovery across treatment groups after 1 year. Results: A total of 269 patients (113 women) with a comorbid lifetime anxiety. disorder (N=177) or without a comorbid lifetime anxiety disorder (N=92) were included in the analysis. Participants with a lifetime anxiety disorder were more likely to recover with psychotherapy than with collaborative care (66% compared with 49% recovered over 1 year; number needed to treat=5.88, small to medium effect). For patients without a lifetime anxiety disorder, there was no difference between rates of recovery in psychotherapy compared with collaborative care (64% compared with 62% recovered; number needed to treat=50, small effect). Participants with one lifetime anxiety disorder were likely to benefit from intensive psychotherapy compared with collaborative care (84% compared with 53% recovered; number needed to treat=3.22, medium to large effect), whereas patients with multiple anxiety disorders exhibited no difference in response to the two treatments (54% compared with 46% recovered; number needed to treat=12.5, small effect). Conclusions: Depressed patients with bipolar disorder and comorbid anxiety may be in particular need of additional psychotherapy for treating acute depression. These results need to be replicated in studies that stratify bipolar patients to treatments based on their anxiety comorbidity status. C1 [Deckersbach, Thilo] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. Hosp Clin Porto Alegre, Natl Inst Translat Med, Porto Alegre, RS, Brazil. Boston Univ, Boston, MA 02215 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. Deakin Univ, Melbourne, Vic, Australia. Univ Melbourne, Melbourne, Vic, Australia. RP Deckersbach, T (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM tdeckersbach@partners.org RI Magalhaes, Pedro/A-8519-2008; OI Magalhaes, Pedro/0000-0002-5644-6357; Miklowitz, David/0000-0002-9647-6147; Berk, Michael/0000-0002-5554-6946 FU Boston University; Brain Cells; Catalan; Massachusetts General Hospital Psychiatry Academy; Systems Research and Applications Corporation; NIMH [N01MH80001, MH-29618, MH-43931, MH-55101, 1K23MH074895-01A2]; American Psychological Association Press; Guilford Press; Lundbeck; Servier International; Attias Family Foundation; Brain and Behavior Research Foundation; Danny Alberts Foundation; Deutsch Foundation; Kayne Foundation; Knapp Foundation; Autism Foundation; Australia National Health and Medical Research Council; Beyond Blue; Bristol-Myers Squibb; Cooperative Research Centre; Eli Lilly; Geelong Medical Research Foundation; GlaxoSmithKline; Mayne Pharma; Medical Benefits Fund; Meat and Livestock Board; NIH; Novartis; Organon; Rotary Health; Servier; Simons Cancer Council of Victoria; Stanley Medical Research Foundation; Woolworths; Forest Pharmaceuticals; Sanofi Synthelabo; Sepracor; Pfizer; UCB Pharma; Wyeth-Ayerst Laboratories; AstraZeneca; Cephalon; Janssen Pharmaceutica; Agency for Healthcare Research and Quality; Cederroth; Cyberonics; Elan; Lichtwer Pharma; Mylin; NARSAD; Pamlab; Shire; Stanley Foundation; Wyeth-Ayerst; International OCD Foundation; burette Syndrome Association; Tufts University FX Dr. Deckersbach has received honoraria, consultation fees, and/or royalties from Boston University, Brain Cells, the Catalan, Massachusetts General Hospital Psychiatry Academy, and Systems Research and Applications Corporation. Dr. Sylvia has served as a consultant to Bracket and Clintara and received royalties from New Harbinger. Dr. Otto has served as a consultant to Micro Transponder and has received research support from NIMH and royalties from Oxford University Press and Rout ledge. Dr. Frank has received research support or royalties from American Psychological Association Press, Guilford Press, Lundbeck, and Servier International. Dr. Miklowitz has received research grant support from the Attias Family Foundation, the Brain and Behavior Research Foundation, the Danny Alberts Foundation, the Deutsch, Kayne, and Knapp Foundations, and NIMH, and he has received royalties from Guilford Press and John Wiley and Sons. Dr. Berk has received research support from the Autism Foundation, the Australia National Health and Medical Research Council, Beyond Blue, Bristol-Myers Squibb, Cooperative Research Centre, Eli Lilly, the Geelong Medical Research Foundation, GlaxoSmithKline, Mayne Pharma, Medical Benefits Fund, Meat and Livestock Board, NIH, Novartis, Organon, Rotary Health, Servier, Simons Cancer Council of Victoria, Stanley Medical Research Foundation, and Woolworths and has served as a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, and Wyeth and a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, and Servier. Dr. Kinrys has received research support from Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Sanofi Synthelabo, Sepracor, Pfizer, UCB Pharma, and Wyeth-Ayerst Laboratories, advisory and consulting fees from AstraZeneca, Cephalon, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer, Sepracor, UCB Pharma, and Wyeth-Ayerst Laboratories, and speaker's fees from AstraZeneca, Forest Pharmaceuticals, GlaxoSmithKline, Sepracor, and Wyeth-Ayerst Laboratories. Dr.; Nierenberg is a consultant for Abbott Laboratories, AstraZeneca, Basilea, Brain Cells, Brandeis University, Bristol-Myers Squibb, Cephalon, Corcept, Eli Lilly, Forest, Genaissance, GlaxoSmithKline, Innapharma, Janssen Pharmaceutica, Jazz Pharmaceuticals, Lundbeck, Merck, Novartis, Pamlab, PGx Health, Pfizer, Ridge Diagnostics, Roche, Schering-Plough, Sepracor, Shire, Somerset, Sunovion, Takeda, Targacept, and Teva, and he receives research support from the Agency for Healthcare Research and Quality, Bristol-Myers Squibb, Cederroth, Cyberonics, Elan, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Mylin, NARSAD, NIMH, Pamlab, Pfizer, Shire, the Stanley Foundation, and Wyeth-Ayerst and honoraria from the American Drug Utilization Review Society, the American Society for Clinical Psychopharmacology, AstraZeneca, Biomedical Development, Boston Center for the Arts, Brandeis University, Eli Lilly, Forest, the Harold Grinspoon Charitable Foundation, Health New England, Janssen, International Society for Bipolar Disorder, Massachusetts General Hospital Psychiatry Academy, Mid-Atlantic Permanente Research Institute, Second Meeting of East Asian Bipolar Forum, University of Pisa, University of Texas Southwestern Medical Center, University of Wisconsin at Madison, and Zucker Hillside Hospital and other income from Belvior Publications, Controlled Risk Insurance Company, MBL Publishing, and Slack, and he holds a joint ownership copyright with Massachusetts General Hospital for the Structured Clinical Interview for the Montgomery Asberg Depression Rating Scale and the Clinical Positive Affect Scale and is a stakeholder with Appliance Computing (Mind Site), Brain Cells, and InfoMed.; STEP-BD was funded in part by NIMH contract N01MH80001. Support for the development of the psychosocial treatments was provided by NIMH grants MH-29618 (to Dr. Frank) and MH-43931 and MH-55101 (to Dr. Miklowitz), as well as NARSAD (to Dr. Miklowitz). Supported in part by a K-23 NIMH Career Award (1K23MH074895-01A2) and grants from NARSAD, International OCD Foundation, burette Syndrome Association, and Tufts University (to Dr. Deckersbach). NR 48 TC 25 Z9 25 U1 1 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2014 VL 171 IS 2 BP 178 EP 186 DI 10.1176/appi.ajp.2013.13020225 PG 9 WC Psychiatry SC Psychiatry GA 302JP UT WOS:000330601100011 PM 24077657 ER PT J AU Wingert, JR Welder, C Foo, P AF Wingert, Jason R. Welder, Catherine Foo, Patrick TI Age-Related Hip Proprioception Declines: Effects on Postural Sway and Dynamic Balance SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Aging; Kinesthesis; Postural balance; Proprioception; Rehabilitation ID JOINT-POSITION SENSE; OLDER-ADULTS; MUSCLE-SPINDLES; RISK-FACTORS; TAI-CHI; ELDERLY POPULATION; CEREBRAL-PALSY; HEALTHY-YOUNG; FALL; STABILITY AB Objective: To evaluate the effects of age on hip proprioception, and determine whether age-related hip proprioception declines disrupt balance. Design: Survey of proprioception and balance differences between 3 age groups. Setting: University balance laboratory. Participants: Volunteer sample of independent community-dwelling adults (N=102) without sensory or other neurologic impairments in 3 age groups: younger (mean age, 24.6y; range, 19-37y), mid-aged (mean age, 53.3y; range, 40-64y), and older adults (mean age, 76.3y; range, 65-94y). Interventions: Not applicable. Main Outcome Measures: Hip joint position sense (JPS) and kinesthesia were measured using a custom-built device. JPS error was determined by the magnitude of matching errors during vision and no-vision conditions. Kinesthesia was evaluated by the ability to detect passive limb rotation without vision. Postural sway was assessed during static stance and measured using root mean square of center of pressure (COP) displacement and velocity of COP displacement. Clinical balance and fear of falling were assessed with the mini-Balance Evaluation Systems Test (mini-BESTest) and Activities-specific Balance Confidence Scale, respectively. Results: Both older and mid-aged adults had significantly increased JPS error compared with younger adults (P<.05). Kinesthesia accuracy was significantly decreased in older adults compared with mid-aged and younger adults (P <=.01). Both measures of proprioception error correlated with age (P <=.001). There were no relationships between hip proprioception error and postural sway during static stance. However, older adults with lower proprioceptive error had significantly higher mini-BESTest scores of dynamic balance abilities (P=.005) Conclusions: These results provide evidence of significant hip proprioception declines with age. Although these declines are not related to increases in postural sway, participants with hip proprioception declines demonstrated disrupted dynamic balance, as indicated by decreased mini-BESTest scores. (C) 2014 by the American Congress of Rehabilitation Medicine C1 [Wingert, Jason R.] UNC Asheville, Dept Hlth & Wellness, Asheville, NC 28804 USA. [Welder, Catherine] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA. [Foo, Patrick] Univ N Carolina, Dept Psychol, Asheville, NC 28804 USA. RP Wingert, JR (reprint author), UNC Asheville, Dept Hlth & Wellness, CPO 4030,One Univ Hts, Asheville, NC 28804 USA. EM jwingert@unca.edu FU North Carolina Center for Health and Wellness through Blue Cross Blue Shield Foundation FX Supported by the North Carolina Center for Health and Wellness through funding from the Blue Cross Blue Shield Foundation. NR 57 TC 10 Z9 13 U1 7 U2 48 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2014 VL 95 IS 2 BP 253 EP 261 DI 10.1016/j.apmr.2013.08.012 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA AA2LW UT WOS:000330927100007 PM 23994251 ER PT J AU Hebels, DGA Jetten, MJA Aerts, HJW Herwig, R Theunissen, DHJ Gaj, S van Delft, JH Kleinjans, JCS AF Hebels, Dennie G. A. Jetten, Marlon J. A. Aerts, Hugo J. W. Herwig, Ralf Theunissen, Daniel H. J. Gaj, Stan van Delft, Joost H. Kleinjans, Jos C. S. TI Evaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicity SO BIOMARKERS IN MEDICINE LA English DT Article DE "omics databases; biomarker; DILI; diXa; drug-induced liver injury; hepatotoxicity; over-representation analysis; pathway development; text-mining databases; toxicogenomics ID INDUCED LIVER-INJURY; DRUG-INDUCED HEPATOTOXICITY; PRIMARY HUMAN HEPATOCYTES; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; BIOLOGICAL PATHWAYS; PRIMARY CULTURE; MODELS; METABOLISM; FAILURE AB Current testing models for predicting drug-induced liver injury are inadequate, as they basically under-report human health risks. We present here an approach towards developing pathways based on hepatotoxicity-associated gene groups derived from two types of publicly accessible hepatotoxicity databases, in order to develop drug-induced liver injury biomarker profiles. One human liver omics-based and four text-mining-based databases were explored for hepatotoxicity-associated gene lists. Over-representation analysis of these gene lists with a hepatotoxicant-exposed primary human hepatocytes data set showed that human liver omics gene lists performed better than text-mining gene lists and the results of the latter differed strongly between databases. However, both types of databases contained gene lists demonstrating biomarker potential. Visualizing those in pathway format may aid in interpreting the biomolecular background. We conclude that exploiting existing and openly accessible databases in a dedicated manner seems promising in providing venues for translational research in toxicology and biomarker development. C1 [Hebels, Dennie G. A.; Jetten, Marlon J. A.; Theunissen, Daniel H. J.; Gaj, Stan; van Delft, Joost H.; Kleinjans, Jos C. S.] Maastricht Univ, Dept Toxicogen, NL-6229 ER Maastricht, Netherlands. [Aerts, Hugo J. W.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Herwig, Ralf] Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-14195 Berlin, Germany. RP Hebels, DGA (reprint author), Maastricht Univ, Dept Toxicogen, Univ Singel 50, NL-6229 ER Maastricht, Netherlands. EM d.hebels@maastrichtuniversity.nl RI Kleinjans, Jos/E-7241-2015; Aerts, Hugo/P-6350-2015 OI Aerts, Hugo/0000-0002-2122-2003 FU diXa, a part of the EU Seventh Framework Programme [RI-283775] FX This work was supported by diXa, a part of the EU Seventh Framework Programme, under grant agreement number RI-283775. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 93 TC 5 Z9 6 U1 0 U2 12 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1752-0363 EI 1752-0371 J9 BIOMARK MED JI Biomark. Med. PD FEB PY 2014 VL 8 IS 2 BP 185 EP 200 DI 10.2217/bmm.13.154 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AA6MM UT WOS:000331212400005 PM 24521014 ER PT J AU Fitzmaurice, M Pogue, BW Tearney, GJ Tunnell, JW Yang, CH AF Fitzmaurice, Maryann Pogue, Brian W. Tearney, Guillermo J. Tunnell, James W. Yang, Changhuei TI Advances in optics for biotechnology, medicine and surgery SO BIOMEDICAL OPTICS EXPRESS LA English DT Article AB The guest editors introduce a Biomedical Optics Express feature issue that includes contributions from participants at the 2013 conference on Advances in Optics for Biotechnology, Medicine and Surgery XIII. (C) 2014 Optical Society of America C1 [Fitzmaurice, Maryann] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA. [Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Tearney, Guillermo J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Tearney, Guillermo J.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Tunnell, James W.; Yang, Changhuei] Univ Texas Austin, Austin, TX 78712 USA. CALTECH, Pasadena, CA 91125 USA. RP Fitzmaurice, M (reprint author), Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA. EM mxf39@case.edu FU National Institute of Biomedical Imaging and Bioengineering; National Institute of Neurological Disorders and Stroke [R13EB017094]; National Science Foundation [1340558]; Hamamatsu Photonics; Intuitive Surgical and Ocean Optics FX The conference was funded by generous support from the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Neurological Disorders and Stroke, (award number R13EB017094), and the National Science Foundation (award number 1340558). Additional funding was provided by corporate sponsors: Hamamatsu Photonics, Intuitive Surgical and Ocean Optics. It should be noted that the content of this issue is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health or the National Science Foundation. NR 7 TC 0 Z9 0 U1 2 U2 11 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 2156-7085 J9 BIOMED OPT EXPRESS JI Biomed. Opt. Express PD FEB 1 PY 2014 VL 5 IS 2 BP 560 EP 561 DI 10.1364/BOE.5.000560 PG 2 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA AA4NI UT WOS:000331072400018 PM 24575348 ER PT J AU McCullough, AE Dell'Orto, P Reinholz, MM Gelber, RD Dueck, AC Russo, L Jenkins, RB Andrighetto, S Chen, BY Jackisch, C Untch, M Perez, EA Piccart-Gebhart, MJ Viale, G AF McCullough, Ann E. Dell'Orto, Patrizia Reinholz, Monica M. Gelber, Richard D. Dueck, Amylou C. Russo, Leila Jenkins, Robert B. Andrighetto, Stefania Chen, Beiyun Jackisch, Christian Untch, Michael Perez, Edith A. Piccart-Gebhart, Martine J. Viale, Giuseppe TI Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Breast cancer; Estrogen receptor testing; HER2 testing; Central laboratory review; Local versus central laboratory concordance ID CLINICAL-ONCOLOGY/COLLEGE; AMERICAN-SOCIETY; GUIDELINE RECOMMENDATIONS; PROGESTERONE-RECEPTORS; ADJUVANT THERAPY; NCCTG N9831; ESTROGEN AB Choice of therapy for breast cancer relies on human epidermal growth factor receptor-2 (HER2) and estrogen receptor alpha (ER) status. Before randomization in the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial for HER2-positive disease, HER2 and ER were centrally reviewed by Mayo Clinic (Rochester, MN, and Scottsdale, AZ) for North America and by the European Institute of Oncology (IEO; Milan, Italy) for the rest of world (except China). Discordance rates (local vs. central review) differed between Mayo and IEO. Among locally HER2-positive cases, 5.8 % (Mayo) and 14.5 % (IEO) were centrally HER2 negative. Among locally ER-positive cases, 16.2 % (Mayo) and 4.2 % (IEO) were centrally ER-negative. Among locally ER-negative cases, 3.4 % (Mayo) and 21.4 % (IEO) were centrally ER-positive. We, therefore, performed a ring study to identify features contributing to these differing discordance rates. Mayo and IEO exchanged slides for 25 HER2 and 35 ER locally/centrally discordant cases. Both laboratories performed IHC and FISH for HER2 using the HercepTest(A (R)) and PathVysion HER2 DNA probe kit/HER2/centromere 17 probe mixture. IHC for ER was tested centrally using the monoclonal ER 1D5 antibody (Mayo) or the DAKO cocktail of ER 1D5 and 2.123 antibodies (IEO). Mayo and IEO confirmed the central HER2-negative result in 100 % of 25 cases. Mayo and IEO confirmed the central ER result in 29 (85 %) of 34 evaluable cases. The five Mayo-negative/IEO-positive cases were ER-positive when retested at Mayo using the DAKO ER cocktail. In this ring study, ALTTO ineligibility did not change when HER2 testing was performed by either IEO or Mayo central laboratories. However, a dual antibody ER assay had fewer false-negative test results than an assay with a single antibody, and there was more discordance between the two ER reagents than has been previously reported. Using even slightly different assay methods yielded different results, even between experienced central laboratories. C1 [McCullough, Ann E.; Dueck, Amylou C.] Mayo Clin Arizona, Dept Lab Med & Pathol, Scottsdale, AZ 85259 USA. [Dell'Orto, Patrizia; Russo, Leila; Andrighetto, Stefania; Viale, Giuseppe] Univ Milan, European Inst Oncol, Milan, Italy. [Reinholz, Monica M.] Ventana Med Syst, Tucson, AZ USA. [Gelber, Richard D.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Gelber, Richard D.] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA. [Jenkins, Robert B.; Chen, Beiyun] Mayo Clin, Rochester, MN USA. [Jackisch, Christian] Klinikum Offenbach, Offenbach, Germany. [Untch, Michael] HELIOS Klinikum Berlin Buch, Berlin, Germany. [Perez, Edith A.] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA. [Piccart-Gebhart, Martine J.] Univ Libre Brussels, Inst Jules Bordet, Brussels, Belgium. RP McCullough, AE (reprint author), Mayo Clin Arizona, Dept Lab Med & Pathol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA. EM mccullough.ann@mayo.edu; patrizia.dellorto@ieo.it; monica.reinholz@ventana.roche.com; gelber@jimmy.harvard.edu; dueck.amylou@mayo.edu; russobriuccialeila@hotmail.com; rjenkins@mayo.edu; stefania.andrighetto@ieo.it; chen.beiyun@mayo.edu; christian.jackisch@klinikum-offenbach.de; michael.untch@helios-kliniken.de; perez.edith@mayo.edu; martine.piccart@bordet.be; giuseppe.viale@ieo.it FU NIH/NCI [U24 CA114740] FX This work was supported by NIH/NCI Grant, U24 CA114740 (PI: JC Buckner). NR 9 TC 27 Z9 28 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD FEB PY 2014 VL 143 IS 3 BP 485 EP 492 DI 10.1007/s10549-013-2827-0 PG 8 WC Oncology SC Oncology GA AA3DS UT WOS:000330973700008 PM 24395109 ER PT J AU Niederst, MJ Benes, CH AF Niederst, Matthew J. Benes, Cyril H. TI EMT Twists the Road to PI3K SO CANCER DISCOVERY LA English DT Editorial Material ID LUNG-CANCER; RESISTANCE; INHIBITORS; CELLS; ERBB3 AB Epithelial-to-mesenchymal transition (EMT) is important for many developmental events and has been linked to tumor dissemination and therapeutic resistance. Salt and colleagues identify how EMT affects how proliferation signals flow to phosphoinositide 3-kinase in non-small cell lung cancer. (C) 2014 AACR. C1 Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA. [Benes, Cyril H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. RP Benes, CH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, CNY 149,13th St, Charlestown, MA 02129 USA. EM mniederst@mgh.harvard.edu; cbenes@mgh.harvard.edu FU NCI NIH HHS [R01 CA140594]; NHGRI NIH HHS [U54 HG006097, RC2 HG005693]; Wellcome Trust [086357] NR 12 TC 1 Z9 1 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD FEB PY 2014 VL 4 IS 2 BP 149 EP 151 DI 10.1158/2159-8290.CD-13-1030 PG 3 WC Oncology SC Oncology GA AA4SC UT WOS:000331085400020 PM 24501304 ER PT J AU Shern, JF Chen, L Chmielecki, J Wei, JS Patidar, R Rosenberg, M Ambrogio, L Auclair, D Wang, JJ Song, YK Tolman, C Hurd, L Liao, HL Zhang, SL Bogen, D Brohl, AS Sindiri, S Catchpoole, D Badgett, T Getz, G Mora, J Anderson, JR Skapek, SX Barr, FG Meyerson, M Hawkins, DS Khan, J AF Shern, Jack F. Chen, Li Chmielecki, Juliann Wei, Jun S. Patidar, Rajesh Rosenberg, Mara Ambrogio, Lauren Auclair, Daniel Wang, Jianjun Song, Young K. Tolman, Catherine Hurd, Laura Liao, Hongling Zhang, Shile Bogen, Dominik Brohl, Andrew S. Sindiri, Sivasish Catchpoole, Daniel Badgett, Thomas Getz, Gad Mora, Jaume Anderson, James R. Skapek, Stephen X. Barr, Frederic G. Meyerson, Matthew Hawkins, Douglas S. Khan, Javed TI Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors SO CANCER DISCOVERY LA English DT Article ID CHILDRENS ONCOLOGY GROUP; DNA-SEQUENCING DATA; EMBRYONAL RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; CHILDHOOD RHABDOMYOSARCOMA; INTERGROUP RHABDOMYOSARCOMA; SOMATIC MUTATIONS; CDNA MICROARRAYS; RAS GENES; RNA-SEQ AB Despite gains in survival, outcomes for patients with metastatic or recurrent rhabdomyosarcoma remain dismal. In a collaboration between the National Cancer Institute, Children's Oncology Group, and Broad Institute, we performed whole-genome, whole-exome, and transcriptome sequencing to characterize the landscape of somatic alterations in 147 tumor/ normal pairs. Two genotypes are evident in rhabdomyosarcoma tumors: those characterized by the PAX3 or PAX7 fusion and those that lack these fusions but harbor mutations in key signaling pathways. The overall burden of somatic mutations in rhabdomyosarcoma is relatively low, especially in tumors that harbor a PAX3/7 gene fusion. In addition to previously reported mutations in NRAS, KRAS, HRAS, FGFR4, PIK3CA, and CTNNB1, we found novel recurrent mutations in FBXW7 and BCOR, providing potential new avenues for therapeutic intervention. Furthermore, alteration of the receptor tyrosine kinase/RAS/PIK3CA axis affects 93% of cases, providing a framework for genomics-directed therapies that might improve outcomes for patients with rhabdomyosarcoma. SIGNIFICANCE: This is the most comprehensive genomic analysis of rhabdomyosarcoma to date. Despite a relatively low mutation rate, multiple genes were recurrently altered, including NRAS, KRAS, HRAS, FGFR4, PIK3CA, CTNNB1, FBXW7, and B COR. In addition, a majority of rhabdomyosarcoma tumors alter the receptor tyrosine kinase/RAS/PIK3CA axis, providing an opportunity for genomics-guided intervention. C1 [Shern, Jack F.; Chen, Li; Wei, Jun S.; Patidar, Rajesh; Wang, Jianjun; Song, Young K.; Tolman, Catherine; Hurd, Laura; Liao, Hongling; Zhang, Shile; Bogen, Dominik; Brohl, Andrew S.; Sindiri, Sivasish; Badgett, Thomas; Khan, Javed] NCI, Pediat Oncol Branch, Oncogenom Sect, Ctr Canc Res,NIH, Bethesda, MD 20892 USA. [Barr, Frederic G.] NCI, Pathol Lab, Bethesda, MD 20892 USA. [Chmielecki, Juliann; Rosenberg, Mara; Ambrogio, Lauren; Auclair, Daniel; Getz, Gad; Meyerson, Matthew] Broad Inst MIT & Harvard, Cambridge, MA USA. [Chmielecki, Juliann; Meyerson, Matthew] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Chmielecki, Juliann; Meyerson, Matthew] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Meyerson, Matthew] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Anderson, James R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Skapek, Stephen X.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Hematol Oncol, Dallas, TX 75390 USA. [Catchpoole, Daniel] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Childrens Hosp, Dept Pediat, Seattle, WA 98195 USA. [Catchpoole, Daniel] Childrens Hosp Westmead, Childrens Canc Res Unit, Tumour Bank, Westmead, NSW, Australia. [Mora, Jaume] Hosp Sant Joan de Deu Barcelona, Dept Oncol, Barcelona, Spain. RP Khan, J (reprint author), NCI, Oncogenom Sect, Pediat Oncol Branch, Ctr Canc Res, 37 Convent Dr,Room 2016B, Bethesda, MD 20892 USA. EM khanjav@mail.nih.gov RI Khan, Javed/P-9157-2014; OI Khan, Javed/0000-0002-5858-0488; sindiri, sivasish/0000-0003-2516-969X FU Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; American Cancer Society AstraZeneca Postdoctoral Fellowship; Discipline of Pediatrics and Child Health, Sydney Medical School, University of Sydney; Kids Cancer Project FX J.F. Shern, L. Chen, J.S. Wei, R. Patidar, J. Wang, Y.K. Song, C. Tolman, L. Hurd, H. Liao, S. Zhang, D. Bogen, A. S. Brohl, S. Sindiri, T. Badgett, F. G. Barr, and J. Khan are supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. M. Meyerson is supported by M. B. Zuckerman and Team Dragonfly of the Pan-Mass Challenge. J. Chmielecki is supported by an American Cancer Society AstraZeneca Postdoctoral Fellowship. D. Catchpoole is supported by a joint appointment with the Discipline of Pediatrics and Child Health, Sydney Medical School, University of Sydney, and receives funding support through The Kids Cancer Project. NR 67 TC 108 Z9 114 U1 0 U2 14 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD FEB PY 2014 VL 4 IS 2 BP 216 EP 231 DI 10.1158/2159-8290.CD-13-0639 PG 16 WC Oncology SC Oncology GA AA4SC UT WOS:000331085400027 PM 24436047 ER PT J AU Mahida, S Mills, RW Tucker, NR Simonson, B Macri, V Lemoine, MD Das, S Milan, DJ Ellinor, PT AF Mahida, Saagar Mills, Robert W. Tucker, Nathan R. Simonson, Bridget Macri, Vincenzo Lemoine, Marc D. Das, Saumya Milan, David J. Ellinor, Patrick T. TI Overexpression of KCNN3 results in sudden cardiac death SO CARDIOVASCULAR RESEARCH LA English DT Article DE Arrhythmias; Atrial fibrillation; Ion channels; Heart block; Potassium channel ID CA2+-ACTIVATED K+ CHANNELS; ACTIVATED POTASSIUM CHANNELS; SMALL-CONDUCTANCE; ATRIAL-FIBRILLATION; MYOCARDIAL-INFARCTION; FUNCTIONAL ROLES; HEART-RATE; CALCIUM; MOUSE; MICE AB A recent genome-wide association study identified a susceptibility locus for atrial fibrillation at the KCNN3 gene. Since the KCNN3 gene encodes for a small conductance calcium-activated potassium channel, we hypothesized that overexpression of the SK3 channel increases susceptibility to cardiac arrhythmias. We characterized the cardiac electrophysiological phenotype of a mouse line with overexpression of the SK3 channel. We generated homozygote (SK3(T/T)) and heterozygote (SK3(/T)) mice with overexpression of the channel and compared them with wild-type (WT) controls. We observed a high incidence of sudden death among SK3(T/T) mice (7 of 19 SK3(T/T) mice). Ambulatory monitoring demonstrated that sudden death was due to heart block and bradyarrhythmias. SK3(T/T) mice displayed normal body weight, temperature, and cardiac function on echocardiography; however, histological analysis demonstrated that these mice have abnormal atrioventricular node morphology. Optical mapping demonstrated that SK3(T/T) mice have slower ventricular conduction compared with WT controls (SK3(T/T) vs. WT; 0.45 0.04 vs. 0.60 0.09 mm/ms, P 0.001). Programmed stimulation in 1-month-old SK3(T/T) mice demonstrated inducible atrial arrhythmias (50 of SK3(T/T) vs. 0 of WT mice) and also a shorter atrioventricular nodal refractory period (SK3(T/T) vs. WT; 43 6 vs. 52 9 ms, P 0.02). Three-month-old SK3(T/T) mice on the other hand displayed a trend towards a more prolonged atrioventricular nodal refractory period (SK3(T/T) vs. WT; 61 1 vs. 52 6 ms, P 0.06). Overexpression of the SK3 channel causes an increased risk of sudden death associated with bradyarrhythmias and heart block, possibly due to atrioventricular nodal dysfunction. C1 [Mahida, Saagar; Mills, Robert W.; Tucker, Nathan R.; Macri, Vincenzo; Milan, David J.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA. [Simonson, Bridget; Das, Saumya] Beth Israel Deaconess Med Ctr, Cardiovasc Inst, Boston, MA 02215 USA. [Lemoine, Marc D.] Univ Munster, Univ Hosp Munster, Dept Cardiol & Angiol, D-48149 Munster, Germany. [Milan, David J.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. RP Ellinor, PT (reprint author), Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA. EM pellinor@partners.org OI Simonson, Bridget/0000-0002-3190-4796 FU National Institutes of Health [7K08HL089319, 5R21DA026982, 5R01HL109004, 5T32HL007298-35, 5R21DA027021, 1RO1HL104156, 1K24HL105780]; American Heart Association [13EIA14220013]; Biotronik; Heart Rhythm Society FX This work was supported by the National Institutes of Health (7K08HL089319 to S. D., 5R21DA026982 and 5R01HL109004 to D.J.M., 5T32HL007298-35 to R. M. and N.R.T., 5R21DA027021, 1RO1HL104156, and 1K24HL105780 to P. T. E.); and the American Heart Association (13EIA14220013 to P. T. E.); and the Biotronik and Heart Rhythm Society Postdoctoral fellowship award to (V.M.). NR 31 TC 15 Z9 15 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0008-6363 EI 1755-3245 J9 CARDIOVASC RES JI Cardiovasc. Res. PD FEB 1 PY 2014 VL 101 IS 2 BP 326 EP 334 DI 10.1093/cvr/cvt269 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AA1DA UT WOS:000330835300017 PM 24296650 ER PT J AU Almendro, V Cheng, YK Randles, A Itzkovitz, S Marusyk, A Ametller, E Gonzalez-Farre, X Munoz, M Russnes, HG Helland, A Rye, IH Borresen-Dale, AL Maruyama, R van Oudenaarden, A Dowsett, M Jones, RL Reis, J Gascon, P Gonen, M Michor, F Polyak, K AF Almendro, Vanessa Cheng, Yu-Kang Randles, Amanda Itzkovitz, Shalev Marusyk, Andriy Ametller, Elisabet Gonzalez-Farre, Xavier Munoz, Montse Russnes, Hege G. Helland, Aslaug Rye, Inga H. Borresen-Dale, Anne-Lise Maruyama, Reo van Oudenaarden, Alexander Dowsett, Mitchell Jones, Robin L. Reis-Filho, Jorge Gascon, Pere Goenen, Mithat Michor, Franziska Polyak, Kornelia TI Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity SO CELL REPORTS LA English DT Article ID BREAST-CANCER CELLS; PATHOLOGICAL COMPLETE RESPONSE; NEOADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; ESOPHAGEAL ADENOCARCINOMA; MOLECULAR PORTRAITS; HETEROGENEITY; RESISTANCE; PROGRESSION; CARCINOMAS AB Cancer therapy exerts a strong selection pressure that shapes tumor evolution, yet our knowledge of how tumors change during treatment is limited. Here, we report the analysis of cellular heterogeneity for genetic and phenotypic features and their spatial distribution in breast tumors pre- and post-neoadjuvant chemotherapy. We found that intratumor genetic diversity was tumor-subtype specific, and it did not change during treatment in tumors with partial or no response. However, lower pretreatment genetic diversity was significantly associated with pathologic complete response. In contrast, phenotypic diversity was different between pre- and post-treatment samples. We also observed significant changes in the spatial distribution of cells with distinct genetic and phenotypic features. We used these experimental data to develop a stochastic computational model to infer tumor growth patterns and evolutionary dynamics. Our results highlight the importance of integrated analysis of genotypes and phenotypes of single cells in intact tissues to predict tumor evolution. C1 [Almendro, Vanessa; Marusyk, Andriy; Maruyama, Reo; Polyak, Kornelia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Almendro, Vanessa; Marusyk, Andriy; Maruyama, Reo; Polyak, Kornelia] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Almendro, Vanessa; Marusyk, Andriy; Maruyama, Reo; Polyak, Kornelia] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Almendro, Vanessa; Ametller, Elisabet; Gonzalez-Farre, Xavier; Munoz, Montse; Gascon, Pere] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Med Oncol, E-08036 Barcelona, Spain. [Cheng, Yu-Kang; Randles, Amanda; Michor, Franziska] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Cheng, Yu-Kang; Randles, Amanda; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Randles, Amanda] Lawrence Livermore Natl Lab, Ctr Appl Sci Comp, Livermore, CA 94550 USA. [Itzkovitz, Shalev; van Oudenaarden, Alexander] MIT, Dept Phys, Cambridge, MA 02139 USA. [Itzkovitz, Shalev; van Oudenaarden, Alexander] MIT, Dept Biol, Cambridge, MA 02139 USA. [Itzkovitz, Shalev; van Oudenaarden, Alexander] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Itzkovitz, Shalev] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel. [Russnes, Hege G.; Helland, Aslaug; Rye, Inga H.; Borresen-Dale, Anne-Lise] Oslo Univ Hosp, Radiumhosp, Inst Canc Res, Dept Genet, N-0424 Oslo, Norway. [Russnes, Hege G.; Rye, Inga H.; Borresen-Dale, Anne-Lise] Univ Oslo, Fac Med, Inst Clin Med, KG Jebsen Ctr Breast Canc Res, N-0316 Oslo, Norway. [Russnes, Hege G.] Oslo Univ Hosp, Dept Pathol, N-0424 Oslo, Norway. [Helland, Aslaug] Oslo Univ Hosp, Dept Oncol, N-0424 Oslo, Norway. [Helland, Aslaug] Univ Oslo, Fac Med, Inst Clin Med, N-0316 Oslo, Norway. [van Oudenaarden, Alexander] Royal Netherlands Acad Arts & Sci, Hubrecht Inst, NL-3584 CT Utrecht, Netherlands. [van Oudenaarden, Alexander] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands. [Dowsett, Mitchell; Jones, Robin L.; Reis-Filho, Jorge] Royal Marsden Hosp, Breakthrough Breast Canc Res Ctr, Inst Canc Res, London SW3 6JJ, England. [Jones, Robin L.] Seattle Canc Care Alliance, Seattle, WA 98109 USA. [Reis-Filho, Jorge] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA. [Goenen, Mithat] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA. [Polyak, Kornelia] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Polyak, Kornelia] Broad Inst, Cambridge, MA 02142 USA. RP Michor, F (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. EM michor@jimmy.harvard.edu; kornelia_polyak@dfci.harvard.edu RI Gascon, Pere/F-7905-2015; Helland, Aslaug/H-3910-2015; Russnes, Hege/N-6170-2015; Silva, Mariana/B-9530-2012; OI Helland, Aslaug/0000-0002-5520-0275; Russnes, Hege/0000-0001-8724-1891; Randles, Amanda/0000-0001-6318-3885; Gonzalez Farre, Xavier/0000-0002-5797-7037 FU National Cancer Institute Physical Sciences Oncology Center [U54CA143874, U54CA143798]; Susan G. Komen Foundation; Cellex Foundation; Redes Tematicas de Investigacion en Cancer [RD12/0036/0055]; Breast Cancer Research Foundation; U.S. Department of Energy by Lawrence Livermore National Laboratory [DE-AC52-07NA27344] FX We thank members of our laboratories for their critical reading of this manuscript and useful discussions. We thank Lisa Cameron in the DFCI Confocal Microscopy for her technical support. This work was supported by the National Cancer Institute Physical Sciences Oncology Center U54CA143874 (to A.v.O.) and U54CA143798 (to F.M.), the Susan G. Komen Foundation (to R.M.), Cellex Foundation (to V.A.), by Redes Tematicas de Investigacion en Cancer (RD12/0036/0055 to P.G. and E.A.), and the Breast Cancer Research Foundation (to K.P.). Part of this work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344. NR 51 TC 102 Z9 105 U1 2 U2 31 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD FEB PY 2014 VL 6 IS 3 BP 514 EP 527 DI 10.1016/j.celrep.2013.12.041 PG 14 WC Cell Biology SC Cell Biology GA AA5VT UT WOS:000331168400010 PM 24462293 ER PT J AU Zhai, RH Yu, XJ Shafer, A Wain, JC Christiani, DC AF Zhai, Rihong Yu, Xiaojin Shafer, Andrea Wain, John C. Christiani, David C. TI The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection SO CHEST LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; PROGNOSTIC-FACTORS; SMOKING HISTORY; PREVALENCE; DIAGNOSIS; RISK; PATHOGENESIS; METAANALYSIS; SMOKERS; INFLAMMATION AB Background: COPD is a recognized risk factor for lung cancer, but studies of coexisting COPD in relation to lung cancer outcomes are limited. We assessed the impact of COPD on overall survival (OS) and progression-free survival (PFS) in patients with early-stage non-small cell lung cancer (NSCLC). Methods: Patients (N = 902) with early-stage (stage IA-IIB) NSCLC treated with surgical resection were retrospectively analyzed. The association of self-reported, physician-diagnosed COPD with survivals of NSCLC was assessed using the log-rank and Cox regression models, adjusting for age, sex, BMI, smoking, stages, and performance status. Results: Among this cohort of patients with NSCLC, 330 cases had physician-diagnosed COPD, and 572 did not have COPD. The 5-year OS in patients with COPD (54.4%) was significantly lower (P = .0002) than that in patients without COPD (69.0%). The 5-year PFS rates for patients with COPD and without COPD were 50.1% and 60.6%, respectively (P = .007). Compared with patients without COPD, patients with COPD had increased risk of worse OS (adjusted hazard ratio [HRadj] = 1.41, P = .002) and PFS (HRadj = 1.67, P = .003). The associations between COPD and worse survival outcomes were stronger in men and in squamous cell carcinoma (SCC). Conclusions: Coexisting COPD is associated with worse survival outcomes in patients with early-stage NSCLC, particularly for men and for SCC. C1 [Zhai, Rihong; Yu, Xiaojin; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Shafer, Andrea; Christiani, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Wain, John C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA. RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave,I-1401, Boston, MA 02115 USA. EM dchris@hsph.harvard.edu FU National Institutes of Health [CA092824, CA074386, CA090578, ES00002] FX The work was supported by the National Institutes of Health [Grants CA092824, CA074386, CA090578, and ES00002]. NR 43 TC 21 Z9 21 U1 0 U2 4 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2014 VL 145 IS 2 BP 346 EP 353 DI 10.1378/chest.13-1176 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AA2WO UT WOS:000330955100026 PM 24008835 ER PT J AU Bersohn, MM Shapiro, S AF Bersohn, Malcolm M. Shapiro, Shelley TI Systolic BP and Heart Rate in Pulmonary Hypertension Response SO CHEST LA English DT Letter C1 [Bersohn, Malcolm M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Bersohn, MM (reprint author), VA Greater Los Angeles Healthcare Syst, Cardiol 111E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mbersohn@ucla.edu NR 2 TC 0 Z9 0 U1 1 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2014 VL 145 IS 2 BP 414 EP 415 DI 10.1378/chest.13-2401 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AA2WO UT WOS:000330955100039 PM 24493520 ER PT J AU Jefferson, JA Escudero, E Johnson, RJ Swenson, ER Hurtado, A AF Jefferson, J. Ashley Escudero, Elizabeth Johnson, Richard J. Swenson, Erik R. Hurtado, Abdias TI Increased Oxidative Stress at Altitude SO CHEST LA English DT Letter ID HYPOXIA C1 [Jefferson, J. Ashley] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Escudero, Elizabeth; Hurtado, Abdias] Univ Cayetano Heredia, Carlos Monge Cassinelli Nephrol Ctr, Lima, Peru. [Johnson, Richard J.] Univ Colorado, Div Nephrol, Aurora, CO USA. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98195 USA. RP Jefferson, JA (reprint author), Univ Washington, Div Nephrol, 1959 NE Pacific St,Box 356174, Seattle, WA 98195 USA. EM jashleyj@u.washington.edu NR 7 TC 1 Z9 1 U1 1 U2 3 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2014 VL 145 IS 2 BP 423 EP 423 DI 10.1378/chest.13-2062 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AA2WO UT WOS:000330955100051 PM 24493532 ER PT J AU Vardi, M Debidda, M Bhatt, DL Mauri, L Cannon, CP AF Vardi, Moshe Debidda, Marcella Bhatt, Deepak L. Mauri, Laura Cannon, Christopher P. TI Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among US Cardiologists SO CLINICAL CARDIOLOGY LA English DT Article ID ASSOCIATION TASK-FORCE; ORAL ANTICOAGULANT TREATMENT; HEART-RHYTHM-ASSOCIATION; DRUG-ELUTING STENTS; ANTIPLATELET THERAPY; PRACTICE GUIDELINES; MYOCARDIAL-INFARCTION; RANDOMIZED EVALUATION; COMPETENCE NETWORK; CONTROLLED-TRIAL AB BackgroundMany patients treated with oral anticoagulants for atrial fibrillation undergo percutaneous stent implantation, where dual antiplatelet therapy (DAPT) is also recommended. The current evidence to support triple oral antithrombotic therapy (TOAT) in these patients is limited, and new strategies are being discussed to optimize outcomes. HypothesisThere will be variation in antithrombotic strategies in patients with atrial fibrillation needing stenting. MethodsWe surveyed US-based cardiologists serving as clinical investigators in academic sites and posted an online question of the month on . ResultsSeventy-five (10.7%) responses were received to the email survey and 119 to the online question. Bare-metal stenting (BMS) was a priori preferred over drug-eluting stenting (DES) for 50.6% of patients. Only 8.8% of the responders chose newer anticoagulants in addition to DAPT as the preferred oral anticoagulant. For duration of TOAT, 79.4% of physicians recommended stopping DAPT at 1 month when BMS was used in patients presenting without acute coronary syndrome (ACS) vs 57.4% in patients with ACS. In patients implanted with a DES, 73.5% and 76.5% preferred stopping DAPT at 6 to 12 months (no ACS vs ACS, respectively). When asked which of the 2 antiplatelet agents they would recommend stopping after the above durations, 50% chose to quit aspirin. ConclusionsThe survey highlights an interest in the new strategy of dropping aspirin, but the lack of concrete evidence triggers undesired diversity in clinical approaches. High-quality data on the efficacy and safety of such interventions are needed to further consolidate these approaches. C1 [Vardi, Moshe; Debidda, Marcella; Mauri, Laura; Cannon, Christopher P.] Harvard Clin Res Inst, Boston, MA 02215 USA. [Vardi, Moshe] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Cardiol Sect, Boston, MA USA. [Bhatt, Deepak L.; Mauri, Laura; Cannon, Christopher P.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Bhatt, Deepak L.; Mauri, Laura; Cannon, Christopher P.] Harvard Univ, Sch Med, Boston, MA USA. RP Vardi, M (reprint author), Harvard Clin Res Inst, 930 Commonwealth Ave, Boston, MA 02215 USA. EM moshe.vardi@hcri.harvard.edu FU Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Medtronic; sanofi aventis; Abbott; Boston Scientific; Cordis; Eli Lilly; Daiichi Sankyo; Bristol Myers Squibb; Accumetrics; CSL Behring; Essentialis; GlaxoSmithKline; Merck; Regeneron; Sanofi; Takeda FX Dr. Deepak L. Bhatt discloses the following: Advisory Board: Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Get With The Guidelines Steering Committee; Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), WebMD (CME steering committees); Other: Senior Associate Editor, Journal of Invasive Cardiology; Data Monitoring Committees: Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; Research Grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, sanofi aventis, The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda. Dr. Laura Mauri disclosed the following: Grant support to institution from Abbott, Boston Scientific, Cordis, Medtronic, Eli Lilly, Daiichi Sankyo, Bristol Myers Squibb, sanofi aventis. Consulting: St. Jude, Biotronik. Dr. Christopher P. Cannon discloses the following: Research grants/support from the following companies: Accumetrics, AstraZeneca, CSL Behring, Essentialis, GlaxoSmithKline, Merck, Regeneron, Sanofi, Takeda. Advisory Board (funds donated to charity): Alnylam, Bristol-Myers Squibb, Lipimedix, Pfizer. NR 35 TC 7 Z9 7 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-9289 EI 1932-8737 J9 CLIN CARDIOL JI Clin. Cardiol. PD FEB PY 2014 VL 37 IS 2 BP 103 EP 107 DI 10.1002/clc.22226 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AA0YZ UT WOS:000330824600007 PM 24672813 ER PT J AU Ersek, M Sefcik, JS Lin, FC Lee, TJ Gilliam, R Hanson, LC AF Ersek, Mary Sefcik, Justine S. Lin, Feng-Chang Lee, Tae Joon Gilliam, Robin Hanson, Laura C. TI Provider Staffing Effect on a Decision Aid Intervention SO CLINICAL NURSING RESEARCH LA English DT Article ID NURSING-HOME RESIDENTS; ADVANCED PRACTICE NURSES; OLDER PERSONS; PHYSICIAN ASSISTANTS; ADVANCED DEMENTIA; CONFLICT SCALE; CARE; TRIAL; DEATH C1 [Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Ersek, Mary; Sefcik, Justine S.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Lin, Feng-Chang] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Lee, Tae Joon] E Carolina Univ, Brody Sch Med, Greenville, NC USA. [Gilliam, Robin; Hanson, Laura C.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. [Hanson, Laura C.] Univ N Carolina, Div Geriatr Med, Chapel Hill, NC USA. RP Ersek, M (reprint author), Univ Penn, Sch Nursing, Philadelphia Vet Affairs Med Ctr, Natl PROMISE Performance Reporting & Outcomes Mea, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM ersekm@nursing.upenn.edu FU National Institute of Nursing Research [RO1NR009826]; Jonas Hartford Scholarship FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by Award Number RO1NR009826 from the National Institute of Nursing Research. JSS was supported by a Jonas Hartford Scholarship. NR 30 TC 1 Z9 1 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1054-7738 EI 1552-3799 J9 CLIN NURS RES JI Clin. Nurs. Res. PD FEB PY 2014 VL 23 IS 1 BP 36 EP 53 PG 18 WC Nursing SC Nursing GA AA5CL UT WOS:000331113200004 PM 23291316 ER PT J AU Freidlin, B Korn, EL Gray, R AF Freidlin, Boris Korn, Edward L. Gray, Robert TI Marker Sequential Test (MaST) design SO CLINICAL TRIALS LA English DT Article ID RANDOMIZED CLINICAL-TRIALS; BIOMARKERS; CANCER AB Background New targeted anticancer therapies often benefit only a subset of patients with a given cancer. Definitive evaluation of these agents may require phase III randomized clinical trial designs that integrate evaluation of the new treatment and the predictive ability of the biomarker that putatively determines the sensitive subset. Purpose We propose a new integrated biomarker design, the Marker Sequential Test (MaST) design, that allows sequential testing of the treatment effect in the biomarker subgroups and overall population while controlling the relevant type I error rates. Methods After defining the testing and error framework for integrated biomarker designs, we review the commonly used approaches to integrated biomarker testing. We then present a general form of the MaST design and describe how it can be used to provide proper control of false-positive error rates for biomarker-positive and biomarker-negative subgroups. The operating characteristics of the MaST design are compared by analytical methods and simulations to the sequential subgroup-specific design that sequentially assesses the treatment effect in the biomarker subgroups. Practical aspects of MaST design implementation are discussed. Results The MaST design is shown to have higher power relative to the sequential subgroup-specific design in situations where the treatment effect is homogeneous across biomarker subgroups, while preserving the power for settings where treatment benefit is limited to biomarker-positive subgroup. For example, in the time-to-event setting considered with 30% biomarker-positive prevalence, the MaST design provides up to a 30% increase in power in the biomarker-positive and biomarker-negative subgroups when the treatment benefits all patients equally, while sustaining less than a 2% loss of power against alternatives where the benefit is limited to the biomarker-positive subgroup. Limitations The proposed design is appropriate for settings where it is reasonable to assume that the treatment will not be effective in the biomarker-negative patients unless it is effective in the biomarker-positive patients. Conclusion The MaST trial design is a useful alternative to the sequential subgroup-specific design when it is important to consider the treatment effect in the biomarker-positive and biomarker-negative subgroups. C1 [Freidlin, Boris; Korn, Edward L.] NCI, Biometr Res Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA. [Gray, Robert] Dana Farber Canc Inst, Eastern Cooperat Oncol Grp, Boston, MA 02115 USA. RP Freidlin, B (reprint author), NCI, Biometr Res Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA. EM freidlinb@ctep.nci.nih.gov NR 15 TC 8 Z9 8 U1 0 U2 6 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD FEB PY 2014 VL 11 IS 1 BP 19 EP 27 DI 10.1177/1740774513503739 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AA6QI UT WOS:000331222500005 PM 24085774 ER PT J AU Nierenberg, AA Sylvia, LG Leon, AC Reilly-Harrington, NA Shesler, LW McElroy, SL Friedman, ES Thase, ME Shelton, RC Bowden, CL Tohen, M Singh, V Deckersbach, T Ketter, TA Kocsis, JH McInnis, MG Schoenfeld, D Bobo, WV Calabrese, JR AF Nierenberg, Andrew A. Sylvia, Louisa G. Leon, Andrew C. Reilly-Harrington, Noreen A. Shesler, Leah W. McElroy, Susan L. Friedman, Edward S. Thase, Michael E. Shelton, Richard C. Bowden, Charles L. Tohen, Mauricio Singh, Vivek Deckersbach, Thilo Ketter, Terence A. Kocsis, James H. McInnis, Melvin G. Schoenfeld, David Bobo, William V. Calabrese, Joseph R. CA Bipolar CHOICE Study Grp TI Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): A pragmatic trial of complex treatment for a complex disorder SO CLINICAL TRIALS LA English DT Article ID PLACEBO-CONTROLLED TRIAL; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; COMORBIDITY SURVEY REPLICATION; PSYCHIATRY WFSBP GUIDELINES; WEEKLY SYMPTOMATIC STATUS; CORONARY HEART DISEASE; DOUBLE-BLIND; I-DISORDER; DSM-IV; DEPRESSIVE-DISORDERS AB Background Classic and second-generation antipsychotic mood stabilizers are recommended for treatment of bipolar disorder, yet there are no randomized comparative effectiveness studies that have examined the real-world' advantages and disadvantages of these medications. Purpose We describe the strategic decisions in the design of the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE). This article outlines the key issues and solutions the investigators faced in designing a clinical trial that would maximize generalizability and inform real-world clinical treatment of bipolar disorder. Methods Bipolar CHOICE was a 6-month, multi-site, prospective, randomized clinical trial of outpatients with bipolar disorder. This study compares the effectiveness of quetiapine versus lithium, each with adjunctive personalized treatments (APTs). The co-primary outcomes selected are the overall benefits and harms of the study medications (as measured by the Clinical Global Impression-Efficacy Index) and the Necessary Clinical Adjustments (a measure of the number of medication changes). Secondary outcomes are continuous measures of mood, the Framingham General Cardiovascular Risk Score, and the Longitudinal Interval Follow up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT). Results The final study design consisted of a single-blind, randomized comparative effectiveness trial of quetiapine versus lithium, plus APT, across 10 sites. Other important study considerations included limited exclusion criteria to maximize generalizability, flexible dosing of APT medications to mimic real-world treatment, and an intent-to-treat analysis plan. In all, 482 participants were randomized to the study, and 364 completed the study. Limitations The potential limitations of the study include the heterogeneity of APT, selection of study medications, lack of a placebo-control group, and participants' ability to pay for study medications. Conclusion We expect that this study will inform our understanding of the benefits and harms of lithium, a classic mood stabilizer, compared to quetiapine, a second-generation antipsychotic with broad-spectrum activity in bipolar disorder, and will provide an example of a well-designed and well-conducted randomized comparative effectiveness clinical trial. C1 [Nierenberg, Andrew A.; Sylvia, Louisa G.; Reilly-Harrington, Noreen A.; Shesler, Leah W.; Deckersbach, Thilo] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Leon, Andrew C.; Kocsis, James H.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. [Leon, Andrew C.; Kocsis, James H.] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA. [McElroy, Susan L.] Lindner Ctr Hope, Dept Psychiat, Mason, OH USA. [Friedman, Edward S.] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Shelton, Richard C.] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL USA. [Bowden, Charles L.; Tohen, Mauricio; Singh, Vivek] Univ Texas Hlth Sci, Dept Psychiat, San Antonio, TX USA. [Ketter, Terence A.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA. [McInnis, Melvin G.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Schoenfeld, David] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. [Bobo, William V.] Vanderbilt Univ, Dept Psychiat, Nashville, TN 37235 USA. [Calabrese, Joseph R.] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA. RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St, Boston, MA 02114 USA. EM anierenberg@mgh.harvard.edu RI Lohoff, Falk/M-7951-2016; OI Bernstein, Emily/0000-0001-8609-3153 FU Agency for Healthcare Research and Quality (AHRQ) [1R01HS019371-01] FX This research was funded by the Agency for Healthcare Research and Quality (AHRQ): 1R01HS019371-01. NR 60 TC 19 Z9 19 U1 4 U2 10 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD FEB PY 2014 VL 11 IS 1 BP 114 EP 127 DI 10.1177/1740774513512184 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AA6QI UT WOS:000331222500015 PM 24346608 ER PT J AU Wu, J Spiegelman, BM AF Wu, Jun Spiegelman, Bruce M. TI Irisin ERKs the Fat SO DIABETES LA English DT Editorial Material ID BROWN ADIPOSE-TISSUE; ENERGY-EXPENDITURE; CIRCULATING LEVELS; MESSENGER-RNA; EXERCISE; HUMANS; THERMOGENESIS; EXPRESSION; FNDC5; METABOLISM C1 [Wu, Jun; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Wu, J (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM jun_wu@dfci.harvard.edu; bruce_spiegelman@dfci.harvard.edu FU NIDDK NIH HHS [R01 DK054477] NR 25 TC 5 Z9 5 U1 1 U2 14 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2014 VL 63 IS 2 BP 381 EP 383 DI 10.2337/db13-1586 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA5BG UT WOS:000331110000001 PM 24464712 ER PT J AU Wang, J Gong, B Zhao, W Tang, C Varghese, M Nguyen, T Bi, WN Bilski, A Begum, S Vempati, P Knable, L Ho, L Pasinetti, GM AF Wang, Jun Gong, Bing Zhao, Wei Tang, Cheuk Varghese, Merina Tuyen Nguyen Bi, Weina Bilski, Amanda Begum, Shimul Vempati, Prashant Knable, Lindsay Ho, Lap Pasinetti, Giulio M. TI Epigenetic Mechanisms Linking Diabetes and Synaptic Impairments SO DIABETES LA English DT Article ID HISTONE DEACETYLASE INHIBITORS; INDEPENDENT COMPONENT ANALYSIS; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; METABOLIC SYNDROME; MEMORY FORMATION; DNA METHYLATION; MOUSE MODEL; BRAIN MRI; MELLITUS AB Diabetes is one of the major risk factors for dementia. However, the molecular mechanism underlying the risk of diabetes for dementia is largely unknown. Recent studies revealed that epigenetic modifications may play a role in the pathogenesis of diabetes. We hypothesized that diabetes may cause epigenetic changes in the brain that may adversely affect synaptic function. We found significant elevation in the expression of histone deacetylases (HDACs) class IIa in the brains of diabetic subjects compared with control subjects, and these changes coincide with altered expression of synaptic proteins. In a mouse model of diet-induced type 2 diabetes (T2D), we found that, similar to humans, T2D mice also showed increased expression of HDAC IIa in the brain, and these alterations were associated with increased susceptibility to oligomeric A-induced synaptic impairments in the hippocampal formation and eventually led to synaptic dysfunction. Pharmacological inhibition of HDAC IIa restored synaptic plasticity. Our study demonstrates that diabetes may induce epigenetic modifications affecting neuropathological mechanisms in the brain leading to increased susceptibility to insults associated with neurodegenerative or vascular impairments. Our study provides, for the first time, an epigenetic explanation for the increased risk of diabetic patients developing dementia. C1 [Wang, Jun; Gong, Bing; Zhao, Wei; Varghese, Merina; Bi, Weina; Bilski, Amanda; Begum, Shimul; Vempati, Prashant; Knable, Lindsay; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Tang, Cheuk; Tuyen Nguyen] Mt Sinai Sch Med, Dept Radiol, New York, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 NR 50 TC 13 Z9 13 U1 0 U2 11 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2014 VL 63 IS 2 BP 645 EP 654 DI 10.2337/db13-1063 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA5BG UT WOS:000331110000031 PM 24154559 ER PT J AU Isganaitis, E Woo, M Ma, HJ Chen, M Kong, W Lytras, A Sales, V DeCoste-Lopez, J Lee, KJ Leatherwood, C Lee, D Fitzpatrick, C Gall, W Watkins, S Patti, ME AF Isganaitis, Elvira Woo, Melissa Ma, Huijuan Chen, Michael Kong, Wen Lytras, Aristides Sales, Vicencia DeCoste-Lopez, Jennifer Lee, Kyung-Ju Leatherwood, Cianna Lee, Deborah Fitzpatrick, Connor Gall, Walter Watkins, Steven Patti, Mary-Elizabeth TI Developmental Programming by Maternal Insulin Resistance: Hyperinsulinemia, Glucose Intolerance, and Dysregulated Lipid Metabolism in Male Offspring of Insulin-Resistant Mice SO DIABETES LA English DT Article ID HIGH-FAT DIET; WEIGHT-GAIN; PROSPECTIVE COHORT; URIC-ACID; OBESITY; PREGNANCY; ADIPONECTIN; ADIPOSITY; RECEPTOR; LEPTIN AB Maternal obesity and gestational diabetes mellitus (GDM) are associated with obesity and diabetes risk in offspring. We tested whether maternal insulin resistance, which frequently coexists with GDM and obesity, could independently contribute to dysregulation of offspring metabolism. Female mice haploinsufficient for insulin receptor substrate-1 (IRS1-het) are hyperinsulinemic and insulin resistant during pregnancy, despite normal plasma glucose and body weight, and thus serve as a model of isolated maternal insulin resistance. Wild-type (WT) offspring of IRS1-het dams insulin resistance-exposed [IR-exposed] were compared with WT offspring of WT dams. Despite no differences in adiposity, male IR-exposed pups were glucose intolerant (P = 0.04) and hyperinsulinemic (1.3-fold increase, P = 0.02) by 1 month of age and developed progressive fasting hyperglycemia. Moreover, male IR-exposed pups challenged with high-fat diet exhibited insulin resistance. Liver lipidomic analysis of 3-week-old IR-exposed males revealed increases in the 16:1n7 fraction of several lipid classes, suggesting increased Scd1 activity. By 6 months of age, IR-exposed males had increased lipid accumulation in liver as well as increased plasma refed fatty acids, consistent with disrupted lipid metabolism. Our results indicate that isolated maternal insulin resistance, even in the absence of hyperglycemia or obesity, can promote metabolic perturbations in male offspring. C1 [Isganaitis, Elvira; Woo, Melissa; Ma, Huijuan; Chen, Michael; Kong, Wen; Lytras, Aristides; Sales, Vicencia; DeCoste-Lopez, Jennifer; Lee, Kyung-Ju; Leatherwood, Cianna; Lee, Deborah; Fitzpatrick, Connor; Patti, Mary-Elizabeth] Joslin Diabet Ctr, Div Integrat Physiol & Metab, Boston, MA 02215 USA. [Gall, Walter] Metabolon Inc, Res Triangle Pk, NC USA. [Watkins, Steven] Lipomics Inc, West Sacramento, CA USA. RP Patti, ME (reprint author), Joslin Diabet Ctr, Div Integrat Physiol & Metab, Boston, MA 02215 USA. EM mary.elizabeth.patti@joslin.harvard.edu OI Chen, Michael/0000-0002-1590-768X FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [K99/R00]; Pediatric Endocrine Society; Canadian Institutes of Health Research; American Diabetes Association; Graetz Foundation; Marie-Curie International Outgoing Fellowship for Career Development [MC-IOF-2009-253131]; Joslin Diabetes Research Center [DK-036836]; Vanderbilt Mouse Metabolic Phenotyping Center [DK-59637] FX Grant support was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development K99/R00, the Pediatric Endocrine Society, the Canadian Institutes of Health Research (to E.I.); and by the American Diabetes Association and the Graetz Foundation (to M.-E.P.). A.L. was the recipient of a Marie-Curie International Outgoing Fellowship for Career Development (MC-IOF-2009-253131). The authors thank the Joslin Diabetes Research Center (DK-036836) and Vanderbilt Mouse Metabolic Phenotyping Center (DK-59637). NR 44 TC 24 Z9 24 U1 0 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2014 VL 63 IS 2 BP 688 EP 700 DI 10.2337/db13-0558 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA5BG UT WOS:000331110000035 PM 24186867 ER PT J AU Hoogenboom, WS Marder, TJ Flores, VL Huisman, S Eaton, HP Schneiderman, JS Bolo, NR Simonson, DC Jacobson, AM Kubicki, M Shenton, ME Musen, G AF Hoogenboom, Wouter S. Marder, Thomas J. Flores, Veronica L. Huisman, Susanne Eaton, Hana P. Schneiderman, Jason S. Bolo, Nicolas R. Simonson, Donald C. Jacobson, Alan M. Kubicki, Marek Shenton, Martha E. Musen, Gail TI Cerebral White Matter Integrity and Resting-State Functional Connectivity in Middle-aged Patients With Type 2 Diabetes SO DIABETES LA English DT Article ID VOXEL-BASED MORPHOMETRY; DEFAULT MODE NETWORK; DIFFUSION-TENSOR MRI; ALZHEIMERS-DISEASE; STRUCTURAL CONNECTIVITY; COGNITIVE PERFORMANCE; INSULIN SENSITIVITY; IN-VIVO; BRAIN; ABNORMALITIES AB Early detection of brain abnormalities at the preclinical stage can be useful for developing preventive interventions to abate cognitive decline. We examined whether middle-aged type 2 diabetic patients show reduced white matter integrity in fiber tracts important for cognition and whether this abnormality is related to preestablished altered resting-state functional connectivity in the default mode network (DMN). Diabetic and nondiabetic participants underwent diffusion tensor imaging, functional magnetic resonance imaging, and cognitive assessment. Multiple diffusion measures were calculated using streamline tractography, and correlations with DMN functional connectivity were determined. Diabetic patients showed lower fractional anisotropy (FA) (a measure of white matter integrity) in the cingulum bundle and uncinate fasciculus. Control subjects showed stronger functional connectivity than patients between the posterior cingulate and both left fusiform and medial frontal gyri. FA of the cingulum bundle was correlated with functional connectivity between the posterior cingulate and medial frontal gyrus for combined groups. Thus, middle-aged patients with type 2 diabetes show white matter abnormalities that correlate with disrupted functional connectivity in the DMN, suggesting that common mechanisms may underlie structural and functional connectivity. Detecting brain abnormalities in middle age enables implementation of therapies to slow progression of neuropathology. C1 [Hoogenboom, Wouter S.; Marder, Thomas J.; Flores, Veronica L.; Huisman, Susanne; Eaton, Hana P.; Jacobson, Alan M.; Musen, Gail] Joslin Diabet Ctr, Boston, MA 02215 USA. [Hoogenboom, Wouter S.; Schneiderman, Jason S.; Kubicki, Marek; Shenton, Martha E.] Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Dept Psychiat, Boston, MA 02115 USA. [Huisman, Susanne] Univ Amsterdam, Acad Med Ctr, Fac Med, NL-1105 AZ Amsterdam, Netherlands. [Schneiderman, Jason S.] Univ Penn, Perelman Sch Med, Unit Expt Psychiat, Philadelphia, PA 19104 USA. [Bolo, Nicolas R.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Bolo, Nicolas R.; Simonson, Donald C.; Jacobson, Alan M.; Kubicki, Marek; Shenton, Martha E.; Musen, Gail] Harvard Univ, Sch Med, Boston, MA USA. [Simonson, Donald C.] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Jacobson, Alan M.] Winthrop Univ Hosp, Res Inst, Mineola, NY 11501 USA. [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Brockton Div, Dept Psychiat, Clin Neurosci Div,Lab Neurosci, Brockton, MA USA. RP Musen, G (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA. EM gail.musen@joslin.harvard.edu FU National Institutes of Health [5R01-AG-034165-A2, P30-DK-36836]; Herbert Graetz Fund FX This study was supported in part by National Institutes of Health grants 5R01-AG-034165-A2 (G.M.) and P30-DK-36836 (to the Joslin Diabetes Research Center, Genetics Core) and by the Herbert Graetz Fund. NR 49 TC 34 Z9 39 U1 1 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2014 VL 63 IS 2 BP 728 EP 738 DI 10.2337/db13-1219 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA5BG UT WOS:000331110000038 PM 24203723 ER PT J AU Thalacker-Mercer, AE Ingram, KH Guo, FJ Ilkayeva, O Newgard, CB Garvey, WT AF Thalacker-Mercer, Anna E. Ingram, Katherine H. Guo, Fangjian Ilkayeva, Olga Newgard, Christopher B. Garvey, W. Timothy TI BMI, RQ, Diabetes, and Sex Affect the Relationships Between Amino Acids and Clamp Measures of Insulin Action in Humans SO DIABETES LA English DT Article ID RESISTANCE SYNDROME; AFRICAN-AMERICANS; SKELETAL-MUSCLE; WEIGHT-LOSS; GLUCOSE; SENSITIVITY; SECRETION; OBESITY; FAT; METABOLISM AB Previous studies have used indirect measures of insulin sensitivity to link circulating amino acids with insulin resistance and identify potential biomarkers of diabetes risk. Using direct measures (i.e., hyperinsulinemic-euglycemic clamps), we examined the relationships between the metabolomic amino acid profile and insulin action (i.e., glucose disposal rate [GDR]). Relationships between GDR and serum amino acids were determined among insulin-sensitive, insulin-resistant, and type 2 diabetic (T2DM) individuals. In all subjects, glycine (Gly) had the strongest correlation with GDR (positive association), followed by leucine/isoleucine (Leu/Ile) (negative association). These relationships were dramatically influenced by BMI, the resting respiratory quotient (RQ), T2DM, and sex. Gly had a strong positive correlation with GDR regardless of BMI, RQ, or sex but became nonsignificant in T2DM. In contrast, Leu/Ile was negatively associated with GDR in nonobese and T2DM subjects. Increased resting fat metabolism (i.e., low RQ) and obesity were observed to independently promote and negate the association between Leu/Ile and insulin resistance, respectively. Additionally, the relationship between Leu/Ile and GDR was magnified in T2DM males. Future studies are needed to determine whether Gly has a mechanistic role in glucose homeostasis and whether dietary Gly enrichment may be an effective intervention in diseases characterized by insulin resistance. C1 [Thalacker-Mercer, Anna E.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [Thalacker-Mercer, Anna E.; Ingram, Katherine H.; Guo, Fangjian; Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA. [Thalacker-Mercer, Anna E.; Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Thalacker-Mercer, Anna E.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA. [Ingram, Katherine H.] Kennesaw State Univ, Dept Exercise Sci & Sport Management, Kennesaw, GA USA. [Ilkayeva, Olga; Newgard, Christopher B.] Duke Univ, Dept Med, Durham, NC USA. [Newgard, Christopher B.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. EM garveyt@uab.edu RI Guo, Fangjian/B-7705-2015 OI Guo, Fangjian/0000-0003-3729-2724 FU National Institutes of Health [DK-038765, DK-083562, P01 HL-55782, P01 DK58398]; Merit Review program of the Department of Veterans Affairs; University of Alabama at Birmingham (UAB) Center for Clinical and Translational Science [UL1 RR025777]; Nutrition and Obesity Research Center [P30-DK-56336]; UAB Diabetes Research and Training Center [P60 DK-079626] FX This work was supported by grants from the National Institutes of Health (DK-038765, DK-083562, P01 HL-55782, and P01 DK58398 to W.T.G.) and the Merit Review program (to W.T.G.) of the Department of Veterans Affairs. The authors also acknowledge support from the University of Alabama at Birmingham (UAB) Center for Clinical and Translational Science (UL1 RR025777), the Nutrition and Obesity Research Center (P30-DK-56336), and the UAB Diabetes Research and Training Center (P60 DK-079626). NR 36 TC 18 Z9 18 U1 1 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2014 VL 63 IS 2 BP 791 EP 800 DI 10.2337/db13-0396 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA5BG UT WOS:000331110000044 PM 24130332 ER PT J AU Frakt, AB AF Frakt, Austin B. TI The End of Hospital Cost Shifting and the Quest for Hospital Productivity SO HEALTH SERVICES RESEARCH LA English DT Editorial Material ID ALTERNATIVE QUALITY; SYSTEM; MORTALITY; PROVIDERS; CONTRACT; BUDGET; IMPACT C1 [Frakt, Austin B.] VA Boston Healthcare Syst, Boston, MA USA. [Frakt, Austin B.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Frakt, Austin B.] Sch Publ Hlth, Boston, MA USA. [Frakt, Austin B.] Univ Penn, Leonard Davis Inst, Philadelphia, PA 19104 USA. RP Frakt, AB (reprint author), VA Boston Healthcare Syst, Boston, MA USA. EM frakt@bu.edu NR 33 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2014 VL 49 IS 1 BP 1 EP 10 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AA3LU UT WOS:000330994800001 PM 24102445 ER PT J AU Dai, Y Zheng, KN Clark, J Swerdlow, RH Pulst, SM Sutton, JP Shinobu, LA Simon, DK AF Dai, Ying Zheng, Kangni Clark, Joanne Swerdlow, Russell H. Pulst, Stefan M. Sutton, James P. Shinobu, Leslie A. Simon, David K. TI Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation SO HUMAN MOLECULAR GENETICS LA English DT Article ID HEREDITARY OPTIC NEUROPATHY; MTDNA MUTATIONS; OXIDATIVE STRESS; SKELETAL-MUSCLE; GENE-THERAPY; CYBRID CELLS; AUTOPHAGY; MITOPHAGY; DISEASE; CANCER AB Mitochondrial DNA(mtDNA) mutations cause a variety of mitochondrial disorders for which effective treatments are lacking. Emerging data indicate that selective mitochondrial degradation through autophagy (mitophagy) plays a critical role in mitochondrial quality control. Inhibition of mammalian target of rapamycin (mTOR) kinase activity can activate mitophagy. To test the hypothesis that enhancing mitophagy would drive selection against dysfunctional mitochondria harboring higher levels of mutations, thereby decreasing mutation levels over time, we examined the impact of rapamycin on mutation levels in a human cytoplasmic hybrid (cybrid) cell line expressing a heteroplasmic mtDNA G11778A mutation, the most common cause of Leber's hereditary optic neuropathy. Inhibition of mTORC1/S6 kinase signaling by rapamycin induced colocalization of mitochondria with autophagosomes, and resulted in a striking progressive decrease in levels of the G11778A mutation and partial restoration of ATP levels. Rapamycin-induced upregulation of mitophagy was confirmed by electron microscopic evidence of increased autophagic vacuoles containing mitochondria-like organelles. The decreased mutational burden was not due to rapamycin-induced cell death or mtDNA depletion, as there was no significant difference in cytotoxicity/apoptosis or mtDNA copy number between rapamycin and vehicle treated cells. These data demonstrate the potential for pharmacological inhibition of mTOR kinase activity to activate mitophagy as a strategy to drive selection against a heteroplasmic mtDNA G11778A mutation and raise the exciting possibility that rapamycin may have therapeutic potential for the treatment of mitochondrial disorders associated with heteroplasmic mtDNA mutations, although further studies are needed to determine if a similar strategy will be effective for other mutations and other cell types. C1 [Dai, Ying; Zheng, Kangni; Clark, Joanne; Simon, David K.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. [Dai, Ying; Zheng, Kangni; Clark, Joanne; Shinobu, Leslie A.; Simon, David K.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Swerdlow, Russell H.] Univ Kansas, Sch Med, Dept Neurol, Kansas City, KS 66160 USA. [Swerdlow, Russell H.] Univ Kansas, Sch Med, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA. [Swerdlow, Russell H.] Univ Kansas, Sch Med, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA. [Pulst, Stefan M.] Univ Utah, Dept Neurol, Salt Lake City, UT 84132 USA. [Sutton, James P.] Pacific Neurosci Med Grp, Oxnard, CA 93030 USA. [Shinobu, Leslie A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02215 USA. RP Dai, Y (reprint author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Room CLS 628, Boston, MA 02215 USA. EM ydai@bidmc.harvard.edu FU National Institute of Neurological Disorders and Stroke [1R21NS077758]; United Mitochondrial Disease Foundation [UMDF11-095] FX This work was supported by the National Institute of Neurological Disorders and Stroke (1R21NS077758 to D. K. S.); and the United Mitochondrial Disease Foundation (UMDF11-095 to Y.D.). NR 52 TC 16 Z9 17 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD FEB 1 PY 2014 VL 23 IS 3 BP 637 EP 647 DI 10.1093/hmg/ddt450 PG 11 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA AA1FK UT WOS:000330841700006 PM 24101601 ER PT J AU Zhang, XL Johnson, AD Hendricks, AE Hwang, SJ Tanriverdi, K Ganesh, SK Smith, NL Peyser, PA Freedman, JE O'Donnell, CJ AF Zhang, Xiaoling Johnson, Andrew D. Hendricks, Audrey E. Hwang, Shih-Jen Tanriverdi, Kahraman Ganesh, Santhi K. Smith, Nicholas L. Peyser, Patricia A. Freedman, Jane E. O'Donnell, Christopher J. TI Genetic associations with expression for genes implicated in GWAS studies for atherosclerotic cardiovascular disease and blood phenotypes SO HUMAN MOLECULAR GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; HEART-DISEASE; MYOCARDIAL-INFARCTION; CHARGE CONSORTIUM; DNA VARIANTS; FACTOR-VII; LOCI; RISK AB Genome-wide association studies (GWAS) have uncovered many genetic associations for cardiovascular disease (CVD). However, data are limited regarding causal genetic variants within implicated loci. We sought to identify regulatory variants (cis-and trans-eQTLs) affecting expression levels of 93 genes selected by their proximity to SNPs with significant associations in prior GWAS for CVD traits. Expression levels were measured by qRT-PCR in leukocytes from 1846 Framingham Heart Study participants. An additive genetic model was applied to 2.5 million imputed SNPs for each gene. Approximately 45% of genes (N = 38) harbored at least one cis-eSNP after a regional multiple-test adjustment. Applying a more rigorous significance threshold (P < 5 x 10(-8)), we found the expression level of 10 genes was significantly associated with more than one cis-eSNP. The top cis-eSNPs for 7 of these 10 genes exhibited moderate-to-strong association with >= 1 CVD clinical phenotypes. Several eSNPs or proxy SNPs (r(2) = 1) were replicated by other eQTL studies. After adjusting for the lead GWAS SNPs for the 10 genes, expression variances explained by top cis-eSNPs were attenuated markedly for LPL, FADS2 and C6orf184, suggesting a shared genetic basis for the GWAS and expression trait. A significant association between cis-eSNPs, gene expression and lipid levels was discovered for LPL and C6orf184. In conclusion, strong cis-acting variants are localized within nearly half of the GWAS loci studied, with particularly strong evidence for a regulatory role of the top GWAS SNP for expression of LPL, FADS2 and C6orf184. C1 [Zhang, Xiaoling; Johnson, Andrew D.; Hendricks, Audrey E.; Hwang, Shih-Jen; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Framingham, MA 01702 USA. [Zhang, Xiaoling; Johnson, Andrew D.; Hendricks, Audrey E.; Hwang, Shih-Jen; O'Donnell, Christopher J.] NHLBIs Framingham Heart Study, Framingham, MA USA. [Tanriverdi, Kahraman; Freedman, Jane E.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Ganesh, Santhi K.] Univ Michigan Hlth Care Syst, Div Cardiovasc Med, Dept Internal Med, Ann Arbor, MI USA. [Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Smith, Nicholas L.] Seattle Epidemiol Res & Informat Ctr, VA Off Res & Dev, Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA USA. [Peyser, Patricia A.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [O'Donnell, Christopher J.] Massachusetts Gen Hosp, Div Cardiol, Framingham, MA USA. RP O'Donnell, CJ (reprint author), NHLBI, Div Intramural Res, NHLBIs Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. EM odonnellc@nhlbi.nih.gov RI Hendricks, Audrey/I-4127-2016; Johnson, Andrew/G-6520-2013 OI Hendricks, Audrey/0000-0002-7152-0287; FU National Heart, Lung and Blood Institute, Division of Intramural Research FX This work was supported by the National Heart, Lung and Blood Institute, Division of Intramural Research. NR 61 TC 16 Z9 16 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD FEB 1 PY 2014 VL 23 IS 3 BP 782 EP 795 DI 10.1093/hmg/ddt461 PG 14 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA AA1FK UT WOS:000330841700018 PM 24057673 ER PT J AU Sedaghat, AR Phipatanakul, W Cunningham, MJ AF Sedaghat, Ahmad R. Phipatanakul, Wanda Cunningham, Michael J. TI Prevalence of and associations with allergic rhinitis in children with chronic rhinosinusitis SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY LA English DT Article DE Allergic rhinitis; Hypersensitivity; Sinusitis; Pediatrics; Asthma; Chronic rhinosinusitis ID CYSTIC-FIBROSIS; CHRONIC SINUSITIS; ASTHMA; INFLAMMATION; MANAGEMENT; INFECTION AB Objectives: Chronic rhinosinusitis (CRS) in children has been associated with a variety of disorders including atopic disease, cystic fibrosis, immunologic disorders and ciliary dyskinesia. Although a strong association, or even cause and effect relationship, between allergic rhinitis (AR) and CRS is commonly assumed, the epidemiologic relationship between these disorders has not yet been defined in children. Methods: A retrospective review of all children diagnosed with CRS on otolaryngology or allergy office evaluation at a large tertiary-care pediatric hospital over a ten-year period was performed. Demographic data and concomitant diagnoses of AR, cystic fibrosis, immunologic disorders and primary ciliary dyskinesia were analyzed for relationships with CRS. Results: A total of 4044 children with an average age of 8.9 years and a slight male predominance (53.8%) with CRS were identified. Of these children, 0.2% had primary ciliary dyskinesia, 4.1% had cystic fibrosis, 12.3% had an immunologic disorder, and 26.9% had AR. A concomitant asthma diagnosis was positively associated with a diagnosis of AR (OR = 6.24,95% CI: 5.27-7.39, P < 0.001), whereas a concomitant cystic fibrosis diagnosis was negatively associated (OR = 0.12, 95% CI: 0.06-0.26, P < 0.001). Conclusions: AR is more prevalent than the other comorbidities combined in children with CRS, and is independently associated with the presence of asthma. Formal allergy testing, guided by clinical history and regional allergen sensitivity prevalence, should be strongly considered in all children with CRS, in particular those with reactive airway disease. (C) 2013 Published by Elsevier Ireland Ltd. C1 [Sedaghat, Ahmad R.] Massachusetts Eye & Ear Infirmaiy, Dept Otolaryngol Head & Neck Surg, Boston, MA USA. [Phipatanakul, Wanda] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Allergy & Immunol,Dept Pediat, Boston, MA USA. [Cunningham, Michael J.] Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Boston, MA USA. [Sedaghat, Ahmad R.; Cunningham, Michael J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA USA. RP Sedaghat, AR (reprint author), 243 Charles St, Boston, MA 02114 USA. EM ahmad_sedaghat@meei.harvard.edu FU NCRR NIH HHS [UL1 RR025758]; NIAID NIH HHS [K24 AI106822] NR 29 TC 11 Z9 11 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-5876 EI 1872-8464 J9 INT J PEDIATR OTORHI JI Int. J. Pediatr. Otorhinolaryngol. PD FEB PY 2014 VL 78 IS 2 BP 343 EP 347 DI 10.1016/j.ijporl.2013.12.006 PG 5 WC Otorhinolaryngology; Pediatrics SC Otorhinolaryngology; Pediatrics GA AA2HQ UT WOS:000330916100033 PM 24388318 ER PT J AU Rubinson, DA Hochster, HS Ryan, DP Wolpin, BM McCleary, NJ Abrams, TA Chan, JA Iqbal, S Lenz, HJ Lim, D Rose, J Bekaii-Saab, T Chen, HX Fuchs, CS Ng, K AF Rubinson, Douglas A. Hochster, Howard S. Ryan, David P. Wolpin, Brian M. McCleary, Nadine Jackson Abrams, Thomas A. Chan, Jennifer A. Iqbal, Syma Lenz, Heinz J. Lim, Dean Rose, Jeffrey Bekaii-Saab, Tanios Chen, Helen X. Fuchs, Charles S. Ng, Kimmie TI Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE Pertuzumab; Cetuximab; Phase I; Phase II; Colorectal Cancer ID GROWTH-FACTOR RECEPTOR; DIMERIZATION INHIBITOR; ACQUIRED-RESISTANCE; CLINICAL ACTIVITY; OVARIAN-CANCER; SOLID TUMORS; CHEMOTHERAPY; TRIAL; EGFR; COMBINATION AB Purpose Resistance to cetuximab, a monoclonal antibody against the epithelial growth factor receptor (EGFR), in colorectal cancer (CRC) may result from compensatory signaling through ErbB receptors, ErbB2/neu/HER2 (HER2) and ErbB3/HER3 (HER3). Pertuzumab is a monoclonal antibody that blocks HER2 hetero-dimerization; thus the combination of pertuzumab and cetuximab could possibly overcome cetuximab resistance. Patients and methods This single-arm, open-label, multicenter phase I/II study was designed to assess the safety and efficacy of pertuzumab and cetuximab in patients with cetuximab-resistant KRAS wild type metastatic CRC. Thirteen patients were enrolled and received cetuximab in combination with pertuzumab at several dose levels in a 3 + 3 design. Patients were assessed for dose-limiting toxicity (DLT) during the first cycle. A phase II portion was planned, but not initiated due to toxicity. Results Six of the thirteen patients (46 %) experienced DLTs, therefore the study was terminated early. Grade 3 or higher DLTs included dermatitis with desquamation and/or acneiform rash (n = 6), mucositis or stomatitis (n = 5), and diarrhea (n = 2). There was one Grade 5 event (myocardial infarction) attributed to underlying disease. Among the 13 patients, seven (54 %) were evaluable for response. The objective response rate was 14 %: one patient had a partial response lasting 6 months. Two patients had stable disease (29 %), and four had progressive disease (57 %). Median progression free survival was 2.1 months (95 % CI, 1.5-4.9) and median overall survival was 3.7 months (95 % CI, 1.6-7.9). Conclusion Combination pertuzumab and cetuximab in refractory CRC was associated with potential antitumor activity; however, the combination was not tolerable due to overlapping toxicities. C1 [Rubinson, Douglas A.; Wolpin, Brian M.; McCleary, Nadine Jackson; Abrams, Thomas A.; Chan, Jennifer A.; Fuchs, Charles S.; Ng, Kimmie] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Hochster, Howard S.] Yale Univ, Ctr Canc, Dept Med Oncol, New Haven, CT USA. [Ryan, David P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Iqbal, Syma; Lenz, Heinz J.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Div Med Oncol,Sharon A Carpenter Lab, Los Angeles, CA 90033 USA. [Lim, Dean] City Hope Natl Med Ctr, Div Med Oncol & Therapeut Res, Duarte, CA 91010 USA. [Rose, Jeffrey] Lowcountry Hematol & Oncol, Mt Pleasant, MI USA. [Bekaii-Saab, Tanios] Ohio State Univ, Coll Med, Dept Pharmacol, Columbus, OH 43210 USA. [Chen, Helen X.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. RP Ng, K (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM Kimmie_Ng@dfci.harvard.edu FU NCI; Genentech FX Pertuzumab was supplied by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) in Bethesda, MD. The trial was conducted under a Phase 2 Consortium contract with the NCI. Genentech also provided supplementary funding for the study. NR 35 TC 10 Z9 10 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0167-6997 EI 1573-0646 J9 INVEST NEW DRUG JI Invest. New Drugs PD FEB PY 2014 VL 32 IS 1 BP 113 EP 122 DI 10.1007/s10637-013-9956-5 PG 10 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA AA3BY UT WOS:000330969100012 PM 23568716 ER PT J AU Rosenberg, JE Bambury, RM Van Allen, EM Drabkin, HA Lara, PN Harzstark, AL Wagle, N Figlin, RA Smith, GW Garraway, LA Choueiri, T Erlandsson, F Laber, DA AF Rosenberg, Jonathan E. Bambury, Richard M. Van Allen, Eliezer M. Drabkin, Harry A. Lara, Primo N., Jr. Harzstark, Andrea L. Wagle, Nikhil Figlin, Robert A. Smith, Gregory W. Garraway, Levi A. Choueiri, Toni Erlandsson, Fredrik Laber, Damian A. TI A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE AS1411; Nucleolin; Renal cell carcinoma; Aptamer ID BREAST-CANCER CELLS; INTERFERON-ALPHA; CYCLE ARREST; INHIBITION; SUNITINIB; SURVIVAL; DRUG; RNA AB Background DNA aptamers represent a novel strategy in anti-cancer medicine. AS1411, a DNA aptamer targeting nucleolin (a protein which is overexpressed in many tumor types), was evaluated in patients with metastatic, clear-cell, renal cell carcinoma (RCC) who had failed treatment with a parts per thousand yen1 prior tyrosine kinase inhibitor. Methods In this phase II, single-arm study, AS1411 was administered at 40 mg/kg/day by continuous intravenous infusion on days 1-4 of a 28-day cycle, for two cycles. Primary endpoint was overall response rate; progression-free survival (PFS) and safety were secondary endpoints. Results 35 patients were enrolled and treated. One patient (2.9 %) had a response to treatment. The response was dramatic (84 % reduction in tumor burden by RECIST 1.0 criteria) and durable (patient remains free of progression 2 years after completing therapy). Whole exome sequencing of this patient's tumor revealed missense mutations in the mTOR and FGFR2 genes which is of interest because nucleolin is known to upregulate mTOR pathway activity by enhancing AKT1 mRNA translation. No other responses were seen. Thirty-four percent of patients had an AS1411-related adverse event, all of which were mild or moderate. Conclusions AS1411 appears to have minimal activity in unselected patients with metastatic RCC. However, rare, dramatic and durable responses can be observed and toxicity is low. One patient in this study had an excellent response and was found to have FGFR2 and mTOR mutations which will be of interest in future efforts to discover and validate predictive biomarkers of response to nucleolin targeted compounds. DNA aptamers represent a novel way to target cancer cells at a molecular level and continue to be developed with a view to improving treatment and imaging in cancer medicine. C1 [Rosenberg, Jonathan E.; Van Allen, Eliezer M.; Choueiri, Toni] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Rosenberg, Jonathan E.; Bambury, Richard M.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA. [Van Allen, Eliezer M.; Wagle, Nikhil; Garraway, Levi A.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Drabkin, Harry A.] MUSC, Charleston, SC USA. [Lara, Primo N., Jr.] Univ Calif Davis, Sacramento, CA 95817 USA. [Harzstark, Andrea L.] UCSF, San Francisco, CA USA. [Figlin, Robert A.] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Smith, Gregory W.] St Francis Hosp, Beech Grove, IN USA. [Erlandsson, Fredrik] AstraZeneca R&D, Molndal, Sweden. [Laber, Damian A.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. RP Rosenberg, JE (reprint author), 1275 York Ave, New York, NY 10065 USA. EM rosenbj1@mskcc.org OI Rosenberg, Jonathan/0000-0003-2637-4249 FU Antisoma Research, Ltd. FX This study was sponsored by Antisoma Research, Ltd. NR 27 TC 52 Z9 54 U1 13 U2 62 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0167-6997 EI 1573-0646 J9 INVEST NEW DRUG JI Invest. New Drugs PD FEB PY 2014 VL 32 IS 1 BP 178 EP 187 DI 10.1007/s10637-013-0045-6 PG 10 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA AA3BY UT WOS:000330969100019 PM 24242861 ER PT J AU Blashill, AJ Gordon, JR Safren, SA AF Blashill, Aaron J. Gordon, Janna R. Safren, Steven A. TI Depression longitudinally mediates the association of appearance concerns to ART non-adherence in HIV-infected individuals with a history of injection drug use SO JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE HIV/AIDS; Appearance; Body image; Depression; ART adherence; Lipodystrophy ID ACTIVE ANTIRETROVIRAL THERAPY; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; BODY-IMAGE; VIRAL LOAD; MEDICATION ADHERENCE; HAART ADHERENCE; SELF-PERCEPTION; ADIPOSE-TISSUE AB Appearance concerns are common among HIV-infected individuals, and previous cross-sectional and longitudinal data indicate that these concerns are associated with antiretroviral therapy (ART) non-adherence. However, to date, no known prospective data have explored the mechanism behind this relationship. Thus, the aim of the current study was to test depression severity as a prospective mediator of the relationship between appearance concerns and ART non-adherence in HIV-infected individuals with a history of injection drug use (IDU). Participants were 89 HIV-infected individuals with a history of IDU who participated in a prospective, randomized controlled trial of cognitive behavioral therapy for depression and medication adherence. Clinician-administered measures of depression severity and appearance concerns, along with electronic monitoring of ART non-adherence were included. Data were analyzed using longitudinal linear mixed-level modeling, and mediation was tested via the Monte Carlo Method of Assessing Mediation. Appearance concerns were predictive of depression severity, gamma = .31, SE = .076, 95 % CI [.16, .46], t = 4.1, p = .0001, and depression severity was predictive of ART non-adherence, gamma = 3.3, SE = 1.3, 95 % CI [.8, 5.8], t = 2.6, p = .01. The effect of appearance concerns on ART non-adherence, however, was significantly mediated by depression severity, gamma = 1.02, 95 % CI [.21, 2.1]. Appearance concerns are associated with depression severity, which in turn is associated with ART non-adherence. Integrative interventions addressing appearance concerns, depression and ART adherence are needed, as this is one potential pathway towards worse health outcomes in HIV-infected individuals. C1 [Blashill, Aaron J.; Gordon, Janna R.; Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Blashill, Aaron J.; Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Blashill, AJ (reprint author), Harvard Univ, Sch Med, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM ablashill@partners.org FU NIAID NIH HHS [5P30 AI060354-08, P30 AI060354]; NIDA NIH HHS [R01 DA018603]; NIMH NIH HHS [K23 MH096647, K24 MH094214] NR 49 TC 4 Z9 4 U1 3 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0160-7715 EI 1573-3521 J9 J BEHAV MED JI J. Behav. Med. PD FEB PY 2014 VL 37 IS 1 BP 166 EP 172 DI 10.1007/s10865-012-9476-3 PG 7 WC Psychology, Clinical SC Psychology GA AA0KV UT WOS:000330784900016 PM 23180286 ER PT J AU Northern, LR Dhawan, R Bas, HP Vidal-Melo, MF Mohr, FW Garbade, J AF Northern, Luke R. Dhawan, Richa Bas, Heidi Petra Vidal-Melo, Marcos F. Mohr, Friedrich-Wilhelm Garbade, Jens TI CASE 1-2014 Left Ventricular Assist Device Insertion and the Mitral Valve SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE LVAD function; valvular lesion ID TO-EDGE TECHNIQUE; VALVULAR REGURGITATION; HEART-FAILURE; REPAIR; IMPLANTATION; MANAGEMENT; INSUFFICIENCY; EXPERIENCE; PATIENT; SUPPORT C1 [Northern, Luke R.; Dhawan, Richa] Univ Chicago, Med Ctr, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA. [Bas, Heidi Petra; Vidal-Melo, Marcos F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mohr, Friedrich-Wilhelm; Garbade, Jens] Univ Leipzig, Ctr Heart, Dept Cardiac Surg, D-04109 Leipzig, Germany. RP Dhawan, R (reprint author), Univ Chicago, Med Ctr, Dept Anesthesia & Crit Care, 5841 S Maryland Ave,MC 4028, Chicago, IL 60637 USA. EM rdhawan@dacc.uchicago.edu NR 29 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD FEB PY 2014 VL 28 IS 1 BP 174 EP 180 DI 10.1053/j.jvca.2013.01.022 PG 7 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA AA2LG UT WOS:000330925500029 PM 23938398 ER PT J AU Gellad, WF AF Gellad, Walid F. TI Targeted Cancer Therapy: From Bench to Bedside to Patient SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID CHRONIC MYELOID-LEUKEMIA; MEDICATION ADHERENCE; BREAST-CANCER; NONADHERENCE; IMATINIB; COST; IBRUTINIB; OUTCOMES; AGENTS; WOMEN C1 Univ Pittsburgh, Ctr Hlth Equity Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. RP Gellad, WF (reprint author), Univ Pittsburgh, Ctr Hlth Equity Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. EM walid.gellad@va.gov NR 28 TC 1 Z9 1 U1 0 U2 8 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2014 VL 32 IS 4 BP 268 EP 270 DI 10.1200/JCO.2013.53.8413 PG 3 WC Oncology SC Oncology GA AA4LH UT WOS:000331066600002 PM 24366939 ER PT J AU Fenske, TS Zhang, MJ Carreras, J Ayala, E Burns, LJ Cashen, A Costa, LJ Freytes, CO Gale, RP Hamadani, M Holmberg, LA Inwards, DJ Lazarus, HM Maziarz, RT Munker, R Perales, MA Rizzieri, DA Schouten, HC Smith, SM Waller, EK Wirk, BM Laport, GG Maloney, DG Montoto, S Hari, PN AF Fenske, Timothy S. Zhang, Mei-Jie Carreras, Jeanette Ayala, Ernesto Burns, Linda J. Cashen, Amanda Costa, Luciano J. Freytes, Cesar O. Gale, Robert P. Hamadani, Mehdi Holmberg, Leona A. Inwards, David J. Lazarus, Hillard M. Maziarz, Richard T. Munker, Reinhold Perales, Miguel-Angel Rizzieri, David A. Schouten, Harry C. Smith, Sonali M. Waller, Edmund K. Wirk, Baldeep M. Laport, Ginna G. Maloney, David G. Montoto, Silvia Hari, Parameswaran N. TI Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID INTERNATIONAL PROGNOSTIC INDEX; PROSPECTIVE RANDOMIZED-TRIAL; MARROW TRANSPLANT; INDUCTION REGIMEN; IMPROVES RESPONSE; FOLLOW-UP; PHASE-II; SURVIVAL; RITUXIMAB; IMMUNOCHEMOTHERAPY AB Purpose To examine the outcomes of patients with chemotherapy-sensitive mantle-cell lymphoma (MCL) following a first hematopoietic stem-cell transplantation (HCT), comparing outcomes with autologous (auto) versus reduced-intensity conditioning allogeneic (RIC allo) HCT and with transplantation applied at different times in the disease course. Patients and Methods In all, 519 patients who received transplantations between 1996 and 2007 and were reported to the Center for International Blood and Marrow Transplant Research were analyzed. The early transplantation cohort was defined as those patients in first partial or complete remission with no more than two lines of chemotherapy. The late transplantation cohort was defined as all the remaining patients. Results Auto-HCT and RIC allo-HCT resulted in similar overall survival from transplantation for both the early (at 5 years: 61% auto-HCT v 62% RIC allo-HCT; P = .951) and late cohorts (at 5 years: 44% auto-HCT v 31% RIC allo-HCT; P = .202). In both early and late transplantation cohorts, progression/relapse was lower and nonrelapse mortality was higher in the allo-HCT group. Overall survival and progression-free survival were highest in patients who underwent auto-HCT in first complete response. Multivariate analysis of survival from diagnosis identified a survival benefit favoring early HCT for both auto-HCT and RIC allo-HCT. Conclusion For patients with chemotherapy-sensitive MCL, the optimal timing for HCT is early in the disease course. Outcomes are particularly favorable for patients undergoing auto-HCT in first complete remission. For those unable to achieve complete remission after two lines of chemotherapy or those with relapsed disease, either auto-HCT or RIC allo-HCT may be effective, although the chance for long-term remission and survival is lower. C1 [Fenske, Timothy S.; Hamadani, Mehdi] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Zhang, Mei-Jie; Carreras, Jeanette; Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Ayala, Ernesto] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Wirk, Baldeep M.] Shands Healthcare, Gainesville, FL USA. [Wirk, Baldeep M.] Univ Florida, Gainesville, FL USA. [Burns, Linda J.] Univ Minnesota, Med Ctr, Fairview, Minneapolis, MN 55455 USA. [Inwards, David J.] Mayo Clin Rochester, Rochester, MN USA. [Cashen, Amanda] Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO USA. [Costa, Luciano J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Gale, Robert P.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England. [Montoto, Silvia] Queen Mary Univ London, Barts Canc Inst, London, England. [Holmberg, Leona A.; Maloney, David G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Munker, Reinhold] Louisiana State Univ, Hlth Sci Ctr Shreveport, Shreveport, LA 71105 USA. [Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Rizzieri, David A.] Duke Univ, Med Ctr, Durham, NC USA. [Schouten, Harry C.] Acad Ziekenhuis Maastricht, Maastricht, Netherlands. [Smith, Sonali M.] Univ Chicago Hosp, Chicago, IL 60637 USA. [Waller, Edmund K.] Emory Univ Hosp, Atlanta, GA 30322 USA. [Laport, Ginna G.] Stanford Hosp & Clin, Stanford, CA USA. RP Fenske, TS (reprint author), Med Coll Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. EM tfenske@mcw.edu OI Hari, Parameswaran/0000-0002-8800-297X FU Otsuka American Pharmaceutical; Merck; Millennium Pharmaceuticals; sanofi-aventis; Seattle Genetics; Genentech FX Cesar O. Freytes, Otsuka American Pharmaceutical, Merck; Leona A. Holmberg, Millennium Pharmaceuticals, Merck, Otsuka American Pharmaceutical, sanofi-aventis, Seattle Genetics; Silvia Montoto, Genentech NR 29 TC 25 Z9 27 U1 0 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2014 VL 32 IS 4 BP 273 EP + DI 10.1200/JCO.2013.49.2454 PG 11 WC Oncology SC Oncology GA AA4LH UT WOS:000331066600004 PM 24344210 ER PT J AU Dusetzina, SB Winn, AN Abel, GA Huskamp, HA Keating, NL AF Dusetzina, Stacie B. Winn, Aaron N. Abel, Gregory A. Huskamp, Haiden A. Keating, Nancy L. TI Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID MARGINAL STRUCTURAL MODELS; HEALTH; MEDICATION; FORMULARIES; OUTCOMES; THERAPY; DRUGS; NONADHERENCE; CONFOUNDERS; SENSITIVITY AB Purpose The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to imatinib and other TKIs undoubtedly results in disease progression and treatment resistance. We examined trends in imatinib expenditures from 2002 to 2011 and assessed the association between copayment requirements for imatinib and TKI adherence. Patients and Methods We used MarketScan health plan claims from 2002 to 2011 to identify adults (age 18 to 64 years) with CML who initiated imatinib therapy between January 1, 2002, and June 30, 2011, and had insurance coverage for at least 3 months before through 6 months after initiation (N = 1,541). Primary outcomes were TKI discontinuation and nonadherence. The primary independent variable was out-of-pocket cost for a 30-day supply of imatinib. By using a propensity-score weighted sample, we estimated the risk of discontinuation and nonadherence for patients with higher (top quartile) versus lower copayments. Results Monthly copayments for imatinib averaged $108; median copayments were $30 (range, $0 to $4,792). Mean total monthly expenditures for imatinib nearly doubled between 2002 and 2011, from $2,798 to $4,892. Approximately 17% of patients with higher copayments and 10% with lower copayments discontinued TKIs during the first 180 days following initiation (adjusted risk ratio [aRR], 1.70; 95% CI, 1.30 to 2.22). Similarly, patients with higher copayments were 42% more likely to be nonadherent (aRR, 1.42; 95% CI, 1.19 to 1.69). Conclusion Patients with higher copayments are more likely to discontinue or be nonadherent to TKIs. Given the importance of these therapies for patients with CML, our data suggest a critical need to reduce patient costs for these therapies. C1 [Dusetzina, Stacie B.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA. [Dusetzina, Stacie B.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Dusetzina, Stacie B.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA. [Dusetzina, Stacie B.; Winn, Aaron N.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Abel, Gregory A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Huskamp, Haiden A.; Keating, Nancy L.] Harvard Univ, Sch Med, Boston, MA USA. [Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Dusetzina, SB (reprint author), Univ N Carolina, Div Gen Med & Clin Epidemiol, 5034 Old Clin Bldg,CB 7110, Chapel Hill, NC 27599 USA. EM dusetzina@unc.edu NR 32 TC 92 Z9 94 U1 1 U2 8 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2014 VL 32 IS 4 BP 306 EP 311 DI 10.1200/JCO.2013.52.9123 PG 6 WC Oncology SC Oncology GA AA4LH UT WOS:000331066600008 PM 24366936 ER PT J AU Zhao, FM Chang, VT Cleeland, C Cleary, JF Mitchell, EP Wagner, LI Fisch, MJ AF Zhao, Fengmin Chang, Victor T. Cleeland, Charles Cleary, James F. Mitchell, Edith P. Wagner, Lynne I. Fisch, Michael J. TI Determinants of Pain Severity Changes in Ambulatory Patients With Cancer: An Analysis From Eastern Cooperative Oncology Group Trial E2Z02 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PREVALENCE; MANAGEMENT; CARE; INTENSITY; RECOMMENDATIONS; MULTICENTER; OUTPATIENTS; REGRESSION; SYSTEM AB Purpose To understand changes in pain severity over time and to explore the factors associated with pain changes in ambulatory patients with solid tumors. Patients and Methods We enrolled 3,106 patients with invasive cancer of the breast, prostate, colon/rectum, or lung from multiple sites. At baseline and 4 to 5 weeks later, patients rated their pain level on a 0 to 10 numerical rating scale. A 2-point change in pain score was defined as a clinically significant change in pain. Multivariable logistic models were fitted to examine the effects of pain management and demographic and clinical factors on change in pain severity. Results We analyzed 2,761 patients for changes in pain severity. At initial assessment, 53.0% had no pain, 23.5% had mild pain, 10.3% had moderate pain, and 13.2% had severe pain. Overall, one third of patients with initial pain had pain reduction within 1 month of follow-up, and one fifth had an increase, and the improvement and worsening of pain varied by baseline pain score. Of the patients without pain at initial assessment, 28.4% had pain (8.9% moderate to severe) at the follow-up assessment. Logistic regression analysis showed that inadequate pain management was significantly associated with pain deterioration, as were lower baseline pain level, younger age, and poor health status. Conclusion One third of patients have pain improvement and one fifth experience pain deterioration within 1 month after initial assessment. Inadequate pain management, baseline pain severity, and certain patient demographic and disease characteristics are associated with pain deterioration. C1 [Zhao, Fengmin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chang, Victor T.] Rutgers New Jersey Med Sch, Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA. [Cleeland, Charles; Fisch, Michael J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Cleary, James F.] Univ Wisconsin, Madison, WI USA. [Mitchell, Edith P.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Wagner, Lynne I.] Northwestern Univ Feinberg, Sch Med, Chicago, IL USA. RP Zhao, FM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM fezhao@jimmy.harvard.edu FU National Cancer Institute of the National Institutes of Health [U10 CA37403, U10 CA17145]; MD Anderson Cancer Center Support Grant [P30 CA016672]; [R01 CA026582] FX Supported in part by grants to the Eastern Cooperative Oncology Group from the National Cancer Institute of the National Institutes of Health, including Grants No. U10 CA37403 and U10 CA17145. Additional support comes from Grant No. R01 CA026582 to C. S. C. and MD Anderson Cancer Center Support Grant No. P30 CA016672 to R. A. DePinho. NR 37 TC 4 Z9 4 U1 0 U2 8 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2014 VL 32 IS 4 BP 312 EP + DI 10.1200/JCO.2013.50.6071 PG 12 WC Oncology SC Oncology GA AA4LH UT WOS:000331066600009 PM 24366929 ER PT J AU D'Amico, AV AF D'Amico, Anthony V. TI US Food and Drug Administration Approval of Drugs for the Treatment of Prostate Cancer: A New Era Has Begun SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter C1 [D'Amico, Anthony V.] Brigham & Womens Hosp, Boston, MA 02115 USA. [D'Amico, Anthony V.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP D'Amico, AV (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM adamico@partners.org NR 4 TC 6 Z9 7 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2014 VL 32 IS 4 BP 362 EP 364 DI 10.1200/JCO.2013.53.9528 PG 3 WC Oncology SC Oncology GA AA4LH UT WOS:000331066600020 PM 24344221 ER PT J AU Leventhal, AM Piper, ME Japuntich, SJ Baker, TB Cook, JW AF Leventhal, Adam M. Piper, Megan E. Japuntich, Sandra J. Baker, Timothy B. Cook, Jessica W. TI Anhedonia, Depressed Mood, and Smoking Cessation Outcome SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE anhedonia; depressed mood; smoking; smoking cessation; depression ID COGNITIVE-BEHAVIORAL TREATMENT; MAJOR DEPRESSION; NEGATIVE-AFFECT; POSITIVE AFFECT; SMOKERS; SYMPTOMS; NICOTINE; MOTIVATION; RELAPSE; QUESTIONNAIRE AB Objective: Although the relation between lifetime depression and smoking cessation outcome has been well studied, the proposition that different symptomatic expressions of depression exert disparate predictive effects on risk of smoking cessation failure has largely gone uninvestigated. This study analyzed the individual contributions of depression's 2 hallmark affective symptoms, anhedonia (i.e., diminished interest in normally enjoyable activities) and depressed mood (i.e., elevated sadness), to the prediction of smoking cessation outcome. Method: Participants were adult daily smokers (N = 1,469; mean age = 45 years, 58% female, 84% White) enrolled in a smoking cessation treatment study. Lifetime history of anhedonia and depressed mood were classified via structured interview prior to quit day. Seven-day point prevalence smoking abstinence was assessed at 8 weeks and 6 months postquit. Results: When examined separately, both lifetime anhedonia, OR (95% CI) = 1.42 (1.16, 1.73), p = .004, and depressed mood, OR (95% CI) = 1.35 (1.11, 1.63), p = .002, predicted increased odds of relapse. These relations remained after adjusting for covariates, including lifetime depressive disorder, which did not predict outcome. After controlling for the covariation between lifetime anhedonia and depressed mood, anhedonia predicted cessation outcome, OR (95% CI) = 1.31 (1.05, 1.62), p = .02, while depressed mood did not (p = .19). Symptom duration (>2 weeks), treatment, and substance use disorder did not modify relations of lifetime anhedonia and depressed mood with cessation outcome. Conclusions: Results suggest that (1) symptoms of affective disturbance capture depression-relevant risk of cessation failure, which is not adequately demarcated by the lifetime depressive disorder diagnosis, and (2) anhedonia is a more sensitive index of this affective disturbance than depressed mood per se. Clinical attention to anhedonia may facilitate smoking cessation. C1 [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Psychol, Los Angeles, CA 90033 USA. [Piper, Megan E.; Baker, Timothy B.; Cook, Jessica W.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Dept Med, Madison, WI 53706 USA. [Japuntich, Sandra J.] Vet Affairs Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. RP Leventhal, AM (reprint author), Univ So Calif, Keck Sch Med, 2250 Alcazar St,CSC 240, Los Angeles, CA 90033 USA. EM adam.leventhal@usc.edu FU NCATS NIH HHS [UL1 TR000427]; NCI NIH HHS [1K05CA139871, K05 CA139871, R01 CA168676]; NCRR NIH HHS [KL2 RR025012, 1KL2RR025012-0, 1UL1RR025011 FROM, UL1 RR025011]; NHLBI NIH HHS [R01 HL109031]; NIDA NIH HHS [K08 DA021311, K08 DA025041, K08DA021311, K08DA02504, P50 DA019706, P50DA019706] NR 38 TC 20 Z9 20 U1 5 U2 16 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD FEB PY 2014 VL 82 IS 1 BP 122 EP 129 DI 10.1037/a0035046 PG 8 WC Psychology, Clinical SC Psychology GA AA1FU UT WOS:000330842700012 PM 24219183 ER PT J AU Genthon, A Wilcox, SR AF Genthon, Alissa Wilcox, Susan R. TI CRUSH SYNDROME: A CASE REPORT AND REVIEW OF THE LITERATURE SO JOURNAL OF EMERGENCY MEDICINE LA English DT Review DE rhabdomyolysis; crush syndrome; renal failure; resuscitation; hyperkalemia ID ACUTE-RENAL-FAILURE; COMPARTMENT SYNDROME; WENCHUAN EARTHQUAKE; SEVERE HYPERKALEMIA; MARMARA EARTHQUAKE; RHABDOMYOLYSIS; VICTIMS; INJURY; BICARBONATE; INFECTIONS AB Background: Crush trauma to the extremities, even if not involving vital organs, can be life threatening. Crush syndrome, the systemic manifestation of the breakdown of muscle cells with release of contents into the circulation, leads to metabolic derangement and acute kidney injury. Although common in disaster scenarios, emergency physicians also see the syndrome in patients after motor-vehicle collisions and patients "found down" due to intoxication. Objective: The objectives of this review are to discuss the pathophysiology of crush syndrome, report on prehospital and emergency department treatment, and discuss the relationship between crush syndrome and compartment syndrome. Discussion: We present the case of a young man found down after an episode of intoxication, with compartment syndrome of his lower extremity and crush syndrome. Although he eventually required an amputation, aggressive fluid resuscitation prevented further kidney injury and metabolic derangement. Conclusions: Early, aggressive resuscitation in the prehospital setting, before extrication if possible, is recommended to reduce the complications of crush syndrome. Providers must be aware of the risk of hyperkalemia shortly after extrication. Ongoing resuscitation with i.v. fluids is the mainstay of treatment. Compartment syndrome is a common complication, and prompt fasciotomiesshould be performed when compartment syndrome is present. (C) 2014 Elsevier Inc. C1 [Genthon, Alissa] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Genthon, Alissa; Wilcox, Susan R.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Wilcox, Susan R.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA. RP Wilcox, SR (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St, Boston, MA 02115 USA. OI Wilcox, Susan/0000-0001-7477-7531 NR 36 TC 10 Z9 10 U1 5 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 EI 1090-1280 J9 J EMERG MED JI J. Emerg. Med. PD FEB PY 2014 VL 46 IS 2 BP 313 EP 319 DI 10.1016/j.jemermed.2013.08.052 PG 7 WC Emergency Medicine SC Emergency Medicine GA 302CK UT WOS:000330578700038 PM 24199724 ER PT J AU Kudchadkar, SR Hamrick, JT Mai, CL Berkowitz, I Tunkel, D AF Kudchadkar, Sapna R. Hamrick, Justin T. Mai, Christine L. Berkowitz, Ivor Tunkel, David TI THE HEAT IS ON ... THERMAL EPIGLOTTITIS AS A LATE PRESENTATION OF AIRWAY STEAM INJURY SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE airway obstruction; burns; transport medicine; intubation; emergency; pediatrics ID HOT COFFEE; CHILDREN; IMMUNIZATION; INFANTS; SCALD AB Background: Thermal epiglottitis is a rare but potentially life-threatening disease. Diagnosis requires a thorough history and high clinical level of suspicion, particularly in children. Thermal epiglottitis from steam inhalation can have a slow onset without oropharyngeal signs of thermal injury, findings that can hide the clinical diagnosis. Objective: Our aim was to review the pathophysiology and clinical presentation of thermal epiglottitis and the challenges involved in diagnosis and management of this form of atypical epiglottitis. Case Report: We describe the case of a 22-month-old male presenting to the pediatric emergency department after a scald burn from steam and boiling water resulting in 12% body surface area burns to his chin, chest, and shoulder, with no obvious oropharyngeal or neck injuries. At the time of presentation, he was afebrile and well appearing. Six hours after the injury, he was sitting in the "tripod position,'' drooling, with pooled saliva in his mouth and inspiratory stridor. Intubation in the operating room using conventional direct laryngoscopy was not successful and he was intubated using an operative endoscope. Laryngoscopy demonstrated thermal epiglottitis. A tracheostomy was performed to secure the airway, and he was admitted to the pediatric intensive care unit. He was discharged home and decannulated 4 weeks later, when airway endoscopy showed complete recovery with normal airway structures. Conclusion: A thorough history and physical examination together with a high level of suspicion and aggressive, collaborative airway management is vital in preventing catastrophic airway obstruction in atypical forms of epiglottitis. (C) 2014 Elsevier Inc. C1 [Kudchadkar, Sapna R.; Hamrick, Justin T.; Berkowitz, Ivor] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Div Pediat Anesthesiol & Crit Care Med, Baltimore, MD USA. [Mai, Christine L.] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. [Tunkel, David] Johns Hopkins Univ, Dept Otolaryngol & Head & Neck Surg, Div Pediat Otolaryngol, Baltimore, MD USA. RP Kudchadkar, SR (reprint author), Johns Hopkins Univ Hosp, 1800 Orleans St,Suite 6318B, Baltimore, MD 21287 USA. OI Kudchadkar, Sapna/0000-0003-3089-0318 NR 17 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 EI 1090-1280 J9 J EMERG MED JI J. Emerg. Med. PD FEB PY 2014 VL 46 IS 2 BP E43 EP E46 DI 10.1016/j.jemermed.2013.08.033 PG 4 WC Emergency Medicine SC Emergency Medicine GA 302CK UT WOS:000330578700005 PM 24113478 ER PT J AU Kravitz, RL Ganguli, I AF Kravitz, Richard L. Ganguli, Ishani TI Only Connect SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Kravitz, Richard L.] Univ Calif Davis, Div Gen Med, Sacramento, CA 95817 USA. [Ganguli, Ishani] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Kravitz, RL (reprint author), Univ Calif Davis, Div Gen Med, 4150 V St,Suite 2400 PSSB, Sacramento, CA 95817 USA. EM rlkravitz@ucdavis.edu OI Kravitz, Richard/0000-0001-5575-529X NR 6 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 265 EP 266 DI 10.1007/s11606-013-2728-2 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500001 PM 24323463 ER PT J AU Williams, JLS Egede, LE AF Williams, Joni L. Strom Egede, Leonard E. TI Nontraditional Risk Factors as Mediators of Racial Differences in Diabetes Risk SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID DEPRESSION; ASSOCIATION; TYPE-2 C1 [Williams, Joni L. Strom; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Williams, Joni L. Strom; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston VA HSR&D COIN, Charleston, VA USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [K24 DK093699, K24DK093699, R01 DK098529, R01DK098529] NR 10 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 271 EP 272 DI 10.1007/s11606-013-2650-7 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500004 PM 24129857 ER PT J AU Iverson, KM AF Iverson, Katherine M. TI Routine Screening for Intimate Partner Violence in VHA: A Timely Opportunity SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Letter C1 [Iverson, Katherine M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Iverson, Katherine M.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Iverson, KM (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 South Huntington Ave 116B-3, Boston, MA USA. EM Katherine.Iverson@va.gov NR 4 TC 2 Z9 2 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 280 EP 280 DI 10.1007/s11606-013-2716-6 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500008 PM 24263799 ER PT J AU Kangovi, S Barg, FK Carter, T Levy, K Sellman, J Long, JA Grande, D AF Kangovi, Shreya Barg, Frances K. Carter, Tamala Levy, Kathryn Sellman, Jeffrey Long, Judith A. Grande, David TI Challenges Faced by Patients with Low Socioeconomic Status During the Post-Hospital Transition SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE post-hospital transition; disparities; goal-setting ID HEART-FAILURE; HEALTH-CARE; TASK-PERFORMANCE; FOLLOW-UP; OUTCOMES; RISK; REHOSPITALIZATION; READMISSIONS; EXPERIENCES; MOTIVATION AB Patients with low socioeconomic status (low-SES) are at risk for poor outcomes during the post-hospital transition. Few prior studies explore perceived reasons for poor outcomes from the perspectives of these high-risk patients. We explored low-SES patients' perceptions of hospitalization, discharge and post-hospital transition in order to generate hypotheses and identify common experiences during this transition. We conducted a qualitative study using in-depth semi-structured interviewing. We interviewed 65 patients who were: 1) uninsured, insured by Medicaid or dually eligible for Medicaid and Medicare; 2) residents of five low-income ZIP codes; 3) had capacity or a caregiver who could be interviewed as a proxy; and 4) hospitalized on the general medicine or cardiology services of two academically affiliated urban hospitals. Our interview guide investigated patients' perceptions of hospitalization, discharge and the post-hospital transition, and their performance of recommended post-hospital health behaviors related to: 1) experience of hospitalization and discharge; 2) external constraints on patients' ability to execute discharge instructions; 3) salience of health behaviors; and 4) self-efficacy to execute discharge instructions. We used a modified grounded theory approach to analysis. We identified six themes that low-SES patients shared in their narratives of hospitalization, discharge and post-hospital transition. These were: 1) powerlessness during hospitalization due to illness and socioeconomic factors; 2) misalignment of patient and care team goals; 3) lack of saliency of health behaviors due to competing issues; 4) socioeconomic constraints on patients' ability to perform recommended behaviors; 5) abandonment after discharge; and 6) loss of self-efficacy resulting from failure to perform recommended behaviors. Low-SES patients describe discharge goals that are confusing, unrealistic in the face of significant socioeconomic constraints, and in conflict with their own immediate goals. We hypothesize that this goal misalignment leads to a cycle of low achievement and loss of self-efficacy that may underlie poor post-hospital outcomes among low-SES patients. C1 [Kangovi, Shreya; Long, Judith A.] PhiladelphiaVet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Sellman, Jeffrey] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Levy, Kathryn; Long, Judith A.; Grande, David] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Long, Judith A.; Grande, David] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Barg, Frances K.; Carter, Tamala] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Kangovi, Shreya; Carter, Tamala] Univ Penn Hlth Syst, Penn Ctr Community Hlth Workers, Philadelphia, PA USA. RP Kangovi, S (reprint author), PhiladelphiaVet Affairs Med Ctr, 13th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kangovi@mail.med.upenn.edu OI Levy, Kathryn/0000-0003-1646-729X FU Leonard Davis Institute of Health Economics at the University of Pennsylvania FX This study was supported by the Leonard Davis Institute of Health Economics at the University of Pennsylvania. NR 37 TC 24 Z9 24 U1 2 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 283 EP 289 DI 10.1007/s11606-013-2571-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500011 PM 23918162 ER PT J AU Lopez, L AF Lopez, Lenny TI Capsule Commentary on Paradies et al., 'A Systematic Review of the Extent and Measurement of Healthcare Provider Racism' SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID DISCRIMINATION C1 Brigham & Womens Hosp, Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. RP Lopez, L (reprint author), Brigham & Womens Hosp, Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. EM Llopez1@partners.org NR 5 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 362 EP 362 DI 10.1007/s11606-013-2621-z PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500027 PM 24065380 ER PT J AU Feingold, KR AF Feingold, Kenneth R. TI Capsule Commentary on Radin, Pitfalls in Hemoglobin A1c Measurement: When Results May Be Misleading SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID COMPLICATIONS C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Feingold, KR (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Kenneth.feingold@ucsf.edu NR 5 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 363 EP 363 DI 10.1007/s11606-013-2632-9 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500028 PM 24065382 ER PT J AU Ganguli, I AF Ganguli, Ishani TI Training for Primary Care's Future SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Ganguli, I (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA. EM ishani.ganguli@gmail.com NR 7 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 404 EP 406 DI 10.1007/s11606-013-2641-8 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500033 PM 24197632 ER PT J AU Bartonicek, J Kozanek, M Jupiter, JB AF Bartonicek, Jan Kozanek, Michal Jupiter, Jesse B. TI History of Operative Treatment of Forearm Diaphyseal Fractures SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Diaphyseal fractures; forearm; history; osteosynthesis ID COMPRESSION-PLATE FIXATION; LONG BONES; RADIUS; ULNA; DISLOCATION; ADULTS; HEAD AB Diaphyseal fractures of the forearm have accompanied humanity throughout its history. Nonsurgical techniques dominated the treatment for centuries, and complications including nonunion and malunion were common. The 19th century featured the recognition of distinct injury patterns. With the development of anesthesia and antisepsis, the operative treatment became widespread. In 1878, Heine described fixation of the diaphyseal nonunion of the distal ulna using an intramedullary ivory peg. Parkhill reported on the application of external fixation for forearm fractures in 1897-1898. Hansmann published the case of plate osteosynthesis of an acute fracture of the radius in 1886. In 1913, Schone published the technique of closed intramedullary fixation of diaphyseal fractures of the forearm using a silver wire. During the first 2 decades of the 20th century, plate osteosynthesis quickly spread across Europe and North America owing to the influence of Lambotte and Lane. After the World War II, plate osteosynthesis became the surgical treatment of choice for forearm diaphyseal fractures. (Copyright (C) 2014 by the American Society for Surgery of the Hand. All rights reserved.) C1 Charles Univ Prague, Fac Med 1, Dept Orthopaed Trauma, Prague, Czech Republic. [Jupiter, Jesse B.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. Harvard Combined Orthopaed Residency Program, Boston, MA USA. RP Jupiter, JB (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, YAW 2,55 Fruit St, Boston, MA 02114 USA. EM JJUPITER1@PARTNERS.ORG RI Bartonicek, Jan/E-8217-2017 OI Bartonicek, Jan/0000-0002-2228-1443 NR 70 TC 2 Z9 2 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD FEB PY 2014 VL 39 IS 2 BP 335 EP 342 DI 10.1016/j.jhsa.2013.06.020 PG 8 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AA3QX UT WOS:000331008500019 PM 24332651 ER PT J AU Bot, AGJ Jupiter, JB AF Bot, Arian G. J. Jupiter, Jesse B. TI Malunited Fractures in the Hand SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Corrective osteotomy; malunion ID METACARPAL ROTATIONAL OSTEOTOMY; STEP-CUT OSTEOTOMY; INTRAARTICULAR OSTEOTOMY; BENNETTS-FRACTURE; PROXIMAL PHALANX; FINGERS; DEFORMITY AB Posttraumatic deformity of a tubular bone in the hand after malunion can impact function due to alteration in mobility, strength, or associated pain. Surgical intervention is often indicated, with the surgical options based on both the type and location of the deformity, as well as any associated articular, tendon, or soft tissue constraints. This article provides a management approach based on the deformity classification, location, and any associated conditions. Copyright (C) 2014 by the American Society for Surgery of the Hand. All rights reserved. C1 [Bot, Arian G. J.; Jupiter, Jesse B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Bot, AGJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv, 55 Fruit St,Suite 2100, Boston, MA 02114 USA. EM a.g.j.bot@gmail.com NR 28 TC 0 Z9 0 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD FEB PY 2014 VL 39 IS 2 BP 378 EP 384 DI 10.1016/j.jhsa.2013.07.014 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AA3QX UT WOS:000331008500029 PM 24411293 ER PT J AU Ring, D AF Ring, David TI Inconsistent Acronym Use Reply SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Letter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD FEB PY 2014 VL 39 IS 2 BP 402 EP 402 DI 10.1016/j.jhsa.2013.11.034 PG 1 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AA3QX UT WOS:000331008500035 ER PT J AU Seif, F Patel, SR Walia, HK Rueschman, M Bhatt, DL Blumenthal, RS Quan, SF Gottlieb, DJ Lewis, EF Patil, SP Punjabi, NM Babineau, DC Redline, S Mehra, R AF Seif, Fadi Patel, Sanjay R. Walia, Harneet K. Rueschman, Michael Bhatt, Deepak L. Blumenthal, Roger S. Quan, Stuart F. Gottlieb, Daniel J. Lewis, Eldrin F. Patil, Susheel P. Punjabi, Naresh M. Babineau, Denise C. Redline, Susan Mehra, Reena TI Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk SO JOURNAL OF HYPERTENSION LA English DT Article DE cardiovascular disease; hypertension; hypoxia; sleep apnea ID AMBULATORY BLOOD-PRESSURE; PROGNOSTIC-SIGNIFICANCE; HYPERTENSION; ASSOCIATION; VARIABILITY; POPULATION; RELEVANCE; HYPOXIA; DECLINE; PATTERN AB Rationale:We hypothesized increasing obstructive sleep apnea (OSA) severity would be associated with nondipping blood pressure (BP) in increased cardiovascular disease (CVD) risk.Methods:Baseline data from 298 cardiology patients recruited for a multicenter randomized controlled trial were examined. Dipping was defined as a sleep-related BP or heart rate (HR) reduction of at least 10%. Logistic regression models were fit, adjusting for age, sex, race, BMI, CVD risk factors, CVD, and study site.Results:There was a statistically significant 4% increase in the odds of nondipping SBP per 1-unit increase in both apnea hypopnea index (AHI) and oxygen desaturation index (ODI). There was no significant relationship between AHI and nondipping mean arterial pressure (MAP); however, a 3% increase in the odds of nondipping MAP per 1-unit increase in ODI was observed [odds ratio (OR)=1.03; 95% confidence interval (CI) 1.00-1.05]. At severe OSA levels, a 10 and 4% increase in odds of nondipping DBP per 1-unit increase in AHI and ODI were observed, respectively. A 6% [OR=1.06; 95% CI (1.01-1.10)] increase in nondipping HR odds was observed with each increase in ODI until the upper quartile of ODI.Conclusion:In patients at cardiovascular risk and moderate-to-severe OSA, increasing AHI and/or ODI were associated with increased odds of nondipping SBP and nondipping MAP. More severe levels of AHI and ODI also were associated with nondipping DBP. These results support progressive BP burden associated with increased OSA severity even in patients managed by cardiology specialty care. C1 [Seif, Fadi] Case Sch Med, Dept Med, Cleveland, OH USA. [Patel, Sanjay R.; Rueschman, Michael; Bhatt, Deepak L.; Quan, Stuart F.; Gottlieb, Daniel J.; Lewis, Eldrin F.; Redline, Susan] Brigham & Womens Hosp, Boston, MA 02115 USA. [Patel, Sanjay R.; Redline, Susan] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Bhatt, Deepak L.; Gottlieb, Daniel J.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA. [Blumenthal, Roger S.; Patil, Susheel P.; Punjabi, Naresh M.] Johns Hopkins Univ, Baltimore, MD USA. [Babineau, Denise C.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. [Walia, Harneet K.; Mehra, Reena] Case Western Reserve Univ, Cleveland Clin, Cleveland Clin Lerner Coll Med, Cleveland, OH 44106 USA. RP Mehra, R (reprint author), Cleveland Clin, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM reena.mehra@case.edu OI Mehra, Reena/0000-0002-6222-2675; Patel, Sanjay/0000-0002-9142-5172 FU NIH National Heart Lung Blood Institute [RC2 HL101417]; National Center for Research Resources (NCRR) [K23 HL079114, M01 RR00080, UL1 RR024989] FX The present study is supported by NIH National Heart Lung Blood Institute RC2 HL101417 and K23 HL079114, NIH M01 RR00080, NIH UL1 RR024989 from the National Center for Research Resources (NCRR). NR 43 TC 11 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 EI 1473-5598 J9 J HYPERTENS JI J. Hypertens. PD FEB PY 2014 VL 32 IS 2 BP 267 EP 275 DI 10.1097/HJH.0000000000000011 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AA1SM UT WOS:000330876000011 PM 24351803 ER PT J AU Krishna, V Andrews, H Varma, A Mintzer, J Kindy, MS Guest, J AF Krishna, Vibhor Andrews, Hampton Varma, Abhay Mintzer, Jacobo Kindy, Mark S. Guest, James TI Spinal Cord Injury: How Can We Improve the Classification and Quantification of Its Severity and Prognosis? SO JOURNAL OF NEUROTRAUMA LA English DT Review ID MOTOR-EVOKED-POTENTIALS; TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; CERVICAL SPONDYLOTIC MYELOPATHY; INTRATHECAL OXYGEN-TENSION; BLOOD-PRESSURE MANAGEMENT; PROTON MR SPECTROSCOPY; NEUROFILAMENT NF-H; ONE-YEAR EVOLUTION; INTERNATIONAL STANDARDS C1 [Krishna, Vibhor; Andrews, Hampton; Varma, Abhay; Mintzer, Jacobo; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Mintzer, Jacobo; Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Guest, James] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA. [Guest, James] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA. RP Guest, J (reprint author), Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA. EM kindyms@musc.edu; jguest@med.miami.edu FU National Institutes of Health [ES016774]; VA Merit Review [RX000331]; NSF EPSCoR [EPS-0903795]; Institutional Development Award (IdeA, COBRE) from the National Institute of General Medical Sciences [P20GM103444]; clinical trials program of the Miami Project to Cure Paralysis FX We gratefully acknowledge the assistance of the Department of Neurosciences and the Veteran Affairs for the continued support of our research. Support was partially provided by the National Institutes of Health grant ES016774, VA Merit Review RX000331, NSF EPSCoR grant EPS-0903795 and Institutional Development Award (IdeA, COBRE) from the National Institute of General Medical Sciences grant P20GM103444 to Dr. Kindy. Dr. Guest received support from the clinical trials program of the Miami Project to Cure Paralysis. NR 144 TC 7 Z9 7 U1 0 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD FEB 1 PY 2014 VL 31 IS 3 BP 215 EP 227 PG 13 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA AA4RT UT WOS:000331084500001 PM 23895105 ER PT J AU Song, XQ Yaskell, T Klepac-Ceraj, V Lynch, MC Soukos, NS AF Song, Xiaoqing Yaskell, Tina Klepac-Ceraj, Vanja Lynch, Michael C. Soukos, Nikolaos S. TI Antimicrobial Action of Minocycline Microspheres Versus 810-nm Diode Laser on Human Dental Plaque Microcosm Biofilms SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Biofilms; dental plaque; in vitro; infrared rays; microspheres; minocycline ID PERIODONTAL POCKETS; PHOTODYNAMIC THERAPY; DISEASE; PREVALENCE; RESISTANCE; BACTERIA; ADJUNCT AB Background: The purpose of this study is to investigate the antimicrobial effects of minocycline hydrochloride microspheres versus infrared light at 810 nm from a diode laser on multispecies oral biofilms in vitro. These biofilms were grown from dental plaque inoculum (oral microcosms) and were obtained from six systemically healthy individuals with generalized chronic periodontitis. Methods: Multispecies biofilms were derived using supra-and subgingival plaque samples from mesio-buccal aspects of premolars and molars exhibiting probing depths in the 4- to 5-mm range and 1- to 2-mm attachment loss. Biofilms were developed anaerobically on blood agar surfaces in 96-well plates using a growth medium of prereduced, anaerobically sterilized brain-heart infusion with 2% horse serum. Minocycline HCl 1 mg microspheres were applied on biofilms on days 2 and 5 of their development. Biofilms were also exposed on days 2 and 5 of their growth to 810-nm light for 30 seconds using a power of 0.8 W in a continuous-wave mode. The susceptibility of microorganisms to minocycline or infrared light was evaluated by a colony-forming assay and DNA probe analysis at different time points. Results: At all time points of survival assessment, minocycline was more effective (>2 log10 colony-forming unit reduction) than light treatment (P < 0.002). Microbial analysis did not reveal susceptibility of certain dental plaque pathogens to light, and it was not possible after treatment with minocycline due to lack of bacterial growth. Conclusion: The cumulative action of minocycline microspheres on multispecies oral biofilms in vitro led to enhanced killing of microorganisms, whereas a single exposure of light at 810 nm exhibited minimal and non-selective antimicrobial effects. C1 [Song, Xiaoqing; Yaskell, Tina; Klepac-Ceraj, Vanja; Soukos, Nikolaos S.] Forsyth Inst, Appl Mol Photomed Lab, Dept Appl Oral Sci, Cambridge, MA 02142 USA. [Klepac-Ceraj, Vanja] Wellesley Coll, Dept Biol Sci, Wellesley, MA 02181 USA. RP Soukos, NS (reprint author), Forsyth Inst, Appl Mol Photomed Lab, 245 First St, Cambridge, MA 02142 USA. EM nsoukos@forsyth.org OI Klepac-Ceraj, Vanja/0000-0001-5387-5706 FU OraPharma, Horsham, Pennsylvania FX This study was supported by OraPharma, Horsham, Pennsylvania. The authors report no conflicts of interest related to this study. NR 31 TC 2 Z9 2 U1 2 U2 6 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 EI 1943-3670 J9 J PERIODONTOL JI J. Periodont. PD FEB PY 2014 VL 85 IS 2 BP 335 EP 342 DI 10.1902/jop.2013.130007 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA AA5LI UT WOS:000331140100018 PM 23805814 ER PT J AU Allen, JD Perez, JE Pischke, CR Tom, LS Juarez, A Ospino, H Gonzalez-Suarez, E AF Allen, Jennifer D. Perez, John E. Pischke, Claudia R. Tom, Laura S. Juarez, Alan Ospino, Hosffman Gonzalez-Suarez, Elizabeth TI Dimensions of Religiousness and Cancer Screening Behaviors Among Church-Going Latinas SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE Latino; Religion; Spirituality; Cancer screening; Coping; Health ID SPIRITUAL HEALTH LOCUS; AFRICAN-AMERICAN WOMEN; HISPANIC WOMEN; ATTENDANCE; TRIAL; INTERVENTIONS; VALIDATION; PROMOTION; ADHERENCE; BELIEFS AB Churches are a promising setting through which to reach Latinas with cancer control efforts. A better understanding of the dimensions of religiousness that impact health behaviors could inform efforts to tailor cancer control programs for this setting. The purpose of this study was to explore relationships between dimensions of religiousness with adherence to cancer screening recommendations among church-going Latinas. Female Spanish-speaking members, aged 18 and older from a Baptist church in Boston, Massachusetts (N = 78), were interviewed about cancer screening behaviors and dimensions of religiousness. We examined adherence to individual cancer screening tests (mammography, Pap test, and colonoscopy), as well as adherence to all screening tests for which participants were age-eligible. Dimensions of religiousness assessed included church participation, religious support, active and passive spiritual health locus of control, and positive and negative religious coping. Results showed that roughly half (46 %) of the sample had not received all of the cancer screening tests for which they were age-eligible. In multivariate analyses, positive religious coping was significantly associated with adherence to all age-appropriate screening (OR = 5.30, p < .01). Additional research is warranted to replicate these results in larger, more representative samples and to examine the extent to which enhancement of religious coping could increase the impact of cancer control interventions for Latinas. C1 [Allen, Jennifer D.; Tom, Laura S.; Gonzalez-Suarez, Elizabeth] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA. [Perez, John E.] Univ San Francisco, Dept Psychol, San Francisco, CA 94117 USA. [Pischke, Claudia R.] Inst Epidemiol & Prevent Res BIPS, D-28359 Bremen, Germany. [Juarez, Alan] Iglesia Cristiana Nueva Vida, Boston, MA 02128 USA. [Ospino, Hosffman] Boston Coll, Sch Theol & Minist, Chestnut Hill, MA 02467 USA. RP Allen, JD (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave, Boston, MA 02215 USA. EM jennifer_allen@dfci.harvard.edu; Laura_Tom@dfci.harvard.edu RI Allen, Jennifer/M-2113-2015 FU NCI NIH HHS [U56 CA118641, R25 CA057713-05] NR 49 TC 11 Z9 11 U1 3 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 EI 1573-6571 J9 J RELIG HEALTH JI J. Relig. Health PD FEB PY 2014 VL 53 IS 1 BP 190 EP 203 DI 10.1007/s10943-012-9606-9 PG 14 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA AA1AK UT WOS:000330828300018 PM 22618412 ER PT J AU Primack, BA Douglas, EL Land, SR Miller, E Fine, MJ AF Primack, Brian A. Douglas, Erika L. Land, Stephanie R. Miller, Elizabeth Fine, Michael J. TI Comparison of Media Literacy and Usual Education to Prevent Tobacco Use: A Cluster-Randomized Trial SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE adolescents; attitudes; media education; media literacy; normative beliefs; school-based; smoking; social influences; tobacco; youth ID LOW HEALTH LITERACY; ADOLESCENT SMOKING; CIGARETTE-SMOKING; VIEWING SMOKING; ASSOCIATION; MOVIES; INITIATION; EXPOSURE; CHILDREN; ALCOHOL AB BACKGROUNDMedia literacy programs have shown potential for reduction of adolescent tobacco use. We aimed to determine if an anti-smoking media literacy curriculum improves students' media literacy and affects factors related to adolescent smoking. METHODSWe recruited 1170 9th-grade students from 64 classrooms in 3 public urban high schools. Students were randomized by classroom to a media literacy curriculum versus a standard educational program. In an intent-to-treat analysis, we used multilevel modeling to determine if changes in study outcomes were associated with the curricular intervention, controlling for baseline student covariates and the clustering of students within classrooms. RESULTSAmong participants, mean age was 14.5 years and 51% were male, with no significant differences in baseline characteristics between groups. Smoking media literacy changed more among intervention participants compared with control participants (0.24 vs. 0.08, p < .001). Compared with controls, intervention students exhibited a greater reduction in the perceived prevalence of smoking (-14.0% vs. -4.6%, p < .001). Among those initially susceptible to smoking, intervention participants more commonly reverted to being nonsusceptible post-intervention (24% vs. 16%, p = .08). CONCLUSIONSA school-based media literacy curriculum is more effective than a standard educational program in teaching media literacy and improving perceptions of the true prevalence of smoking among adolescents. C1 [Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Douglas, Erika L.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15219 USA. [Land, Stephanie R.] NCI, NIH, Bethesda, MD 20892 USA. [Miller, Elizabeth] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15213 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, 230 McKee Pl Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu; douglasel@upmc.edu; stephanie.land@nih.gov; elizabeth.miller@chp.edu; finemj@upmc.edu FU Maurice Falk Foundation; Robert Wood Johnson Foundation; National Cancer Institute [K07-CA114315] FX B.A.P. was supported in part by a grant from the Maurice Falk Foundation, a Physician Faculty Scholar Award from the Robert Wood Johnson Foundation, and a career development award from the National Cancer Institute (K07-CA114315). NR 45 TC 5 Z9 5 U1 2 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD FEB PY 2014 VL 84 IS 2 BP 106 EP 115 DI 10.1111/josh.12130 PG 10 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA AA0KN UT WOS:000330784100005 PM 25099425 ER PT J AU Green, JG Johnson, RM Dunn, EC Lindsey, MA Xuan, ZM Zaslavsky, AM AF Green, Jennifer Greif Johnson, Renee M. Dunn, Erin C. Lindsey, Michael A. Xuan, Ziming Zaslavsky, Alan M. TI Mental Health Service Use Among High School Students Exposed to Interpersonal Violence SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE adolescents; mental health; service use; suicide; victimization; violence ID NATIONAL COMORBIDITY SURVEY; ADULT PSYCHIATRIC-DISORDERS; COMMUNITY VIOLENCE; CHILDHOOD ADVERSITIES; NCS-A; CHILDREN; YOUTH; VICTIMIZATION; ADOLESCENTS; INTERVENTION AB BACKGROUNDViolence-exposed youth rarely receive mental health services, even though exposure increases risk for academic and psychosocial problems. This study examines the association between violence exposure and mental health service contact. The 4 forms of violence exposure were peer, family, sexual, and witnessing. METHODSData are from 1534 Boston public high school students who participated in a 2008 self-report survey of violence exposure and its correlates. Multivariate logistic regressions estimated associations between each form of violence with service contact, then examined whether associations persisted when controlling for suicidality and self-injurious behaviors. RESULTSIn unadjusted models, violence-exposed students more often reported service contact than their peers. However, in multivariate models, only exposure to family (odds ratio [OR] = 1.69, 95% confidence interval [CI] = 1.23-2.31) and sexual violence (OR = 2.34, 95% CI = 1.29-4.20) were associated with service contact. Associations attenuated when controlling for suicidality and self-injurious behaviors, indicating they were largely explained by self-harm. Sexual violence alone remained associated with mental health service contact in fully adjusted models, but only for girls (OR=3.32, 95% CI=1.30-8.45), suggesting sex-specific pathways. CONCLUSIONSAssociations between adolescent violence exposure and mental health service contact vary by forms of exposure. Outreach to a broader set of exposed youth may reduce the impact of violence and its consequences for vulnerable students. C1 [Green, Jennifer Greif] Boston Univ, Sch Educ, Boston, MA 02215 USA. [Johnson, Renee M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA. [Dunn, Erin C.] Massachusetts Gen Hosp, Richard B Simches Res Ctr, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Lindsey, Michael A.] NYU, Silver Sch Social Work, New York, NY 10003 USA. [Xuan, Ziming] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA. [Zaslavsky, Alan M.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. RP Green, JG (reprint author), Boston Univ, Sch Educ, 2 Silber Way, Boston, MA 02215 USA. EM jggreen@bu.edu; rejohnso@jhsph.edu; erindunn@pngu.mgh.harvard.edu; michael.lindsey@nyu.edu; zxuan@bu.edu; zaslavsky@hcp.med.harvard.edu OI Johnson, Renee/0000-0001-5083-8686 FU NCIPC CDC HHS [U49 CE000740]; NIDA NIH HHS [K01 DA031738, R03 DA025823, L40 DA034573]; NIMH NIH HHS [K01 MH085710] NR 40 TC 2 Z9 3 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD FEB PY 2014 VL 84 IS 2 BP 141 EP 149 DI 10.1111/josh.12125 PG 9 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA AA0KN UT WOS:000330784100009 PM 25099429 ER PT J AU Ekberg, P Su, R Chang, EW Yun, SH Mattsson, L AF Ekberg, Peter Su, Rong Chang, Ernest W. Yun, Seok Hyun Mattsson, Lars TI Fast and accurate metrology of multi-layered ceramic materials by an automated boundary detection algorithm developed for optical coherence tomography data SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND VISION LA English DT Article ID SEGMENTATION AB Optical coherence tomography (OCT) is useful for materials defect analysis and inspection with the additional possibility of quantitative dimensional metrology. Here, we present an automated image-processing algorithm for OCT analysis of roll-to-roll multilayers in 3D manufacturing of advanced ceramics. It has the advantage of avoiding filtering and preset modeling, and will, thus, introduce a simplification. The algorithm is validated for its capability of measuring the thickness of ceramic layers, extracting the boundaries of embedded features with irregular shapes, and detecting the geometric deformations. The accuracy of the algorithm is very high, and the reliability is better than 1 mu m when evaluating with the OCT images using the same gauge block step height reference. The method may be suitable for industrial applications to the rapid inspection of manufactured samples with high accuracy and robustness. (C) 2014 Optical Society of America C1 [Ekberg, Peter; Su, Rong; Mattsson, Lars] KTH Royal Inst Technol, Dept Prod Engn, S-10044 Stockholm, Sweden. [Chang, Ernest W.; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Su, R (reprint author), KTH Royal Inst Technol, Dept Prod Engn, 68 Brinellvagen, S-10044 Stockholm, Sweden. EM rongs@kth.se OI Su, Rong/0000-0003-0776-3716 FU European project Multilayer [FP7-NMP4-2007-214122]; National Institutes of Health [P41EB015903] FX This work was partly supported by the joint European project Multilayer (FP7-NMP4-2007-214122) and National Institutes of Health (P41EB015903). The authors would like to acknowledge Dr. Johanna Stiernstedt from Swerea IVF, Dr. Petko Petkov from MEC, Cardiff University, and Olle Rosenqvist from Thorlabs Sweden AB. NR 22 TC 4 Z9 4 U1 0 U2 8 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 1084-7529 EI 1520-8532 J9 J OPT SOC AM A JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis. PD FEB PY 2014 VL 31 IS 2 BP 217 EP 226 DI 10.1364/JOSAA.31.000217 PG 10 WC Optics SC Optics GA AA4MT UT WOS:000331070600001 PM 24562018 ER PT J AU Barr, JD Jensen, ME Hirsch, JA McGraw, JK Barr, RM Brook, AL Meyers, PM Munk, PL Murphy, KJ O'Toole, JE Rasmussen, PA Ryken, TC Sanelli, PC Schwartzberg, MS Seidenwurm, D Tutton, SM Zoarski, GH Kuo, MD Rose, SC Cardella, JF AF Barr, John D. Jensen, Mary E. Hirsch, Joshua A. McGraw, J. Kevin Barr, Robert M. Brook, Allan L. Meyers, Philip M. Munk, Peter L. Murphy, Kieran J. O'Toole, John E. Rasmussen, Peter A. Ryken, Timothy C. Sanelli, Pina C. Schwartzberg, Marc S. Seidenwurm, David Tutton, Sean M. Zoarski, Gregg H. Kuo, Michael D. Rose, Steven C. Cardella, John F. TI Position Statement on Percutaneous Vertebral Augmentation: A Consensus Statement Developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spine Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS) SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Editorial Material ID OSTEOPOROTIC COMPRESSION FRACTURES; RANDOMIZED CONTROLLED-TRIAL; PEDICLE SCREW FIXATION; CLINICAL FOLLOW-UP; BALLOON KYPHOPLASTY; HEIGHT RESTORATION; CONSERVATIVE THERAPY; SINGLE-CENTER; PAIN RELIEF; POLYMETHYLMETHACRYLATE VERTEBROPLASTY C1 [Barr, John D.] Calif Ctr Neurointervent Surg, La Jolla, CA 92037 USA. [Seidenwurm, David] Radiol Associates Sacramento, Sacramento, CA USA. [Kuo, Michael D.] Univ Calif Los Angeles, Sch Med, Dept Radiol, Los Angeles, CA 90024 USA. [Rose, Steven C.] Univ Calif San Diego, Med Ctr, Dept Radiol, San Diego, CA 92103 USA. [Jensen, Mary E.] Univ Virginia Hlth Syst, Dept Radiol, Charlottesville, VA USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Div Neurointervent Radiol, Boston, MA 02114 USA. [McGraw, J. Kevin] Riverside Methodist Hosp, Riverside Intervent Consultants, Columbus, OH USA. [Rasmussen, Peter A.] Cleveland Clin, Cerebrovasc Ctr & Neurol Inst, Cleveland, OH 44106 USA. [Barr, Robert M.] Mecklenburg Radiol Associates, Charlotte, NC USA. [Brook, Allan L.] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA. [Meyers, Philip M.] Columbia Univ Coll Phys & Surg, Dept Neurol Surg, New York, NY 10032 USA. [Sanelli, Pina C.] Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Radiol, New York, NY USA. [Sanelli, Pina C.] Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Publ Hlth, New York, NY USA. [O'Toole, John E.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Waterloo, IA USA. [Schwartzberg, Marc S.] Radiol Associates Cent Florida, Leesburg, FL USA. [Tutton, Sean M.] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Dept Radiol, Milwaukee, WI 53226 USA. [Zoarski, Gregg H.] Christiana Care Hlth Syst, Dept Neurointervent Surg, Newark, DE USA. [Cardella, John F.] Geisinger Hlth Syst, Dept Radiol, Danville, PA USA. [Munk, Peter L.] Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V5Z 1M9, Canada. [Murphy, Kieran J.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada. RP Barr, JD (reprint author), Calif Ctr Neurointervent Surg, 9834 Genesee Ave Suite 411, La Jolla, CA 92037 USA. EM jb@calcns.com NR 164 TC 13 Z9 17 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD FEB PY 2014 VL 25 IS 2 BP 171 EP 181 DI 10.1016/j.jvir.2013.10.001 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA AA2KU UT WOS:000330924300003 PM 24325929 ER PT J AU Zurkiya, O Walker, TG AF Zurkiya, Omar Walker, T. Gregory TI Quadrilateral Space Syndrome SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Editorial Material C1 [Zurkiya, Omar] Massachusetts Gen Hosp, Dept Radiol, Div Intervent Radiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Zurkiya, O (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Intervent Radiol, 55 Fruit St, Boston, MA 02114 USA. EM ozurkiya@gmail.com NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD FEB PY 2014 VL 25 IS 2 BP 229 EP 229 DI 10.1016/j.jvir.2013.10.016 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA AA2KU UT WOS:000330924300010 PM 24611184 ER PT J AU Chen, L Black, C Hirsch, JA Beall, D Munk, P Murphy, K AF Chen, Long Black, Carl Hirsch, Joshua A. Beall, Doug Munk, Peter Murphy, Kieran TI Vertebroplasty Trials: The Medium Is the Message SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Letter ID VERTEBRAL COMPRESSION FRACTURES; RANDOMIZED-TRIAL; ASSOCIATION; SPINE C1 [Chen, Long; Murphy, Kieran] Univ Toronto, Toronto Western Hosp, Dept Radiol, Toronto, ON M5S 3E2, Canada. [Black, Carl] Utah Valley Reg Med Ctr, Provo, UT USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Beall, Doug] Summit Med Ctr, Serv Radiol, Oklahoma City, OK USA. [Munk, Peter] Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V5Z 1M9, Canada. RP Chen, L (reprint author), Univ Toronto, Toronto Western Hosp, Dept Radiol, Fitzgerald Bldg,150 Coll St,Room 112, Toronto, ON M5S 3E2, Canada. NR 16 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD FEB PY 2014 VL 25 IS 2 BP 323 EP 325 DI 10.1016/j.jvir.2013.10.005 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA AA2KU UT WOS:000330924300022 PM 24461134 ER PT J AU Bhatia, S AF Bhatia, Sameer TI Lost in Translation? Error in Review Article in October JVIR SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Letter C1 Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Bhatia, S (reprint author), Birmingham VA Med Ctr, 700 South 19th St, Birmingham, AL 35233 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD FEB PY 2014 VL 25 IS 2 BP 325 EP 325 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA AA2KU UT WOS:000330924300023 PM 24461135 ER PT J AU Arthur, JM Hill, EG Alge, JL Lewis, EC Neely, BA Janech, MG Tumlin, JA Chawla, LS Shaw, AD AF Arthur, John M. Hill, Elizabeth G. Alge, Joseph L. Lewis, Evelyn C. Neely, Benjamin A. Janech, Michael G. Tumlin, James A. Chawla, Lakhmir S. Shaw, Andrew D. CA SAKInet Investigators TI Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery SO KIDNEY INTERNATIONAL LA English DT Article DE acute kidney injury; clinical nephrology; hemodialysis; outcomes; renal injury; statistics ID GELATINASE-ASSOCIATED LIPOCALIN; POOR OUTCOMES; RISK; AKI AB Biomarkers for acute kidney injury (AKI) have been used to predict the progression of AKI, but a systematic comparison of the prognostic ability of each biomarker alone or in combination has not been performed. In order to assess this, we measured the concentration of 32 candidate biomarkers in the urine of 95 patients with AKIN stage 1 after cardiac surgery. Urine markers were divided into eight groups based on the putative pathophysiological mechanism they reflect. We then compared the ability of the markers alone or in combination to predict the primary outcome of worsening AKI or death (23 patients) and the secondary outcome of AKIN stage 3 or death (13 patients). IL-18 was the best predictor of both outcomes (AUC of 0.74 and 0.89). L-FABP (AUC of 0.67 and 0.85), NGAL (AUC of 0.72 and 0.83), and KIM-1 (AUC of 0.73 and 0.81) were also good predictors. Correlation between most of the markers was generally related to their predictive ability, but KIM-1 had a relatively weak correlation with other markers. The combination of IL-18 and KIM-1 had a very good predictive value with an AUC of 0.93 to predict AKIN 3 or death. Thus, a combination of IL-18 and KIM-1 would result in improved identification of high-risk patients for enrollment in clinical trials. C1 [Arthur, John M.; Janech, Michael G.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA. [Arthur, John M.; Alge, Joseph L.; Lewis, Evelyn C.; Neely, Benjamin A.; Janech, Michael G.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Hill, Elizabeth G.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Tumlin, James A.] Univ Tennessee, Dept Med, Chattanooga, TN USA. [Chawla, Lakhmir S.] George Washington Univ, Dept Med, Washington, DC USA. [Chawla, Lakhmir S.] George Washington Univ, Dept Anesthesiol, Washington, DC USA. [Chawla, Lakhmir S.] George Washington Univ, Dept Crit Care Med, Washington, DC USA. [Shaw, Andrew D.] Durham VA Med Ctr, Dept Anesthesiol, Durham, NC USA. [Shaw, Andrew D.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA. RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Box 250623, Charleston, SC 29425 USA. EM arthurj@musc.edu OI Neely, Benjamin/0000-0001-6120-7695; Alge, Joseph/0000-0002-2491-1066; Janech, Michael/0000-0002-3202-4811 FU NIH [R01DK080234]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs FX This work was supported by an NIH grant number R01DK080234 and a VA Merit Award from the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. The contents do not necessarily represent the views of the Department of Veterans Affairs or the US Government. Additional members of the SAKInet consortium (www.sakinet.org): Medical University of South Carolina, Nithin Karakala, Juan Carlos Q Velez, Milos N Budisavljevic, Rick G Schnellmann; Vanderbilt University, Frederick T (Josh) Billings, Edward D Siew, and T Alp Ikizler. NR 24 TC 31 Z9 31 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2014 VL 85 IS 2 BP 431 EP 438 DI 10.1038/ki.2013.333 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AA5QV UT WOS:000331155600028 PM 24005224 ER PT J AU Beauchamp, EM Woods, BA Dulak, AM Tan, L Xu, CX Gray, NS Bass, AJ Wong, KK Meyerson, M Hammerman, PS AF Beauchamp, Ellen M. Woods, Brittany A. Dulak, Austin M. Tan, Li Xu, Chunxiao Gray, Nathanael S. Bass, Adam J. Wong, Kwok-kin Meyerson, Matthew Hammerman, Peter S. TI Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID DISCOIDIN DOMAIN RECEPTOR-2; EGFR KINASE DOMAIN; TYROSINE KINASE; MET AMPLIFICATION; RAF INHIBITION; PHASE-II; GEFITINIB; GENE; IDENTIFICATION; ERLOTINIB AB The treatment of non-small cell lung cancer has evolved dramatically over the past decade with the adoption of widespread use of effective targeted therapies in patients with distinct molecular alterations. In lung squamous cell carcinoma (lung SqCC), recent studies have suggested that DDR2 mutations are a biomarker for therapeutic response to dasatinib and clinical trials are underway testing this hypothesis. Although targeted therapeutics are typically quite effective as initial therapy for patients with lung cancer, nearly all patients develop resistance with long-term exposure to targeted drugs. Here, we use DDR2-dependent lung cancer cell lines to model acquired resistance to dasatinib therapy. We perform targeted exome sequencing to identify two distinct mechanisms of acquired resistance: acquisition of the T654I gatekeeper mutation in DDR2 and loss of NF1. We show that NF1 loss activates a bypass pathway, which confers ERK dependency downstream of RAS activation. These results indicate that acquired resistance to dasatinib can occur via both second-site mutations in DDR2 and by activation of bypass pathways. These data may help to anticipate mechanisms of resistance that may be identified in upcoming clinical trials of anti-DDR2 therapy in lung cancer and suggest strategies to overcome resistance. Mol Cancer Ther; 13(2); 475-82. (C) 2013 AACR. C1 [Beauchamp, Ellen M.; Woods, Brittany A.; Dulak, Austin M.; Xu, Chunxiao; Bass, Adam J.; Wong, Kwok-kin; Meyerson, Matthew; Hammerman, Peter S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Gray, Nathanael S.] Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA. [Tan, Li] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Wong, Kwok-kin] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA. [Meyerson, Matthew] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Bass, Adam J.; Meyerson, Matthew; Hammerman, Peter S.] Broad Inst Canc Program, Cambridge, MA USA. [Woods, Brittany A.] Mem Sloan Kettering Canc Ctr, Grad Sch Biomed Sci, New York, NY 10021 USA. RP Hammerman, PS (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Dana 810A, Boston, MA 02215 USA. EM phammerman@partners.org OI wong, kwok kin/0000-0001-6323-235X FU National Lung Cancer Partnership; American Society of Clinical Oncology; NCI [K08 CA163677, P01 CA154303]; Stephen D. and Alice Cutler Fund FX This work was supported by Young Investigator Awards from the National Lung Cancer Partnership and American Society of Clinical Oncology as well as NCI K08 CA163677 and the Stephen D. and Alice Cutler Fund to P. S. Hammerman and NCI P01 CA154303 to M. Meyerson. NR 53 TC 12 Z9 13 U1 0 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 EI 1538-8514 J9 MOL CANCER THER JI Mol. Cancer Ther. PD FEB PY 2014 VL 13 IS 2 BP 475 EP 482 DI 10.1158/1535-7163.MCT-13-0817 PG 8 WC Oncology SC Oncology GA AA4LX UT WOS:000331068200019 PM 24296828 ER PT J AU Nascimento, MM Browngardt, C Xiaohui, X Klepac-Ceraj, V Paster, BJ Burne, RA AF Nascimento, M. M. Browngardt, C. Xiaohui, X. Klepac-Ceraj, V. Paster, B. J. Burne, R. A. TI The effect of arginine on oral biofilm communities SO MOLECULAR ORAL MICROBIOLOGY LA English DT Article DE arginine; biofilm; plaque; microflora; caries ID HUMAN SALIVARY BACTERIA; DENTAL-CARIES; STREPTOCOCCUS-MUTANS; PLAQUE PH; DEIMINASE SYSTEM; UREASE ACTIVITY; ROOT CARIES; MICROARRAY; CHILDREN; INDIVIDUALS AB Alkali production by oral bacteria via the arginine deiminase system (ADS) increases the pH of oral biofilms and reduces the risk for development of carious lesions. This study tested the hypothesis that increased availability of arginine in the oral environment through an exogenous source enhances the ADS activity levels in saliva and dental plaque. Saliva and supra-gingival plaque samples were collected from 19 caries-free (CF) individuals (DMFT = 0) and 19 caries-active (CA) individuals (DMFT >= 2) before and after treatment, which comprised the use of a fluoride-free toothpaste containing 1.5% arginine, or a regular fluoride-containing toothpaste twice daily for 4 weeks. ADS activity was measured by quantification of ammonia produced from arginine by oral samples at baseline, after washout period, 4 weeks of treatment, and 2 weeks post-treatment. Higher ADS activity levels were observed in plaque samples from CF compared to those of CA individuals (P = 0.048) at baseline. The use of the arginine toothpaste significantly increased ADS activity in plaque of CA individuals (P = 0.026). The plaque microbial profiles of CA treated with the arginine toothpaste showed a shift in bacterial composition to a healthier community, more similar to that of CF individuals. Thus, an anti-caries effect may be expected from arginine-containing formulations due in large part to the enhancement of ADS activity levels and potential favorable modification to the composition of the oral microbiome. C1 [Nascimento, M. M.] Univ Florida, Dept Restorat Dent Sci, Div Operat Dent, Gainesville, FL 32610 USA. [Browngardt, C.; Burne, R. A.] Univ Florida, Dept Oral Biol, Gainesville, FL 32610 USA. [Xiaohui, X.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Epidemiol, Gainesville, FL 32610 USA. [Paster, B. J.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA. [Klepac-Ceraj, V.] Wellesley Coll, Wellesley, MA 02181 USA. [Paster, B. J.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. RP Nascimento, MM (reprint author), Univ Florida, Dept Restorat Dent Sci, Div Operat Dent, 1395 Ctr Dr,Room D9-6,POB 100415, Gainesville, FL 32610 USA. EM mnascimento@dental.ufl.edu OI Burne, Robert/0000-0002-4234-0316 FU Colgate Palmolive FX This work was supported by Colgate Palmolive. The authors declare that there are no conflicts of interest. NR 37 TC 10 Z9 10 U1 2 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2041-1006 EI 2041-1014 J9 MOL ORAL MICROBIOL JI Mol. Oral Microbiol. PD FEB PY 2014 VL 29 IS 1 BP 45 EP 54 DI 10.1111/omi.12044 PG 10 WC Dentistry, Oral Surgery & Medicine; Microbiology SC Dentistry, Oral Surgery & Medicine; Microbiology GA AA2VD UT WOS:000330951400005 PM 24289808 ER PT J AU Fan, XD Yun, SH AF Fan, Xudong Yun, Seok-Hyun TI The potential of optofluidic biolasers SO NATURE METHODS LA English DT Article ID RING-RESONATOR LASERS; DYE-LASER; FLUORESCENT PROTEIN; LASING DROPLETS; DNA; SINGLE; EMISSION; MICRODROPLETS; MICROSCOPY; GAIN AB Optofluidic biolasers are emerging as a highly sensitive way to measure changes in biological molecules. Biolasers, which incorporate biological material into the gain medium and contain an optical cavity in a fluidic environment, can use the amplification that occurs during laser generation to quantify tiny changes in biological processes in the gain medium. We describe the principle of the optofluidic biolaser, review recent progress and provide our outlooks on potential applications and directions for developing this technology. C1 [Fan, Xudong] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA. [Yun, Seok-Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA USA. [Yun, Seok-Hyun] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Fan, XD (reprint author), Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA. EM xsfan@umich.edu; syun@hms.harvard.edu FU US National Science Foundation [CBET-1037097, ECCS-1045621, CBET-1158638, ECCS-1101947, CBET-1264356]; US National Institutes of Health [P41EB015903] FX The authors acknowledge support from the US National Science Foundation (grants CBET-1037097 and ECCS-1045621 and CBET-1158638 to X. F. and ECCS-1101947 and CBET-1264356 to S.-H.Y.) and US National Institutes of Health (P41EB015903 to S.-H.Y.). We thank D. Psaltis, Z. Li and M. Gather for providing original figures (Figs. 2b and 4b) and I. White for proofreading the manuscript. NR 59 TC 67 Z9 68 U1 19 U2 120 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 EI 1548-7105 J9 NAT METHODS JI Nat. Methods PD FEB PY 2014 VL 11 IS 2 BP 141 EP 147 DI 10.1038/NMETH.2805 PG 7 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA AA5LW UT WOS:000331141600014 PM 24481219 ER PT J AU Prescott, SA Ma, QF De Koninck, Y AF Prescott, Steven A. Ma, Qiufu De Koninck, Yves TI Normal and abnormal coding of somatosensory stimuli causing pain SO NATURE NEUROSCIENCE LA English DT Review ID DORSAL SPINAL-CORD; I SPINOPARABRACHIAL NEURONS; NEUROPATHIC PAIN; HORN NEURONS; INHIBITORY INTERNEURONS; SOMATIC SENSATIONS; THERMAL GRILL; BURNING PAIN; COLOR-VISION; RECEPTOR AB Noxious stimuli usually cause pain and pain usually arises from noxious stimuli, but exceptions to these apparent truisms are the basis for clinically important problems and provide valuable insight into the neural code for pain. In this Review, we discuss how painful sensations arise. We argue that, although primary somatosensory afferents are tuned to specific stimulus features, natural stimuli often activate more than one type of afferent. Manipulating coactivation patterns can alter perception in ways that argue against each type of afferent acting independently (as expected for strictly labeled lines), suggesting instead that signals conveyed by different types of afferents interact. Deciphering the central circuits that mediate those interactions is critical for explaining the generation and modulation of neural signals that ultimately elicit pain. The advent of genetic and optical dissection techniques promise to dramatically accelerate progress toward this goal, which will facilitate the rational design of future pain therapeutics. C1 [Prescott, Steven A.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Prescott, Steven A.] Univ Toronto, Dept Physiol, Toronto, ON, Canada. [Ma, Qiufu] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ma, Qiufu] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [De Koninck, Yves] Univ Laval, Inst Univ Sante Mentale Quebec, Quebec City, PQ, Canada. [De Koninck, Yves] Univ Laval, Dept Psychiat & Neurosci, Quebec City, PQ, Canada. RP Prescott, SA (reprint author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM steve.prescott@sickkids.ca RI De Koninck, Yves/C-2659-2008 OI De Koninck, Yves/0000-0002-5779-9330 FU US National Institutes of Health (NIH) [R01 NS047710, P01 NS0272040, R01 NS086372]; NIH [R01 NS076706, R21 NS074146]; Canadian Institutes of Health Research (CIHR); CIHR [MOP 12942]; CIHR Neurophysics program FX This work was supported by US National Institutes of Health (NIH) grants R01 NS047710, P01 NS0272040 and R01 NS086372 to Q.M., NIH grants R01 NS076706 and R21 NS074146 and a New Investigator Award from the Canadian Institutes of Health Research (CIHR) to S.A.P., and CIHR grant MOP 12942 to Y.D.K. and the CIHR Neurophysics program. The idea of using intersectional genetic manipulations to dissect spinal pain circuits has been jointly developed by M. Goulding at the Salk Institute and by Q.M. We thank Sylvain Cote for expert assistance with artwork. NR 94 TC 38 Z9 39 U1 5 U2 40 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1097-6256 EI 1546-1726 J9 NAT NEUROSCI JI Nat. Neurosci. PD FEB PY 2014 VL 17 IS 2 BP 183 EP 191 DI 10.1038/nn.3629 PG 9 WC Neurosciences SC Neurosciences & Neurology GA AA2FH UT WOS:000330910000010 PM 24473266 ER PT J AU Zwang, NA Turka, LA AF Zwang, Nicholas A. Turka, Laurence A. TI New approaches to diagnosis of rejection SO NATURE REVIEWS NEPHROLOGY LA English DT Editorial Material ID ANTIBODY-MEDIATED REJECTION; KIDNEY-TRANSPLANT BIOPSIES; MOLECULAR DIAGNOSIS; ALLOGRAFTS; REPRODUCIBILITY AB In 2013, a key theme of research in renal transplantation was the diagnosis of rejection. Data from key studies published in the past year highlight aspects of rejection that warrant further investigation and should prompt the consideration of adjunctive tests to complement traditional histological assessment of allograft biopsy samples. C1 [Zwang, Nicholas A.; Turka, Laurence A.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Charlestown, MA 02129 USA. RP Zwang, NA (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Room 5102, Charlestown, MA 02129 USA. EM nzwang@partners.org FU NIDDK NIH HHS [T32 DK007540] NR 10 TC 0 Z9 1 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 EI 1759-507X J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD FEB PY 2014 VL 10 IS 2 BP 72 EP 74 DI 10.1038/nrneph.2013.262 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA AA2GX UT WOS:000330914200004 PM 24342957 ER PT J AU Reiser, J Sever, S Faul, C AF Reiser, Jochen Sever, Sanja Faul, Christian TI Signal transduction in podocytes-spotlight on receptor tyrosine kinases SO NATURE REVIEWS NEPHROLOGY LA English DT Review ID FIBROBLAST-GROWTH-FACTOR; EXPERIMENTAL MEMBRANOUS NEPHROPATHY; CHRONIC RENAL-DISEASE; DIABETIC-NEPHROPATHY; GLOMERULAR PODOCYTE; ANGIOTENSIN-II; EGF RECEPTOR; VEGF-A; CELL-PROLIFERATION; NEPHROTIC SYNDROME AB The mammalian kidney filtration barrier is a complex multicellular, multicomponent structure that maintains homeostasis by regulating electrolytes, acid-base balance, and blood pressure (via maintenance of salt and water balance). To perform these multiple functions, podocytes-an important component of the filtration apparatus-must process a series of intercellular signals. Integrating these signals with diverse cellular responses enables a coordinated response to various conditions. Although mature podocytes are terminally differentiated and cannot proliferate, they are able to respond to growth factors. It is possible that the initial response of podocytes to growth factors is beneficial and protective, and might include the induction of hypertrophic cell growth. However, extended and/or uncontrolled growth factor signalling might be maladaptive and could result in the induction of apoptosis and podocyte loss. Growth factors signal via the activation of receptor tyrosine kinases (RTKs) on their target cells and around a quarter of the 58 RTK family members that are encoded in the human genome have been identified in podocytes. Pharmacological inhibitors of many RTKs exist and are currently used in experimental and clinical cancer therapy. The identification of pathological RTK-mediated signal transduction pathways in podocytes could provide a starting point for the development of novel therapies for glomerular disorders. C1 [Reiser, Jochen] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA. [Sever, Sanja] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Charlestown, MA 02129 USA. [Sever, Sanja] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Faul, Christian] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA. RP Reiser, J (reprint author), Rush Univ, Med Ctr, Dept Med, 1735 West Harrison St,Cohn Bldg,Suite 724, Chicago, IL 60612 USA. EM jochen_reiser@rush.edu; cfaul@med.miami.edu FU NIH [DK073495, DK089394, DK093773, DK101350, DK087985]; American Society of Nephrology FX J. Reiser's research is supported by NIH grants DK073495, DK089394, DK093773 and DK101350. S. Sever's research is funded by NIH grant DK087985. C. Faul's research is funded by a Carl W. Gottschalk Research Scholar Grant from the American Society of Nephrology. NR 169 TC 7 Z9 7 U1 1 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 EI 1759-507X J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD FEB PY 2014 VL 10 IS 2 BP 104 EP 115 DI 10.1038/nrneph.2013.274 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA AA2GX UT WOS:000330914200008 PM 24394191 ER PT J AU Huse, JT Wallace, M Aldape, KD Berger, MS Bettegowda, C Brat, DJ Cahill, DP Cloughesy, T Haas-Kogan, DA Marra, M Miller, CR Nelson, SJ Salama, SR Soffietti, R Wen, PY Yip, S Yen, K Costello, JF Chang, S AF Huse, Jason T. Wallace, Max Aldape, Kenneth D. Berger, Mitchel S. Bettegowda, Chetan Brat, Daniel J. Cahill, Daniel P. Cloughesy, Timothy Haas-Kogan, Daphne A. Marra, Marco Miller, C. Ryan Nelson, Sarah J. Salama, Sofie R. Soffietti, Riccardo Wen, Patrick Y. Yip, Stephen Yen, Katharine Costello, Joseph F. Chang, Susan TI Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC(2)) Low-grade Glioma Research Workshop SO NEURO-ONCOLOGY LA English DT Review DE clinical trials; genomics; low-grade glioma; personalized medicine ID RANDOMIZED-TRIAL; RADIATION-THERAPY; MALIGNANT GLIOMAS; IDH2 MUTATIONS; FREQUENT ATRX; OLIGODENDROGLIOMA; TUMORS; DIFFERENTIATION; GLIOBLASTOMA; ADULTS AB Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable avenues for therapeutic development. As such, the field of neuro-oncology now seems poised to capitalize on these gains to achieve significant benefit for LGG patients. This report will briefly recount the proceedings of a workshop held in January 2013 and hosted by Accelerate Brain Cancer Cure (ABC(2)) on the subject of LGG. While much of the meeting covered recent insights into LGG biology, its focus remained on how best to advance the clinical management, whether by improved preclinical modeling, more effective targeted therapeutics and clinical trial design, or innovative imaging technology. C1 [Huse, Jason T.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Huse, Jason T.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Wallace, Max] Accelerate Brain Canc Cure, Washington, DC USA. [Aldape, Kenneth D.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Berger, Mitchel S.; Haas-Kogan, Daphne A.; Nelson, Sarah J.; Costello, Joseph F.; Chang, Susan] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Neurol Surg, San Francisco, CA 94143 USA. [Bettegowda, Chetan] Johns Hopkins Med Inst, Dept Neurol Surg, Baltimore, MD 21205 USA. [Bettegowda, Chetan] Ludwig Ctr Canc Genet, Baltimore, MD USA. [Bettegowda, Chetan] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD USA. [Brat, Daniel J.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Brat, Daniel J.] Emory Winship Canc Inst, Atlanta, GA USA. [Cahill, Daniel P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg,Brain Tumor Ctr, Boston, MA USA. [Cloughesy, Timothy] Ronald Reagan UCLA Med Ctr, Dept Neurol, Los Angeles, CA USA. [Marra, Marco] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Marra, Marco] BC Canc Agcy, Genome Sci Ctr, Vancouver, BC, Canada. [Miller, C. Ryan] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA. [Miller, C. Ryan] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Neurol, Chapel Hill, NC 27599 USA. [Miller, C. Ryan] Univ N Carolina, Ctr Neurosci, Chapel Hill, NC USA. [Salama, Sofie R.] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA. [Salama, Sofie R.] Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA. [Soffietti, Riccardo] Univ Turin, Dept Neurol, Turin, Italy. [Soffietti, Riccardo] Univ Turin, Dept Neurooncol, Turin, Italy. [Wen, Patrick Y.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. [Yip, Stephen] BC Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC, Canada. [Yen, Katharine] Agios Pharmaceut, Cambridge, MA USA. RP Chang, S (reprint author), UCSF Helen Diller Family Comprehens Canc Ctr, Dept Neurol Surg, 400 Parnassus Ave,A808, San Francisco, CA 94143 USA. EM changs@neurosurg.ucsf.edu RI Miller, Ryan/B-9365-2008; OI Miller, Ryan/0000-0002-0096-8762; Cahill, Daniel/0000-0003-2552-6546 FU Novartis Pharmaceuticals FX PYW sits on the advisory board and receives research support from Novartis Pharmaceuticals. KY is a full-time employee at Agios Pharmaceuticals with equity in the company. MW is the chief executive officer of Accelerate Brain Cancer Cure. Remaining authors have no conflicts of interest to disclose. NR 40 TC 10 Z9 10 U1 2 U2 16 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD FEB PY 2014 VL 16 IS 2 BP 173 EP 178 DI 10.1093/neuonc/not229 PG 6 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AA1GJ UT WOS:000330844300002 PM 24305708 ER PT J AU Hwang, YJ Han, D Kim, KY Min, SJ Kowall, NW Yang, L Lee, J Kim, Y Ryu, H AF Hwang, Yu Jin Han, Dohyun Kim, Ki Yoon Min, Sun-Joon Kowall, Neil W. Yang, Liu Lee, Junghee Kim, Youngsoo Ryu, Hoon TI ESET methylates UBF at K232/254 and regulates nucleolar heterochromatin plasticity and rDNA transcription SO NUCLEIC ACIDS RESEARCH LA English DT Article ID RNA-POLYMERASE-I; HISTONE H3; HUNTINGTONS-DISEASE; BINDING PROTEIN; GENE-EXPRESSION; CBP; POLYGLUTAMINE; ACETYLATION; CHROMATIN; METHYLTRANSFERASE AB The remodeling of chromatin in the nucleolus is important for the control of ribosomal DNA (rDNA) transcription and ribosome biogenesis. Herein, we found that upstream binding factor (UBF) interacts with ESET, a histone H3K9 methyltransferase and is trimethylated at Lys (K) 232/254 by ESET. UBF trimethylation leads to nucleolar chromatin condensation and decreased rDNA transcriptional activity. UBF mutations at K232/254A and K232/254R restored rDNA transcriptional activity in response to ESET. Both ESET-Delta SET mutant and knockdown of ESET by short hairpin RNA reduced trimethylation of UBF and resulted in the restoration of rDNA transcription. Atomic force microscopy confirmed that UBF trimethylated by ESET modulates the plasticity of nucleolar chromatin. We further demonstrated that UBF trimethylation at K232/254 by ESET deregulates rDNA transcription in a cell model of Huntington's disease. Together, our findings show that a novel epigenetic modification of UBF is linked to impaired rDNA transcription and nucleolar chromatin remodeling, which may play key roles in the pathogenesis of neurodegeneration. C1 [Hwang, Yu Jin; Kim, Ki Yoon] Seoul Natl Univ, Coll Med, World Class Univ Neurocyt Grp, Dept Biomed Sci, Seoul 110799, South Korea. [Han, Dohyun; Kim, Youngsoo] Seoul Natl Univ, Coll Med, Seoul 110799, South Korea. [Min, Sun-Joon; Ryu, Hoon] Korea Inst Sci & Technol, Brain Sci Inst, Ctr Neuromed, Seoul 136791, South Korea. [Kowall, Neil W.; Lee, Junghee; Ryu, Hoon] VA Boston Healthcare Syst, Boston, MA 02130 USA. [Kowall, Neil W.; Lee, Junghee; Ryu, Hoon] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA. [Kowall, Neil W.; Lee, Junghee; Ryu, Hoon] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Yang, Liu] Univ Washington, Sch Med, Dept Orthoped, Seattle, WA 98195 USA. [Yang, Liu] Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA. [Yang, Liu] VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. RP Ryu, H (reprint author), Korea Inst Sci & Technol, Brain Sci Inst, Ctr Neuromed, Seoul 136791, South Korea. EM biolab@snu.ac.kr; hoonryu@bu.edu RI Kowall, Neil/G-6364-2012; Kim, Youngsoo/D-6046-2012; OI Kowall, Neil/0000-0002-6624-0213; Min, Sun-Joon/0000-0003-0867-4416 FU National Institutes of Health/NINDS [R01 NS067283]; Korea Government [MEST] [2011-0030740]; Brain Science Flagship Grant from the Korea Institute of Science and Technology [2E24183, 2E24380]; NIH [R01 NS067283] FX National Institutes of Health/NINDS [R01 NS067283 to H.R.]; Proteogenomic Research Program Grant from the Korea Government [MEST] [No. 2011-0030740 to Y.K.]; Brain Science Flagship Grant from the Korea Institute of Science and Technology [2E24183 to S.-J.M. and 2E24380 to H.R.]. Funding for open access charge: NIH [R01 NS067283]. NR 41 TC 3 Z9 3 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD FEB PY 2014 VL 42 IS 3 BP 1628 EP 1643 DI 10.1093/nar/gkt1041 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AA5KX UT WOS:000331138800024 PM 24234436 ER PT J AU Lebeau, A Kriegsmann, M Burandt, E Sinn, H-P AF Lebeau, A. Kriegsmann, M. Burandt, E. Sinn, H. -P. TI Invasive breast cancer: the current WHO classification SO PATHOLOGE LA German DT Article DE Histopathological definition; Diagnostic criteria; Therapy response; Prognosis; Predictive parameters ID TERM FOLLOW-UP; PATHOLOGICAL PROGNOSTIC FACTORS; LOBULAR CARCINOMA; ESTROGEN-RECEPTOR; HISTOLOGICAL TYPE; IN-SITU; THERAPY; DIFFERENTIATION; FEATURES; DISTINCT AB The World Health Organization (WHO) classification of tumors of the breast defines the international standards for tumor categorization and nomenclature. The fourth edition, published in 2012, provides an update on the current knowledge concerning the classification, immunohistology profile, differential diagnosis and genetics of these lesions. Compared to the previous edition, some terms have been modified, some entities were reclassified and some current molecular data have been added. This article focuses on invasive carcinomas. Definitions for histological diagnosis are supplemented by clinical, macroscopic and molecular characteristics as well as prognostic and predictive features. C1 [Lebeau, A.; Burandt, E.] Univ Klinikum Hamburg Eppendorf, Inst Pathol, D-20246 Hamburg, Germany. [Lebeau, A.] Gemeinschaftspraxis Pathol, Lubeck, Germany. [Kriegsmann, M.; Sinn, H. -P.] Univ Klinikum Heidelberg, Inst Pathol, Heidelberg, Germany. [Burandt, E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA. RP Lebeau, A (reprint author), Univ Klinikum Hamburg Eppendorf, Inst Pathol, D-20246 Hamburg, Germany. EM a.lebeau@uke.de NR 31 TC 3 Z9 3 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0172-8113 EI 1432-1963 J9 PATHOLOGE JI Pathologe PD FEB PY 2014 VL 35 IS 1 BP 7 EP + DI 10.1007/s00292-013-1841-7 PG 10 WC Pathology SC Pathology GA AA3AB UT WOS:000330964200002 PM 24496990 ER PT J AU Tsai, A McDonald, AG Rosenberg, AE Gupta, R Kleinman, PK AF Tsai, Andy McDonald, Anna G. Rosenberg, Andrew E. Gupta, Rajiv Kleinman, Paul K. TI High-resolution CT with histopathological correlates of the classic metaphyseal lesion of infant abuse SO PEDIATRIC RADIOLOGY LA English DT Article DE Child abuse; Classic metaphyseal lesion; Micro-CT; High-resolution flat-panel CT; Subperiosteal bone collar; Zone of provisional calcification; Infant ID PANEL VOLUME CT; REGIONAL APPROACH; GROWTH-PLATE; GROWING BONE; CHILD-ABUSE; CALCIFICATION; FRACTURES; OSSIFICATION; CARTILAGE; RANVIER AB The classic metaphyseal lesion (CML) is a common high specificity indicator of infant abuse and its imaging features have been correlated histopathologically in infant fatalities. High-resolution CT imaging and histologic correlates were employed to (1) characterize the normal infant anatomy surrounding the chondro-osseous junction, and (2) confirm the 3-D model of the CML previously inferred from planar radiography and histopathology. Long bone specimens from 5 fatally abused infants, whose skeletal survey showed definite or suspected CMLs, were studied postmortem. After skeletal survey, selected specimens were resected and imaged with high-resolution digital radiography. They were then scanned with micro-CT (isotropic resolution of 45 mu m(3)) or with high-resolution flat-panel CT (isotropic resolutions of 200 mu m(3)). Visualization of the bony structures was carried out using image enhancement, segmentation and isosurface extraction, together with volume rendering and multiplanar reformatting. These findings were then correlated with histopathology. Study of normal infant bone clarifies the 3-D morphology of the subperiosteal bone collar (SPBC) and the radiographic zone of provisional calcification (ZPC). Studies on specimens with CML confirm that this lesion is a fracture extending in a planar fashion through the metaphysis, separating a mineralized fragment. This disk-like mineralized fragment has two components: (1) a thick peripheral component encompassing the SPBC; and (2) a thin central component comprised predominantly of the radiologic ZPC. By manipulating the 3-D model, the varying appearances of the CML are displayed. High-resolution CT coupled with histopathology provides elucidation of the morphology of the CML, a strong indicator of infant abuse. This new information may prove useful in assessing the biomechanical factors that produce this strong indicator of abusive assaults in infants. C1 [Tsai, Andy; Kleinman, Paul K.] Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA. [McDonald, Anna G.] Off Chief Med Examiner, Boston, MA USA. [Rosenberg, Andrew E.] Univ Miami Hosp, Dept Pathol, Miami, FL USA. [Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Tsai, A (reprint author), Boston Childrens Hosp, Dept Radiol, 300 Longwood Ave, Boston, MA 02115 USA. EM andy.tsai@childrens.harvard.edu NR 47 TC 11 Z9 11 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 EI 1432-1998 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD FEB PY 2014 VL 44 IS 2 BP 124 EP 140 DI 10.1007/s00247-013-2813-z PG 17 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA AA3JE UT WOS:000330987900001 PM 24481795 ER PT J AU Xiong, Y Sheen, J AF Xiong, Yan Sheen, Jen TI The Role of Target of Rapamycin Signaling Networks in Plant Growth and Metabolism SO PLANT PHYSIOLOGY LA English DT Review ID NOVO PYRIMIDINE SYNTHESIS; MTOR COMPLEX 1; ARABIDOPSIS-THALIANA; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CELL-GROWTH; S6 KINASE; CHLAMYDOMONAS-REINHARDTII; PHOSPHOPROTEOME REVEALS; RNA EXPRESSION AB The target of rapamycin (TOR) kinase, a master regulator that is evolutionarily conserved among yeasts (Saccharomyces cerevisiae), plants, animals, and humans, integrates nutrient and energy signaling to promote cell proliferation and growth. Recent breakthroughs made possible by integrating chemical, genetic, and genomic analyses have greatly increased our understanding of the molecular functions and dynamic regulation of the TOR kinase in photosynthetic plants. TOR signaling plays fundamental roles in embryogenesis, meristem activation, root and leaf growth, flowering, senescence, and life span determination. The molecular mechanisms underlying TOR-mediated ribosomal biogenesis, translation promotion, readjustment of metabolism, and autophagy inhibition are now being uncovered. Moreover, monitoring photosynthesis-derived Glc and bioenergetics relays has revealed that TOR orchestrates unprecedented transcriptional networks that wire central metabolism and biosynthesis for energy and biomass production. In addition, these networks integrate localized stem/progenitor cell proliferation through interorgan nutrient coordination to control developmental transitions and growth. C1 [Xiong, Yan] Chinese Acad Sci, Shanghai Ctr Plant Stress Biol, Shanghai 200032, Peoples R China. [Xiong, Yan; Sheen, Jen] Harvard Univ, Sch Med, Dept Mol Biol, Boston, MA 02114 USA. [Xiong, Yan; Sheen, Jen] Harvard Univ, Sch Med, Ctr Computat & Integrat Biol, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Xiong, Yan; Sheen, Jen] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. RP Sheen, J (reprint author), Harvard Univ, Sch Med, Dept Mol Biol, Boston, MA 02114 USA. EM yanxiong@sibs.ac.cn; sheen@molbio.mgh.harvard.edu FU Chinese Academy of Sciences; Massachusetts General Hospital Tosteson Postdoctoral Fellowship; National Science Foundation [IOS-0843244]; National Institutes of Health [GM60493, GM70567] FX This work was supported by the Chinese Academy of Sciences and a Massachusetts General Hospital Tosteson Postdoctoral Fellowship (to Y.X.), and the research on Glc-target of rapamycin signaling was supported by the National Science Foundation (grant no. IOS-0843244 to J.S.) and the National Institutes of Health (grant nos. GM60493 and GM70567 to J.S.). NR 93 TC 41 Z9 42 U1 8 U2 81 PU AMER SOC PLANT BIOLOGISTS PI ROCKVILLE PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA SN 0032-0889 EI 1532-2548 J9 PLANT PHYSIOL JI Plant Physiol. PD FEB PY 2014 VL 164 IS 2 BP 499 EP 512 DI 10.1104/pp.113.229948 PG 14 WC Plant Sciences SC Plant Sciences GA AA5JN UT WOS:000331132300001 PM 24385567 ER PT J AU Roh, S Hoeppner, SS Schoenfeld, D Fullerton, CA Stoeckel, LE Evins, AE AF Roh, Sungwon Hoeppner, Susanne S. Schoenfeld, David Fullerton, Catherine A. Stoeckel, Luke E. Evins, A. Eden TI Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia SO PSYCHOPHARMACOLOGY LA English DT Article DE Schizophrenia; Mecamylamine; Varenicline; Nicotine; Cognitive function; Smoking; Attention; Working memory ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; RECEPTOR PARTIAL AGONIST; VISUOSPATIAL WORKING-MEMORY; IDENTICAL PAIRS VERSION; SCHIZOAFFECTIVE DISORDER; TRANSDERMAL NICOTINE; SMOKING ABSTINENCE; SMOKERS; ANTAGONIST; ADULTS AB Nicotinic acetylcholine receptors (nAChRs) have been implicated in the pathophysiology of cognitive deficits in the domains of attention and memory in schizophrenia. While nicotinic agonists and antagonists have been proposed as smoking cessation aids, few comparisons have been made of these agents on cognitive performance in individuals with schizophrenia. This study investigated the acute effects of a nAChR antagonist, mecamylamine, and partial agonist, varenicline, on cognitive function in non-smokers with and without schizophrenia. Single oral doses of mecamylamine 10 mg, varenicline 1 mg, and placebo were administered 1 week apart in random order to adults with schizophrenia (n = 30) and to healthy volunteers (n = 41) in a double-blind, crossover design. The primary outcome of interest was sustained attention as assessed with hit reaction time variability (HRT-SD) on the identical pairs continuous performance test (CPT-IP). Mecamylamine worsened performance on CPT-IP HRT-SD, a measure of attention, compared to varenicline in both groups. Performance on mecamylamine was worse than performance on both placebo and varenicline on several additional measures of attention, including CPT-IP hit reaction time (HRT) and random errors at various levels of task difficulty. There was a treatment by diagnosis interaction, such that mecamylamine worsened performance on CPT-IP 2-digit HRT, 3-digit random errors, and 4-digit hit rate compared to placebo and varenicline in participants with schizophrenia; effects not observed in controls. These findings support a role for nAChRs in attention and suggest that those with schizophrenia may be particularly sensitive to nAChR blockade. C1 [Roh, Sungwon; Hoeppner, Susanne S.; Schoenfeld, David; Fullerton, Catherine A.; Stoeckel, Luke E.; Evins, A. Eden] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. [Roh, Sungwon; Hoeppner, Susanne S.; Schoenfeld, David; Fullerton, Catherine A.; Stoeckel, Luke E.; Evins, A. Eden] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Evins, AE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, 60 Staniford St, Boston, MA 02114 USA. EM a_eden_evins@hms.harvard.edu RI Hoeppner, Susanne/C-4631-2015 OI Hoeppner, Susanne/0000-0003-2060-1666 FU NARSAD; Bowman Family Foundation; Charles A. King Trust; NIDA [K23DA00510, K24DA030443]; [K23 DA032612] FX Primary funding for this study was provided by NARSAD Young Investigator Awards (CAF, LES) and by a grant from the Bowman Family Foundation (AEE). Additional support was provided by the Charles A. King Trust and K23 DA032612 (LES) and by NIDA K23DA00510 and K24DA030443 (AEE). NR 48 TC 9 Z9 9 U1 3 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD FEB PY 2014 VL 231 IS 4 BP 765 EP 775 DI 10.1007/s00213-013-3286-3 PG 11 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AA3HM UT WOS:000330983500013 PM 24114425 ER PT J AU Hay, JL Atkinson, TM Reeve, BB Mitchell, SA Mendoza, TR Willis, G Minasian, LM Clauser, SB Denicoff, A O'Mara, A Chen, A Bennett, AV Paul, DB Gagne, J Rogak, L Sit, L Viswanath, V Schrag, D Basch, E AF Hay, Jennifer L. Atkinson, Thomas M. Reeve, Bryce B. Mitchell, Sandra A. Mendoza, Tito R. Willis, Gordon Minasian, Lori M. Clauser, Steven B. Denicoff, Andrea O'Mara, Ann Chen, Alice Bennett, Antonia V. Paul, Diane B. Gagne, Joshua Rogak, Lauren Sit, Laura Viswanath, Vish Schrag, Deborah Basch, Ethan CA NCI PRO-CTCAE Study Grp TI Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) SO QUALITY OF LIFE RESEARCH LA English DT Article DE Drug toxicity; Neoplasms; Psychometrics; Reproducibility of results; Qualitative research ID TASK-FORCE REPORT; TOXICITY DATA; SELF-REPORTS; DRUG-SAFETY; CLINICIAN; TRIALS; RECOMMENDATIONS; QUESTIONNAIRE; INSTRUMENTS; EXPERIENCES AB The National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a library of question items that enables patient reporting of adverse events (AEs) in clinical trials. This study contributes content validity evidence of the PRO-CTCAE by incorporating cancer patient input of the relevance and comprehensiveness of the item library. Cognitive interviews were conducted among patients undergoing chemotherapy or radiation therapy at multiple sites to evaluate comprehension, memory retrieval, judgment, and response mapping related to AE terms (e.g., nausea), attribute terms (regarding frequency, severity, or interference), response options, and recall period. Three interview rounds were conducted with a parts per thousand yen20 patients completing each item per round. Items were modified and retested if a parts per thousand yen3 patients exhibited cognitive difficulties or if experienced by a parts per thousand currency sign25 % patients. One hundred and twenty-seven patients participated (35 % a parts per thousand currency signhigh school, 28 % non-white, and 59 % female). Most AE terms (63/80) generated no cognitive difficulties. The remaining 17 were modified without further difficulties by Round 3. Terms were comprehended regardless of education level. Attribute terms and response options required no modifications. Patient adherence to recall period (7 days) was improved when the reference period was incorporated. This study provides evidence confirming comprehension of the US English language versions of items in the PRO-CTCAE library for measuring symptomatic AEs from the patient perspective within the context of cancer treatment. Several minor changes were made to the items to improve item clarity, comprehension, and ease of response judgment. This study helps to establish the content validity of PRO-CTCAE items for patient reporting of AEs during cancer treatment. C1 [Hay, Jennifer L.; Atkinson, Thomas M.; Rogak, Lauren; Sit, Laura; Basch, Ethan] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10022 USA. [Reeve, Bryce B.; Bennett, Antonia V.; Basch, Ethan] Univ N Carolina, Chapel Hill, NC USA. [Mitchell, Sandra A.; Willis, Gordon; Minasian, Lori M.; Clauser, Steven B.; Denicoff, Andrea; O'Mara, Ann; Chen, Alice] United States Natl Canc Inst, Rockville, MD USA. [Mendoza, Tito R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Gagne, Joshua; Viswanath, Vish; Schrag, Deborah] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Hay, JL (reprint author), Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 641 Lexington Ave,7th Floor, New York, NY 10022 USA. EM hayj@mskcc.org FU United States National Cancer Institute [HHSN261201000043C, HHSN261201000063C] FX Work described in this report was supported by contracts from the United States National Cancer Institute, HHSN261201000043C and HHSN261201000063C. Each author met all International Committee of Medical Journal Editors (ICMJE) requirements (i.e., conception/design/acquisition/analysis, drafting/revising article, and final approval) for authorship. NR 48 TC 22 Z9 22 U1 2 U2 16 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD FEB PY 2014 VL 23 IS 1 BP 257 EP 269 DI 10.1007/s11136-013-0470-1 PG 13 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AA1BL UT WOS:000330831100027 PM 23868457 ER PT J AU Sun, DD Kahle, KT AF Sun, Dandan Kahle, Kristopher T. TI Dysregulation of Diverse Ion Transport Pathways Controlling Cell Volume Homoestasis Contribute to Neuroglial Cell Injury Following Ischemic Stroke SO TRANSLATIONAL STROKE RESEARCH LA English DT Editorial Material ID BRAIN-INJURY C1 [Sun, Dandan] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15217 USA. [Kahle, Kristopher T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Kahle, Kristopher T.] Harvard Med, Boston, MA 02115 USA. [Kahle, Kristopher T.] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA. RP Sun, DD (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15217 USA. EM sund@upmc.edu NR 17 TC 3 Z9 3 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD FEB PY 2014 VL 5 IS 1 BP 1 EP 2 DI 10.1007/s12975-014-0324-3 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA2TO UT WOS:000330947200001 PM 24464825 ER PT J AU Khanna, A Kahle, KT Walcott, BP Gerzanich, V Simard, JM AF Khanna, Arjun Kahle, Kristopher T. Walcott, Brian P. Gerzanich, Volodymyr Simard, J. Marc TI Disruption of Ion Homeostasis in the Neurogliovascular Unit Underlies the Pathogenesis of Ischemic Cerebral Edema SO TRANSLATIONAL STROKE RESEARCH LA English DT Article DE Blood-brain barrier; Stroke; Ischemia; SUR1; Glyburide; Bumetanide; Ion channel; Edema; NKCC1; Tumor; Hemorrhage; TRPM4; Hypertonic ID BLOOD-BRAIN-BARRIER; REGULATED ANION CHANNELS; K+-CL-COTRANSPORTER; CAPILLARY ENDOTHELIAL-CELLS; NONSELECTIVE CATION CHANNEL; NA+/H+ EXCHANGER ISOFORMS; ARTERY OCCLUSION MODEL; EXCITATORY AMINO-ACIDS; RECEPTOR POTENTIAL CHANNELS; GAP-JUNCTION HEMICHANNELS AB Cerebral edema is a major cause of morbidity and mortality following ischemic stroke, but its underlying molecular pathophysiology is incompletely understood. Recent data have revealed the importance of ion flux via channels and transporters expressed in the neurogliovascular unit in the development of ischemia-triggered cytotoxic edema, vasogenic edema, and hemorrhagic conversion. Disruption of homeostatic mechanisms governing cell volume regulation and epithelial/endothelial ion transport due to ischemia-associated energy failure results in the thermodynamically driven re-equilibration of solutes and water across the CSF-blood and blood-brain barriers that ultimately increases the brain's extravascular volume. Additionally, hypoxia, inflammation, and other stress-triggered increases in the functional expression of ion channels and transporters normally expressed at low levels in the neurogliovascular unit cause disruptions in ion homeostasis that contribute to ischemic cerebral edema. Here, we review the pathophysiological significance of several molecular mediators of ion transport expressed in the neurogliovascular unit, including targets of existing FDA-approved drugs, which might be potential nodes for therapeutic intervention. C1 [Khanna, Arjun; Kahle, Kristopher T.; Walcott, Brian P.] Harvard Univ, Sch Med, Boston, MA USA. [Khanna, Arjun; Kahle, Kristopher T.; Walcott, Brian P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Gerzanich, Volodymyr; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA. [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA. [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA. RP Walcott, BP (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg 502, Boston, MA 02114 USA. EM walcott.brian@mgh.harvard.edu; msimard@smail.umaryland.edu FU National Heart, Lung and Blood Institute [HL082517]; National Institute of Neurological Disorders and Stroke [NS061808]; Brain Aneurysm Foundation FX This work was supported by grants to JMS from the National Heart, Lung and Blood Institute (HL082517) and the National Institute of Neurological Disorders and Stroke (NS061808) and to BPW from the Brain Aneurysm Foundation. NR 172 TC 19 Z9 19 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD FEB PY 2014 VL 5 IS 1 BP 3 EP 16 DI 10.1007/s12975-013-0307-9 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA2TO UT WOS:000330947200002 PM 24323726 ER PT J AU Baxter, P Chen, YT Xu, Y Swanson, RA AF Baxter, Paul Chen, Yanting Xu, Yun Swanson, Raymond A. TI Mitochondrial Dysfunction Induced by Nuclear Poly(ADP-Ribose) Polymerase-1: a Treatable Cause of Cell Death in Stroke SO TRANSLATIONAL STROKE RESEARCH LA English DT Review DE Ischemia; Mitochondrial depolarization; Mitochondrial permeability transition; Poly(ADP-ribose) polymerase-1; NAD(+); Apoptosis-inducing factor ID FOCAL CEREBRAL-ISCHEMIA; METHYL-D-ASPARTATE; HYPOGLYCEMIC NEURONAL DEATH; TRANSIENT FOREBRAIN ISCHEMIA; PERMEABILITY TRANSITION; GAMMA-HYDROXYBUTYRATE; ARTERY OCCLUSION; RAT-BRAIN; NITRIC-OXIDE; COGNITIVE IMPAIRMENT AB Many drugs targeting excitotoxic cell death have demonstrated robust neuroprotective effects in animal models of cerebral ischemia. However, these neuroprotective effects have almost universally required drug administration at relatively short time intervals after ischemia onset. This finding has translated to clinical trial results; interventions targeting excitotoxicity have had no demonstrable efficacy when initiated hours after ischemia onset, but beneficial effects have been reported with more rapid initiation. Consequently, there continues to be a need for interventions with efficacy at later time points after ischemia. Here, we focus on mitochondrial dysfunction as both a relatively late event in ischemic neuronal death and a recognized cause of delayed neuronal death. Activation of poly(ADP-ribose) polymerase-1 (PARP-1) is a primary cause of mitochondrial depolarization and subsequent mitochondria-triggered cell death in ischemia reperfusion. PARP-1 consumes cytosolic NAD(+), thereby blocking both glycolytic ATP production and delivery of glucose carbon to mitochondria for oxidative metabolism. However, ketone bodies such as pyruvate, beta- and gamma-hydroxybutyrate, and 1,4-butanediol can fuel mitochondrial metabolism in cells with depleted cytosolic NAD(+) as long as the mitochondria remain functional. Ketone bodies have repeatedly been shown to be highly effective in preventing cell death in animal models of ischemia, but a rigorous study of the time window of opportunity for this approach remains to be performed. C1 [Baxter, Paul; Chen, Yanting; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Baxter, Paul; Chen, Yanting; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA 94121 USA. [Chen, Yanting; Xu, Yun] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurol, Nanjing 210008, Jiangsu, Peoples R China. RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM Raymond.swanson@ucsf.edu OI Swanson, Raymond/0000-0002-3664-5359 FU Chinese Research Scholarship Council; U.S. National Institutes of Health [NS041421]; U.S. Department of Veterans Affairs FX This work was supported by the Chinese Research Scholarship Council (Y.C.), the U.S. National Institutes of Health (grant no. NS041421, R.A.S.), and the U.S. Department of Veterans Affairs. NR 90 TC 17 Z9 17 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD FEB PY 2014 VL 5 IS 1 BP 136 EP 144 DI 10.1007/s12975-013-0283-0 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA2TO UT WOS:000330947200013 PM 24323707 ER PT J AU Hoogenboom, WS Perlis, RH Smoller, JW Zeng-Treitler, Q Gainer, VS Murphy, SN Churchill, SE Kohane, IS Shenton, ME Iosifescu, DV AF Hoogenboom, Wouter S. Perlis, Roy H. Smoller, Jordan W. Zeng-Treitler, Qing Gainer, Vivian S. Murphy, Shawn N. Churchill, Susanne E. Kohane, Isaac S. Shenton, Martha E. Iosifescu, Dan V. TI Limbic system white matter microstructure and long-term treatment outcome in major depressive disorder: A diffusion tensor imaging study using legacy data SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY LA English DT Article DE Major depressive disorder (MDD); diffusion tensor imaging (DTI); natural language processing (NLP); fornix; limbic system ID TREATMENT-RESISTANT DEPRESSION; PRINCIPAL EIGENVECTOR MEASUREMENTS; MILD COGNITIVE IMPAIRMENT; LATE-LIFE DEPRESSION; ALZHEIMERS-DISEASE; MAGNETIC-RESONANCE; FRACTIONAL ANISOTROPY; GERIATRIC DEPRESSION; MEAN DIFFUSIVITY; MOOD DISORDERS AB Objectives. Treatment-resistant depression is a common clinical occurrence among patients with major depressive disorder (MDD), but its neurobiology is poorly understood. We used data collected as part of routine clinical care to study white matter integrity of the brain's limbic system and its association to treatment response. Methods. Electronic medical records of multiple large New England hospitals were screened for patients with an MDD billing diagnosis, and natural language processing was subsequently applied to find those with concurrent diffusion-weighted images, but without any diagnosed brain pathology. Treatment outcome was determined by review of clinical charts. MDD patients (n = 29 non-remitters, n = 26 partial-remitters, and n = 37 full-remitters), and healthy control subjects (n = 58) were analyzed for fractional anisotropy (FA) of the fornix and cingulum bundle. Results. Failure to achieve remission was associated with lower FA among MDD patients, statistically significant for the medial body of the fornix. Moreover, global and regional-selective age-related FA decline was most pronounced in patients with treatment-refractory, non-remitted depression. Conclusions. These findings suggest that specific brain microstructural white matter abnormalities underlie persistent, treatment-resistant depression. They also demonstrate the feasibility of investigating white matter integrity in psychiatric populations using legacy data. C1 [Hoogenboom, Wouter S.; Perlis, Roy H.; Iosifescu, Dan V.] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA. [Hoogenboom, Wouter S.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02115 USA. [Perlis, Roy H.] Massachusetts Gen Hosp, Lab Psychiat Pharmacogen, Ctr Human Genet Res, Boston, MA 02114 USA. [Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Psychiat Genet Program Mood & Anxiety Disorders, Boston, MA 02114 USA. [Zeng-Treitler, Qing] Univ Utah, Dept Biomed Informat, Salt Lake City, UT USA. [Zeng-Treitler, Qing] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Gainer, Vivian S.; Murphy, Shawn N.] Partners HealthCare Syst Inc, Informat Syst, Charlestown, MA USA. [Murphy, Shawn N.] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. [Churchill, Susanne E.; Kohane, Isaac S.] Brigham & Womens Hosp, Natl Ctr Biomed Comp i2b2, Boston, MA 02215 USA. [Shenton, Martha E.] VA Boston Healthcare Syst, Dept Psychiat, Neurosci Lab, Clin Neurosci Div, Brockton, MA 02301 USA. [Shenton, Martha E.] Harvard Univ, Sch Med, Boston, MA USA. [Iosifescu, Dan V.] Mt Sinai Sch Med, Mood & Anxiety Disorders Program, New York, NY USA. RP Hoogenboom, WS (reprint author), Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA. EM hoogenboomw@gmail.com FU Aspect Medical Systems; Forest Laboratories; Janssen Pharmaceutica; Concordant Rater Systems; Proteus Biomedical; RIDventures; National Institutes of Health [NIH U54-LM008748, R01 MH 50740]; National Institutes of Health Career Development Award [K23 MH067111]; Department of Veterans Affairs (VA); National Institute of Mental Health [MH086026] FX Dr Iosifescu has received research support from Aspect Medical Systems, Forest Laboratories and Janssen Pharmaceutica; he has been a speaker for Eli Lilly & Co., Forest Laboratories, Pfizer, Inc. and Reed Medical Education. Dr Perlis has received consulting fees from Concordant Rater Systems, Proteus Biomedical, and RIDventures. All other contributors have none to declare.; This research is supported as a Driving Biological Project (PI: Dr Iosifescu) with the i2b2 grant (National Institutes of Health, NIH U54-LM008748; PI: Dr Kohane). Dr Iosifescu is also supported by the National Institutes of Health Career Development Award K23 MH067111. Dr Shenton is supported by grants from the National Institutes of Health (R01 MH 50740), and the Department of Veterans Affairs (VA) (VA Merit Award and VA Schizophrenia Research Center Grant). Dr Perlis is supported by a grant from the National Institute of Mental Health (MH086026). NR 57 TC 11 Z9 11 U1 2 U2 9 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1562-2975 EI 1814-1412 J9 WORLD J BIOL PSYCHIA JI World J. Biol. Psychiatry PD FEB PY 2014 VL 15 IS 2 BP 122 EP 134 DI 10.3109/15622975.2012.669499 PG 13 WC Psychiatry SC Psychiatry GA AA5JO UT WOS:000331132400005 PM 22540406 ER PT J AU Saboo, SS Ramaiya, N Jacene, H Rainville, I Diller, L Hornick, JL George, S AF Saboo, Sachin S. Ramaiya, Nikhil Jacene, Heather Rainville, Irene Diller, Lisa Hornick, Jason L. George, Suzanne TI Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation SO ABDOMINAL IMAGING LA English DT Article DE Leiomyosarcoma; MRI; CT; F-18-FDG PET/CT; RB1 mutation ID UTERINE LEIOMYOSARCOMA; RETINOBLASTOMA; FEATURES; CANCER; TUMORS AB A 72-year-old Caucasian man presenting with non-specific upper abdominal pain had asymmetric soft tissue thickening of the small bowel wall on computed tomography (CT), which was pathologically proven to be leiomyosarcoma (LMS). At the same time point patient had incidentally but retrospectively detected lesion in IVC on CT scan which was subsequently imaged with PET/CT and MRI and was histologically proven to be also LMS. We present clinical and imaging features along with pedigree of this unique case of synchronous primary LMS involving the small bowel and inferior vena cava in a patient with RB1 gene mutation and a significant family history of multiple malignancies. To our knowledge, the synchronous primary LMS at two different sites has not been described. Clinicians and radiologists should keep in mind the possibility of a synchronous primary LMS in patients with genetic predisposition before making the diagnosis of a metastatic lesion or other malignancy as localized primary tumors remain potentially curable, whereas metastatic sarcoma is most often incurable. C1 [Saboo, Sachin S.; Ramaiya, Nikhil; Jacene, Heather] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02215 USA. [Saboo, Sachin S.; Ramaiya, Nikhil; Jacene, Heather; Rainville, Irene; Diller, Lisa; George, Suzanne] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Rainville, Irene] Dana Farber Canc Inst, Dept Genet, Boston, MA 02215 USA. [Diller, Lisa] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [George, Suzanne] Dana Farber Canc Inst, Dept Oncol, Boston, MA 02215 USA. RP Saboo, SS (reprint author), Dana Farber Canc Inst, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA. EM ssaboo@partners.org NR 14 TC 2 Z9 2 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0942-8925 EI 1432-0509 J9 ABDOM IMAGING JI Abdom. Imaging PD FEB PY 2014 VL 39 IS 1 BP 33 EP 39 DI 10.1007/s00261-012-9904-4 PG 7 WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging GA 304EE UT WOS:000330728900005 PM 22581272 ER PT J AU Muniappan, A Tapias, LF Butala, P Wain, JC Wright, CD Donahue, DM Gaissert, HA Lanuti, M Mathisen, DJ AF Muniappan, Ashok Tapias, Luis F. Butala, Parag Wain, John C. Wright, Cameron D. Donahue, Dean M. Gaissert, Henning A. Lanuti, Michael Mathisen, Douglas J. TI Surgical Therapy of Pulmonary Aspergillomas: A 30-Year North American Experience SO ANNALS OF THORACIC SURGERY LA English DT Article ID LONG-TERM OUTCOMES; COMPLEX ASPERGILLOMA; TOPICAL TREATMENT; CLINICAL PROFILE; SURGERY; HEMOPTYSIS; PROGNOSIS; RESECTION AB Background. Pulmonary aspergilloma is resected to control life-threatening complications such as massive hemoptysis. The role of prophylactic resection in asymptomatic patients is unclear. Methods. A retrospective review was conducted of 60 patients treated at a tertiary center from 1980 to 2010. Results. The mean age in 34 (56.7%) men and 26 (43.3%) women was 51 years. Immunosuppression, most commonly from chronic steroid use, was present in 17 (28.3%) patients, and preexisting lung disease was present in 47 (78.3%) patients. Hemoptysis occurred in 33 (55%) patients, whereas 9 (15.0%) patients were asymptomatic. Aspergilloma was simple in 13 (21.7%) patients and complex in 47 (78.3%) patients. Surgical approach was by thoracotomy (n = 51 [85.0%]), video-assisted thoracoscopic surgery (n = 7 [11.7%]), or a cavernostomy (n = 2 [3.3%]). Sublobar resections (n = 28 [46.7%]) were most common, followed by lobectomy (n = 27 [45%]) and pneumonectomy (n = 3 [5%]). Postoperative morbidity occurred in 18 (30%) patients, with prolonged air leak the most frequent complication (n = 9 [15%]). Two (3.3%) patients experienced empyema, and 4 (6.7%) patients had bronchopleural fistulas (BPFs). Two patients died within 30 days (3.3%). During a mean follow-up of 54.1 +/- 62.2 months, 3 patients had recurrent aspergillomas (5.0%). Actuarial 10-year survival was 62.5% for simple and 68.5% for complex aspergillomas (p [0.858). Comorbid conditions (human immunodeficiency virus [HIV] positivity, malignancy) and male sex were associated with lower survival. Conclusions. Selective surgical treatment favoring lesser pulmonary resection results in fungal eradication and control in most patients. Overall survival is similar after surgical management of simple and complex aspergillomas. (C) 2014 by The Society of Thoracic Surgeons C1 [Muniappan, Ashok; Tapias, Luis F.; Butala, Parag; Wain, John C.; Wright, Cameron D.; Donahue, Dean M.; Gaissert, Henning A.; Lanuti, Michael; Mathisen, Douglas J.] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA. RP Muniappan, A (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Blake 1570, Boston, MA 02114 USA. EM amuniappan@partners.org NR 28 TC 10 Z9 11 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2014 VL 97 IS 2 BP 432 EP 438 DI 10.1016/j.athoracsur.2013.10.050 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 302CQ UT WOS:000330579400017 PM 24365218 ER PT J AU Duval, D Lardeux, A Le Tourneau, T Norris, RA Markwald, RR Sauzeau, V Probst, V Le Marec, H Levine, R Schott, JJ Merot, J AF Duval, D. Lardeux, A. Le Tourneau, T. Norris, R. A. Markwald, R. R. Sauzeau, V. Probst, V. Le Marec, H. Levine, R. Schott, J. J. Merot, J. TI Valvular dystrophy associated filamin A mutations reveal a new role of its first repeats in small-GTPase regulation SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH LA English DT Article DE Mitral valve prolapse; Filamin A; Rac1; RhoA; FilGAP ID ACTIN-BINDING; CELL-MIGRATION; RAC; PROTEIN; FILGAP; ACTIVATION; GENE; HETEROTOPIA; VIMENTIN; ADHESION AB Filamin A (FlnA) is a ubiquitous actin binding protein which anchors various transmembrane proteins to the cell cytoskeleton and provides a scaffold to many cytoplasmic signaling proteins involved in actin cytoskeleton remodeling in response to mechanical stress and cytokines stimulation. Although the vast majority of FlnA binding partners interact with the carboxy-terminal immunoglobulin like (Igl) repeats of FlnA, little is known on the role of the amino-N-terminal repeats. Here, using cardiac mitral valvular dystrophy associated FlnA-G288R and P637Q mutations located in the N-terminal Igl repeat 1 and 4 respectively as a model, we identified a new role of FlnA N-terminal repeats in small Rho-GTPases regulation. Using FlnA-deficient melanoma and HT1080 cell lines as expression systems we showed that FlnA mutations reduce cell spreading and migration capacities. Furthermore, we defined a signaling network in which FlnA mutations alter the balance between RhoA and Rac1 GTPases activities in favor of RhoA and provided evidences for a role of the Rac1 specific GTPase activating protein FilGAP in this process. Together our work ascribed a new role to the N-terminal repeats of FlnA in Small GTPases regulation and supports a conceptual framework for the role of FlnA mutations in cardiac valve diseases centered around signaling molecules regulating cellular actin cytoskeleton in response to mechanical stress. (C) 2013 Elsevier B.V. All rights reserved. C1 [Duval, D.; Lardeux, A.; Le Tourneau, T.; Sauzeau, V.; Probst, V.; Le Marec, H.; Schott, J. J.; Merot, J.] CNRS, UMR 6291, INSERM UMR1087, Inst Thorax, F-44007 Nantes, France. [Norris, R. A.; Markwald, R. R.] Med Univ S Carolina, Childrens Res Inst, Cardiovasc Dev Biol Ctr, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Levine, R.] Massachusetts Gen Hosp, Dept Med, Noninvas Cardiac Lab, Boston, MA 02114 USA. RP Merot, J (reprint author), CNRS, UMR 6291, INSERM UMR1087, Inst Thorax, 8 Quai Moncousu, F-44007 Nantes, France. EM damien.duval@etu.univ-nantes.fr; aurelie.lardeux@gmail.com; thletourneau@yahoo.fr; norrisra@musc.edu; markwald@musc.edu; vincent.sauzeau@inserm.fr; vincent.probst@chu-nantes.fr; herve.lemarec@univ-nantes.fr; RLEVINE@PARTNERS.ORG; jjschott@univ-nantes.fr; jean.merot@univ-nantes.fr RI Schott, jean-Jacques/F-8842-2013; Le Marec, Herve/D-2718-2015; Sauzeau, Vincent/D-3548-2015; Le Tourneau, Thierry/D-5428-2015; MEROT, Jean/D-5741-2015; probst, vincent/D-4996-2015 OI Le Marec, Herve/0000-0002-8288-8693; FU Foundation Leducq, Transatlantic Mitral Network of xCELLigence (Paris, France) [07CVD04]; Federation Francaise de Cardiologie (FFC) Paris, France [R11065NN/RAK1190NNA]; National Institutes of Health [C06 RR018823]; Extramural Research Facilities Program of the National Center for Research Resources; National Heart Lung and Blood Institute [R01-HL33756, COBRE 1P30 GM103342, 8P20 GM103444]; American Heart Association [11SDG5270006]; National Science Foundation [EPS-0903795]; NHLBI [K24 HL67434, HL109506] FX This work was funded by The Foundation Leducq, Transatlantic Mitral Network of xCELLigence grant 07CVD04 (Paris, France) and the Federation Francaise de Cardiologie, Grant R11065NN/RAK1190NNA (TL, JM) (FFC, Paris, France). The work at MUSC was performed in a facility constructed with support from the National Institutes of Health, Grant Number C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources. Other funding sources: National Heart Lung and Blood Institute: R01-HL33756 (RRM), COBRE 1P30 GM103342 (RRM, RAN), 8P20 GM103444 (RRM and RAN); American Heart Association: 11SDG5270006 (RAN); National Science Foundation: EPS-0903795 (RRM); NHLBI K24 HL67434 and HL109506 (RAL). NR 38 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-4889 EI 0006-3002 J9 BBA-MOL CELL RES JI Biochim. Biophys. Acta-Mol. Cell Res. PD FEB PY 2014 VL 1843 IS 2 BP 234 EP 244 DI 10.1016/j.bbamcr.2013.10.022 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 302LQ UT WOS:000330606400002 PM 24200678 ER PT J AU Bozic, KJ Lau, E Ong, K Chan, V Kurtz, S Vail, TP Rubash, HE Berry, DJ AF Bozic, Kevin J. Lau, Edmund Ong, Kevin Chan, Vanessa Kurtz, Steven Vail, Thomas P. Rubash, Harry E. Berry, Daniel J. TI Risk Factors for Early Revision After Primary Total Hip Arthroplasty in Medicare Patients SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article; Proceedings Paper CT Open Scientific Meeting of the Hip-Society in Conjunction with the Annual Meeting of the American-Academy-of-Orthopaedic-Surgeons (AAOS) CY 2013 CL Chicago, IL SP Hip Soc, Amer Acad Orthopaed Surg ID PERIPROSTHETIC JOINT INFECTION; TOTAL KNEE REPLACEMENT; COMORBIDITY; AGE; OSTEOARTHRITIS AB Patient, surgeon, health system, and device factors are all known to influence outcomes in THA. However, patient-related factors associated with an increased risk of early failure are poorly understood, particularly in elderly patients. We identified specific demographic and clinical characteristics associated with increased risk of early revision in Medicare patients with THA. The Medicare 5% national sample administrative database was used to calculate the relative risk of revision within 12 months following primary THA as a function of baseline medical comorbidities in 56,030 Medicare patients who underwent primary THA between 1998 and 2010. The impact of 29 comorbid conditions on risk of early revision was examined using Cox regression, controlling for age, sex, race, US Census region, socioeconomic status, and all other baseline comorbidities. Depression, rheumatologic disease, psychoses, renal disease, chronic urinary tract infection, and congestive heart failure were associated with revision THA within 12 months of the index arthroplasty (p a parts per thousand currency sign 0.038 for all comparisons; risk factors listed in order of significance). This information is important when counseling elderly patients with THA regarding the risk of early failure and for risk stratifying publicly reported outcomes in Medicare patients with THA. Level II, prognostic study. See Instructions for Authors for a complete description of levels of evidence. C1 [Bozic, Kevin J.; Chan, Vanessa; Vail, Thomas P.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. [Bozic, Kevin J.; Chan, Vanessa] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Lau, Edmund] Exponent Inc, Menlo Pk, CA USA. [Ong, Kevin; Kurtz, Steven] Exponent Inc, Philadelphia, PA USA. [Rubash, Harry E.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Berry, Daniel J.] Mayo Clin, Dept Orthopaed Surg, Rochester, MN USA. RP Bozic, KJ (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 500 Parnassus Ave,MU 320 W, San Francisco, CA 94143 USA. EM kevin.bozic@ucsf.edu NR 23 TC 35 Z9 35 U1 3 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X EI 1528-1132 J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD FEB PY 2014 VL 472 IS 2 BP 449 EP 454 DI 10.1007/s11999-013-3081-9 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 302EP UT WOS:000330585000011 PM 23716117 ER PT J AU Kojic, M Milosevic, M Kojic, N Kim, K Ferrari, M Ziemys, A AF Kojic, M. Milosevic, M. Kojic, N. Kim, K. Ferrari, M. Ziemys, A. TI A multiscale MD-FE model of diffusion in composite media with internal surface interaction based on numerical homogenization procedure SO COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING LA English DT Article DE Diffusion; Multiscale; Homogenization; Composite media; Finite element method; Molecular dynamics ID TISSUE REGENERATION; MOLECULAR-DYNAMICS; STRATUM-CORNEUM; TRANSPORT; CONDUCTIVITY; NANOCHANNELS; MEMBRANES; SCAFFOLD; VOLUME AB Mass transport by diffusion within composite materials may depend not only on internal microstructural geometry, but also on the chemical interactions between the transported substance and the material of the microstructure. Retrospectively, there is a gap in methods and theory to connect material microstructure properties with macroscale continuum diffusion characteristics. Here we present a new hierarchical multiscale model for diffusion within composite materials that couples material microstructural geometry and interactions between diffusing particles and the material matrix. This model, which bridges molecular dynamics (MD) and the finite element (FE) method, is employed to construct a continuum diffusion model based on a novel numerical homogenization procedure. The procedure is general and robust for evaluating constitutive material parameters of the continuum model. These parameters include the traditional bulk diffusion coefficients and, additionally, the distances from the solid surface accounting for surface interaction effects. We implemented out models to glucose diffusion through the following two geometrical/material configurations: tightly packed silica nanospheres, and a complex fibrous structure surrounding nanospheres. Then, rhodamine 6G diffusion analysis through an agarose gel network was performed, followed by a model validation using our experimental results. The microstructural model, numerical homogenization and continuum model offer a new platform for modeling and predicting mass diffusion through complex biological environment and within composite materials that are used in a wide range of applications, like drug delivery and nanoporous catalysts. (C) 2013 Elsevier B.V. All rights reserved. C1 [Kojic, M.; Kim, K.; Ferrari, M.; Ziemys, A.] Houston Methodist Res Inst, Dept Nanomed, Houston, TX 77030 USA. [Kojic, M.; Milosevic, M.] Belgrade Metropolitan Univ, Bioengn Res & Dev Ctr BioIRC Kragujevac, Kragujevac 3400, Serbia. [Kojic, N.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. RP Kojic, M (reprint author), Houston Methodist Res Inst, Dept Nanomed, 6670 Bertner Ave,R7-117, Houston, TX 77030 USA. EM mkojic42@gmail.com FU Houston Methodist Research Institute; Serbian Ministry of Education and Science [01 174028, III 41007]; City of Kragujevac - Serbia; Ernest Cockrell Jr. Distinguished Endowed Chair; US Department of Defense [W81XWH-09-1-0212]; National Institute of Health [U54CA143837, U54CA151668] FX The authors acknowledge the Texas Advanced Computing Center (TACC) at The University of Texas at Austin for providing HPC resources that have contributed to the research results reported within this paper. This project has been partially supported with Houston Methodist Research Institute, by the grants 01 174028 and III 41007 of the Serbian Ministry of Education and Science, and City of Kragujevac - Serbia. Authors also acknowledge partial supports from the following funding sources: the Ernest Cockrell Jr. Distinguished Endowed Chair (M.F.), US Department of Defense (W81XWH-09-1-0212) (M.F.), National Institute of Health (U54CA143837, U54CA151668) (M.F.). NR 43 TC 6 Z9 6 U1 1 U2 18 PU ELSEVIER SCIENCE SA PI LAUSANNE PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND SN 0045-7825 EI 1879-2138 J9 COMPUT METHOD APPL M JI Comput. Meth. Appl. Mech. Eng. PD FEB 1 PY 2014 VL 269 BP 123 EP 138 DI 10.1016/j.cma.2013.11.010 PG 16 WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary Applications; Mechanics SC Engineering; Mathematics; Mechanics GA AA0VQ UT WOS:000330815900007 PM 24578582 ER PT J AU Gharedaghi, MH Seyedabadi, M Ghia, JE Dehpour, AR Rahimian, R AF Gharedaghi, Mohammad Hadi Seyedabadi, Mohammad Ghia, Jean-Eric Dehpour, Ahmad Reza Rahimian, Reza TI The role of different serotonin receptor subtypes in seizure susceptibility SO EXPERIMENTAL BRAIN RESEARCH LA English DT Review DE Epilepsy; Seizure; Serotonin ID TEMPORAL-LOBE EPILEPSY; GENETIC RAT MODEL; COCAINE-INDUCED CONVULSIONS; SPIKE-WAVE DISCHARGES; FREELY-MOVING RATS; 5-HT TERMINAL AUTORECEPTOR; FOCAL HIPPOCAMPAL SEIZURES; ATYPICAL ABSENCE SEIZURES; IN-VIVO CHARACTERIZATION; SOUND-INDUCED SEIZURES AB 5-Hydroxytryptamine (5-HT) has the most diverse set of receptors in comparison with any other neurotransmitter or hormone in the body. To date, seven families of 5-HT receptors have been characterized. A great number of studies have been published regarding the role of 5-HT and its receptors in seizures. However, with a few exceptions, the net effect of activating or inhibiting each 5-HT receptor subtype on the development or severity of seizures remains controversial. Additionally, the results of studies, which have used knockout animals to investigate the role of 5-HT receptors in seizures, have sometimes been contradictory to those which have used pharmacological tools. The present study aims to review the available data regarding the influence of each receptor subtype on seizure development and, when possible, reconcile between the apparently different results obtained in these studies. C1 [Gharedaghi, Mohammad Hadi; Dehpour, Ahmad Reza; Rahimian, Reza] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran. [Gharedaghi, Mohammad Hadi; Dehpour, Ahmad Reza] Univ Tehran Med Sci, Brain & Spinal Injury Res Ctr, Tehran, Iran. [Gharedaghi, Mohammad Hadi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA. [Seyedabadi, Mohammad] Bushehr Univ Med Sci, Persian Gulf Biomed Sci Res Inst, Bushehr, Iran. [Ghia, Jean-Eric] Univ Manitoba, Fac Med, Dept Immunol & Internal Med, Gastroenterol Sect, Winnipeg, MB, Canada. RP Rahimian, R (reprint author), Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran. EM rahimian78@gmail.com RI SEYEDABADI, Mohammad/C-7132-2009; OI SEYEDABADI, Mohammad/0000-0003-0044-8270; dehpour, ahmad reza/0000-0002-8001-5565 NR 179 TC 10 Z9 10 U1 0 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0014-4819 EI 1432-1106 J9 EXP BRAIN RES JI Exp. Brain Res. PD FEB PY 2014 VL 232 IS 2 BP 347 EP 367 DI 10.1007/s00221-013-3757-0 PG 21 WC Neurosciences SC Neurosciences & Neurology GA AA0GG UT WOS:000330773000001 PM 24232860 ER PT J AU Lee, JH Chen, HX Kolev, V Aull, KH Jung, I Wang, J Miyamoto, S Hosoi, J Mandinova, A Fisher, DE AF Lee, Ju Hee Chen, Hongxiang Kolev, Vihren Aull, Katherine H. Jung, Inhee Wang, Jun Miyamoto, Shoko Hosoi, Junichi Mandinova, Anna Fisher, David E. TI High-throughput, high-content screening for novel pigmentation regulators using a keratinocyte/melanocyte co-culture system SO EXPERIMENTAL DERMATOLOGY LA English DT Article DE co-culture; high-content screening; keratinocyte; melanocyte; microphthalmia transcription factor; pigmentation ID MELANOSOME TRANSFER; HUMAN MELANOCYTES; MELANIN TRANSFER; SKIN PIGMENTATION; GENE-EXPRESSION; IN-VITRO; MELANOGENESIS; CELLS; TRANSCRIPTION; MECHANISM AB Skin pigmentation is a complex process including melanogenesis within melanocytes and melanin transfer to the keratinocytes. To develop a comprehensive screening method for novel pigmentation regulators, we used immortalized melanocytes and keratinocytes in co-culture to screen large numbers of compounds. High-throughput screening plates were subjected to digital automated microscopy to quantify the pigmentation via brightfield microscopy. Compounds with pigment suppression were secondarily tested for their effects on expression of microphthalmia transcription factor (MITF) and several pigment regulatory genes, and further validated in terms of non-toxicity to keratinocytes/melanocytes and dose-dependent activity. The results demonstrate a high-throughput, high-content screening approach, which is applicable to the analysis of large chemical libraries using a co-culture system. We identified candidate pigmentation inhibitors from 4000 screened compounds including zoxazolamine, 3-methoxycatechol and alpha-mangostin, which were also shown to modulate expression of MITF and several key pigmentation factors and are worthy of further evaluation for potential translation to clinical use. C1 [Lee, Ju Hee; Chen, Hongxiang; Kolev, Vihren; Aull, Katherine H.; Jung, Inhee; Wang, Jun; Mandinova, Anna; Fisher, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Cutaneous Biol Res Ctr, Boston, MA 02114 USA. [Lee, Ju Hee; Jung, Inhee] Yonsei Univ, Coll Med, Dept Dermatol, Cutaneous Biol Res Inst, Seoul, South Korea. [Miyamoto, Shoko; Hosoi, Junichi] Shiseido Life Sci Res Ctr, Yokohama, Kanagawa, Japan. RP Fisher, DE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Melanoma Program MGH Canc Ctr, Dept Dermatol,Cutaneous Biol Res Ctr,Med Sch, Bartlett 6,55 Fruit St, Boston, MA 02114 USA. EM dfisher3@partners.org OI Aull, Katherine/0000-0003-4289-1342 FU NIH [NIAMS 2R01 AR043369-17]; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Massachusetts General Hospital/Shiseido Co. Ltd Agreement FX The authors gratefully acknowledge support for this research by a grant from NIH (NIAMS 2R01 AR043369-17), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation and the Massachusetts General Hospital/Shiseido Co. Ltd Agreement. The authors also acknowledge useful discussions and advice from members of the Fisher Lab. NR 40 TC 4 Z9 4 U1 0 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0906-6705 EI 1600-0625 J9 EXP DERMATOL JI Exp. Dermatol. PD FEB PY 2014 VL 23 IS 2 BP 125 EP 129 DI 10.1111/exd.12322 PG 5 WC Dermatology SC Dermatology GA 297UY UT WOS:000330281700013 PM 24438532 ER PT J AU Brady, P Imudia, AN Awonuga, AO Wright, DL Styer, AK Toth, TL AF Brady, Paula Imudia, Anthony N. Awonuga, Awoniyi O. Wright, Diane L. Styer, Aaron K. Toth, Thomas L. TI Pregnancies of unknown location after in vitro fertilization: minimally invasive management with Karman cannula aspiration SO FERTILITY AND STERILITY LA English DT Article DE Beta-human chorionic gonadotropin; early pregnancy; ectopic pregnancy; IVF/ICSI; pregnancy of unknown location ID HUMAN CHORIONIC-GONADOTROPIN; ECTOPIC PREGNANCY; ENDOMETRIAL ASPIRATION; DEFINITIVELY DIAGNOSE; SERUM HCG; GESTATION; THICKNESS; PIPELLE; WOMEN; RISK AB Objective: To describe a standardized protocol for the assessment of asymptomatic patients with pregnancies of unknown location (PUL) after IVF. Design: Retrospective cohort study. Setting: University-based infertility clinic. Patient(s): Women undergoing fresh IVF/intracytoplasmic sperm injection (ICSI) cycles between 2005 and 2011. Intervention(s): Endometrial sampling using Karman suction cannula in patients with PUL and abnormal beta-hCG trend (increase < 53% or decrease < 15% in 2 days) and a pelvic ultrasound unremarkable for an intrauterine pregnancy (IUP) or an ectopic pregnancy (EP). Main Outcome Measure(s): Proportion of patients spared methotrexate (MTX) administration. Result(s): Endometrial sampling was performed in 45 patients. Of these, 31 (68.9%) were diagnosed with failed IUP by either a sampling after the beta-hCG decline (>= 15%) and/or the presence of villi on final pathology. No further intervention was required. Fourteen patients (31.1%) were diagnosed with presumed EP by persistent beta-hCG level after negative pathology. Ten of these patients (71%) were successfully treated with a single dose of MTX; three required an additional dose, and one required laparoscopy for a ruptured EP. Conclusion(s): In asymptomatic patients with PUL and abnormal beta-hCG trends after IVF, the utility of Karman aspiration to confirm an IUP may obviate treatment with MTX in more than two-thirds of patients. (C) 2014 by American Society for Reproductive Medicine. C1 [Brady, Paula; Wright, Diane L.; Styer, Aaron K.; Toth, Thomas L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Dept Obstet & Gynecol, Boston, MA USA. [Imudia, Anthony N.] Univ S Florida, Morsani Sch Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Tampa, FL 33606 USA. [Awonuga, Awoniyi O.] Wayne State Univ, Sch Med, Div Reprod Endocrinol & Infertil, Detroit, MI USA. [Wright, Diane L.; Styer, Aaron K.; Toth, Thomas L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Fertil Ctr,Vincent Dept Obstet & Gynecol, Boston, MA USA. RP Imudia, AN (reprint author), Univ S Florida, 2 Tampa Gen Circle,Suite 6022, Tampa, FL 33606 USA. EM aimudia@health.usf.edu OI Brady, Paula/0000-0002-2225-1148 NR 29 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD FEB PY 2014 VL 101 IS 2 BP 420 EP 426 DI 10.1016/j.fertnstert.2013.10.056 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 302CD UT WOS:000330578000025 PM 24331836 ER PT J AU Akagi, K Li, JF Broutian, TR Padilla-Nash, H Xiao, WH Jiang, B Rocco, JW Teknos, TN Kumar, B Wangsa, D He, DD Ried, T Symer, DE Gillison, ML AF Akagi, Keiko Li, Jingfeng Broutian, Tatevik R. Padilla-Nash, Hesed Xiao, Weihong Jiang, Bo Rocco, James W. Teknos, Theodoros N. Kumar, Bhavna Wangsa, Danny He, Dandan Ried, Thomas Symer, David E. Gillison, Maura L. TI Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability SO GENOME RESEARCH LA English DT Article ID HUMAN-PAPILLOMAVIRUS TYPE-16; SQUAMOUS-CELL CARCINOMA; HEPATITIS-B-VIRUS; HEPATOCELLULAR-CARCINOMA; CERVICAL-CARCINOMA; RNA-SEQ; STRUCTURAL ALTERATIONS; REPLICATION CENTERS; GENETIC INSTABILITY; DNA AB Genomic instability is a hallmark of human cancers, including the 5% caused by human papillomavirus (HPV). Here we report a striking association between HPV integration and adjacent host genomic structural variation in human cancer cell lines and primary tumors. Whole-genome sequencing revealed HPV integrants flanking and bridging extensive host genomic amplifications and rearrangements, including deletions, inversions, and chromosomal translocations. We present a model of "looping" by which HPV integrant-mediated DNA replication and recombination may result in viral-host DNA concatemers, frequently disrupting genes involved in oncogenesis and amplifying HPV oncogenes E6 and E7. Our high-resolution results shed new light on a catastrophic process, distinct from chromothripsis and other mutational processes, by which HPV directly promotes genomic instability. C1 [Akagi, Keiko; Li, Jingfeng; He, Dandan; Symer, David E.] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA. [Akagi, Keiko; Li, Jingfeng; Broutian, Tatevik R.; Xiao, Weihong; Jiang, Bo; He, Dandan; Symer, David E.; Gillison, Maura L.] Ohio State Univ, Ctr Comprehens Canc, Viral Oncol Program, Columbus, OH 43210 USA. [Akagi, Keiko; Li, Jingfeng; He, Dandan; Symer, David E.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. [Broutian, Tatevik R.; Xiao, Weihong; Jiang, Bo; Symer, David E.; Gillison, Maura L.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA. [Padilla-Nash, Hesed; Wangsa, Danny; Ried, Thomas] NCI, Canc Genom Sect, Ctr Canc Res, Bethesda, MD 20814 USA. [Rocco, James W.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA. [Rocco, James W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Rocco, James W.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02115 USA. [Teknos, Theodoros N.; Kumar, Bhavna] Ohio State Univ, Wexner Med Ctr, Dept Otolaryngol Head & Neck Surg, Columbus, OH 43210 USA. [Symer, David E.] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA. RP Symer, DE (reprint author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA. EM david.symer@osumc.edu; maura.gillison@osumc.edu FU Ohio State University Comprehensive Cancer Center; Ohio Supercomputer Center [PAS0425]; Ohio Cancer Research Associate grant [GRT00024299]; Oral Cancer Foundation; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research FX We thank Dr. Douglas Lowy (National Cancer Institute) for insightful comments on the manuscript; Anthony S. Baker for expert help preparing graphical figures; Dr. Yanqiang Wang (OSUCCC) for help with Northern blots; Sylwia Wojcik for help with initial characterization of insertional breakpoints; and other members of the Gillison and Symer laboratories for helpful discussions. We thank Drs. Thomas Carey (University of Michigan), Susanne M. Gollin (University of Pittsburgh), and Henning Bier (University of Dusseldorf) for their kind gifts of cell lines. This study was funded by The Ohio State University Comprehensive Cancer Center (D.E.S., M.L.G.), the Ohio Supercomputer Center (PAS0425; K.A., D.E.S.), an Ohio Cancer Research Associate grant (GRT00024299; K.A.), the Oral Cancer Foundation (M.L.G.), and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (T.R.). NR 85 TC 65 Z9 68 U1 5 U2 32 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1088-9051 EI 1549-5469 J9 GENOME RES JI Genome Res. PD FEB PY 2014 VL 24 IS 2 BP 185 EP 199 DI 10.1101/gr.164806.113 PG 15 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 303TG UT WOS:000330696800002 PM 24201445 ER PT J AU Sexton, BS Avey, D Druliner, BR Fincher, JA Vera, DL Grau, DJ Borowsky, ML Gupta, S Girimurugan, SB Chicken, E Zhang, JF Noble, WS Zhu, FX Kingston, RE Dennis, JH AF Sexton, Brittany S. Avey, Denis Druliner, Brooke R. Fincher, Justin A. Vera, Daniel L. Grau, Daniel J. Borowsky, Mark L. Gupta, Shobhit Girimurugan, Senthil B. Chicken, Eric Zhang, Jinfeng Noble, William S. Zhu, Fanxiu Kingston, Robert E. Dennis, Jonathan H. TI The spring-loaded genome: Nucleosome redistributions are widespread, transient, and DNA-directed SO GENOME RESEARCH LA English DT Article ID SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; IN-VIVO; SEQUENCE PREFERENCES; CHROMATIN; ORGANIZATION; PROMOTER; ELEMENTS; HISTONE; TRANSCRIPTION AB Nucleosome occupancy plays a key role in regulating access to eukaryotic genomes. Although various chromatin regulatory complexes are known to regulate nucleosome occupancy, the role of DNA sequence in this regulation remains unclear, particularly in mammals. To address this problem, we measured nucleosome distribution at high temporal resolution in human cells at hundreds of genes during the reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV). We show that nucleosome redistribution peaks at 24 h post-KSHV reactivation and that the nucleosomal redistributions are widespread and transient. To clarify the role of DNA sequence in these nucleosomal redistributions, we compared the genes with altered nucleosome distribution to a sequence-based computer model and in vitro-assembled nucleosomes. We demonstrate that both the predicted model and the assembled nucleosome distributions are concordant with the majority of nucleosome redistributions at 24 h post-KSHV reactivation. We suggest a model in which loci are held in an unfavorable chromatin architecture and "spring" to a transient intermediate state directed by DNA sequence information. We propose that DNA sequence plays a more considerable role in the regulation of nucleosome positions than was previously appreciated. The surprising findings that nucleosome redistributions are widespread, transient, and DNA-directed shift the current perspective regarding regulation of nucleosome distribution in humans. C1 [Sexton, Brittany S.; Avey, Denis; Druliner, Brooke R.; Fincher, Justin A.; Vera, Daniel L.; Zhu, Fanxiu; Dennis, Jonathan H.] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA. [Grau, Daniel J.; Borowsky, Mark L.; Kingston, Robert E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol,Dept Genet, Boston, MA 02114 USA. [Gupta, Shobhit; Noble, William S.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Girimurugan, Senthil B.; Chicken, Eric; Zhang, Jinfeng] Florida State Univ, Dept Stat, Tallahassee, FL 32306 USA. RP Dennis, JH (reprint author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA. EM dennis@bio.fsu.edu FU National Institutes of Health [R37 GM048405, R01 DA033775, R01 GM071923, R01 DE016680] FX We are grateful to M. Simon, S. Bowman, M. Charrel-Dennis, D. Gilbert, D. Houle, and A. Thistle for critical reading of the manuscript. We thank Drs. Jinjong Myoung and Don Ganem for providing iSLK.rKSHV219 cells. J.H.D. and R.E.K. were supported by National Institutes of Health Award R37 GM048405. J.H.D., J.Z., S.G., and B.S.S. were supported by National Institutes of Health Award R01 DA033775. S.G. and W.S.N. were supported by National Institutes of Health Award R01 GM071923. F.Z. and D.A. were supported by National Institutes of Health Award R01 DE016680. NR 45 TC 12 Z9 12 U1 0 U2 11 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1088-9051 EI 1549-5469 J9 GENOME RES JI Genome Res. PD FEB PY 2014 VL 24 IS 2 BP 251 EP 259 DI 10.1101/gr.160150.113 PG 9 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 303TG UT WOS:000330696800007 PM 24310001 ER PT J AU Zhang, Y Vastenhouw, NL Feng, JX Fu, K Wang, CF Ge, Y Pauli, A van Hummelen, P Schier, AF Liu, XS AF Zhang, Yong Vastenhouw, Nadine L. Feng, Jianxing Fu, Kai Wang, Chenfei Ge, Ying Pauli, Andrea van Hummelen, Paul Schier, Alexander F. Liu, X. Shirley TI Canonical nucleosome organization at promoters forms during genome activation SO GENOME RESEARCH LA English DT Article ID POSITIONS IN-VIVO; SACCHAROMYCES-CEREVISIAE; ZYGOTIC TRANSITION; EUKARYOTIC GENOME; HIGH-RESOLUTION; GENE-REGULATION; DETERMINANTS; IDENTIFICATION; ENHANCERS; DYNAMICS AB The organization of nucleosomes influences transcriptional activity by controlling accessibility of DNA binding proteins to the genome. Genome-wide nucleosome binding profiles have identified a canonical nucleosome organization at gene promoters, where arrays of well-positioned nucleosomes emanate from nucleosome-depleted regions. The mechanisms of formation and the function of canonical promoter nucleosome organization remain unclear. Here we analyze the genome- wide location of nucleosomes during zebrafish embryogenesis and show that well-positioned nucleosome arrays appear on thousands of promoters during the activation of the zygotic genome. The formation of canonical promoter nucleosome organization is independent of DNA sequence preference, transcriptional elongation, and robust RNA polymerase II (Pol II) binding. Instead, canonical promoter nucleosome organization correlates with the presence of histone H3 lysine 4 trimethylation (H3K4me3) and affects future transcriptional activation. These findings reveal that genome activation is central to the organization of nucleosome arrays during early embryogenesis. C1 [Zhang, Yong; Feng, Jianxing; Fu, Kai; Wang, Chenfei; Ge, Ying; Liu, X. Shirley] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China. [Zhang, Yong; Fu, Kai; Wang, Chenfei; Ge, Ying] Tongji Univ, Shanghai Key Lab Signaling & Dis Res, Shanghai 200092, Peoples R China. [Vastenhouw, Nadine L.] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany. [Pauli, Andrea; Schier, Alexander F.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. [van Hummelen, Paul] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Zhang, Y (reprint author), Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China. EM yzhang@tongji.edu.cn; vastenhouw@mpi-cbg.de; schier@fas.harvard.edu; xsliu@jimmy.harvard.edu RI Zhang, Yong/B-4838-2011 OI Zhang, Yong/0000-0001-6316-2734 FU National Basic Research Program of China (973 Programs) [2010CB944904, 2011CB965104]; National Natural Science Foundation of China [31071114, 31322031, 31371288, 31329003]; Shanghai Rising-Star Program [13QH1402200]; US National Institutes of Health [HD071298, HD072733, GM056211, 5K99HD067220-02]; Human Frontiers Science Program; Medical Foundation; Max Planck Society FX We thank Housheng H. He for technical help. This project was supported by the National Basic Research Program of China (973 Programs: 2010CB944904, 2011CB965104), the National Natural Science Foundation of China (31071114, 31322031, 31371288, 31329003), the Shanghai Rising-Star Program (13QH1402200), the US National Institutes of Health (HD071298, HD072733, GM056211, 5K99HD067220-02), the Human Frontiers Science Program, the Medical Foundation, and the Max Planck Society. NR 43 TC 25 Z9 26 U1 4 U2 18 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1088-9051 EI 1549-5469 J9 GENOME RES JI Genome Res. PD FEB PY 2014 VL 24 IS 2 BP 260 EP 266 DI 10.1101/gr.157750.113 PG 7 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 303TG UT WOS:000330696800008 PM 24285721 ER PT J AU Greaney, ML Puleo, E Bennett, GG Haines, J Viswanath, K Gillman, MW Sprunck-Harrild, K Coeling, M Rusinak, D Emmons, KM AF Greaney, Mary L. Puleo, Elaine Bennett, Gary G. Haines, Jess Viswanath, K. Gillman, Matthew W. Sprunck-Harrild, Kim Coeling, Molly Rusinak, Donna Emmons, Karen M. TI Factors Associated With Choice of Web or Print Intervention Materials in the Healthy Directions 2 Study SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE computer-based health education; health promotion; multiple risk behaviors; multiple risk factor interventions; print intervention ID RANDOMIZED CONTROLLED-TRIAL; CANCER PREVENTION INTERVENTION; LIFE-STYLE CHARACTERISTICS; ILLNESS RESOURCES SURVEY; BEHAVIORAL RISK-FACTORS; PHYSICAL-ACTIVITY; UNITED-STATES; WORKING-CLASS; PRIMARY-CARE; MULTIETHNIC POPULATIONS AB Background. Many U.S. adults have multiple behavioral risk factors, and effective, scalable interventions are needed to promote population-level health. In the health care setting, interventions are often provided in print, although accessible to nearly everyone, are brief (e.g., pamphlets), are not interactive, and can require some logistics around distribution. Web-based interventions offer more interactivity but may not be accessible to all. Healthy Directions 2 was a primary care-based cluster randomized controlled trial designed to improve five behavioral cancer risk factors among a diverse sample of adults (n = 2,440) in metropolitan Boston. Intervention materials were available via print or the web. Purpose. To (a) describe the Healthy Directions 2 study design and (b) identify baseline factors associated with whether participants opted for print or web-based materials. Methods. Hierarchical regression models corrected for clustering by physician were built to examine factors associated with choice of intervention modality. Results. At baseline, just 4.0% of participants met all behavioral recommendations. Nearly equivalent numbers of intervention participants opted for print and web-based materials (44.6% vs. 55.4%). Participants choosing web-based materials were younger, and reported having a better financial status, better perceived health, greater computer comfort, and more frequent Internet use (p < .05) than those opting for print. In addition, Whites were more likely to pick web-based material than Black participants. Conclusions. Interventions addressing multiple behaviors are needed in the primary care setting, but they should be available in web and print formats as nearly equal number of participants chose each option, and there are significant differences in the population groups using each modality. C1 [Greaney, Mary L.; Viswanath, K.; Sprunck-Harrild, Kim; Emmons, Karen M.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Puleo, Elaine] Univ Massachusetts, Amherst, MA 01003 USA. [Bennett, Gary G.] Duke Univ, Durham, NC USA. [Haines, Jess] Univ Guelph, Guelph, ON N1G 2W1, Canada. [Viswanath, K.; Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Gillman, Matthew W.; Rusinak, Donna] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Coeling, Molly] Univ Chicago, Chicago, IL 60637 USA. RP Greaney, ML (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave, Boston, MA 02215 USA. EM mary_greaney@dfci.harvard.edu FU NCI NIH HHS [1K05 CA124415, R01 CA123228, K05 CA124415] NR 54 TC 3 Z9 3 U1 2 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD FEB PY 2014 VL 41 IS 1 BP 52 EP 62 DI 10.1177/1090198113486803 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 302SU UT WOS:000330626000008 PM 23720532 ER PT J AU Carreno, FR Frazer, A AF Carreno, Flavia Regina Frazer, Alan TI Activation of signaling pathways downstream of the brain-derived neurotrophic factor receptor, TrkB, in the rat brain by vagal nerve stimulation and antidepressant drugs SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Article DE Antidepressants; desipramine; sertraline; TrkB; vagal nerve stimulation ID TREATMENT-RESISTANT DEPRESSION; PHARMACOLOGICALLY DIVERSE ANTIDEPRESSANTS; CHRONIC MILD STRESS; NEURONAL PLASTICITY; FACTOR EXPRESSION; MAJOR DEPRESSION; CREB ACTIVATION; GENE-EXPRESSION; MESSENGER-RNA; MOUSE-BRAIN AB Vagal nerve stimulation (VNS) has been approved for treatment resistant depression (TRD) by the Food and Drug Administration (FDA) since 2005. However, the cellular and molecular targets responsible for its effects are still not characterized. Previously, chronic administration of VNS to rats was found to phosphorylate tyrosine 515 on TrkB, the neurotrophin receptor, whereas traditional antidepressants did not do this. In the present study, Western blot analysis was used to characterize activation due to phosphorylation in the hippocampus of down-stream pathways linked to specific key tyrosine residues on TrkB (namely Y816 and Y515) after either acute or chronic administration of VNS and traditional antidepressant drugs. Chronic administration of VNS caused phosphorylation of effectors linked to Y 515; namely Akt, ERK and p70S6 kinase, but this was not produced by either desipramine or sertraline. All the treatments, when given chronically, caused phosphorylation of the transcription factor, CREB. Acute administration of all the treatments also caused phosphorylation of PLC1 but this was not maintained with chronic treatment. Further research is required to determine what role, if any, activation of down-stream targets of Y515 plays in the behavioural effects of VNS. C1 [Carreno, Flavia Regina; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Frazer, Alan] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Carreno, FR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM carreno@uthscsa.edu FU NIMH [MH082933] FX This work was supported by NIMH grant MH082933 (A.F). The electrodes, VNS stimulators and dummy stimulators were gifts from Cyberonics Inc. NR 68 TC 7 Z9 8 U1 1 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD FEB PY 2014 VL 17 IS 2 BP 247 EP 258 DI 10.1017/S1461145713000977 PG 12 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 302HL UT WOS:000330594200007 PM 24103847 ER PT J AU Yuan, YS Shi, FX Yin, YB Tong, MJ Lang, HN Polley, DB Liberman, MC Edge, ASB AF Yuan, Yasheng Shi, Fuxin Yin, Yanbo Tong, Mingjie Lang, Hainan Polley, Daniel B. Liberman, M. Charles Edge, Albert S. B. TI Ouabain-Induced Cochlear Nerve Degeneration: Synaptic Loss and Plasticity in a Mouse Model of Auditory Neuropathy SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY LA English DT Article DE hair cells; ribbon synapse; neurodegeneration ID SPIRAL GANGLION NEURONS; INNER HAIR-CELLS; MAMMALIAN COCHLEA; ROUND WINDOW; REGENERATION; ORGAN; CORTI; RAT; RESPONSES; SYNAPSES AB Ouabain application to the round window can selectively destroy type-I spiral ganglion cells, producing an animal model of auditory neuropathy. To assess the long-term effects of this deafferentation on synaptic organization in the organ of Corti and cochlear nucleus, and to ask whether surviving cochlear neurons show any post-injury plasticity in the adult, we quantified the peripheral and central synapses of type-I neurons at posttreatment times ranging from 1 to 3 months. Measures of normal DPOAEs and greatly reduced auditory brainstem responses (ABRs) confirmed the neuropathy phenotype. Counts of presynaptic ribbons and postsynaptic glutamate receptor patches in the inner hair cell area decreased with post-exposure time, as did counts of cochlear nerve terminals in the cochlear nucleus. Although these counts provided no evidence of new synapse formation via branching from surviving neurons, the regular appearance of ectopic neurons in the inner hair cell area suggested that neurite extension is not uncommon. Correlations between pathophysiology and histopathology showed that ABR thresholds are very insensitive to even massive neural degeneration, whereas the amplitude of ABR wave 1 is a better metric of synaptic degeneration. C1 [Yuan, Yasheng; Shi, Fuxin; Yin, Yanbo; Tong, Mingjie; Polley, Daniel B.; Liberman, M. Charles; Edge, Albert S. B.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Yuan, Yasheng; Shi, Fuxin; Yin, Yanbo; Tong, Mingjie; Polley, Daniel B.; Liberman, M. Charles; Edge, Albert S. B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Lang, Hainan] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Edge, ASB (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM albert_edge@meei.harvard.edu OI Lang, Hainan/0000-0003-2210-7856; Polley, Daniel/0000-0002-5120-2409 FU National Institute on Deafness [RO1 DC007174, R01 DC 00188, R01 DC009836, P30 DC05209] FX This work was supported by grants from the National Institute on Deafness and other Communicative Disorders: RO1 DC007174 (AE), R01 DC 00188 (MCL), R01 DC009836 (DBP), and P30 DC05209 (MCL). NR 37 TC 28 Z9 29 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1525-3961 EI 1438-7573 J9 JARO-J ASSOC RES OTO JI JARO PD FEB PY 2014 VL 15 IS 1 BP 31 EP 43 DI 10.1007/s10162-013-0419-7 PG 13 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 302YL UT WOS:000330641000003 PM 24113829 ER PT J AU von Bornstadt, D Kunz, A Endres, M AF von Bornstaedt, Daniel Kunz, Alexander Endres, Matthias TI Impact of particulate matter exposition on the risk of ischemic stroke: epidemiologic evidence and putative mechanisms SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Review DE air pollution; atherosclerosis; ischemic stroke; particulate matter; systemic inflammation ID AMBIENT AIR-POLLUTION; AMERICAN-HEART-ASSOCIATION; CASE-CROSSOVER ANALYSIS; SHORT-TERM EXPOSURE; CARDIOVASCULAR-DISEASE; HOSPITAL ADMISSIONS; HEMORRHAGIC STROKE; IMMUNE-RESPONSE; BLOOD-PRESSURE; UNITED-STATES AB Ambient particulate matter (PM) pollution is estimated to be responsible for 3.2 million deaths annually worldwide. Although many studies have demonstrated PM as a serious risk factor for cardiovascular diseases, less is known on its association with cerebrovascular events. Over the last decade, however, an increasing number of studies have provided data showing a relationship between PM exposure and ischemic stroke (IS). In this article, we will report on existing epidemiologic findings for an association between, PM exposure and IS based on a systemic literature search. Thus, despite inconsistencies in the results, currently available data suggest that PM exposure is a risk factor for IS, especially in patients with preexisting illnesses. With regards to the mechanisms leading to PM-dependent vascular damage, in particular proinflammatory, prooxidative, as well as proatherogenic pathways have been suggested to be involved. Notably, to date there is only one study published, which demonstrates the influence of PM exposure on cerebrovascular function. We will discuss reasonable approaches for future neurovascular research in this field. C1 [von Bornstaedt, Daniel; Kunz, Alexander; Endres, Matthias] Charite, Dept Neurol, D-13353 Berlin, Germany. [von Bornstaedt, Daniel; Kunz, Alexander; Endres, Matthias] Charite, Ctr Stroke Res Berlin, D-13353 Berlin, Germany. [von Bornstaedt, Daniel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurovasc Res Lab, Boston, MA USA. [Endres, Matthias] Charite, Neurocure Cluster Excellence, D-13353 Berlin, Germany. RP von Bornstadt, D (reprint author), Charitepl 1, D-10117 Berlin, Germany. EM daniel.von-bornstaedt@charite.de NR 54 TC 3 Z9 3 U1 0 U2 11 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD FEB PY 2014 VL 34 IS 2 BP 215 EP 220 DI 10.1038/jcbfm.2013.212 PG 6 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 304LK UT WOS:000330748200004 PM 24301290 ER PT J AU Purkayastha, S Fadar, O Mehregan, A Salat, DH Moscufo, N Meier, DS Guttmann, CRG Fisher, NDL Lipsitz, LA Sorond, FA AF Purkayastha, Sushmita Fadar, Otite Mehregan, Aujan Salat, David H. Moscufo, Nicola Meier, Dominik S. Guttmann, Charles R. G. Fisher, Naomi D. L. Lipsitz, Lewis A. Sorond, Farzaneh A. TI Impaired cerebrovascular hemodynamics are associated with cerebral white matter damage SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE aging; cerebral white matter; DTI; dynamic cerebral autoregulation; TCD ID SMALL VESSEL DISEASE; TRANSCRANIAL DOPPLER ULTRASOUND; BLOOD-PRESSURE; SPONTANEOUS FLUCTUATIONS; ARTERIAL STIFFNESS; LESIONS; LEUKOARAIOSIS; AUTOREGULATION; HYPERTENSION; INTEGRITY AB White matter hyperintensities (WMH) in elderly individuals with vascular diseases are presumed to be due to ischemic small vessel diseases; however, their etiology is unknown. We examined the cross-sectional relationship between cerebrovascular hemodynamics and white matter structural integrity in elderly individuals with vascular risk factors. White matter hyperintensity volumes, fractional anisotropy (FA), and mean diffusivity (MD) were obtained from MRI in 48 subjects (75 +/- 7years). Pulsatility index (PI) and dynamic cerebral autoregulation (dCA) was assessed using transcranial Doppler ultrasound of the middle cerebral artery. Dynamic cerebral autoregulation was calculated from transfer function analysis (phase and gain) of spontaneous blood pressure and flow velocity oscillations in the low (LF, 0.03 to 0.15 Hz) and high (HF, 0.16 to 0.5 Hz) frequency ranges. Higher PI was associated with greater WMH (P < 0.005). Higher phase across all frequency ranges was associated with greater FA and lower MD (P < 0.005). Lower gain was associated with higher FA in the LF range (P = 0.001). These relationships between phase and FA were significant in the territories limited to the middle cerebral artery as well as across the entire brain. Our results show a strong relationship between impaired cerebrovascular hemodynamics (PI and dCA) and loss of cerebral white matter structural integrity (WMH and DTI metrics) in elderly individuals. C1 [Purkayastha, Sushmita; Lipsitz, Lewis A.; Sorond, Farzaneh A.] Hebrew SeniorLife, Inst Aging Res, Boston, MA 02131 USA. [Purkayastha, Sushmita; Lipsitz, Lewis A.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA. [Purkayastha, Sushmita; Fadar, Otite; Salat, David H.; Moscufo, Nicola; Meier, Dominik S.; Guttmann, Charles R. G.; Fisher, Naomi D. L.; Lipsitz, Lewis A.; Sorond, Farzaneh A.] Harvard Univ, Sch Med, Boston, MA USA. [Fadar, Otite; Mehregan, Aujan; Sorond, Farzaneh A.] Brigham & Womens Hosp, Dept Neurol, Stroke Div, Boston, MA 02115 USA. [Salat, David H.] Massachusetts Gen Hosp, Dept Radiol, Athinoula Martinos Ctr Biomed Imaging, MGH MIT HMS, Boston, MA 02114 USA. [Salat, David H.] Neuroimaging Res Vet Ctr, Boston VA Healthcare Syst, Boston, MA USA. [Moscufo, Nicola; Meier, Dominik S.; Guttmann, Charles R. G.] Brigham & Womens Hosp, Ctr Neurol Imaging, Dept Radiol, Boston, MA 02115 USA. [Fisher, Naomi D. L.] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. RP Purkayastha, S (reprint author), Hebrew SeniorLife, Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA. EM sushmitapurkayastha@hsl.harvard.edu FU NIH [T32 AG23480, RO1HL089570, R01 NR010827, P01 AG004390, R37 AG025037, K23 AG030967] FX This work was supported by NIH grants T32 AG23480 (SP), RO1HL089570 (NDLF), R01 NR010827 (DHS), P01 AG004390 (LAL) and R37 AG025037 (LAL), K23 AG030967 (FAS). NR 37 TC 26 Z9 27 U1 0 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD FEB PY 2014 VL 34 IS 2 BP 228 EP 234 DI 10.1038/jcbfm.2013.180 PG 7 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 304LK UT WOS:000330748200006 PM 24129749 ER PT J AU Shin, HK Huang, PL Ayata, C AF Shin, Hwa Kyoung Huang, Paul L. Ayata, Cenk TI Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE ApoE knockout; distal middle cerebral artery occlusion; fasudil; hydroxyfasudil; hyperlipidemia; laser speckle flowmetry ID FOCAL CEREBRAL-ISCHEMIA; BLOOD-FLOW; DEPOLARIZATIONS; MOUSE; HYPERCHOLESTEROLEMIA; DYSFUNCTION; MODEL AB Hyperlipidemia is a major cardiovascular risk factor associated with progressive cerebrovascular dysfunction and diminished collateral perfusion in stroke. Rho-associated kinase (ROCK) may be an important mediator of hyperlipidemic vascular dysfunction. We tested the efficacy of acute or chronic ROCK inhibition on the size of dynamic perfusion defect using laser speckle flowmetry in hyperlipidemic apolipoprotein E knockout mice fed on a high-fat diet for 8 weeks. Mice were studied at an age before the development of flow-limiting atherosclerotic stenoses in aorta and major cervical arteries. Focal ischemia was induced by distal middle cerebral artery occlusion (dMCAO) during optical imaging. The ROCK inhibitor fasudil (10 mg/kg) was administered either as a single dose 1 hour before ischemia onset, or daily for 4 weeks. Fasudil decreased both baseline arterial blood pressure and cerebrovascular resistance (CVR) by similar to 15%, and significantly improved tissue perfusion during dMCAO. Interestingly, pen-infarct depolarizations were also reduced. Chronic treatment did not further enhance these benefits compared with acute treatment with a single dose. These data show that ROCK inhibition improves CVR and ischemic tissue perfusion in hyperlipidemic mice. C1 [Shin, Hwa Kyoung] Pusan Natl Univ, Div Meridian & Struct Med, Sch Korean Med, Yangsan, South Korea. [Huang, Paul L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA USA. [Huang, Paul L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Charlestown, MA USA. [Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurovasc Res Lab,Dept Radiol, Charlestown, MA USA. [Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke Serv,Dept Neurol, Charlestown, MA USA. [Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosci Intens Care Unit, Charlestown, MA USA. RP Ayata, C (reprint author), Massachusetts Gen Hosp, Dept Radiol, Neurovasc Res Lab, 149 13th St,Room 6408, Charlestown, MA 02129 USA. EM cayata@partners.org FU National Institutes of Health [NS055104, NS061505, NS33335]; Basic Science Research Program through the National Research Foundation (NRF) of Korea; Ministry of Education, Science and Technology [2010-0007470]; Andrew David Heitman Foundation; The Ellison Foundation FX This work was supported by the National Institutes of Health (NS055104, NS061505, and NS33335), Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology (Grant 2010-0007470), Neuroendovascular Research Fund from the Andrew David Heitman Foundation, and The Ellison Foundation. NR 24 TC 6 Z9 6 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD FEB PY 2014 VL 34 IS 2 BP 284 EP 287 DI 10.1038/jcbfm.2013.195 PG 4 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 304LK UT WOS:000330748200013 PM 24192634 ER PT J AU Moller, K Boltze, J Posel, C Seeger, J Stahl, T Wagner, DC AF Moeller, Karoline Boltze, Johannes Poesel, Claudia Seeger, Johannes Stahl, Tobias Wagner, Daniel-Christoph TI Sterile inflammation after permanent distal MCA occlusion in hypertensive rats SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE cerebral ischemia; flow cytometry; inflammation; microglia; spontaneously hypertensive rat ID ISCHEMIC-STROKE; DENDRITIC CELLS; BRAIN-INJURY; T-CELLS; MONOCYTES; MICROGLIA; RESPONSES; BLOOD; MICE; EAE AB The pathophysiology of stroke is governed by immune reactions within and remote from the injured brain. Hypertension, a major cause and comorbidity of stroke, entails systemic vascular inflammation and may influence poststroke immune responses. This aspect is, however, underestimated in previous studies. Here we aimed to delineate the sequence of cellular inflammation after stroke in spontaneously hypertensive (SH) rats. Spontaneously hypertensive rats were subjected to permanent middle cerebral artery occlusion and killed after 1 or 4 days. Immune cells of the peripheral blood and those which have infiltrated the injured brain were identified and quantified by flow cytometry. The spatial distribution of myeloid cells and T lymphocytes, and the infarct volume were assessed by histology. We observed a concerted infiltration of immune cells into the ischemic brain of SH rats. At day 1, primarily neutrophils, monocytes, macrophages, and myeloid dendritic cells entered the brain, whereas the situation at day 4 was dominated by microglia, macrophages, lymphatic dendritic cells, and T cells. Postischemic inflammation did not cause secondary tissue damage during the subacute stage of experimental stroke in SH rats. Considering the intrinsic vascular pathology of SH rats, our study validates this strain for further translational research in poststroke inflammation. C1 [Moeller, Karoline; Boltze, Johannes; Poesel, Claudia; Wagner, Daniel-Christoph] Fraunhofer Inst Cell Therapy & Immunol, D-04103 Leipzig, Germany. [Moeller, Karoline; Seeger, Johannes] Univ Leipzig, Inst Vet Anat, D-04109 Leipzig, Germany. [Boltze, Johannes; Wagner, Daniel-Christoph] Univ Leipzig, Translat Ctr Regenerat Med, D-04109 Leipzig, Germany. [Boltze, Johannes] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Boltze, Johannes] Harvard Univ, Sch Med, Boston, MA USA. [Stahl, Tobias] IDT Biol GmbH, Dessau Rosslau, Germany. RP Moller, K (reprint author), Fraunhofer Inst Cell Therapy & Immunol, Perlickstr 1, D-04103 Leipzig, Germany. EM karoline.moeller@izi.fraunhofer.de NR 40 TC 11 Z9 11 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD FEB PY 2014 VL 34 IS 2 BP 307 EP 315 DI 10.1038/jcbfm.2013.199 PG 9 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 304LK UT WOS:000330748200016 PM 24220169 ER PT J AU Bouts, MJRJ Tiebosch, IACW van der Toorn, A Hendrikse, J Dijkhuizen, RM AF Bouts, Mark J. R. J. Tiebosch, Ivo A. C. W. van der Toorn, Annette Hendrikse, Jeroen Dijkhuizen, Rick M. TI Lesion development and reperfusion benefit in relation to vascular occlusion patterns after embolic stroke in rats SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE diffusion-weighted imaging; ischemic stroke; magnetic resonance angiography perfusion imaging; prediction ID MIDDLE CEREBRAL-ARTERY; INTRAVENOUS THROMBOLYSIS; COLLATERAL CIRCULATION; DIFFUSION; PERFUSION; MISMATCH; ISCHEMIA; INFARCT; MRI; LOCATION AB Vascular occlusion sites largely determine the pattern of cerebral tissue damage and likelihood of subsequent reperfusion after acute ischemic stroke. We aimed to elucidate relationships between flow obstruction in segments of the internal carotid artery (ICA) and middle cerebral artery (MCA), and (1) profiles of acute ischemic lesions and (2) probability of subsequent beneficial reperfusion. Embolic stroke was induced by unilateral intracardtid blood clot injection in normotensive (n = 53) or spontaneously hypertensive (n 20) rats, followed within 2-hours by magnetic resonance (MR) angiography (MRA), diffusion- (DWI) and perfusion-weighted Magnetic resonance imaging (MRI) (PWI). In a subset of animals (n = 9), MRI was repeated after 24 and 168 hours to determine the predictive Value of the occlusion pattern on benefit of reperfusion. The extent of cerebral perfusion and diffusion abnorrnality was related to the pattern of flow obstruction in ICA and MCA segments. Hypertensive animals displayed significantly larger Cortical perfusion lesions. Acute perfusion diffusion lesion mismatches were detected in all animals that subsequently benefitted from reperfusion. Yet, the presence of an angiography-diffution mismatch was More specific in predicting reperfusion benefit. Combination of DWI, PWI, and MRA exclusively informs on the impact of arterial occlusion profiles after acute isthemic stroke, which may improve prognostication and subsequent treatment decisions. C1 [Bouts, Mark J. R. J.; Tiebosch, Ivo A. C. W.; van der Toorn, Annette; Dijkhuizen, Rick M.] Univ Med Ctr Utrecht, Image Sci Inst, Biomed MR Imaging & Spect Grp, Utrecht, Netherlands. [Bouts, Mark J. R. J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Hendrikse, Jeroen] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands. RP Dijkhuizen, RM (reprint author), Image Sci Inst, Biomed MR Imaging & Spect Grp, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands. EM r.m.dijkhuizen@umcutrecht.nl FU Netherlands Heart Foundation [20058156]; European Union [201024]; European Stroke Network [202213] FX The research leading to these results was funded by the Netherlands Heart Foundation (20058156), and the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreements no. 201024 and no. 202213 (European Stroke Network). NR 31 TC 6 Z9 6 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD FEB PY 2014 VL 34 IS 2 BP 332 EP 338 DI 10.1038/jcbfrn.2013202 PG 7 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 304LK UT WOS:000330748200019 PM 24301289 ER PT J AU Kalpathy-Cramer, J Awan, M Bedrick, S Rasch, CRN Rosenthal, DI Fuller, CD AF Kalpathy-Cramer, Jayashree Awan, Musaddiq Bedrick, Steven Rasch, Coen R. N. Rosenthal, David I. Fuller, Clifton D. TI Development of a Software for Quantitative Evaluation Radiotherapy Target and Organ-at-Risk Segmentation Comparison SO JOURNAL OF DIGITAL IMAGING LA English DT Article DE Segmentation; Imaging informatics; Image segmentation; Radiation oncology; Algorithms; Teaching ID MODULATED RADIATION-THERAPY; VOLUME DELINEATION; NECK-CANCER; OBSERVER VARIATION; LUNG-CANCER; CONSENSUS GUIDELINES; COMPUTER INTERACTION; QUALITY-ASSURANCE; RECTAL-CANCER; BREAST-CANCER AB Modern radiotherapy requires accurate region of interest (ROI) inputs for plan optimization and delivery. Target delineation, however, remains operator-dependent and potentially serves as a major source of treatment delivery error. In order to optimize this critical, yet observer-driven process, a flexible web-based platform for individual and cooperative target delineation analysis and instruction was developed in order to meet the following unmet needs: (1) an open-source/open-access platform for automated/semiautomated quantitative interobserver and intraobserver ROI analysis and comparison, (2) a real-time interface for radiation oncology trainee online self-education in ROI definition, and (3) a source for pilot data to develop and validate quality metrics for institutional and cooperative group quality assurance efforts. The resultant software, Target Contour Testing/Instructional Computer Software (TaCTICS), developed using Ruby on Rails, has since been implemented and proven flexible, feasible, and useful in several distinct analytical and research applications. C1 [Kalpathy-Cramer, Jayashree] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Harvard Med Sch,Dept Radiol & Neurosci, Charlestown, MA USA. [Bedrick, Steven] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR USA. [Awan, Musaddiq; Rosenthal, David I.; Fuller, Clifton D.] Univ Texas MD Anderson Canc Ctr, Head & Neck Sect, Div Radiat Oncol, Houston, TX 77030 USA. [Rasch, Coen R. N.] Univ Amsterdam, Acad Med Ctr, Dept Radiotherapy, NL-1105 AZ Amsterdam, Netherlands. RP Fuller, CD (reprint author), Univ Texas MD Anderson Canc Ctr, Head & Neck Sect, Div Radiat Oncol, Houston, TX 77030 USA. EM cdfuller@mdanderson.org OI Kalpathy-Cramer, Jayashree/0000-0001-8906-9618; Fuller, Clifton/0000-0002-5264-3994 FU National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering, "Multidisciplinary Training Program in Human Imaging" [T32EB000817]; National Institutes of Health Clinician Scientist Loan Repayment Program [L30CA136381]; European Society for Therapeutic Radiology and Oncology Technology Transfer Grant; Society of Imaging Informatics in Medicine (SIIM) Product Development Grant; National Institutes of Health/National Library of Medicine Pathway to Independence Award [K99/R00LM009889]; NCI [5U01CA154601] FX CDF received support by a training grant from the National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering, "Multidisciplinary Training Program in Human Imaging" (T32EB000817), the National Institutes of Health Clinician Scientist Loan Repayment Program (L30CA136381) the European Society for Therapeutic Radiology and Oncology Technology Transfer Grant, and the Society of Imaging Informatics in Medicine (SIIM) Product Development Grant. JKC is supported in part by a National Institutes of Health/National Library of Medicine Pathway to Independence Award (K99/R00LM009889) and NCI grant 5U01CA154601. These funders played no role in the study design, collection, analysis, and interpretation of data, manuscript writing, or decision to submit the report for publication. Portions of this data were selected for a presentation at the SIIM 2010 Annual Meeting, 3-6 June, Minneapolis, MN, USA. NR 58 TC 4 Z9 4 U1 0 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0897-1889 EI 1618-727X J9 J DIGIT IMAGING JI J. Digit. Imaging PD FEB PY 2014 VL 27 IS 1 BP 108 EP 119 DI 10.1007/s10278-013-9633-4 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 304FY UT WOS:000330733700014 PM 24043593 ER PT J AU Makam, AN Lanham, HJ Batchelor, K Moran, B Howell-Stampley, T Kirk, L Cherukuri, M Samal, L Santini, N Leykum, LK Halm, EA AF Makam, Anil N. Lanham, Holly J. Batchelor, Kim Moran, Brett Howell-Stampley, Temple Kirk, Lynne Cherukuri, Manjula Samal, Lipika Santini, Noel Leykum, Luci K. Halm, Ethan A. TI The good, the bad and the early adopters: providers' attitudes about a common, commercial EHR SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE LA English DT Article DE attitude of health personnel; attitude to computers; early adopter; electronic health record; physicians; primary care; primary health care ID ELECTRONIC HEALTH RECORDS; INFORMATION-TECHNOLOGY; AMBULATORY-CARE; USER ACCEPTANCE; MEDICAL-RECORDS; QUALITY; IMPACT; PHYSICIANS; BARRIERS; TRENDS AB Rationale, aims and objectivesTo describe primary care providers' (PCP) attitudes about the impact of a mature, commercial electronic health records (EHR) on clinical practice in settings with experience using the system and to evaluate whether a provider's propensity to adopt new technologies is associated with more favourable perceptions. MethodWe surveyed PCPs in 11 practices affiliated with three health systems in Texas. Most practices had greater than 5 years of experience with the Epic EHR. The effect of early adopter of technology status was evaluated using logistic regression. ResultsOne hundred forty-six PCPs responded (70%). Most thought the EHR had a positive impact on routine tasks, such as prescription refills (94%), whereas fewer agreed for complex tasks, such as delivery of guideline-concordant care for chronic illnesses (51%). Two-thirds (62%) thought it interfered with eye contact with patients, and 40% reported that it interfered with in-visit communication. Early adopters of technology reported greater positive effects of the EHR, even after adjusting for age, ranging from 2% to 15% higher on satisfaction ratings. ConclusionPCPs practicing in settings with considerable experience using a common commercial EHR identified many positive effects, as well as two key areas for improvement - patient centredness and intelligent decision support. Providers with a propensity to adopt new technologies have more favourable perceptions of the EHR. C1 [Makam, Anil N.; Batchelor, Kim; Moran, Brett; Howell-Stampley, Temple; Kirk, Lynne; Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA. [Lanham, Holly J.; Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, San Antonio, TX 78229 USA. [Lanham, Holly J.; Leykum, Luci K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Cherukuri, Manjula] Univ N Texas, Hlth Sci Ctr, Dept Family & Community Med, Ft Worth, TX USA. [Samal, Lipika] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA. [Santini, Noel] Parkland Hlth & Hosp Syst, Community Med Div, Dallas, TX USA. RP Makam, AN (reprint author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM anil.makam@utsouthwestern.edu OI Makam, Anil/0000-0001-7072-9946 FU University of Texas; NRSA [T32HP19025-07-00] FX We would like to thank the primary care providers who participated in this study. This study was supported by a grant from the University of Texas Chancellors Fellow for Health Information Technology program (PI, Halm). Much of Dr. Makam's work on this project was completed while he was a Primary Care Research Fellow at the University of California San Francisco, funded by an NRSA training grant (T32HP19025-07-00). We have no conflicts of interest to disclose. The design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication were solely the discretion of the authors. Preliminary results of this study were presented at the Society of General Internal Medicine annual meeting in Orlando, Florida, in 2012. NR 21 TC 10 Z9 10 U1 1 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1356-1294 EI 1365-2753 J9 J EVAL CLIN PRACT JI J. Eval. Clin. Pract. PD FEB PY 2014 VL 20 IS 1 BP 36 EP 42 DI 10.1111/jep.12076 PG 7 WC Health Care Sciences & Services; Medical Informatics; Medicine, General & Internal SC Health Care Sciences & Services; Medical Informatics; General & Internal Medicine GA AA0QQ UT WOS:000330802100006 PM 23962319 ER PT J AU Hage, FG AF Hage, Fadi G. TI Left ventricular mechanical dyssynchrony by phase analysis as a prognostic indicator in heart failure SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID CARDIAC-RESYNCHRONIZATION THERAPY; BUNDLE-BRANCH BLOCK; ASSOCIATION; DYSFUNCTION; GUIDELINES; UPDATE; CRT C1 Univ Alabama Birmingham, Div Cardiovascular Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 23 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2014 VL 21 IS 1 BP 67 EP 70 DI 10.1007/s12350-013-9822-z PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AA0MI UT WOS:000330788800008 PM 24272972 ER PT J AU Hage, FG Aggarwal, H Patel, K Chen, J Jacobson, AF Heo, J Ahmed, A Iskandrian, AE AF Hage, Fadi G. Aggarwal, Himanshu Patel, Kanan Chen, Ji Jacobson, Arnold F. Heo, Jaekyeong Ahmed, Ali Iskandrian, Ami E. TI The relationship of left ventricular mechanical dyssynchrony and cardiac sympathetic denervation to potential sudden cardiac death events in systolic heart failure SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Dyssynchrony; heart failure; MIBG; phase analysis; sudden cardiac death ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; PHASE-ANALYSIS; NUCLEAR CARDIOLOGY; PROGNOSTIC VALUE; TASK-FORCE; RISK; COLLABORATION; GUIDELINES; DIAGNOSIS; SOCIETY AB Patients with heart failure (HF) are at increased risk for left ventricular (LV) dyssynchrony which is associated with sudden cardiac death (SCD). This study examined the association of LV mechanical dyssynchrony and cardiac sympathetic denervation with potential SCD events in symptomatic patients with HF and reduced ejection fraction (HFrEF). Of the 917 HFrEF patients in ADMIRE-HF, 92 experienced adjudicated potential SCD events during a 17 months median follow-up. Propensity scores were used to assemble a matched cohort of 85 pairs of patients with and without potential SCD events. ADMIRE-HF subjects had rest gated SPECT Tc-99m and I-123 MIBG imaging. Perfusion images were processed using phase analysis software to derive phase standard deviation (SD), an index of mechanical dyssynchrony. Of the 92 patients who experienced adjudicated potential SCD events 23 had SCD, 5 fatal myocardial infarction, 7 resuscitated cardiac arrest, 46 had appropriate ICD therapy, and 11 had sustained ventricular tachycardia. Patients who experienced potential SCD events had significantly wider phase SD than matched control patients (62.3 +/- A 2.4A(0) vs 55.5 +/- A 2.3A(0), P = .03) and were more likely to have a phase SD a parts per thousand yen 60A(0) (53 % vs 35 %, P = .03). Fewer patients with potential SCD events (6 % vs 15 % of the controls, P = .08) had an MIBG heart/mediastinum uptake-ratio a parts per thousand yen1.6. Among symptomatic HFrEF patients, LV mechanical dyssynchrony is independently associated with potential SCD events. Phase analysis may provide incremental prognostic information on top of current indicators of SCD risk in HFrEF. C1 [Hage, Fadi G.; Aggarwal, Himanshu; Patel, Kanan; Heo, Jaekyeong; Ahmed, Ali; Iskandrian, Ami E.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Hage, Fadi G.; Ahmed, Ali] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Chen, Ji] Emory Univ, Atlanta, GA 30322 USA. [Jacobson, Arnold F.] GE Healthcare, Princeton, NJ USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Zeigler Res Bldg 1024,703 19th St South, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU GE Healthcare FX This study was supported by an investigator initiated Grant by GE Healthcare. Dr Jacobson is an employee of GE Healthcare. NR 23 TC 10 Z9 10 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2014 VL 21 IS 1 BP 78 EP 85 DI 10.1007/s12350-013-9807-y PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AA0MI UT WOS:000330788800010 PM 24170623 ER PT J AU Dzierzewski, JM Buman, MP Giacobbi, PR Roberts, BL Aiken-Morgan, AT Marsiske, M McCrae, CS AF Dzierzewski, Joseph M. Buman, Matthew P. Giacobbi, Peter R., Jr. Roberts, Beverly L. Aiken-Morgan, Adrienne T. Marsiske, Michael McCrae, Christina S. TI Exercise and sleep in community-dwelling older adults: evidence for a reciprocal relationship SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE daily associations; elderly; exercise; older adults; reciprocal relationships; sleep ID RANDOMIZED CONTROLLED-TRIAL; MODERATE-INTENSITY EXERCISE; PHYSICAL-ACTIVITY; QUALITY; MAINTENANCE AB Exercise behaviour and sleep are both important health indicators that demonstrate significant decreases with age, and remain modifiable well into later life. The current investigation examined both the chronic and acute relationships between exercise behaviour and self-reported sleep in older adults through a secondary analysis of a clinical trial of a lifestyle intervention. Seventy-nine community-dwelling, initially sedentary, older adults (mean age=63.58years, SD=8.66years) completed daily home-based assessments of exercise behaviour and sleep using daily diary methodology. Assessments were collected weekly and continued for 18 consecutive weeks. Multilevel models revealed a small positive chronic (between-person mean-level) association between exercise and wake time after sleep onset, and a small positive acute (within-person, day-to-day) association between exercise and general sleep quality rating. The within-person exercise and general sleep quality rating relationship was found to be reciprocal (i.e. sleep quality also predicted subsequent exercise behaviour). As such, it appears exercise and sleep are dynamically related in older adults. Efforts to intervene on either sleep or exercise in late-life would be wise to take the other into account. Light exposure, temperature regulation and mood may be potential mechanisms of action through which exercise can impact sleep in older adults. C1 [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Buman, Matthew P.] Arizona State Univ, Phoenix, AZ USA. [Giacobbi, Peter R., Jr.] W Virginia Univ, Morgantown, WV 26506 USA. [Roberts, Beverly L.; Marsiske, Michael; McCrae, Christina S.] Univ Florida, Gainesville, FL USA. [Aiken-Morgan, Adrienne T.] Duke Univ, Med Ctr, Durham, NC USA. RP Dzierzewski, JM (reprint author), Greater Los Angeles Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. EM Joseph.Dzierzewski@va.gov OI Marsiske, Michael/0000-0001-5973-2116; McCrae, Christina/0000-0003-4313-6867 FU National Institute on Aging [1R36AG029664-01]; University of Florida; Research Opportunity Fund in the College of Health and Human Performance at the University of Florida; Department of Veterans Affairs Advanced Geriatrics Fellowship Program, an Institutional Training Grant [T32-AG-020499]; University of Florida by the National Institute on Aging, and an Individual Training Grant [F31-AG-032802]; Public Health Service Training Grant [5-T32-HL-007034]; National Heart, Lung, and Blood Institute; Institutional Training Grant [T32-AG000029]; National Institute on Aging FX This work was supported by the National Institute on Aging (1R36AG029664-01, PI: A. T. A.-M.), University of Florida (Age Network research award, PI: C. S. M.), and a Research Opportunity Fund in the College of Health and Human Performance at the University of Florida. J. M. D. was supported by the Department of Veterans Affairs Advanced Geriatrics Fellowship Program, an Institutional Training Grant, T32-AG-020499, awarded to the University of Florida by the National Institute on Aging, and an Individual Training Grant, F31-AG-032802, awarded by the National Institute on Aging. M. P. B. was supported by Public Health Service Training Grant, 5-T32-HL-007034, from the National Heart, Lung, and Blood Institute. A. T. A.-M. was supported by an Institutional Training Grant, T32-AG000029, to Duke University by the National Institute on Aging. None of the authors have declared a conflict of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding sources, nor were funding sources responsible for the design, methods, subject recruitment, data collection, analysis or preparation of paper. NR 30 TC 17 Z9 17 U1 5 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD FEB PY 2014 VL 23 IS 1 BP 61 EP 68 DI 10.1111/jsr.12078 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA0QD UT WOS:000330800200008 PM 23980920 ER EF